Transcriptional	O
activation	O
of	O
the	O
HIV	O
enhancer	O
was	O
also	O
subject	O
to	O
regulation	O
by	O
recently	O
cloned	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
(	O
MAD-3	B-protein
)	O
.	O

Recombinant	O
I	O
kappa	O
B-alpha	O
(	O
MAD-3	B-protein
)	O
inhibited	O
the	O
DNA	O
binding	O
activity	O
of	O
p65	B-protein
,	O
p49/p65	B-protein
,	O
and	O
p50/p65	B-protein
but	O
stimulated	O
the	O
binding	O
of	O
NFKB2	B-protein
(	O
p49	B-protein
)	O
or	O
NFKB1	O
(	O
p50	O
)	O
.	O

Functional	O
activation	O
of	O
an	O
HIV	O
reporter	O
plasmid	O
by	O
p49/p65	B-protein
in	O
transiently	B-cell_line
transfected	I-cell_line
Jurkat	I-cell_line
T-leukemia	I-cell_line
cells	I-cell_line
was	O
also	O
inhibited	O
by	O
coexpression	O
of	O
MAD-3	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
c-rel	B-protein
protooncogene	I-protein
product	I-protein
represses	O
NF-kappa	B-protein
B	I-protein
p65	B-protein
-mediated	O
transcriptional	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
.	O

The	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
and	O
the	O
5	B-DNA
'	I-DNA
regulatory	I-DNA
region	I-DNA
of	O
the	O
gene	O
encoding	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
share	O
functional	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
elements	I-DNA
involved	O
in	O
the	O
regulation	O
of	O
these	O
inducible	O
transcription	O
units	O
during	O
T-cell	O
activation	O
.	O

These	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
elements	I-DNA
are	O
recognized	O
by	O
a	O
structurally	O
related	O
family	O
of	O
interactive	O
proteins	O
that	O
includes	O
p50	B-protein
,	O
p65	B-protein
,	O
and	O
the	O
product	O
of	O
the	O
c-rel	B-DNA
protooncogene	I-DNA
(	O
c-Rel	B-protein
)	O
.	O

Recent	O
biochemical	O
studies	O
have	O
shown	O
that	O
p65	B-protein
and	O
p50	B-protein
form	O
the	O
prototypical	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
,	O
which	O
is	O
rapidly	O
translocated	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
during	O
T-cell	O
activation	O
.	O

This	O
intracellular	O
signaling	O
complex	O
potently	O
stimulates	O
kappa	O
B-directed	O
transcription	O
from	O
either	O
the	O
HIV-1	B-DNA
LTR	I-DNA
or	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
via	O
the	O
strong	O
transactivation	O
domain	O
present	O
in	O
p65	B-protein
.	O

We	O
now	O
demonstrate	O
that	O
nuclear	O
expression	O
of	O
human	O
c-Rel	B-protein
,	O
which	O
is	O
induced	O
by	O
either	O
phorbol	O
ester	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
with	O
delayed	O
kinetics	O
relative	O
to	O
p65	B-protein
,	O
markedly	O
represses	O
p65	B-protein
-mediated	O
activation	O
of	O
these	O
transcription	O
units	O
.	O

These	O
inhibitory	O
effects	O
of	O
c-Rel	B-protein
correlate	O
with	O
its	O
DNA-binding	O
activity	O
but	O
not	O
with	O
its	O
ability	O
to	O
heterodimerize	O
with	O
p50	B-protein
,	O
suggesting	O
that	O
c-Rel	B-protein
inhibition	O
involves	O
competition	O
with	O
p50/p65	B-protein
for	O
occupancy	O
of	O
the	O
kappa	O
B	O
enhancer	O
element	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
one	O
function	O
of	O
c-Rel	B-protein
is	O
as	O
a	O
physiologic	O
repressor	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
and	O
IL-2R	B-protein
alpha	I-protein
promoters	O
,	O
serving	O
to	O
efficiently	O
counter	O
the	O
strong	O
transcriptional	O
activating	O
effects	O
of	O
p65	B-protein
.	O

Ras	B-DNA
oncogene	I-DNA
transformation	O
of	O
human	B-cell_type
B	I-cell_type
lymphoblasts	I-cell_type
is	O
associated	O
with	O
lymphocyte	O
activation	O
and	O
with	O
a	O
block	O
of	O
differentiation	O
.	O

The	O
p21ras	B-protein
small	I-protein
GTP	I-protein
binding	I-protein
proteins	I-protein
participate	O
in	O
signal	O
transduction	O
from	O
cell	O
surface	O
receptors	O
and	O
affect	O
neoplastic	O
transformation	O
and	O
development	O
in	O
many	O
different	O
cell	O
types	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
relationship	O
between	O
ras	O
transformation	O
and	O
differentiation	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
show	O
that	O
the	O
constitutive	O
expression	O
of	O
the	O
T24	B-DNA
Ha-ras	I-DNA
oncogene	I-DNA
in	O
EBV-immortalized	B-cell_line
B	I-cell_line
lymphoblasts	I-cell_line
was	O
associated	O
with	O
the	O
induction	O
of	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
,	O
with	O
an	O
impaired	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
,	O
altered	O
adhesion	O
properties	O
and	O
increased	O
survival	O
in	O
serum-free	O
medium	O
.	O

Since	O
induction	O
of	O
the	O
IL-2	B-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
is	O
a	O
hallmark	O
of	O
lymphocyte	B-cell_type
activation	O
,	O
we	O
suggest	O
that	O
p21ras	B-protein
naturally	O
triggers	O
B	B-cell_type
cell	I-cell_type
activation	O
.	O

The	O
ras-transformed	B-cell_line
lymphocytes	I-cell_line
displayed	O
a	O
fully	O
functional	O
IL-2r	B-protein
,	O
as	O
assessed	O
by	O
c-fos	B-DNA
induction	O
following	O
treatment	O
with	O
IL-2	B-protein
;	O
nevertheless	O
,	O
they	O
were	O
not	O
growth	O
stimulated	O
by	O
this	O
lymphokine	B-protein
.	O

The	O
decreased	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
indicates	O
that	O
the	O
ras	B-DNA
oncogene	I-DNA
blocks	O
terminal	O
differentiation	O
to	O
plasma	B-cell_type
cells	I-cell_type
,	O
possibly	O
by	O
inhibiting	O
the	O
activity	O
of	O
lymphocyte-specific	B-protein
transcription	I-protein
factors	I-protein
.	O

Somewhat	O
unexpectedly	O
,	O
the	O
constitutive	O
p21ras	B-protein
activity	O
did	O
not	O
cause	O
an	O
increased	O
DNA	O
binding	O
of	O
transcription	B-protein
factors	I-protein
PEA1	B-protein
(	O
AP1	B-protein
)	O
,	O
PEA3	B-protein
,	O
Oct-2	B-protein
or	O
NF-kB	B-protein

Comparative	O
analysis	O
of	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
complex	O
in	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	B-protein
)	O
is	O
a	O
transcriptional	B-protein
activator	I-protein
that	O
binds	O
to	O
sequences	O
in	O
the	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
and	O
is	O
thought	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
T	O
cell-specific	O
inducibility	O
of	O
IL-2	B-protein
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
showed	O
that	O
specific	O
NFAT	B-protein
binding	O
activity	O
could	O
also	O
be	O
induced	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
B	B-protein
cell	I-protein
NFAT	I-protein
complex	I-protein
,	O
however	O
,	O
was	O
not	O
functional	O
,	O
since	O
it	O
failed	O
to	O
activate	O
transcription	O
from	O
an	O
NFAT-driven	B-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
construct	I-DNA
.	O

Competition	O
with	O
an	O
AP-1	B-DNA
motif	I-DNA
or	O
with	O
anti-Jun	B-protein
and	O
anti-Fos	B-protein
antibodies	I-protein
abolished	O
binding	O
to	O
the	O
NFAT	B-DNA
motif	I-DNA
in	O
both	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
indicating	O
that	O
Jun	O
and	O
Fos	O
are	O
critical	O
for	O
NFAT	B-protein
complex	I-protein
formation	O
in	O
both	O
cell	O
types	O
.	O

Purified	O
recombinant	O
Jun	B-protein
and	I-protein
Fos	I-protein
proteins	I-protein
failed	O
to	O
bind	O
directly	O
to	O
the	O
NFAT	B-DNA
motif	I-DNA
.	O

However	O
,	O
when	O
combined	O
with	O
unstimulated	O
B	O
or	O
T	O
cell	O
extracts	O
,	O
full-length	O
,	O
but	O
not	O
truncated	O
,	O
Jun/Fos	O
heterodimers	O
were	O
able	O
to	O
form	O
an	O
NFAT	B-protein
complex	I-protein
,	O
indicating	O
the	O
presence	O
of	O
a	O
constitutively	B-protein
expressed	I-protein
nuclear	I-protein
factor	I-protein
(	O
s	O
)	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
necessary	O
for	O
the	O
formation	O
of	O
the	O
NFAT	B-protein
complex	I-protein
in	O
both	O
cell	O
types	O
.	O

An	O
NFAT	B-protein
oligonucleotide	O
carrying	O
mutations	O
in	O
the	O
5	B-DNA
'	I-DNA
purine-rich	I-DNA
part	I-DNA
of	O
the	O
NFAT	B-DNA
sequence	I-DNA
failed	O
to	O
form	O
a	O
complex	O
and	O
to	O
compete	O
with	O
the	O
wild	O
type	O
motif	O
for	O
NFAT	B-protein
complex	I-protein
formation	O
in	O
both	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

We	O
therefore	O
propose	O
a	O
model	O
whereby	O
a	O
core	O
NFAT	B-protein
complex	I-protein
consisting	O
of	O
Jun	B-protein
,	O
Fos	B-protein
,	O
and	O
a	O
constitutive	B-protein
nuclear	I-protein
factor	I-protein
is	O
formed	O
in	O
both	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
an	O
additional	O
factor	O
and/or	O
post-translational	O
modification	O
of	O
a	O
factor	O
,	O
missing	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
might	O
be	O
required	O
for	O
transactivation	O
by	O
NFAT	B-protein
.	O

Differential	O
autoregulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
in	O
human	B-cell_line
T-	I-cell_line
and	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
.	O

Regulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	O
)	O
expression	O
by	O
its	O
cognate	O
ligand	O
was	O
examined	O
in	O
the	O
glucocorticoid-sensitive	B-cell_line
human	I-cell_line
leukemic	I-cell_line
T-cell	I-cell_line
line	I-cell_line
6TG1.1	I-cell_line
and	O
in	O
the	O
human	B-cell_line
B-cell	I-cell_line
line	I-cell_line
IM-9	I-cell_line
.	O

In	O
contrast	O
to	O
the	O
decrease	O
in	O
GR	B-RNA
mRNA	I-RNA
seen	O
in	O
IM-9	B-cell_line
cells	I-cell_line
after	O
treatment	O
with	O
1	O
microM	O
dexamethasone	O
for	O
16-18	O
h	O
,	O
treatment	O
of	O
6TG1.1	B-cell_line
cells	I-cell_line
resulted	O
in	O
an	O
8-fold	O
increase	O
in	O
GR	B-RNA
mRNA	I-RNA
,	O
as	O
determined	O
by	O
Northern	O
blot	O
and	O
RNase	B-protein
protection	O
analysis	O
,	O
with	O
a	O
corresponding	O
3-	O
to	O
4-fold	O
increase	O
in	O
GR	B-protein
protein	I-protein
.	O

Half-maximal	O
induction	O
of	O
GR	B-RNA
mRNA	I-RNA
and	O
protein	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
was	O
observed	O
between	O
10-100	O
nM	O
dexamethasone	O
,	O
and	O
inclusion	O
of	O
1	O
microM	O
RU	O
38486	O
completely	O
blocked	O
the	O
effects	O
of	O
100	O
nM	O
dexamethasone	O
,	O
demonstrating	O
that	O
positive	O
autoregulation	O
of	O
GR	B-protein
expression	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
is	O
a	O
receptor-mediated	O
response	O
.	O

Positive	O
autoregulation	O
of	O
GR	B-protein
expression	O
was	O
also	O
observed	O
in	O
glucocorticoid-resistant	B-cell_line
CEM-C1	I-cell_line
cells	I-cell_line
,	O
which	O
contain	O
functional	O
GR	B-protein
,	O
but	O
whose	O
growth	O
is	O
unaffected	O
by	O
glucocorticoids	O
.	O

Thus	O
,	O
positive	O
autoregulation	O
is	O
neither	O
a	O
consequence	O
nor	O
the	O
sole	O
cause	O
of	O
growth	O
arrest	O
.	O

The	O
degree	O
of	O
negative	O
autoregulation	O
in	O
IM-9	B-cell_line
cells	I-cell_line
and	O
positive	O
autoregulation	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
was	O
unaffected	O
by	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
.	O

Measurement	O
of	O
GR	B-RNA
mRNA	I-RNA
turnover	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
treated	O
with	O
actinomycin-D	O
revealed	O
a	O
half-life	O
of	O
2.5	O
h	O
,	O
which	O
was	O
unaffected	O
by	O
dexamethasone	O
treatment	O
.	O

A	O
similar	O
half-life	O
was	O
determined	O
in	O
IM-9	B-cell_line
cells	I-cell_line
and	O
was	O
also	O
unaffected	O
by	O
steroid	O
treatment	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
glucocorticoid-mediated	O
autoregulation	O
of	O
GR	O
expression	O
is	O
a	O
tissue-specific	O
primary	O
transcriptional	O
response	O
.	O

Induction	O
of	O
CD8	B-protein
antigen	I-protein
and	O
suppressor	O
activity	O
by	O
glucocorticoids	O
in	O
a	O
CEM	B-cell_line
human	I-cell_line
leukemic	I-cell_line
cell	I-cell_line
clone	I-cell_line
.	O

The	O
relationship	O
between	O
glucocorticoid	O
effect	O
and	O
regulation	O
of	O
cell	B-protein
surface	I-protein
antigens	I-protein
was	O
investigated	O
in	O
two	O
models	O
of	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
CEM	B-cell_line
C7	I-cell_line
denoted	O
(	O
r+	O
,	O
ly+	O
)	O
and	O
CEM	B-cell_line
C1	I-cell_line
(	O
r+	O
,	O
ly-	O
)	O
.	O

The	O
reactivity	O
of	O
murine	B-protein
monoclonal	I-protein
antibodies	I-protein
,	O
anti-CD4-FITC	B-protein
,	O
anti-CD8-FITC	B-protein
,	O
anti-CD2-FITC	B-protein
and	O
anti-calla-FITC	B-protein
,	O
were	O
analyzed	O
using	O
flow	O
cytometry	O
.	O

The	O
suppressor	O
function	O
was	O
determined	O
using	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
into	O
phytohemagglutinin-activated	B-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
.	O

Dexamethasone	O
treatment	O
of	O
a	O
human	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
clone	I-cell_line
CEM	I-cell_line
C7	I-cell_line
caused	O
an	O
increase	O
in	O
a	O
subset	O
of	O
cells	O
expressing	O
the	O
surface	B-protein
antigen	I-protein
CD8	I-protein
,	O
which	O
is	O
present	O
on	O
suppressor	O
and	O
cytotoxic	B-cell_type
T-lymphocytes	I-cell_type
.	O

By	O
comparison	O
,	O
there	O
was	O
no	O
modification	O
of	O
the	O
expression	O
of	O
CD4	B-protein
antigen	I-protein
,	O
which	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
these	O
cells	O
.	O

After	O
two	O
days	O
of	O
treatment	O
with	O
5	O
x	O
10	O
(	O
-8	O
)	O
M	O
dexamethasone	O
,	O
CEM	B-cell_line
C7	I-cell_line
cells	I-cell_line
showed	O
a	O
two-fold	O
increase	O
in	O
suppressor	O
activity	O
compared	O
to	O
untreated	O
cells	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
regulation	O
by	O
glucocorticoids	O
of	O
either	O
the	O
CD8	B-protein
or	O
CD4	B-protein
antigens	I-protein
in	O
the	O
leukemic	B-cell_line
clone	I-cell_line
CEM	I-cell_line
C1	I-cell_line
.	O

Furthermore	O
,	O
no	O
modification	O
of	O
the	O
suppressor	O
function	O
in	O
CEM	B-cell_line
C1	I-cell_line
cells	I-cell_line
by	O
dexamethasone	O
was	O
observed	O
.	O

In	O
the	O
human	O
leukemic	O
cells	O
studied	O
here	O
,	O
the	O
ability	O
to	O
induce	O
CD8	B-protein
antigen	I-protein
expression	O
in	O
a	O
CD4+	B-cell_line
cells	I-cell_line
correlates	O
with	O
the	O
ability	O
to	O
induce	O
cell	O
lysis	O
in	O
a	O
glucocorticoid	B-cell_line
receptor	I-cell_line
positive	I-cell_line
cell	I-cell_line
population	I-cell_line
.	O

Adenovirus	O
E1A	O
inhibits	O
IFN	B-protein
-induced	O
resistance	O
to	O
cytolysis	O
by	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

Infection	O
of	O
target	B-cell_type
cells	I-cell_type
with	O
cytopathic	O
viruses	O
inhibits	O
IFN	B-protein
induction	O
of	O
cytolytic	O
resistance	O
to	O
NK	O
cell-mediated	O
cytolysis	O
[	O
IFN	B-protein
-mediated	O
cytoprotection	O
(	O
IFN	B-protein
-MCP	O
)	O
]	O
.	O

It	O
has	O
been	O
thought	O
that	O
the	O
virally	O
induced	O
inhibition	O
of	O
IFN	B-protein
-MCP	O
is	O
secondary	O
to	O
the	O
shutdown	O
of	O
cellular	O
macromolecular	O
synthesis	O
that	O
accompanies	O
cytopathic	O
virus	O
infections	O
.	O

Group	O
C	O
,	O
adenovirus	O
serotype	O
5	O
(	O
Ad5	O
)	O
infection	O
inhibits	O
both	O
IFN	B-protein
-MCP	O
and	O
cellular	B-protein
protein	I-protein
synthesis	O
.	O

This	O
study	O
determined	O
if	O
the	O
Ad5-induced	O
inhibition	O
of	O
IFN	B-protein
-MCP	O
was	O
independent	O
of	O
adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
secondary	O
only	O
to	O
the	O
expression	O
of	O
the	O
Ad	B-DNA
early	I-DNA
region	I-DNA
1A	I-DNA
gene	I-DNA
(	O
E1A	B-DNA
)	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
4-h	O
NK	O
cytolysis	O
assays	O
were	O
performed	O
on	O
IFN-gamma-treated	B-cell_line
human	I-cell_line
cells	I-cell_line
infected	O
with	O
an	O
Ad5	O
E1A	B-DNA
deletion	O
mutant	O
,	O
dl343	O
,	O
or	O
transfected	O
with	O
the	O
Ad5	B-DNA
E1A	I-DNA
gene	I-DNA
.	O

IFN	B-protein
-MCP	O
was	O
not	O
inhibited	O
by	O
infection	O
with	O
dl343	O
,	O
despite	O
the	O
production	O
of	O
large	O
amounts	O
of	O
both	O
early	O
(	O
E1B	B-protein
,	O
p55	B-protein
)	O
and	O
late	O
(	O
hexon	B-protein
)	O
Ad	B-protein
proteins	I-protein
.	O

In	O
contrast	O
to	O
E1A-negative	B-cell_line
,	I-cell_line
parental	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
IFN	B-protein
-MCP	O
was	O
blocked	O
in	O
Ad5	O
E1A-transfected	B-cell_line
epithelial	I-cell_line
and	O
fibroblastic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Genetic	O
mapping	O
studies	O
within	O
the	O
E1A	B-DNA
gene	I-DNA
demonstrated	O
that	O
expression	O
of	O
only	O
the	O
first	O
exon	O
of	O
E1A	B-DNA
was	O
sufficient	O
to	O
inhibit	O
IFN	B-protein
-MCP	O
.	O

DNA	O
sequence	O
homology	O
of	O
E1A	B-DNA
genes	O
between	O
different	O
Ad	O
groups	O
(	O
group	O
A	O
,	O
Ad12	O
;	O
group	O
C	O
,	O
Ad5	O
)	O
is	O
limited	O
almost	O
entirely	O
to	O
three	O
conserved	O
regions	O
located	O
within	O
the	O
first	O
exon	O
of	O
E1A	B-DNA
.	O

Because	O
IFN	B-protein
-MCP	O
was	O
also	O
blocked	O
in	O
Ad12	B-cell_line
E1A-transfected	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
expression	O
of	O
one	O
or	O
more	O
of	O
the	O
E1A-conserved	B-DNA
regions	I-DNA
may	O
be	O
necessary	O
to	O
inhibit	O
IFN	B-protein
-MCP	O
.	O

In	O
summary	O
,	O
the	O
expression	O
of	O
E1A	B-protein
gene	I-protein
products	I-protein
inhibited	O
IFN	B-protein
-MCP	O
independently	O
of	O
virus	O
infection	O
.	O

E1A	B-DNA
's	O
inhibition	O
of	O
IFN	B-protein
-MCP	O
has	O
the	O
net	O
effect	O
of	O
promoting	O
the	O
selective	O
NK	O
cell-mediated	O
clearance	O
of	O
Ad-infected	O
or	O
Ad-transformed	B-cell_line
human	I-cell_line
cells	I-cell_line
.	O

A	O
protein	O
of	O
the	O
AP-1	B-protein
family	I-protein
is	O
a	O
component	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O

Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
is	O
a	O
transcriptional	B-protein
activator	I-protein
involved	O
in	O
the	O
induction	O
of	O
IL-2	B-protein
gene	O
expression	O
.	O

The	O
response	O
element	O
for	O
NF-AT	B-protein
is	O
a	O
sequence	O
localized	O
between	O
-285/-254	B-DNA
in	O
the	O
IL-2	B-DNA
regulatory	I-DNA
region	I-DNA
.	O

The	O
composition	O
of	O
NF-AT	B-protein
protein	O
is	O
still	O
not	O
fully	O
elucidated	O
.	O

We	O
demonstrate	O
that	O
,	O
in	O
normal	O
human	O
T	B-cell_type
cells	I-cell_type
,	O
an	O
AP-1	B-protein
protein	I-protein
is	O
a	O
component	O
of	O
the	O
NF-AT	B-protein
protein	I-protein
complex	I-protein
.	O

This	O
was	O
evidenced	O
by	O
the	O
ability	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
to	O
compete	O
with	O
the	O
NF-AT	B-protein
site	O
for	O
binding	O
to	O
NF-AT	B-protein
and	O
by	O
the	O
capacity	O
of	O
immobilized	B-protein
anti-Jun	I-protein
and	O
anti-Fos	B-protein
antibodies	O
to	O
deplete	O
NF-AT	B-protein
-binding	O
activity	O
from	O
nuclear	O
extracts	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

There	O
was	O
no	O
detectable	O
binding	O
of	O
in	O
vitro	O
translated	O
Jun/Fos	B-protein
heterodimer	I-protein
(	O
AP-1	B-protein
)	O
to	O
the	O
NF-AT	B-protein
sequence	O
,	O
and	O
the	O
NF-AT	B-DNA
sequence	I-DNA
was	O
unable	O
to	O
inhibit	O
the	O
binding	O
of	O
Jun/Fos	B-protein
to	O
the	O
AP-1	B-DNA
sequence	I-DNA
.	O

The	O
presence	O
of	O
an	O
AP-1	B-protein
protein	O
in	O
the	O
NF-AT	B-protein
protein	O
complex	O
may	O
regulate	O
NF-AT	B-protein
-binding	O
activity	O
through	O
protein-protein	O
interaction	O
.	O

Interaction	O
between	O
NF-kappa	B-protein
B	I-protein
-and	O
serum	B-protein
response	I-protein
factor	I-protein
-binding	O
elements	O
activates	O
an	O
interleukin-2	B-DNA
receptor	I-DNA
alpha-chain	I-DNA
enhancer	I-DNA
specifically	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
find	O
that	O
a	O
short	O
enhancer	O
element	O
containing	O
the	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
from	O
the	O
interleukin-2	B-DNA
receptor	I-DNA
alpha-chain	I-DNA
gene	I-DNA
(	O
IL-2R	B-protein
alpha	I-protein
)	O
is	O
preferentially	O
activated	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
IL-2R	B-protein
alpha	I-protein
enhancer	O
binds	O
NF-kappa	B-protein
B	I-protein
poorly	O
and	O
is	O
only	O
weakly	O
activated	O
by	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
alone	O
.	O

Serum	B-protein
response	I-protein
factor	I-protein
(	O
SRF	B-protein
)	O
binds	O
to	O
a	O
site	O
adjacent	O
to	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
in	O
the	O
IL-2R	B-DNA
enhancer	I-DNA
,	O
and	O
both	O
sites	O
together	O
have	O
strong	O
transcriptional	O
activity	O
specifically	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Surprisingly	O
,	O
the	O
levels	O
of	O
SRF	B-protein
constitutively	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
are	O
consistently	O
higher	O
than	O
in	O
other	O
cell	O
types	O
.	O

Overexpression	O
of	O
SRF	B-protein
in	O
B	B-cell_type
cells	I-cell_type
causes	O
the	O
IL-2R	B-DNA
enhancer	I-DNA
to	O
function	O
as	O
well	O
as	O
it	O
does	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
the	O
high	O
level	O
of	O
SRF	B-protein
binding	O
in	O
T	B-cell_type
cells	I-cell_type
is	O
functionally	O
important	O
.	O

Mutual	O
regulation	O
of	O
the	O
transcriptional	B-protein
activator	I-protein
NF-kappa	B-protein
B	I-protein
and	O
its	O
inhibitor	O
,	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
.	O

The	O
NK-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
is	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
the	O
inhibitory	O
protein	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
(	O
MAD-3	B-protein
)	O
.	O

Various	O
cellular	O
stimuli	O
relieve	O
this	O
inhibition	O
by	O
mechanisms	O
largely	O
unknown	O
,	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
nuclear	O
localization	O
and	O
transactivation	O
of	O
its	O
target	O
genes	O
.	O

It	O
is	O
demonstrated	O
here	O
with	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
monocytes	B-cell_type
that	O
different	O
stimuli	O
,	O
including	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
cause	O
rapid	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
,	O
with	O
concomitant	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
followed	O
by	O
a	O
dramatic	O
increase	O
in	O
I	B-RNA
kappa	I-RNA
B-alpha	I-RNA
mRNA	I-RNA
and	O
protein	O
synthesis	O
.	O

Transfection	O
studies	O
reveal	O
that	O
the	O
I	B-RNA
kappa	I-RNA
B-alpha	I-RNA
mRNA	I-RNA
and	O
the	O
encoded	O
protein	O
are	O
potently	O
induced	O
by	O
NF-kappa	B-protein
B	I-protein
and	O
by	O
homodimers	O
of	O
p65	B-protein
and	O
of	O
c-Rel	B-protein
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
NF-kappa	B-protein
B	I-protein
and	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
mutually	O
regulate	O
each	O
other	O
in	O
a	O
cycle	O
:	O
saturating	O
amounts	O
of	O
the	O
inhibitory	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
protein	O
are	O
destroyed	O
upon	O
stimulation	O
,	O
allowing	O
rapid	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Subsequently	O
,	O
I	B-RNA
kappa	I-RNA
B-alpha	I-RNA
mRNA	I-RNA
and	O
protein	O
levels	O
are	O
quickly	O
induced	O
by	O
the	O
activated	O
NF-kappa	B-protein
B	I-protein
.	O

This	O
resurgence	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
protein	O
acts	O
to	O
restore	O
an	O
equilibrium	O
in	O
which	O
NF-kappa	B-protein
B	I-protein
is	O
again	O
inhibited	O
.	O

Replication	O
of	O
type	O
1	O
human	O
immunodeficiency	O
viruses	O
containing	O
linker	O
substitution	O
mutations	O
in	O
the	O
-201	B-DNA
to	I-DNA
-130	I-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O

In	O
previous	O
transfection	O
analyses	O
using	O
the	O
chloramphenicol	B-protein
acetyltransferase	I-protein
reporter	B-DNA
gene	I-DNA
system	O
,	O
we	O
determined	O
that	O
linker	O
substitution	O
(	O
LS	O
)	O
mutations	O
between	O
-201	B-DNA
and	I-DNA
-130	I-DNA
(	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
caused	O
moderate	O
decreases	O
in	O
LTR	B-DNA
transcriptional	O
activity	O
in	O
a	O
T-cell	B-cell_line
line	I-cell_line
(	O
S.L.Zeichner	O
,	O
J.Y.H.	O
Kim	O
,	O
and	O
J.C.Alwine	O
,	O
J.Virol.65	O
:	O
2436-2444	O
,	O
1991	O
)	O
.	O

In	O
order	O
to	O
confirm	O
the	O
significance	O
of	O
this	O
region	O
in	O
the	O
context	O
of	O
viral	O
replication	O
,	O
we	O
constructed	O
several	O
of	O
these	O
LS	O
mutations	O
(	O
-201	B-DNA
to	I-DNA
-	I-DNA
184	I-DNA
,	O
-183	B-DNA
to	I-DNA
-166	I-DNA
,	O
-165	B-DNA
to	I-DNA
-148	I-DNA
,	O
and	O
-148	B-DNA
to	I-DNA
-130	I-DNA
)	O
in	O
proviruses	O
and	O
prepared	O
viral	O
stocks	O
by	O
cocultivation	O
of	O
transfected	B-cell_line
RD	I-cell_line
cells	I-cell_line
with	O
CEMx174	B-cell_line
cells	I-cell_line
.	O

In	O
addition	O
,	O
two	O
mutations	O
between	O
-93	B-DNA
and	I-DNA
-76	I-DNA
and	O
between	O
-75	B-DNA
and	I-DNA
-58	I-DNA
were	O
utilized	O
,	O
since	O
they	O
affect	O
the	O
nuclear	B-DNA
factor	I-DNA
kappa	I-DNA
B	I-DNA
(	I-DNA
NF-kappa	I-DNA
B	I-DNA
)	I-DNA
-	I-DNA
and	I-DNA
Sp1-binding	I-DNA
sites	I-DNA
and	O
were	O
expected	O
to	O
diminish	O
viral	O
replication	O
.	O

Our	O
results	O
suggest	O
that	O
while	O
transfection	O
analyses	O
offer	O
an	O
adequate	O
approximation	O
of	O
the	O
effects	O
of	O
the	O
LS	O
mutations	O
,	O
the	O
analysis	O
of	O
viral	O
replication	O
using	O
a	O
mutant	O
viral	O
stock	O
presents	O
a	O
more	O
accurate	O
picture	O
,	O
which	O
is	O
sometimes	O
at	O
variance	O
with	O
the	O
transfection	O
results	O
.	O

Three	O
mutants	O
(	O
-201/-184	O
NXS	O
,	O
-165/-148	O
NXS	O
,	O
and	O
-147/-130	O
NXS	O
)	O
had	O
effects	O
on	O
viral	O
replication	O
that	O
were	O
much	O
more	O
severe	O
than	O
the	O
effects	O
predicted	O
from	O
their	O
performance	O
in	O
transfection	O
analyses	O
,	O
and	O
the	O
effects	O
of	O
two	O
LS	O
mutations	O
(	O
-201/-184	O
NXS	O
and	O
-183/-166	O
NXS	O
)	O
were	O
not	O
predicted	O
by	O
their	O
effects	O
in	O
transfection	O
.	O

In	O
addition	O
,	O
we	O
observed	O
cell	O
type-specific	O
permissiveness	O
to	O
replication	O
of	O
some	O
mutant	O
viruses	O
.	O

In	O
the	O
cell	O
types	O
tested	O
,	O
the	O
LS	O
mutations	O
indicated	O
an	O
apparent	O
requirement	O
not	O
only	O
for	O
the	O
intact	O
NF-kappa	B-protein
B	I-protein
and	O
SP1-binding	B-DNA
sites	I-DNA
but	O
also	O
for	O
several	O
regions	O
between	O
-201	B-DNA
and	I-DNA
-130	I-DNA
not	O
previously	O
associated	O
with	O
viral	O
infectivity	O
.	O

Transcription	B-protein
factor	I-protein
GATA-1	B-protein
and	O
erythroid	O
development	O
.	O

In	O
summary	O
,	O
we	O
derived	O
an	O
experimental	O
system	O
that	O
allows	O
us	O
to	O
dissect	O
the	O
function	O
of	O
GATA-1	B-protein
in	O
red	B-cell_type
cell	I-cell_type
development	O
at	O
a	O
genetic	O
level	O
.	O

We	O
have	O
established	O
the	O
essential	O
nature	O
of	O
GATA-1	B-protein
during	O
both	O
primitive	O
and	O
definitive	O
erythropoiesis	O
.	O

By	O
ablating	O
the	O
expression	O
of	O
the	O
endogenous	O
GATA-1	B-DNA
gene	I-DNA
,	O
we	O
are	O
in	O
a	O
position	O
to	O
introduce	O
a	O
variety	O
of	O
constructs	O
that	O
harbor	O
subtle	O
modifications	O
in	O
flanking	O
or	O
protein-coding	B-DNA
sequences	I-DNA
.	O

We	O
can	O
now	O
study	O
regulatory	O
regions	O
and	O
functional	O
domains	O
of	O
the	O
protein	O
in	O
the	O
context	O
of	O
a	O
true	O
erythroid	O
environment	O
,	O
experiments	O
that	O
have	O
not	O
been	O
possible	O
heretofore	O
.	O

Although	O
the	O
assay	O
involves	O
the	O
dramatic	O
loss	O
of	O
red	O
cell	O
production	O
,	O
it	O
should	O
be	O
possible	O
to	O
define	O
important	O
regulatory	O
domains	O
that	O
can	O
then	O
be	O
assayed	O
using	O
less	O
stringent	O
systems	O
,	O
such	O
as	O
cell-free	O
extracts	O
for	O
in	O
vitro	O
transcription	O
.	O

The	O
ideal	O
situation	O
would	O
be	O
analyses	O
conducted	O
in	O
GATA-1	B-cell_line
-erythroid	I-cell_line
cells	I-cell_line
.	O

However	O
,	O
these	O
cells	O
have	O
been	O
impossible	O
to	O
generate	O
given	O
the	O
requirement	O
of	O
GATA-1	B-protein
for	O
Epo	B-protein
receptor	I-protein
expression	O
and	O
red	B-cell_type
cell	I-cell_type
viability	O
(	O
C.	O
Simon	O
and	O
S.	O
Orkin	O
,	O
unpublished	O
observations	O
)	O
.	O

It	O
may	O
be	O
possible	O
to	O
produce	O
such	O
cells	O
by	O
first	O
expressing	O
the	O
Epo	B-protein
receptor	I-protein
under	O
the	O
influence	O
of	O
a	O
constitutive	O
promoter	O
and	O
then	O
targeting	O
the	O
GATA-1	B-DNA
gene	I-DNA
.	O

If	O
GATA-1	B-cell_line
-red	I-cell_line
cells	I-cell_line
were	O
available	O
,	O
the	O
analyses	O
would	O
involve	O
the	O
actual	O
transcription	O
of	O
or	O
chromatin	O
structure	O
surrounding	O
the	O
globin	B-DNA
genes	I-DNA
.	O

Structure-function	O
studies	O
of	O
the	O
GATA-1	B-protein
protein	O
could	O
be	O
greatly	O
simplified	O
and	O
a	O
larger	O
number	O
of	O
mutants	O
studied	O
.	O

However	O
,	O
the	O
ES	O
cell	O
system	O
can	O
be	O
used	O
as	O
an	O
alternative	O
until	O
targeted	B-cell_line
erythroleukemia	I-cell_line
cells	I-cell_line
become	O
available	O
.	O

Other	O
applications	O
involve	O
the	O
introduction	O
of	O
other	O
GATA-binding	B-protein
protein	I-protein
family	I-protein
members	I-protein
to	O
determine	O
whether	O
they	O
rescue	O
the	O
mutation	O
.	O

If	O
they	O
can	O
not	O
,	O
chimeric	B-protein
proteins	I-protein
can	O
be	O
tested	O
to	O
identify	O
which	O
amino	O
acids	O
distinguish	O
the	O
different	O
family	O
members	O
.	O

We	O
feel	O
that	O
these	O
experiments	O
are	O
vital	O
to	O
understanding	O
the	O
function	O
of	O
GATA-1	B-protein
during	O
erythroid	O
ontogeny	O
.	O

How	O
does	O
GATA-1	B-protein
regulate	O
red	B-DNA
cell	I-DNA
genes	I-DNA
like	O
globin	B-DNA
or	O
the	O
Epo	B-protein
receptor	I-protein
?	O
Once	O
we	O
identify	O
the	O
functional	O
domains	O
of	O
the	O
GATA-binding	B-protein
proteins	I-protein
,	O
we	O
hope	O
to	O
learn	O
what	O
proteins	O
GATA-1	B-protein
binds	O
to	O
in	O
the	O
basic	O
transcription	O
machinery	O
or	O
in	O
chromatin	O
.	O

Is	O
GATA-1	B-protein
necessary	O
for	O
globin	O
gene	O
switching	O
?	O
GATA-1	B-protein
may	O
be	O
modified	O
differently	O
during	O
development	O
so	O
that	O
the	O
locus	O
control	O
region	O
can	O
interact	O
with	O
different	O
globin	B-DNA
promoters	I-DNA
.	O

We	O
may	O
find	O
that	O
one	O
region	O
of	O
the	O
protein	O
is	O
required	O
for	O
embryonic	O
expression	O
and	O
another	O
for	O
adult	O
globin	B-DNA
gene	I-DNA
expression	O
.	O

A	O
human	B-DNA
putative	I-DNA
lymphocyte	I-DNA
G0/G1	I-DNA
switch	I-DNA
gene	I-DNA
homologous	O
to	O
a	O
rodent	B-DNA
gene	I-DNA
encoding	O
a	O
zinc-binding	B-protein
potential	I-protein
transcription	I-protein
factor	I-protein
.	O

G0S24	B-DNA
is	O
a	O
member	O
of	O
a	O
set	O
of	O
genes	O
(	O
putative	B-DNA
G0/G1	I-DNA
switch	I-DNA
regulatory	I-DNA
genes	I-DNA
)	O
that	O
are	O
expressed	O
transiently	O
within	O
1-2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	B-protein
or	O
cycloheximide	O
to	O
human	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Comparison	O
of	O
a	O
full-length	B-DNA
cDNA	I-DNA
sequence	I-DNA
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
of	O
326	O
amino	O
acids	O
,	O
distributed	O
across	O
two	O
exons	B-DNA
.	O

Potential	O
phosphorylation	B-protein
sites	I-protein
include	O
the	O
sequence	O
PSPTSPT	B-protein
,	O
which	O
resembles	O
an	O
RNA	B-protein
polymerase	I-protein
II	I-protein
repeat	I-protein
reported	O
to	O
be	O
a	O
target	O
of	O
the	O
cell	B-protein
cycle	I-protein
control	I-protein
kinase	I-protein
cdc2	I-protein
.	O

Comparison	O
of	O
the	O
derived	O
protein	O
sequence	O
with	O
those	O
of	O
rodent	O
homologs	O
allows	O
classification	O
into	O
three	O
groups	O
.	O

Group	O
1	O
contains	O
G0S24	B-DNA
and	O
the	O
rat	B-DNA
and	I-DNA
mouse	I-DNA
TIS11	I-DNA
genes	I-DNA
(	O
also	O
known	O
as	O
TTP	B-DNA
,	O
Nup475	B-DNA
,	O
and	O
Zfp36	B-DNA
)	O
.	O

Members	O
of	O
this	O
group	O
have	O
three	B-protein
tetraproline	I-protein
repeats	I-protein
.	O

Groups	O
1	O
and	O
2	O
have	O
a	O
serine-rich	B-protein
region	I-protein
and	O
an	O
``	O
arginine	B-protein
element	I-protein
``	O
(	O
RRLPIF	B-protein
)	O
at	O
the	O
carboxyl	B-protein
terminus	I-protein
.	O

All	O
groups	O
contain	O
cysteine-	B-protein
and	I-protein
histidine-rich	I-protein
putative	I-protein
zinc	I-protein
finger	I-protein
domains	I-protein
and	O
a	O
serine-phenylalanine	B-protein
``	I-protein
SFS	I-protein
''	I-protein
domain	I-protein
similar	O
to	O
part	O
of	O
the	O
large	O
subunit	O
of	O
eukaryotic	B-protein
RNA	I-protein
polymerase	I-protein
II	I-protein
.	O

Comparison	O
of	O
group	O
1	O
human	B-DNA
and	I-DNA
mouse	I-DNA
genomic	I-DNA
sequences	I-DNA
shows	O
high	O
conservation	O
in	O
the	O
5	B-DNA
'	I-DNA
flank	I-DNA
and	O
exons	B-DNA
.	O

A	O
CpG	O
island	O
suggests	O
expression	O
in	O
the	O
germ	O
line	O
.	O

G0S24	B-DNA
has	O
potential	O
sites	O
for	O
transcription	B-protein
factors	I-protein
in	O
the	O
5	B-DNA
'	I-DNA
flank	I-DNA
and	O
intron	B-DNA
;	O
these	O
include	O
a	O
serum	B-DNA
response	I-DNA
element	I-DNA
.	O

Protein	O
and	O
genomic	O
sequences	O
show	O
similarities	O
with	O
those	O
of	O
a	O
variety	O
of	O
proteins	O
involved	O
in	O
transcription	O
,	O
suggesting	O
that	O
the	O
G0S24	B-protein
product	I-protein
has	O
a	O
similar	O
role	O
.	O

Regulation	O
of	O
lymphoid-specific	B-DNA
immunoglobulin	I-DNA
mu	I-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
enhancer	I-DNA
by	O
ETS-domain	O
proteins	O
.	O

The	O
enhancer	B-DNA
for	O
the	O
immunoglobulin	B-DNA
mu	I-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
(	O
IgH	B-protein
)	O
activates	O
a	O
heterologous	B-DNA
gene	I-DNA
at	O
the	O
pre-B	O
cell	O
stage	O
of	O
B	B-cell_type
lymphocyte	I-cell_type
differentiation	O
.	O

A	O
lymphoid-specific	B-DNA
element	I-DNA
,	O
microB	B-DNA
,	O
is	O
necessary	O
for	O
enhancer	B-DNA
function	O
in	O
pre-B	B-cell_type
cells	I-cell_type
.	O

A	O
microB	B-protein
binding	I-protein
protein	I-protein
is	O
encoded	O
by	O
the	O
PU.1/Spi-1	B-DNA
proto-oncogene	I-DNA
.	O

Another	O
sequence	B-DNA
element	I-DNA
,	O
microA	B-DNA
,	O
was	O
identified	O
in	O
the	O
mu	B-DNA
enhancer	I-DNA
that	O
binds	O
the	O
product	O
of	O
the	O
ets-1	B-DNA
proto-oncogene	I-DNA
.	O

The	O
microA	B-DNA
motif	O
was	O
required	O
for	O
microB-dependent	B-DNA
enhancer	I-DNA
activity	O
,	O
which	O
suggests	O
that	O
a	O
minimal	B-DNA
B	I-DNA
cell-specific	I-DNA
enhancer	I-DNA
is	O
composed	O
of	O
both	O
the	O
PU.1	B-DNA
and	I-DNA
Ets-1	I-DNA
binding	I-DNA
sites	I-DNA
.	O

Co-expression	O
of	O
both	O
PU.1	B-protein
and	O
Ets-1	B-protein
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
trans-activated	B-DNA
reporter	I-DNA
plasmids	I-DNA
that	O
contained	O
the	O
minimal	O
mu	B-DNA
enhancer	I-DNA
.	O

These	O
results	O
implicate	O
two	O
members	O
of	O
the	O
Ets	B-protein
family	I-protein
in	O
the	O
activation	O
of	O
IgH	B-DNA
gene	I-DNA
expression	O
.	O

1	O
,	O
25-Dihydroxy	O
vitamin	O
D3	O
and	O
12-O-tetradecanoyl	O
phorbol-13-acetate	O
synergistically	O
induce	O
monocytic	B-cell_type
cell	I-cell_type
differentiation	O
:	O
FOS	B-protein
and	O
RB	B-protein
expression	O
.	O

1	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
and	O
12-O-tetradecanoyl	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
interact	O
synergistically	O
to	O
induce	O
monocytic	O
differentiation	O
of	O
U937	B-cell_line
histiocytic	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
.	O

Addition	O
of	O
TPA	O
causes	O
an	O
otherwise	O
ineffective	O
dose	O
of	O
1	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
to	O
induce	O
differentiation	O
.	O

The	O
induced	O
differentiation	O
depends	O
on	O
the	O
simultaneous	O
(	O
vs.	O
sequential	O
)	O
presence	O
of	O
both	O
agents	O
.	O

The	O
kinetics	O
of	O
induced	O
differentiation	O
are	O
consistent	O
with	O
a	O
G1	O
specific	O
cellular	O
response	O
to	O
initiate	O
the	O
metabolic	O
cascade	O
culminating	O
in	O
cell	O
differentiation	O
.	O

The	O
induced	O
differentiation	O
occurs	O
with	O
down-regulation	O
of	O
c-fos	B-protein
protein	I-protein
and	O
an	O
accompanying	O
up-regulation	O
of	O
RB	B-protein
protein	I-protein
expression	O
,	O
consistent	O
with	O
a	O
possible	O
need	O
for	O
up-regulated	O
RB	B-protein
expression	O
to	O
maintain	O
a	O
given	O
differentiated	O
phenotype	O
and	O
suppress	O
transcriptional	B-protein
activators	I-protein
that	O
might	O
typically	O
be	O
associated	O
with	O
proliferation	O
.	O

Ectopic	O
expression	O
of	O
a	O
conditional	O
GATA-2/estrogen	B-protein
receptor	I-protein
chimera	I-protein
arrests	O
erythroid	O
differentiation	O
in	O
a	O
hormone-dependent	O
manner	O
.	O

The	O
GATA	B-protein
factors	I-protein
are	O
a	O
family	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
in	O
eukaryotes	O
that	O
share	O
extensive	O
homology	O
in	O
their	O
DNA-binding	B-protein
domains	I-protein
.	O

One	O
enigmatic	O
aspect	O
of	O
GATA	B-protein
factor	I-protein
expression	O
is	O
that	O
several	O
GATA	B-protein
proteins	I-protein
,	O
which	O
ostensibly	O
share	O
the	O
same	O
DNA-binding	B-protein
site	I-protein
specificity	O
,	O
are	O
coexpressed	O
in	O
erythroid	O
cells	O
.	O

To	O
elucidate	O
the	O
roles	O
of	O
individual	O
GATA	B-protein
factors	I-protein
in	O
erythropoiesis	O
,	O
conditional	O
alleles	O
of	O
GATA-1	B-protein
,	O
GATA-2	B-protein
,	O
and	O
GATA-3	B-protein
were	O
prepared	O
by	O
fusing	O
each	O
of	O
the	O
factors	O
to	O
the	O
hormone-binding	B-protein
domain	I-protein
of	O
the	O
human	B-protein
estrogen	I-protein
receptor	I-protein
(	O
ER	B-protein
)	O
.	O

These	O
GATA/ER	B-protein
chimeric	I-protein
factors	I-protein
were	O
shown	O
to	O
be	O
hormone-inducible	B-protein
trans-activating	I-protein
proteins	I-protein
in	O
transient	O
transfection	O
assays	O
.	O

When	O
stably	O
introduced	O
into	O
primary	B-cell_type
erythroblasts	I-cell_type
or	O
conditionally	B-cell_line
transformed	I-cell_line
erythroid	I-cell_line
progenitors	I-cell_line
cells	I-cell_line
,	O
exogenous	O
GATA-2/ER	B-protein
promoted	O
proliferation	O
and	O
inhibited	O
terminal	O
differentiation	O
in	O
an	O
estrogen-dependent	O
manner	O
.	O

These	O
phenotypic	O
effects	O
are	O
specifically	O
attributable	O
to	O
the	O
action	O
of	O
ectopically	O
expressed	O
GATA-2/ER	B-protein
because	O
erythroblasts	O
expressing	O
exogenous	O
GATA-2	B-protein
are	O
constitutively	O
arrested	O
in	O
differentiation	O
and	O
because	O
erythroid	B-cell_line
progenitors	I-cell_line
expressing	O
either	O
Gal/ER	B-protein
or	O
GATA-3/ER	B-protein
do	O
not	O
display	O
a	O
hormone-responsive	O
block	O
in	O
differentiation	O
.	O

Thus	O
,	O
the	O
GATA-2	B-protein
transcription	I-protein
factor	I-protein
appears	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
self-renewal	O
capacity	O
of	O
early	B-cell_type
erythroid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

Mice	O
deficient	O
for	O
the	O
55	B-protein
kd	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
are	O
resistant	O
to	O
endotoxic	O
shock	O
,	O
yet	O
succumb	O
to	O
L.	O
monocytogenes	O
infection	O
.	O

The	O
multiple	O
biological	O
activities	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
are	O
mediated	O
by	O
two	O
distinct	O
cell	B-protein
surface	I-protein
receptors	I-protein
of	O
55	B-protein
kd	I-protein
(	O
TNFRp55	B-protein
)	O
and	O
75	B-protein
kd	I-protein
(	O
TNFRp75	B-protein
)	O
.	O

Using	O
gene	O
targeting	O
,	O
we	O
generated	O
a	O
TNFRp55	B-protein
-deficient	O
mouse	O
strain	O
.	O

Cells	O
from	O
TNFRp55-/-mutant	O
mice	O
lack	O
expression	O
of	O
TNFRp55	B-protein
but	O
display	O
normal	O
numbers	O
of	O
high	B-protein
affinity	I-protein
TNFRp75	I-protein
molecules	I-protein
.	O

Thymocyte	B-cell_type
development	O
and	O
lymphocyte	B-cell_type
populations	I-cell_type
are	O
unaltered	O
,	O
and	O
clonal	O
deletion	O
of	O
potentially	O
self-reactive	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
not	O
impaired	O
.	O

However	O
,	O
TNF	B-protein
signaling	O
is	O
largely	O
abolished	O
,	O
as	O
judged	O
by	O
the	O
failure	O
of	O
TNF	B-protein
to	O
induce	O
NF-kappa	B-protein
B	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
TNFRp55	B-protein
-deficient	O
mice	O
.	O

The	O
loss	O
of	O
TNFRp55	B-protein
function	O
renders	O
mice	O
resistant	O
to	O
lethal	O
dosages	O
of	O
either	O
lipopolysaccharides	O
or	O
S.	B-protein
aureus	I-protein
enterotoxin	I-protein
B	I-protein
.	O

In	O
contrast	O
,	O
TNFRp55-deficient	O
mice	O
are	O
severely	O
impaired	O
to	O
clear	O
L.	O
monocytogenes	O
and	O
readily	O
succumb	O
to	O
infection	O
.	O

Thus	O
,	O
the	O
55	B-protein
kd	I-protein
TNFR	I-protein
plays	O
a	O
decisive	O
role	O
in	O
the	O
host	O
's	O
defense	O
against	O
microorganisms	O
and	O
their	O
pathogenic	O
factors	O
.	O

Costimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cell	I-cell_type
activation	O
by	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

Enhanced	O
IL-2	B-protein
transcription	O
correlates	O
with	O
increased	O
c-fos	B-protein
synthesis	O
and	O
increased	O
Fos	B-protein
content	O
of	O
AP-1	B-protein
.	O

Endothelial	B-cell_type
cells	I-cell_type
(	O
EC	B-cell_type
)	O
act	O
as	O
APC	O
for	O
resting	B-cell_type
PBL	I-cell_type
in	O
vitro	O
,	O
and	O
may	O
have	O
important	O
roles	O
in	O
vivo	O
in	O
the	O
pathogenesis	O
of	O
allograft	O
rejection	O
and	O
delayed	O
hypersensitivity	O
.	O

We	O
previously	O
reported	O
that	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
EC	I-cell_type
provide	O
costimulatory	O
signals	O
to	O
PHA-stimulated	B-cell_type
PBL	I-cell_type
via	O
CD2	B-protein
:	I-protein
lymphocyte	I-protein
function-associated	I-protein
Ag-3	I-protein
and	O
an	O
unidentified	O
ligand	O
pair	O
,	O
resulting	O
in	O
a	O
three-	O
to	O
eight-fold	O
enhancement	O
of	O
IL-2	B-protein
production	O
.	O

The	O
physiologic	O
relevance	O
of	O
this	O
increase	O
was	O
demonstrated	O
by	O
the	O
proliferative	O
advantage	O
provided	O
by	O
EC	B-cell_type
to	O
PBL	B-cell_type
suboptimally	O
stimulated	O
with	O
mAb	B-protein
OKT3	I-protein
.	O

We	O
now	O
report	O
that	O
EC	B-cell_type
costimulation	O
causes	O
increased	O
levels	O
of	O
IL-2	B-RNA
mRNA	I-RNA
as	O
a	O
result	O
of	O
increased	O
IL-2	B-protein
transcription	O
in	O
PBL	B-cell_type
.	O

We	O
therefore	O
examined	O
the	O
effects	O
of	O
EC	B-cell_type
on	O
T	B-protein
cell	I-protein
nuclear	I-protein
factors	I-protein
known	O
to	O
regulate	O
IL-2	B-protein
transcription	O
,	O
including	O
c-jun	B-protein
and	O
c-fos-two	B-protein
components	I-protein
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
,	O
NFAT	B-protein
,	O
and	O
others	O
.	O

PBL	B-cell_type
constitutively	O
express	O
c-jun	B-protein
transcripts	I-protein
,	O
and	O
the	O
level	O
of	O
c-jun	B-RNA
mRNA	I-RNA
is	O
not	O
altered	O
by	O
PHA	B-protein
activation	O
in	O
the	O
absence	O
or	O
presence	O
of	O
EC	B-cell_type
.	O

In	O
contrast	O
,	O
c-fos	B-RNA
mRNA	I-RNA
is	O
absent	O
from	O
resting	O
T	B-cell_type
cells	I-cell_type
and	O
is	O
induced	O
on	O
PHA	B-protein
activation	O
.	O

EC	B-cell_type
alone	O
do	O
not	O
induce	O
c-fos	B-RNA
mRNA	I-RNA
but	O
augment	O
the	O
level	O
of	O
c-fos	B-RNA
mRNA	I-RNA
in	O
PHA-activated	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
3-	O
to	O
10-fold	O
.	O

This	O
effect	O
is	O
largely	O
independent	O
of	O
the	O
CD2	O
:	O
lymphocyte	O
function-associated	O
Ag-3	O
pathway	O
.	O

Gel-shift	O
analysis	O
reveals	O
the	O
constitutive	O
presence	O
of	O
nuclear	O
factors	O
in	O
resting	B-cell_type
PBL	I-cell_type
that	O
bind	O
to	O
the	O
proximal	B-DNA
AP-1	I-DNA
site	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
that	O
contain	O
immunoreactive	O
c-Jun	B-protein
but	O
not	O
c-Fos	B-protein
protein	O
.	O

In	O
contrast	O
,	O
AP-1	B-protein
from	O
PHA-activated	B-cell_type
cells	I-cell_type
contains	O
c-Jun	B-protein
and	O
low	O
levels	O
of	O
c-Fos	B-protein
.	O

Strikingly	O
,	O
costimulation	O
with	O
EC	B-cell_type
results	O
in	O
a	O
dramatic	O
increase	O
(	O
up	O
to	O
15-fold	O
)	O
in	O
the	O
c-Fos	B-protein
content	O
of	O
AP-1	B-protein
.	O

Levels	O
of	O
other	O
nuclear	B-protein
factors	I-protein
involved	O
in	O
IL-2	B-protein
regulation	O
were	O
not	O
altered	O
by	O
EC	B-cell_type
,	O
although	O
NFAT-DNA	B-protein
complexes	I-protein
migrated	O
at	O
a	O
slightly	O
different	O
mobility	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
changes	O
in	O
the	O
composition	O
of	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
is	O
a	O
key	O
molecular	O
mechanism	O
for	O
increasing	O
IL-2	B-protein
transcription	O
and	O
may	O
underlie	O
the	O
phenomenon	O
of	O
costimulation	O
by	O
EC	B-cell_type
.	O

Transcriptional	O
activation	O
of	O
human	B-DNA
zeta	I-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
by	O
the	O
alpha	B-DNA
globin	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
HS-40	B-DNA
)	O
:	O
functional	O
role	O
of	O
specific	O
nuclear	B-protein
factor-DNA	I-protein
complexes	I-protein
.	O

We	O
studied	O
the	O
functional	O
interaction	O
between	O
human	B-DNA
embryonic	I-DNA
zeta	I-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
and	O
the	O
alpha	B-DNA
globin	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
HS-40	B-DNA
)	O
located	O
40	B-DNA
kb	I-DNA
upstream	I-DNA
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
gene	I-DNA
.	O

It	O
was	O
shown	O
by	O
transient	O
expression	O
assay	O
that	O
HS-40	B-DNA
behaved	O
as	O
an	O
authentic	O
enhancer	B-DNA
for	O
high-level	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
activity	O
in	O
K562	B-cell_line
cells	I-cell_line
,	O
an	O
erythroid	O
cell	O
line	O
of	O
embryonic	O
and/or	O
fetal	O
origin	O
.	O

Although	O
sequences	O
located	O
between	O
-559	O
and	O
-88	O
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
gene	I-DNA
were	O
dispensable	O
for	O
its	O
expression	O
on	O
enhancerless	B-DNA
plasmids	I-DNA
,	O
they	O
were	O
required	O
for	O
the	O
HS-40	B-DNA
enhancer	I-DNA
-mediated	O
activity	O
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
.	O

Site-directed	O
mutagenesis	O
demonstrated	O
that	O
this	O
HS-40	B-DNA
enhancer-	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
interaction	O
is	O
mediated	O
by	O
the	O
two	O
GATA-1	O
factor	O
binding	O
motifs	O
located	O
at	O
-230	O
and	O
-104	O
,	O
respectively	O
.	O

The	O
functional	O
domains	O
of	O
HS-40	B-DNA
were	O
also	O
mapped	O
.	O

Bal	O
31	O
deletion	O
mapping	O
data	O
suggested	O
that	O
one	O
GATA-1	O
motif	O
,	O
one	O
GT	O
motif	O
,	O
and	O
two	O
NF-E2/AP1	O
motifs	O
together	O
formed	O
the	O
functional	O
core	O
of	O
HS-40	B-DNA
in	O
the	O
erythroid-specific	O
activation	O
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
.	O

Site-directed	O
mutagenesis	O
further	O
demonstrated	O
that	O
the	O
enhancer	B-DNA
function	O
of	O
one	O
of	O
the	O
two	O
NF-E2/AP1	O
motifs	O
of	O
HS-40	B-DNA
is	O
mediated	O
through	O
its	O
binding	O
to	O
NF-E2	B-protein
but	O
not	O
AP1	B-protein
transcription	I-protein
factor	I-protein
.	O

Finally	O
,	O
we	O
did	O
genomic	O
footprinting	O
of	O
the	O
HS-40	B-DNA
enhancer	I-DNA
region	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
,	O
adult	B-cell_line
nucleated	I-cell_line
erythroblasts	I-cell_line
,	O
and	O
different	O
nonerythroid	B-cell_type
cells	I-cell_type
.	O

All	O
sequence	O
motifs	O
within	O
the	O
functional	O
core	O
of	O
HS-40	B-DNA
,	O
as	O
mapped	O
by	O
transient	O
expression	O
analysis	O
,	O
appeared	O
to	O
bind	O
a	O
nuclear	B-protein
factor	I-protein
(	O
s	O
)	O
in	O
living	O
K562	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
nonerythroid	B-cell_type
cells	I-cell_type
.	O

On	O
the	O
other	O
hand	O
,	O
only	O
one	O
of	O
the	O
apparently	O
nonfunctional	B-DNA
sequence	I-DNA
motifs	I-DNA
was	O
bound	O
with	O
factors	O
in	O
vivo	O
.	O

In	O
comparison	O
to	O
K562	B-cell_line
,	O
nucleated	B-cell_line
erythroblasts	I-cell_line
from	O
adult	O
human	O
bone	O
marrow	O
exhibited	O
a	O
similar	O
but	O
nonidentical	O
pattern	O
of	O
nuclear	B-protein
factor	I-protein
binding	O
in	O
vivo	O
at	O
the	O
HS-40	B-DNA
region	O
.	O

These	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
human	B-DNA
embryonic	I-DNA
zeta	I-DNA
2	I-DNA
globin	I-DNA
gene	I-DNA
and	O
the	O
fetal/adult	B-DNA
alpha	I-DNA
globin	I-DNA
genes	I-DNA
is	O
mediated	O
by	O
erythroid	O
cell-specific	O
and	O
developmental	B-protein
stage-specific	I-protein
nuclear	I-protein
factor-DNA	I-protein
complexes	I-protein
which	O
form	O
at	O
the	O
enhancer	B-DNA
(	O
HS-40	B-DNA
)	O
and	O
the	O
globin	B-DNA
promoters	I-DNA
.	O

Transcriptional	O
regulation	O
of	O
the	O
pyruvate	B-DNA
kinase	I-DNA
erythroid-specific	I-DNA
promoter	I-DNA
.	O

Mammal	B-protein
pyruvate	I-protein
kinases	I-protein
are	O
encoded	O
by	O
two	O
genes	O
.	O

The	O
L	B-DNA
gene	I-DNA
produces	O
the	O
erythroid	B-protein
(	O
R-PK	B-protein
)	O
or	O
the	O
hepatic	B-protein
(	I-protein
L-PK	I-protein
)	I-protein
isozymes	I-protein
by	O
the	O
alternative	O
use	O
of	O
two	O
promoters	B-DNA
.	O

We	O
report	O
the	O
characterization	O
of	O
the	O
cis-	B-DNA
and	I-DNA
trans-acting	I-DNA
elements	I-DNA
involved	O
in	O
the	O
tissue-specific	O
activity	O
of	O
the	O
L	B-DNA
gene	I-DNA
erythroid	I-DNA
promoter	I-DNA
.	O

A	O
R-PK	B-DNA
DNA	I-DNA
fragment	I-DNA
extending	O
from	O
-870	O
to	O
+54	O
relative	O
to	O
the	O
cap	B-DNA
site	I-DNA
confers	O
erythroid	O
specificity	O
to	O
a	O
reporter	B-DNA
gene	I-DNA
.	O

Within	O
this	O
region	O
,	O
we	O
define	O
a	O
minimal	B-DNA
promoter	I-DNA
(	O
-62	O
to	O
+54	O
)	O
that	O
displays	O
erythroid-specific	O
activity	O
and	O
contains	O
two	O
DNA	O
binding	O
sites	O
.	O

One	O
,	O
located	O
at	O
-50	O
,	O
binds	O
members	O
of	O
the	O
CCACC/Sp1	B-protein
family	I-protein
and	O
the	O
other	O
,	O
located	O
at	O
-20	O
,	O
binds	O
the	O
erythroid	B-protein
factor	I-protein
GATA-1	I-protein
.	O

Although	O
the	O
-20	O
GATA	B-DNA
binding	I-DNA
site	I-DNA
(	O
AGATAA	O
)	O
is	O
also	O
a	O
potential	O
TFIID	B-DNA
binding	I-DNA
site	I-DNA
,	O
it	O
does	O
not	O
bind	O
TFIID	B-protein
.	O

Furthermore	O
,	O
the	O
substitution	O
of	O
this	O
GATA	B-DNA
binding	I-DNA
site	I-DNA
by	O
a	O
canonical	O
TFIID	B-DNA
binding	I-DNA
site	I-DNA
suppresses	O
the	O
promoter	O
activity	O
.	O

Mutations	O
and	O
deletions	O
of	O
both	O
sites	O
indicate	O
that	O
only	O
the	O
association	O
of	O
CCACC/Sp1	B-protein
and	O
GATA	B-DNA
binding	I-DNA
sites	I-DNA
can	O
drive	O
efficient	O
and	O
tissue-specific	O
expression	O
of	O
this	O
R-PK	B-protein
minimal	B-DNA
promoter	I-DNA
.	O

Finally	O
,	O
by	O
co-transfection	O
experiments	O
,	O
we	O
study	O
the	O
elements	O
involved	O
in	O
the	O
hGATA-1	O
transactivation	O
of	O
the	O
R-PK	B-DNA
promoter	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Protease	O
treatment	O
of	O
nuclear	O
extracts	O
distinguishes	O
between	O
class	B-protein
II	I-protein
MHC	I-protein
X1	I-protein
box	I-protein
DNA-binding	I-protein
proteins	I-protein
in	O
wild-type	B-cell_line
and	I-cell_line
class	I-cell_line
II-deficient	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

The	O
X	B-DNA
box	I-DNA
region	I-DNA
is	O
critical	O
for	O
directing	O
the	O
expression	O
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
genes	I-DNA
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Although	O
several	O
class	B-protein
II	I-protein
promoter-specific	I-protein
DNA	I-protein
binding	I-protein
factors	I-protein
have	O
been	O
described	O
,	O
only	O
the	O
X	B-DNA
box	I-DNA
region	I-DNA
factor	O
,	O
RFX	B-protein
,	O
shows	O
a	O
genetic	O
correlation	O
with	O
class	O
II	O
expression	O
,	O
being	O
deficient	O
in	O
some	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
derived	O
from	O
patients	O
with	O
class	O
II-deficient	O
congenital	O
immunodeficiency	O
.	O

To	O
further	O
evaluate	O
the	O
role	O
of	O
X	B-protein
box	I-protein
DNA-binding	I-protein
proteins	I-protein
in	O
class	B-DNA
II	I-DNA
gene	I-DNA
expression	O
,	O
the	O
role	O
of	O
the	O
X	B-DNA
box	I-DNA
region	I-DNA
was	O
examined	O
in	O
both	O
class	B-cell_line
II-positive	I-cell_line
and	O
-negative	B-cell_line
lymphoid	I-cell_line
cells	I-cell_line
.	O

In	O
addition	O
to	O
the	O
wild-type	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
Raji	I-cell_line
,	O
two	B-cell_line
class	I-cell_line
II	I-cell_line
transcriptional	I-cell_line
mutant	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
SJO	B-cell_line
and	O
RJ2.2.5	B-cell_line
,	O
and	O
Jurkat	B-cell_line
,	O
a	O
class	B-cell_line
II	I-cell_line
negative	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
were	O
examined	O
.	O

In	O
contrast	O
to	O
wild-type	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
neither	O
of	O
the	O
class	B-cell_line
II	I-cell_line
mutant	I-cell_line
cell	I-cell_line
lines	I-cell_line
could	O
use	O
the	O
X	B-DNA
box	I-DNA
region	I-DNA
to	O
direct	O
the	O
expression	O
of	O
a	O
transiently	O
transfected	O
reporter	B-DNA
gene	I-DNA
,	O
indicating	O
that	O
the	O
X	O
box-dependent	O
transcriptional	O
pathway	O
is	O
defective	O
in	O
these	O
cells	O
.	O

The	O
binding	O
activity	O
of	O
the	O
X1	B-protein
box	I-protein
DNA-binding	I-protein
protein	I-protein
RFX	B-protein
was	O
examined	O
and	O
found	O
to	O
be	O
present	O
in	O
wild-type	B-cell_line
B	I-cell_line
cells	I-cell_line
and	O
the	O
mutant	O
RJ2.2.5	B-cell_line
but	O
was	O
absent	O
in	O
SJO	B-cell_line
and	O
Jurkat	B-cell_line
.	O

However	O
,	O
other	O
X1	O
box-specific	O
activities	O
were	O
detected	O
in	O
all	O
these	O
cell	B-cell_line
lines	I-cell_line
.	O

To	O
determine	O
whether	O
these	O
different	O
X1	O
box	O
activities	O
represented	O
distinct	O
DNA	B-protein
binding	I-protein
proteins	I-protein
or	O
multimeric	O
forms	O
of	O
the	O
same	O
factor	O
(	O
s	O
)	O
,	O
protease	B-protein
treatment	O
of	O
the	O
crude	O
nuclear	O
extracts	O
followed	O
by	O
DNA-binding	O
assays	O
were	O
carried	O
out	O
and	O
demonstrated	O
that	O
B	O
cell	O
extracts	O
contain	O
at	O
least	O
two	O
X1-specific	B-protein
factors	I-protein
.	O

One	O
of	O
these	O
cleaved	O
products	O
(	O
band	O
1	O
pk	O
)	O
correlates	O
with	O
RFX	B-protein
activity	O
.	O

A	O
similar	O
comparison	O
with	O
protease-treated	O
extracts	O
prepared	O
from	O
Jurkat	B-cell_line
cells	I-cell_line
demonstrated	O
the	O
presence	O
of	O
the	O
band	O
1pk	O
activity	O
despite	O
an	O
absence	O
of	O
the	O
native	O
RFX	B-protein
activity	O
.	O

In	O
contrast	O
,	O
protease	O
treatment	O
and	O
analysis	O
of	O
SJO	B-cell_line
extracts	O
showed	O
no	O
detectable	O
levels	O
of	O
the	O
band	O
1pk	O
activity	O
.	O

These	O
results	O
demonstrate	O
that	O
multiple	O
X1	O
box-specific	O
DNA-binding	O
activities	O
exist	O
in	O
all	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
but	O
the	O
presence	O
of	O
an	O
actively	O
binding	O
RFX	B-protein
species	O
correlates	O
with	O
class	O
II	O
transcription	O
.	O

Human	O
immunodeficiency	O
viruses	O
containing	O
heterologous	B-DNA
enhancer/promoters	I-DNA
are	O
replication	O
competent	O
and	O
exhibit	O
different	O
lymphocyte	O
tropisms	O
.	O

The	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
contains	O
binding	O
sites	O
for	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
and	O
the	O
constitutively	O
expressed	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
,	O
both	O
of	O
which	O
are	O
highly	O
conserved	O
in	O
HIV	O
and	O
simian	O
immunodeficiency	O
virus	O
isolates	O
.	O

To	O
delineate	O
the	O
effects	O
of	O
these	O
motifs	O
on	O
the	O
replicative	O
capacity	O
of	O
HIV	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
extending	O
the	O
virus	O
host	O
range	O
,	O
known	O
heterologous	B-DNA
enhancer/promoters	I-DNA
were	O
inserted	O
into	O
the	O
HIV-1	B-DNA
LTR	I-DNA
in	O
place	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
.	O

The	O
effects	O
of	O
these	O
substitutions	O
on	O
viral	O
replication	O
in	O
transfected	O
HeLa	B-cell_line
cells	I-cell_line
and	O
on	O
HIV	O
infection	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
or	O
continuous	B-cell_line
T-leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
evaluated	O
.	O

HIVs	O
in	O
which	O
the	O
NF-kappa	B-DNA
B/Sp1	I-DNA
enhancer	I-DNA
plus	O
the	O
downstream	B-DNA
TATA	I-DNA
element	I-DNA
were	O
replaced	O
with	O
heterologous	B-DNA
enhancer/promoters	I-DNA
were	O
also	O
constructed	O
.	O

Viruses	O
containing	O
the	O
human	B-DNA
cytomegalovirus	I-DNA
immediate-early	I-DNA
enhancer	I-DNA
exhibited	O
infectious	O
kinetics	O
similar	O
to	O
that	O
of	O
wild-type	O
HIV	O
in	O
activated	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
AA2	B-cell_line
cells	I-cell_line
but	O
replicated	O
less	O
efficiently	O
in	O
H9	B-cell_line
and	I-cell_line
CEM	I-cell_line
cells	I-cell_line
.	O

These	O
studies	O
indicate	O
that	O
heterologous	B-DNA
enhancer	I-DNA
elements	I-DNA
are	O
capable	O
of	O
restoring	O
Tat	B-protein
responsiveness	O
to	O
the	O
HIV	B-DNA
LTR	I-DNA
in	O
the	O
context	O
of	O
directing	O
reporter	B-DNA
gene	I-DNA
expression	O
as	O
well	O
as	O
in	O
the	O
production	O
of	O
infectious	O
progeny	O
virions	O
.	O

Tyrosine	O
phosphorylation	O
is	O
a	O
mandatory	O
proximal	O
step	O
in	O
radiation-induced	O
activation	O
of	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
pathway	O
in	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursors	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1993	O
Apr	O
15	O
;	O
90	O
(	O
8	O
)	O
:	O
3775	O
]	O

Ionizing	O
radiation	O
triggers	O
a	O
signal	O
in	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursors	I-cell_type
that	O
is	O
intimately	O
linked	O
to	O
an	O
active	O
protein-tyrosine	B-protein
kinase	I-protein
regulatory	O
pathway	O
.	O

We	O
show	O
that	O
in	O
B-lymphocyte	B-cell_type
precursors	I-cell_type
,	O
irradiation	O
with	O
gamma-rays	O
leads	O
to	O
(	O
i	O
)	O
stimulation	O
of	O
phosphatidylinositol	O
turnover	O
;	O
(	O
ii	O
)	O
downstream	O
activation	O
by	O
covalent	O
modification	O
of	O
multiple	O
serine-specific	B-protein
protein	I-protein
kinases	I-protein
,	O
including	O
protein	B-protein
kinase	I-protein
C	I-protein
;	O
and	O
(	O
iii	O
)	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
.	O

All	O
of	O
the	O
radiation-induced	O
signals	O
were	O
effectively	O
prevented	O
by	O
the	O
protein-tyrosine	B-protein
kinase	I-protein
inhibitors	I-protein
genistein	I-protein
and	I-protein
herbimycin	I-protein
A	I-protein
.	O

Thus	O
,	O
tyrosine	O
phosphorylation	O
is	O
an	O
important	O
and	O
perhaps	O
mandatory	O
proximal	O
step	O
in	O
the	O
activation	O
of	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
cascade	O
in	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursors	I-cell_type
.	O

Our	O
report	O
expands	O
current	O
knowledge	O
of	O
the	O
radiation-induced	O
signaling	O
cascade	O
by	O
clarifying	O
the	O
chronological	O
sequence	O
of	O
biochemical	O
events	O
that	O
follow	O
irradiation	O
.	O

Detection	O
of	O
adenovirus	B-DNA
DNA	I-DNA
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

Adenovirus	O
can	O
establish	O
persistent	O
infections	O
which	O
may	O
reactivate	O
and	O
cause	O
disease	O
in	O
immunocompromised	O
hosts	O
.	O

Lymphocytes	B-cell_type
have	O
been	O
postulated	O
to	O
serve	O
as	O
a	O
site	O
of	O
adenoviral	O
persistence	O
based	O
upon	O
the	O
ability	O
to	O
isolate	O
adenovirus	O
from	O
tonsils	O
and	O
to	O
detect	O
adenovirus	B-DNA
DNA	I-DNA
by	O
Southern	O
blot	O
hybridization	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
a	O
more	O
sensitive	O
and	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
was	O
developed	O
to	O
detect	O
adenovirus	B-DNA
DNA	I-DNA
.	O

Two	O
sets	O
of	O
nested	B-DNA
primers	I-DNA
were	O
designed	O
to	O
conserved	O
sequences	O
in	O
the	O
adenovirus	B-DNA
E1A	I-DNA
and	I-DNA
hexon	I-DNA
genes	I-DNA
.	O

The	O
E1A	B-DNA
and	I-DNA
hexon	I-DNA
primers	I-DNA
amplified	O
DNA	O
from	O
representative	O
adenoviral	O
serotypes	O
in	O
all	O
six	O
adenoviral	O
groups	O
(	O
A-F	O
)	O
.	O

Both	O
primers	O
detected	O
a	O
single	O
copy	O
of	O
the	O
adenovirus	B-DNA
type	I-DNA
2	I-DNA
genome	I-DNA
but	O
were	O
less	O
sensitive	O
for	O
the	O
group	O
B	O
type	O
35	O
.	O

None	O
of	O
33	O
PBMC	B-cell_type
specimens	O
from	O
healthy	O
adults	O
and	O
only	O
one	O
of	O
40	O
pediatric	O
samples	O
was	O
positive	O
(	O
at	O
a	O
low	O
level	O
)	O
for	O
adenovirus	B-DNA
DNA	I-DNA
by	O
nested	O
PCR	O
assay	O
.	O

In	O
comparison	O
,	O
PBMC	B-cell_type
from	O
two	O
children	O
with	O
fatal	O
adenoviral	O
infection	O
were	O
both	O
strongly	O
positive	O
for	O
adenovirus	B-DNA
DNA	I-DNA
.	O

It	O
is	O
concluded	O
that	O
,	O
in	O
contrast	O
to	O
a	O
previous	O
study	O
,	O
PBMC	B-cell_type
are	O
not	O
a	O
common	O
site	O
of	O
persistent	O
group	O
C	O
adenoviral	O
infection	O
.	O

In	O
addition	O
,	O
assay	O
of	O
PBMC	B-cell_type
by	O
the	O
adenovirus-specific	O
PCR	O
may	O
help	O
detect	O
early	O
invasive	O
disease	O
and	O
warrants	O
further	O
evaluation	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
expression	O
and	O
signal	O
transduction	O
in	O
HIV-1-infected	B-cell_type
cells	I-cell_type
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
inter-relationship	O
between	O
HIV-1	O
infection	O
and	O
the	O
cell	O
surface	O
receptors	O
for	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
,	O
an	O
immunoregulatory	O
cytokine	O
that	O
can	O
enhance	O
HIV-1	O
replication	O
.	O

DESIGN	O
:	O
Infected	O
promyelocytic	B-cell_type
and	O
promonocytic	B-cell_type
cells	I-cell_type
were	O
examined	O
because	O
they	O
normally	O
express	O
both	O
types	O
of	O
TNF	B-protein
receptors	I-protein
.	O

METHODS	O
:	O
TNF	B-protein
receptor	O
surface	O
expression	O
was	O
determined	O
by	O
specific	O
monoclonal	B-protein
antibody	I-protein
recognition	O
and	O
flow	O
cytometry	O
,	O
and	O
signal	O
transduction	O
was	O
detected	O
by	O
gel	O
shift	O
analysis	O
.	O

HIV-1	O
activation	O
and	O
expression	O
was	O
quantitated	O
by	O
reverse	B-protein
transcriptase	I-protein
assay	O
.	O

RESULTS	O
:	O
In	O
the	O
OM-10.1	O
promyelocytic	O
model	O
of	O
chronic	O
infection	O
,	O
TNF-alpha-induced	O
HIV-1	O
expression	O
also	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
75	B-protein
kd	I-protein
TNF	I-protein
receptor	I-protein
(	O
TR75	B-protein
)	O
expression	O
although	O
55	B-protein
kD	I-protein
TNF	I-protein
receptor	I-protein
(	O
TR55	B-protein
)	O
levels	O
were	O
not	O
dramatically	O
altered	O
.	O

A	O
series	O
of	O
uninfected	B-cell_line
parental	I-cell_line
HL-60	I-cell_line
subclones	I-cell_line
all	O
reduced	O
TR75	B-protein
surface	O
expression	O
in	O
response	O
to	O
TNF-alpha	B-protein
treatment	O
.	O

Enhanced	O
TR75	B-protein
expression	O
on	O
OM-10.1	O
cells	O
followed	O
the	O
same	O
TNF-alpha	B-protein
-dose	O
dependency	O
as	O
that	O
observed	O
for	O
HIV-1	O
production	O
.	O

An	O
increase	O
in	O
TR75	B-protein
expression	O
was	O
also	O
evident	O
during	O
the	O
peak	O
of	O
an	O
acute	O
HIV-1	O
infection	O
of	O
HL-60	B-cell_line
promyelocytes	I-cell_line
.	O

Although	O
TR55	B-protein
expression	O
was	O
unaltered	O
during	O
TNF-alpha	B-protein
-induced	O
HIV	O
activation	O
,	O
this	O
receptor	O
was	O
still	O
involved	O
in	O
the	O
viral	O
activation	O
process	O
.	O

Antibody	O
cross-linking	O
of	O
TR55	B-protein
,	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
TNF-alpha	I-protein
,	O
induced	O
maximal	O
HIV-1	O
expression	O
,	O
an	O
up-modulation	O
of	O
surface	O
TR75	B-protein
,	O
and	O
nuclear	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
OM-10.1	O
cultures	O
.	O

Surprisingly	O
,	O
this	O
was	O
the	O
case	O
even	O
when	O
an	O
antagonistic	B-protein
anti-TR55	I-protein
antibody	I-protein
was	O
used	O
.	O

Anti-TR55	B-protein
antibody	I-protein
cross-linking	O
in	O
chronically	B-cell_line
infected	I-cell_line
U1	I-cell_line
promonocytic	I-cell_line
cultures	I-cell_line
could	O
only	O
partially	O
substitute	O
for	O
TNF-alpha-induced	O
HIV-1	O
expression	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
demonstrated	O
that	O
HIV-1	O
infection	O
can	O
selectively	O
influence	O
the	O
surface	O
expression	O
of	O
TNF	B-protein
receptors	I-protein
,	O
potentially	O
influencing	O
its	O
own	O
expression	O
and	O
altering	O
normal	O
immunoregulatory	B-protein
signal	O
transduction	O
.	O

Comparative	O
mapping	O
of	O
SRY	B-DNA
in	O
the	O
great	O
apes	O
.	O

Cytogenetic	O
studies	O
of	O
the	O
primate	B-DNA
Y	I-DNA
chromosomes	I-DNA
have	O
suggested	O
that	O
extensive	O
rearrangements	O
have	O
occurred	O
during	O
evolution	O
of	O
the	O
great	O
apes	O
.	O

We	O
have	O
used	O
in	O
situ	O
hybridization	O
to	O
define	O
these	O
rearrangements	O
at	O
the	O
molecular	O
level	O
.	O

pHU-14	B-DNA
,	O
a	O
probe	O
including	O
sequences	O
from	O
the	O
sex	B-DNA
determining	I-DNA
gene	I-DNA
SRY	I-DNA
,	O
hybridizes	O
close	O
to	O
the	O
early	O
replicating	O
pseudoautosomal	O
segment	O
in	O
a	O
telomeric	O
or	O
subtelomeric	O
position	O
of	O
the	O
Y	B-DNA
chromosomes	I-DNA
of	O
all	O
great	O
apes	O
.	O

The	O
low	B-DNA
copy	I-DNA
repeat	I-DNA
detected	O
by	O
the	O
probe	O
Fr35-II	B-DNA
is	O
obviously	O
included	O
in	O
Y	O
chromosomal	O
rearrangements	O
during	O
hominid	O
evolution	O
.	O

These	O
results	O
,	O
combined	O
with	O
previous	O
studies	O
,	O
suggest	O
that	O
the	O
Y	O
chromosome	O
in	O
great	O
apes	O
has	O
a	O
conserved	O
region	O
including	O
the	O
pseudoautosomal	B-DNA
region	I-DNA
and	O
the	O
testis-determining	O
region	O
.	O

The	O
rest	O
of	O
the	O
Y	B-DNA
chromosome	I-DNA
has	O
undergone	O
several	O
rearrangements	O
in	O
the	O
different	O
great	O
apes	O
.	O

Calcium	O
dependent	O
activation	O
of	O
the	O
NF-AT	B-protein
transcription	I-protein
factor	I-protein
by	O
p59fyn	B-protein
.	O

A	O
reporter	B-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
a	O
T-cell	B-DNA
antigen	I-DNA
receptor	I-DNA
element	I-DNA
was	O
activated	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
by	O
antigen	O
receptor	O
triggering	O
or	O
by	O
a	O
combination	O
of	O
phorbol	O
myristate	O
acetate	O
,	O
which	O
activates	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
a	O
calcium	O
ionophore	O
.	O

Both	O
these	O
signals	O
were	O
necessary	O
for	O
expression	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
.	O

When	O
co-transfected	O
with	O
a	O
construct	O
capable	O
of	O
overexpressing	O
the	O
tyrosine	B-protein
kinase	I-protein
p59fyn	B-protein
,	O
the	O
reporter	B-DNA
gene	I-DNA
was	O
activated	O
by	O
PMA	B-protein
alone	O
.	O

Thus	O
p59fyn	B-protein
could	O
replace	O
the	O
calcium	O
ionophore	O
but	O
not	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

The	O
activation	O
by	O
p59fyn	B-protein
plus	O
PMA	B-protein
was	O
blocked	O
by	O
EGTA	O
and	O
by	O
the	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
.	O

Dependence	O
for	O
the	O
proliferative	O
response	O
to	O
erythropoietin	B-protein
on	O
an	O
established	O
erythroid	O
differentiation	O
program	O
in	O
a	O
human	B-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
UT-7	B-cell_line
.	O

Erythroid	O
differentiation	O
involves	O
the	O
activation	O
of	O
a	O
number	O
of	O
erythroid-specific	O
genes	O
,	O
most	O
of	O
which	O
,	O
including	O
the	O
globin	B-DNA
genes	I-DNA
and	O
the	O
erythropoietin	B-DNA
receptor	I-DNA
(	I-DNA
Epo-R	I-DNA
)	I-DNA
gene	I-DNA
,	O
are	O
,	O
at	O
least	O
in	O
part	O
,	O
regulated	O
by	O
the	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
.	O

In	O
order	O
to	O
understand	O
the	O
relationship	O
,	O
if	O
any	O
,	O
between	O
expression	O
of	O
GATA-1	B-protein
,	O
response	O
to	O
Epo	O
and	O
erythroid	O
differentiation	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
GATA-1	B-protein
,	O
Epo-R	B-protein
and	O
globin	B-DNA
genes	I-DNA
in	O
an	O
Epo-dependent	O
human	O
cell	O
line	O
,	O
UT-7	B-cell_line
Epo	O
.	O

The	O
results	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
the	O
parental	B-cell_line
granulocyte-macrophage	I-cell_line
colony-stimulating	I-cell_line
factor	I-cell_line
(	I-cell_line
GM-CSF	I-cell_line
)	I-cell_line
-dependent	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
UT-7	B-cell_line
,	O
which	O
has	O
a	O
predominantly	O
megakaryoblastic	O
phenotype	O
and	O
is	O
unable	O
to	O
proliferate	O
continuously	O
in	O
the	O
presence	O
of	O
Epo	B-protein
.	O

UT-7	B-protein
Epo	I-protein
and	O
UT-7	B-cell_line
expressed	O
similar	O
levels	O
of	O
GATA-1	B-RNA
mRNA	I-RNA
and	O
binding	O
activity	O
.	O

The	O
two	O
lines	O
also	O
expressed	O
comparable	O
levels	O
of	O
Epo-R	B-RNA
mRNA	I-RNA
while	O
the	O
number	O
of	O
Epo	B-protein
-binding	O
sites	O
on	O
UT-7	B-cell_line
Epo	I-cell_line
cells	I-cell_line
was	O
one-sixth	O
the	O
number	O
of	O
UT-7	B-cell_line
cells	I-cell_line
(	O
2400	O
+/-	O
3	O
vs.	O
13	O
,	O
800	O
+/-	O
300	O
)	O
.	O

This	O
difference	O
in	O
the	O
number	O
of	O
binding	O
sites	O
could	O
be	O
due	O
to	O
differences	O
in	O
cell	O
surface	O
(	O
UT-7	B-cell_line
cells	I-cell_line
are	O
20	O
%	O
smaller	O
than	O
the	O
parental	O
UT-7	B-cell_line
cells	I-cell_line
)	O
or	O
in	O
receptor	O
turnover	O
.	O

By	O
Northern	O
analysis	O
,	O
UT-7	B-cell_line
cells	I-cell_line
expressed	O
detectable	O
levels	O
of	O
beta-	B-protein
and	I-protein
gamma-globin	I-protein
but	O
not	O
alpha-globin	B-protein
.	O

In	O
comparison	O
,	O
UT-7	B-cell_line
Epo	I-cell_line
cells	I-cell_line
expressed	O
alpha-globin	O
and	O
higher	O
levels	O
of	O
gamma-globin	B-protein
(	O
5-fold	O
)	O
and	O
beta-globin	B-protein
(	O
from	O
barely	O
to	O
clearly	O
detectable	O
)	O
.	O

Globin	B-protein
chains	I-protein
(	O
alpha	B-protein
,	O
beta	B-protein
and	O
gamma	B-protein
)	O
were	O
clearly	O
detectable	O
by	O
affinity	O
chromatography	O
in	O
UT-7	B-protein
Epo	I-protein
but	O
not	O
in	O
UT-7	B-cell_line
cells	I-cell_line
.	O

The	O
frequency	O
of	O
the	O
cells	O
which	O
expressed	O
beta-	B-DNA
and	I-DNA
gamma-	I-DNA
globin	I-DNA
genes	I-DNA
in	O
the	O
two	O
cell	O
populations	O
was	O
measured	O
by	O
immunofluorescence	O
with	O
beta-	B-protein
and	I-protein
gamma-specific	I-protein
antibodies	I-protein
.	O

The	O
number	O
of	O
gamma-positive	B-cell_line
cells	I-cell_line
and	O
their	O
fluorescence	O
intensity	O
were	O
higher	O
in	O
UT-7	B-protein
Epo	I-protein
than	O
in	O
UT-7	B-cell_line
cells	I-cell_line
(	O
0	O
to	O
17	O
%	O
barely	O
positive	O
cells	O
and	O
23	O
to	O
40	O
%	O
clearly	O
positive	O
cells	O
,	O
respectively	O
)	O
,	O
indicating	O
that	O
the	O
increase	O
in	O
globin	B-RNA
mRNA	I-RNA
observed	O
in	O
UT-7	B-protein
Epo	I-protein
is	O
due	O
to	O
both	O
an	O
increase	O
of	O
gene	O
expression	O
per	O
cell	O
and	O
an	O
increase	O
in	O
numbers	O
of	O
cells	O
containing	O
gamma-globin	B-protein
.	O

The	O
levels	O
of	O
GATA-1	B-protein
,	O
Epo-R	B-protein
and	O
globin	B-RNA
mRNA	I-RNA
expressed	O
were	O
not	O
affected	O
by	O
a	O
24-hour	O
incubation	O
of	O
either	O
cell	O
line	O
with	O
Epo	B-protein
,	O
GM-CSF	B-protein
or	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

The	O
Sp1	B-protein
transcription	I-protein
factor	I-protein
binds	O
the	O
CD11b	B-DNA
promoter	I-DNA
specifically	O
in	O
myeloid	O
cells	O
in	O
vivo	O
and	O
is	O
essential	O
for	O
myeloid-specific	B-DNA
promoter	I-DNA
activity	O
.	O

The	O
myeloid	B-protein
integrin	I-protein
CD11b	I-protein
is	O
expressed	O
selectively	O
on	O
the	O
surface	O
of	O
mature	B-cell_type
macrophages	I-cell_type
,	O
monocytes	B-cell_type
,	O
neutrophils	B-cell_type
,	O
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

Lineage-specific	O
expression	O
is	O
controlled	O
at	O
the	O
level	O
of	O
mRNA	O
transcription	O
.	O

Recent	O
isolation	O
of	O
the	O
CD11b	B-DNA
promoter	I-DNA
shows	O
that	O
92	O
base	O
pairs	O
(	O
bp	O
)	O
of	O
5'-flanking	B-DNA
DNA	I-DNA
are	O
sufficient	O
to	O
direct	O
myeloid-specific	O
expression	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
.	O

To	O
characterize	O
regulatory	O
sequences	O
important	O
for	O
promoter	O
activity	O
,	O
we	O
performed	O
linker	O
scanning	O
analysis	O
of	O
the	O
92-bp	B-DNA
CD11b	I-DNA
promoter	I-DNA
and	O
demonstrate	O
that	O
a	O
sequence	O
at	O
bp	O
-60	O
is	O
essential	O
for	O
CD11b	B-DNA
promoter	I-DNA
activity	O
.	O

We	O
show	O
that	O
this	O
sequence	O
binds	O
the	O
transcription	B-protein
factor	I-protein
Sp1	B-protein
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vivo	O
the	O
Sp1	B-DNA
site	I-DNA
is	O
bound	O
only	O
in	O
myeloid	B-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
not	O
in	O
cervical	B-cell_line
carcinoma	I-cell_line
(	I-cell_line
HeLa	I-cell_line
)	I-cell_line
cells	I-cell_line
.	O

In	O
addition	O
,	O
the	O
macrophage	O
transcription	B-protein
factor	I-protein
PU.1	O
binds	O
the	O
CD11b	B-DNA
promoter	I-DNA
in	O
vitro	O
and	O
in	O
vivo	O
close	O
to	O
the	O
Sp1	B-DNA
site	I-DNA
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
binding	O
of	O
a	O
myeloid-specific	B-protein
factor	I-protein
(	O
PU.1	B-protein
)	O
allows	O
a	O
general	O
factor	O
(	O
Sp1	B-protein
)	O
to	O
bind	O
in	O
a	O
tissue-specific	O
fashion	O
thereby	O
contributing	O
to	O
the	O
myeloid-specific	O
expression	O
of	O
CD11b	B-cell_line
.	O

Transcription	O
factor	O
jun-B	O
is	O
target	O
of	O
autoreactive	B-cell_type
T-cells	I-cell_type
in	O
IDDM	O
.	O

Target	O
antigens	O
defined	O
by	O
autoantibodies	B-protein
in	O
IDDM	O
include	O
insulin	O
,	O
a	O
putative	O
glycolipid	O
that	O
reacts	O
with	O
islet	B-protein
cell	I-protein
antibodies	I-protein
,	O
and	O
a	O
64	B-protein
,	I-protein
000-M	I-protein
(	I-protein
r	I-protein
)	I-protein
protein	I-protein
recently	O
identified	O
as	O
glutamic	B-protein
acid	I-protein
decarboxylase	I-protein
.	O

In	O
addition	O
,	O
some	O
IDDM	O
sera	O
that	O
contain	O
antibodies	B-protein
to	O
glutamic	B-protein
acid	I-protein
decarboxylase	I-protein
also	O
coprecipitate	O
a	O
38	B-protein
,	I-protein
000-M	I-protein
(	I-protein
r	I-protein
)	I-protein
protein	I-protein
from	O
islets	O
.	O

This	O
study	O
used	O
a	O
high	O
titer	O
anti-38	O
,	O
000-M	O
(	O
r	O
)	O
serum	O
to	O
screen	O
bacteriophage	B-DNA
lambda	I-DNA
cDNA	I-DNA
expression	O
libraries	O
and	O
identified	O
human	B-cell_type
islet	I-cell_type
and	O
placental	B-cell_line
clones	I-cell_line
encoding	O
jun-B	B-protein
,	O
the	O
nuclear	B-protein
transcription	I-protein
protein	I-protein
,	O
of	O
predicted	O
38	O
,	O
000	O
M	O
(	O
r	O
)	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
T-cells	I-cell_type
exhibited	O
significant	O
proliferation	O
in	O
response	O
to	O
a	O
recombinant	O
fragment	O
of	O
jun-B	B-protein
(	O
amino	O
acids	O
1-180	O
)	O
in	O
12	O
of	O
17	O
(	O
71	O
%	O
)	O
recent-onset	O
IDDM	O
subjects	O
,	O
8	O
of	O
16	O
(	O
50	O
%	O
)	O
ICA-positive	O
first-degree	O
relatives	O
of	O
IDDM	O
subjects	O
who	O
were	O
at	O
risk	O
,	O
3	O
of	O
12	O
(	O
25	O
%	O
)	O
other	O
autoimmune	O
disease	O
subjects	O
,	O
and	O
0	O
of	O
10	O
healthy	O
control	O
subjects	O
.	O

Proliferation	O
to	O
tetanus	O
toxoid	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O

Responses	O
to	O
jun-B	B-protein
were	O
not	O
related	O
to	O
age	O
,	O
sex	O
,	O
or	O
human	B-protein
leukocyte	I-protein
antigen	I-protein
status	O
.	O

Thus	O
,	O
autoreactive	B-cell_type
T-cells	I-cell_type
identify	O
a	O
novel	B-protein
antigen	I-protein
,	O
p38	B-protein
jun-B	I-protein
,	O
in	O
IDDM	O
and	O
appear	O
to	O
indicate	O
subjects	O
at	O
risk	O
for	O
the	O
development	O
of	O
clinical	O
disease	O
.	O

Stimulation	O
of	O
interleukin-1	B-protein
alpha	I-protein
and	O
interleukin-1	B-protein
beta	I-protein
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
by	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	O
.	O

Protein	B-protein
phosphatases	I-protein
1	I-protein
and	I-protein
2A	I-protein
are	O
important	O
in	O
regulating	O
cellular	O
functions	O
by	O
controlling	O
the	O
phosphorylation	O
state	O
of	O
their	O
substrates	O
.	O

In	O
human	B-cell_type
monocytes	I-cell_type
,	O
the	O
inhibitors	O
of	O
these	O
phosphatases	B-protein
,	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
were	O
found	O
to	O
increase	O
the	O
mRNA	O
accumulation	O
and	O
cytokine	O
production	O
of	O
interleukin-1	B-protein
beta	I-protein
and	O
interleukin-1	B-protein
alpha	I-protein
.	O

The	O
increased	O
mRNA	B-RNA
accumulation	O
was	O
found	O
to	O
be	O
primarily	O
because	O
of	O
the	O
increase	O
in	O
the	O
transcription	O
rate	O
of	O
the	O
interleukin-1	B-DNA
genes	I-DNA
.	O

Stimulation	O
of	O
interleukin-1	B-DNA
gene	I-DNA
transcription	O
may	O
be	O
caused	O
by	O
the	O
stimulation	O
of	O
transcription	B-protein
factor	I-protein
activities	O
,	O
including	O
those	O
of	O
AP-1	B-protein
,	O
by	O
these	O
protein	B-protein
phosphatase	I-protein
inhibitors	O
.	O

Okadaic	O
acid	O
increased	O
the	O
synthesis	O
of	O
the	O
interleukin-1	B-protein
beta	I-protein
precursor	O
and	O
mature	O
forms	O
and	O
their	O
secretion	O
.	O

This	O
increased	O
processing	O
and	O
secretion	O
correlated	O
with	O
the	O
stimulation	O
of	O
IL-1	B-RNA
beta	I-RNA
convertase	I-RNA
mRNA	I-RNA
accumulation	O
.	O

The	O
stimulation	O
of	O
interleukin-1	B-protein
alpha	I-protein
production	O
by	O
okadaic	O
acid	O
was	O
more	O
modest	O
than	O
that	O
of	O
interleukin-1	B-protein
beta	I-protein
.	O

However	O
,	O
the	O
phosphorylation	O
of	O
the	O
precursor	B-protein
interleukin-1	I-protein
alpha	I-protein
cytokine	I-protein
was	O
increased	O
.	O

These	O
results	O
show	O
that	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	O
exert	O
multiple	O
effects	O
on	O
cytokine	O
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
suggest	O
that	O
these	O
two	O
phosphatases	B-protein
play	O
important	O
roles	O
in	O
regulating	O
interleukin-1	B-protein
production	O
.	O

The	O
interleukin	B-protein
2	I-protein
CD28-responsive	I-protein
complex	I-protein
contains	O
at	O
least	O
three	O
members	O
of	O
the	O
NF	B-protein
kappa	I-protein
B	I-protein
family	I-protein
:	O
c-Rel	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
.	O

Optimal	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
requires	O
at	O
least	O
two	O
signals	O
.	O

One	O
signal	O
can	O
be	O
delivered	O
by	O
the	O
antigen-specific	B-protein
T-cell	I-protein
receptor	I-protein
,	O
and	O
the	O
second	O
signal	O
is	O
provided	O
by	O
the	O
costimulatory	O
molecule	O
(	O
s	O
)	O
delivered	O
by	O
the	O
antigen-presenting	B-cell_type
cell	I-cell_type
.	O

CD28	B-protein
is	O
a	O
T-cell	B-protein
surface	I-protein
molecule	I-protein
and	O
stimulation	O
through	O
this	O
protein	O
plays	O
an	O
important	O
role	O
in	O
delivering	O
the	O
second	O
activation	O
signal	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
CD28	B-protein
-mediated	O
signal	O
transduction	O
involves	O
the	O
rel	B-protein
family	I-protein
proteins	I-protein
--	O
c-Rel	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
.	O

Treatment	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
anti-CD28	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
results	O
in	O
augmentation	O
of	O
nuclear	B-protein
c-Rel	I-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
,	O
and	O
this	O
augmentation	O
can	O
occur	O
in	O
the	O
presence	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
.	O

It	O
is	O
also	O
shown	O
in	O
this	O
report	O
that	O
,	O
in	O
response	O
to	O
PMA/anti-CD28	B-protein
mAb	I-protein
or	O
anti-CD3/anti-CD28	B-protein
mAb	I-protein
,	O
c-Rel	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
are	O
associated	O
with	O
CD28-responsive	B-DNA
element	I-DNA
present	O
in	O
the	O
promoter	B-DNA
of	O
the	O
human	B-DNA
interleukin	I-DNA
2	I-DNA
gene	I-DNA
.	O

The	O
functional	O
significance	O
of	O
c-Rel	B-protein
involvement	O
in	O
the	O
CD28-responsive	B-protein
complex	I-protein
is	O
demonstrated	O
by	O
transient	O
transfection	O
analysis	O
,	O
where	O
cotransfection	O
of	O
c-Rel	B-protein
augments	O
the	O
level	O
of	O
expression	O
of	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
linked	O
to	O
the	O
CD28-responsive	B-DNA
element	I-DNA
.	O

Expression	O
of	O
tal-1	B-protein
and	O
GATA-binding	B-protein
proteins	I-protein
during	O
human	O
hematopoiesis	O
.	O

Tal-1	B-protein
rearrangements	O
are	O
associated	O
with	O
nearly	O
30	O
%	O
of	O
human	O
T	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Tal-1	B-DNA
gene	I-DNA
encodes	O
a	O
putative	O
transcription	B-protein
factor	I-protein
with	O
a	O
basic	B-protein
helix-loop-helix	I-protein
domain	I-protein
and	O
is	O
known	O
to	O
be	O
predominantly	O
expressed	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

We	O
investigated	O
the	O
pattern	O
of	O
tal-1	B-protein
expression	O
in	O
purified	B-cell_type
human	I-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
by	O
in	O
situ	O
hybridization	O
and	O
reverse	B-protein
transcriptase	I-protein
polymerase	I-protein
chain	O
reaction	O
analysis	O
.	O

Both	O
methods	O
demonstrated	O
that	O
the	O
tal-1	B-protein
gene	O
is	O
expressed	O
in	O
megakaryocytes	O
and	O
erythroblasts	O
as	O
well	O
as	O
in	O
basophilic	B-cell_type
granulocytes	I-cell_type
.	O

In	O
addition	O
,	O
our	O
results	O
indicate	O
that	O
the	O
tal-1	B-DNA
1A	I-DNA
promoter	I-DNA
,	O
which	O
contains	O
two	O
consensus	O
GATA-binding	B-DNA
sites	I-DNA
,	O
is	O
active	O
mainly	O
in	O
these	O
lineages	O
.	O

Because	O
the	O
GATA-1	B-DNA
gene	I-DNA
is	O
known	O
to	O
transactivate	O
several	O
genes	O
specific	O
for	O
the	O
erythroid	B-cell_type
,	I-cell_type
megakaryocytic	I-cell_type
,	I-cell_type
and	I-cell_type
mastocytic/basophilic	I-cell_type
lineages	I-cell_type
,	O
we	O
studied	O
GATA-1	B-protein
expression	O
in	O
these	O
purified	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

We	O
found	O
that	O
GATA-1	B-DNA
and	I-DNA
tal-1	I-DNA
genes	I-DNA
are	O
coexpressed	O
in	O
these	O
three	O
lineages	O
.	O

Remarkably	O
,	O
the	O
expression	O
of	O
both	O
genes	O
is	O
downmodulated	O
during	O
erythroid	O
and	O
megakaryocytic	O
terminal	O
maturation	O
.	O

In	O
immature	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
,	O
tal-1	B-DNA
and	I-DNA
GATA-1	I-DNA
genes	I-DNA
are	O
coexpressed	O
in	O
committed	B-cell_type
progenitors	I-cell_type
cells	I-cell_type
(	O
CD34+/CD38	B-cell_line
(	I-cell_line
2+	I-cell_line
)	I-cell_line
)	O
,	O
whereas	O
they	O
are	O
not	O
detectable	O
in	O
the	O
most	O
primitive	B-cell_type
cells	I-cell_type
(	O
CD34	B-cell_line
(	I-cell_line
2+	I-cell_line
)	I-cell_line
/CD38-	I-cell_line
)	O
.	O

In	O
contrast	O
,	O
GATA-2	B-protein
is	O
strongly	O
expressed	O
in	O
both	O
most	B-cell_type
primitive	I-cell_type
and	I-cell_type
committed	I-cell_type
progenitors	I-cell_type
cells	I-cell_type
,	O
whereas	O
GATA-3	B-protein
is	O
mostly	O
detected	O
in	O
most	O
primitive	O
ones	O
.	O

Altogether	O
our	O
results	O
strongly	O
suggest	O
that	O
GATA-1	B-protein
modulates	O
the	O
transcription	O
of	O
tal-1	B-protein
during	O
the	O
differentiation	O
of	O
the	O
erythroid	B-cell_type
,	I-cell_type
megakaryocytic	I-cell_type
,	I-cell_type
and	I-cell_type
basosophilic	I-cell_type
lineages	I-cell_type
.	O

The	O
lytic	O
transition	O
of	O
Epstein-Barr	O
virus	O
is	O
imitated	O
by	O
recombinant	B-cell_line
B-cells	I-cell_line
.	O

Lytic	O
transition	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
initiated	O
by	O
distinct	O
immediate	O
early	O
regulators	O
of	O
the	O
viral	O
cycle	O
,	O
in	O
synchronization	O
to	O
temporary	O
,	O
permissive	O
conditions	O
during	O
host	O
cell	O
differentiation	O
.	O

We	O
developed	O
eukaryotic	O
vectors	O
suitable	O
to	O
imitate	O
the	O
processes	O
involved	O
in	O
lytic	O
transition	O
in	O
cell	O
culture	O
systems	O
.	O

Two	O
stable	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
established	O
:	O
R59Z	B-cell_line
activator	I-cell_line
cells	I-cell_line
were	O
used	O
to	O
induce	O
lytic	O
EBV	O
expression	O
in	O
a	O
constitutive	O
manner	O
by	O
the	O
production	O
of	O
the	O
BZLF	B-protein
1	I-protein
trans-activator	I-protein
(	O
Zta	B-protein
)	O
.	O

R7-57	B-cell_line
reporter	I-cell_line
cells	I-cell_line
,	O
on	O
the	O
other	O
hand	O
,	O
signaled	O
induced	O
activity	O
of	O
the	O
lytic	B-DNA
origin	I-DNA
of	I-DNA
EBV	I-DNA
replication	I-DNA
(	O
ori	B-DNA
Lyt	I-DNA
)	O
.	O

Different	O
modes	O
,	O
like	O
chemical	O
induction	O
,	O
lytic	O
superinfection	O
with	O
EBV	O
and	O
single	O
gene	O
trans-activation	O
converted	O
the	O
recombinant	B-DNA
ori	I-DNA
Lyt	I-DNA
element	I-DNA
in	O
R7-57	B-cell_line
reporter	I-cell_line
cells	I-cell_line
.	O

BZLF	B-protein
1	I-protein
,	O
transiently	O
expressed	O
in	O
R7-57	B-cell_line
reporter	I-cell_line
cells	I-cell_line
,	O
was	O
the	O
only	O
EBV	B-protein
trans-activator	I-protein
found	O
,	O
sufficient	O
in	O
inducing	O
the	O
viral	O
lytic	O
cycle	O
.	O

Basing	O
on	O
these	O
experiments	O
,	O
trans-cellular	O
activation	O
of	O
EBV	O
was	O
tested	O
by	O
cocultivation	O
of	O
BZLF	B-cell_type
1-expressing	I-cell_type
R59Z	I-cell_type
activator	I-cell_type
cells	I-cell_type
with	O
the	O
R7-57	B-cell_line
reporter	I-cell_line
line	I-cell_line
.	O

No	O
lytic	O
effect	O
on	O
the	O
reporter	O
cells	O
could	O
be	O
measured	O
,	O
neither	O
by	O
cocultivation	O
of	O
activator	B-cell_line
cells	I-cell_line
nor	O
by	O
coincubation	O
of	O
BZLF	B-protein
1	I-protein
-containing	O
cell	O
lysates	O
.	O

Latency	O
breaking	O
activity	O
,	O
however	O
,	O
was	O
transferred	O
from	O
activator	B-cell_line
to	O
reporter	B-cell_line
cells	I-cell_line
when	O
active	O
,	O
exogenous	O
virus	O
was	O
added	O
.	O

The	O
cell	O
system	O
described	O
in	O
these	O
experiments	O
provides	O
a	O
tool	O
for	O
the	O
detection	O
of	O
EBV	O
reactivation	O
and	O
demonstrates	O
the	O
potential	O
of	O
the	O
lytic	O
regulatory	B-DNA
gene	I-DNA
BZLF	I-DNA
1	I-DNA

Costimulation	O
of	O
cAMP	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
pathways	O
inhibits	O
the	O
CD3	B-protein
-dependent	O
T	O
cell	O
activation	O
and	O
leads	O
to	O
a	O
persistent	O
expression	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
.	O

The	O
effects	O
mediated	O
by	O
a	O
combined	O
stimulation	O
of	O
cAMP	O
-and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
-dependent	O
pathways	O
have	O
been	O
investigated	O
in	O
different	O
cellular	O
systems	O
,	O
and	O
it	O
has	O
been	O
shown	O
that	O
they	O
may	O
complement	O
each	O
other	O
in	O
activating	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
upon	O
the	O
stimulation	O
of	O
both	O
pathways	O
T	B-cell_type
lymphocytes	I-cell_type
became	O
refractory	O
to	O
activation	O
via	O
the	O
CD3/T	B-protein
cell	I-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
complex	O
.	O

T	B-cell_type
cells	I-cell_type
preincubated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
dibutyryl	O
cAMP	O
(	O
Bt2cAMP	O
)	O
displayed	O
a	O
deficient	O
proliferative	O
ability	O
in	O
response	O
to	O
anti-CD3	B-protein
mAb	I-protein
stimulation	O
,	O
whereas	O
lymphocytes	B-cell_type
treated	O
individually	O
with	O
either	O
Bt2cAMP	O
or	O
PMA	O
responded	O
comparably	O
to	O
untreated	O
samples	O
.	O

We	O
detected	O
an	O
association	O
between	O
the	O
reduced	O
mitogenic	O
response	O
and	O
low	O
expression	O
of	O
both	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
the	O
alpha	B-protein
chain	I-protein
(	O
CD25	B-protein
)	O
of	O
the	O
IL-2	B-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	O
.	O

Analysis	O
of	O
intracellular	O
Ca2+	O
mobilization	O
suggested	O
that	O
the	O
CD3	B-protein
/	O
TcR	B-protein
-dependent	O
signal	O
transduction	O
was	O
impaired	O
in	O
PMA/Bt2cAMP-treated	B-cell_line
cells	I-cell_line
.	O

Remarkably	O
,	O
we	O
observed	O
that	O
these	O
samples	O
displayed	O
a	O
persistent	O
expression	O
of	O
the	O
c-fos	B-DNA
protooncogene	I-DNA
,	O
associated	O
to	O
an	O
increased	O
AP-1	B-protein
DNA-binding	O
activity	O
,	O
whereas	O
no	O
variations	O
of	O
CREB	B-protein
or	O
NF-kB	B-protein
were	O
detected	O
.	O

Neither	O
Bt2cAMP	O
nor	O
PMA	O
individually	O
mediated	O
these	O
sustained	O
effects	O
,	O
which	O
therefore	O
appear	O
as	O
a	O
consequence	O
of	O
the	O
interplay	O
between	O
both	O
metabolic	O
stimuli	O
.	O

Altogether	O
,	O
the	O
data	O
provide	O
the	O
evidence	O
that	O
both	O
pathways	O
complement	O
each	O
other	O
in	O
regulating	O
gene	O
expression	O
and	O
,	O
conversely	O
,	O
downregulate	O
the	O
TcR	B-protein
transduction	O
mechanisms	O
.	O

The	O
lymphotoxin	B-DNA
promoter	I-DNA
is	O
stimulated	O
by	O
HTLV-I	B-protein
tax	I-protein
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

The	O
HTLV-I	B-protein
transcriptional	I-protein
activator	I-protein
tax	I-protein
was	O
used	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
lymphotoxin	B-DNA
(	I-DNA
LT	I-DNA
;	I-DNA
TNF-beta	I-DNA
)	I-DNA
gene	I-DNA
induction	O
.	O

Tax-expressing	B-cell_line
cell	I-cell_line
lines	I-cell_line
produce	O
LT	B-protein
biologic	O
activity	O
.	O

An	O
LT	B-DNA
promoter	I-DNA
(	I-DNA
LT-293	I-DNA
)	I-DNA
CAT	I-DNA
construct	I-DNA
that	O
contained	O
an	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
was	O
active	O
in	O
the	O
LT-producing	B-cell_line
C81-66-45	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
contains	O
defective	O
HTLV-I	O
but	O
expresses	O
tax	B-protein
.	O

The	O
observation	O
that	O
a	O
mutated	B-DNA
LT-kappa	I-DNA
B	I-DNA
construct	I-DNA
(	O
M1-CAT	B-DNA
)	O
was	O
inactive	O
in	O
C81-66-45	B-cell_line
,	O
confirmed	O
the	O
importance	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
LT	B-protein
gene	O
expression	O
.	O

Tax	B-protein
was	O
transfected	O
into	O
HTLV-I-negative	B-cell_line
human	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stably	O
expressing	O
tax	B-protein
contained	O
elevated	O
levels	O
of	O
NF-kappa	B-protein
B	I-protein
that	O
directly	O
bound	O
to	O
the	O
LT-kappa	B-DNA
B	I-DNA
site	I-DNA
.	O

Tax	B-protein
co-transfected	O
with	O
reporter	B-DNA
constructs	I-DNA
into	O
Jurkat	B-cell_line
cells	I-cell_line
maximally	O
activated	O
HTLV-I-LTR-CAT	B-protein
and	O
kappa	B-protein
B-fos-CAT	I-protein
and	O
also	O
activated	O
LT-293	B-DNA
to	O
a	O
lesser	O
extent	O
.	O

In	O
JM	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
tax	B-protein
induced	O
LT-293	B-DNA
activity	O
by	O
two-	O
to	O
four-fold	O
,	O
though	O
there	O
was	O
no	O
induction	O
of	O
M1-CAT	B-protein
.	O

The	O
increase	O
in	O
LT-293	B-DNA
CAT	B-protein
activity	O
mirrored	O
the	O
increase	O
in	O
LT	B-protein
biologic	O
activity	O
seen	O
under	O
these	O
conditions	O
.	O

These	O
studies	O
,	O
the	O
first	O
to	O
demonstrate	O
induction	O
of	O
LT	B-DNA
promoter	I-DNA
activity	O
over	O
basal	O
levels	O
,	O
indicate	O
that	O
HTLV-I	B-protein
tax	I-protein
causes	O
low-level	O
activation	O
of	O
both	O
endogenous	O
LT	B-protein
and	O
the	O
LT	B-DNA
promoter	I-DNA
,	O
at	O
least	O
in	O
part	O
through	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

A	O
concatenated	O
form	O
of	O
Epstein-Barr	B-DNA
viral	I-DNA
DNA	I-DNA
in	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
induced	O
by	O
transfection	O
with	O
BZLF1	B-protein
.	O

The	O
replicative	O
form	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
DNA	O
was	O
studied	O
using	O
two	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
X50-7	O
and	O
6F11	O
,	O
which	O
are	O
latently	O
infected	O
by	O
Epstein-Barr	O
virus	O
.	O

The	O
lytic	O
cycle	O
of	O
EBV	O
infection	O
was	O
induced	O
by	O
transfection	O
of	O
the	O
cells	O
with	O
the	O
BRLF1/BZLF1	B-DNA
coding	I-DNA
region	I-DNA
of	O
the	O
P3HR-1	B-DNA
defective	I-DNA
genome	I-DNA
.	O

We	O
combined	O
two	O
techniques	O
to	O
identify	O
the	O
productive	O
replicative	O
form	O
of	O
Epstein-Barr	B-DNA
viral	I-DNA
DNA	I-DNA
in	O
the	O
lytic	B-cell_line
cycle-induced	I-cell_line
cells	I-cell_line
.	O

Restriction	O
enzyme	O
analysis	O
followed	O
by	O
Southern	O
blot	O
hybridization	O
identified	O
a	O
significant	O
increase	O
in	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	B-DNA
DNA	I-DNA
.	O

This	O
indicates	O
an	O
increase	O
in	O
either	O
episomal	B-DNA
DNA	I-DNA
or	O
concatameric	B-DNA
linear	I-DNA
DNA	I-DNA
.	O

Southern	O
blot	O
analysis	O
of	O
in	O
situ	O
lysing	O
gels	O
revealed	O
that	O
the	O
cellular	O
content	O
of	O
linear	B-DNA
EBV	I-DNA
DNA	I-DNA
was	O
also	O
increased	O
significantly	O
after	O
the	O
initiation	O
of	O
the	O
viral	O
lytic	O
cycle	O
,	O
while	O
the	O
amount	O
of	O
circular	O
DNA	O
remained	O
approximately	O
constant	O
.	O

We	O
propose	O
from	O
these	O
results	O
that	O
the	O
source	O
of	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	B-DNA
DNA	I-DNA
is	O
a	O
concatenated	B-DNA
linear	I-DNA
EBV	I-DNA
DNA	I-DNA
molecule	I-DNA
,	O
and	O
that	O
such	O
a	O
concatenated	O
molecule	O
most	O
likely	O
represents	O
a	O
replicative	O
form	O
of	O
EBV	B-DNA
DNA	I-DNA
in	O
productively	O
infected	O
cells	O
.	O

Expression	O
levels	O
of	O
the	O
thyrotropin	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
autoimmune	O
thyroid	O
disease	O
:	O
coregulation	O
with	O
parameters	O
of	O
thyroid	O
function	O
and	O
inverse	O
relation	O
to	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
classes	I-protein
I	I-protein
and	I-protein
II	I-protein
.	O

Using	O
a	O
human	B-DNA
TSH	I-DNA
receptor	I-DNA
(	I-DNA
TSH-R	I-DNA
)	I-DNA
cDNA	I-DNA
probe	I-DNA
,	O
we	O
investigated	O
TSH-R	B-protein
transcript	O
levels	O
in	O
13	O
human	O
thyroid	O
fragments	O
by	O
Northern	O
blot	O
analysis	O
;	O
7	O
Graves	O
'	O
disease	O
,	O
2	O
Hashimoto	O
's	O
disease	O
,	O
3	O
endemic	O
goiter	O
,	O
and	O
1	O
healthy	O
thyroid	O
gland	O
were	O
studied	O
.	O

TSH-R	B-protein
expression	O
levels	O
were	O
variable	O
,	O
but	O
displayed	O
a	O
close	O
correlation	O
to	O
the	O
expression	O
of	O
thyroid	B-protein
peroxidase	I-protein
(	O
r	O
=	O
0.703	O
;	O
P	O
<	O
0.05	O
)	O
,	O
thyroglobulin	B-protein
(	O
r	O
=	O
0.817	O
;	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
nuclear	B-DNA
oncogene	I-DNA
c-fos	I-DNA
(	O
r	O
=	O
0.935	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
c-myc	B-protein
.	O

Overall	O
,	O
TSH-R	B-protein
transcript	O
levels	O
were	O
low	O
or	O
absent	O
in	O
those	O
thyroids	O
in	O
which	O
expression	O
of	O
the	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
or	I-protein
II	I-protein
(	O
MHC	B-protein
I	I-protein
or	I-protein
II	I-protein
)	O
was	O
high	O
,	O
thus	O
establishing	O
an	O
inverse	O
relation	O
(	O
MHC	B-protein
I	I-protein
,	O
r	O
=	O
-0.791	O
;	O
P	O
<	O
0.01	O
;	O
MHC	B-protein
II	I-protein
,	O
r	O
=	O
-0.784	O
;	O
P	O
<	O
0.01	O
)	O
.	O

In	O
situ	O
hybridization	O
showed	O
that	O
apart	O
from	O
lymphocytes	B-cell_type
,	O
thyroid	B-cell_type
cells	I-cell_type
themselves	O
were	O
the	O
source	O
of	O
MHC	B-protein
II	I-protein
transcripts	I-protein
.	O

gamma-Interferon	B-protein
expression	O
was	O
only	O
detectable	O
in	O
1	O
Hashimoto	O
's	O
goiter	O
.	O

Our	O
findings	O
suggest	O
that	O
next	O
to	O
lymphocyte	O
infiltration	O
,	O
active	O
regulatory	O
events	O
in	O
the	O
thyrocyte	B-cell_type
are	O
responsible	O
for	O
the	O
inverse	O
relation	O
between	O
functional	O
parameters	O
(	O
TSH-R	B-protein
,	O
thyroid	B-protein
peroxidase	I-protein
,	O
thyroglobulin	B-protein
,	O
and	O
c-fos	O
)	O
and	O
immunological	O
markers	O
(	O
MHC	B-protein
I	I-protein
and	I-protein
II	I-protein
)	O
.	O

Functional	O
antagonism	O
between	O
vitamin	O
D3	O
and	O
retinoic	O
acid	O
in	O
the	O
regulation	O
of	O
CD14	O
and	O
CD23	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	B-cell_line
cells	I-cell_line
.	O

1	O
,	O
25	O
alpha-Dihydroxicholecalciferol	O
(	O
VitD3	O
)	O
and	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
important	O
regulators	O
of	O
the	O
proliferation	O
and	O
differentiation	O
of	O
several	O
cell	O
types	O
.	O

This	O
paper	O
describes	O
how	O
the	O
expression	O
of	O
the	O
monocyte-macrophage	B-protein
Ag	I-protein
,	O
CD14	B-protein
,	O
and	O
the	O
low	O
affinity	B-protein
Fc	I-protein
receptor	I-protein
for	O
IgE	B-protein
,	O
CD23	B-protein
,	O
were	O
inversely	O
regulated	O
during	O
VitD3	O
-and	O
RA-induced	O
monocytic	O
differentiation	O
of	O
human	B-cell_line
U-937	I-cell_line
monoblasts	I-cell_line
.	O

PMA	O
induced	O
the	O
expression	O
of	O
both	O
CD14	B-protein
and	O
CD23	B-RNA
mRNA	I-RNA
and	O
protein	O
.	O

Exposure	O
to	O
VitD3	O
rapidly	O
induced	O
the	O
de	O
novo	O
expression	O
of	O
CD14	B-RNA
mRNA	I-RNA
and	O
protein	O
.	O

The	O
addition	O
of	O
cycloheximide	O
completely	O
blocked	O
the	O
VitD3	O
induction	O
of	O
CD14	B-RNA
mRNA	I-RNA
expression	O
,	O
indicating	O
that	O
the	O
induction	O
was	O
dependent	O
on	O
ongoing	O
protein	O
synthesis	O
.	O

While	O
inducing	O
CD14	B-protein
expression	O
,	O
VitD3	O
concomitantly	O
suppressed	O
the	O
basal	O
,	O
PMA-	O
,	O
and	O
RA-inducible	O
CD23	B-protein
expression	O
in	O
a	O
dose-dependent	O
manner	O
.	O

In	O
contrast	O
,	O
U-937	B-cell_line
cells	I-cell_line
induced	O
by	O
RA	O
strongly	O
increased	O
their	O
expression	O
of	O
CD23	B-RNA
mRNA	I-RNA
and	O
protein	O
,	O
whereas	O
they	O
completely	O
lacked	O
detectable	O
CD14	O
cell	O
surface	O
or	O
mRNA	O
expression	O
.	O

Furthermore	O
,	O
the	O
VitD3	O
-and	O
the	O
PMA-induced	O
CD14	B-protein
expression	O
was	O
inhibited	O
as	O
a	O
temporal	O
consequence	O
of	O
the	O
RA-induced	O
differentiation	O
.	O

The	O
results	O
suggest	O
that	O
there	O
exists	O
a	O
functional	O
antagonism	O
between	O
VitD3	O
and	O
RA	O
that	O
may	O
have	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
certain	O
immune	O
and	O
inflammatory	O
responses	O
through	O
their	O
inverse	O
effects	O
on	O
CD14	O
and	O
CD23	O
gene	O
expression	O
.	O

Cell-specific	O
bifunctional	O
role	O
of	O
Jun	B-DNA
oncogene	I-DNA
family	I-DNA
members	I-DNA
on	O
glucocorticoid	B-protein
receptor	I-protein
-dependent	O
transcription	O
.	O

Interaction	O
between	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
-	O
and	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
-mediated	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
the	O
PKC	B-protein
activating	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
to	O
inhibit	O
GR	B-protein
-dependent	O
transcription	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

Here	O
we	O
report	O
that	O
this	O
interference	O
is	O
cell	O
specific	O
,	O
as	O
TPA	O
augmented	O
dexamethasone-induced	O
transcriptional	O
activation	O
of	O
the	O
MMTV	B-DNA
LTR	I-DNA
in	O
several	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
but	O
was	O
inhibitory	O
in	O
NIH-3T3	B-cell_line
fibroblasts	I-cell_line
.	O

TPA-GR	O
synergism	O
was	O
determined	O
to	O
have	O
occurred	O
at	O
the	O
GR-responsive	B-DNA
element	I-DNA
(	O
GRE	B-DNA
)	O
level	O
by	O
functional	O
analysis	O
of	O
deletion	B-DNA
mutants	I-DNA
or	O
synthetic	B-DNA
GRE	I-DNA
oligonucleotides	I-DNA
driving	O
chloramphenicol	B-protein
acetyl-transferase	I-protein
expression	O
.	O

Synergism	O
required	O
an	O
intact	O
GR	B-protein
DNA-binding	I-protein
domain	I-protein
,	O
whereas	O
amino-	B-protein
or	I-protein
carboxyl-terminal	I-protein
domains	I-protein
were	O
dispensable	O
.	O

The	O
effect	O
was	O
abrogated	O
by	O
the	O
PKC	B-protein
inhibitor	O
staurosporine	O
,	O
suggesting	O
a	O
role	O
for	O
PKC	B-protein
.	O

Increased	O
c-jun	B-protein
,	O
jun-B	B-protein
,	O
and	O
jun-D	B-protein
expression	O
above	O
basal	O
levels	O
and	O
increased	O
transcriptional	O
activity	O
of	O
AP-1/TPA	B-DNA
responsive	I-DNA
elements	I-DNA
fused	O
to	O
chloramphenicol	B-DNA
acetyl-transferase	I-DNA
vectors	I-DNA
were	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
treated	O
with	O
TPA	O
alone	O
or	O
in	O
combination	O
with	O
dexamethasone	O
.	O

The	O
ability	O
of	O
Jun	B-protein
proteins	I-protein
to	O
cooperate	O
with	O
GR	B-protein
in	O
T	B-cell_type
cells	I-cell_type
has	O
been	O
investigated	O
after	O
transfection	O
of	O
c-jun	B-DNA
,	I-DNA
jun-B	I-DNA
,	I-DNA
or	I-DNA
jun-D	I-DNA
expression	I-DNA
vectors	I-DNA
,	O
which	O
augmented	O
GR	B-protein
-dependent	O
transcription	O
from	O
either	O
MMTV	B-DNA
LTR	I-DNA
or	O
GRE	B-DNA
.	O

Conversely	O
,	O
c-jun	B-protein
and	O
jun-B	B-protein
transfection	O
blunted	O
GR	B-protein
-dependent	O
transcription	O
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

The	O
presence	O
of	O
c-fos	B-protein
had	O
a	O
negative	O
influence	O
on	O
GR	B-protein
function	O
and	O
correlated	O
with	O
the	O
cell-specific	O
synergistic	O
or	O
antagonistic	O
activity	O
of	O
Jun	B-protein
with	O
respect	O
to	O
GR	B-protein
;	O
high	O
basal	O
expression	O
of	O
c-fos	B-protein
as	O
well	O
as	O
AP-1	B-protein
DNA	O
binding	O
and	O
transcriptional	O
activity	O
were	O
observed	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
but	O
not	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
overexpression	O
of	O
exogenous	B-protein
c-fos	I-protein
has	O
an	O
inhibitory	O
effect	O
on	O
GR	B-protein
-dependent	O
transcription	O
from	O
GRE	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
propose	O
that	O
Jun	B-protein
plays	O
a	O
bifunctional	O
role	O
on	O
GR	B-protein
-dependent	O
transcriptional	O
activation	O
of	O
GRE	B-DNA
,	O
selecting	O
either	O
synergistic	O
or	O
antagonistic	O
activity	O
depending	O
on	O
the	O
cell-specific	O
microenvironment	O
.	O

In	O
this	O
regard	O
,	O
intracellular	O
levels	O
of	O
c-fos	B-protein
appear	O
to	O
be	O
influential	O
.	O

Cell	O
type-	O
and	O
stage-specific	O
expression	O
of	O
the	O
CD20/B1	B-protein
antigen	I-protein
correlates	O
with	O
the	O
activity	O
of	O
a	O
diverged	O
octamer	O
DNA	O
motif	O
present	O
in	O
its	O
promoter	B-DNA
.	O

The	O
CD20	B-DNA
(	I-DNA
B1	I-DNA
)	I-DNA
gene	I-DNA
encodes	O
a	O
B	B-protein
cell-specific	I-protein
protein	I-protein
involved	O
in	O
the	O
regulation	O
of	O
human	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Studies	O
with	O
5	B-DNA
'	I-DNA
deletion	I-DNA
CD20	I-DNA
promoter-CAT	I-DNA
constructs	I-DNA
have	O
previously	O
revealed	O
two	O
regions	O
of	O
the	O
promoter	B-DNA
between	O
bases	O
-186	O
and	O
-280	O
and	O
between	O
bases	O
-280	O
and	O
-454	O
which	O
contained	O
positive	B-DNA
regulatory	I-DNA
elements	I-DNA
.	O

In	O
this	O
study	O
we	O
identified	O
a	O
sequence	B-DNA
element	I-DNA
present	O
in	O
the	O
most	O
proximal	O
region	O
located	O
between	O
bases	O
-214	O
and	O
-201	O
,	O
TTCTTCTAATTAA	O
,	O
which	O
is	O
important	O
in	O
the	O
high	O
constitutive	O
expression	O
of	O
CD20	B-protein
in	O
mature	O
B	O
cells	O
and	O
the	O
induction	O
of	O
CD20	B-protein
in	O
pre-B	B-cell_type
cells	I-cell_type
.	O

This	O
sequence	B-DNA
element	I-DNA
was	O
referred	O
to	O
as	O
the	O
BAT	B-DNA
box	I-DNA
and	O
its	O
deletion	O
significantly	O
reduced	O
the	O
activity	O
of	O
a	O
CD20	O
promoter-CAT	O
construct	O
in	O
B	O
cells	O
.	O

Mobility	O
shift	O
assays	O
with	O
various	O
mutant	O
probes	O
and	O
B	O
cell	O
nuclear	O
extracts	O
demonstrated	O
that	O
the	O
core	O
sequence	O
TAAT	O
was	O
essential	O
for	O
binding	O
to	O
this	O
site	O
.	O

Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	B-DNA
box	I-DNA
,	O
and	O
a	O
TA-rich	O
sequence	O
present	O
in	O
the	O
CD21	B-DNA
promoter	I-DNA
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	B-protein
proteins	I-protein
suggesting	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
were	O
Oct-1	B-protein
and	O
Oct-2	B-protein
.	O

Southwestern	O
blotting	O
and	O
UV	O
cross-linking	O
studies	O
confirmed	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
were	O
Oct-1	B-protein
and	O
Oct-2	B-protein
.	O

The	O
affinity	O
of	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
for	O
the	O
BAT	B-DNA
box	I-DNA
was	O
approximately	O
25-fold	O
less	O
than	O
for	O
the	O
octamer	B-DNA
sequence	I-DNA
and	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
dissociated	O
from	O
the	O
BAT	B-DNA
box	I-DNA
10-fold	O
more	O
rapidly	O
than	O
from	O
the	O
octamer	B-DNA
sequence	I-DNA
.	O

Despite	O
this	O
lower	O
affinity	O
,	O
a	O
trimer	O
of	O
the	O
BAT	B-DNA
box	I-DNA
sequence	I-DNA
was	O
as	O
efficiently	O
transactivated	O
by	O
an	O
Oct-2	B-DNA
expression	I-DNA
vector	I-DNA
as	O
was	O
a	O
trimer	O
of	O
the	O
octamer	B-DNA
sequence	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

The	O
BAT	B-DNA
box	I-DNA
and	O
Oct-2	B-protein
were	O
also	O
implicated	O
in	O
the	O
induction	O
of	O
CD20	B-protein
in	O
the	O
pre-B	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PB-697	B-cell_line
,	O
via	O
phorbol	O
esters	O
.	O

The	O
induction	O
of	O
CD20	B-RNA
mRNA	I-RNA
was	O
temporally	O
associated	O
with	O
induction	O
of	O
Oct-2	B-RNA
mRNA	I-RNA
and	O
a	O
BAT	B-DNA
box-deleted	I-DNA
CD20-CAT	I-DNA
construct	I-DNA
,	O
in	O
contrast	O
to	O
the	O
wild	O
type	O
,	O
was	O
poorly	O
induced	O
by	O
phorbol	O
esters	O
.	O

Together	O
these	O
results	O
suggest	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
are	O
important	O
in	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
CD20	B-protein
and	O
perhaps	O
CD21	B-protein
.	O

Human	B-cell_type
CD4	I-cell_type
lymphocytes	I-cell_type
specifically	O
recognize	O
a	O
peptide	O
representing	O
the	O
fusion	O
region	O
of	O
the	O
hybrid	B-protein
protein	I-protein
pml/RAR	B-protein
alpha	I-protein
present	O
in	O
acute	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

Fusion	O
proteins	O
present	O
in	O
leukemic	B-cell_type
cells	I-cell_type
frequently	O
contain	O
a	O
new	O
amino	O
acid	O
at	O
the	O
fusion	B-protein
point	I-protein
.	O

We	O
tested	O
whether	O
a	O
peptide	O
(	O
BCR1/25	O
)	O
encompassing	O
the	O
fusion	B-protein
region	I-protein
of	O
the	O
hybrid	O
molecule	O
pml/RAR	B-protein
alpha	I-protein
,	O
which	O
is	O
selectively	O
expressed	O
by	O
acute	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
(	I-cell_type
APL	I-cell_type
)	I-cell_type
cells	I-cell_type
,	O
can	O
be	O
recognized	O
by	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
vitro	O
.	O

CD4+	B-cell_type
lymphocytes	I-cell_type
,	O
at	O
both	O
polyclonal	O
and	O
clonal	O
level	O
,	O
recognized	O
peptide	O
BCR1/25	O
in	O
an	O
HLA-DR	B-protein
--	O
restricted	O
fashion	O
on	O
presentation	O
by	O
autologous	B-cell_type
antigen-presenting	I-cell_type
cell	I-cell_type
(	O
APC	B-cell_type
)	O
or	O
by	O
APC	B-cell_type
expressing	O
the	O
HLA-DR11	B-protein
restricting	I-protein
molecule	I-protein
.	O

Control	O
peptides	O
corresponding	O
to	O
the	O
normal	O
pml	B-protein
and	O
RAR	B-protein
alpha	I-protein
proteins	I-protein
were	O
not	O
recognized	O
.	O

One	O
clone	O
(	O
DEG5	B-cell_line
)	O
also	O
exerted	O
a	O
high	O
and	O
specific	O
cytotoxicity	O
against	O
autologous	B-cell_line
cells	I-cell_line
pulsed	O
with	O
BCR1/25	O
.	O

The	O
autologous	B-cell_line
DE	I-cell_line
LCL	I-cell_line
containing	O
a	O
transduced	O
pml/RAR	B-DNA
alpha	I-DNA
fusion	I-DNA
gene	I-DNA
and	O
expressing	O
a	O
bcr1	O
type	O
of	O
the	O
pml/RAR	B-protein
alpha	I-protein
hybrid	O
protein	O
induced	O
the	O
proliferation	O
of	O
DE	B-cell_line
anti-BCR1/25	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
.	O

It	O
is	O
concluded	O
that	O
the	O
bcr1	B-protein
type-pml/RAR	I-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
of	O
APL	B-cell_line
contains	O
an	O
antigenic	O
site	O
,	O
absent	O
from	O
the	O
normal	O
parent	O
molecules	O
and	O
recognized	O
by	O
human	B-cell_line
CD4+	I-cell_line
lymphocytes	I-cell_line
.	O

The	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
Egr-1	B-protein
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
along	O
the	O
macrophage	B-cell_type
lineage	I-cell_type
.	O

We	O
have	O
isolated	O
cDNA	B-DNA
clones	I-DNA
of	O
myeloid	B-DNA
differentiation	I-DNA
primary	I-DNA
response	I-DNA
(	I-DNA
MyD	I-DNA
)	I-DNA
genes	I-DNA
,	O
activated	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
following	O
induction	O
for	O
differentiation	O
along	O
either	O
the	O
macrophage	B-cell_type
or	O
granulocyte	B-cell_type
lineage	I-cell_type
in	O
human	O
myeloblastic	B-cell_line
leukemia	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
.	O

One	O
cDNA	B-DNA
clone	I-DNA
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr-1	B-protein
,	O
a	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
.	O

The	O
Egr-1	B-DNA
gene	I-DNA
was	O
observed	O
to	O
be	O
transcriptionally	O
silent	O
in	O
HL-60	B-cell_line
cells	I-cell_line
,	O
but	O
active	O
in	O
U-937	B-cell_line
and	O
M1	B-cell_line
cells	I-cell_line
,	O
the	O
latter	O
two	O
being	O
predetermined	O
for	O
macrophage	O
differentiation	O
.	O

Egr-1	B-protein
antisense	O
oligomers	O
in	O
the	O
culture	O
media	O
blocked	O
macrophage	O
differentiation	O
in	O
both	O
myeloid	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
normal	O
myeloblasts	B-cell_type
.	O

HL-60	B-cell_line
cells	I-cell_line
constitutively	O
expressing	O
an	O
Egr-1	B-DNA
transgene	I-DNA
(	O
HL-60Egr-1	B-DNA
)	O
could	O
be	O
induced	O
for	O
macrophage	B-cell_type
,	O
but	O
not	O
granulocyte	B-cell_type
,	O
differentiation	O
.	O

These	O
observations	O
indicate	O
that	O
expression	O
of	O
Egr-1	B-protein
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
of	O
myeloblasts	B-cell_type
along	O
the	O
macrophage	B-cell_type
lineage	I-cell_type
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
interacts	O
with	O
an	O
EBNA2	B-DNA
responsive	I-DNA
cis-element	I-DNA
of	O
the	O
terminal	B-DNA
protein	I-DNA
1	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
protein	I-protein
EBNA2	I-protein
acts	O
as	O
a	O
transcriptional	B-protein
activator	I-protein
of	O
cellular	B-DNA
and	I-DNA
viral	I-DNA
genes	I-DNA
and	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
immortalization	O
of	O
human	B-cell_type
primary	I-cell_type
B-cells	I-cell_type
by	O
EBV	O
.	O

We	O
have	O
shown	O
previously	O
that	O
EBNA2	B-protein
transactivates	O
the	O
promoters	O
of	O
the	O
latent	B-protein
membrane	I-protein
antigens	I-protein
LMP	B-protein
,	O
TP1	B-protein
and	O
TP2	B-protein
.	O

The	O
promoter	B-DNA
of	O
the	O
TP1	B-DNA
gene	I-DNA
was	O
chosen	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
molecular	O
mechanism	O
of	O
EBNA2	B-protein
mediated	O
transactivation	O
.	O

To	O
identify	O
an	O
EBNA2	B-DNA
dependent	I-DNA
cis-acting	I-DNA
element	I-DNA
,	O
various	O
TP1	B-DNA
promoter-reporter	I-DNA
gene	I-DNA
constructs	I-DNA
were	O
transfected	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
EBNA2	B-DNA
expression	I-DNA
vector	I-DNA
into	O
the	O
established	O
B-cell	B-cell_line
line	I-cell_line
BL41-P3HR1	I-cell_line
.	O

We	O
were	O
able	O
to	O
delineate	O
an	O
81	B-DNA
bp	I-DNA
EBNA2	I-DNA
responsive	I-DNA
region	I-DNA
between	O
-258	O
and	O
-177	O
relative	O
to	O
the	O
TP1	B-DNA
RNA	I-DNA
start	I-DNA
site	I-DNA
.	O

The	O
element	O
worked	O
in	O
either	O
orientation	O
and	O
could	O
mediate	O
EBNA2	B-protein
dependent	O
transactivation	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
three	O
specific	O
protein-DNA	B-protein
complexes	I-protein
formed	O
with	O
sequences	O
of	O
the	O
EBNA2	B-DNA
responsive	I-DNA
element	I-DNA
.	O

Two	O
of	O
these	O
were	O
not	O
cell	O
type	O
specific	O
,	O
but	O
the	O
third	O
was	O
detected	O
only	O
in	O
EBNA2	B-protein
positive	O
cell	O
extracts	O
.	O

Gel-shift	O
analysis	O
in	O
the	O
presence	O
of	O
EBNA2	B-protein
specific	O
monoclonal	O
antibodies	O
revealed	O
that	O
EBNA2	B-protein
is	O
a	O
component	O
of	O
the	O
third	O
complex	O
.	O

Thus	O
,	O
these	O
experiments	O
demonstrate	O
that	O
EBNA2	B-protein
interacts	O
with	O
an	O
EBNA2	B-DNA
responsive	I-DNA
cis-element	I-DNA
of	O
the	O
TP1	B-DNA
promoter	I-DNA

Minimally	O
modified	O
low	O
density	O
lipoprotein	B-protein
-induced	O
inflammatory	O
responses	O
in	O
endothelial	B-cell_type
cells	I-cell_type
are	O
mediated	O
by	O
cyclic	O
adenosine	O
monophosphate	O
.	O

We	O
have	O
previously	O
shown	O
that	O
minimally	B-cell_line
oxidized	I-cell_line
LDL	I-cell_line
(	I-cell_line
MM-LDL	I-cell_line
)	I-cell_line
activated	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
to	O
increase	O
their	O
interaction	O
with	O
monocytes	B-cell_type
but	O
not	O
neutrophils	B-cell_type
,	O
inducing	O
monocyte	O
but	O
not	O
neutrophil	O
binding	O
and	O
synthesis	O
of	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
and	O
monocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
M-CSF	B-protein
)	O
.	O

In	O
the	O
present	O
studies	O
we	O
have	O
examined	O
the	O
signaling	O
pathways	O
by	O
which	O
this	O
monocyte-specific	O
response	O
is	O
induced	O
.	O

Both	O
induction	O
of	O
monocyte	O
binding	O
and	O
mRNA	O
levels	O
for	O
M-CSF	B-protein
by	O
MM-LDL	B-protein
were	O
not	O
inhibited	O
in	O
protein	O
kinase	O
C-depleted	O
endothelial	B-cell_type
cells	I-cell_type
.	O

A	O
number	O
of	O
our	O
studies	O
indicate	O
that	O
cAMP	O
is	O
the	O
second	O
messenger	O
for	O
the	O
effects	O
of	O
MM-LDL	B-protein
cited	O
above	O
.	O

Incubation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
MM-LDL	B-protein
caused	O
a	O
173	O
%	O
increase	O
in	O
intracellular	O
cAMP	O
levels	O
.	O

Agents	O
which	O
increased	O
cAMP	O
levels	O
,	O
including	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	O
cAMP	O
,	O
and	O
isoproterenol	O
mimicked	O
the	O
actions	O
of	O
MM-LDL	B-protein
.	O

Agents	O
which	O
elevated	O
cAMP	O
were	O
also	O
shown	O
to	O
activate	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
suggesting	O
a	O
role	O
for	O
this	O
transcription	O
factor	O
in	O
activation	O
of	O
monocyte-endothelial	O
interactions	O
.	O

Although	O
endothelial	B-RNA
leukocyte	I-RNA
adhesion	I-RNA
molecule	I-RNA
(	I-RNA
ELAM	I-RNA
)	I-RNA
mRNA	I-RNA
synthesis	O
can	O
be	O
regulated	O
by	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
ELAM	B-protein
was	O
not	O
expressed	O
and	O
ELAM	B-RNA
mRNA	I-RNA
was	O
only	O
slightly	O
elevated	O
in	O
response	O
to	O
MM-LDL	B-protein
.	O

We	O
present	O
evidence	O
that	O
induction	O
of	O
neutrophil	B-cell_type
binding	O
by	O
LPS	O
is	O
actually	O
suppressed	O
by	O
agents	O
that	O
elevated	O
cAMP	O
levels	O
.	O

Human	B-protein
T	I-protein
cell	I-protein
transcription	I-protein
factor	I-protein
GATA-3	B-protein
stimulates	O
HIV-1	O
expression	O
.	O

A	O
family	O
of	O
transcriptional	O
activating	O
proteins	O
,	O
the	O
GATA	B-protein
factors	I-protein
,	O
has	O
been	O
shown	O
to	O
bind	O
to	O
a	O
consensus	O
motif	O
through	O
a	O
highly	B-protein
conserved	I-protein
C4	I-protein
zinc	I-protein
finger	I-protein
DNA	I-protein
binding	I-protein
domain	I-protein
.	O

One	O
member	O
of	O
this	O
multigene	O
family	O
,	O
GATA-3	B-protein
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
a	O
cellular	O
target	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
replication	O
.	O

In	O
vitro	O
DNase	B-protein
I	I-protein
footprinting	O
analysis	O
revealed	O
six	O
hGATA-3	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
U3	B-DNA
region	I-DNA
(	O
the	O
transcriptional	B-DNA
regulatory	I-DNA
domain	I-DNA
)	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O

Cotransfection	O
of	O
an	O
hGATA-3	B-DNA
expression	I-DNA
plasmid	I-DNA
with	O
a	O
reporter	B-DNA
plasmid	I-DNA
whose	O
transcription	O
is	O
directed	O
by	O
the	O
HIV-1	B-DNA
LTR	I-DNA
resulted	O
in	O
6-	O
to	O
10-fold	O
stimulation	O
of	O
LTR	B-DNA
-mediated	O
transcription	O
,	O
whereas	O
site	O
specific	O
mutation	O
of	O
these	O
GATA	B-DNA
sites	I-DNA
resulted	O
in	O
virtual	O
abrogation	O
of	O
the	O
activation	O
by	O
hGATA-3	B-protein
.	O

Further	O
,	O
deletion	O
of	O
the	O
hGATA-3	B-DNA
transcriptional	I-DNA
activation	I-DNA
domain	I-DNA
abolished	O
GATA-dependent	O
HIV-1	O
trans-activation	O
,	O
showing	O
that	O
the	O
stimulation	O
of	O
viral	O
transcription	O
observed	O
is	O
a	O
direct	O
effect	O
of	O
cotransfected	B-protein
hGATA-3	I-protein
.	O

Introduction	O
of	O
the	O
HIV-1	B-DNA
plasmids	I-DNA
in	O
which	O
the	O
GATA	B-DNA
sites	I-DNA
have	O
been	O
mutated	O
into	O
human	O
T	B-cell_type
lymphocytes	I-cell_type
also	O
caused	O
a	O
significant	O
reduction	O
in	O
LTR	B-DNA
-mediated	O
transcription	O
at	O
both	O
the	O
basal	O
level	O
and	O
in	O
(	O
PHA-	O
plus	O
PMA-	O
)	O
stimulated	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

These	O
observations	O
suggest	O
that	O
in	O
addition	O
to	O
its	O
normal	O
role	O
in	O
T	B-cell_type
lymphocyte	I-cell_type
gene	O
regulation	O
,	O
hGATA-3	B-protein
may	O
also	O
play	O
a	O
significant	O
role	O
in	O
HIV-1	O
transcriptional	O
activation	O
.	O

Cytokine	O
modulation	O
of	O
HIV	O
expression	O
.	O

Cytokines	B-protein
,	O
the	O
peptide	B-protein
hormones	I-protein
which	O
control	O
the	O
homeostasis	O
of	O
the	O
immune	O
system	O
and	O
also	O
play	O
a	O
fundamental	O
role	O
in	O
inflammatory	O
and	O
immune	O
mediated	O
reactions	O
,	O
have	O
been	O
involved	O
at	O
multiple	O
levels	O
in	O
the	O
pathogenesis	O
of	O
the	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
.	O

Infection	O
with	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
has	O
been	O
shown	O
to	O
induce	O
production	O
of	O
several	O
cytokines	B-protein
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Conversely	O
,	O
several	O
cytokines	B-protein
modulate	O
the	O
levels	O
of	O
HIV	O
expression	O
in	O
infected	O
cells	O
of	O
both	O
T	B-cell_type
lymphocytic	I-cell_type
and	I-cell_type
mononuclear	I-cell_type
phagocytic	I-cell_type
lineage	I-cell_type
.	O

Activated	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
,	O
particularly	O
B	B-cell_type
cells	I-cell_type
which	O
are	O
in	O
a	O
state	O
of	O
chronic	O
activation	O
in	O
HIV	O
infected	O
individuals	O
,	O
release	O
HIV-inductive	B-protein
cytokines	I-protein
and	O
thus	O
play	O
a	O
potentially	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
infection	O
.	O

Cloning	O
and	O
functional	O
characterization	O
of	O
early	B-protein
B-cell	I-protein
factor	I-protein
,	O
a	O
regulator	O
of	O
lymphocyte-specific	O
gene	O
expression	O
.	O

Early	B-protein
B-cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
was	O
identified	O
previously	O
as	O
a	O
tissue-specific	O
and	O
differentiation	O
stage-specific	O
DNA-binding	B-protein
protein	I-protein
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
pre-B	B-DNA
and	I-DNA
B	I-DNA
lymphocyte-specific	I-DNA
mb-1	I-DNA
gene	I-DNA
.	O

Partial	O
amino	O
acid	O
sequences	O
obtained	O
from	O
purified	O
EBF	B-protein
were	O
used	O
to	O
isolate	O
cDNA	B-DNA
clones	I-DNA
,	O
which	O
by	O
multiple	O
criteria	O
encode	O
EBF	B-protein
.	O

The	O
recombinant	B-protein
polypeptide	I-protein
formed	O
sequence-specific	O
complexes	O
with	O
the	O
EBF-binding	B-DNA
site	I-DNA
in	O
the	O
mb-1	B-DNA
promoter	I-DNA
.	O

The	O
cDNA	B-DNA
hybridized	O
to	O
multiple	O
transcripts	O
in	O
pre-B	B-cell_line
and	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
but	O
transcripts	O
were	O
not	O
detected	O
at	O
significant	O
levels	O
in	O
plasmacytoma	B-cell_line
,	O
T-cell	B-cell_line
,	O
and	O
nonlymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Expression	O
of	O
recombinant	O
EBF	B-protein
in	O
transfected	B-cell_line
nonlymphoid	I-cell_line
cells	I-cell_line
strongly	O
activated	O
transcription	O
from	O
reporter	O
plasmids	O
containing	O
functional	O
EBF-binding	B-DNA
sites	I-DNA
.	O

Analysis	O
of	O
DNA	O
binding	O
by	O
deletion	O
mutants	O
of	O
EBF	B-protein
identified	O
an	O
amino-terminal	B-protein
cysteine-rich	I-protein
DNA-binding	I-protein
domain	I-protein
lacking	O
obvious	O
sequence	O
similarity	O
to	O
known	O
transcription	B-protein
factors	I-protein
.	O

DNA-binding	O
assays	O
with	O
cotranslated	O
wild-type	O
and	O
truncated	O
forms	O
of	O
EBF	B-protein
indicated	O
that	O
the	O
protein	O
interacts	O
with	O
its	O
site	O
as	O
a	O
homodimer	B-protein
.	O

Deletions	O
delineated	O
a	O
carboxy-terminal	B-protein
dimerization	I-protein
region	I-protein
containing	O
two	O
repeats	O
of	O
15	O
amino	O
acids	O
that	O
show	O
similarity	O
with	O
the	O
dimerization	B-protein
domains	I-protein
of	O
basic-helix-loop-helix	B-protein
proteins	I-protein
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	B-protein
represents	O
a	O
novel	O
regulator	O
of	O
B	O
lymphocyte-specific	O
gene	O
expression	O
.	O

Cell-specific	O
expression	O
of	O
helix-loop-helix	B-protein
transcription	I-protein
factors	I-protein
encoded	O
by	O
the	O
E2A	B-DNA
gene	I-DNA
.	O

The	O
E2A	B-DNA
gene	I-DNA
encodes	O
transcription	B-protein
factors	I-protein
of	O
the	O
helix-loop-helix	B-protein
family	I-protein
that	O
are	O
implicated	O
in	O
cell-specific	O
gene	O
expression	O
as	O
part	O
of	O
dimeric	B-protein
complexes	I-protein
that	O
interact	O
with	O
E	B-DNA
box	I-DNA
enhancer	I-DNA
elements	I-DNA
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
transcripts	O
of	O
the	O
E2A	B-DNA
gene	I-DNA
can	O
be	O
detected	O
in	O
a	O
wide	O
range	O
of	O
cell	O
types	O
.	O

We	O
have	O
now	O
examined	O
expression	O
of	O
the	O
mouse	B-DNA
E2A	I-DNA
gene	I-DNA
at	O
the	O
protein	O
level	O
using	O
polyclonal	O
antisera	O
directed	O
against	O
distinct	O
portions	O
of	O
the	O
E2A	B-protein
protein	I-protein
to	O
probe	O
blots	O
of	O
cellular	O
extracts	O
.	O

A	O
73	B-protein
kDa	I-protein
protein	I-protein
was	O
identified	O
by	O
this	O
analysis	O
:	O
this	O
protein	O
is	O
highly	O
enriched	O
in	O
cell	B-cell_line
lines	I-cell_line
of	I-cell_line
B	I-cell_line
lymphoid	I-cell_line
origin	I-cell_line
as	O
compared	O
to	O
pancreatic	B-cell_type
beta-cells	I-cell_type
and	O
fibroblast	B-cell_type
cells	I-cell_type
.	O

The	O
detection	O
of	O
this	O
protein	O
selectively	O
in	O
extracts	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
correlates	O
with	O
the	O
presence	O
of	O
the	O
E	B-DNA
box	I-DNA
-binding	O
activity	O
LEF1/BCF1	B-protein
in	O
these	O
cells	O
;	O
this	O
binding	O
activity	O
was	O
previously	O
shown	O
to	O
be	O
efficiently	O
recognized	O
by	O
antiserum	O
directed	O
against	O
E2A	B-protein
gene	I-protein
products	I-protein
.	O

Transfection	O
of	O
cells	O
with	O
full	O
length	O
E2A	B-DNA
cDNA	I-DNA
leads	O
to	O
appearance	O
of	O
protein	O
co-migrating	O
with	O
the	O
73	B-protein
kDa	I-protein
protein	I-protein
on	O
SDS	O
gel	O
electrophoresis	O
and	O
co-migrating	O
with	O
LEF1/BCF1	B-protein
on	O
mobility	O
shift	O
analysis	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
view	O
that	O
the	O
DNA-binding	O
activity	O
LEF1/BCF1	B-protein
is	O
a	O
homodimer	B-protein
of	I-protein
E2A	I-protein
proteins	I-protein
;	O
the	O
selective	O
appearance	O
of	O
this	O
putative	O
cell-specific	O
transcription	O
factor	O
in	O
B	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
seems	O
to	O
be	O
attributable	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
elevated	O
E2A	B-protein
protein	I-protein
concentrations	O
in	O
these	O
cells	O
.	O

Hypertension	O
in	O
pregnancy	O
.	O

Pregnancy-induced	O
hypertension	O
(	O
PIH	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
maternal	O
and	O
neonatal	O
morbidity	O
and	O
mortality	O
.	O

In	O
the	O
present	O
study	O
we	O
focused	O
on	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
mainly	O
on	O
the	O
role	O
of	O
mineralocorticoids	O
,	O
reversed	O
blood	O
pressure	O
patterns	O
,	O
and	O
the	O
resulting	O
necessity	O
of	O
continuous	O
monitoring	O
of	O
the	O
preeclamptic	O
mother	O
.	O

Problems	O
of	O
antihypertensive	O
therapy	O
are	O
discussed	O
and	O
the	O
first	O
results	O
of	O
a	O
pilot	O
study	O
with	O
Urapidil	O
are	O
presented	O
.	O

To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxy-corticosterone	O
(	O
18-OH-B	O
)	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
in	O
25	O
healthy	O
pregnant	O
women	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
count	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
the	O
2	O
groups	O
.	O

The	O
MR-count	O
was	O
significantly	O
decreased	O
in	O
the	O
PIH-group	O
.	O

The	O
values	O
of	O
plasma	O
aldosterone	O
and	O
18-OH-B	O
were	O
also	O
low	O
.	O

These	O
results	O
can	O
not	O
be	O
explained	O
by	O
receptor	O
down-regulation	O
due	O
to	O
higher	O
level	O
of	O
mineralocorticoids	O
of	O
the	O
zona	O
glomerulosa	O
.	O

Perhaps	O
deoxycorticosterone	O
or	O
a	O
hitherto	O
unknown	O
mineralocorticoid	O
is	O
responsible	O
for	O
the	O
hypertension	O
and	O
altered	O
MR	B-protein
-status	O
.	O

The	O
first	O
results	O
of	O
continuous	O
blood	O
pressure	O
measurements	O
with	O
a	O
noninvasive	O
,	O
real-time	O
blood	O
pressure	O
monitor	O
(	O
Finapres	O
)	O
are	O
presented	O
.	O

The	O
comparison	O
of	O
the	O
obtained	O
values	O
with	O
intraarterial	O
measurements	O
demonstrates	O
a	O
good	O
correlation	O
between	O
the	O
two	O
methods	O
.	O

We	O
also	O
report	O
on	O
the	O
first	O
experiences	O
with	O
Urapidil	O
in	O
the	O
treatment	O
of	O
hypertension	O
in	O
severe	O
preeclampsia	O
.	O

The	O
data	O
show	O
that	O
hypertension	O
in	O
preeclamptic	O
women	O
can	O
be	O
treated	O
by	O
Urapidil	O
without	O
side	O
effects	O
or	O
reflex-tachycardia	O
.	O

Further	O
studies	O
will	O
have	O
to	O
prove	O
if	O
Urapidil	O
is	O
suited	O
for	O
prepartal	O
treatment	O
of	O
PIH	O
as	O
well	O
.	O

Suppression	O
of	O
a	O
cellular	O
differentiation	O
program	O
by	O
phorbol	O
esters	O
coincides	O
with	O
inhibition	O
of	O
binding	O
of	O
a	O
cell-specific	B-protein
transcription	I-protein
factor	I-protein
(	O
NF-E2	B-protein
)	O
to	O
an	O
enhancer	B-DNA
element	I-DNA
required	O
for	O
expression	O
of	O
an	O
erythroid-specific	B-DNA
gene	I-DNA
.	O

Induction	O
by	O
hemin	O
increases	O
,	O
while	O
induction	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
represses	O
,	O
erythroid-specific	B-DNA
gene	I-DNA
expression	O
in	O
the	O
human	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
.	O

We	O
analyzed	O
the	O
effects	O
of	O
hemin	O
or	O
TPA	O
induction	O
on	O
the	O
binding	O
and	O
activity	O
of	O
transcription	B-protein
factors	I-protein
at	O
a	O
regulatory	B-DNA
element	I-DNA
found	O
within	O
the	O
transcriptional	B-DNA
regulatory	I-DNA
sequences	I-DNA
of	O
many	O
erythroid-specific	B-DNA
genes	I-DNA
.	O

TPA	O
induction	O
increases	O
the	O
binding	O
of	O
ubiquitous	B-protein
AP-1	I-protein
factors	I-protein
to	O
this	O
element	O
.	O

TPA	O
induction	O
inhibits	O
the	O
binding	O
of	O
the	O
lineage	B-protein
limited	I-protein
transcription	I-protein
factor	I-protein
NF-E2	B-protein
to	O
this	O
transcriptional	B-DNA
control	I-DNA
element	I-DNA
.	O

Hemin	O
induction	O
of	O
K562	B-cell_line
cells	I-cell_line
does	O
not	O
facilitate	O
the	O
binding	O
of	O
NF-E2	B-protein
to	O
its	O
recognition	O
site	O
.	O

Hemin	O
induction	O
appears	O
to	O
nonspecifically	O
increase	O
the	O
expression	O
of	O
transiently	O
transfected	O
genes	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

Beyond	O
this	O
nonspecific	O
increase	O
in	O
gene	O
expression	O
,	O
hemin	B-protein
induction	O
acts	O
to	O
increase	O
the	O
activity	O
of	O
the	O
lineage	B-protein
limited	I-protein
transcription	I-protein
factor	I-protein
NF-E2	O
.	O

The	O
divergent	O
effects	O
of	O
hemin	O
and	O
TPA	O
on	O
gene	O
expression	O
in	O
K562	B-cell_line
cells	I-cell_line
are	O
mediated	O
,	O
in	O
part	O
,	O
by	O
their	O
contrasting	O
effects	O
on	O
the	O
transcription	B-protein
factor	I-protein
NF-E2	B-protein
.	O

Interleukin-3	B-protein
expression	O
by	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
involves	O
an	O
inducible	O
,	O
T-cell-specific	B-protein
factor	I-protein
and	O
an	O
octamer	B-protein
binding	I-protein
protein	I-protein
.	O

Interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
is	O
exclusively	O
expressed	O
by	O
activated	B-cell_type
T	I-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
,	O
a	O
function	O
that	O
is	O
tightly	O
controlled	O
both	O
in	O
a	O
lineage-specific	O
and	O
in	O
a	O
stimulation-dependent	O
manner	O
.	O

We	O
have	O
investigated	O
the	O
protein	O
binding	O
characteristics	O
and	O
functional	O
importance	O
of	O
the	O
ACT-1-activating	B-DNA
region	I-DNA
of	O
the	O
IL-3	B-protein
promoter	O
.	O

This	O
region	O
binds	O
an	O
inducible	O
,	O
T-cell-specific	B-protein
factor	I-protein
over	O
its	O
5	B-DNA
'	I-DNA
end	I-DNA
,	O
a	O
site	O
that	O
is	O
necessary	O
for	O
the	O
expression	O
of	O
IL-3	B-protein
in	O
the	O
absence	O
of	O
other	O
upstream	O
elements	O
.	O

Over	O
its	O
3	B-DNA
'	I-DNA
end	I-DNA
,	O
it	O
binds	O
a	O
factor	O
that	O
is	O
ubiquitously	O
and	O
constitutively	O
expressed	O
.	O

This	O
factor	O
is	O
Oct-1	B-protein
or	O
an	O
immunologically	B-protein
related	I-protein
octamer-binding	I-protein
protein	I-protein
,	O
and	O
it	O
plays	O
a	O
role	O
in	O
coordinating	O
the	O
activity	O
of	O
several	O
regulatory	B-DNA
elements	I-DNA
.	O

These	O
characteristics	O
make	O
the	O
ACT-1	B-DNA
site	I-DNA
analogous	O
to	O
the	O
activating	O
ARRE-1	B-DNA
site	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

Furthermore	O
,	O
and	O
despite	O
a	O
lack	O
of	O
sequence	O
homology	O
,	O
the	O
promoters	O
of	O
IL-3	B-protein
and	O
IL-2	B-protein
share	O
an	O
organizational	O
pattern	O
of	O
regulatory	O
elements	O
that	O
is	O
likely	O
to	O
be	O
important	O
for	O
the	O
T-cell-specific	O
expression	O
of	O
these	O
genes	O
.	O

Interleukin-4	B-protein
inhibits	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
c-jun	B-RNA
and	I-RNA
c-fos	I-RNA
messenger	I-RNA
RNA	I-RNA
and	O
activator	B-protein
protein-1	I-protein
binding	O
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

We	O
studied	O
the	O
effect	O
of	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
on	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
two	O
immediate	O
early	O
genes	O
c-fos	B-DNA
and	O
c-jun	B-DNA
.	O

These	O
genes	O
encode	O
proteins	O
that	O
form	O
the	O
dimeric	B-protein
complex	I-protein
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
which	O
is	O
active	O
as	O
a	O
transcriptional	B-protein
factor	I-protein
.	O

Maximal	O
accumulation	O
of	O
either	O
c-fos	B-RNA
and	I-RNA
c-jun	I-RNA
messenger	I-RNA
RNA	I-RNA
(	O
mRNA	O
)	O
occurred	O
30	O
minutes	O
after	O
LPS	O
addition	O
.	O

When	O
cells	O
were	O
treated	O
with	O
IL-4	B-protein
for	O
5	O
hours	O
before	O
LPS	O
activation	O
,	O
both	O
the	O
c-fos	O
and	O
the	O
c-jun	O
mRNA	O
expression	O
was	O
decreased	O
.	O

The	O
inhibition	O
of	O
c-fos	B-DNA
and	O
c-jun	O
expression	O
by	O
IL-4	B-protein
in	O
LPS-treated	B-cell_type
cells	I-cell_type
was	O
shown	O
to	O
be	O
due	O
to	O
a	O
lower	O
transcription	O
rate	O
of	O
the	O
c-fos	B-DNA
and	I-DNA
c-jun	I-DNA
genes	I-DNA
.	O

IL-4	B-protein
did	O
not	O
affect	O
the	O
stability	O
of	O
the	O
c-fos	B-protein
and	O
c-jun	B-protein
transcripts	I-protein
.	O

Finally	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
evidence	O
was	O
obtained	O
that	O
IL-4	B-protein
inhibits	O
LPS-induced	O
expression	O
of	O
AP-1	B-protein
protein	O
.	O

These	O
data	O
indicate	O
that	O
IL-4	B-protein
suppresses	O
the	O
induction	O
of	O
transcription	B-protein
factors	I-protein
in	O
human	B-cell_type
activated	I-cell_type
monocytes	I-cell_type
.	O

Transient	O
pseudohypoaldosteronism	O
in	O
obstructive	O
renal	O
disease	O
with	O
transient	O
reduction	O
of	O
lymphocytic	B-protein
aldosterone	I-protein
receptors	I-protein
.	O

Results	O
in	O
two	O
affected	O
infants	O
.	O

We	O
report	O
two	O
patients	O
with	O
transient	O
pseudohypoaldosteronism	O
due	O
to	O
obstructive	O
renal	O
disease	O
.	O

Both	O
patients	O
presented	O
with	O
a	O
salt-losing	O
episode	O
simulating	O
adrenal	O
insufficiency	O
.	O

In	O
one	O
patient	O
,	O
transient	O
reduction	O
of	O
aldosterone	B-protein
receptors	I-protein
could	O
be	O
documented	O
,	O
while	O
in	O
the	O
second	O
patient	O
the	O
clinical	O
and	O
biochemical	O
parameters	O
were	O
consistent	O
with	O
transient	O
pseudohypoaldosteronism	O
.	O

Aldosterone	B-protein
receptors	I-protein
were	O
normal	O
in	O
both	O
patients	O

Aldosterone-specific	B-protein
membrane	I-protein
receptors	I-protein
and	O
rapid	O
non-genomic	O
actions	O
of	O
mineralocorticoids	O
.	O

Functional	O
studies	O
in	O
extrarenal	B-cell_type
,	I-cell_type
non-epithelial	I-cell_type
cells	I-cell_type
such	O
as	O
smooth	B-cell_type
muscle	I-cell_type
cells	I-cell_type
and	O
more	O
recently	O
circulating	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
,	O
non-genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium/proton	B-protein
exchanger	I-protein
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
min	O
.	O

A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol	O
1	O
,	O
4	O
,	O
5-trisphosphate/calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O

Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane	O
related	O
rapid	O
responses	O
.	O

The	O
mechanisms	O
underlying	O
these	O
rapid	O
effects	O
of	O
aldosterone	O
on	O
electrolytes	O
have	O
been	O
extensively	O
studied	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
which	O
thus	O
may	O
represent	O
valuable	O
tools	O
in	O
the	O
delineation	O
of	O
the	O
receptor-effector	O
mechanisms	O
involved	O
.	O

The	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
its	O
rapid	O
time	O
course	O
,	O
10	O
,	O
000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

Human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
Nef	I-protein
protein	I-protein
inhibits	O
NF-kappa	B-protein
B	I-protein
induction	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
can	O
establish	O
a	O
persistent	O
and	O
latent	O
infection	O
in	O
CD4+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
W.C.Greene	O
,	O
N.Engl.J.	O
Med.324	O
:	O
308-317	O
,	O
1991	O
;	O
S.M.Schnittman	O
,	O
M.C.Psallidopoulos	O
,	O
H.C.	O
Lane	O
,	O
L.Thompson	O
,	O
M.Baseler	O
,	O
F.Massari	O
,	O
C.H.Fox	O
,	O
N.P.Salzman	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
245	O
:	O
305-308	O
,	O
1989	O
)	O
.	O

Production	O
of	O
HIV-1	O
from	O
latently	O
infected	O
cells	O
requires	O
host	O
cell	O
activation	O
by	O
T-cell	B-protein
mitogens	I-protein
(	O
T.Folks	O
,	O
D.M.Powell	O
,	O
M.M.Lightfoote	O
,	O
S.Benn	O
,	O
M.A.	O
Martin	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
231	O
:	O
600-602	O
,	O
1986	O
;	O
D.Zagury	O
,	O
J.	O
Bernard	O
,	O
R.Leonard	O
,	O
R.Cheynier	O
,	O
M.Feldman	O
,	O
P.S.Sarin	O
,	O
and	O
R.C.	O
Gallo	O
,	O
Science	O
231	O
:	O
850-853	O
,	O
1986	O
)	O
.	O

This	O
activation	O
is	O
mediated	O
by	O
the	O
host	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
[	O
G.Nabel	O
and	O
D.Baltimore	O
,	O
Nature	O
(	O
London	O
)	O
326	O
:	O
711-717	O
,	O
1987	O
]	O
.	O

We	O
report	O
here	O
that	O
the	O
HIV-1-encoded	B-protein
Nef	I-protein
protein	I-protein
inhibits	O
the	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
by	O
T-	B-protein
cell	I-protein
mitogens	I-protein
.	O

However	O
,	O
Nef	B-protein
does	O
not	O
affect	O
the	O
DNA-binding	O
activity	O
of	O
other	O
transcription	B-protein
factors	I-protein
implicated	O
in	O
HIV-1	O
regulation	O
,	O
including	O
SP-1	B-protein
,	O
USF	B-protein
,	O
URS	B-protein
,	O
and	O
NF-AT	B-protein
.	O

Additionally	O
,	O
Nef	B-protein
inhibits	O
the	O
induction	O
of	O
HIV-1-	O
and	O
interleukin	O
2-directed	O
gene	O
expression	O
,	O
and	O
the	O
effect	O
on	O
HIV-1	O
transcription	O
depends	O
on	O
an	O
intact	O
NF-kappa	B-DNA
B-binding	I-DNA
site	I-DNA
.	O

These	O
results	O
indicate	O
that	O
defective	O
recruitment	O
of	O
NF-kappa	B-protein
B	I-protein
may	O
underlie	O
Nef	B-protein
's	O
negative	O
transcriptional	O
effects	O
on	O
the	O
HIV-1	B-DNA
and	I-DNA
interleukin	I-DNA
2	I-DNA
promoters	I-DNA
.	O

Further	O
evidence	O
suggests	O
that	O
Nef	B-protein
inhibits	O
NF-kappa	B-protein
B	I-protein
induction	O
by	O
interfering	O
with	O
a	O
signal	O
derived	O
from	O
the	O
T-cell	B-protein
receptor	I-protein
complex	I-protein
.	O

Expression	O
of	O
c-fos	B-DNA
,	O
c-jun	B-DNA
and	O
jun	B-DNA
B	I-DNA
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
adults	O
.	O

The	O
expression	O
of	O
c-fos	B-DNA
,	I-DNA
c-jun	I-DNA
and	I-DNA
jun	I-DNA
B	I-DNA
proto-oncogenes	I-DNA
was	O
studied	O
in	O
phytohemagglutinin	B-cell_line
(	I-cell_line
PHA	I-cell_line
)	I-cell_line
activated	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
(	O
PBL	B-cell_type
)	O
from	O
young	O
and	O
aged	O
humans	O
.	O

Specific	O
mRNAs	B-RNA
for	O
c-fos	B-DNA
and	O
c-jun	B-DNA
were	O
detectable	O
within	O
30	O
min	O
after	O
cell	O
activation	O
and	O
reached	O
maximal	O
levels	O
within	O
2	O
h	O
.	O

Both	O
c-fos	B-RNA
and	I-RNA
jun	I-RNA
B	I-RNA
mRNAs	I-RNA
decreased	O
to	O
pre-activation	O
levels	O
within	O
6	O
h	O
,	O
while	O
c-jun	B-RNA
mRNA	I-RNA
remained	O
elevated	O
.	O

In	O
PHA-activated	B-cell_line
PBL	I-cell_line
,	O
no	O
age-related	O
differences	O
were	O
observed	O
in	O
c-fos	O
or	O
jun	O
B	O
mRNA	O
expression	O
.	O

However	O
,	O
c-jun	B-RNA
mRNA	I-RNA
levels	O
decreased	O
significantly	O
(	O
1.73	O
+/-	O
0.08	O
vs.	O
1.16	O
+/-	O
0.09	O
arbitrary	O
units	O
,	O
P	O
<	O
0.01	O
,	O
young	O
vs.	O
old	O
)	O
in	O
PBL	B-cell_type
from	O
elderly	O
individuals	O
activated	O
with	O
PHA	B-protein
.	O

Because	O
previous	O
work	O
has	O
demonstrated	O
that	O
T	B-cell_type
cells	I-cell_type
from	O
elderly	O
individuals	O
may	O
display	O
normal	O
proliferative	O
responses	O
when	O
activated	O
via	O
the	O
anti-CD2	B-protein
pathway	O
,	O
c-jun	O
and	O
jun	O
B	O
mRNA	O
expression	O
was	O
also	O
studied	O
in	O
anti-CD2-activated	B-cell_line
purified	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

No	O
age-related	O
differences	O
were	O
found	O
in	O
the	O
expression	O
of	O
either	O
of	O
these	O
two	O
proto-oncogenes	B-DNA
by	O
anti-CD2	O
activated	O
T	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
decreased	O
IL-2	B-protein
production	O
and	O
proliferative	O
response	O
displayed	O
by	O
PHA-activated	B-cell_line
PBL	I-cell_line
from	O
elderly	O
adults	O
may	O
be	O
related	O
to	O
age-related	O
changes	O
in	O
c-jun	B-RNA
mRNA	I-RNA
expression	O
and	O
in	O
the	O
ratio	O
of	O
c-fos	O
to	O
c-jun	B-RNA
mRNA	I-RNA
.	O

Oct2	B-protein
transactivation	O
from	O
a	O
remote	B-DNA
enhancer	I-DNA
position	I-DNA
requires	O
a	O
B-cell-restricted	O
activity	O
.	O

Previous	O
cotransfection	O
experiments	O
had	O
demonstrated	O
that	O
ectopic	O
expression	O
of	O
the	O
lymphocyte-specific	B-protein
transcription	I-protein
factor	I-protein
Oct2	B-protein
could	O
efficiently	O
activate	O
a	O
promoter	B-DNA
containing	O
an	O
octamer	O
motif	O
.	O

Oct2	B-protein
expression	O
was	O
unable	O
to	O
stimulate	O
a	O
multimerized	B-DNA
octamer	I-DNA
enhancer	I-DNA
element	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
however	O
.	O

We	O
have	O
tested	O
a	O
variety	O
of	O
Oct2	B-protein
isoforms	I-protein
generated	O
by	O
alternative	O
splicing	O
for	O
the	O
capability	O
to	O
activate	O
an	O
octamer	B-DNA
enhancer	I-DNA
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
and	O
a	O
B-cell	B-cell_line
line	I-cell_line
.	O

Our	O
analyses	O
show	O
that	O
several	O
Oct2	B-protein
isoforms	I-protein
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	B-cell_type
cells	I-cell_type
.	O

This	O
result	O
indicates	O
the	O
involvement	O
of	O
either	O
a	O
B-cell-specific	B-protein
cofactor	I-protein
or	O
a	O
specific	O
modification	O
of	O
a	O
cofactor	B-protein
or	O
the	O
Oct2	B-protein
protein	I-protein
in	O
Oct2	B-protein
-mediated	O
enhancer	O
activation	O
.	O

Mutational	O
analyses	O
indicate	O
that	O
the	O
carboxy-terminal	B-protein
domain	I-protein
of	O
Oct2	B-protein
is	O
critical	O
for	O
enhancer	O
activation	O
.	O

Moreover	O
,	O
this	O
domain	O
conferred	O
enhancing	O
activity	O
when	O
fused	O
to	O
the	O
Oct1	B-protein
protein	I-protein
,	O
which	O
by	O
itself	O
was	O
unable	O
to	O
stimulate	O
from	O
a	O
remote	O
position	O
.	O

The	O
glutamine-rich	B-protein
activation	I-protein
domain	I-protein
present	O
in	O
the	O
amino-terminal	B-protein
portion	I-protein
of	I-protein
Oct2	I-protein
and	O
the	O
POU	B-protein
domain	I-protein
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O

The	O
promoter	B-DNA
of	O
the	O
CD19	B-DNA
gene	I-DNA
is	O
a	O
target	O
for	O
the	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
BSAP	B-protein
.	O

The	O
CD19	B-protein
protein	I-protein
is	O
expressed	O
on	O
the	O
surface	O
of	O
all	O
B-lymphoid	B-cell_type
cells	I-cell_type
with	O
the	O
exception	O
of	O
terminally	B-cell_type
differentiated	I-cell_type
plasma	I-cell_type
cells	I-cell_type
and	O
has	O
been	O
implicated	O
as	O
a	O
signal-transducing	O
receptor	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
.	O

Here	O
we	O
demonstrate	O
complete	O
correlation	O
between	O
the	O
expression	O
pattern	O
of	O
the	O
CD19	B-DNA
gene	I-DNA
and	O
the	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
BSAP	B-protein
in	O
a	O
large	O
panel	O
of	O
B-lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
human	B-DNA
CD19	I-DNA
gene	I-DNA
has	O
been	O
cloned	O
,	O
and	O
several	O
BSAP-binding	B-DNA
sites	I-DNA
have	O
been	O
mapped	O
by	O
in	O
vitro	O
protein-DNA	O
binding	O
studies	O
.	O

In	O
particular	O
,	O
a	O
high-affinity	B-DNA
BSAP-binding	I-DNA
site	I-DNA
instead	O
of	O
a	O
TATA	B-DNA
sequence	I-DNA
is	O
located	O
in	O
the	O
-30	B-DNA
promoter	I-DNA
region	I-DNA
upstream	O
of	O
a	O
cluster	O
of	O
heterogeneous	O
transcription	O
start	O
sites	O
.	O

Moreover	O
,	O
this	O
site	O
is	O
occupied	O
by	O
BSAP	B-protein
in	O
vivo	O
in	O
a	O
CD19-expressing	B-cell_line
B-cell	I-cell_line
line	I-cell_line
but	O
not	O
in	O
plasma	B-cell_type
or	O
HeLa	B-cell_line
cells	I-cell_line
.	O

This	O
high-affinity	B-DNA
site	I-DNA
has	O
been	O
conserved	O
in	O
the	O
promoters	B-DNA
of	O
both	O
human	B-DNA
and	I-DNA
mouse	I-DNA
CD19	I-DNA
genes	I-DNA
and	O
was	O
furthermore	O
shown	O
to	O
confer	O
B-cell	O
specificity	O
to	O
a	O
beta-globin	O
reporter	O
gene	O
in	O
transient	O
transfection	O
experiments	O
.	O

In	O
addition	O
,	O
BSAP	B-protein
was	O
found	O
to	O
be	O
the	O
only	O
abundant	O
DNA-binding	O
activity	O
of	O
B-cell	O
nuclear	O
extracts	O
that	O
interacts	O
with	O
the	O
CD19	B-DNA
promoter	I-DNA
.	O

Together	O
,	O
this	O
evidence	O
strongly	O
implicates	O
BSAP	B-protein
in	O
the	O
regulation	O
of	O
the	O
CD19	B-DNA
gene	I-DNA
.	O

Eicosanoids	O
in	O
breast	O
cancer	O
patients	O
before	O
and	O
after	O
mastectomy	O
.	O

In	O
19	O
patients	O
with	O
a	O
malignant	O
breast	O
tumor	O
,	O
tumor	O
tissue	O
and	O
blood	O
were	O
taken	O
to	O
determine	O
the	O
eicosanoid	O
profile	O
and	O
platelet	B-cell_type
aggregation	O
.	O

Values	O
were	O
compared	O
with	O
those	O
of	O
patients	O
with	O
benign	O
tumors	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
undergoing	O
a	O
mammary	O
reduction	O
(	O
n	O
=	O
7	O
)	O
.	O

Postoperatively	O
,	O
blood	O
was	O
taken	O
as	O
well	O
in	O
order	O
to	O
compare	O
pre-	O
and	O
postoperative	O
values	O
.	O

Eicosanoids	O
were	O
measured	O
in	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
mammary	O
tissue	O
by	O
means	O
of	O
HPLC	O
;	O
furthermore	O
,	O
TXA2	O
,	O
6-keto-PGF1	O
alpha	O
,	O
and	O
PGE2	O
were	O
determined	O
by	O
RIA	O
.	O

Differences	O
in	O
pre-	O
and	O
postoperative	O
values	O
of	O
cancer	O
patients	O
were	O
seen	O
in	O
plasma	O
RIA	O
values	O
:	O
PGE2	O
and	O
6-k-PGF1	O
alpha	O
were	O
significantly	O
higher	O
preoperatively	O
when	O
compared	O
with	O
postoperatively	O
,	O
however	O
,	O
such	O
differences	O
were	O
seen	O
in	O
the	O
control	O
groups	O
as	O
well	O
.	O

Compared	O
to	O
benign	O
tumor	O
or	O
mammary	O
reduction	O
test	O
material	O
the	O
eicosanoid	O
profile	O
of	O
tissue	O
obtained	O
from	O
malignant	O
mammary	O
tumors	O
showed	O
important	O
differences	O
.	O

Except	O
for	O
PGF2	O
alpha	O
,	O
HHT	O
and	O
15-HETE	O
no	O
detectable	O
quantities	O
of	O
eicosanoids	O
were	O
found	O
in	O
the	O
non-tumor	O
material	O
,	O
whereas	O
in	O
the	O
malignant	O
tumor	O
material	O
substantial	O
quantities	O
of	O
a	O
number	O
of	O
eicosanoid	O
metabolites	O
were	O
present	O
.	O

Statistically	O
significant	O
correlations	O
could	O
be	O
established	O
between	O
patient/histopathology	O
data	O
and	O
the	O
results	O
of	O
the	O
platelet	B-cell_type
aggregation	O
assays	O
,	O
e.g.	O
between	O
menopausal	O
status	O
and	O
ADP	O
aggregation	O
;	O
oestrogen	B-protein
receptor	I-protein
(	O
+/-	O
)	O
and	O
collagen	B-protein
and	O
arachidonic	O
acid	O
aggregation	O
,	O
inflammatory	O
cell	O
infiltration	O
score	O
and	O
arachidonic	O
acid	O
aggregation	O
and	O
fibrosis	O
score	O
and	O
ADP	O
aggregation	O
.	O

The	O
results	O
show	O
that	O
eicosanoid	O
synthesis	O
in	O
material	O
from	O
mammary	O
cancer	O
patients	O
is	O
different	O
from	O
that	O
in	O
benign	O
mammary	O
tissue	O
.	O

The	O
implications	O
,	O
in	O
particular	O
,	O
in	O
relation	O
to	O
future	O
prognosis	O
of	O
the	O
patient	O
,	O
remain	O
obscure	O
.	O

Mineralocorticoids	O
and	O
mineralocorticoid	B-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
patients	O
with	O
pregnancy-induced	O
hypertension	O
.	O

To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
pregnancy-induced	O
hypertension	O
(	O
PIH	O
)	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxycorticosterone	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
25	O
normal	O
pregnant	O
women	O
,	O
as	O
controls	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
status	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
the	O
2	O
groups	O
.	O

MR	B-protein
count	O
was	O
significantly	O
(	O
P	O
less	O
than	O
0.0005	O
)	O
decreased	O
in	O
the	O
PIH	O
group	O
(	O
148	O
+/-	O
9	O
binding	O
sites/cell	O
)	O
compared	O
with	O
the	O
control	O
group	O
(	O
300	O
+/-	O
17	O
binding	O
sites/cell	O
;	O
mean	O
+/-	O
SEM	O
)	O
.	O

Plasma	O
aldosterone	O
in	O
women	O
with	O
PIH	O
was	O
281	O
+/-	O
61	O
pmol/L	O
;	O
in	O
normal	O
pregnant	O
women	O
it	O
was	O
697	O
+/-	O
172	O
pmol/L	O
(	O
P	O
less	O
than	O
0.025	O
)	O
.	O

Plasma	O
18-hydroxycorticosterone	O
was	O
also	O
significantly	O
(	O
P	O
less	O
than	O
0.025	O
)	O
lower	O
(	O
PIH	O
,	O
1071	O
+/-	O
149	O
pmol/L	O
;	O
controls	O
,	O
1907	O
+/-	O
318	O
pmol/L	O
)	O
.	O

These	O
values	O
were	O
determined	O
at	O
the	O
onset	O
of	O
clinical	O
symptoms	O
of	O
PIH	O
.	O

These	O
results	O
can	O
not	O
be	O
explained	O
by	O
receptor	O
down-regulation	O
due	O
to	O
higher	O
levels	O
of	O
mineralocorticoids	O
in	O
PIH	O
;	O
a	O
hitherto	O
unknown	O
mineralocorticoid	O
may	O
,	O
thus	O
,	O
be	O
responsible	O
for	O
the	O
hypertension	O
and	O
altered	O
MR	B-protein
status	O
.	O

Structure	O
function	O
analysis	O
of	O
vitamin	O
D	O
analogs	O
with	O
C-ring	O
modifications	O
.	O

Analogs	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
)	O
with	O
substitutions	O
on	O
C-11	O
were	O
synthesized	O
.	O

Small	O
apolar	O
substitutions	O
(	O
11	O
alpha-methyl	O
,	O
11	O
alpha-fluoromethyl	O
)	O
did	O
not	O
markedly	O
decrease	O
the	O
affinity	O
for	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
,	O
but	O
larger	O
(	O
11	O
alpha-chloromethyl	O
or	O
11	O
alpha-	O
or	O
11	O
beta-phenyl	O
)	O
or	O
more	O
polar	O
substitutions	O
(	O
11	O
alpha-hydroxymethyl	O
,	O
11	O
alpha-	O
(	O
2-hydroxyethyl	O
]	O
decreased	O
the	O
affinity	O
to	O
less	O
than	O
5	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-OH	O
)	O
2D3	O
.	O

Their	O
affinity	O
for	O
the	O
vitamin	B-protein
D-binding	I-protein
protein	I-protein
,	O
however	O
,	O
increased	O
up	O
to	O
4-fold	O
.	O

The	O
biological	O
activity	O
of	O
11	O
alpha-methyl-1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
closely	O
resembled	O
that	O
of	O
the	O
natural	O
hormone	O
on	O
normal	O
and	O
leukemic	B-cell_type
cell	I-cell_type
proliferation	O
and	O
bone	O
resorption	O
,	O
whereas	O
its	O
in	O
vivo	O
effect	O
on	O
calcium	O
metabolism	O
of	O
the	O
rachitic	O
chick	O
was	O
about	O
50	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O

The	O
11	O
beta-methyl	O
analog	O
had	O
a	O
greater	O
than	O
10-fold	O
lower	O
activity	O
.	O

The	O
differentiating	O
effects	O
of	O
the	O
other	O
C-11	O
analogs	O
on	O
human	B-cell_line
promyeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
(	O
HL-60	B-cell_line
)	O
agreed	O
well	O
with	O
their	O
bone-resorbing	O
activity	O
and	O
receptor	O
affinity	O
,	O
but	O
they	O
demonstrated	O
lower	O
calcemic	O
effects	O
in	O
vivo	O
.	O

Large	O
or	O
polar	O
substitutions	O
on	O
C-11	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
thus	O
impair	O
the	O
binding	O
of	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
but	O
increase	O
the	O
affinity	O
to	O
vitamin	B-protein
D-binding	I-protein
protein	I-protein
.	O

The	O
effects	O
of	O
many	O
C-11-substituted	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
analogs	O
on	O
HL-60	B-cell_line
cell	O
differentiation	O
exceeded	O
their	O
activity	O
on	O
calcium	O
metabolism	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
binding	O
in	O
three	O
different	O
cell	O
types	O
in	O
major	O
depressive	O
disorder	O
:	O
lack	O
of	O
evidence	O
of	O
receptor	O
binding	O
defect	O
.	O

1	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
apparent	O
glucocorticoid	O
resistance	O
in	O
major	O
depressive	O
disorder	O
,	O
circadian	O
variation	O
in	O
cortisol	O
concentration	O
,	O
dexamethasone	O
suppression	O
and	O
glucocorticoid	O
receptor	O
binding	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
,	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
and	O
cultured	B-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
were	O
measured	O
in	O
rigidly	O
defined	O
major	O
depressive	O
disorder	O
patients	O
and	O
non-depressed	O
psychiatric	O
controls	O
.	O

2	O
.	O

Mononuclear	B-cell_type
leukocytes	I-cell_type
binding	O
to	O
glucocorticoid	O
correlated	O
significantly	O
with	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
binding	O
to	O
glucocorticoid	O
,	O
but	O
both	O
determinations	O
failed	O
to	O
differentiate	O
major	O
depressive	O
disorder	O
and	O
control	O
subjects	O
.	O

3	O
.	O

Initial	O
and	O
post-dexamethasone	O
in	O
vitro	O
fibroblast	O
binding	O
to	O
glucocorticoid	O
was	O
not	O
different	O
between	O
major	O
depressive	O
disorder	O
and	O
non-depressed	O
control	O
subjects	O
.	O

4	O
.	O

The	O
phenomenon	O
of	O
glucocorticoid	O
resistance	O
in	O
major	O
depressive	O
disorder	O
remains	O
unexplained	O
.	O

High	O
affinity	O
aldosterone	O
binding	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
from	O
mononuclear	B-cell_type
leukocytes	I-cell_type
:	O
is	O
there	O
a	O
membrane	B-protein
receptor	I-protein
for	O
mineralocorticoids	O
?	O

In	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
the	O
intracellular	O
concentrations	O
of	O
sodium	O
,	O
potassium	O
and	O
calcium	O
,	O
cell	O
volume	O
and	O
the	O
sodium-proton-antiport	B-protein
have	O
been	O
described	O
in	O
intact	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
HML	B-cell_type
)	O
.	O

In	O
the	O
present	O
paper	O
,	O
the	O
binding	O
of	O
a	O
[	O
125I	O
]	O
-labeled	O
aldosterone	O
derivative	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
of	O
HML	B-cell_type
was	O
studied	O
.	O

High	O
affinity	O
binding	O
of	O
the	O
radioligand	O
with	O
an	O
apparent	O
Kd	O
of	O
approximately	O
0.1	O
nM	O
was	O
found	O
.	O

Aldosterone	O
displaced	O
the	O
tracer	O
at	O
a	O
similar	O
Kd	O
.	O

Both	O
canrenone	O
and	O
cortisol	O
were	O
inactive	O
as	O
ligands	O
up	O
to	O
concentrations	O
of	O
0.1	O
microM	O
.	O

The	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
sites	O
with	O
a	O
high	O
affinity	O
for	O
aldosterone	O
,	O
but	O
not	O
for	O
cortisol	O
.	O

These	O
data	O
are	O
perfectly	O
compatible	O
with	O
major	O
properties	O
of	O
steroidal	O
effects	O
on	O
the	O
sodium-proton-antiport	B-protein
in	O
HML	B-cell_type
and	O
thus	O
very	O
likely	O
represent	O
membrane	B-protein
receptors	I-protein
for	O
aldosterone	O
.	O

Natural	O
variants	O
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
:	O
analysis	O
of	O
promoters	B-DNA
with	O
duplicated	O
DNA	B-DNA
regulatory	I-DNA
motifs	I-DNA
.	O

Sequence	O
variation	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
LTR	I-DNA
)	I-DNA
region	I-DNA
of	O
HIV-1	O
was	O
analyzed	O
in	O
viral	O
isolates	O
of	O
17	O
infected	O
individuals	O
.	O

Two	O
classes	O
of	O
LTR	O
size	O
variants	O
were	O
found	O
.	O

One	O
HIV-1	O
variant	O
was	O
detected	O
containing	O
an	O
additional	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
Sp1	O
.	O

Another	O
LTR	B-DNA
size	I-DNA
variation	I-DNA
was	O
observed	O
in	O
four	O
patients	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
enhancer	I-DNA
.	O

This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	B-DNA
DNA	I-DNA
sequence	I-DNA
(	O
CTG-motif	B-DNA
)	O
.	O

Cell	O
culture	O
experiments	O
demonstrated	O
that	O
the	O
natural	O
variant	O
with	O
four	O
Sp1	B-DNA
sites	I-DNA
had	O
a	O
slightly	O
higher	O
promoter	O
activity	O
and	O
viral	O
replication	O
rate	O
than	O
the	O
isogenic	B-DNA
control	I-DNA
LTR	I-DNA
with	O
three	O
Sp1	B-DNA
sites	I-DNA
.	O

No	O
positive	O
effect	O
of	O
the	O
duplicated	O
CTG-motif	B-DNA
could	O
be	O
detected	O
.	O

In	O
order	O
to	O
measure	O
small	O
differences	O
in	O
virus	O
production	O
more	O
accurately	O
,	O
equal	O
amounts	O
of	O
a	O
size	O
variant	O
and	O
the	O
wild-type	B-DNA
plasmid	I-DNA
were	O
cotransfected	O
into	O
T-cells	B-cell_type
.	O

The	O
virus	O
with	O
four	O
Sp1	O
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	O
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG-monomer	O
virus	O
outcompeted	O
the	O
CTG-dimer	O
virus	O
in	O
42	O
days	O
.	O

Based	O
on	O
these	O
results	O
we	O
estimate	O
a	O
5-10	O
%	O
difference	O
in	O
virus	O
production	O
of	O
the	O
LTR	B-DNA
variants	I-DNA
when	O
compared	O
to	O
that	O
of	O
wild-type	O
.	O

A	O
novel	B-protein
B	I-protein
cell-derived	I-protein
coactivator	I-protein
potentiates	O
the	O
activation	O
of	O
immunoglobulin	B-DNA
promoters	I-DNA
by	O
octamer-binding	B-protein
transcription	I-protein
factors	I-protein
.	O

A	O
novel	O
B	O
cell-restricted	O
activity	O
,	O
required	O
for	O
high	O
levels	O
of	O
octamer	B-DNA
/	O
Oct	B-DNA
-dependent	O
transcription	O
from	O
an	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
promoter	I-DNA
,	O
was	O
detected	O
in	O
an	O
in	O
vitro	O
system	O
consisting	O
of	O
HeLa	B-cell_line
cell	I-cell_line
-derived	O
extracts	O
complemented	O
with	O
fractionated	B-protein
B	I-protein
cell	I-protein
nuclear	I-protein
proteins	I-protein
.	O

The	O
factor	O
responsible	O
for	O
this	O
activity	O
was	O
designated	O
Oct	B-protein
coactivator	I-protein
from	O
B	B-cell_type
cells	I-cell_type
(	O
OCA-B	B-protein
)	O
.	O

OCA-B	B-protein
stimulates	O
the	O
transcription	O
from	O
an	O
IgH	B-DNA
promoter	I-DNA
in	O
conjunction	O
with	O
either	O
Oct-1	B-protein
or	O
Oct-2	B-protein
but	O
shows	O
no	O
significant	O
effect	O
on	O
the	O
octamer	B-DNA
/	O
Oct	B-DNA
-dependent	O
transcription	O
of	O
the	O
ubiquitously	B-DNA
expressed	I-DNA
histone	I-DNA
H2B	I-DNA
promoter	I-DNA
and	O
the	O
transcription	O
of	O
USF-	B-DNA
and	I-DNA
Sp1-regulated	I-DNA
promoters	I-DNA
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
OCA-B	B-protein
is	O
a	O
tissue-	B-protein
,	I-protein
promoter-	I-protein
,	I-protein
and	I-protein
factor-specific	I-protein
coactivator	I-protein
and	O
that	O
OCA-B	B-protein
may	O
be	O
a	O
major	O
determinant	O
for	O
B	O
cell-specific	O
activation	O
of	O
immunoglobulin	B-DNA
promoters	I-DNA
.	O

In	O
light	O
of	O
the	O
evidence	O
showing	O
physical	O
and	O
functional	O
interactions	O
between	O
Oct	B-protein
factors	I-protein
and	O
OCA-B	B-protein
,	O
we	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
OCA-B	B-protein
and	O
discuss	O
the	O
implications	O
of	O
OCA-B	B-protein
for	O
the	O
transcriptional	O
regulation	O
of	O
other	O
tissue-specific	B-DNA
promoters	I-DNA
.	O

SCL	B-protein
and	O
related	O
hemopoietic	B-protein
helix-loop-helix	I-protein
transcription	I-protein
factors	I-protein
.	O

The	O
helix-loop-helix	B-protein
(	I-protein
HLH	I-protein
)	I-protein
proteins	I-protein
are	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
include	O
proteins	O
critical	O
to	O
differentiation	O
and	O
development	O
in	O
species	O
ranging	O
from	O
plants	O
to	O
mammals	O
.	O

Five	O
members	O
of	O
this	O
family	O
(	O
MYC	B-protein
,	O
SCL	B-protein
,	O
TAL-2	B-protein
,	O
LYL-1	B-protein
and	O
E2A	B-protein
)	O
are	O
implicated	O
in	O
oncogenic	O
events	O
in	O
human	O
lymphoid	O
tumors	O
because	O
of	O
their	O
consistent	O
involvement	O
in	O
chromosomal	O
translocations	O
.	O

Although	O
activated	O
in	O
T	O
cell	O
leukemias	O
,	O
expression	O
of	O
SCL	B-protein
and	O
LYL-1	B-protein
is	O
low	O
or	O
undetectable	O
in	O
normal	B-cell_type
T	I-cell_type
cell	I-cell_type
populations	I-cell_type
.	O

SCL	B-protein
is	O
expressed	O
in	O
erythroid	B-cell_type
,	I-cell_type
megakaryocyte	I-cell_type
and	I-cell_type
mast	I-cell_type
cell	I-cell_type
populations	I-cell_type
(	O
the	O
same	O
cell	O
lineages	O
as	O
GATA-1	B-protein
,	O
a	O
zinc-finger	B-protein
transcription	I-protein
factor	I-protein
)	O
.	O

In	O
addition	O
,	O
both	O
SCL	B-protein
and	O
GATA-1	B-protein
undergo	O
coordinate	O
modulation	O
during	O
chemically	O
induced	O
erythroid	O
differentiation	O
of	O
mouse	B-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
and	O
are	O
down-modulated	O
during	O
myeloid	O
differentiation	O
of	O
human	B-cell_line
K562	I-cell_line
cells	I-cell_line
,	O
thus	O
implying	O
a	O
role	O
for	O
SCL	B-protein
in	O
erythroid	O
differentiation	O
events	O
.	O

However	O
,	O
in	O
contrast	O
to	O
GATA-1	B-protein
,	O
SCL	B-protein
is	O
expressed	O
in	O
the	O
developing	O
brain	O
.	O

Studies	O
of	O
the	O
function	O
of	O
SCL	B-protein
suggest	O
it	O
is	O
also	O
important	O
in	O
proliferation	O
and	O
self-renewal	O
events	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

Induction	O
of	O
the	O
POU	B-protein
domain	I-protein
transcription	I-protein
factor	I-protein
Oct-2	B-protein
during	O
T-cell	B-cell_type
activation	O
by	O
cognate	O
antigen	O
.	O

Oct-2	B-protein
is	O
a	O
transcription	B-protein
factor	I-protein
that	O
binds	O
specifically	O
to	O
octamer	B-DNA
DNA	I-DNA
motifs	I-DNA
in	O
the	O
promoters	B-DNA
of	O
immunoglobulin	B-DNA
and	I-DNA
interleukin-2	I-DNA
genes	I-DNA
.	O

All	O
tumor	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
and	O
a	O
few	O
from	O
the	O
T-cell	B-cell_type
lineage	I-cell_type
express	O
Oct-2	B-protein
.	O

To	O
address	O
the	O
role	O
of	O
Oct-2	B-protein
in	O
the	O
T-cell	B-cell_type
lineage	I-cell_type
,	O
we	O
studied	O
the	O
expression	O
of	O
Oct-2	B-RNA
mRNA	I-RNA
and	O
protein	O
in	O
nontransformed	B-cell_line
human	I-cell_line
and	I-cell_line
mouse	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Oct-2	B-protein
was	O
found	O
in	O
CD4+	B-cell_line
and	I-cell_line
CD8+	I-cell_line
T	I-cell_line
cells	I-cell_line
prepared	O
from	O
human	O
peripheral	O
blood	O
and	O
in	O
mouse	B-cell_type
lymph	I-cell_type
node	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
a	O
T-cell	B-cell_line
clone	I-cell_line
specific	O
for	O
pigeon	B-protein
cytochrome	I-protein
c	I-protein
in	O
the	O
context	O
of	O
I-Ek	B-protein
,	O
Oct-2	B-protein
was	O
induced	O
by	O
antigen	O
stimulation	O
,	O
with	O
the	O
increase	O
in	O
Oct-2	B-protein
protein	I-protein
seen	O
first	O
at	O
3	O
h	O
after	O
activation	O
and	O
continuing	O
for	O
at	O
least	O
24	O
h	O
.	O

Oct-2	B-RNA
mRNA	I-RNA
induction	O
during	O
antigen-driven	O
T-cell	B-cell_type
activation	O
was	O
blocked	O
by	O
cyclosporin	O
A	O
,	O
as	O
well	O
as	O
by	O
protein	O
synthesis	O
inhibitors	O
.	O

These	O
results	O
suggest	O
that	O
Oct-2	B-protein
participates	O
in	O
transcriptional	O
regulation	O
during	O
T-cell	B-cell_type
activation.	O
The	O
relatively	O
delayed	O
kinetics	O
of	O
Oct-2	B-protein
induction	O
suggests	O
that	O
Oct-2	B-protein
mediates	O
the	O
changes	O
in	O
gene	O
expression	O
which	O
occur	O
many	O
hours	O
or	O
days	O
following	O
antigen	O
stimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Glucocorticoid	B-protein
receptor	I-protein
in	O
patients	O
with	O
lupus	O
nephritis	O
:	O
relationship	O
between	O
receptor	O
levels	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
and	O
effect	O
of	O
glucocorticoid	O
therapy	O
.	O

We	O
investigated	O
the	O
clinical	O
significance	O
of	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
in	O
20	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
who	O
afterwards	O
developed	O
nephrotic	O
syndrome	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
concentrations	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
(	O
MNL	B-cell_type
)	O
in	O
these	O
patients	O
were	O
comparable	O
with	O
those	O
in	O
both	O
other	O
patients	O
with	O
SLE	O
and	O
healthy	O
persons	O
.	O

Improvement	O
in	O
urinary	O
protein	O
excretion	O
and	O
in	O
disease	O
activity	O
,	O
which	O
was	O
scored	O
according	O
to	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
system	O
of	O
the	O
University	O
of	O
Toronto	O
,	O
closely	O
related	O
to	O
the	O
glucocorticoid	B-protein
receptor	I-protein
concentrations	O
in	O
MNL	B-cell_type
isolated	O
from	O
the	O
corresponding	O
patients	O
.	O

In	O
summary	O
,	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
in	O
patients	O
with	O
lupus	O
nephritis	O
may	O
be	O
a	O
predictive	O
clue	O
for	O
assessing	O
responsiveness	O
to	O
glucocorticoid	O
therapy	O
.	O

[	O
Changes	O
in	O
plasma	B-protein
interleukin-1	I-protein
and	O
their	O
possible	O
relationship	O
with	O
the	O
changes	O
in	O
glucocorticoid	B-protein
receptor	I-protein
in	O
aged	O
long-distance	O
runner	O
]	O

For	O
the	O
study	O
of	O
the	O
changes	O
in	O
plasma	B-protein
interleukin-1	I-protein
(	O
IL-1	B-protein
)	O
and	O
their	O
possible	O
relationship	O
with	O
the	O
changes	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
,	O
plasma	B-protein
IL-1	I-protein
and	O
GR	B-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
aged	O
long-distance	O
runner	O
were	O
measured	O
simultaneously	O
.	O

The	O
activity	O
of	O
IL-1	B-protein
was	O
expressed	O
as	O
its	O
ability	O
to	O
stimulate	O
3H-TdR	B-protein
incorporation	O
in	O
the	O
thymocytes	B-cell_type
of	O
C57	O
mice	O
.	O

GR	B-protein
was	O
determined	O
by	O
whole	O
cell	O
assay	O
with	O
3H-Dex	O
.	O

The	O
results	O
showed	O
that	O
the	O
activity	O
of	O
plasma	O
IL-1	B-protein
in	O
aged	O
long-distance	O
runner	O
was	O
209	O
%	O
,	O
223	O
%	O
and	O
145	O
%	O
of	O
the	O
control	O
at	O
14.7-18.7	O
,	O
3.8-7.0	O
and	O
1.5-2.6	O
KD	O
fractions	O
.	O

The	O
GR	B-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
aged	O
runner	O
was	O
65	O
%	O
of	O
the	O
control	O
.	O

Possible	O
relationship	O
between	O
the	O
changes	O
in	O
IL-1	B-protein
and	O
GR	B-protein
in	O
aged	O
long-distance	O
runner	O
and	O
its	O
physiological	O
significance	O
are	O
discussed	O
.	O

Mineralocorticoid	O
effector	O
mechanism	O
in	O
preeclampsia	O
.	O

Mineralocorticoid	O
effector	O
mechanisms	O
were	O
evaluated	O
in	O
29	O
patients	O
with	O
preeclampsia	O
and	O
in	O
25	O
uncomplicated	O
pregnancies	O
by	O
measurement	O
of	O
plasma	O
aldosterone	O
,	O
levels	O
of	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
in	O
mononuclear	B-cell_type
leucocytes	I-cell_type
,	O
and	O
subtraction	O
potential	O
difference	O
(	O
SPD	O
;	O
rectal	O
minus	O
oral	O
values	O
)	O
.	O

Mean	O
values	O
for	O
plasma	O
aldosterone	O
were	O
not	O
different	O
between	O
the	O
two	O
groups	O
,	O
but	O
significant	O
differences	O
were	O
observed	O
for	O
MR	B-protein
(	O
preeclampsia	O
,	O
81	O
+/-	O
44	O
receptors/cell	O
;	O
controls	O
,	O
306	O
+/-	O
168	O
)	O
and	O
SPD	O
(	O
preeclampsia	O
,	O
65	O
+/-	O
7	O
mV	O
;	O
controls	O
,	O
12	O
+/-	O
5	O
mV	O
)	O
.	O

In	O
six	O
cases	O
we	O
determined	O
MR	B-protein
,	O
plasma	O
aldosterone	O
,	O
and	O
SPD	O
in	O
patients	O
with	O
preeclampsia	O
before	O
and	O
3	O
months	O
after	O
delivery	O
.	O

MR	B-protein
were	O
reduced	O
before	O
delivery	O
(	O
96	O
+/-	O
27	O
receptors/cell	O
)	O
,	O
and	O
SPD	O
increased	O
(	O
64	O
+/-	O
8	O
mV	O
)	O
,	O
with	O
both	O
parameters	O
normalizing	O
after	O
delivery	O
(	O
MR	B-protein
,	O
242	O
+/-	O
79	O
;	O
SPD	O
,	O
14.0	O
+/-	O
4	O
mV	O
)	O
.	O

Aldosterone	O
levels	O
returned	O
to	O
normal	O
nonpregnant	O
values	O
after	O
delivery	O
.	O

These	O
data	O
suggest	O
an	O
important	O
role	O
for	O
abnormalities	O
in	O
mineralocorticoid	O
effector	O
mechanisms	O
in	O
the	O
etiology	O
of	O
preeclampsia	O
and	O
could	O
be	O
an	O
useful	O
marker	O
for	O
diagnosis	O
.	O

Kinetics	O
of	O
nuclear	O
translocation	O
and	O
turnover	O
of	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
in	O
human	B-cell_line
HL60	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
--	O
coincident	O
rise	O
of	O
DNA-relaxing	O
activity	O
in	O
nuclear	O
extracts	O
.	O

High	B-protein
affinity	I-protein
receptors	I-protein
(	O
VDR	B-protein
)	O
for	O
1	O
,	O
25-dihydroxycholecalciferol	O
(	O
calcitriol	O
)	O
are	O
expressed	O
in	O
HL60	O
human	O
leukemia	O
cells	O
and	O
in	O
low	O
numbers	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
.	O

HL60	B-cell_line
cells	I-cell_line
,	O
expressing	O
some	O
characteristics	O
of	O
promyelocytes	B-cell_line
,	O
can	O
be	O
induced	O
to	O
monocytoid	O
differentiation	O
by	O
calcitriol	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	B-protein
3H	I-protein
]	I-protein
calcitriol/VDR	I-protein
was	O
examined	O
after	O
exposure	O
of	O
whole	B-cell_type
cells	I-cell_type
to	O
10	O
(	O
-9	O
)	O
M/l	O
calcitriol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
500-fold	O
excess	O
of	O
unlabeled	O
ligand	O
and	O
subsequent	O
isolation	O
of	O
nuclei	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	B-protein
3H	I-protein
]	I-protein
calcitriol/VDR	I-protein
was	O
found	O
to	O
be	O
time	O
dependent	O
reaching	O
a	O
maximum	O
of	O
approximately	O
2100	O
binding	O
sites/nucleus	O
after	O
3	O
h	O
of	O
incubation	O
in	O
HL60	B-cell_line
cells	I-cell_line
,	O
whereas	O
a	O
maximum	O
of	O
approximately	O
310	O
binding	O
sites/nucleus	O
was	O
found	O
after	O
3	O
h	O
in	O
PBL	B-cell_type
.	O

Pulse	O
exposure	O
of	O
HL60	B-cell_line
to	O
radiolabeled	O
hormone	O
for	O
3	O
h	O
followed	O
by	O
culture	O
in	O
medium	O
without	O
serum	O
and	O
calcitriol	O
lead	O
to	O
nuclear	O
retention	O
of	O
approximately	O
1600	B-protein
radiolabeled	I-protein
VDR	I-protein
by	O
8	O
h	O
and	O
approximately	O
1000	O
VDR	B-protein
by	O
24	O
h	O
.	O

Radiolabeled	B-protein
VDR	I-protein
disappeared	O
from	O
the	O
nuclear	O
compartment	O
with	O
a	O
halflife	O
of	O
approximately	O
30	O
min	O
if	O
cells	O
were	O
cultured	O
with	O
identical	O
concentrations	O
of	O
unlabeled	O
hormone	O
after	O
the	O
pulse	O
(	O
pulse/chase-experiments	O
)	O
.	O

No	O
difference	O
of	O
VDR	B-protein
retention	O
in	O
pulse	O
and	O
pulse/chase-experiments	O
was	O
seen	O
in	O
PBL	B-cell_type
,	O
where	O
VDR	B-protein
halflife	O
was	O
approximately	O
30	O
min	O
.	O

No	O
specific	O
translocation	O
into	O
the	O
nuclear	O
compartment	O
was	O
seen	O
when	O
isolated	O
nuclei	O
were	O
incubated	O
in	O
[	O
3H	O
]	O
calcitriol	O
.	O

Radiolabeled	B-protein
hormone/receptor	I-protein
complexes	I-protein
of	O
nuclei	O
isolated	O
from	O
cells	O
exposed	O
for	O
3	O
h	O
to	O
radiolabeled	O
hormone	O
--	O
in	O
contrast	O
to	O
identical	O
experiments	O
with	O
intact	O
cells	O
--	O
did	O
not	O
disappear	O
from	O
the	O
nuclear	O
compartment	O
upon	O
incubation	O
of	O
nuclei	O
with	O
identical	O
concentrations	O
of	O
the	O
unlabeled	O
compound	O
.	O

The	O
activity	O
of	O
DNA	B-protein
relaxing	I-protein
enzymes	I-protein
(	O
e.g	O
.	O
topoisomerases	B-protein
I	I-protein
and	I-protein
II	I-protein
)	O
in	O
nuclear	O
extracts	O
was	O
measured	O
using	O
a	O
PBR	O
322-relaxation-assay	O
.	O

Enhanced	O
overall	O
enzyme	O
activity	O
was	O
found	O
in	O
nuclear	O
extracts	O
by	O
1	O
h	O
after	O
incubation	O
with	O
calcitriol	O
(	O
final	O
ethanol	O
concentration	O
0.0001	O
%	O
v/v	O
)	O
in	O
HL60	B-cell_line
and	O
PBL	B-cell_type
.	O

The	O
enhanced	O
activity	O
disappeared	O
after	O
2	O
h	O
in	O
PBL	B-cell_type
,	O
whereas	O
it	O
was	O
still	O
enhanced	O
by	O
4	O
h	O
in	O
HL60	B-cell_line
.	O

No	O
effect	O
was	O
seen	O
in	O
ethanol	B-cell_line
treated	I-cell_line
controls	I-cell_line
.	O

We	O
conclude	O
that	O
a	O
specific	O
nuclear	O
translocation	O
mechanism	O
exists	O
for	O
calcitriol	O
in	O
both	O
cell	O
types	O
examined	O
,	O
most	O
likely	O
due	O
to	O
translocation	O
of	O
receptor	B-protein
proteins	I-protein
after	O
hormone	O
binding	O
.	O

Translocated	B-protein
hormone/receptor	I-protein
complexes	I-protein
compete	O
for	O
a	O
limited	O
number	O
of	O
specific	O
nuclear	O
binding	O
sites	O
.	O

Enhanced	O
activity	O
of	O
topoisomerases	B-protein
in	O
nuclear	O
extracts	O
upon	O
translocation	O
of	O
VDR	B-protein
might	O
reflect	O
interaction	O
of	O
both	O
within	O
the	O
nuclear	O
compartment	O
,	O
thus	O
initiating	O
DNA-unwinding	O
,	O
a	O
prerequisite	O
of	O
transcription	O
initiation	O
.	O

Influence	O
of	O
estradiol	O
and	O
tamoxifen	O
on	O
susceptibility	O
of	O
human	B-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
lysis	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

The	O
design	O
of	O
combination	O
hormonal	O
and	O
immunotherapeutic	O
protocols	O
for	O
breast	O
cancer	O
patients	O
may	O
be	O
facilitated	O
by	O
analysis	O
of	O
preclinical	O
in	O
vitro	O
model	O
systems	O
.	O

Estrogen	B-cell_line
receptor	I-cell_line
positive	I-cell_line
(	I-cell_line
ER+	I-cell_line
:	I-cell_line
MCF-7	I-cell_line
)	I-cell_line
and	I-cell_line
negative	I-cell_line
(	I-cell_line
ER-	I-cell_line
:	I-cell_line
MDA-MB-231	I-cell_line
)	I-cell_line
human	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
utilized	O
to	O
evaluate	O
the	O
effects	O
of	O
tamoxifen	O
(	O
TAM	O
)	O
and	O
estradiol	O
(	O
E2	O
)	O
on	O
modulation	O
of	O
breast	O
cancer	O
target	O
susceptibility	O
to	O
lysis	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
(	I-cell_type
LAK	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

E2-stimulated	B-cell_line
ER+	I-cell_line
cells	I-cell_line
were	O
more	O
susceptible	O
to	O
lysis	O
by	O
LAK	B-cell_type
cells	I-cell_type
than	O
corresponding	O
TAM-treated	B-cell_line
or	O
control	B-cell_type
cells	I-cell_type
,	O
while	O
treatment	O
of	O
ER-	B-cell_line
cells	I-cell_line
with	O
either	O
E2	O
or	O
TAM	O
alone	O
did	O
not	O
alter	O
from	O
control	O
their	O
susceptibility	O
to	O
this	O
immune-mediated	O
lysis	O
.	O

All	O
ER+	B-cell_line
and	I-cell_line
ER-	I-cell_line
cells	I-cell_line
tested	O
remained	O
sensitive	O
after	O
treatment	O
with	O
TAM	O
to	O
lysis	O
by	O
LAK	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
an	O
adenocarcinoma	B-protein
reactive	I-protein
human-mouse	I-protein
chimeric	I-protein
monoclonal	I-protein
antibody	I-protein
(	O
ING-1	B-protein
)	O
was	O
able	O
to	O
significantly	O
boost	O
in	O
vivo	O
generated	O
LAK	O
cell-mediated	O
lysis	O
of	O
control	B-cell_line
,	I-cell_line
E2-treated	I-cell_line
,	I-cell_line
and	I-cell_line
TAM-treated	I-cell_line
ER+	I-cell_line
and	I-cell_line
ER-	I-cell_line
cells	I-cell_line
.	O

These	O
in	O
vitro	O
results	O
provide	O
a	O
preclinical	O
rationale	O
for	O
in	O
vivo	O
testing	O
of	O
TAM	O
,	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
,	O
and	O
breast	O
cancer	O
reactive	O
antibody-dependent	O
cellular	O
cytotoxicity	O
facilitating	O
antibody	O
in	O
patients	O
with	O
refractory	O
or	O
high	O
risk	O
breast	O
cancer	O
.	O

The	O
cellular	B-DNA
oncogene	I-DNA
c-myb	B-DNA
can	O
interact	O
synergistically	O
with	O
the	O
Epstein-Barr	B-protein
virus	I-protein
BZLF1	I-protein
transactivator	I-protein
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

Regulation	O
of	O
replicative	O
functions	O
in	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
genome	I-DNA
is	O
mediated	O
through	O
activation	O
of	O
a	O
virally	B-protein
encoded	I-protein
transcription	I-protein
factor	I-protein
,	O
Z	B-protein
(	O
BZLF1	B-protein
)	O
.	O

We	O
have	O
shown	O
that	O
the	O
Z	B-protein
gene	I-protein
product	I-protein
,	O
which	O
binds	O
to	O
AP-1	B-DNA
sites	I-DNA
as	O
a	O
homodimer	O
and	O
has	O
sequence	O
similarity	O
to	O
c-Fos	B-DNA
,	O
can	O
efficiently	O
activate	O
the	O
EBV	B-DNA
early	I-DNA
promoter	I-DNA
,	O
BMRF1	B-DNA
,	O
in	O
certain	O
cell	O
types	O
(	O
i.e.	O
,	O
HeLa	B-cell_line
cells	I-cell_line
)	O
but	O
not	O
others	O
(	O
i.e.	O
,	O
Jurkat	B-cell_line
cells	I-cell_line
)	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
c-myb	B-protein
proto-oncogene	I-protein
product	I-protein
,	O
which	O
is	O
itself	O
a	O
DNA-binding	B-protein
protein	I-protein
and	O
transcriptional	B-protein
transactivator	I-protein
,	O
can	O
interact	O
synergistically	O
with	O
Z	B-protein
in	O
activating	O
the	O
BMRF1	B-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
a	O
T-cell	B-cell_line
line	I-cell_line
)	O
or	O
Raji	B-cell_line
cells	I-cell_line
(	O
an	O
EBV-positive	B-cell_line
B-cell	I-cell_line
)	O
,	O
whereas	O
the	O
c-myb	B-protein
gene	I-protein
product	I-protein
by	O
itself	O
has	O
little	O
effect	O
.	O

The	O
simian	B-DNA
virus	I-DNA
40	I-DNA
early	I-DNA
promoter	I-DNA
is	O
also	O
synergistically	O
activated	O
by	O
the	O
Z/c-myb	B-protein
combination	I-protein
.	O

Synergistic	O
transactivation	O
of	O
the	O
BMRF1	B-DNA
promoter	I-DNA
by	O
the	O
Z/c-myb	B-protein
combination	I-protein
appears	O
to	O
involve	O
direct	O
binding	O
by	O
the	O
Z	B-protein
protein	I-protein
but	O
not	O
the	O
c-myb	B-protein
protein	I-protein
.	O

A	O
30-bp	B-DNA
sequence	I-DNA
in	O
the	O
BMRF1	B-DNA
promoter	I-DNA
which	O
contains	O
a	O
Z	B-DNA
binding	I-DNA
site	I-DNA
(	O
a	O
consensus	B-DNA
AP-1	I-DNA
site	I-DNA
)	O
is	O
sufficient	O
to	O
transfer	O
high-level	O
lymphoid-specific	O
responsiveness	O
to	O
the	O
Z/c-myb	B-protein
combination	I-protein
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

That	O
the	O
c-myb	B-protein
oncogene	I-protein
product	I-protein
can	O
interact	O
synergistically	O
with	O
an	O
EBV-encoded	B-protein
member	I-protein
of	O
the	O
leucine	B-protein
zipper	I-protein
protein	I-protein
family	I-protein
suggests	O
c-myb	B-DNA
is	O
likely	O
to	O
engage	O
in	O
similar	O
interactions	O
with	O
cellularly	B-protein
encoded	I-protein
transcription	I-protein
factors	I-protein
.	O

Alpha-lipoic	O
acid	O
is	O
a	O
potent	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
results	O
from	O
infection	O
with	O
a	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

The	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
LTR	I-DNA
)	I-DNA
region	I-DNA
of	O
HIV	B-DNA
proviral	I-DNA
DNA	I-DNA
contains	O
binding	O
sites	O
for	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
and	O
this	O
transcriptional	B-protein
activator	I-protein
appears	O
to	O
regulate	O
HIV	O
activation	O
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

The	O
present	O
study	O
was	O
based	O
on	O
reports	O
that	O
antioxidants	O
which	O
eliminate	O
ROS	O
should	O
block	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
subsequently	O
HIV	O
transcription	O
,	O
and	O
thus	O
antioxidants	O
can	O
be	O
used	O
as	O
therapeutic	O
agents	O
for	O
AIDS	O
.	O

Incubation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
(	O
1	O
x	O
10	O
(	O
6	O
)	O
cells/ml	O
)	O
with	O
a	O
natural	O
thiol	O
antioxidant	O
,	O
alpha-lipoic	O
acid	O
,	O
prior	O
to	O
the	O
stimulation	O
of	O
cells	O
was	O
found	O
to	O
inhibit	O
NF-kappa	B-protein
B	I-protein
activation	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
25	O
ng/ml	O
)	O
or	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
50	O
ng/ml	O
)	O
.	O

The	O
inhibitory	O
action	O
of	O
alpha-lipoic	O
acid	O
was	O
found	O
to	O
be	O
very	O
potent	O
as	O
only	O
4	O
mM	O
was	O
needed	O
for	O
a	O
complete	O
inhibition	O
,	O
whereas	O
20	O
mM	O
was	O
required	O
for	O
N-acetylcysteine	O
.	O

These	O
results	O
indicate	O
that	O
alpha-lipoic	O
acid	O
may	O
be	O
effective	O
in	O
AIDS	O
therapeutics	O
.	O

Reticuloendotheliosis	B-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
elements	I-DNA
are	O
efficient	O
promoters	B-DNA
in	O
cells	O
of	O
various	O
species	O
and	O
tissue	O
origin	O
,	O
including	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

Promiscuous	O
transcriptional	O
activity	O
of	O
the	O
reticuloendotheliosis	B-DNA
virus	I-DNA
(	I-DNA
REV	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
was	O
detected	O
in	O
transient	O
expression	O
assays	O
using	O
LTR-chloramphenicol	B-DNA
acetyltransferase-encoding	I-DNA
gene	I-DNA
chimeras	I-DNA
,	O
and	O
cells	O
of	O
diverse	O
species	O
and	O
tissue	O
type	O
;	O
levels	O
of	O
expression	O
from	O
two	O
different	O
REV	B-DNA
LTRs	I-DNA
correlate	O
with	O
reports	O
of	O
pathogenicity	O
of	O
the	O
respective	O
viruses	O
in	O
vivo	O
.	O

REVs	O
do	O
not	O
encode	O
a	O
transactivator	O
targeted	O
to	O
the	O
viral	B-DNA
LTR	I-DNA
,	O
and	O
cells	O
infected	O
with	O
Marek	O
's	O
disease	O
virus	O
,	O
a	O
herpesvirus	O
with	O
an	O
overlapping	O
host	O
range	O
,	O
do	O
not	O
express	O
factors	O
that	O
preferentially	O
enhance	O
expression	O
from	O
REV	O
or	O
avian	B-DNA
sarcoma/leukemia	I-DNA
virus	I-DNA
LTRs	I-DNA
.	O

REV	B-DNA
LTRs	I-DNA
work	O
efficiently	O
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
and	O
are	O
viable	O
alternatives	O
to	O
promoters	B-DNA
commonly	O
used	O
for	O
expression	O
of	O
cloned	B-DNA
genes	I-DNA
.	O

They	O
may	O
also	O
prove	O
useful	O
in	O
the	O
identification	O
of	O
new	O
,	O
ubiquitous	B-protein
cellular	I-protein
transcription	I-protein
factors	I-protein
.	O

A	O
novel	O
Ets-related	B-protein
transcription	I-protein
factor	I-protein
,	O
Elf-1	B-protein
,	O
binds	O
to	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
regulatory	I-DNA
elements	I-DNA
that	O
are	O
required	O
for	O
inducible	O
trans	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
HIV-2	O
are	O
structurally	O
related	O
retroviruses	O
which	O
both	O
cause	O
AIDS	O
in	O
humans	O
.	O

Although	O
both	O
viruses	O
establish	O
latency	O
in	O
quiescent	O
human-peripheral-blood	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
the	O
asymptomatic	O
phase	O
of	O
HIV-2	O
infection	O
may	O
be	O
more	O
prolonged	O
than	O
that	O
of	O
HIV-1	O
.	O

The	O
latent	O
phases	O
of	O
both	O
HIV-1	O
and	O
HIV-2	O
infection	O
have	O
been	O
shown	O
to	O
be	O
disrupted	O
by	O
T-cell	O
activation	O
,	O
a	O
process	O
that	O
requires	O
host	O
cell	O
transcription	O
factors	O
.	O

In	O
the	O
case	O
of	O
HIV-1	O
,	O
the	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
is	O
sufficient	O
for	O
inducible	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
,	O
factors	O
in	O
addition	O
to	O
NF-kappa	B-protein
B	I-protein
are	O
required	O
to	O
activate	O
HIV-2	O
transcription	O
in	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
a	O
novel	O
Ets-related	B-protein
transcription	I-protein
factor	I-protein
,	O
Elf-1	B-protein
,	O
binds	O
specifically	O
to	O
two	B-DNA
purine-rich	I-DNA
motifs	I-DNA
in	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
.	O

Mutagenesis	O
experiments	O
demonstrated	O
that	O
these	O
Elf-1	B-DNA
binding	I-DNA
sites	I-DNA
are	O
required	O
for	O
induction	O
of	O
HIV-2	O
transcription	O
following	O
T-cell-receptor-mediated	O
T-cell	O
activation	O
.	O

Moreover	O
,	O
Elf-1	B-protein
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T-cell	O
nuclear	O
extracts	O
that	O
binds	O
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Thus	O
,	O
Elf-1	B-protein
is	O
a	O
novel	B-protein
transcription	I-protein
factor	I-protein
that	O
appears	O
to	O
be	O
required	O
for	O
the	O
T-cell-receptor-mediated	O
trans	O
activation	O
of	O
HIV-2	O
gene	O
expression	O
.	O

These	O
results	O
may	O
explain	O
differences	O
in	O
the	O
clinical	O
spectra	O
of	O
diseases	O
caused	O
by	O
HIV-1	O
and	O
HIV-2	O
and	O
may	O
also	O
have	O
implications	O
for	O
the	O
design	O
of	O
therapeutic	O
approaches	O
to	O
HIV-2	O
infection	O
.	O

Okadaic	O
acid	O
is	O
a	O
potent	O
inducer	O
of	O
AP-1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

Treatment	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
with	O
an	O
optimal	O
concentration	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	B-protein
1	I-protein
and	I-protein
2A	I-protein
,	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
AP-1	B-protein
and	O
a	O
marked	O
increase	O
in	O
NF-kappa	B-protein
B	I-protein
levels	O
.	O

In	O
contrast	O
,	O
no	O
effect	O
on	O
the	O
levels	O
of	O
the	O
octamer	B-protein
binding	I-protein
proteins	I-protein
,	O
Oct-1	B-protein
or	O
Oct-2	B-protein
,	O
were	O
found	O
.	O

Since	O
both	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
have	O
been	O
reported	O
to	O
be	O
important	O
in	O
the	O
induction	O
of	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
(	I-DNA
TNF-alpha	I-DNA
)	I-DNA
gene	I-DNA
we	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
on	O
TNF-alpha	B-RNA
mRNA	I-RNA
levels	O
.	O

Treatment	O
with	O
okadaic	O
acid	O
resulted	O
in	O
a	O
striking	O
increase	O
in	O
TNF-alpha	B-RNA
mRNA	I-RNA
transcripts	O
within	O
1	O
h	O
of	O
stimulation	O
and	O
large	O
amounts	O
of	O
TNF-alpha	B-protein
were	O
released	O
into	O
the	O
culture	O
media	O
.	O

Although	O
okadaic	O
acid	O
provides	O
a	O
potent	O
inductive	O
signal	O
for	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
it	O
did	O
not	O
induce	O
either	O
B	O
cell	O
proliferation	O
or	O
immunoglobulin	B-protein
secretion	O
.	O

Heterodimerization	O
and	O
transcriptional	O
activation	O
in	O
vitro	O
by	O
NF-kappa	B-protein
B	I-protein
proteins	I-protein
.	O

The	O
NF-kappa	B-protein
B	I-protein
family	I-protein
of	O
transcription	B-protein
proteins	I-protein
represents	O
multiple	O
DNA	O
binding	O
,	O
rel	B-protein
related	I-protein
polypeptides	I-protein
that	O
contribute	O
to	O
regulation	O
of	O
genes	O
involved	O
in	O
immune	O
responsiveness	O
and	O
inflammation	O
,	O
as	O
well	O
as	O
activation	O
of	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

In	O
this	O
study	O
multiple	O
NF-kappa	B-protein
B	I-protein
related	I-protein
polypeptides	I-protein
ranging	O
from	O
85	O
to	O
45	O
kDa	O
were	O
examined	O
for	O
their	O
capacity	O
to	O
interact	O
with	O
the	O
PRDII	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
interferon	B-DNA
beta	I-DNA
and	O
were	O
shown	O
to	O
possess	O
distinct	O
intrinsic	O
DNA	O
binding	O
affinities	O
for	O
this	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
and	O
form	O
multiple	B-protein
DNA	I-protein
binding	I-protein
homo-	I-protein
and	I-protein
heterodimer	I-protein
complexes	I-protein
in	O
co-renaturation	O
experiments	O
.	O

Furthermore	O
,	O
using	O
DNA	B-DNA
templates	I-DNA
containing	O
two	O
copies	O
of	O
the	O
PRDII	B-DNA
domain	I-DNA
linked	O
to	O
the	O
rabbit	B-DNA
beta	I-DNA
globin	I-DNA
gene	I-DNA
,	O
the	O
purified	O
polypeptides	O
specifically	O
stimulated	O
NF-kappa	B-protein
B	I-protein
dependent	O
transcription	O
in	O
an	O
in	O
vitro	O
reconstitution	O
assay	O
as	O
heterodimers	O
but	O
not	O
as	O
p50	B-protein
homodimers	I-protein
.	O

These	O
experiments	O
emphasize	O
the	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
dimerization	O
as	O
a	O
distinct	O
level	O
of	O
transcriptional	O
control	O
that	O
may	O
permit	O
functional	O
diversification	O
of	O
a	O
limited	O
number	O
of	O
regulatory	B-protein
proteins	I-protein
.	O

c-myc	B-RNA
mRNA	I-RNA
expression	O
in	O
minor	O
salivary	O
glands	O
of	O
patients	O
with	O
Sjogren	O
's	O
syndrome	O
.	O

c-myc	B-DNA
protooncogene	I-DNA
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
B	O
cell	O
lymphoid	O
malignancies	O
and	O
high	O
levels	O
of	O
c-myc	B-RNA
mRNA	I-RNA
expression	O
are	O
observed	O
in	O
activated	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
is	O
characterized	O
by	O
lymphocytic	B-cell_type
infiltrates	I-cell_type
of	O
exocrine	O
glands	O
,	O
remarkable	O
B	O
cell	O
hyperreactivity	O
and	O
a	O
strong	O
predisposition	O
to	O
B	O
cell	O
neoplasia	O
.	O

In	O
this	O
study	O
,	O
c-myc	B-RNA
protooncogene	I-RNA
mRNA	I-RNA
expression	O
in	O
29	O
labial	O
minor	O
salivary	O
gland	O
biopsies	O
from	O
patients	O
with	O
primary	O
SS	O
and	O
15	O
controls	O
was	O
examined	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
.	O

Two	O
40mer	O
oligonucleotides	O
from	O
the	O
1st	B-DNA
and	I-DNA
the	I-DNA
2nd	I-DNA
exon	I-DNA
of	O
the	O
c-myc	B-DNA
gene	I-DNA
,	O
labeled	O
with	O
35S	O
,	O
were	O
used	O
as	O
probes	O
.	O

To	O
detect	O
the	O
origin	O
of	O
the	O
cell	O
hybridized	O
with	O
a	O
c-myc	B-DNA
probe	I-DNA
,	O
a	O
combined	O
immunochemistry	O
in	O
situ	O
hybridization	O
histochemistry	O
technique	O
was	O
used	O
.	O

High	O
c-myc	B-RNA
mRNA	I-RNA
expression	O
was	O
detected	O
on	O
acinar	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

c-myc	B-protein
did	O
not	O
correlate	O
with	O
c-fos	B-protein
and	O
c-jun	B-protein
protein	O
expression	O
.	O

Stronger	O
c-myc	B-RNA
mRNA	I-RNA
expression	O
was	O
detected	O
in	O
labial	O
salivary	O
glands	O
of	O
patients	O
with	O
longer	O
disease	O
duration	O
(	O
p	O
less	O
than	O
or	O
equal	O
to	O
0.002	O
)	O
and	O
more	O
intense	O
T	B-cell_type
lymphocyte	I-cell_type
infiltrates	I-cell_type
(	O
p	O
less	O
than	O
0.05	O
)	O
although	O
these	O
patients	O
revealed	O
no	O
hypergammaglobulinemia	O
.	O

No	O
correlation	O
was	O
observed	O
between	O
c-myc	B-RNA
mRNA	I-RNA
and	O
B	O
lymphocyte	O
monoclonicity	O
or	O
lymphoma	O
.	O

In	O
conclusion	O
,	O
strong	O
c-myc	B-RNA
mRNA	I-RNA
expression	O
was	O
observed	O
on	O
epithelial	B-cell_type
cells	I-cell_type
of	O
labial	O
salivary	O
glands	O
from	O
patients	O
with	O
primary	O
SS	O
.	O

Our	O
findings	O
may	O
indicate	O
the	O
presence	O
of	O
a	O
reactivated	O
virus	O
hosted	O
in	O
these	O
cells	O
.	O

Corticosteroid	B-protein
receptors	I-protein
and	O
lymphocyte	B-cell_type
subsets	I-cell_type
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
aging	O
.	O

Plasma	O
cortisol	O
and	O
aldosterone	O
levels	O
and	O
number	O
of	O
related	O
receptors	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
measured	O
in	O
49	O
healthy	O
aged	O
subjects	O
(	O
62-97	O
yr	O
)	O
and	O
in	O
21	O
adult	O
controls	O
(	O
21-50	O
yr	O
)	O
.	O

In	O
all	O
subjects	O
,	O
in	O
addition	O
,	O
lymphocyte	B-cell_type
subsets	I-cell_type
were	O
determined	O
as	O
an	O
index	O
of	O
corticosteroid	O
action	O
.	O

The	O
mean	O
number	O
of	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
receptors	I-protein
was	O
significantly	O
lower	O
in	O
aged	O
subjects	O
than	O
in	O
controls	O
(	O
respectively	O
,	O
198	O
+/-	O
96	O
and	O
272	O
+/-	O
97	O
receptors	B-protein
/cell	O
for	O
type	B-protein
I	I-protein
,	O
and	O
1	O
,	O
794	O
+/-	O
803	O
and	O
3	O
,	O
339	O
+/-	O
918	O
for	O
type	O
II	B-protein
receptors	I-protein
)	O
.	O

Plasma	O
aldosterone	O
and	O
cortisol	O
and	O
lymphocyte	B-cell_type
subsets	I-cell_type
were	O
not	O
different	O
in	O
the	O
two	O
groups	O
.	O

All	O
of	O
the	O
parameters	O
were	O
also	O
tested	O
for	O
correlation	O
,	O
and	O
a	O
significant	O
inverse	O
correlation	O
was	O
found	O
between	O
age	O
and	O
type	B-protein
I	I-protein
and	O
type	B-protein
II	I-protein
receptors	I-protein
when	O
all	O
subjects	O
were	O
plotted	O
and	O
between	O
aged	O
and	O
CD4	B-cell_type
and	O
age	O
and	O
CD4/CD8	B-cell_type
in	O
the	O
aged	O
group	O
.	O

These	O
data	O
show	O
that	O
aged	O
subjects	O
have	O
reductions	O
of	O
corticosteroid	B-protein
receptors	I-protein
that	O
are	O
not	O
associated	O
with	O
increase	O
of	O
related	O
steroids	O
and	O
that	O
this	O
situation	O
probably	O
represents	O
a	O
concomitant	O
of	O
the	O
normal	O
aging	O
process	O
.	O

T	O
cell-specific	O
negative	O
regulation	O
of	O
transcription	O
of	O
the	O
human	B-protein
cytokine	I-protein
IL-4	I-protein
.	O

IL-4	B-protein
secreted	O
by	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
a	O
pleiotropic	B-protein
cytokine	I-protein
affecting	O
growth	O
and	O
differentiation	O
of	O
diverse	O
cell	O
types	O
such	O
as	O
T	B-cell_type
cells	I-cell_type
,	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
mast	B-cell_type
cells	I-cell_type
.	O

We	O
investigated	O
the	O
upstream	B-DNA
regulatory	I-DNA
elements	I-DNA
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
.	O

A	O
novel	B-DNA
T	I-DNA
cell-specific	I-DNA
negative	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
NRE	B-DNA
)	O
composed	O
of	O
two	O
protein-binding	O
sites	O
were	O
mapped	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
:	O
-311CTCCCTTCT-303	O
(	O
NRE-I	B-DNA
)	O
and	O
-288CTTTTTGCTT-TGC-300	O
(	O
NRE-II	B-DNA
)	O
.	O

A	O
T	B-protein
cell-specific	I-protein
protein	I-protein
Neg-1	B-protein
and	O
a	O
ubiquitous	B-protein
protein	I-protein
Neg-2	B-protein
binding	O
to	O
NRE-I	B-DNA
and	O
NRE-II	B-DNA
,	O
respectively	O
,	O
were	O
identified	O
.	O

Furthermore	O
,	O
a	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
was	O
found	O
45	B-DNA
bp	I-DNA
downstream	I-DNA
of	O
the	O
NRE	B-DNA
.	O

The	O
enhancer	O
activity	O
of	O
the	O
PRE	B-DNA
was	O
completely	O
suppressed	O
when	O
the	O
NRE	B-DNA
was	O
present	O
.	O

These	O
data	O
suggest	O
that	O
IL-4	B-DNA
promoter	I-DNA
activity	O
is	O
normally	O
down-regulated	O
by	O
an	O
NRE	B-DNA
via	O
repression	O
of	O
the	O
enhancer	B-DNA
positive	I-DNA
regulatory	I-DNA
element	I-DNA
.	O

These	O
data	O
may	O
have	O
implications	O
for	O
the	O
stringent	O
control	O
of	O
IL-4	B-protein
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Interleukin	O
6-induced	O
differentiation	O
of	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
into	O
IgM-secreting	B-cell_type
plasma	I-cell_type
cells	I-cell_type
is	O
mediated	O
by	O
c-fos	B-DNA
.	O

The	O
role	O
of	O
the	O
protooncogene	B-DNA
c-fos	I-DNA
in	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
6	I-protein
-induced	O
B	O
cell	O
differentiation	O
was	O
assessed	O
.	O

Treatment	O
of	O
SKW	O
6.4	O
cells	O
with	O
IL	B-protein
6	I-protein
induced	O
a	O
transient	O
and	O
early	O
stimulation	O
of	O
c-fos	B-RNA
sense	I-RNA
mRNA	I-RNA
expression	O
.	O

The	O
effect	O
appeared	O
within	O
30	O
min	O
and	O
returned	O
to	O
basal	O
levels	O
after	O
2	O
h	O
.	O

The	O
addition	O
of	O
antisense	O
oligonucleotides	O
to	O
c-fos	B-DNA
significantly	O
inhibited	O
IL	B-protein
6	I-protein
-induced	O
IgM	B-protein
production	O
by	O
SKW	B-cell_line
6.4	I-cell_line
cells	I-cell_line
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
whereas	O
control	O
oligonucleotides	O
had	O
no	O
inhibitory	O
effect	O
.	O

These	O
results	O
indicate	O
that	O
activation	O
of	O
c-fos	B-DNA
is	O
involved	O
in	O
IL	B-protein
6	I-protein
-induced	O
differentiation	O
of	O
SKW	B-cell_line
6.4	I-cell_line
cells	I-cell_line
into	O
IgM-secreting	B-cell_line
cells	I-cell_line
.	O

Transcriptional	O
regulation	O
during	O
T-cell	B-cell_type
development	O
:	O
the	O
alpha	B-DNA
TCR	I-DNA
gene	I-DNA
as	O
a	O
molecular	O
model	O
.	O

The	O
regulation	O
of	O
gene	O
expression	O
during	O
lymphocyte	B-cell_type
differentiation	O
is	O
a	O
complex	O
process	O
involving	O
interactions	O
between	O
multiple	B-DNA
positive	I-DNA
and	I-DNA
negative	I-DNA
transcriptional	I-DNA
regulatory	I-DNA
elements	I-DNA
.	O

In	O
this	O
article	O
,	O
transcriptional	O
regulation	O
of	O
the	O
archetypal	B-DNA
T-cell-specific	I-DNA
gene	I-DNA
,	O
alpha	B-DNA
TCR	I-DNA
,	O
is	O
discussed	O
.	O

Major	O
recent	O
developments	O
,	O
including	O
the	O
identification	O
of	O
novel	O
families	O
of	O
transcription	B-DNA
factors	I-DNA
that	O
regulate	O
multiple	O
T-cell	B-DNA
genes	I-DNA
during	O
thymocyte	O
ontogeny	O
and	O
T-cell	B-cell_type
activation	O
,	O
are	O
described	O
.	O

Photoaffinity	O
labeling	O
of	O
plasma	B-protein
membrane	I-protein
receptors	I-protein
for	O
aldosterone	O
from	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O

Non-genomic	O
effects	O
of	O
aldosterone	O
on	O
the	O
sodium-proton-antiport	B-protein
have	O
been	O
shown	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
which	O
could	O
be	O
related	O
to	O
a	O
new	O
aldosterone	B-protein
membrane	I-protein
receptor	I-protein
.	O

In	O
the	O
present	O
paper	O
plasma	O
membranes	O
from	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
were	O
covalently	O
photolabeled	O
with	O
a	O
[	O
125I	O
]	O
-aldosterone	O
derivative	O
.	O

Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
showed	O
significant	O
aldosterone	O
binding	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50000	O
Dalton	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	O
cortisol	O
in	O
the	O
binding	O
media	O
.	O

The	O
presence	O
of	O
the	O
sulfhydryl	O
agent	O
dithiothreitol	O
did	O
not	O
affect	O
results	O
suggesting	O
the	O
absence	O
of	O
disulfide	B-protein
bridges	I-protein
in	O
the	O
steroid	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
receptor	O
.	O

These	O
data	O
are	O
the	O
first	O
to	O
define	O
the	O
molecular	O
weight	O
of	O
the	O
membrane	B-protein
receptor	I-protein
for	O
aldosterone	O
.	O

Redox	O
status	O
of	O
cells	O
influences	O
constitutive	O
or	O
induced	O
NF-kappa	B-protein
B	I-protein
translocation	O
and	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
activity	O
in	O
human	B-cell_line
T	I-cell_line
and	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
have	O
tested	O
the	O
hypothesis	O
that	O
cellular	O
activation	O
events	O
occurring	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
monocytes	B-cell_type
and	O
mediated	O
through	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
are	O
dependent	O
upon	O
the	O
constitutive	O
redox	O
status	O
of	O
these	O
cells	O
.	O

We	O
used	O
phenolic	O
,	O
lipid-soluble	O
,	O
chain-breaking	O
antioxidants	O
(	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
nordihydroquairetic	O
acid	O
,	O
or	O
alpha-tocopherol	O
(	O
vitamin	O
E	O
)	O
to	O
show	O
that	O
peroxyl	O
radical	O
scavenging	O
in	O
unstimulated	B-cell_line
and	I-cell_line
PMA-	I-cell_line
or	I-cell_line
TNF-stimulated	I-cell_line
cells	I-cell_line
blocks	O
the	O
functions	O
depending	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

BHA	O
was	O
found	O
to	O
suppress	O
not	O
only	O
PMA-	O
or	O
TNF-induced	O
,	O
but	O
also	O
constitutive	O
,	O
HIV-enhancer	O
activity	O
concomitant	O
to	O
an	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
both	O
lymphoblastoid	B-cell_line
T	I-cell_line
(	O
J.Jhan	B-cell_line
)	O
and	O
monocytic	B-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

This	O
was	O
also	O
true	O
for	O
KBF	O
(	O
p50	O
homodimer	O
)	O
binding	O
activity	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

Secretion	O
of	O
TNF	B-protein
,	O
the	O
product	O
of	O
another	O
NF-kappa	B-DNA
B-dependent	I-DNA
gene	I-DNA
,	O
was	O
abolished	O
by	O
BHA	O
in	O
PMA-stimulated	B-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

The	O
anti-oxidative	O
effect	O
of	O
BHA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
thiol	O
,	O
but	O
not	O
glutathione	O
,	O
content	O
in	O
stimulated	B-cell_line
and	I-cell_line
unstimulated	I-cell_line
T	I-cell_line
cell	I-cell_line
,	O
whereas	O
TNF	B-protein
stimulation	O
itself	O
barely	O
modified	O
the	O
cellular	O
thiol	O
level	O
.	O

Oxidative	O
stress	O
obtained	O
by	O
the	O
addition	O
of	O
H2O2	O
to	O
the	O
culture	O
medium	O
of	O
J.Jhan	B-cell_line
or	O
U937	B-cell_line
cells	I-cell_line
could	O
not	O
by	O
itself	O
induce	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

These	O
observations	O
suggest	O
that	O
TNF	B-protein
and	O
PMA	B-protein
do	O
not	O
lead	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
through	O
induction	O
of	O
changes	O
in	O
the	O
cell	O
redox	O
status	O
.	O

Rather	O
,	O
TNF	B-protein
and	O
PMA	B-protein
can	O
exert	O
their	O
effect	O
only	O
if	O
cells	O
are	O
in	O
an	O
appropriate	O
redox	O
status	O
,	O
because	O
prior	O
modification	O
toward	O
reduction	O
with	O
BHA	O
treatment	O
prevents	O
this	O
activation	O
.	O

It	O
appears	O
that	O
a	O
basal	O
redox	O
equilibrium	O
tending	O
toward	O
oxidation	O
is	O
a	O
prerequisite	O
for	O
full	O
activation	O
of	O
transduction	O
pathways	O
regulating	O
the	O
activity	O
of	O
NF-kappa	B-DNA
B-dependent	I-DNA
genes	I-DNA
.	O

Selection	O
of	O
optimal	O
kappa	O
B/Rel	O
DNA-binding	O
motifs	O
:	O
interaction	O
of	O
both	O
subunits	O
of	O
NF-kappa	B-protein
B	I-protein
with	O
DNA	O
is	O
required	O
for	O
transcriptional	O
activation	O
.	O

Analysis	O
of	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
has	O
revealed	O
that	O
both	O
proteins	O
can	O
interact	O
with	O
related	O
DNA	O
sequences	O
through	O
either	O
homo-	O
or	O
heterodimer	O
formation	O
.	O

In	O
addition	O
,	O
the	O
product	O
of	O
the	O
proto-oncogene	B-DNA
c-rel	I-DNA
can	O
bind	O
to	O
similar	O
DNA	O
motifs	O
by	O
itself	O
or	O
as	O
a	O
heterodimer	O
with	O
p50	B-protein
or	O
p65	B-protein
.	O

However	O
,	O
these	O
studies	O
have	O
used	O
a	O
limited	O
number	O
of	O
known	O
kappa	O
B	O
DNA	O
motifs	O
,	O
and	O
the	O
question	O
of	O
the	O
optimal	O
DNA	O
sequences	O
preferred	O
by	O
each	O
homodimer	O
has	O
not	O
been	O
addressed	O
.	O

Using	O
purified	O
recombinant	O
p50	B-protein
,	O
p65	B-protein
,	O
and	O
c-Rel	B-protein
proteins	I-protein
,	O
optimal	O
DNA-binding	O
motifs	O
were	O
selected	O
from	O
a	O
pool	O
of	O
random	O
oligonucleotides	O
.	O

Alignment	O
of	O
the	O
selected	O
sequences	O
allowed	O
us	O
to	O
predict	O
a	O
consensus	O
sequence	O
for	O
binding	O
of	O
the	O
individual	O
homodimeric	B-protein
Rel-related	I-protein
proteins	I-protein
,	O
and	O
DNA-protein	O
binding	O
analysis	O
of	O
the	O
selected	O
DNA	O
sequences	O
revealed	O
sequence	O
specificity	O
of	O
the	O
proteins	O
.	O

Contrary	O
to	O
previous	O
assumptions	O
,	O
we	O
observed	O
that	O
p65	B-protein
homodimers	O
can	O
interact	O
with	O
a	O
subset	O
of	O
DNA	O
sequences	O
not	O
recognized	O
by	O
p50	B-protein
homodimers	I-protein
.	O

Differential	O
binding	O
affinities	O
were	O
also	O
obtained	O
with	O
p50-	B-DNA
and	I-DNA
c-Rel-selected	I-DNA
sequences	I-DNA
.	O

Using	O
either	O
a	O
p50-	O
or	O
p65-	O
selected	O
kappa	O
B	O
motif	O
,	O
which	O
displayed	O
differential	O
binding	O
with	O
respect	O
to	O
the	O
other	O
protein	O
,	O
little	O
to	O
no	O
binding	O
was	O
observed	O
with	O
the	O
heterodimeric	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
.	O

Similarly	O
,	O
in	O
transfection	O
experiments	O
in	O
which	O
the	O
selective	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
were	O
used	O
to	O
drive	O
the	O
expression	O
of	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
,	O
the	O
p65	B-DNA
-and	I-DNA
p50-selected	I-DNA
motifs	I-DNA
were	O
activated	O
only	O
in	O
the	O
presence	O
of	O
p65	B-protein
and	O
p50/65	B-protein
(	O
a	O
chimeric	B-protein
protein	I-protein
with	O
the	O
p50	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
and	O
p65	B-protein
activation	I-protein
domain	I-protein
)	O
expression	O
vectors	O
,	O
respectively	O
,	O
and	O
neither	O
demonstrated	O
a	O
significant	O
response	O
to	O
stimuli	O
that	O
induce	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O

These	O
findings	O
demonstrate	O
that	O
interaction	O
of	O
both	O
subunits	O
of	O
the	O
heterodimeric	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
with	O
DNA	O
is	O
required	O
for	O
DNA	O
binding	O
and	O
transcriptional	O
activation	O
and	O
suggest	O
that	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
individual	O
rel-related	B-protein
proteins	I-protein
will	O
differ	O
dramatically	O
,	O
depending	O
on	O
the	O
specific	O
kappa	O
B	O
motifs	O
present	O
.	O

NF-kappa	B-protein
B	I-protein
-dependent	O
induction	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
p50	B-DNA
subunit	I-DNA
gene	I-DNA
promoter	I-DNA
underlies	O
self-perpetuation	O
of	O
human	O
immunodeficiency	O
virus	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
sustained	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
observed	O
in	O
U937	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
were	O
studied	O
.	O

The	O
activity	O
of	O
the	O
promoter	B-DNA
regulating	O
the	O
synthesis	O
of	O
the	O
p105	B-protein
precursor	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
subunit	I-protein
was	O
enhanced	O
in	O
these	O
cells	O
.	O

Deletions	O
in	O
this	O
promoter	B-DNA
indicated	O
that	O
this	O
upregulation	O
was	O
mediated	O
through	O
the	O
NF-kappa	O
B-	O
but	O
not	O
the	O
AP-1-binding	B-DNA
motif	I-DNA
,	O
by	O
bona	O
fide	O
p50/p65	B-protein
heterodimers	I-protein
.	O

Analysis	O
of	O
cytosolic	O
extracts	O
indicated	O
that	O
NF-kappa	B-protein
B	I-protein
levels	O
were	O
increased	O
in	O
HIV-infected	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
to	O
the	O
transient	O
NF-kappa	B-protein
B	I-protein
activation	O
induced	O
by	O
phorbol	O
ester	O
,	O
the	O
permanent	O
NF-kappa	B-protein
B	I-protein
translocation	O
induced	O
by	O
HIV	O
infection	O
was	O
not	O
dependent	O
on	O
PKC	B-protein
isoenzymes	I-protein
alpha	I-protein
and	I-protein
beta	I-protein
as	O
shown	O
by	O
the	O
use	O
of	O
a	O
specific	O
inhibitor	O
(	O
GF	O
109203X	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
during	O
chronic	O
HIV	O
infection	O
of	O
U937	B-cell_line
cells	I-cell_line
,	O
continuous	O
NF-kappa	B-protein
B	I-protein
(	O
p50/p65	B-protein
)	O
translocation	O
results	O
in	O
p105	O
promoter	O
upregulation	O
with	O
subsequent	O
cytosolic	O
NF-kappa	B-protein
B	I-protein
accumulation	O
,	O
ready	O
for	O
further	O
translocation	O
.	O

This	O
HIV-mediated	O
mechanism	O
results	O
in	O
a	O
self-perpetuating	O
loop	O
of	O
NF-kappa	B-protein
B	I-protein
production	O
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
interleukin	B-protein
2	I-protein
in	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

We	O
report	O
here	O
that	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
acts	O
on	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
by	O
enhancing	O
binding	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
(	O
p55	B-protein
)	O
.	O

Similarly	O
,	O
IL-2	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U	I-cell_line
937	I-cell_line
,	O
but	O
not	O
in	O
resting	B-cell_type
human	I-cell_type
T-cells	I-cell_type
.	O

This	O
effect	O
is	O
detectable	O
within	O
15	O
min	O
and	O
peaks	O
1	O
h	O
after	O
exposure	O
to	O
IL-2	B-protein
.	O

Enhanced	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
is	O
followed	O
by	O
functional	O
activation	O
in	O
that	O
inducibility	O
of	O
the	O
IL-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
is	O
mediated	O
by	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	O
and	O
that	O
a	O
heterologous	O
promoter	O
containing	O
the	O
NF-kappa	B-DNA
B	I-DNA
consensus	I-DNA
sequence	I-DNA
(	O
-291	B-DNA
to	I-DNA
-245	I-DNA
)	O
of	O
the	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
gene	I-DNA
is	O
activated	O
.	O

In	O
addition	O
,	O
IL-2	B-protein
is	O
capable	O
of	O
increasing	O
transcript	O
levels	O
of	O
the	O
p50	B-protein
gene	O
coding	O
for	O
the	O
p50	B-protein
subunit	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	O
factor	O
,	O
whereas	O
mRNA	O
levels	O
of	O
the	O
p65	B-protein
NF-kappa	B-DNA
B	I-DNA
gene	I-DNA
remained	O
unchanged	O
.	O

Studies	O
on	O
the	O
biological	O
activity	O
of	O
triiodothyronine	O
sulfate	O
.	O

Hepatic	B-cell_type
microsomes	I-cell_type
and	O
isolated	B-cell_type
hepatocytes	I-cell_type
in	O
short	O
term	O
culture	O
desulfate	O
T3	O
sulfate	O
(	O
T3SO4	O
)	O
.	O

We	O
,	O
therefore	O
,	O
wished	O
to	O
determine	O
whether	O
T3SO4	O
could	O
mimic	O
the	O
action	O
of	O
thyroid	O
hormone	O
in	O
vitro	O
.	O

T3SO4	O
had	O
no	O
thyromimetic	O
effect	O
on	O
the	O
activity	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPase	I-protein
in	O
human	O
erythrocyte	O
membranes	O
at	O
doses	O
up	O
to	O
10	O
,	O
000	O
times	O
the	O
maximally	O
effective	O
dose	O
of	O
T3	O
(	O
10	O
(	O
-10	O
)	O
mol/L	O
)	O
.	O

In	O
GH4C1	B-cell_line
pituitary	I-cell_line
cells	I-cell_line
,	O
T3SO4	O
failed	O
to	O
displace	O
[	O
125I	O
]	O
T3	O
from	O
nuclear	B-protein
receptors	I-protein
in	O
intact	B-cell_line
cells	I-cell_line
or	O
soluble	O
preparations	O
.	O

Thus	O
,	O
T3SO4	O
was	O
not	O
directly	O
thyromimetic	O
in	O
either	O
an	O
isolated	O
human	O
membrane	O
system	O
or	O
a	O
pituitary	O
cell	O
system	O
in	O
which	O
nuclear	O
receptor	O
occupancy	O
correlates	O
with	O
GH	O
synthesis	O
.	O

Thyroid	O
hormones	O
inhibit	O
[	O
3H	O
]	O
glycosaminoglycan	O
synthesis	O
by	O
cultured	B-cell_line
human	I-cell_line
dermal	I-cell_line
fibroblasts	I-cell_line
,	O
and	O
T3SO4	O
displayed	O
about	O
0.5	O
%	O
the	O
activity	O
of	O
T3	O
at	O
72	O
h	O
.	O

Human	B-cell_type
fibroblasts	I-cell_type
contained	O
roughly	O
the	O
same	O
level	O
of	O
microsomal	O
p-nitrophenyl	B-protein
sulfatase	I-protein
activity	O
as	O
that	O
previously	O
observed	O
in	O
hepatic	B-cell_type
microsomes	I-cell_type
.	O

Propylthiouracil	O
(	O
50	O
mumol/L	O
)	O
did	O
not	O
affect	O
the	O
action	O
of	O
T3SO4	O
,	O
suggesting	O
that	O
deiodination	O
was	O
not	O
important	O
for	O
this	O
activity	O
of	O
T3SO4	O
.	O

Thus	O
,	O
it	O
appears	O
T3SO4	O
has	O
no	O
intrinsic	O
biological	O
activity	O
,	O
but	O
,	O
under	O
certain	O
circumstances	O
,	O
may	O
be	O
reactivated	O
by	O
desulfation	O
.	O

Human	O
T	O
cell	O
activation	O
through	O
the	O
activation-inducer	B-protein
molecule/CD69	I-protein
enhances	O
the	O
activity	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

The	O
induction	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
cell	O
differentiation	O
and	O
activation	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
AP-1	B-protein
activity	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
stimulated	O
through	O
the	O
activation	O
inducer	O
molecule	O
(	O
AIM	O
)	O
/	O
CD69	B-protein
activation	O
pathway	O
.	O

Phorbol	O
esters	O
are	O
required	O
to	O
induce	O
AIM/CD69	B-protein
cell-surface	O
expression	O
as	O
well	O
as	O
for	O
triggering	O
the	O
proliferation	O
of	O
T	B-cell_type
cells	I-cell_type
in	O
conjunction	O
with	O
anti-AIM	B-protein
mAb	I-protein
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
addition	O
of	O
anti-AIM	B-protein
mAb	I-protein
to	O
PMA-treated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
markedly	O
enhanced	O
the	O
binding	O
activity	O
of	O
AP-1	B-protein
to	O
its	O
cognate	O
sequence	O
,	O
the	O
phorbol	B-DNA
ester	I-DNA
response	I-DNA
element	I-DNA
.	O

In	O
contrast	O
,	O
anti-AIM	B-protein
mAb	I-protein
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
whose	O
activity	O
is	O
also	O
regulated	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

The	O
increase	O
in	O
AP-1	B-protein
-binding	O
activity	O
was	O
accompanied	O
by	O
the	O
marked	O
stimulation	O
of	O
the	O
transcription	O
of	O
c-fos	B-protein
but	O
not	O
that	O
of	O
c-jun	B-protein
.	O

Blockade	O
of	O
the	O
DNA-binding	B-protein
complexes	I-protein
with	O
an	O
anti-Fos	B-protein
mAb	I-protein
demonstrated	O
a	O
direct	O
participation	O
of	O
c-Fos	B-protein
in	O
the	O
AP-1	B-protein
complexes	I-protein
induced	O
by	O
anti-AIM	B-protein
mAb	I-protein
.	O

Most	O
of	O
the	O
AP-1	B-protein
activity	O
could	O
be	O
eliminated	O
when	O
the	O
anti-AIM	B-protein
mAb	I-protein
was	O
added	O
to	O
the	O
culture	O
medium	O
in	O
the	O
presence	O
of	O
cycloheximide	O
,	O
suggesting	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
AP-1	B-protein
-binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
evidence	O
that	O
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
through	O
the	O
AIM	O
activation	O
pathway	O
regulate	O
the	O
activity	O
of	O
AP-1	B-protein
.	O

Therefore	O
,	O
this	O
pathway	O
appears	O
as	O
a	O
crucial	O
step	O
in	O
the	O
initiation	O
of	O
early	O
T	O
cell	O
activation	O
events	O
.	O

Gangliosides	O
suppress	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Both	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
cells	I-cell_type
contain	O
gangliosides	O
as	O
important	O
cell	O
membrane	O
constituents	O
that	O
,	O
after	O
being	O
shed	O
,	O
may	O
influence	O
cells	O
of	O
the	O
immune	O
system	O
.	O

We	O
have	O
studied	O
the	O
impact	O
of	O
gangliosides	O
on	O
the	O
expression	O
of	O
TNF	B-protein
in	O
blood	B-cell_type
monocytes	I-cell_type
and	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
Mono	I-cell_line
Mac	I-cell_line
6	I-cell_line
.	O

Although	O
under	O
standard	O
culture	O
conditions	O
,	O
bovine	O
brain	O
gangliosides	O
(	O
100	O
micrograms/ml	O
)	O
suppressed	O
LPS-stimulated	O
TNF	B-protein
production	O
5-fold	O
in	O
PBMC	B-cell_type
and	O
10-fold	O
in	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
,	O
suppression	O
was	O
more	O
efficient	O
under	O
serum-free	O
conditions	O
.	O

Looking	O
at	O
highly	O
purified	O
gangliosides	O
,	O
GD3	O
,	O
GD1a	O
,	O
GM3	O
,	O
GM2	O
,	O
and	O
GM1	O
were	O
all	O
effective	O
in	O
reducing	O
TNF	B-protein
production	O
in	O
PBMC	B-cell_type
,	O
and	O
in	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
by	O
factor	O
10	O
to	O
50	O
.	O

The	O
suppressive	O
activity	O
was	O
lost	O
in	O
molecules	O
,	O
lacking	O
the	O
sugar	O
moiety	O
or	O
the	O
lipid	O
moiety	O
.	O

Gangliosides	O
appear	O
to	O
act	O
at	O
an	O
early	O
step	O
of	O
activation	O
in	O
that	O
TNF	B-RNA
transcripts	I-RNA
were	O
reduced	O
and	O
the	O
mobilization	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
was	O
blocked	O
.	O

Furthermore	O
,	O
in	O
time	O
kinetics	O
,	O
gangliosides	O
were	O
effective	O
for	O
up	O
to	O
30	O
min	O
after	O
addition	O
of	O
LPS	O
,	O
but	O
not	O
thereafter	O
.	O

However	O
,	O
the	O
expression	O
of	O
the	O
CD14	B-protein
Ag	I-protein
,	O
a	O
receptor	B-protein
molecule	I-protein
for	O
LPS-LPS	B-protein
binding	I-protein
protein	I-protein
complexes	I-protein
,	O
was	O
unaffected	O
by	O
gangliosides	O
.	O

Finally	O
,	O
when	O
using	O
Staphylococcus	O
aureus	O
or	O
platelet	B-protein
activating	I-protein
factor	I-protein
as	O
a	O
stimulus	O
,	O
gangliosides	O
were	O
able	O
to	O
suppress	O
TNF	B-protein
production	O
in	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
by	O
factor	O
5	O
to	O
10	O
,	O
as	O
well	O
.	O

On	O
the	O
other	O
hand	O
,	O
phorbol	O
ester-induced	O
production	O
of	O
O2-	O
was	O
similar	O
in	O
cells	O
treated	O
with	O
and	O
without	O
gangliosides	O
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
TNF	B-protein
gene	O
expression	O
in	O
monocytes	B-cell_type
induced	O
by	O
different	O
types	O
of	O
stimuli	O
can	O
be	O
blocked	O
by	O
gangliosides	O
at	O
an	O
early	O
step	O
of	O
signal	O
transduction	O
.	O

A	O
novel	O
mitogen-inducible	B-protein
gene	I-protein
product	I-protein
related	O
to	O
p50/p105-NF-kappa	B-protein
B	I-protein
participates	O
in	O
transactivation	O
through	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
.	O

A	O
Rel-related	B-protein
,	I-protein
mitogen-inducible	I-protein
,	I-protein
kappa	I-protein
B-binding	I-protein
protein	I-protein
has	O
been	O
cloned	O
as	O
an	O
immediate-early	B-DNA
activation	I-DNA
gene	I-DNA
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
cDNA	B-DNA
has	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
of	O
900	B-DNA
amino	I-DNA
acids	I-DNA
capable	O
of	O
encoding	O
a	O
97-kDa	B-protein
protein	I-protein
.	O

This	O
protein	O
is	O
most	O
similar	O
to	O
the	O
105-kDa	O
precursor	O
polypeptide	O
of	O
p50-NF-kappa	B-protein
B	I-protein
.	O

Like	O
the	O
105-kDa	O
precursor	O
,	O
it	O
contains	O
an	O
amino-terminal	B-protein
Rel-related	I-protein
domain	I-protein
of	O
about	O
300	O
amino	O
acids	O
and	O
a	O
carboxy-terminal	B-protein
domain	I-protein
containing	O
six	O
full	B-protein
cell	I-protein
cycle	I-protein
or	O
ankyrin	B-protein
repeats	I-protein
.	O

In	O
vitro-translated	B-protein
proteins	I-protein
,	O
truncated	O
downstream	O
of	O
the	O
Rel	B-DNA
domain	I-DNA
and	O
excluding	O
the	O
repeats	O
,	O
bind	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O

We	O
refer	O
to	O
the	O
kappa	B-protein
B-binding	I-protein
,	I-protein
truncated	I-protein
protein	I-protein
as	O
p50B	B-protein
by	O
analogy	O
with	O
p50-NF-kappa	B-protein
B	I-protein
and	O
to	O
the	O
full-length	O
protein	O
as	O
p97	B-protein
.	O

p50B	B-protein
is	O
able	O
to	O
form	O
heteromeric	B-protein
kappa	I-protein
B-binding	I-protein
complexes	I-protein
with	O
RelB	B-protein
,	O
as	O
well	O
as	O
with	O
p65	B-protein
and	O
p50	B-protein
,	O
the	O
two	O
subunits	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Transient-transfection	O
experiments	O
in	O
embryonal	B-cell_line
carcinoma	I-cell_line
cells	I-cell_line
demonstrate	O
a	O
functional	O
cooperation	O
between	O
p50B	B-protein
and	O
RelB	B-protein
or	O
p65	B-protein
in	O
transactivation	O
of	O
a	O
reporter	B-DNA
plasmid	I-DNA
dependent	O
on	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
.	O

The	O
data	O
imply	O
the	O
existence	O
of	O
a	O
complex	O
family	O
of	O
NF-kappa	B-protein
B-like	I-protein
transcription	I-protein
factors	I-protein
.	O

Surrogate	O
thyroglobulin	B-protein
receptors	I-protein
and	O
T	O
cell	O
proliferation	O
in	O
Hashimoto	O
's	O
thyroiditis	O
.	O

Immunoglobulin	B-protein
molecules	I-protein
on	O
the	O
surface	O
of	O
a	O
B	B-cell_type
lymphocyte	I-cell_type
are	O
the	O
endogenous	O
``	O
receptors	O
''	O
to	O
which	O
specific	O
antigens	O
bind	O
.	O

Studies	O
in	O
mice	O
have	O
shown	O
that	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
conjugated	O
with	O
palmitate	O
to	O
provide	O
a	O
lipid	O
tail	O
,	O
can	O
be	O
inserted	O
into	O
the	O
cell	O
membrane	O
to	O
provide	O
a	O
``	O
surrogate	O
''	O
antigen	O
receptor	O
.	O

We	O
have	O
investigated	O
whether	O
a	O
palmitate	B-protein
conjugate	I-protein
of	O
a	O
human	B-protein
monoclonal	I-protein
antibody	I-protein
specific	O
for	O
thyroglobulin	B-protein
(	O
TG	B-protein
)	O
could	O
function	O
as	O
a	O
surrogate	B-protein
TG	I-protein
receptor	I-protein
on	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
separated	O
into	O
fractions	O
enriched	O
for	O
T	B-cell_type
cells	I-cell_type
or	O
depleted	O
of	O
T	B-cell_type
cells	I-cell_type
(	O
non-T	B-cell_type
cells	I-cell_type
)	O
.	O

Using	O
flow	O
cytometry	O
,	O
we	O
detected	O
surrogate	B-protein
TG	I-protein
receptors	I-protein
on	O
non-T	B-cell_type
(	I-cell_type
but	I-cell_type
not	I-cell_type
on	I-cell_type
T	I-cell_type
)	I-cell_type
cells	I-cell_type
from	O
11	O
of	O
11	O
individuals	O
studied	O
(	O
5	O
Hashimoto	O
patients	O
and	O
6	O
control	O
donors	O
)	O
.	O

In	O
contrast	O
,	O
endogenous	B-protein
TG	I-protein
receptors	I-protein
could	O
only	O
be	O
detected	O
on	O
non-T	B-cell_type
cells	I-cell_type
from	O
1	O
of	O
3	O
Hashimoto	O
patients	O
and	O
from	O
0	O
of	O
4	O
control	O
donors	O
.	O

Because	O
of	O
the	O
efficient	O
binding	O
of	O
TG	B-protein
by	O
surrogate	B-protein
receptors	I-protein
on	O
non-T	B-cell_type
cells	I-cell_type
,	O
we	O
assessed	O
the	O
ability	O
of	O
such	O
cells	O
to	O
present	O
TG	B-protein
to	O
T	B-cell_type
cells	I-cell_type
.	O

Proliferation	O
in	O
response	O
to	O
TG	B-protein
was	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
only	O
1	O
of	O
5	O
Hashimoto	O
patients	O
.	O

This	O
low	O
frequency	O
of	O
response	O
was	O
no	O
different	O
from	O
that	O
previously	O
detected	O
using	O
cultures	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
autologous	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
.	O

Therefore	O
,	O
the	O
successful	O
generation	O
of	O
surrogate	B-protein
receptors	I-protein
on	O
non-T	B-cell_type
cells	I-cell_type
is	O
not	O
associated	O
with	O
more	O
efficient	O
TG	B-protein
presentation	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
the	O
significance	O
of	O
the	O
present	O
study	O
is	O
that	O
the	O
T	B-cell_type
cells	I-cell_type
,	O
not	O
the	O
antigen-presenting	B-cell_type
cells	I-cell_type
,	O
are	O
likely	O
to	O
be	O
the	O
limiting	O
element	O
in	O
the	O
T	O
cell	O
proliferative	O
response	O
to	O
TG	B-protein
and	O
other	O
thyroid	B-protein
autoantigens	I-protein
.	O

Targeted	O
degradation	O
of	O
c-Fos	B-protein
,	O
but	O
not	O
v-Fos	B-protein
,	O
by	O
a	O
phosphorylation-dependent	B-protein
signal	I-protein
on	O
c-Jun	B-protein
.	O

The	O
proto-oncogene	B-protein
products	I-protein
c-Fos	B-protein
and	O
c-Jun	B-protein
heterodimerize	O
through	O
their	O
leucine	B-protein
zippers	I-protein
to	O
form	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
heterodimer	O
is	O
regulated	O
by	O
signal-dependent	O
phosphorylation	O
and	O
dephosphorylation	O
events	O
.	O

The	O
stability	O
of	O
c-Fos	B-protein
was	O
found	O
to	O
also	O
be	O
controlled	O
by	O
intracellular	O
signal	O
transduction	O
.	O

In	O
transient	O
expression	O
and	O
in	O
vitro	O
degradation	O
experiments	O
,	O
the	O
stability	O
of	O
c-Fos	B-protein
was	O
decreased	O
when	O
the	O
protein	O
was	O
dimerized	O
with	O
phosphorylated	B-protein
c-Jun	I-protein
.	O

c-Jun	B-protein
protein	O
isolated	O
from	O
phorbol	B-cell_line
ester-induced	I-cell_line
cells	I-cell_line
did	O
not	O
target	O
c-Fos	B-protein
for	O
degradation	O
,	O
which	O
suggests	O
that	O
c-Fos	B-protein
is	O
transiently	O
stabilized	O
after	O
stimulation	O
of	O
cell	O
growth	O
.	O

v-Fos	B-protein
protein	I-protein
,	O
the	O
retroviral	O
counterpart	O
of	O
c-Fos	B-protein
,	O
was	O
not	O
susceptible	O
to	O
degradation	O
targeted	O
by	O
c-Jun	B-protein
.	O

The	O
regulation	O
of	O
the	O
human	B-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
promoter	I-DNA
region	I-DNA
in	O
macrophage	B-cell_line
,	O
T	B-cell_line
cell	I-cell_line
,	O
and	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
1311-base	B-DNA
pair	I-DNA
human	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
(	I-DNA
TNF	I-DNA
)	I-DNA
alpha	I-DNA
promoter	I-DNA
region	I-DNA
was	O
fused	O
to	O
the	O
luciferase	B-DNA
(	I-DNA
Luc	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
and	O
studied	O
in	O
a	O
transient	O
transfection	O
system	O
in	O
three	O
TNF	B-cell_line
producing	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
U937	B-cell_line
macrophage	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
the	O
MLA	B-cell_line
144	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
and	O
the	O
729-6	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

This	O
full	O
length	O
promoter	O
construct	O
can	O
be	O
induced	O
by	O
phorbol	O
13-myristate	O
acetate	O
(	O
PMA	O
)	O
in	O
each	O
of	O
these	O
cell	O
types	O
.	O

Analysis	O
of	O
a	O
series	O
of	O
5'-truncations	B-DNA
showed	O
several	O
peaks	O
of	O
basal	O
and	O
PMA	O
induced	O
activity	O
suggesting	O
the	O
presence	O
of	O
several	O
positive	B-DNA
and	O
negative	O
regulatory	O
elements	O
.	O

A	O
PMA	B-DNA
responsive	I-DNA
element	I-DNA
was	O
localized	O
to	O
a	O
region	O
between	O
-95	B-DNA
and	I-DNA
-36	I-DNA
bp	I-DNA
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O

Within	O
this	O
region	O
,	O
single	O
AP-2-	B-DNA
and	I-DNA
AP-1-	I-DNA
like	I-DNA
consensus	I-DNA
sequences	I-DNA
were	O
noted	O
.	O

These	O
AP-2	B-DNA
and	O
AP-1	B-DNA
sites	I-DNA
were	O
each	O
modified	O
with	O
a	O
double	O
point	O
mutation	O
.	O

A	O
modest	O
(	O
20-50	O
%	O
)	O
reduction	O
in	O
TNF	B-DNA
promoter	I-DNA
activity	O
was	O
observed	O
with	O
the	O
AP-2	B-DNA
site	I-DNA
mutation	I-DNA
.	O

However	O
,	O
mutation	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
markedly	O
diminished	O
both	O
the	O
basal	O
and	O
PMA-activated	O
promoter	O
activity	O
.	O

Also	O
co-transfections	O
of	O
the	O
wild-type	B-DNA
promoter	I-DNA
construct	I-DNA
with	O
an	O
AP-1/c-jun	B-DNA
expression	I-DNA
vector	I-DNA
resulted	O
in	O
augmented	O
basal	O
and	O
PMA-induced	O
promoter	O
activity	O
.	O

Stable	O
expression	O
of	O
transdominant	B-protein
Rev	I-protein
protein	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
inhibits	O
human	O
immunodeficiency	O
virus	O
replication	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
Rev	B-protein
protein	I-protein
is	O
essential	O
for	O
viral	O
structural	O
protein	O
expression	O
(	O
Gag	B-protein
,	O
Pol	B-protein
,	O
and	O
Env	B-protein
)	O
and	O
,	O
hence	O
,	O
for	O
viral	O
replication	O
.	O

In	O
transient	O
transfection	O
assays	O
,	O
mutant	O
forms	O
of	O
Rev	B-protein
have	O
been	O
identified	O
that	O
inhibit	O
wild-type	O
Rev	B-protein
activity	O
and	O
therefore	O
suppress	O
viral	O
replication	O
.	O

To	O
determine	O
whether	O
such	O
transdominant	B-protein
Rev	I-protein
proteins	I-protein
could	O
provide	O
long-term	O
protection	O
against	O
HIV	O
infection	O
without	O
affecting	O
T	O
cell	O
function	O
,	O
T	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
stably	O
transduced	O
with	O
a	O
retroviral	B-DNA
vector	I-DNA
encoding	O
a	O
transdominant	O
mutant	O
of	O
the	O
Rev	B-protein
protein	I-protein
,	O
M10	B-protein
.	O

While	O
all	O
the	O
M10-expressing	B-cell_line
cell	I-cell_line
lines	I-cell_line
remained	O
infectable	O
by	O
HIV-1	O
,	O
these	O
same	O
cells	O
failed	O
to	O
support	O
a	O
productive	O
replication	O
cycle	O
when	O
infected	O
with	O
a	O
cloned	O
isolate	O
of	O
HIV-1	O
.	O

In	O
addition	O
,	O
two	O
out	O
of	O
three	O
M10-expressing	B-cell_line
CEM	I-cell_line
clones	I-cell_line
were	O
also	O
resistant	O
to	O
highly	O
productive	O
infection	O
by	O
a	O
heterogeneous	O
HIV-1	O
pool	O
.	O

Expression	O
of	O
M10	B-protein
did	O
not	O
affect	O
induction	O
of	O
HIV	O
transcription	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
regulatory	I-DNA
element	I-DNA
or	O
Tat	B-protein
.	O

Importantly	O
,	O
constitutive	O
expression	O
of	O
Rev	B-protein
M10	I-protein
did	O
not	O
alter	O
the	O
secretion	O
of	O
interleukin	B-protein
2	I-protein
in	O
response	O
to	O
mitogen	O
stimulation	O
of	O
EL-4	B-cell_line
and	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

The	O
inhibition	O
of	O
HIV	O
infection	O
in	O
cells	O
stably	O
expressing	O
a	O
transdominant	B-protein
Rev	I-protein
protein	I-protein
,	O
in	O
the	O
absence	O
of	O
any	O
deleterious	O
effect	O
on	O
T	O
cell	O
function	O
,	O
suggests	O
that	O
such	O
a	O
strategy	O
could	O
provide	O
a	O
therapeutic	O
effect	O
in	O
the	O
T	B-cell_type
lymphocytes	I-cell_type
of	O
acquired	O
immunodeficiency	O
syndrome	O
patients	O
.	O

Simple	O
derivation	O
of	O
TFIID-dependent	O
RNA	B-protein
polymerase	I-protein
II	I-protein
transcription	O
systems	O
from	O
Schizosaccharomyces	O
pombe	O
and	O
other	O
organisms	O
,	O
and	O
factors	O
required	O
for	O
transcriptional	O
activation	O
.	O

Resolution	O
of	O
whole	O
cell	O
extract	O
through	O
two	O
chromatographic	O
steps	O
yields	O
a	O
single	O
protein	O
fraction	O
requiring	O
only	O
the	O
addition	O
of	O
TFIID	B-protein
for	O
the	O
initiation	O
of	O
transcription	O
at	O
RNA	B-DNA
polymerase	I-DNA
II	I-DNA
promoters	I-DNA
.	O

This	O
approach	O
allows	O
the	O
convenient	O
generation	O
of	O
RNA	B-protein
polymerase	I-protein
II	I-protein
transcription	O
systems	O
from	O
Saccharomyces	O
cerevisiae	O
,	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
Schizosaccharomyces	O
pombe	O
.	O

TFIIDs	B-protein
from	O
all	O
three	O
organisms	O
are	O
interchangeable	O
among	O
all	O
three	O
systems	O
.	O

The	O
S.	O
cerevisiae	O
and	O
Sch.	O
pombe	O
systems	O
support	O
effects	O
of	O
acidic	B-protein
activator	I-protein
proteins	I-protein
,	O
provided	O
a	O
further	O
protein	O
fraction	O
from	O
S.	O
cerevisiae	O
is	O
supplied	O
.	O

This	O
further	O
fraction	O
is	O
distinct	O
from	O
the	O
mediator	O
of	O
transcriptional	O
activation	O
described	O
previously	O
and	O
represents	O
a	O
second	O
component	O
in	O
addition	O
to	O
general	B-protein
initiation	I-protein
factors	I-protein
that	O
may	O
facilitate	O
a	O
response	O
to	O
acidic	B-protein
activators	I-protein
.	O

Regulation	O
of	O
c-jun	B-DNA
expression	O
during	O
induction	O
of	O
monocytic	O
differentiation	O
by	O
okadaic	O
acid	O
.	O

The	O
present	O
work	O
has	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	B-protein
1	I-protein
and	I-protein
2A	I-protein
protein	I-protein
phosphatases	I-protein
,	O
on	O
the	O
regulation	O
of	O
c-jun	B-DNA
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

The	O
results	O
demonstrate	O
that	O
okadaic	O
acid	O
treatment	O
is	O
associated	O
with	O
induction	O
of	O
a	O
differentiated	O
monocyte	O
phenotype	O
characterized	O
by	O
:	O
(	O
a	O
)	O
growth	O
arrest	O
;	O
(	O
b	O
)	O
increases	O
in	O
Mac-1	B-protein
cell	I-protein
surface	I-protein
antigen	I-protein
expression	O
;	O
(	O
c	O
)	O
down-regulation	O
of	O
c-myc	B-protein
transcripts	I-protein
;	O
and	O
(	O
d	O
)	O
induction	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
gene	I-DNA
expression	O
.	O

This	O
induction	O
of	O
monocytic	O
differentiation	O
was	O
associated	O
with	O
transient	O
increases	O
in	O
c-jun	B-RNA
mRNA	I-RNA
levels	O
,	O
which	O
were	O
maximal	O
at	O
6	O
h	O
.	O

Similar	O
effects	O
were	O
obtained	O
for	O
the	O
c-fos	B-DNA
gene	I-DNA
.	O

Run-on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c-jun	B-DNA
transcription	O
in	O
U-937	B-cell_line
cells	I-cell_line
and	O
that	O
this	O
rate	O
is	O
increased	O
approximately	O
40-fold	O
following	O
okadaic	O
acid	O
exposure	O
.	O

c-jun	B-RNA
mRNA	I-RNA
levels	O
were	O
superinduced	O
in	O
cells	O
treated	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
,	O
whereas	O
inhibition	O
of	O
protein	O
synthesis	O
had	O
little	O
,	O
if	O
any	O
,	O
effect	O
on	O
okadaic	O
acid-induced	O
c-jun	B-DNA
transcription	O
.	O

The	O
half-life	O
of	O
c-jun	B-RNA
mRNA	I-RNA
was	O
similar	O
(	O
45-50	O
min	O
)	O
in	O
both	O
untreated	O
and	O
okadaic	B-cell_line
acid-induced	I-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
,	O
treatment	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
was	O
associated	O
with	O
stabilization	O
(	O
t	O
1/2	O
=	O
90	O
min	O
)	O
of	O
c-jun	B-protein
transcripts	I-protein
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
induction	O
of	O
c-jun	B-DNA
transcription	O
by	O
okadaic	O
acid	O
is	O
controlled	O
primarily	O
by	O
a	O
transcriptional	O
mechanism	O
.	O

Since	O
previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
c-jun	B-DNA
gene	I-DNA
is	O
autoinduced	O
by	O
Jun/AP-1	B-protein
,	O
we	O
also	O
studied	O
transcription	O
of	O
c-jun	B-DNA
promoter	I-DNA
(	I-DNA
positions	I-DNA
-132/+170	I-DNA
)	I-DNA
-reporter	I-DNA
gene	I-DNA
constructs	I-DNA
with	O
and	O
without	O
a	O
mutated	O
AP-1	B-DNA
element	I-DNA
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mitogen	O
stimulation	O
of	O
T-cells	O
increases	O
c-Fos	B-protein
and	O
c-Jun	B-protein
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
transcriptional	O
activity	O
.	O

We	O
have	O
analysed	O
the	O
effect	O
of	O
mitogenic	O
lectins	O
on	O
c-Fos	B-protein
and	O
c-Jun	B-protein
protein	O
levels	O
as	O
well	O
as	O
on	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
binding	O
and	O
enhancer	O
activity	O
in	O
Jurkat	O
T-cells	O
.	O

Both	O
c-Fos	B-protein
and	O
c-Jun	B-protein
protein	O
levels	O
were	O
increased	O
after	O
Con	O
A	O
and	O
PHA	O
stimulation	O
.	O

Since	O
T-cell	O
stimulation	O
increases	O
both	O
intracellular	O
Ca2+	O
and	O
cAMP	O
levels	O
and	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
the	O
possible	O
involvement	O
of	O
these	O
intracellular	O
messengers	O
in	O
c-Fos	B-protein
and	O
c-Jun	B-protein
induction	O
was	O
tested	O
.	O

PMA	O
,	O
which	O
directly	O
activates	O
PKC	O
,	O
mimicked	O
the	O
effect	O
of	O
the	O
lectins	O
on	O
c-Fos	O
and	O
c-Jun	B-protein
,	O
but	O
elevation	O
of	O
either	O
intracellular	O
Ca2+	O
or	O
cAMP	O
levels	O
had	O
little	O
or	O
no	O
effect	O
.	O

The	O
mitogen-induced	O
increase	O
of	O
c-Fos	B-protein
and	O
c-Jun	B-protein
immunoreactivity	O
was	O
inhibited	O
by	O
H-7	O
,	O
a	O
kinase	O
inhibitor	O
with	O
relatively	O
high	O
specificity	O
for	O
PKC	O
,	O
and	O
less	O
efficiently	O
by	O
H-8	O
,	O
a	O
structurally	O
related	O
kinase	O
inhibitor	O
less	O
active	O
on	O
PKC	O
,	O
but	O
more	O
active	O
on	O
cyclic	O
nucleotide-dependent	O
kinases	O
.	O

Con	O
A	O
stimulation	O
was	O
found	O
to	O
increase	O
both	O
binding	O
of	O
AP-1	O
to	O
the	O
AP-1	O
consensus	O
sequence	O
,	O
TRE	O
,	O
and	O
AP-1	O
enhancer	O
activity	O
,	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

PMA	O
was	O
also	O
found	O
to	O
increase	O
the	O
AP-1	O
enhancer	O
activity	O
,	O
whereas	O
elevation	O
of	O
Ca2+	O
or	O
cAMP	O
had	O
only	O
minor	O
effects	O
.	O

We	O
conclude	O
that	O
stimulation	O
with	O
mitogenic	O
lectins	O
is	O
sufficient	O
to	O
increase	O
both	O
c-Fos	B-protein
and	O
c-Jun	B-protein
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
enhancer	O
activity	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
and	O
that	O
they	O
act	O
via	O
mechanisms	O
that	O
could	O
involve	O
the	O
activation	O
of	O
PKC	O
.	O

An	O
11-base-pair	O
DNA	O
sequence	O
motif	O
apparently	O
unique	O
to	O
the	O
human	B-DNA
interleukin	I-DNA
4	I-DNA
gene	I-DNA
confers	O
responsiveness	O
to	O
T-cell	O
activation	O
signals	O
.	O

We	O
have	O
identified	O
a	O
DNA	B-DNA
segment	I-DNA
that	O
confers	O
responsiveness	O
to	O
antigen	O
stimulation	O
signals	O
on	O
the	O
human	B-DNA
interleukin	I-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
4	I-DNA
gene	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

The	O
human	B-DNA
IL-4	I-DNA
gene	I-DNA
,	O
of	O
10	O
kilobases	O
,	O
is	O
composed	O
of	O
four	O
exons	B-DNA
and	O
three	O
introns	B-DNA
.	O

A	O
cis-acting	B-DNA
element	I-DNA
(	O
P	B-DNA
sequence	I-DNA
)	O
resides	O
in	O
the	O
5	B-DNA
'	I-DNA
upstream	I-DNA
region	I-DNA
;	O
no	O
additional	O
DNA	B-DNA
segments	I-DNA
with	O
enhancer	O
activity	O
were	O
identified	O
in	O
the	O
human	B-DNA
IL-4	I-DNA
gene	I-DNA
.	O

For	O
further	O
mapping	O
purposes	O
,	O
a	O
fusion	B-DNA
promoter	I-DNA
was	O
constructed	O
with	O
the	O
granulocyte/macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
basic	I-DNA
promoter	I-DNA
containing	O
60	B-DNA
base	I-DNA
pairs	I-DNA
of	I-DNA
sequence	I-DNA
upstream	O
from	O
the	O
cap	B-DNA
site	I-DNA
of	O
the	O
mouse	B-DNA
granulocyte/macrophage	I-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
and	O
various	O
lengths	O
of	O
the	O
5	B-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
of	O
the	O
IL-4	B-DNA
gene	I-DNA
.	O

The	O
P	B-DNA
sequence	I-DNA
was	O
located	O
between	O
positions	O
-79	O
and	O
-69	O
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
of	O
the	O
human	B-DNA
IL-4	I-DNA
gene	I-DNA
,	O
and	O
this	O
location	O
was	O
confirmed	O
by	O
base-substitution	O
mutations	O
.	O

The	O
plasmids	O
carrying	O
multiple	O
copies	O
of	O
the	O
P	B-DNA
sequence	I-DNA
showed	O
higher	O
responsiveness	O
to	O
the	O
stimulation	O
.	O

The	O
binding	B-protein
protein	I-protein
(	O
s	O
)	O
that	O
recognize	O
the	O
P	B-DNA
sequence	I-DNA
of	O
the	O
IL-4	B-DNA
gene	I-DNA
were	O
identified	O
by	O
DNA-mobility-shift	O
assays	O
.	O

The	O
binding	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
(	O
a	O
DNA	B-protein
binding	I-protein
protein	I-protein
that	O
specifically	O
recognizes	O
the	O
P	B-DNA
sequence	I-DNA
)	O
to	O
the	O
P	B-DNA
sequence	I-DNA
was	O
abolished	O
when	O
oligonucleotides	O
carrying	O
base	O
substitutions	O
were	O
used	O
,	O
indicating	O
that	O
the	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
interaction	O
is	O
sequence-specific	O
and	O
that	O
binding	O
specificity	O
of	O
the	O
protein	O
paralleled	O
the	O
sequence	O
requirements	O
for	O
IL-4	B-protein
expression	O
in	O
vivo	O
.	O

The	O
P	B-DNA
sequence	I-DNA
does	O
not	O
share	O
homology	O
with	O
the	O
5	B-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
of	O
the	O
IL-2	B-DNA
gene	I-DNA
,	O
even	O
though	O
surrounding	O
sequences	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
share	O
high	O
homology	O
with	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

We	O
conclude	O
that	O
a	O
different	O
set	O
of	O
proteins	B-protein
recognize	O
IL-2	B-DNA
and	I-DNA
IL-4	I-DNA
genes	I-DNA
.	O

Leukotriene	O
B4	O
stimulates	O
c-fos	O
and	O
c-jun	O
gene	O
transcription	O
and	O
AP-1	B-protein
binding	O
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
,	O
a	O
potent	O
lipid	O
proinflammatory	B-protein
mediator	I-protein
,	O
on	O
the	O
expression	O
of	O
the	O
proto-oncogenes	B-DNA
c-jun	I-DNA
and	I-DNA
c-fos	I-DNA
.	O

In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	B-protein
factors	I-protein
binding	O
specifically	O
to	O
the	O
AP-1	B-DNA
element	I-DNA
after	O
LTB4	O
stimulation	O
.	O

LTB4	O
increased	O
the	O
expression	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
.	O

The	O
c-jun	B-RNA
mRNA	I-RNA
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
human	B-cell_type
peripheral-blood	I-cell_type
monocytes	I-cell_type
at	O
relatively	O
high	O
levels	O
,	O
was	O
also	O
slightly	O
augmented	O
by	O
LTB4	O
,	O
although	O
to	O
a	O
much	O
lower	O
extent	O
than	O
c-fos	B-DNA
.	O

The	O
kinetics	O
of	O
expression	O
of	O
the	O
two	O
genes	O
were	O
also	O
slightly	O
different	O
,	O
with	O
c-fos	B-RNA
mRNA	I-RNA
reaching	O
a	O
peak	O
at	O
15	O
min	O
after	O
stimulation	O
and	O
c-jun	B-DNA
at	O
30	O
min	O
.	O

Both	O
messages	O
rapidly	O
declined	O
thereafter	O
.	O

Stability	O
of	O
the	O
c-fos	B-DNA
and	O
c-jun	B-RNA
mRNA	I-RNA
was	O
not	O
affected	O
by	O
LTB4	O
,	O
as	O
assessed	O
after	O
actinomycin	O
D	O
treatment	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
7-fold	O
and	O
the	O
c-jun	B-DNA
gene	I-DNA
1.4-fold	O
.	O

Resting	B-cell_type
monocytes	I-cell_type
contained	O
nuclear	B-protein
factors	I-protein
binding	O
to	O
the	O
AP-1	B-DNA
element	I-DNA
,	O
but	O
stimulation	O
of	O
monocytes	B-cell_type
with	O
LTB4	O
induced	O
greater	O
AP-1	B-protein
-binding	O
activity	O
of	O
nuclear	B-protein
proteins	I-protein
.	O

These	O
results	O
indicate	O
that	O
LTB4	O
may	O
regulate	O
the	O
production	O
of	O
different	O
cytokines	B-protein
by	O
modulating	O
the	O
yield	O
and/or	O
the	O
function	O
of	O
transcription	B-protein
factors	I-protein
such	O
as	O
AP-1	B-protein
-binding	O
proto-oncogene	B-protein
products	I-protein
.	O

Modulation	O
of	O
normal	O
erythroid	O
differentiation	O
by	O
the	O
endogenous	O
thyroid	O
hormone	O
and	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
:	O
a	O
possible	O
target	O
for	O
v-erbA	B-DNA
oncogene	I-DNA
action	O
.	O

The	O
v-erbA	B-DNA
oncogene	I-DNA
,	O
a	O
mutated	O
version	O
of	O
the	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
alpha	I-protein
(	O
c-erbA/TR-alpha	B-protein
)	O
,	O
inhibits	O
erythroid	O
differentiation	O
and	O
constitutively	O
represses	O
transcription	O
of	O
certain	O
erythrocyte	B-DNA
genes	I-DNA
,	O
suggesting	O
a	O
normal	O
function	O
of	O
the	O
proto-oncogene	B-DNA
c-erbA	I-DNA
in	O
erythropoiesis	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
endogenous	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
alpha	I-protein
(	O
c-erbA/TR-alpha	B-protein
)	O
and	O
the	O
closely	O
related	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
(	O
RAR-alpha	B-protein
)	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
erythroid	O
differentiation	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
distinctly	O
modulated	O
the	O
erythroid	O
differentiation	O
program	O
of	O
normal	B-cell_type
erythroid	I-cell_type
progenitors	I-cell_type
and	O
erythroblasts	O
reversibly	O
transformed	O
by	O
a	O
conditional	O
tyrosine	B-DNA
kinase	I-DNA
oncogene	I-DNA
.	O

When	O
added	O
pulsewise	O
to	O
immature	B-cell_type
cells	I-cell_type
,	O
differentiation	O
was	O
accelerated	O
while	O
more	O
mature	B-cell_type
cells	I-cell_type
underwent	O
premature	O
cell	O
death	O
.	O

Thyroid	O
hormone	O
(	O
T3	O
)	O
alone	O
caused	O
similar	O
but	O
weaker	O
effects	O
.	O

Interestingly	O
,	O
T3	O
strongly	O
enhanced	O
the	O
action	O
of	O
RA	O
,	O
suggesting	O
cooperative	O
action	O
of	O
the	O
two	O
receptors	O
in	O
modulating	O
erythroid	O
differentiation	O
.	O

Expression	O
of	O
the	O
human	B-protein
RAR-alpha	I-protein
in	O
receptor-negative	B-cell_line
erythroblasts	I-cell_line
conferred	O
RA-induced	O
regulation	O
of	O
differentiation	O
to	O
the	O
otherwise	O
unresponsive	B-cell_type
cells	I-cell_type
,	O
thus	O
showing	O
that	O
the	O
RAR-alpha	B-protein
is	O
essential	O
for	O
the	O
RA	O
effect	O
.	O

Likewise	O
,	O
enhanced	O
expression	O
of	O
exogenous	B-protein
c-erbA/TR-alpha	I-protein
in	O
erythroblasts	B-cell_type
rendered	O
them	O
susceptible	O
to	O
modulation	O
of	O
differentiation	O
by	O
T3	O
,	O
suggesting	O
a	O
similar	O
function	O
of	O
both	O
receptors	O
.	O

Activation	O
of	O
lymphokine	B-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
:	O
role	O
of	O
cis-acting	B-DNA
DNA	I-DNA
elements	I-DNA
that	O
respond	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

Activation	O
of	O
T	B-cell_type
cells	I-cell_type
is	O
initiated	O
by	O
the	O
recognition	O
of	O
antigen	O
on	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
to	O
exert	O
the	O
effector	O
functions	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Two	O
types	O
of	O
helper	B-cell_line
T	I-cell_line
cell	I-cell_line
(	I-cell_line
Th	I-cell_line
)	I-cell_line
clones	I-cell_line
(	O
Th1	B-cell_line
and	O
Th2	B-cell_line
)	O
are	O
defined	O
on	O
the	O
basis	O
of	O
different	O
patterns	O
of	O
cytokine	B-protein
(	O
lymphokine	B-protein
)	O
secretion	O
.	O

They	O
determine	O
the	O
outcome	O
of	O
an	O
antigenic	O
response	O
toward	O
humoral	O
or	O
cell-mediated	O
immunity	O
.	O

Although	O
lymphokine	B-DNA
genes	I-DNA
are	O
coordinately	O
regulated	O
upon	O
antigen	O
stimulation	O
,	O
they	O
are	O
regulated	O
by	O
the	O
mechanisms	O
common	O
to	O
all	O
as	O
well	O
as	O
those	O
which	O
are	O
unique	O
to	O
each	O
gene	O
.	O

For	O
most	O
lymphokine	B-DNA
genes	I-DNA
,	O
a	O
combination	O
of	O
phorbol	O
esters	O
(	O
phorbol	O
12-myristate	O
13	O
acetate	O
,	O
PMA	O
)	O
and	O
calcium	O
ionophores	O
(	O
A23187	O
)	O
is	O
required	O
for	O
their	O
maximal	O
induction	O
.	O

Yet	O
phorbol	O
ester	O
alone	O
or	O
calcium	O
ionophore	O
alone	O
produce	O
several	O
lymphokines	B-protein
.	O

The	O
production	O
of	O
the	O
granulocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
completely	O
dependent	O
on	O
the	O
two	O
signals	O
.	O

We	O
have	O
previously	O
found	O
a	O
cis-acting	B-DNA
region	I-DNA
spanning	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
region	I-DNA
(	O
positions	O
-95	O
to	O
+27	O
)	O
that	O
confers	O
inducibility	O
to	O
reporter	B-DNA
genes	I-DNA
in	O
transient	O
transfection	O
assays	O
.	O

Further	O
analysis	O
identified	O
three	O
elements	O
required	O
for	O
efficient	O
induction	O
,	O
referred	O
to	O
as	O
GM2	B-DNA
,	O
GC-box	B-DNA
and	O
conserved	B-DNA
lymphokine	I-DNA
element	I-DNA
(	O
CLE0	B-DNA
)	O
.	O

GM2	B-DNA
defines	O
a	O
binding	B-DNA
site	I-DNA
for	O
protein	O
(	O
s	O
)	O
whose	O
binding	O
is	O
inducible	O
by	O
PMA	O
.	O

One	O
protein	O
,	O
NF-GM2	B-protein
is	O
similar	O
to	O
the	O
transcription	B-protein
factor	I-protein
NF-kB	B-protein
.	O

GC-box	B-DNA
is	O
a	O
binding	B-DNA
site	I-DNA
for	O
constitutively	B-protein
bound	I-protein
proteins	I-protein
.	O

CLEO	O
defines	O
a	O
binding	B-DNA
site	I-DNA
for	O
protein	O
(	O
s	O
)	O
whose	O
optimum	O
binding	O
is	O
stimulated	O
by	O
PMA	O
and	O
A23187	O
.	O

Viral	B-protein
trans-activators	I-protein
such	O
as	O
Tax	B-protein
(	O
human	O
T	O
cell	O
leukemia	O
virus-1	O
,	O
HTLV-1	O
)	O
and	O
E2	B-protein
(	O
bovine	O
papilloma	O
virus	O
,	O
BPV	O
)	O
proteins	O
are	O
other	O
agents	O
which	O
activate	O
lymphokine	B-DNA
gene	I-DNA
expression	O
by	O
bypassing	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
mediated	O
signaling	O
.	O

The	O
trans-activation	O
domain	O
of	O
E2	B-protein
and	O
Tax	B-protein
is	O
interchangeable	O
although	O
they	O
have	O
no	O
obvious	O
sequence	O
homology	O
between	O
them	O
.	O

The	O
viral	B-protein
trans-activators	I-protein
appear	O
to	O
target	O
specific	O
DNA	B-protein
binding	I-protein
protein	I-protein
such	O
as	O
NF-kB	B-protein
and	O
Sp1	B-protein
to	O
cis-acting	B-DNA
DNA	I-DNA
site	I-DNA
and	O
promote	O
lymphokine	B-DNA
gene	I-DNA
expression	O
without	O
TCR	B-protein
-mediated	O
stimulation	O
.	O

Mutations	O
in	O
the	O
Pit-1	B-DNA
gene	I-DNA
in	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
.	O

Pit-1	B-protein
is	O
a	O
pituitary-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
binds	O
to	O
and	O
transactivates	O
promoters	B-DNA
of	O
growth	B-DNA
hormone	I-DNA
and	I-DNA
prolactin	I-DNA
genes	I-DNA
.	O

In	O
three	O
unrelated	O
Japanese	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
,	O
we	O
identified	O
three	O
point	O
mutations	O
in	O
the	O
Pit-1	B-DNA
gene	I-DNA
,	O
Pro24Leu	B-DNA
,	O
Arg143Gln	B-DNA
,	O
and	O
Arg271Trp	B-DNA
,	O
located	O
on	O
the	O
major	B-DNA
transactivation	I-DNA
region	I-DNA
,	O
POU-specific	B-DNA
domain	I-DNA
,	O
and	O
POU-homeodomain	B-DNA
,	O
respectively	O
.	O

Activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
elevation	O
of	O
cAMP	O
interact	O
synergistically	O
to	O
raise	O
c-Fos	B-protein
and	O
AP-1	B-protein
activity	O
in	O
Jurkat	O
cells	O
.	O

We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	B-protein
.	O

Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
which	O
stimulates	O
PKC	B-protein
and	O
a	O
combination	O
of	O
the	O
adenosine	B-protein
receptor	I-protein
agonist	O
NECA	O
(	O
5'-	O
(	O
N-ethyl	O
)	O
-carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	O
of	O
c-Fos	B-protein
and	O
Jun	B-protein
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O

PMA	O
treatment	O
caused	O
a	O
concentration-	O
and	O
time-dependent	O
increase	O
in	O
both	O
c-Fos	O
and	O
Jun	O
immunoreactivity	O
in	O
contrast	O
to	O
cAMP	O
elevation	O
that	O
had	O
only	O
a	O
slight	O
effect	O
.	O

Both	O
PMA	O
and	O
the	O
combination	O
of	O
NECA	O
and	O
forskolin	O
acted	O
together	O
either	O
to	O
increase	O
(	O
c-Fos	B-protein
)	O
or	O
decrease	O
(	O
Jun	B-protein
)	O
protein	O
levels	O
as	O
well	O
as	O
increasing	O
AP-1	B-protein
binding	O
,	O
as	O
judged	O
by	O
gel-shift	O
assay	O
,	O
and	O
AP-1	B-protein
transcriptional	O
activity	O
.	O

Furthermore	O
there	O
was	O
a	O
clear-cut	O
synergy	O
between	O
the	O
PKC	B-protein
stimulator	O
and	O
the	O
cAMP	O
elevating	O
agents	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
PKC	B-protein
and	O
elevation	O
of	O
cAMP	O
leads	O
to	O
an	O
enhanced	O
AP-1	B-protein
transcriptional	O
activity	O
in	O
a	O
T-leukemia	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
suggesting	O
that	O
the	O
previously	O
observed	O
interaction	O
between	O
the	O
parallel	O
signal	O
transduction	O
pathways	O
may	O
have	O
functional	O
consequences	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Inhibition	O
of	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
-induced	O
T-cell	O
proliferation	O
by	O
dexamethasone	O
,	O
isoproterenol	O
,	O
or	O
prostaglandin	O
E2	O
either	O
alone	O
or	O
in	O
combination	O
.	O

1	O
.	O

The	O
purpose	O
of	O
these	O
studies	O
was	O
to	O
investigate	O
the	O
modulation	O
of	O
the	O
proliferation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
obtained	O
from	O
peripheral	O
blood	O
by	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
isoproterenol	O
(	O
ISO	O
)	O
,	O
and	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
.	O

The	O
former	O
two	O
substances	O
interact	O
with	O
T	B-cell_type
cells	I-cell_type
via	O
the	O
glucocorticoid	B-protein
and	I-protein
beta-adrenergic	I-protein
receptors	I-protein
respectively	O
.	O

When	O
occupied	O
by	O
their	O
natural	O
ligands	O
,	O
glucocorticosteroids	O
and	O
catecholamines	O
,	O
these	O
receptors	O
have	O
a	O
role	O
in	O
modulating	O
T-cell	O
function	O
during	O
stress	O
.	O

During	O
the	O
inflammatory	O
response	O
increased	O
levels	O
of	O
PGE2	O
bind	O
to	O
their	O
receptors	O
on	O
T	B-cell_type
cells	I-cell_type
and	O
thus	O
alter	O
responsiveness	O
.	O

Proliferation	O
of	O
T	B-cell_type
cells	I-cell_type
was	O
induced	O
by	O
immobilized	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
an	O
additional	O
costimulatory	O
signal	O
delivered	O
by	O
anti-CD28	B-protein
mAb	I-protein
.	O

2	O
.	O

Various	O
physiologic	O
concentrations	O
of	O
DEX	O
,	O
ISO	O
,	O
or	O
PGE2	O
were	O
added	O
at	O
the	O
time	O
of	O
initiation	O
of	O
the	O
cultures	O
and	O
subsequent	O
proliferation	O
of	O
the	O
unstimulated	O
T	B-cell_type
cells	I-cell_type
was	O
determined	O
.	O

The	O
results	O
demonstrate	O
that	O
physiologic	O
concentrations	O
of	O
all	O
three	O
of	O
these	O
agents	O
inhibit	O
the	O
anti-CD3	B-protein
mAb	I-protein
-induced	O
proliferation	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

3	O
.	O

Although	O
DEX	O
and	O
PGE2	O
were	O
equipotent	O
in	O
suppressing	O
T-cell	O
proliferation	O
,	O
ISO	O
was	O
much	O
less	O
effective	O
.	O

4	O
.	O

Because	O
concomitant	O
elevations	O
in	O
the	O
peripheral	O
levels	O
of	O
these	O
substances	O
may	O
occur	O
,	O
experiments	O
were	O
performed	O
to	O
determine	O
the	O
T-cell	O
inhibitory	O
effects	O
of	O
DEX	O
together	O
with	O
either	O
PGE2	O
or	O
ISO	O
.	O

Synergistic	O
suppression	O
of	O
T-cell	O
proliferation	O
was	O
observed	O
when	O
various	O
concentrations	O
of	O
DEX	O
and	O
PGE2	O
,	O
but	O
not	O
DEX	O
and	O
ISO	O
,	O
were	O
added	O
to	O
cultures	O
.	O

This	O
synergistic	O
suppression	O
could	O
not	O
be	O
explained	O
by	O
an	O
increase	O
in	O
cAMP	O
accumulation	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
with	O
DEX	O
and	O
PGE2	O
.	O

5	O
.	O

Finally	O
,	O
the	O
addition	O
of	O
anti-CD28	B-protein
mAb	I-protein
to	O
anti-CD3	B-cell_type
mAb-stimulated	I-cell_type
T	I-cell_type
cells	I-cell_type
overcame	O
much	O
of	O
the	O
suppression	O
of	O
proliferation	O
induced	O
by	O
PGE2	O
or	O
ISO	O
but	O
less	O
so	O
than	O
that	O
induced	O
by	O
DEX	O
.	O

In	O
vivo	O
footprint	O
analysis	O
of	O
the	O
HLA-DRA	B-DNA
gene	I-DNA
promoter	I-DNA
:	O
cell-specific	O
interaction	O
at	O
the	O
octamer	B-DNA
site	I-DNA
and	O
up-regulation	O
of	O
X	O
box	O
binding	O
by	O
interferon	B-protein
gamma	I-protein
.	O

Analysis	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
promoter	I-DNA
DRA	B-DNA
has	O
previously	O
identified	O
at	O
least	O
five	O
cis-acting	B-DNA
regions	I-DNA
required	O
for	O
maximal	O
expression	O
.	O

We	O
have	O
examined	O
the	O
DRA	B-DNA
promoter	I-DNA
for	O
protein-DNA	O
interactions	O
in	O
the	O
intact	B-cell_type
cell	I-cell_type
,	O
which	O
may	O
mediate	O
transcriptional	O
activation	O
.	O

Using	O
in	O
vivo	O
genomic	O
footprinting	O
we	O
identified	O
interactions	O
in	O
B-cell	B-cell_line
lines	I-cell_line
at	O
the	O
octamer	B-DNA
site	I-DNA
and	O
the	O
Y	B-DNA
,	I-DNA
X1	I-DNA
,	I-DNA
and	I-DNA
X2	I-DNA
boxes	I-DNA
.	O

Class	B-cell_line
II	I-cell_line
antigen	I-cell_line
expressing	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
maintained	O
contacts	O
identical	O
to	O
B-cell	B-cell_line
lines	I-cell_line
,	O
while	O
class	B-cell_line
II-negative	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
exhibited	O
no	O
interactions	O
.	O

In	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
octamer	B-DNA
site	I-DNA
is	O
occupied	O
and	O
required	O
for	O
maximal	O
expression	O
.	O

This	O
is	O
most	O
likely	O
due	O
to	O
the	O
presence	O
of	O
the	O
lymphoid-specific	B-protein
OTF-2	I-protein
factor	I-protein
.	O

In	O
contrast	O
,	O
the	O
class	B-cell_line
II-positive	I-cell_line
nonlymphoid	I-cell_line
glioblastoma	I-cell_line
cell	I-cell_line
line	I-cell_line
does	O
not	O
exhibit	O
interactions	O
at	O
the	O
octamer	B-DNA
site	I-DNA
despite	O
the	O
presence	O
of	O
the	O
ubiquitous	B-protein
OTF-1	I-protein
factor	I-protein
and	O
an	O
open	B-DNA
binding	I-DNA
site	I-DNA
.	O

Thus	O
,	O
the	O
DRA	B-DNA
promoter	I-DNA
discriminates	O
against	O
OTF-1	B-protein
activation	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
in	O
the	O
glioblastoma	B-cell_line
line	I-cell_line
.	O

Interferon	B-protein
gamma	I-protein
induces	O
class	O
II	O
expression	O
in	O
this	O
glioblastoma	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
,	O
in	O
parallel	O
,	O
up-regulates	O
X1	O
and	O
X2	O
box	O
protein-DNA	O
interactions	O
,	O
while	O
all	O
other	O
interactions	O
remain	O
unchanged	O
.	O

These	O
results	O
suggest	O
that	O
interferon	B-protein
gamma	I-protein
functions	O
on	O
a	O
poised	B-DNA
promoter	I-DNA
by	O
altering	O
weak	O
,	O
nonproductive	O
interactions	O
at	O
the	O
X	B-DNA
boxes	I-DNA
to	O
strong	O
interactions	O
.	O

These	O
findings	O
provide	O
direct	O
in	O
vivo	O
evidence	O
to	O
strongly	O
suggest	O
that	O
the	O
modulation	O
of	O
X1	B-DNA
and	O
X2	B-DNA
interactions	O
is	O
an	O
important	O
constituent	O
of	O
the	O
interferon	B-protein
gamma	I-protein
induction	O
pathway	O
.	O

Estrogen	O
binding	O
sites	O
in	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
effects	O
of	O
danazol	O
on	O
their	O
sites	O
in	O
vitro	O
.	O

1	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
presence	O
of	O
estrogen	O
type	O
I	O
(	O
high	O
affinity	O
,	O
low	O
capacity	O
)	O
and	O
type	O
II	O
(	O
low	O
affinity	O
,	O
high	O
capacity	O
)	O
binding	O
sites	O
in	O
human	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
the	O
effects	O
of	O
danazol	O
on	O
these	O
sites	O
.	O

2	O
.	O

These	O
two	O
types	O
of	O
estrogen	O
binding	O
sites	O
existed	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

3	O
.	O

Danazol	O
bound	O
to	O
these	O
sites	O
in	O
high	O
concentration	O
(	O
10	O
(	O
-6	O
)	O
M	O
,	O
clinical	O
serum	O
concentration	O
during	O
danazol	O
therapy	O
)	O
and	O
decreased	O
the	O
number	O
of	O
both	O
sites	O
.	O

4	O
.	O

It	O
is	O
suggested	O
that	O
danazol	O
has	O
an	O
anti-estrogenic	O
action	O
to	O
the	O
monocytes	O
through	O
the	O
competition	O
and	O
suppression	O
of	O
estrogen	O
binding	O
sites	O
as	O
seen	O
in	O
the	O
estrogen	O
target	O
organ	O
.	O

A	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B-protein
receptors	I-protein
:	O
decreased	O
receptor	O
concentration	O
in	O
myocardial	O
infarction	O
.	O

A	O
major	O
difficulty	O
in	O
determination	O
of	O
glucocorticoid	O
receptor	O
sites	O
is	O
the	O
very	O
complicated	O
assay	O
procedure	O
.	O

Therefore	O
,	O
we	O
describe	O
a	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B-protein
receptors	I-protein
which	O
is	O
a	O
whole-cell	O
competitive	O
binding	O
radioassay	O
using	O
[	O
3H	O
]	O
-dexamethasone	O
as	O
radioligand	O
.	O

This	O
modification	O
of	O
a	O
previously	O
described	O
protocol	O
simplifies	O
and	O
reduces	O
laboratory	O
work	O
and	O
allows	O
assay	O
reproducibility	O
to	O
be	O
controlled	O
more	O
reliably	O
.	O

Thus	O
enabled	O
to	O
perform	O
the	O
test	O
on	O
multiple	O
blood	B-cell_type
samples	I-cell_type
in	O
parallel	O
,	O
we	O
investigated	O
cardiac	O
infarction	O
patients	O
over	O
a	O
12-day	O
period	O
to	O
test	O
if	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
is	O
altered	O
in	O
this	O
'stressful	O
'	O
disease	O
.	O

On	O
the	O
first	O
day	O
of	O
the	O
disease	O
,	O
glucocorticoid	B-protein
receptor	I-protein
capacity	O
was	O
significantly	O
decreased	O
without	O
alteration	O
of	O
the	O
receptor-ligand	O
affinity	O
,	O
whereas	O
on	O
days	O
4	O
and	O
12	O
the	O
number	O
of	O
receptor	O
sites	O
was	O
normal	O
again	O
.	O

This	O
result	O
fits	O
well	O
into	O
the	O
general	O
observation	O
of	O
stress-induced	O
down-regulation	O
of	O
immune	O
responses	O
.	O

SRC-related	B-DNA
proto-oncogenes	I-DNA
and	O
transcription	B-protein
factors	I-protein
in	O
primary	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
:	O
modulation	O
by	O
cyclosporin	O
A	O
and	O
FK506	O
.	O

Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
induces	O
transcription	O
of	O
genes	B-DNA
encoding	O
for	O
lymphokines	B-protein
.	O

Interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
expression	O
is	O
controlled	O
transcriptionally	O
by	O
the	O
cooperative	O
activity	O
of	O
specific	O
trans-activating	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
IL-2	B-DNA
enhancer	I-DNA
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
inhibit	O
the	O
production	O
of	O
IL-2	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

A	O
member	O
of	O
the	O
src	B-DNA
gene	I-DNA
family	I-DNA
,	O
the	O
lymphocyte-specific	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
,	O
p56lck	B-protein
,	O
has	O
been	O
implicated	O
in	O
IL-2	B-protein
production	O
.	O

CsA	O
was	O
found	O
not	O
to	O
inhibit	O
lck	B-protein
gene	O
expression	O
,	O
nor	O
the	O
activity	O
of	O
the	O
lck	B-DNA
gene	I-DNA
product	O
.	O

However	O
,	O
CsA	O
and	O
FK506	O
inhibit	O
the	O
appearance	O
of	O
DNA	O
binding	O
activity	O
of	O
factors	O
that	O
bind	O
to	O
the	O
NF-AT	B-DNA
and	O
AP-1	B-DNA
sites	I-DNA
in	O
the	O
IL-2	B-DNA
enhancer	I-DNA
.	O

Since	O
the	O
induction	O
of	O
NF-AT	B-protein
and	O
AP-1	B-protein
is	O
induced	O
by	O
the	O
same	O
stimuli	O
that	O
stimulate	O
IL-2	B-protein
production	O
,	O
these	O
results	O
indicate	O
that	O
the	O
immunosuppressant	O
action	O
of	O
CsA	O
and	O
FK506	O
is	O
exerted	O
at	O
the	O
level	O
of	O
these	O
trans-activating	B-protein
factors	I-protein
.	O

The	O
AP-1	B-DNA
site	I-DNA
at	O
-150	B-DNA
bp	I-DNA
,	O
but	O
not	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
is	O
likely	O
to	O
represent	O
the	O
major	O
target	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
in	O
the	O
interleukin	B-DNA
2	I-DNA
promoter	I-DNA
.	O

Stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	B-protein
,	O
including	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
that	O
may	O
mediate	O
the	O
later	O
induction	O
of	O
activation-related	O
genes	O
.	O

We	O
have	O
examined	O
the	O
potential	O
role	O
of	O
PKC	B-protein
in	O
induction	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
through	O
the	O
T	B-protein
cell	I-protein
receptor/CD3	I-protein
complex	I-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
Ar-5	I-cell_line
with	O
phorbol	O
esters	O
results	O
in	O
downmodulation	O
of	O
the	O
alpha	B-protein
and	I-protein
beta	I-protein
isozymes	I-protein
of	O
PKC	B-protein
,	O
and	O
abrogates	O
induction	O
of	O
IL-2	B-RNA
mRNA	I-RNA
and	O
protein	B-protein
.	O

Here	O
we	O
show	O
that	O
phorbol	O
ester	O
treatment	O
also	O
abolishes	O
induction	O
of	O
chloramphenicol	B-protein
acetyltransferase	I-protein
activity	O
in	O
Ar-5	B-cell_line
cells	I-cell_line
transfected	O
with	O
a	O
plasmid	B-DNA
containing	O
the	O
IL-2	B-DNA
promoter	I-DNA
linked	O
to	O
this	O
reporter	B-DNA
gene	I-DNA
.	O

The	O
IL-2	B-DNA
promoter	I-DNA
contains	O
binding	B-DNA
sites	I-DNA
for	O
nuclear	B-protein
factors	I-protein
including	O
NFAT-1	B-protein
,	O
Oct	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
AP-1	B-protein
,	O
which	O
are	O
all	O
potentially	O
sensitive	O
to	O
activation	O
of	O
PKC	B-protein
.	O

We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	B-DNA
and	I-DNA
Oct	I-DNA
sites	I-DNA
is	O
not	O
sensitive	O
to	O
phorbol	O
ester	O
treatment	O
,	O
and	O
that	O
mutations	O
in	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
have	O
no	O
effect	O
on	O
inducibility	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

In	O
contrast	O
,	O
mutations	O
in	O
the	O
AP-1	B-DNA
site	I-DNA
located	O
at	O
-150	B-DNA
bp	I-DNA
almost	O
completely	O
abrogate	O
induction	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
and	O
appearance	O
of	O
an	O
inducible	B-protein
nuclear	I-protein
factor	I-protein
binding	O
to	O
this	O
site	O
is	O
sensitive	O
to	O
PKC	B-protein
depletion	O
.	O

Moreover	O
,	O
cotransfections	O
with	O
c-fos	O
and	O
c-jun	O
expression	O
plasmids	O
markedly	O
enhance	O
induction	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
minimally	B-cell_line
stimulated	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Our	O
results	O
indicate	O
that	O
the	O
AP-1	B-DNA
site	I-DNA
at	O
-150	B-DNA
bp	I-DNA
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	B-protein
responsiveness	O
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

[	O
Effect	O
of	O
antihypertensive	O
therapy	O
with	O
captopril	O
on	O
gluco-	B-protein
and	I-protein
mineralocorticoid	I-protein
receptors	I-protein
of	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
in	O
hypertensive	O
patients	O
of	O
various	O
age	O
]	O

Binding	O
of	O
3H-dexamethasone	O
and	O
3H-aldosterone	O
by	O
peripheral	B-protein
lymphocyte	I-protein
receptors	I-protein
was	O
investigated	O
in	O
healthy	O
persons	O
and	O
hypertensive	O
patients	O
before	O
and	O
after	O
2-week	O
captopril	O
treatment	O
.	O

The	O
number	O
of	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
binding	I-protein
sites	I-protein
was	O
increased	O
in	O
hypertensives	O
vs	O
normotensives	O
.	O

The	O
treatment	O
with	O
the	O
ACE	O
inhibitor	O
captopril	O
led	O
to	O
activation	O
of	O
hormone-receptor	O
interactions	O
.	O

There	O
was	O
a	O
more	O
marked	O
rise	O
of	O
the	O
number	O
of	O
receptors	B-protein
in	O
middle-aged	O
(	O
44-55	O
years	O
)	O
hypertensives	O
vs	O
elderly	O
(	O
61-80	O
years	O
)	O
subjects	O
after	O
captopril	O
treatment	O
.	O

The	O
use	O
of	O
interferon-gamma-treated	B-cell_line
U937	I-cell_line
cells	I-cell_line
in	O
chemiluminescence	O
assays	O
to	O
detect	O
red	B-protein
cell	I-protein
,	I-protein
platelet	I-protein
and	I-protein
granulocyte	I-protein
antibodies	I-protein
of	O
potential	O
clinical	O
significance	O
.	O

The	O
chemiluminescent	O
(	O
CL	O
)	O
response	O
of	O
interferon-gamma-treated	B-cell_line
U937	I-cell_line
(	I-cell_line
IFN-U937	I-cell_line
)	I-cell_line
cells	I-cell_line
to	O
sensitized	O
target	O
cells	O
has	O
been	O
used	O
to	O
detect	O
red	B-protein
cell	I-protein
,	O
platelet	B-protein
and	O
granulocyte	B-protein
antibodies	I-protein
.	O

A	O
clone	O
of	O
U937	B-cell_line
cells	I-cell_line
was	O
selected	O
which	O
expressed	O
Fc	B-protein
receptor	I-protein
I	I-protein
(	O
Fc	B-protein
gamma	I-protein
RI	I-protein
)	O
and	O
which	O
,	O
after	O
incubation	O
with	O
IFN-gamma	B-protein
for	O
72	O
h	O
,	O
was	O
capable	O
of	O
generating	O
high	O
levels	O
of	O
lucigenin-enhanced	O
CL	O
.	O

The	O
CL	O
responses	O
of	O
IFN-U937	B-cell_line
cells	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
human	I-cell_type
monocytes	I-cell_type
to	O
sensitized	B-cell_type
red	I-cell_type
cells	I-cell_type
,	O
platelets	B-cell_type
or	O
granulocytes	B-cell_type
were	O
then	O
compared	O
.	O

Assays	O
using	O
monocytes	B-cell_type
or	O
IFN-U937	B-cell_line
cells	I-cell_line
were	O
of	O
comparable	O
sensitivity	O
for	O
detection	O
of	O
antibodies	B-protein
against	O
all	O
three	O
types	O
of	O
target	O
cell	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
IFN-U937	B-cell_line
cells	I-cell_line
reduced	O
interassay	O
variation	O
and	O
simplified	O
assay	O
performance	O
.	O

The	O
potential	O
clinical	O
usefulness	O
of	O
these	O
CL	O
assays	O
was	O
suggested	O
by	O
the	O
ability	O
of	O
both	O
monocytes	B-cell_type
and	O
IFN-U937	B-cell_line
cells	I-cell_line
to	O
respond	O
to	O
red	B-cell_type
cells	I-cell_type
,	O
platelets	B-cell_type
or	O
granulocytes	B-cell_type
sensitized	O
with	O
sera	O
from	O
pregnant	O
women	O
whose	O
babies	O
had	O
either	O
haemolytic	O
disease	O
of	O
the	O
newborn	O
(	O
HDN	O
)	O
,	O
alloimmune	O
thrombocytopenia	O
or	O
alloimmune	O
neutropenia	O
respectively	O
.	O

In	O
addition	O
,	O
monocytes	B-cell_type
and	O
IFN-U937	B-cell_line
cells	I-cell_line
both	O
responded	O
to	O
red	B-cell_type
cells	I-cell_type
sensitized	O
with	O
antibodies	B-protein
against	O
a	O
variety	O
of	O
specificities	O
of	O
assumed	O
(	O
although	O
not	O
documented	O
)	O
clinical	O
significance	O
for	O
blood	O
transfusion	O
recipients	O
.	O

In	O
contrast	O
,	O
monocytes	B-cell_type
and	O
IFN-U937	B-cell_line
cells	I-cell_line
responded	O
only	O
weakly	O
to	O
red	B-cell_type
cells	I-cell_type
sensitized	O
with	O
either	O
anti-D	B-protein
in	O
sera	O
from	O
mothers	O
of	O
babies	O
unaffected	O
by	O
HDN	O
,	O
or	O
with	O
antisera	O
containing	O
high	B-protein
titre	I-protein
antibodies	I-protein
with	O
specificities	O
not	O
normally	O
associated	O
with	O
significantly	O
reduced	O
red	B-cell_type
cell	I-cell_type
survival	O
.	O

Ablation	O
of	O
transplanted	O
HTLV-I	O
Tax-transformed	O
tumors	O
in	O
mice	O
by	O
antisense	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1993	O
Mar	O
12	O
;	O
259	O
(	O
5101	O
)	O
:	O
1523	O
]	O

Mice	O
transgenic	O
for	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
leukemia	I-DNA
virus	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
Tax	I-DNA
gene	I-DNA
develop	O
fibroblastic	O
tumors	O
that	O
express	O
NF-kappa	B-DNA
B-inducible	I-DNA
early	I-DNA
genes	I-DNA
.	O

In	O
vitro	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
expression	O
by	O
antisense	O
oligodeoxynucleotides	O
(	O
ODNs	O
)	O
inhibited	O
growth	O
of	O
these	O
culture-adapted	B-cell_line
Tax-transformed	I-cell_line
fibroblasts	I-cell_line
as	O
well	O
as	O
an	O
HTLV-I-transformed	B-cell_line
human	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
.	O

In	O
contrast	O
,	O
antisense	O
inhibition	O
of	O
Tax	B-protein
itself	O
had	O
no	O
apparent	O
effect	O
on	O
cell	O
growth	O
.	O

Mice	O
treated	O
with	O
antisense	O
to	O
NF-kappa	B-protein
B	I-protein
ODNs	O
showed	O
rapid	O
regression	O
of	O
transplanted	O
fibrosarcomas	O
.	O

This	O
suggests	O
that	O
NF-kappa	B-protein
B	I-protein
expression	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
the	O
malignant	O
phenotype	O
and	O
provides	O
a	O
therapeutic	O
approach	O
for	O
HTLV-I-associated	O
disease	O
.	O

Membrane	B-protein
receptors	I-protein
for	O
aldosterone	O
:	O
a	O
novel	O
pathway	O
for	O
mineralocorticoid	O
action	O
.	O

Rapid	O
nongenomic	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
intracellular	O
electrolytes	O
,	O
cell	O
volume	O
,	O
and	O
Na	B-protein
(	I-protein
+	I-protein
)	I-protein
-H+	I-protein
antiport	I-protein
have	O
been	O
found	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
HML	B-cell_type
)	O
.	O

Binding	O
of	O
125I-labeled	O
aldosterone	O
to	O
plasma	O
membranes	O
of	O
HML	B-cell_type
shares	O
important	O
features	O
with	O
these	O
functional	O
data	O
.	O

This	O
includes	O
a	O
very	O
low	O
apparent	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
0.1	O
nM	O
for	O
both	O
aldosterone	O
and	O
the	O
effect	O
on	O
the	O
Na	B-protein
(	I-protein
+	I-protein
)	I-protein
-H	I-protein
(	I-protein
+	I-protein
)	I-protein
-antiport	I-protein
,	O
a	O
high	O
turnover	O
rate	O
,	O
and	O
the	O
almost	O
exclusive	O
binding	O
selectivity	O
for	O
aldosterone	O
.	O

Dexamethasone	O
,	O
RU	O
26988	O
,	O
corticosterone	O
,	O
ouabain	O
,	O
amiloride	O
,	O
and	O
18-hydroxyprogesterone	O
were	O
inactive	O
as	O
ligands	O
.	O

Deoxycorticosterone	O
acetate	O
had	O
an	O
intermediate	O
activity	O
with	O
an	O
apparent	O
Kd	O
of	O
100	O
nM	O
.	O

These	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
of	O
aldosterone	O
being	O
compatible	O
with	O
major	O
aspects	O
of	O
its	O
nongenomic	O
effects	O
.	O

Leukotriene	O
B4	O
transcriptionally	O
activates	O
interleukin-6	B-protein
expression	O
involving	O
NK-chi	B-protein
B	I-protein
and	O
NF-IL6	B-protein
.	O

Leukotriene	O
B4	O
(	O
LTB4	O
)	O
is	O
a	O
notable	O
participant	O
in	O
inflammation	O
and	O
chemotaxis	O
.	O

It	O
is	O
,	O
however	O
,	O
still	O
unclear	O
whether	O
LTB4	O
acts	O
in	O
this	O
regard	O
directly	O
or	O
indirectly	O
by	O
stimulating	O
the	O
release	O
of	O
chemotactic	O
and	O
inflammatory	B-protein
cytokines	I-protein
.	O

Here	O
we	O
report	O
that	O
LTB4	O
induces	O
synthesis	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-6	I-protein
by	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
through	O
transcriptional	O
activation	O
of	O
the	O
IL-6	B-DNA
gene	I-DNA
.	O

We	O
furthermore	O
demonstrate	O
that	O
this	O
process	O
involves	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-chi	B-protein
B	I-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
of	O
NF-IL6	B-protein
,	O
while	O
the	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
,	O
shown	O
to	O
otherwise	O
confer	O
IL-6	B-protein
inducibility	O
,	O
appeared	O
to	O
be	O
unaffected	O
by	O
LTB4	O
.	O

Involvement	O
of	O
NF-chi	B-protein
B	I-protein
and	O
NF-IL6	B-protein
in	O
induction	O
of	O
IL-6	B-protein
transcription	O
by	O
monocytes	O
was	O
demonstrated	O
using	O
deleted	O
forms	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
.	O

Activation	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
by	O
LTB4	O
was	O
not	O
only	O
associated	O
with	O
accumulation	O
of	O
the	O
respective	O
transcripts	O
but	O
resulted	O
in	O
synthesis	O
of	O
functional	O
IL-6	B-protein
protein	I-protein
as	O
well	O
.	O

In	O
addition	O
,	O
LTB4	O
mediated	O
transactivation	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
construct	I-DNA
containing	O
the	O
NF-chi	B-DNA
B	I-DNA
or	O
the	O
NF-IL6	B-DNA
enhancer	I-DNA
,	O
but	O
not	O
the	O
AP-1	B-DNA
enhancer	I-DNA
.	O

The	O
signaling	O
events	O
mediating	O
this	O
effect	O
appeared	O
to	O
involve	O
the	O
release	O
of	O
H2O2	O
,	O
since	O
LTB4	O
failed	O
to	O
induce	O
NF-chi	B-protein
B	I-protein
or	O
NF-IL6	B-protein
in	O
the	O
presence	O
of	O
the	O
scavenger	O
of	O
H2O2	O
,	O
N-acetyl-L-cysteine	O
.	O

Bcl-2	B-protein
:	O
a	O
repressor	O
of	O
lymphocyte	B-cell_type
death	O
.	O

The	O
genes	O
and	O
mechanisms	O
that	O
control	O
programmed	O
cell	O
death	O
are	O
currently	O
the	O
subject	O
of	O
intense	O
study	O
.	O

The	O
bcl-2	B-DNA
gene	I-DNA
,	O
a	O
repressor	O
of	O
lymphocyte	B-cell_type
death	O
,	O
is	O
perhaps	O
the	O
best	O
understood	O
of	O
the	O
programmed	O
cell	O
death	O
associated	O
genes	O
.	O

Here	O
,	O
Stanley	O
Korsmeyer	O
provides	O
a	O
brief	O
overview	O
of	O
bcl-2	B-protein
,	O
concentrating	O
on	O
its	O
roles	O
in	O
B-	O
and	O
T-cell	O
development	O
and	O
in	O
oncogenesis	O
.	O

Cytoplasmic	O
domain	O
heterogeneity	O
and	O
functions	O
of	O
IgG	B-protein
Fc	I-protein
receptors	I-protein
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

B	B-cell_type
lymphocytes	I-cell_type
and	O
macrophages	O
express	O
closely	O
related	O
immunoglobulin	B-protein
G	I-protein
(	I-protein
IgG	I-protein
)	I-protein
Fc	I-protein
receptors	I-protein
(	O
Fc	B-protein
gamma	I-protein
RII	I-protein
)	O
that	O
differ	O
only	O
in	O
the	O
structures	O
of	O
their	O
cytoplasmic	B-protein
domains	I-protein
.	O

Because	O
of	O
cell	O
type-specific	O
alternative	O
messenger	O
RNA	O
splicing	O
,	O
B-cell	B-protein
Fc	I-protein
gamma	I-protein
RII	I-protein
contains	O
an	O
insertion	O
of	O
47	O
amino	O
acids	O
that	O
participates	O
in	O
determining	O
receptor	O
function	O
in	O
these	O
cells	O
.	O

Transfection	O
of	O
an	O
Fc	B-cell_line
gamma	I-cell_line
RII-negative	I-cell_line
B-cell	I-cell_line
line	I-cell_line
with	O
complementary	O
DNA	O
's	O
encoding	O
the	O
two	O
splice	O
products	O
and	O
various	O
receptor	O
mutants	O
indicated	O
that	O
the	O
insertion	O
was	O
responsible	O
for	O
preventing	O
both	O
Fc	B-protein
gamma	I-protein
RII	I-protein
-mediated	O
endocytosis	O
and	O
Fc	B-protein
gamma	I-protein
RII	I-protein
-mediated	O
antigen	O
presentation	O
.	O

The	O
insertion	O
was	O
not	O
required	O
for	O
Fc	B-protein
gamma	I-protein
RII	I-protein
to	O
modulate	O
surface	B-protein
immunoglobulin	I-protein
-triggered	O
B-cell	O
activation	O
.	O

Instead	O
,	O
regulation	O
of	O
activation	O
involved	O
a	O
region	O
of	O
the	O
cytoplasmic	B-protein
domain	I-protein
common	O
to	O
both	O
the	O
lymphocyte	B-protein
and	I-protein
macrophage	I-protein
receptor	I-protein
isoforms	I-protein
.	O

In	O
contrast	O
,	O
the	O
insertion	O
did	O
contribute	O
to	O
the	O
formation	O
of	O
caps	O
in	O
response	O
to	O
receptor	O
cross-linking	O
,	O
consistent	O
with	O
suggestions	O
that	O
the	O
lymphocyte	O
but	O
not	O
macrophage	O
form	O
of	O
the	O
receptor	O
can	O
associate	O
with	O
the	O
detergent-insoluble	O
cytoskeleton	O
.	O

[	O
Age-related	O
changes	O
in	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
healthy	O
persons	O
and	O
patients	O
with	O
hypertension	O
]	O

It	O
has	O
been	O
found	O
that	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
the	O
peripheral	O
blood	O
of	O
healthy	O
elderly	O
subjects	O
increases	O
,	O
while	O
the	O
number	O
of	O
mineralocorticoid	O
receptors	O
decreases	O
.	O

The	O
mechanisms	O
of	O
hormone-receptor	O
interactions	O
in	O
hypertension	O
are	O
activated	O
:	O
the	O
number	O
of	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
binding	I-protein
sites	I-protein
grows	O
in	O
hypertensive	O
patients	O
.	O

Still	O
a	O
more	O
essential	O
rise	O
in	O
the	O
number	O
of	O
receptors	O
is	O
observed	O
in	O
mid-age	O
hypertensive	O
patients	O
than	O
in	O
elderly	O
ones	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
.	O

CsA	O
and	O
FK506	O
are	O
powerful	O
suppressors	O
of	O
the	O
immune	O
system	O
,	O
most	O
notably	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

They	O
act	O
at	O
a	O
point	O
in	O
activation	O
that	O
lies	O
between	O
receptor	O
ligation	O
and	O
the	O
transcription	O
of	O
early	B-DNA
genes	I-DNA
.	O

Here	O
,	O
Stuart	O
Schreiber	O
and	O
Gerald	O
Crabtree	O
review	O
recent	O
findings	O
that	O
indicate	O
CsA	O
and	O
FK506	O
operate	O
as	O
prodrugs	O
:	O
they	O
bind	O
endogenous	B-protein
intracellular	I-protein
receptors	I-protein
,	O
the	O
immunophilins	B-protein
,	O
and	O
the	O
resulting	O
complex	O
targets	O
the	O
protein	B-protein
phosphatase	I-protein
,	I-protein
calcineurin	B-protein
,	O
to	O
exert	O
the	O
immunosuppressive	O
effect	O
.	O

Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF-kappa	B-protein
B	I-protein
-like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	B-cell_type
cells	I-cell_type
.	O

The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O

PLB-985	B-cell_line
cells	I-cell_line
represent	O
a	O
bipotential	B-cell_line
myelomonoblastic	I-cell_line
cell	I-cell_line
population	I-cell_line
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O

By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	B-protein
on	O
the	O
cell	O
surface	O
,	O
PLB-985	B-cell_line
cells	I-cell_line
were	O
chronically	O
infected	O
with	O
HIV-1	O
strain	O
IIIB	O
.	O

PLB-IIIB	B-cell_line
cells	I-cell_line
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	B-cell_type
myeloblasts	I-cell_type
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid-specific	B-protein
surface	I-protein
markers	I-protein
,	O
and	O
transcription	O
of	O
the	O
c-fms	B-DNA
proto-oncogene	I-DNA
.	O

NF-kappa	B-protein
B	I-protein
binding	O
activity	O
was	O
inducible	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
and	O
phorbol	O
myristate	O
acetate	O
in	O
PLB-985	B-cell_line
.	O

However	O
,	O
in	O
PLB-IIIB	B-cell_line
cells	I-cell_line
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O

These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	B-DNA
NF-kappa	I-DNA
B	I-DNA
site	I-DNA
from	O
the	O
interferon	B-DNA
beta	I-DNA
(	I-DNA
IFN-beta	I-DNA
)	I-DNA
promoter	I-DNA
.	O

Mutations	O
affecting	O
the	O
5	B-DNA
'	I-DNA
guanine	I-DNA
residues	I-DNA
of	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
were	O
unable	O
to	O
compete	O
for	O
these	O
NF-kappa	B-protein
B-related	I-protein
proteins	I-protein
.	O

Inducibility	O
of	O
endogenous	O
IFN-beta	B-RNA
and	I-RNA
IFN-alpha	I-RNA
RNA	I-RNA
was	O
also	O
increased	O
in	O
PLB-IIIB	B-cell_line
cells	I-cell_line
.	O

These	O
studies	O
indicate	O
that	O
HIV-1	O
infection	O
of	O
myelomonoblastic	B-cell_type
cells	I-cell_type
may	O
select	O
for	O
a	O
more	O
mature	O
monocytic	O
phenotype	O
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF-kappa	B-protein
B	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
may	O
contribute	O
to	O
differential	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
expression	O
.	O

Cortisol	O
receptor	O
resistance	O
:	O
the	O
variability	O
of	O
its	O
clinical	O
presentation	O
and	O
response	O
to	O
treatment	O
.	O

Primary	O
(	O
partial	O
)	O
cortisol	B-protein
receptor	I-protein
resistance	O
was	O
previously	O
reported	O
in	O
a	O
total	O
of	O
7	O
patients	O
and	O
14	O
asymptomatic	O
family	O
members	O
.	O

Its	O
occurrence	O
is	O
considered	O
to	O
be	O
extremely	O
rare	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
on	O
6	O
patients	O
(	O
2	O
males	O
and	O
4	O
females	O
)	O
with	O
the	O
syndrome	O
.	O

The	O
first	O
male	O
patient	O
presented	O
with	O
mild	O
hypertension	O
.	O

Hydrochlorothiazide	O
therapy	O
resulted	O
in	O
life-threatening	O
hypokalemia	O
.	O

The	O
second	O
male	O
patient	O
had	O
slight	O
hypertension	O
without	O
hypokalemia	O
.	O

All	O
four	O
female	O
patients	O
presented	O
between	O
the	O
age	O
of	O
20-30	O
yr	O
with	O
acne	O
,	O
hirsutism	O
,	O
and	O
irregular	O
menstruations	O
.	O

Low	O
dose	O
dexamethasone	O
therapy	O
(	O
1-1.5	O
mg/day	O
)	O
was	O
of	O
clinical	O
benefit	O
in	O
these	O
patients	O
.	O

All	O
patients	O
showed	O
insufficient	O
suppression	O
of	O
serum	O
cortisol	O
concentrations	O
in	O
the	O
overnight	O
1-mg	O
dexamethasone	O
test	O
.	O

The	O
diurnal	O
rhythm	O
of	O
ACTH	O
and	O
cortisol	O
was	O
intact	O
,	O
albeit	O
at	O
an	O
elevated	O
level	O
.	O

There	O
was	O
a	O
normal	O
increase	O
in	O
ACTH	O
,	O
cortisol	O
,	O
and	O
GH	O
(	O
except	O
in	O
one	O
obese	O
patient	O
)	O
in	O
response	O
to	O
insulin-induced	O
hypoglycemia	O
,	O
while	O
cortisol	O
production	O
was	O
elevated	O
in	O
three	O
patients	O
.	O

Circulating	O
adrenal	O
androgen	O
levels	O
were	O
increased	O
in	O
all	O
patients	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
were	O
investigated	O
in	O
a	O
whole	O
cell	O
dexamethasone	O
binding	O
assay	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O

In	O
the	O
first	O
male	O
patient	O
,	O
the	O
number	O
of	O
receptors	O
was	O
very	O
low	O
,	O
while	O
the	O
affinity	O
was	O
lower	O
than	O
that	O
in	O
controls	O
.	O

A	O
lowered	O
affinity	O
to	O
dexamethasone	O
was	O
found	O
in	O
one	O
female	O
patient	O
,	O
while	O
a	O
lowered	O
number	O
of	O
receptors	O
was	O
found	O
in	O
three	O
patients	O
.	O

In	O
the	O
second	O
male	O
patient	O
,	O
no	O
abnormalities	O
were	O
found	O
.	O

As	O
a	O
bioassay	O
for	O
glucocorticoid	O
action	O
we	O
also	O
measured	O
dexamethasone	O
suppressibility	O
of	O
mitogen-stimulated	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O

In	O
the	O
male	O
patient	O
with	O
normal	O
receptor	O
status	O
,	O
dexamethasone	O
suppressibility	O
of	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
with	O
respect	O
to	O
both	O
maximal	O
suppression	O
and	O
IC50	O
.	O

Partial	O
cortisol	O
receptor	O
resistance	O
might	O
be	O
less	O
rare	O
than	O
previously	O
thought	O
.	O

In	O
the	O
six	O
patients	O
presented	O
,	O
at	O
least	O
three	O
different	O
forms	O
can	O
be	O
recognized	O
.	O

Therapy	O
with	O
dexamethasone	O
was	O
successful	O
in	O
female	O
patients	O
with	O
acne	O
and	O
hirsutism	O
,	O
as	O
the	O
secondary	O
increase	O
in	O
the	O
production	O
of	O
adrenal	O
androgens	O
was	O
effectively	O
controlled	O
.	O

The	O
development	O
of	O
functionally	O
responsive	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
work	O
reviewed	O
in	O
this	O
article	O
separates	O
T	O
cell	O
development	O
into	O
four	O
phases	O
.	O

First	O
is	O
an	O
expansion	O
phase	O
prior	O
to	O
TCR	B-protein
rearrangement	O
,	O
which	O
appears	O
to	O
be	O
correlated	O
with	O
programming	O
of	O
at	O
least	O
some	O
response	O
genes	O
for	O
inducibility	O
.	O

This	O
phase	O
can	O
occur	O
to	O
some	O
extent	O
outside	O
of	O
the	O
thymus	O
.	O

However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	O
that	O
the	O
thymus	O
is	O
by	O
far	O
the	O
most	O
potent	O
site	O
for	O
inducing	O
the	O
expansion	O
per	O
se	O
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O

Second	O
is	O
a	O
controlled	O
phase	O
of	O
TCR	B-DNA
gene	I-DNA
rearrangement	O
.	O

The	O
details	O
of	O
the	O
regulatory	O
mechanism	O
that	O
selects	O
particular	O
loci	B-DNA
for	O
rearrangement	O
are	O
still	O
not	O
known	O
.	O

It	O
seems	O
that	O
the	O
rearrangement	O
of	O
the	O
TCR	B-DNA
gamma	I-DNA
loci	I-DNA
in	O
the	O
gamma	B-cell_type
delta	I-cell_type
lineage	I-cell_type
may	O
not	O
always	O
take	O
place	O
at	O
a	O
developmental	O
stage	O
strictly	O
equivalent	O
to	O
the	O
rearrangement	O
of	O
TCR	B-DNA
beta	I-DNA
in	O
the	O
alpha	B-cell_type
beta	I-cell_type
lineage	I-cell_type
,	O
and	O
it	O
is	O
not	O
clear	O
just	O
how	O
early	O
the	O
two	O
lineages	O
diverge	O
.	O

In	O
the	O
TCR	B-cell_type
alpha	I-cell_type
beta	I-cell_type
lineage	I-cell_type
,	I-cell_type
however	O
,	O
the	O
final	O
gene	O
rearrangement	O
events	O
are	O
accompanied	O
by	O
rapid	O
proliferation	O
and	O
an	O
interruption	O
in	O
cellular	O
response	O
gene	O
inducibility	O
.	O

The	O
loss	O
of	O
conventional	O
responsiveness	O
is	O
probably	O
caused	O
by	O
alterations	O
at	O
the	O
level	O
of	O
signaling	O
,	O
and	O
may	O
be	O
a	O
manifestation	O
of	O
the	O
physiological	O
state	O
that	O
is	O
a	O
precondition	O
for	O
selection	O
.	O

Third	O
is	O
the	O
complex	O
process	O
of	O
selection	O
.	O

Whereas	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
can	O
undergo	O
forms	O
of	O
positive	O
selection	O
(	O
by	O
antigen-driven	O
clonal	O
expansion	O
)	O
and	O
negative	O
selection	O
(	O
by	O
abortive	O
stimulation	O
leading	O
to	O
anergy	O
or	O
death	O
)	O
,	O
neither	O
is	O
exactly	O
the	O
same	O
phenomenon	O
that	O
occurs	O
in	O
the	O
thymic	O
cortex	O
.	O

Negative	O
selection	O
in	O
the	O
cortex	O
appears	O
to	O
be	O
a	O
suicidal	O
inversion	O
of	O
antigen	O
responsiveness	O
:	O
instead	O
of	O
turning	O
on	O
IL-2	B-protein
expression	O
,	O
the	O
activated	B-cell_type
cell	I-cell_type
destroys	O
its	O
own	O
chromatin	B-DNA
.	O

The	O
genes	O
that	O
need	O
to	O
be	O
induced	O
for	O
this	O
response	O
are	O
not	O
yet	O
identified	O
,	O
but	O
it	O
is	O
unquestionably	O
a	O
form	O
of	O
activation	O
.	O

It	O
is	O
interesting	O
that	O
in	O
humans	O
and	O
rats	O
,	O
cortical	B-cell_type
thymocytes	I-cell_type
undergoing	O
negative	O
selection	O
can	O
still	O
induce	O
IL-2R	B-protein
alpha	I-protein
expression	O
and	O
even	O
be	O
rescued	O
in	O
vitro	O
,	O
if	O
exogenous	B-protein
IL-2	I-protein
is	O
provided	O
.	O

Perhaps	O
murine	B-cell_type
thymocytes	I-cell_type
are	O
denied	O
this	O
form	O
of	O
rescue	O
because	O
they	O
shut	O
off	O
IL-2R	B-protein
beta	I-protein
chain	I-protein
expression	O
at	O
an	O
earlier	O
stage	O
or	O
because	O
they	O
may	O
be	O
uncommonly	O
Bcl-2	B-protein
deficient	O
(	O
cf.	O
Sentman	O
et	O
al.	O
,	O
1991	O
;	O
Strasser	O
et	O
al.	O
,	O
1991	O
)	O
.	O

Even	O
so	O
,	O
medullary	B-cell_type
thymocytes	I-cell_type
remain	O
at	O
least	O
partially	O
susceptible	O
to	O
negative	O
selection	O
even	O
as	O
they	O
continue	O
to	O
mature	O
.	O

I	B-protein
kappa	I-protein
B/MAD-3	I-protein
masks	O
the	O
nuclear	O
localization	O
signal	O
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
and	O
requires	O
the	O
transactivation	B-protein
domain	I-protein
to	O
inhibit	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
DNA	O
binding	O
.	O

The	O
active	O
nuclear	O
form	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
is	O
composed	O
of	O
two	O
DNA	B-protein
binding	I-protein
subunits	I-protein
,	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
and	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
,	O
both	O
of	O
which	O
share	O
extensive	O
N-terminal	O
sequence	O
homology	O
with	O
the	O
v-rel	B-protein
oncogene	I-protein
product	I-protein
.	O

The	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
subunit	I-protein
provides	O
the	O
transactivation	O
activity	O
in	O
this	O
complex	O
and	O
serves	O
as	O
an	O
intracellular	O
receptor	O
for	O
a	O
cytoplasmic	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
termed	O
I	O
kappa	O
B	O
.	O

In	O
contrast	O
,	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
alone	O
fails	O
to	O
stimulate	O
kappa	O
B-directed	O
transcription	O
,	O
and	O
based	O
on	O
prior	O
in	O
vitro	O
studies	O
,	O
is	O
not	O
directly	O
regulated	O
by	O
I	B-protein
kappa	I-protein
B	I-protein
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
for	O
the	O
critical	O
regulatory	O
interaction	O
between	O
NF-kappa	B-protein
B	I-protein
and	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
,	O
a	O
series	O
of	O
human	B-protein
NF-kappa	I-protein
B	I-protein
p65	I-protein
mutants	I-protein
was	O
identified	O
that	O
functionally	O
segregated	O
DNA	O
binding	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
-mediated	O
inhibition	O
,	O
and	O
I	B-protein
kappa	I-protein
B	I-protein
-induced	O
nuclear	O
exclusion	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O

Results	O
from	O
in	O
vivo	O
expression	O
studies	O
performed	O
with	O
these	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
mutants	I-protein
revealed	O
the	O
following	O
:	O
1	O
)	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
completely	O
inhibits	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
-dependent	O
transcriptional	O
activation	O
mediated	O
through	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
kappa	I-DNA
B	I-DNA
enhancer	I-DNA
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
2	O
)	O
the	O
binding	O
of	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
to	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
is	O
sufficient	O
to	O
retarget	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
3	O
)	O
selective	O
deletion	O
of	O
the	O
functional	O
nuclear	O
localization	O
signal	O
present	O
in	O
the	O
Rel	B-protein
homology	I-protein
domain	I-protein
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
disrupts	O
its	O
ability	O
to	O
engage	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
,	O
and	O
4	O
)	O
the	O
unique	O
C-terminus	B-protein
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
attenuates	O
its	O
own	O
nuclear	O
localization	O
and	O
contains	O
sequences	O
that	O
are	O
required	O
for	O
I	B-protein
kappa	I-protein
B	I-protein
-mediated	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
DNA	O
binding	O
activity	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
nuclear	O
localization	O
signal	O
and	O
transactivation	B-protein
domain	I-protein
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
constitute	O
a	O
bipartite	O
system	O
that	O
is	O
critically	O
involved	O
in	O
the	O
inhibitory	O
function	O
of	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
.	O

Unexpectedly	O
,	O
our	O
in	O
vivo	O
studies	O
also	O
demonstrate	O
that	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
binds	O
directly	O
to	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
.	O

This	O
interaction	O
is	O
functional	O
as	O
it	O
leads	O
to	O
retargeting	O
of	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

However	O
,	O
no	O
loss	O
of	O
DNA	O
binding	O
activity	O
is	O
observed	O
,	O
presumably	O
reflecting	O
the	O
unique	O
C-terminal	B-protein
domain	I-protein
that	O
is	O
distinct	O
from	O
that	O
present	O
in	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
.	O

Characterization	O
of	O
a	O
new	O
tissue-specific	O
transcription	B-protein
factor	I-protein
binding	O
to	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
enhancer	I-DNA
TC-II	I-DNA
(	I-DNA
NF-kappa	I-DNA
B	I-DNA
)	I-DNA
element	I-DNA
.	O

We	O
have	O
biochemically	O
and	O
functionally	O
characterized	O
a	O
new	O
transcription	B-protein
factor	I-protein
,	O
NP-TCII	B-protein
,	O
which	O
is	O
present	O
in	O
nuclei	O
from	O
unstimulated	B-cell_line
T	I-cell_line
and	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
but	O
is	O
not	O
found	O
in	O
nonhematopoietic	B-cell_type
cells	I-cell_type
.	O

This	O
factor	O
has	O
a	O
DNA-binding	O
specificity	O
similar	O
to	O
that	O
of	O
NF-kappa	B-protein
B	I-protein
but	O
is	O
unrelated	O
to	O
this	O
or	O
other	O
Rel	B-protein
proteins	I-protein
by	O
functional	O
and	O
biochemical	O
criteria	O
.	O

It	O
can	O
also	O
be	O
distinguished	O
from	O
other	O
previously	O
described	O
lymphocyte-specific	B-protein
DNA-binding	I-protein
proteins	I-protein
.	O

The	O
candidate	B-protein
oncoprotein	I-protein
Bcl-3	I-protein
is	O
an	O
antagonist	O
of	O
p50/NF-kappa	B-protein
B	I-protein
-mediated	O
inhibition	O
.	O

The	O
candidate	B-DNA
oncogene	I-DNA
bcl-3	I-DNA
was	O
discovered	O
as	O
a	O
translocation	O
into	O
the	O
immunoglobulin	B-DNA
alpha-locus	I-DNA
in	O
some	O
cases	O
of	O
B-cell	O
chronic	O
lymphocytic	O
leukaemias	O
.	O

The	O
protein	B-protein
Bcl-3	I-protein
contains	O
seven	O
so-called	O
ankyrin	B-protein
repeats	I-protein
.	O

Similar	O
repeat	B-protein
motifs	I-protein
are	O
found	O
in	O
a	O
number	O
of	O
diverse	B-protein
regulatory	I-protein
proteins	I-protein
but	O
the	O
motifs	O
of	O
Bcl-3	B-protein
are	O
most	O
closely	O
related	O
to	O
those	O
found	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
proteins	I-protein
in	O
which	O
the	O
ankyrin	B-protein
repeat	I-protein
domain	O
is	O
thought	O
to	O
be	O
directly	O
involved	O
in	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O

No	O
biological	O
function	O
has	O
yet	O
been	O
described	O
for	O
Bcl-3	B-protein
,	O
but	O
it	O
was	O
noted	O
recently	O
that	O
Bcl-3	B-protein
interferes	O
with	O
DNA-binding	O
of	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
in	O
vitro	O
.	O

Here	O
we	O
demonstrate	O
that	O
Bcl-3	B-protein
can	O
aid	O
kappa	B-DNA
B	I-DNA
site	I-DNA
-dependent	O
transcription	O
in	O
vivo	O
by	O
counteracting	O
the	O
inhibitory	O
effects	O
of	O
p50/NF-kappa	B-protein
B	I-protein
homodimers	I-protein
.	O

Bcl-3	B-protein
may	O
therefore	O
aid	O
activation	O
of	O
select	O
NF-kappa	B-DNA
B-regulated	I-DNA
genes	I-DNA
,	O
including	O
those	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
.	O

[	O
Mechanism	O
of	O
action	O
of	O
steroid	O
hormones.	O
I.	O
Estrogens	O
]	O

The	O
steroid	O
hormone	O
are	O
very	O
versatile	O
molecules	O
:	O
although	O
they	O
are	O
related	O
among	O
them	O
by	O
their	O
chemical	O
structure	O
,	O
they	O
have	O
very	O
diverse	O
functions	O
and	O
including	O
antagonic	O
.	O

Their	O
action	O
mechanism	O
is	O
not	O
completely	O
cleared	O
.	O

The	O
estrogens	O
participate	O
in	O
the	O
regulation	O
of	O
practically	O
all	O
the	O
reproductive	O
and	O
sexual	O
events	O
of	O
the	O
female	O
,	O
although	O
the	O
intracellular	O
actions	O
by	O
which	O
they	O
take	O
place	O
are	O
not	O
well	O
known	O
and	O
the	O
proposed	O
models	O
do	O
not	O
adequately	O
satisfy	O
the	O
questions	O
.	O

Currently	O
it	O
is	O
accepted	O
the	O
existence	O
of	O
a	O
cytoplasmic	B-protein
and/or	I-protein
nuclear	I-protein
receptor	I-protein
,	O
without	O
explaining	O
satisfactorily	O
how	O
the	O
hormones	O
come	O
to	O
the	O
nucleus	O
.	O

The	O
endocrine	O
events	O
that	O
are	O
rapidly	O
expressed	O
(	O
seconds	O
)	O
are	O
due	O
to	O
a	O
possible	O
interaction	O
with	O
cellular	O
membrane	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
analyze	O
and	O
concilliate	O
the	O
reported	O
data	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
estrogens	O
.	O

Reduced	O
susceptibility	O
to	O
HIV-1	O
infection	O
of	O
ethyl-methanesulfonate-treated	B-cell_line
CEM	I-cell_line
subclones	I-cell_line
correlates	O
with	O
a	O
blockade	O
in	O
their	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
pathway	O
.	O

We	O
have	O
described	O
the	O
isolation	O
of	O
chemically	O
induced	O
CEM	B-cell_line
subclones	I-cell_line
that	O
express	O
CD4	B-protein
receptors	I-protein
and	O
bind	O
soluble	O
gp120	B-protein
,	O
yet	O
show	O
a	O
markedly	O
reduced	O
susceptibility	O
to	O
infection	O
with	O
HIV-1	O
.	O

Two	O
subclones	O
were	O
found	O
to	O
have	O
an	O
abnormal	O
response	O
to	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
activator	O
PMA	O
.	O

PMA	O
treatment	O
induced	O
CD3	B-protein
and	I-protein
CD25	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
receptors	I-protein
on	O
the	O
parental	O
line	O
and	O
on	O
other	O
ethyl-methanesulfonate-derived	B-cell_line
subclones	I-cell_line
,	O
but	O
not	O
on	O
these	O
two	O
mutants	O
.	O

Direct	O
assays	O
of	O
PKC	B-protein
activity	O
were	O
conducted	O
.	O

Total	O
cellular	O
PKC	B-protein
enzymatic	O
activity	O
was	O
found	O
to	O
be	O
normal	O
in	O
these	O
subclones	O
.	O

PMA-induced	O
CD4	B-protein
down-modulation	O
occurred	O
normally	O
.	O

In	O
addition	O
,	O
activation	O
of	O
c-raf	B-protein
kinase	I-protein
was	O
normal	O
.	O

Since	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
contains	O
two	O
functional	O
nuclear	B-DNA
factor	I-DNA
kB	I-DNA
(	I-DNA
NF-kB	I-DNA
)	I-DNA
regulatory	I-DNA
elements	I-DNA
,	O
we	O
studied	O
the	O
ability	O
of	O
PMA	O
to	O
induce	O
NF-kB	B-protein
binding	O
activity	O
by	O
different	O
assays	O
.	O

Chloramphenicol	B-protein
acetyl	I-protein
transferase	I-protein
(	O
CAT	B-protein
)	O
assays	O
using	O
the	O
HIV-1	B-DNA
(	I-DNA
-139	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat-CAT	I-DNA
construct	I-DNA
showed	O
no	O
PMA	O
induction	O
of	O
CAT	B-protein
activity	O
in	O
these	O
subclones	O
(	O
unlike	O
the	O
parental	O
line	O
and	O
other	O
subclones	O
)	O
.	O

Okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	B-protein
1	I-protein
and	I-protein
2A	I-protein
,	O
did	O
not	O
overcome	O
the	O
defect	O
in	O
these	O
subclones	O
.	O

Gel	O
retardation	O
assays	O
,	O
using	O
a	O
32P-probe	O
containing	O
the	O
HIV-1	O
NF-kB	B-protein
probe	O
and	O
nuclear	O
extracts	O
from	O
PMA-treated	B-cell_type
cells	I-cell_type
,	O
showed	O
significantly	O
reduced	O
induction	O
of	O
nuclear	B-protein
NF-kB	I-protein
binding	I-protein
proteins	I-protein
in	O
these	O
two	O
subclones	O
compared	O
with	O
wild	B-protein
type	I-protein
CEM	I-protein
and	O
a	O
control	O
subclone	O
.	O

Deoxycholate	O
treatment	O
of	O
cytoplasmic	O
extracts	O
from	O
these	O
subclones	O
released	O
much	O
reduced	O
NF-kB	B-protein
binding	I-protein
proteins	I-protein
from	O
their	O
cytoplasmic	O
pools	O
.	O

Thus	O
,	O
reduced	O
levels	O
of	O
PKC	B-protein
-induced	O
nuclear	O
NF-kB	B-protein
activity	O
in	O
two	O
T	O
cell	O
subclones	O
did	O
not	O
affect	O
their	O
normal	O
cell	O
growth	O
,	O
but	O
correlated	O
with	O
a	O
pronounced	O
reduction	O
in	O
their	O
susceptibility	O
to	O
HIV-1	O
infection	O
.	O

Nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
contains	O
Fos	B-protein
and	O
Jun	B-protein
.	O

The	O
nuclear	B-protein
factor	I-protein
NF-AT	I-protein
(	O
ref.	O
1	O
)	O
is	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
through	O
the	O
T-cell	B-protein
receptor/CD3	I-protein
complex	I-protein
,	O
and	O
is	O
required	O
for	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
induction	O
.	O

Although	O
NF-AT	B-protein
has	O
not	O
been	O
cloned	O
or	O
purified	O
,	O
there	O
is	O
evidence	O
that	O
it	O
is	O
a	O
major	O
target	O
for	O
immunosuppression	O
by	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
(	O
refs	O
2-7	O
)	O
.	O

NF-AT	B-protein
induction	O
may	O
require	O
two	O
activation-dependent	O
events	O
:	O
the	O
CsA-sensitive	O
translocation	O
of	O
a	O
pre-existing	O
component	O
and	O
the	O
CsA-resistant	O
synthesis	O
of	O
a	O
nuclear	B-protein
component	I-protein
.	O

Here	O
we	O
report	O
that	O
the	O
newly	O
synthesized	O
nuclear	B-protein
component	I-protein
of	O
NF-AT	B-protein
is	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
.	O

We	O
show	O
that	O
the	O
inducible	O
nuclear	O
form	O
of	O
NF-AT	B-protein
contains	O
Fos	B-protein
and	O
Jun	B-protein
proteins	O
.	O

Furthermore	O
,	O
we	O
identify	O
a	O
pre-existing	B-protein
NF-AT-binding	I-protein
factor	I-protein
that	O
is	O
present	O
in	O
hypotonic	O
extracts	O
of	O
unstimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

On	O
the	O
basis	O
of	O
binding	O
,	O
reconstitution	O
and	O
cotransfection	O
experiments	O
,	O
we	O
propose	O
that	O
activation	O
of	O
NF-AT	B-protein
occurs	O
in	O
at	O
least	O
two	O
stages	O
:	O
a	O
CsA-sensitive	O
stage	O
involving	O
modification	O
and/or	O
translocation	O
of	O
the	O
pre-existing	O
NF-AT	B-protein
complex	I-protein
,	O
and	O
a	O
CsA-insensitive	O
stage	O
involving	O
the	O
addition	O
of	O
newly	O
synthesized	O
Fos	B-protein
or	O
Fos/Jun	B-protein
proteins	I-protein
to	O
the	O
pre-existing	B-protein
complex	I-protein
.	O

A	O
lymphoid	B-protein
cell-specific	I-protein
nuclear	I-protein
factor	I-protein
containing	O
c-Rel-like	B-protein
proteins	I-protein
preferentially	O
interacts	O
with	O
interleukin-6	B-DNA
kappa	I-DNA
B-related	I-DNA
motifs	I-DNA
whose	O
activities	O
are	O
repressed	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

The	O
proto-oncoprotein	B-protein
c-Rel	I-protein
is	O
a	O
member	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
,	O
which	O
includes	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
.	O

We	O
show	O
here	O
that	O
c-Rel	B-protein
binds	O
to	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
as	O
homodimers	B-protein
as	O
well	O
as	O
heterodimers	B-protein
with	O
p50	B-protein
.	O

These	O
homodimers	B-protein
and	O
heterodimers	B-protein
show	O
distinct	O
DNA-binding	O
specificities	O
and	O
affinities	O
for	O
various	O
kappa	B-DNA
B	I-DNA
motifs	I-DNA
.	O

In	O
particular	O
,	O
the	O
c-Rel	B-protein
homodimer	I-protein
has	O
a	O
high	O
affinity	O
for	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
and	O
beta	B-DNA
interferon	I-DNA
kappa	I-DNA
B	I-DNA
sites	I-DNA
.	O

In	O
spite	O
of	O
its	O
association	O
with	O
p50	B-protein
in	O
vitro	O
,	O
however	O
,	O
we	O
found	O
a	O
lymphoid	B-protein
cell-specific	I-protein
nuclear	I-protein
factor	I-protein
in	O
vivo	O
that	O
contains	O
c-Rel	B-protein
but	O
not	O
p50	B-protein
epitopes	I-protein
;	O
this	O
factor	O
,	O
termed	O
IL-6	B-protein
kappa	I-protein
B	I-protein
binding	I-protein
factor	I-protein
II	I-protein
,	O
appears	O
to	O
contain	O
the	O
c-Rel	B-protein
homodimer	I-protein
and	O
preferentially	O
recognizes	O
several	O
IL-6	B-DNA
kappa	I-DNA
B-related	I-DNA
kappa	I-DNA
B	I-DNA
motifs	I-DNA
.	O

Although	O
it	O
has	O
been	O
previously	O
shown	O
that	O
the	O
IL-6	B-DNA
kappa	I-DNA
B	I-DNA
motif	I-DNA
functions	O
as	O
a	O
potent	O
IL-1/tumor	B-DNA
necrosis	I-DNA
factor-responsive	I-DNA
element	I-DNA
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
,	O
its	O
activity	O
was	O
found	O
to	O
be	O
repressed	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
such	O
as	O
a	O
Jurkat	B-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O

We	O
also	O
present	O
evidence	O
that	O
IL-6	B-protein
kappa	I-protein
B	I-protein
binding	I-protein
factor	I-protein
II	I-protein
functions	O
as	O
a	O
repressor	O
specific	O
for	O
IL-6	B-DNA
kappa	I-DNA
B-related	I-DNA
kappa	I-DNA
B	I-DNA
motifs	I-DNA
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

Cortisol	O
resistance	O
in	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

This	O
study	O
concerns	O
9	O
iv	O
drug	O
abusers	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
who	O
developed	O
hypercortisolism	O
without	O
the	O
clinical	O
signs	O
or	O
metabolic	O
consequences	O
of	O
hypercortisolism	O
.	O

All	O
patients	O
were	O
characterized	O
by	O
an	O
Addisonian	O
picture	O
(	O
weakness	O
,	O
weight	O
loss	O
,	O
hypotension	O
,	O
hyponatremia	O
,	O
and	O
intense	O
mucocutaneous	O
melanosis	O
)	O
.	O

An	O
acquired	O
form	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
was	O
suspected	O
.	O

We	O
,	O
therefore	O
,	O
examined	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
is	O
one	O
of	O
the	O
effects	O
of	O
glucocorticoid	B-protein
receptor	I-protein
activation	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
density	O
was	O
increased	O
in	O
AIDS	O
patients	O
with	O
an	O
Addisonian	O
picture	O
(	O
group	O
1	O
;	O
16.2	O
+/-	O
9.4	O
fmol/million	O
cells	O
)	O
compared	O
to	O
values	O
in	O
12	O
AIDS	O
patients	O
without	O
an	O
Addisonian	O
picture	O
(	O
group	O
2	O
;	O
6.05	O
+/-	O
2.6	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
and	O
sex-	O
and	O
age-matched	O
controls	O
(	O
3.15	O
+/-	O
2.3	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

The	O
affinity	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
Kd	O
)	O
was	O
strikingly	O
decreased	O
(	O
9.36	O
+/-	O
3.44	O
nM	O
in	O
group	O
1	O
;	O
3.2	O
+/-	O
1.5	O
nM	O
in	O
group	O
2	O
;	O
2.0	O
+/-	O
0.8	O
nM	O
in	O
controls	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

[	O
3H	O
]	O
Thymidine	O
incorporation	O
was	O
decreased	O
dose-dependently	O
by	O
dexamethasone	O
in	O
controls	O
and	O
patients	O
;	O
the	O
effect	O
was	O
significantly	O
blunted	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
group	O
1	O
patients	O
,	O
which	O
suggests	O
that	O
activation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
is	O
impaired	O
as	O
a	O
result	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
abnormality	O
.	O

In	O
conclusion	O
,	O
AIDS	O
patients	O
with	O
hypercortisolism	O
and	O
clinical	O
features	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
are	O
characterized	O
by	O
abnormal	B-protein
glucocorticoid	I-protein
receptors	I-protein
on	O
lymphocytes	B-cell_type
.	O

Resistance	O
to	O
glucocorticoids	O
implies	O
a	O
complex	O
change	O
in	O
immune-endocrine	O
function	O
,	O
which	O
may	O
be	O
important	O
in	O
the	O
course	O
of	O
immunodeficiency	O
syndrome	O
.	O

A	O
novel	O
primer	O
extension	O
method	O
to	O
detect	O
the	O
number	O
of	O
CAG	O
repeats	O
in	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
families	O
with	O
X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
.	O

X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
(	O
SBMA	O
)	O
,	O
an	O
adult-onset	O
form	O
of	O
motor	O
neuron	O
disease	O
,	O
was	O
recently	O
reported	O
to	O
be	O
caused	O
by	O
amplification	O
of	O
the	O
CAG	O
repeats	O
in	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
.	O

We	O
report	O
here	O
a	O
simple	O
and	O
rapid	O
strategy	O
to	O
detect	O
the	O
precise	O
number	O
of	O
the	O
CAGs	O
.	O

After	O
the	O
DNA	B-DNA
fragment	I-DNA
containing	O
the	O
CAG	B-DNA
repeats	I-DNA
is	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
a	O
primer	O
extension	O
is	O
carried	O
out	O
;	O
the	O
extension	O
of	O
the	O
end-labelled	B-DNA
reverse	I-DNA
primer	I-DNA
adjacent	O
to	O
3	B-DNA
'	I-DNA
end	I-DNA
of	O
CAG	B-DNA
repeats	I-DNA
stops	O
at	O
the	O
first	O
T	O
after	O
CAG	B-DNA
repeats	I-DNA
with	O
the	O
incorporation	O
of	O
dideoxy	O
ATP	O
in	O
the	O
reaction	O
mixture	O
.	O

The	O
resultant	O
primer	B-DNA
products	I-DNA
are	O
analysed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
autoradiography	O
.	O

This	O
method	O
could	O
be	O
quite	O
useful	O
to	O
detect	O
not	O
only	O
CAG	B-DNA
repeats	I-DNA
in	O
SBMA	O
but	O
also	O
other	O
polymorphic	B-DNA
dinucleotide	I-DNA
and	O
trinucleotide	B-DNA
repeats	I-DNA
.	O

Cellular	O
immune	O
and	O
cytokine	O
pathways	O
resulting	O
in	O
tissue	B-protein
factor	I-protein
expression	O
and	O
relevance	O
to	O
septic	O
shock	O
.	O

Cells	O
of	O
monocyte	O
lineage	O
serve	O
as	O
effector	B-cell_type
cells	I-cell_type
in	O
the	O
cellular	O
immune	O
response	O
.	O

In	O
addition	O
,	O
they	O
respond	O
to	O
LPS	O
and	O
cytokines	O
with	O
activation	O
and	O
expression	O
of	O
inflammatory	B-protein
effector	I-protein
gene	I-protein
products	I-protein
similar	O
to	O
those	O
elicited	O
by	O
the	O
antigen	O
driven	O
response	O
.	O

The	O
response	O
to	O
antigen	O
proceeds	O
at	O
the	O
T	B-cell_type
helper	I-cell_type
cell	I-cell_type
level	O
through	O
two	O
independent	O
forms	O
of	O
cellular	O
collaboration	O
,	O
contact	O
and	O
lymphokine	B-protein
.	O

We	O
review	O
the	O
control	O
of	O
expression	O
of	O
the	O
Tissue	B-DNA
Factor	I-DNA
(	I-DNA
TF	I-DNA
)	I-DNA
gene	I-DNA
and	O
the	O
function	O
of	O
the	O
TF	B-protein
protein	I-protein
.	O

The	O
enhanced	O
initiation	O
of	O
transcription	O
of	O
the	O
TF	O
gene	O
appears	O
to	O
require	O
engagement	O
of	O
a	O
56	O
bp	O
LPS	B-DNA
Response	I-DNA
Element	I-DNA
,	O
an	O
enhancer	O
that	O
is	O
engaged	O
by	O
both	O
AP-1	B-protein
type	I-protein
heterodimeric	I-protein
complexes	I-protein
as	O
well	O
as	O
NF	B-protein
kappa	I-protein
B	I-protein
like	I-protein
heterodimeric	I-protein
complexes	I-protein
.	O

Dissociation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
from	O
Ig	B-protein
kappa	I-protein
B	I-protein
by	O
cytokine	O
and	O
LPS	O
stimulation	O
,	O
and	O
possibly	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
may	O
represent	O
a	O
common	O
pathway	O
to	O
induction	O
of	O
the	O
TF	B-DNA
and	I-DNA
other	I-DNA
inflammatory	I-DNA
genes	I-DNA
.	O

Enhancement	O
of	O
expression	O
of	O
TF	B-protein
is	O
observed	O
upon	O
adhesion	O
of	O
Mo	O
to	O
endothelial	B-cell_type
cells	I-cell_type
and	O
extracellular	O
matrix	O
proteins	O
,	O
as	O
well	O
as	O
upon	O
engagement	O
of	O
leukocyte	B-protein
integrins	I-protein
.	O

The	O
biological	O
effects	O
that	O
follow	O
from	O
expression	O
of	O
TF	B-protein
by	O
vascular	O
cells	O
have	O
been	O
resolved	O
by	O
analysis	O
of	O
function	O
aided	O
by	O
the	O
use	O
of	O
recombinant	B-protein
full	I-protein
length	I-protein
TF	I-protein
and	O
truncated	B-protein
surface	I-protein
domain	I-protein
of	O
TF	B-protein
.	O

The	O
rules	O
of	O
assembly	O
of	O
the	O
cognate	O
ligands	O
of	O
TF	B-protein
,	O
namely	O
the	O
zymogen	B-protein
plasma	I-protein
factors	I-protein
VII	I-protein
and	O
the	O
serine	B-protein
protease	I-protein
factor	I-protein
VIIa	I-protein
,	O
with	O
the	O
soluble	B-protein
surface	I-protein
domain	I-protein
of	O
TF	B-protein
in	O
free	O
solution	O
,	O
in	O
the	O
presence	O
of	O
phospholipid	O
surfaces	O
and	O
cell	O
surface	O
and	O
of	O
the	O
anchored	B-protein
TF	I-protein
molecule	I-protein
have	O
been	O
described	O
.	O

It	O
is	O
evident	O
that	O
assembly	O
of	O
the	O
surface	B-protein
domain	I-protein
of	O
TF	B-protein
with	O
VIIa	B-protein
to	O
form	O
the	O
binary	O
TF.VIIa	B-protein
complex	I-protein
induces	O
a	O
significant	O
increase	O
in	O
the	O
Kcat	O
of	O
the	O
catalytic	B-protein
domain	I-protein
of	O
VIIa	B-protein
for	O
small	O
peptidyl	O
substrates	O
and	O
more	O
profoundly	O
for	O
protein	B-protein
substrate	I-protein
.	O

This	O
provides	O
substantial	O
evidence	O
for	O
an	O
allosteric	O
effect	O
on	O
the	O
catalytic	O
cleft	O
of	O
VIIa	B-protein
that	O
is	O
imparted	O
by	O
binding	O
to	O
TF	B-protein
,	O
its	O
cognate	O
catalytic	O
cofactor	B-protein
.	O

It	O
is	O
also	O
evident	O
that	O
the	O
TF.VIIa	B-protein
complex	I-protein
is	O
proteolytically	O
active	O
and	O
can	O
activate	O
the	O
zymogen	B-protein
plasma	I-protein
factor	I-protein
X	I-protein
to	O
the	O
serine	B-protein
protease	I-protein
Xa	I-protein
in	O
free	O
solution	O
,	O
inferring	O
that	O
extended	O
substrate	O
recognition	O
by	O
induced	O
structural	O
loci	O
of	O
the	O
TF.VIIa	B-protein
complex	I-protein
are	O
created	O
from	O
either	O
or	O
both	O
proteins	O
to	O
constitute	O
a	O
new	B-protein
recognition	I-protein
structure	I-protein
.	O

It	O
is	O
also	O
evident	O
that	O
association	O
of	O
X	B-protein
with	O
charged	O
phospholipid	O
surfaces	O
enhances	O
the	O
proteolytic	O
activation	O
of	O
this	O
zymogen	B-protein
by	O
increasing	O
recognition	O
and	O
susceptibility	O
of	O
the	O
sessile	O
peptide	O
bond	O
deduced	O
from	O
the	O
markedly	O
decreased	O
Km	O
and	O
increased	O
Kcat	O
.	O

Phorbol	O
ester	O
reduces	O
constitutive	B-protein
nuclear	I-protein
NF	I-protein
kappa	I-protein
B	I-protein
and	O
inhibits	O
HIV-1	O
production	O
in	O
mature	B-cell_type
human	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

NF	B-protein
kappa	I-protein
B	I-protein
is	O
a	O
potent	O
mediator	O
of	O
specific	O
gene	O
expression	O
in	O
human	O
monocytes	O
and	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
transcription	O
of	O
the	O
HIV-1	O
genome	O
in	O
promonocytic	O
leukemias	O
.	O

There	O
is	O
little	O
information	O
available	O
on	O
the	O
response	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
to	O
cytokines	B-protein
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

We	O
have	O
used	O
a	O
32P-labeled	O
oligonucleotide	O
derived	O
from	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
which	O
contains	O
a	O
tandem	O
repeat	O
of	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sequence	I-DNA
,	O
as	O
a	O
probe	O
in	O
a	O
gel	O
retardation	O
assay	O
to	O
study	O
this	O
transcription	B-protein
factor	I-protein
.	O

Using	O
this	O
assay	O
,	O
we	O
have	O
detected	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
extracts	O
of	O
nuclei	O
from	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

Treatment	O
of	O
normal	B-cell_type
monocytes	I-cell_type
with	O
12-0-tetradecanoyl	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
for	O
4-24	O
h	O
caused	O
the	O
complete	O
disappearance	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
from	O
nuclear	O
extracts	O
of	O
monocytes	O
.	O

A	O
similar	O
result	O
was	O
obtained	O
with	O
the	O
mature	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
.	O

The	O
constitutive	B-protein
transcription	I-protein
factor	I-protein
SP1	B-protein
was	O
unaffected	O
by	O
addition	O
of	O
TPA	O
.	O

The	O
disappearance	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
from	O
the	O
nucleus	O
was	O
concentration	O
dependent	O
between	O
10	O
and	O
50	O
ng/ml	O
of	O
phorbol	O
ester	O
.	O

In	O
THP-1	O
cells	O
,	O
TPA	O
also	O
induced	O
a	O
new	O
,	O
faster-migrating	B-protein
NF	I-protein
kappa	I-protein
B	I-protein
species	I-protein
not	O
induced	O
in	O
monocytes	B-cell_type
.	O

Protein	O
kinase	O
C	O
inhibitor	O
staurosporine	O
,	O
but	O
not	O
cyclic	O
nucleotide-dependent	O
protein	O
kinase	O
inhibitor	O
HA-1004	O
,	O
also	O
dramatically	O
reduced	O
constitutive	O
levels	O
of	O
nuclear	B-protein
NF	I-protein
kappa	I-protein
B	I-protein
.	O

Finally	O
,	O
TPA	O
addition	O
to	O
monocytes	B-cell_type
infected	O
with	O
HIV-1	O
inhibited	O
HIV-1	O
replication	O
,	O
as	O
determined	O
by	O
reverse	B-protein
transcriptase	I-protein
assays	O
,	O
in	O
a	O
concentration-dependent	O
manner	O
.	O

These	O
results	O
are	O
in	O
striking	O
contrast	O
to	O
the	O
increase	O
in	O
nuclear	O
NF	B-protein
kappa	I-protein
B	I-protein
and	O
HIV-1	O
replication	O
induced	O
by	O
phorbol	O
esters	O
in	O
promonocytic	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
U937	I-cell_line
and	O
HL-60	B-cell_line
,	O
and	O
emphasize	O
the	O
importance	O
of	O
studying	O
cytokine	B-protein
regulation	O
of	O
HIV-1	O
in	O
normal	B-cell_type
monocytes	I-cell_type
.	O

A	O
mechanism	O
for	O
the	O
antiinflammatory	O
effects	O
of	O
corticosteroids	O
:	O
the	O
glucocorticoid	B-protein
receptor	I-protein
regulates	O
leukocyte	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
and	O
expression	O
of	O
endothelial-leukocyte	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
and	O
intercellular	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
.	O

Corticosteroids	O
are	O
the	O
preeminent	O
antiinflammatory	O
agents	O
although	O
the	O
molecular	O
mechanisms	O
that	O
impart	O
their	O
efficacy	O
have	O
not	O
been	O
defined	O
.	O

The	O
endothelium	O
plays	O
a	O
critical	O
role	O
in	O
inflammation	O
by	O
directing	O
circulating	B-cell_type
leukocytes	I-cell_type
into	O
extravascular	O
tissues	O
by	O
expressing	O
adhesive	B-protein
molecules	I-protein
for	O
leukocytes	B-cell_type
[	O
e.g.	O
,	O
endothelial-leukocyte	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
ELAM-1	B-protein
)	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
ICAM-1	B-protein
)	O
]	O
.	O

We	O
therefore	O
determined	O
whether	O
corticosteroids	O
suppress	O
inflammation	O
by	O
inhibiting	O
endothelial	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
for	O
neutrophils	B-cell_type
(	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
)	O
.	O

Preincubation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
endotoxin	O
[	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
1	O
microgram/ml	O
]	O
led	O
to	O
a	O
4-fold	O
increase	O
in	O
subsequent	O
adherence	O
of	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
(	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
10	O
)	O
to	O
endothelial	B-cell_type
cells	I-cell_type
,	O
an	O
increase	O
that	O
was	O
markedly	O
attenuated	O
when	O
endothelial	B-cell_type
cells	I-cell_type
were	O
treated	O
with	O
dexamethasone	O
(	O
IC50	O
<	O
1	O
nM	O
,	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
6	O
or	O
7	O
)	O
during	O
preincubation	O
with	O
LPS	O
.	O

Moreover	O
,	O
the	O
steroid	B-protein
receptor	I-protein
agonist	O
cortisol	O
(	O
10	O
microM	O
)	O
,	O
but	O
not	O
its	O
inactive	O
metabolite	O
tetrahydrocortisol	O
(	O
10	O
microM	O
)	O
,	O
diminished	O
LPS-induced	O
endothelial	O
cell	O
adhesiveness	O
.	O

Further	O
evidence	O
that	O
the	O
action	O
of	O
dexamethasone	O
was	O
mediated	O
through	O
ligation	O
of	O
corticosteroid	B-protein
receptors	I-protein
[	O
human	B-protein
glucocorticoid	I-protein
receptors	I-protein
(	O
hGRs	B-protein
)	O
]	O
was	O
provided	O
by	O
experiments	O
utilizing	O
the	O
steroid	O
antagonist	O
RU-486	O
.	O

RU-486	O
(	O
10	O
microM	O
)	O
,	O
which	O
prevents	O
translocation	O
of	O
ligated	O
hGR	B-protein
to	O
the	O
nucleus	O
by	O
inhibiting	O
dissociation	O
of	O
hGR	B-protein
from	O
heat	O
shock	O
protein	O
90	O
,	O
completely	O
aborted	O
the	O
effect	O
of	O
dexamethasone	O
on	O
adhesiveness	O
of	O
endothelial	B-cell_type
cells	I-cell_type
(	O
P	O
<	O
0.0005	O
,	O
n	O
=	O
3	O
)	O
.	O

Treatment	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
stimulated	O
transcription	O
of	O
ELAM-1	B-protein
,	O
as	O
shown	O
by	O
Northern	O
blot	O
analysis	O
,	O
and	O
expression	O
of	O
membrane-associated	B-protein
ELAM-1	I-protein
and	O
ICAM-1	B-protein
,	O
as	O
shown	O
by	O
quantitative	O
immunofluorescence	O
(	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
9	O
)	O
.	O

Dexamethasone	O
markedly	O
inhibited	O
LPS-stimulated	O
accumulation	O
of	O
mRNA	O
for	O
ELAM-1	B-protein
and	O
expression	O
of	O
ELAM-1	B-protein
and	O
ICAM-1	B-protein
(	O
IC50	O
<	O
10	O
nM	O
,	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
4-9	O
)	O
;	O
inhibition	O
of	O
expression	O
by	O
dexamethasone	O
was	O
reversed	O
by	O
RU-486	O
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
4-6	O
)	O
.	O

As	O
in	O
the	O
adhesion	O
studies	O
,	O
cortisol	O
but	O
not	O
tetrahydrocortisol	O
inhibited	O
expression	O
of	O
ELAM-1	B-protein
and	O
ICAM-1	B-protein
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
3	O
or	O
4	O
)	O
.	O

In	O
contrast	O
,	O
sodium	O
salicylate	O
(	O
1	O
mM	O
)	O
inhibited	O
neither	O
adhesion	O
nor	O
expression	O
of	O
these	O
adhesion	B-protein
molecules	I-protein
.	O

These	O
studies	O
suggest	O
that	O
antagonism	O
by	O
dexamethasone	O
of	O
endotoxin	B-protein
-induced	O
inflammation	O
is	O
a	O
specific	O
instance	O
of	O
the	O
general	O
biological	O
principle	O
that	O
the	O
glucocorticoid	B-protein
receptor	I-protein
is	O
a	O
hormone-dependent	O
regulator	O
of	O
transcription	O
.	O

Pax-5	B-DNA
encodes	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
and	O
is	O
expressed	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
developing	O
CNS	O
,	O
and	O
adult	O
testis	O
.	O

BSAP	B-protein
has	O
been	O
identified	O
previously	O
as	O
a	O
transcription	B-protein
factor	I-protein
that	O
is	O
expressed	O
at	O
early	O
,	O
but	O
not	O
late	O
,	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

Biochemical	O
purification	O
and	O
cDNA	O
cloning	O
has	O
now	O
revealed	O
that	O
BSAP	B-protein
belongs	O
to	O
the	O
family	O
of	O
paired	B-protein
domain	I-protein
proteins	I-protein
.	O

BSAP	B-protein
is	O
encoded	O
by	O
the	O
Pax-5	B-DNA
gene	I-DNA
and	O
has	O
been	O
highly	O
conserved	O
between	O
human	O
and	O
mouse	O
.	O

An	O
intact	O
paired	O
domain	O
was	O
shown	O
to	O
be	O
both	O
necessary	O
and	O
sufficient	O
for	O
DNA	O
binding	O
of	O
BSAP	B-protein
.	O

Binding	O
studies	O
with	O
several	O
BSAP	B-DNA
recognition	I-DNA
sequences	I-DNA
demonstrated	O
that	O
the	O
sequence	O
specificity	O
of	O
BSAP	B-protein
differs	O
from	O
that	O
of	O
the	O
distantly	O
related	O
paired	B-protein
domain	I-protein
protein	I-protein
Pax-1	I-protein
.	O

During	O
embryogenesis	O
,	O
the	O
BSAP	B-DNA
gene	I-DNA
is	O
transiently	O
expressed	O
in	O
the	O
mesencephalon	O
and	O
spinal	O
cord	O
with	O
a	O
spatial	O
and	O
temporal	O
expression	O
pattern	O
that	O
is	O
distinct	O
from	O
that	O
of	O
other	O
Pax	B-DNA
genes	I-DNA
in	O
the	O
developing	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Later	O
,	O
the	O
expression	O
of	O
the	O
BSAP	B-DNA
gene	I-DNA
shifts	O
to	O
the	O
fetal	O
liver	O
where	O
it	O
correlates	O
with	O
the	O
onset	O
of	O
B	O
lymphopoiesis	O
.	O

BSAP	B-protein
expression	O
persists	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
is	O
also	O
seen	O
in	O
the	O
testis	O
of	O
the	O
adult	O
mouse	O
.	O

All	O
of	O
this	O
evidence	O
indicates	O
that	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
may	O
not	O
only	O
play	O
an	O
important	O
role	O
in	O
B-cell	O
differentiation	O
but	O
also	O
in	O
neural	O
development	O
and	O
spermatogenesis	O
.	O

Cell	O
cycle-dependent	O
initiation	O
and	O
lineage-dependent	O
abrogation	O
of	O
GATA-1	B-protein
expression	O
in	O
pure	B-cell_type
differentiating	I-cell_type
hematopoietic	I-cell_type
progenitors	I-cell_type
.	O

The	O
programmed	O
activation/repression	O
of	O
transcription	B-protein
factors	I-protein
in	O
early	O
hematopoietic	O
differentiation	O
has	O
not	O
yet	O
been	O
explored	O
.	O

The	O
DNA-binding	B-protein
protein	I-protein
GATA-1	B-protein
is	O
required	O
for	O
normal	O
erythroid	O
development	O
and	O
regulates	O
erythroid-expressed	B-DNA
genes	I-DNA
in	O
maturing	B-cell_type
erythroblasts	I-cell_type
.	O

We	O
analyzed	O
GATA-1	B-protein
expression	O
in	O
early	O
human	O
adult	O
hematopoiesis	O
by	O
using	O
an	O
in	O
vitro	O
system	O
in	O
which	O
``	O
pure	O
''	O
early	B-cell_type
hematopoietic	I-cell_type
progenitors	I-cell_type
are	O
induced	O
to	O
gradual	O
and	O
synchronized	O
differentiation	O
selectively	O
along	O
the	O
erythroid	O
or	O
granulocyte-macrophage	O
pathway	O
by	O
differential	O
treatment	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

The	O
GATA-1	B-DNA
gene	I-DNA
,	O
though	O
virtually	O
silent	O
in	O
quiescent	B-cell_type
progenitors	I-cell_type
,	O
is	O
activated	O
after	O
entrance	O
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

Subsequently	O
,	O
increasing	O
expression	O
along	O
the	O
erythroid	O
pathway	O
contrasts	O
with	O
an	O
abrupt	O
downregulation	O
in	O
the	O
granulocyte-macrophage	B-cell_type
lineage	I-cell_type
.	O

These	O
results	O
suggest	O
a	O
microenvironment-directed	O
,	O
two-step	O
model	O
for	O
GATA-1	B-protein
expression	O
in	O
differentiating	B-cell_type
hematopoietic	I-cell_type
progenitors	I-cell_type
that	O
involves	O
(	O
i	O
)	O
cycle-dependent	O
initiation	O
and	O
(	O
ii	O
)	O
lineage-dependent	O
maintenance	O
or	O
suppression	O
.	O

Hypothetically	O
,	O
on/off	O
switches	O
of	O
lineage-restricted	B-protein
transactivators	I-protein
may	O
underlie	O
the	O
binary	O
fate	O
decisions	O
of	O
hematopoietic	B-cell_type
progenitors	I-cell_type
.	O

Specific	O
NF-kappa	B-protein
B	I-protein
subunits	I-protein
act	O
in	O
concert	O
with	O
Tat	B-protein
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
protein	B-protein
complex	I-protein
which	O
functions	O
in	O
concert	O
with	O
the	O
tat-I	B-protein
gene	I-protein
product	I-protein
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O

To	O
determine	O
whether	O
specific	O
members	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
family	I-protein
contribute	O
to	O
this	O
effect	O
,	O
we	O
have	O
examined	O
the	O
abilities	O
of	O
different	O
NF-kappa	B-protein
B	I-protein
subunits	I-protein
to	O
act	O
with	O
Tat-I	B-protein
to	O
stimulate	O
transcription	O
of	O
HIV	O
in	O
Jurkat	B-cell_type
T-leukemia	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
found	O
that	O
the	O
p49	B-protein
(	I-protein
100	I-protein
)	I-protein
DNA	I-protein
binding	I-protein
subunit	I-protein
,	O
together	O
with	O
p65	B-protein
,	O
can	O
act	O
in	O
concert	O
with	O
Tat-I	B-protein
to	O
stimulate	O
the	O
expression	O
of	O
HIV-CAT	B-DNA
plasmid	I-DNA
.	O

Little	O
effect	O
was	O
observed	O
with	O
50-kDa	B-protein
forms	I-protein
of	O
p105	B-protein
NF-kappa	B-protein
B	I-protein
or	O
rel	B-protein
,	O
in	O
combination	O
with	O
p65	B-protein
or	O
full-length	B-protein
c-rel	I-protein
,	O
which	O
do	O
not	O
stimulate	O
the	O
HIV	B-DNA
enhancer	I-DNA
in	O
these	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
combination	O
of	O
p49	B-protein
(	I-protein
100	I-protein
)	I-protein
and	O
p65	B-protein
NF-kappa	B-protein
B	I-protein
can	O
act	O
in	O
concert	O
with	O
the	O
tat-I	B-protein
gene	I-protein
product	I-protein
to	O
stimulate	O
the	O
synthesis	O
of	O
HIV	B-RNA
RNA	I-RNA
.	O

Stable	O
expression	O
of	O
HB24	B-DNA
,	O
a	O
diverged	B-DNA
human	I-DNA
homeobox	I-DNA
gene	I-DNA
,	O
in	O
T	O
lymphocytes	O
induces	O
genes	O
involved	O
in	O
T	O
cell	O
activation	O
and	O
growth	O
.	O

A	O
diverged	B-DNA
homeobox	I-DNA
gene	I-DNA
,	O
HB24	B-DNA
,	O
which	O
is	O
known	O
to	O
be	O
induced	O
following	O
lymphocyte	O
activation	O
,	O
was	O
introduced	O
into	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
under	O
the	O
control	O
of	O
a	O
constitutive	B-DNA
promoter	I-DNA
.	O

Stable	O
transfectants	O
of	O
HB24	B-DNA
were	O
established	O
that	O
expressed	O
high	O
levels	O
of	O
HB24	B-RNA
mRNA	I-RNA
and	O
possessed	O
an	O
altered	O
phenotype	O
suggestive	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

A	O
number	O
of	O
genes	O
known	O
to	O
be	O
induced	O
following	O
T	O
cell	O
activation	O
and	O
associated	O
with	O
cell	O
growth	O
were	O
increased	O
in	O
the	O
transfectants	B-cell_line
,	O
including	O
c-fos	B-DNA
,	O
c-myc	B-DNA
,	O
c-myb	B-DNA
,	O
HLA-DR	B-DNA
,	O
lck	B-DNA
,	O
NF-kappa	B-protein
B	I-protein
,	O
interleukin-2	B-DNA
and	O
interleukin-2	B-DNA
receptor	I-DNA
alpha	I-DNA
(	O
IL-2R	B-DNA
alpha	I-DNA
)	O
.	O

Analysis	O
of	O
IL-2R	B-protein
alpha	I-protein
expression	O
by	O
transient	O
transfection	O
of	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
constructs	I-DNA
into	O
the	O
HB24	B-cell_line
transfectants	I-cell_line
revealed	O
constitutive	O
expression	O
(	O
about	O
60	O
%	O
of	O
phytohemagglutinin-	B-cell_line
and	I-cell_line
phorbol	I-cell_line
ester-activated	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
)	O
that	O
was	O
dependent	O
on	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
in	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Furthermore	O
,	O
as	O
a	O
consequence	O
of	O
the	O
increased	O
HB24	B-RNA
mRNA	I-RNA
levels	O
,	O
the	O
Jurkat	B-cell_line
HB24	I-cell_line
transfectants	I-cell_line
proliferated	O
more	O
rapidly	O
than	O
control	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Thus	O
,	O
stable	O
expression	O
of	O
HB24	B-DNA
confers	O
an	O
activation	O
phenotype	O
on	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
implicating	O
this	O
gene	O
as	O
an	O
important	O
transcriptional	B-protein
factor	I-protein
during	O
T	O
cell	O
activation	O
and	O
growth	O
.	O

Functional	O
interaction	O
between	O
the	O
two	O
zinc	B-protein
finger	I-protein
domains	I-protein
of	O
the	O
v-erb	B-protein
A	I-protein
oncoprotein	I-protein
.	O

The	O
v-erb	B-DNA
A	I-DNA
oncogene	I-DNA
of	O
avian	O
erythroblastosis	O
virus	O
is	O
a	O
mutated	O
and	O
virally	O
transduced	O
copy	O
of	O
a	O
host	B-DNA
cell	I-DNA
gene	I-DNA
encoding	O
a	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
.	O

The	O
protein	O
expressed	O
by	O
the	O
v-erb	B-DNA
A	I-DNA
oncogene	I-DNA
binds	O
to	O
DNA	O
and	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
both	O
the	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
and	O
the	O
closely	O
related	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
.	O

The	O
v-erb	B-protein
A	I-protein
protein	I-protein
has	O
sustained	O
two	O
amino	O
acid	O
alterations	O
within	O
its	O
DNA-binding	B-protein
domain	I-protein
relative	O
to	O
that	O
of	O
c-erb	B-protein
A	I-protein
,	O
one	O
of	O
which	O
,	O
at	O
serine	O
61	O
,	O
is	O
known	O
to	O
be	O
important	O
for	O
v-erb	B-protein
A	I-protein
function	O
in	O
the	O
neoplastic	B-cell_type
cell	I-cell_type
.	O

We	O
report	O
here	O
that	O
the	O
second	O
alteration	O
,	O
at	O
threonine	O
78	O
,	O
also	O
plays	O
an	O
important	O
,	O
although	O
more	O
indirect	O
,	O
role	O
:	O
alteration	O
of	O
the	O
sequence	O
at	O
threonine	O
78	O
such	O
that	O
it	O
resembles	O
that	O
of	O
c-erb	B-protein
A	I-protein
can	O
act	O
as	O
an	O
intragenic	O
suppressor	O
and	O
can	O
partially	O
restore	O
function	O
to	O
a	O
v-erb	B-protein
A	I-protein
protein	I-protein
rendered	O
defective	O
due	O
to	O
a	O
mutation	O
at	O
position	B-protein
61	I-protein
.	O

Threonine	O
78	O
lies	O
within	O
the	O
D-box	B-protein
of	O
the	O
v-erb	B-protein
A	I-protein
protein	I-protein
,	O
a	O
region	O
thought	O
to	O
mediate	O
receptor-receptor	O
dimerizations	O
,	O
and	O
is	O
not	O
in	O
physical	O
proximity	O
to	O
the	O
serine	O
at	O
position	B-protein
61	I-protein
.	O

It	O
therefore	O
appears	O
that	O
an	O
indirect	O
interaction	O
occurs	O
between	O
these	O
two	O
sites	O
and	O
that	O
this	O
interaction	O
is	O
crucial	O
for	O
v-erb	B-protein
A	I-protein
function	O
.	O

cis-acting	B-DNA
sequences	I-DNA
required	O
for	O
inducible	O
interleukin-2	B-DNA
enhancer	I-DNA
function	O
bind	O
a	O
novel	O
Ets-related	B-protein
protein	I-protein
,	O
Elf-1	B-protein
.	O

The	O
recent	O
definition	O
of	O
a	O
consensus	O
DNA	B-DNA
binding	I-DNA
sequence	I-DNA
for	O
the	O
Ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
has	O
allowed	O
the	O
identification	O
of	O
potential	O
Ets	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
promoters	B-DNA
and	O
enhancers	B-DNA
of	O
many	O
inducible	B-DNA
T-cell	I-DNA
genes	I-DNA
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
have	O
identified	O
two	O
potential	O
Ets	B-DNA
binding	I-DNA
sites	I-DNA
,	O
EBS1	O
and	O
EBS2	B-DNA
,	O
which	O
are	O
conserved	O
in	O
both	O
the	O
human	B-DNA
and	I-DNA
murine	I-DNA
interleukin-2	I-DNA
enhancers	I-DNA
.	O

Within	O
the	O
human	B-DNA
enhancer	I-DNA
,	O
these	O
two	O
sites	O
are	O
located	O
within	O
the	O
previously	O
defined	O
DNase	B-protein
I	I-protein
footprints	O
,	O
NFAT-1	B-DNA
and	O
NFIL-2B	B-DNA
,	O
respectively	O
.	O

Electrophoretic	O
mobility	O
shift	O
and	O
methylation	O
interference	O
analyses	O
demonstrated	O
that	O
EBS1	O
and	O
EBS2	B-DNA
are	O
essential	O
for	O
the	O
formation	O
of	O
the	O
NFAT-1	B-protein
and	I-protein
NFIL-2B	I-protein
nuclear	I-protein
protein	I-protein
complexes	I-protein
.	O

Furthermore	O
,	O
in	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
inducible	O
interleukin-2	B-DNA
enhancer	I-DNA
function	O
requires	O
the	O
presence	O
of	O
either	O
EBS1	O
or	O
EBS2	B-DNA
.	O

Two	O
well-characterized	O
Ets	B-protein
family	I-protein
members	I-protein
,	O
Ets-1	B-protein
and	O
Ets-2	B-protein
,	O
are	O
reciprocally	O
expressed	O
during	O
T-cell	O
activation	O
.	O

Surprisingly	O
,	O
however	O
,	O
neither	O
of	O
these	O
proteins	O
bound	O
in	O
vitro	O
to	O
EBS1	O
or	O
EBS2	B-DNA
.	O

We	O
therefore	O
screened	O
a	O
T-cell	B-DNA
cDNA	I-DNA
library	O
under	O
low-stringency	O
conditions	O
with	O
a	O
probe	O
from	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
Ets-1	B-protein
and	O
isolated	O
a	O
novel	B-protein
Ets	I-protein
family	I-protein
member	I-protein
,	O
Elf-1	B-protein
.	O

Elf-1	B-protein
contains	O
a	O
DNA	B-protein
binding	I-protein
domain	I-protein
that	O
is	O
nearly	O
identical	O
to	O
that	O
of	O
E74	B-protein
,	O
the	O
ecdysone-inducible	B-protein
Drosophila	I-protein
transcription	I-protein
factor	I-protein
required	O
for	O
metamorphosis	O
(	O
hence	O
the	O
name	O
Elf-1	B-protein
,	O
for	O
E74-like	B-protein
factor	I-protein
1	I-protein
)	O
.	O

Elf-1	B-protein
bound	O
specifically	O
to	O
both	O
EBS1	O
and	O
EBS2	B-DNA
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

It	O
also	O
bound	O
to	O
the	O
purine-rich	B-DNA
CD3R	I-DNA
element	I-DNA
from	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
which	O
is	O
required	O
for	O
inducible	O
virus	O
expression	O
in	O
response	O
to	O
signalling	O
through	O
the	O
T-cell	B-protein
receptor	I-protein
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
multiple	B-protein
Ets	I-protein
family	I-protein
members	I-protein
with	O
apparently	O
distinct	O
DNA	O
binding	O
specificities	O
regulate	O
differential	O
gene	O
expression	O
in	O
resting	B-cell_type
and	I-cell_type
activated	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Binding	O
of	O
erythroid	B-protein
and	I-protein
non-erythroid	I-protein
nuclear	I-protein
proteins	I-protein
to	O
the	O
silencer	B-DNA
of	O
the	O
human	B-DNA
epsilon-globin-encoding	I-DNA
gene	I-DNA
.	O

To	O
clarify	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
developmental	O
control	O
of	O
hemoglobin-encoding	B-DNA
genes	I-DNA
we	O
have	O
been	O
studying	O
the	O
expression	O
of	O
these	O
genes	B-DNA
in	O
human	B-cell_type
cells	I-cell_type
in	O
continuous	O
culture	O
.	O

We	O
have	O
previously	O
reported	O
the	O
presence	O
of	O
a	O
transcriptional	B-DNA
control	I-DNA
element	I-DNA
with	O
the	O
properties	O
of	O
a	O
silencer	B-DNA
extending	O
from	O
-392	B-DNA
to	I-DNA
-177	I-DNA
bp	I-DNA
relative	O
to	O
the	O
cap	B-DNA
site	I-DNA
of	O
the	O
human	B-DNA
epsilon-globin-encoding	I-DNA
gene	I-DNA
[	O
Cao	O
et	O
al.	O
,	O
Proc.Natl.Acad.Sci.USA	O
86	O
(	O
1989	O
)	O
5306-5309	O
]	O
.	O

We	O
also	O
showed	O
that	O
this	O
silencer	B-DNA
has	O
stronger	O
inhibitory	O
activity	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
as	O
compared	O
to	O
K562	B-cell_line
human	I-cell_line
erythroleukemia	I-cell_line
cells	I-cell_line
.	O

Using	O
deletion	B-DNA
mutants	I-DNA
and	O
cis-cloned	O
synthetic	O
oligodeoxyribonucleotides	O
in	O
transient	O
expression	O
assays	O
,	O
nucleotide	O
sequences	O
responsible	O
for	O
this	O
effect	O
have	O
now	O
been	O
further	O
delimited	O
to	O
44	O
bp	O
located	O
from	O
-294	B-DNA
to	I-DNA
-251	I-DNA
bp	I-DNA
.	O

Gel	O
electrophoresis	O
mobility	O
shift	O
assays	O
and	O
DNaseI	B-protein
footprinting	O
assays	O
demonstrate	O
that	O
these	O
negative	O
regulatory	O
sequences	O
are	O
recognized	O
differently	O
by	O
proteins	O
present	O
in	O
nuclear	O
extracts	O
obtained	O
from	O
HeLa	B-cell_line
and	O
K562	B-cell_line
cells	I-cell_line
.	O

Two	O
binding	O
proteins	O
are	O
detected	O
in	O
K562	O
nuclear	O
extracts	O
,	O
while	O
only	O
one	O
is	O
found	O
in	O
extracts	O
from	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Possible	O
mechanisms	O
by	O
which	O
these	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
epsilon-globin-encoding	B-DNA
gene	I-DNA
in	O
erythroid	B-cell_type
and	I-cell_type
non-erythroid	I-cell_type
cells	I-cell_type
are	O
discussed	O
.	O

Calcitriol	O
:	O
a	O
hematolymphopoietrope	O
?	O
[	O
editorial	O
]	O

A	O
MEDLINE	O
search	O
of	O
the	O
English-language	O
literature	O
was	O
conducted	O
using	O
the	O
indexing	O
terms	O
'immunology	O
,	O
calcitriol	O
and	O
vitamin	O
D	O
'	O
to	O
identify	O
studies	O
indicating	O
a	O
role	O
for	O
calcitriol	O
as	O
a	O
primary	O
immunomodulator	O
.	O

Sixty-six	O
papers	O
published	O
between	O
January	O
1956	O
and	O
June	O
1991	O
were	O
identified	O
.	O

Forty-five	O
of	O
these	O
reports	O
are	O
cited	O
in	O
this	O
review	O
.	O

The	O
data	O
strongly	O
suggest	O
an	O
endocrine	O
,	O
autocrine	O
and/or	O
paracrine	O
role	O
for	O
calcitriol	O
in	O
immune	O
regulation	O
.	O

No	O
unifying	O
hypothesis	O
has	O
yet	O
emerged	O
explaining	O
this	O
collection	O
of	O
data	O
.	O

This	O
paper	O
provides	O
a	O
brief	O
review	O
of	O
immune	O
properties	O
currently	O
attributed	O
to	O
calcitriol	O
.	O

Transcription	O
of	O
the	O
hypersensitive	B-DNA
site	I-DNA
HS2	I-DNA
enhancer	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

In	O
the	O
human	B-DNA
genome	I-DNA
,	O
the	O
erythroid-specific	B-DNA
hypersensitive	I-DNA
site	I-DNA
HS2	I-DNA
enhancer	I-DNA
regulates	O
the	O
transcription	O
of	O
the	O
downstream	B-DNA
beta-like	I-DNA
globin	I-DNA
genes	I-DNA
10-50	B-DNA
kilobases	I-DNA
away	O
.	O

The	O
mechanism	O
of	O
HS2	B-DNA
enhancer	I-DNA
function	O
is	O
not	O
known	O
.	O

The	O
present	O
study	O
employs	O
RNA	O
protection	O
assays	O
to	O
analyze	O
the	O
transcriptional	O
status	O
of	O
the	O
HS2	B-DNA
enhancer	I-DNA
in	O
transfected	B-DNA
recombinant	I-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
plasmids	I-DNA
.	O

In	O
erythroid	B-cell_line
K562	I-cell_line
cells	I-cell_line
in	O
which	O
the	O
HS2	B-DNA
enhancer	I-DNA
is	O
active	O
,	O
the	O
HS2	B-DNA
sequence	I-DNA
directs	O
the	O
synthesis	O
of	O
long	O
enhancer	O
transcripts	O
that	O
are	O
initiated	O
apparently	O
from	O
within	O
the	O
enhancer	B-DNA
and	O
elongated	O
through	O
the	O
intervening	O
DNA	O
into	O
the	O
cis-linked	B-DNA
CAT	I-DNA
gene	I-DNA
.	O

In	O
nonerythroid	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
in	O
which	O
the	O
HS2	B-DNA
enhancer	I-DNA
is	O
inactive	O
,	O
long	B-RNA
enhancer	I-RNA
transcripts	I-RNA
are	O
not	O
detectable	O
.	O

Splitting	O
the	O
HS2	B-DNA
enhancer	I-DNA
between	O
two	O
tandem	B-DNA
Ap1	I-DNA
sites	I-DNA
abolishes	O
the	O
synthesis	O
of	O
a	O
group	O
of	O
long	B-RNA
enhancer	I-RNA
transcripts	I-RNA
and	O
results	O
in	O
loss	O
of	O
enhancer	O
function	O
and	O
transcriptional	O
silencing	O
of	O
the	O
cis-linked	O
CAT	O
gene	O
.	O

In	O
directing	O
the	O
synthesis	O
of	O
RNA	B-RNA
through	O
the	O
intervening	O
DNA	B-DNA
and	O
the	O
gene	O
by	O
a	O
tracking	O
and	O
transcription	O
mechanism	O
,	O
the	O
HS2	B-DNA
enhancer	I-DNA
may	O
(	O
i	O
)	O
open	O
up	O
the	O
chromatin	B-DNA
structure	I-DNA
of	O
a	O
gene	B-DNA
domain	I-DNA
and	O
(	O
ii	O
)	O
deliver	O
enhancer	B-protein
binding	I-protein
proteins	I-protein
to	O
the	O
promoter	O
sequence	O
where	O
they	O
may	O
stimulate	O
the	O
transcription	O
of	O
the	O
gene	O
at	O
the	O
cap	B-DNA
site	I-DNA
.	O

Characterization	O
of	O
a	O
novel	B-protein
T	I-protein
lymphocyte	I-protein
protein	I-protein
which	O
binds	O
to	O
a	O
site	O
related	O
to	O
steroid/thyroid	B-DNA
hormone	I-DNA
receptor	I-DNA
response	I-DNA
elements	I-DNA
in	O
the	O
negative	B-DNA
regulatory	I-DNA
sequence	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

We	O
have	O
previously	O
identified	O
a	O
T	B-protein
lymphocyte	I-protein
protein	I-protein
which	O
binds	O
to	O
a	O
site	O
within	O
the	O
LTR	B-DNA
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
virus	O
gene	O
expression	O
.	O

The	O
palindromic	B-DNA
site	I-DNA
(	O
site	B-DNA
B	I-DNA
)	O
recognized	O
by	O
this	O
protein	O
is	O
related	O
to	O
the	O
palindromic	B-DNA
binding	I-DNA
sites	I-DNA
of	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
family	I-protein
.	O

Here	O
we	O
characterize	O
the	O
T	B-protein
cell	I-protein
protein	I-protein
binding	O
to	O
this	O
site	O
as	O
a	O
100	O
kD	O
protein	O
which	O
is	O
most	O
abundant	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
which	O
binds	O
to	O
site	B-DNA
B	I-DNA
as	O
a	O
200	B-protein
kD	I-protein
complex	I-protein
.	O

This	O
protein	O
is	O
distinct	O
from	O
other	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
family	I-protein
including	O
the	O
COUP	B-protein
protein	I-protein
which	O
has	O
a	O
closely	O
related	O
DNA	O
binding	O
specificity	O
.	O

TAR	B-DNA
-independent	O
transactivation	O
by	O
Tat	B-protein
in	O
cells	O
derived	O
from	O
the	O
CNS	O
:	O
a	O
novel	O
mechanism	O
of	O
HIV-1	O
gene	O
regulation	O
.	O

The	O
Tat	B-protein
protein	I-protein
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
essential	O
for	O
productive	O
infection	O
and	O
is	O
a	O
potential	O
target	O
for	O
antiviral	O
therapy	O
.	O

Tat	B-protein
,	O
a	O
potent	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
,	O
serves	O
to	O
greatly	O
increase	O
the	O
rate	O
of	O
transcription	O
directed	O
by	O
the	O
viral	B-DNA
promoter	I-DNA
.	O

This	O
induction	O
,	O
which	O
seems	O
to	O
be	O
an	O
important	O
component	O
in	O
the	O
progression	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
,	O
may	O
be	O
due	O
to	O
increased	O
transcriptional	O
initiation	O
,	O
increased	O
transcriptional	O
elongation	O
,	O
or	O
a	O
combination	O
of	O
these	O
processes	O
.	O

Much	O
attention	O
has	O
been	O
focused	O
on	O
the	O
interaction	O
of	O
Tat	B-protein
with	O
a	O
specific	O
RNA	B-RNA
target	I-RNA
termed	O
TAR	B-RNA
(	O
transactivation	B-RNA
responsive	I-RNA
)	O
which	O
is	O
present	O
in	O
the	O
leader	O
sequence	O
of	O
all	O
HIV-1	B-RNA
mRNAs	I-RNA
.	O

This	O
interaction	O
is	O
believed	O
to	O
be	O
an	O
important	O
component	O
of	O
the	O
mechanism	O
of	O
transactivation	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
in	O
certain	O
CNS-derived	B-cell_line
cells	I-cell_line
Tat	B-protein
is	O
capable	O
of	O
activating	O
HIV-1	O
through	O
a	O
TAR	B-DNA
-independent	O
pathway	O
.	O

A	O
Tat-responsive	B-DNA
element	I-DNA
is	O
found	O
upstream	O
within	O
the	O
viral	B-DNA
promoter	I-DNA
that	O
in	O
glial-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	B-RNA
.	O

Deletion	O
mapping	O
and	O
hybrid	B-DNA
promoter	I-DNA
constructs	I-DNA
demonstrate	O
that	O
the	O
newly	O
identified	O
Tat-responsive	B-DNA
element	I-DNA
corresponds	O
to	O
a	O
sequence	O
within	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
previously	O
identified	O
as	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
,	O
or	O
NF-kappa	B-DNA
B	I-DNA
domain	I-DNA
.	O

DNA	O
band-shift	O
analysis	O
reveals	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
glial	O
cells	O
that	O
differs	O
from	O
that	O
present	O
in	O
T	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

Further	O
,	O
we	O
observe	O
that	O
TAR-deleted	B-DNA
mutants	I-DNA
of	O
HIV-1	O
demonstrate	O
normal	O
late	O
gene	O
expression	O
in	O
glial	B-cell_type
cells	I-cell_type
as	O
evidenced	O
by	O
syncytia	O
formation	O
and	O
production	O
of	O
viral	B-protein
p24	I-protein
antigen	I-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Transcription	B-protein
factor	I-protein
AP-2	I-protein
activates	O
gene	O
expression	O
of	O
HTLV-I	O
.	O

The	O
HTLV-I	B-DNA
LTR	I-DNA
contains	O
three	O
conserved	O
regulatory	B-DNA
elements	I-DNA
known	O
as	O
21	B-DNA
base	I-DNA
pair	I-DNA
repeats	I-DNA
which	O
are	O
required	O
for	O
stimulation	O
of	O
gene	O
expression	O
by	O
the	O
transactivator	B-protein
protein	I-protein
tax	B-protein
.	O

Mutagenesis	O
indicates	O
that	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
can	O
be	O
subdivided	O
into	O
three	O
motifs	O
,	O
A	O
,	O
B	O
and	O
C	O
,	O
each	O
of	O
which	O
influences	O
the	O
level	O
of	O
tax	B-protein
activation	O
.	O

The	O
A	B-DNA
site	I-DNA
in	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
has	O
strong	O
homology	O
with	O
previously	O
described	O
binding	B-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
AP-2	I-protein
.	O

We	O
demonstrated	O
that	O
AP-2	B-RNA
mRNA	I-RNA
was	O
present	O
in	O
T-lymphocytes	B-cell_type
and	O
that	O
cellular	O
factors	O
from	O
both	O
non-transformed	O
and	O
transformed	O
T-lymphocytes	B-cell_type
specifically	O
bound	O
to	O
the	O
consensus	B-DNA
motif	I-DNA
for	O
AP-2	B-protein
in	O
each	O
21	O
bp	O
.	O

To	O
determine	O
the	O
role	O
of	O
AP-2	B-protein
in	O
the	O
regulation	O
of	O
the	O
HTLV-I	B-DNA
LTR	I-DNA
gene	O
expression	O
,	O
we	O
used	O
an	O
AP-2	B-DNA
cDNA	I-DNA
in	O
DNA	O
binding	O
and	O
transient	O
expression	O
assays	O
.	O

Gel	O
retardation	O
and	O
methylation	O
interference	O
studies	O
revealed	O
that	O
bacterially	B-protein
produced	I-protein
AP-2	I-protein
bound	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
all	O
three	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
,	O
and	O
that	O
it	O
required	O
the	O
core	B-DNA
sequence	I-DNA
AGGC	O
for	O
specific	O
binding	O
.	O

Binding	O
of	O
AP-2	B-protein
prevented	O
the	O
subsequent	O
binding	O
of	O
members	O
of	O
the	O
CREB/ATF	B-protein
family	I-protein
to	O
an	O
adjacent	B-DNA
regulatory	I-DNA
motif	I-DNA
in	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
.	O

Transfection	O
of	O
an	O
AP-2	B-DNA
expression	I-DNA
construct	I-DNA
into	O
T-lymphocytes	B-cell_type
activated	O
gene	O
expression	O
from	O
the	O
HTLV-I	B-DNA
LTR	I-DNA
.	O

At	O
least	O
two	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
were	O
required	O
for	O
high	O
levels	O
of	O
AP-2	B-protein
activation	O
and	O
mutagenesis	O
of	O
the	O
AP-2	B-DNA
consensus	I-DNA
binding	I-DNA
sequences	I-DNA
in	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
eliminate	O
this	O
activation	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Activation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
enhancer	I-DNA
is	O
not	O
dependent	O
on	O
NFAT-1	B-protein
.	O

The	O
function	O
of	O
a	O
putative	B-DNA
NFAT-1	I-DNA
site	I-DNA
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
enhancer	I-DNA
has	O
been	O
analyzed	O
.	O

Activation	O
by	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
is	O
minimal	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
and	O
is	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O

The	O
putative	B-DNA
NFAT-1	I-DNA
region	I-DNA
is	O
not	O
required	O
for	O
the	O
response	O
to	O
anti-CD3	B-protein
or	O
to	O
mitogens	B-protein
in	O
T-cell	B-cell_line
,	O
B-cell	B-cell_line
,	O
or	O
monocyte/macrophage	B-cell_line
leukemia	I-cell_line
lines	I-cell_line
,	O
nor	O
is	O
it	O
a	O
cis-acting	B-DNA
negative	I-DNA
regulatory	I-DNA
element	I-DNA
.	O

The	O
B	B-protein
cell-specific	I-protein
nuclear	I-protein
factor	I-protein
OTF-2	B-protein
positively	O
regulates	O
transcription	O
of	O
the	O
human	B-DNA
class	I-DNA
II	I-DNA
transplantation	I-DNA
gene	I-DNA
,	O
DRA	B-DNA
.	O

The	O
promoter	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
DRA	B-DNA
contains	O
an	O
octamer	B-DNA
element	I-DNA
(	O
ATTTGCAT	O
)	O
that	O
is	O
required	O
for	O
efficient	O
DRA	B-DNA
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Several	O
DNA-binding	B-protein
proteins	I-protein
are	O
known	O
to	O
bind	O
this	O
sequence	O
.	O

The	O
best	O
characterized	O
are	O
the	O
B	B-protein
cell-specific	I-protein
OTF-2	I-protein
and	O
the	O
ubiquitous	O
OTF-1	B-protein
.	O

This	O
report	O
directly	O
demonstrates	O
that	O
OTF-2	B-protein
but	O
not	O
OTF-1	B-protein
regulates	O
the	O
DRA	B-DNA
gene	I-DNA
.	O

In	O
vitro	O
transcription	O
analysis	O
using	O
protein	O
fractions	O
enriched	O
for	O
the	O
octamer-binding	O
protein	O
OTF-2	B-protein
demonstrate	O
a	O
positive	O
functional	O
role	O
for	O
OTF-2	B-protein
in	O
DRA	B-DNA
gene	I-DNA
transcription	O
.	O

In	O
contrast	O
,	O
OTF-1	B-protein
-enriched	O
protein	O
fractions	O
did	O
not	O
affect	O
DRA	B-DNA
gene	I-DNA
transcription	O
although	O
it	O
functionally	O
enhanced	O
the	O
transcription	O
of	O
another	O
gene	O
.	O

Recombinant	B-protein
OTF-2	I-protein
protein	I-protein
produced	O
by	O
in	O
vitro	O
transcription/translation	O
could	O
also	O
enhance	O
DRA	B-DNA
gene	I-DNA
transcription	O
in	O
vitro	O
.	O

In	O
vivo	O
transient	O
transfection	O
studies	O
utilizing	O
an	O
OTF-2	B-DNA
expression	I-DNA
vector	I-DNA
resulted	O
in	O
similar	O
findings	O
:	O
that	O
OTF-2	B-protein
protein	I-protein
enhanced	O
DRA	B-DNA
gene	I-DNA
transcription	O
,	O
and	O
that	O
this	O
effect	O
requires	O
an	O
intact	O
octamer	B-DNA
element	I-DNA
.	O

Together	O
these	O
results	O
constitute	O
the	O
first	O
direct	O
evidence	O
of	O
a	O
positive	O
role	O
for	O
the	O
lymphoid-specific	B-protein
octamer-binding	I-protein
factor	I-protein
in	O
DRA	O
gene	O
transcription	O
.	O

Interferon-gamma	B-protein
potentiates	O
the	O
antiviral	O
activity	O
and	O
the	O
expression	O
of	O
interferon-stimulated	B-DNA
genes	I-DNA
induced	O
by	O
interferon-alpha	B-cell_line
in	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

Binding	O
of	O
type	B-protein
I	I-protein
interferon	I-protein
(	I-protein
IFN-alpha/beta	I-protein
)	I-protein
to	I-protein
specific	I-protein
receptors	I-protein
results	O
in	O
the	O
rapid	O
transcriptional	O
activation	O
,	O
independent	O
of	O
protein	O
synthesis	O
,	O
of	O
IFN-alpha-stimulated	B-DNA
genes	I-DNA
(	O
ISGs	B-DNA
)	O
in	O
human	B-cell_type
fibroblasts	I-cell_type
and	O
HeLa	B-cell_line
and	O
Daudi	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
binding	O
of	O
ISGF3	B-protein
(	O
IFN-stimulated	B-protein
gene	I-protein
factor	I-protein
3	I-protein
)	O
to	O
the	O
conserved	O
IFN-stimulated	B-DNA
response	I-DNA
element	I-DNA
(	O
ISRE	B-DNA
)	O
results	O
in	O
transcriptional	O
activation	O
.	O

This	O
factor	O
is	O
composed	O
of	O
a	O
DNA-binding	B-protein
protein	I-protein
(	O
ISGF3	B-protein
gamma	I-protein
)	O
,	O
which	O
normally	O
is	O
present	O
in	O
the	O
cytoplasm	O
,	O
and	O
other	O
IFN-alpha-activated	B-protein
proteins	I-protein
which	O
preexist	O
as	O
latent	B-protein
cytoplasmic	I-protein
precursors	I-protein
(	O
ISGF3	B-protein
alpha	I-protein
)	O
.	O

We	O
have	O
found	O
that	O
ISG	O
expression	O
in	O
the	O
monocytic	B-cell_line
U937	I-cell_line
cell	I-cell_line
line	I-cell_line
differs	O
from	O
most	O
cell	B-cell_line
lines	I-cell_line
previously	O
examined	O
.	O

U937	B-cell_line
cells	I-cell_line
express	O
both	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IFN	I-protein
receptors	I-protein
,	O
but	O
only	O
IFN-alpha	B-protein
is	O
capable	O
of	O
inducing	O
antiviral	O
protection	O
in	O
these	O
cells	O
.	O

Pretreatment	O
with	O
IFN-gamma	B-protein
potentiates	O
the	O
IFN-alpha	B-protein
-induced	O
protection	O
,	O
but	O
IFN-gamma	B-protein
alone	O
does	O
not	O
have	O
any	O
antiviral	O
activity	O
.	O

ISG15	B-RNA
mRNA	I-RNA
accumulation	O
in	O
U937	B-cell_line
cells	I-cell_line
is	O
not	O
detectable	O
before	O
6	O
h	O
of	O
IFN-alpha	B-protein
treatment	O
,	O
peaks	O
at	O
24	O
h	O
,	O
and	O
requires	O
protein	O
synthesis	O
.	O

Although	O
IFN-gamma	B-protein
alone	O
does	O
not	O
induce	O
ISG	O
expression	O
,	O
IFN-gamma	B-protein
pretreatment	O
markedly	O
increases	O
and	O
hastens	O
ISG	O
expression	O
and	O
transcriptional	O
induction	O
.	O

Nuclear	O
extracts	O
assayed	O
for	O
the	O
presence	O
of	O
ISRE	B-protein
binding	I-protein
factors	I-protein
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
ISGF3	B-protein
is	O
induced	O
by	O
IFN-alpha	B-protein
within	O
6	O
h	O
from	O
undetectable	O
basal	O
levels	O
in	O
untreated	O
U937	B-cell_line
cells	I-cell_line
.	O

Activation	O
of	O
ISGF3	B-protein
alpha	I-protein
,	O
the	O
latent	O
component	O
of	O
ISGF3	B-protein
,	O
occurs	O
rapidly	O
.	O

However	O
,	O
the	O
increase	O
in	O
ISGF3	B-protein
activity	O
ultimately	O
correlates	O
with	O
the	O
accumulation	O
of	O
ISGF3	B-protein
gamma	I-protein
induced	O
by	O
IFN-alpha	B-protein
or	O
IFN-gamma	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Single	O
point	O
estimation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
normal	O
subjects	O
and	O
of	O
children	O
under	O
long	O
term	O
glucocorticoid	O
treatment	O
.	O

A	O
single	O
point	O
assay	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
human	O
lymphocytes	B-cell_type
based	O
on	O
the	O
measurement	O
of	O
specific	O
dexamethasone	O
binding	O
has	O
been	O
developed	O
and	O
compared	O
with	O
a	O
common	O
multi-point	O
Scatchard	O
analysis	O
.	O

The	O
assay	O
conditions-concentration	O
of	O
the	O
ligand	O
20	O
nmol/l	O
,	O
incubation	O
time	O
2	O
h	O
and	O
the	O
cell	O
count	O
2-6	O
mil	O
.	O

cells/tube	O
in	O
the	O
assay	O
volume	O
0.25	O
ml	O
were	O
found	O
to	O
be	O
optimal	O
.	O

An	O
attempt	O
was	O
also	O
undertaken	O
to	O
use	O
a	O
cell	O
harvester	O
for	O
the	O
separation	O
of	O
cells	O
from	O
unbound	O
ligand	O
.	O

Though	O
specifically	O
bound	O
dexamethasone	O
measured	O
by	O
whole-cell	O
assay	O
and	O
that	O
using	O
cell	O
harvester	O
correlated	O
well	O
,	O
almost	O
by	O
one	O
order	O
lower	O
values	O
obtained	O
with	O
the	O
latter	O
method	O
render	O
it	O
non-applicable	O
for	O
receptor	O
quantitation	O
.	O

The	O
results	O
from	O
9	O
healthy	O
volunteers	O
(	O
average	O
GR	B-protein
concentration	O
7131	O
+/-	O
1256	O
sites/cell	O
)	O
correlated	O
excellently	O
with	O
those	O
obtained	O
by	O
the	O
Scatchard	O
analysis	O
.	O

The	O
single	O
point	O
assay	O
has	O
been	O
also	O
applied	O
for	O
determination	O
of	O
GH	O
in	O
10	O
children	O
treated	O
with	O
large	O
doses	O
of	O
prednisone	O
.	O

The	O
average	O
values	O
from	O
healthy	O
volunteers	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
found	O
in	O
these	O
children	O
,	O
though	O
much	O
broader	O
range	O
was	O
found	O
in	O
patients	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
and	O
inhibition	O
of	O
3-O-methyl-D-glucose	O
uptake	O
by	O
glucocorticoids	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
from	O
normal	O
humans	O
:	O
correlation	O
between	O
receptor	O
level	O
and	O
hormone	O
effect	O
in	O
vitro	O
.	O

We	O
have	O
measured	O
the	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
in	O
mononuclear	B-cell_type
and	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
,	O
both	O
of	O
which	O
were	O
isolated	O
from	O
peripheral	O
blood	O
from	O
ten	O
healthy	O
male	O
volunteers	O
.	O

In	O
parallel	O
,	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	O
on	O
3-O-methyl-D-glucose	O
uptake	O
was	O
assayed	O
in	O
the	O
corresponding	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O

The	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
correlated	O
with	O
those	O
in	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
,	O
and	O
there	O
was	O
a	O
linear	O
relationship	O
between	O
the	O
cellular	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
and	O
glucocorticoid-mediated	O
inhibition	O
of	O
the	O
uptake	O
of	O
3-O-methyl-D-glucose	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O

When	O
mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
incubated	O
in	O
the	O
presence	O
of	O
8-bromo-cAMP	O
,	O
cellular	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
increased	O
and	O
a	O
more	O
pronounced	O
inhibitory	O
effect	O
of	O
dexamethasone	O
was	O
observed	O
on	O
the	O
transport	O
of	O
3-O-methyl-D-glucose	O
.	O

We	O
conclude	O
that	O
the	O
cellular	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
reflect	O
in	O
vitro	O
responsiveness	O
to	O
glucocorticoids	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
from	O
healthy	O
males	O
,	O
and	O
that	O
the	O
individual	O
responsiveness	O
may	O
alter	O
upon	O
changes	O
in	O
the	O
cellular	O
levels	O
of	O
glucocorticoid	B-protein
receptor	I-protein
.	O

Transcription	B-protein
factor	I-protein
activation	O
and	O
functional	O
stimulation	O
of	O
human	B-cell_type
monocytes	I-cell_type
.	O

Activation	O
of	O
expression	O
of	O
genes	B-DNA
encoding	O
transcription	B-protein
factors	I-protein
:	O
c-fos	B-DNA
and	O
c-jun	B-DNA
and	O
formation	O
of	O
AP1	B-protein
transcriptional	I-protein
complex	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
was	O
investigated	O
.	O

It	O
was	O
found	O
that	O
lipopolysaccharide	O
induced	O
strongly	O
both	O
c-fos	B-DNA
and	O
c-jun	B-DNA
expression	O
as	O
well	O
as	O
AP1	B-protein
formation	O
.	O

Interferon	B-protein
gamma	I-protein
activated	O
strongly	O
c-fos	B-DNA
and	O
weakly	O
c-jun	B-DNA
and	O
AP1	B-protein
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
induced	O
slightly	O
c-fos	B-DNA
and	O
had	O
almost	O
no	O
effect	O
on	O
c-jun	B-DNA
and	O
AP1	B-protein
.	O

The	O
data	O
suggest	O
that	O
differences	O
in	O
functional	O
responses	O
elicited	O
in	O
monocytes	B-cell_type
by	O
all	O
three	O
factors	B-protein
may	O
be	O
dependent	O
on	O
different	O
routes	O
on	O
nuclear	O
signalling	O
employed	O
by	O
the	O
factors	B-protein
.	O

Regulation	O
of	O
interleukin-1	B-protein
beta	I-protein
production	O
by	O
glucocorticoids	O
in	O
human	B-cell_type
monocytes	I-cell_type
:	O
the	O
mechanism	O
of	O
action	O
depends	O
on	O
the	O
activation	O
signal	O
.	O

Glucocorticoids	O
are	O
known	O
to	O
downregulate	O
interleukin-1	B-protein
beta	I-protein
production	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
two	O
different	O
mechanims	O
:	O
direct	O
inhibition	O
of	O
the	O
gene	O
transcription	O
and	O
destabilization	O
of	O
the	O
preformed	O
interleukin-1	B-RNA
beta	I-RNA
mRNA	I-RNA
.	O

Now	O
we	O
have	O
examined	O
the	O
effect	O
of	O
the	O
nature	O
of	O
the	O
monocyte	O
activating	O
signal	O
on	O
these	O
two	O
inhibitory	O
mechanims	O
.	O

When	O
human	B-cell_type
monocytes	I-cell_type
were	O
preincubated	O
with	O
dexamethasone	O
for	O
1	O
hour	O
and	O
then	O
stimulated	O
either	O
with	O
bacterial	O
lipopolysaccharide	O
or	O
phorbol	O
myristate	O
,	O
it	O
was	O
found	O
that	O
dexamethasone	O
inhibited	O
the	O
lipopolysaccharide-induced	O
interleukin-1	B-protein
beta	I-protein
protein	O
production	O
,	O
but	O
the	O
phorbol	O
myristate-induced	O
production	O
was	O
increased	O
3-10	O
fold	O
.	O

This	O
difference	O
was	O
also	O
seen	O
at	O
the	O
mRNA	O
level	O
.	O

When	O
dexamethasone	O
was	O
added	O
to	O
the	O
cultures	O
3	O
hours	O
after	O
the	O
stimulators	O
,	O
it	O
clearly	O
decreased	O
the	O
interleukin-1	B-RNA
beta	I-RNA
mRNA	I-RNA
levels	O
regardless	O
of	O
the	O
stimulator	O
used	O
(	O
although	O
the	O
effect	O
was	O
clearly	O
weaker	O
on	O
the	O
PMA-induced	B-RNA
mRNA	I-RNA
)	O
.	O

Thus	O
these	O
data	O
suggest	O
that	O
the	O
phorbol	O
myristate-induced	O
signal	O
(	O
prolonged	O
protein	B-protein
kinase	I-protein
C	I-protein
activation	O
?	O
)	O
can	O
not	O
be	O
inhibited	O
by	O
prior	O
incubation	O
with	O
dexamethasone	O
and	O
it	O
also	O
protects	O
the	O
induced	B-RNA
mRNA	I-RNA
for	O
the	O
degradative	O
action	O
of	O
dexamethasone	O
.	O

Nuclear	B-protein
transcription	I-protein
factors	I-protein
that	O
bind	O
to	O
elements	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

Induction	O
requirements	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Prior	O
studies	O
have	O
identified	O
several	O
elements	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
the	O
stimulated	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Jurkat	B-cell_line
.	O

The	O
sites	O
and	O
their	O
corresponding	O
nuclear	O
binding	O
factors	O
include	O
:	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
AP-3	B-protein
,	O
OCT-1	B-protein
,	O
and	O
NF-AT	B-protein
.	O

The	O
latter	O
``	O
nuclear	B-protein
factor	I-protein
for	I-protein
activated	I-protein
T	I-protein
cells	I-protein
``	O
likely	O
contributes	O
to	O
the	O
tissue	O
specificity	O
of	O
IL-2	B-DNA
gene	I-DNA
expression	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
have	O
studied	O
these	O
transcription	B-protein
factors	I-protein
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
human	O
blood	O
to	O
verify	O
their	O
presence	O
in	O
a	O
physiologic	O
setting	O
and	O
to	O
identify	O
the	O
signals	O
that	O
stimulate	O
factor	O
activity	O
.	O

All	O
factors	O
are	O
induced	O
in	O
the	O
nuclei	O
of	O
T	B-cell_type
cells	I-cell_type
upon	O
activation	O
with	O
mitogens	B-protein
but	O
not	O
with	O
exogenous	B-protein
IL-2	I-protein
growth	I-protein
factor	I-protein
.	O

However	O
,	O
the	O
signaling	O
requirements	O
and	O
sensitivity	O
to	O
protein	O
synthesis	O
inhibitors	O
differ	O
considerably	O
.	O

Only	O
the	O
activities	O
for	O
NF-AT	B-DNA
and	I-DNA
AP-1	I-DNA
sites	I-DNA
require	O
two	O
signals	O
for	O
optimal	O
induction	O
,	O
i.e.	O
,	O
PMA	O
plus	O
either	O
lectin	B-protein
or	O
antibody	B-protein
to	O
the	O
CD3	B-protein
or	O
CD28	B-protein
surface	I-protein
molecules	I-protein
.	O

Other	O
factors	O
are	O
induced	O
by	O
lectin	B-protein
,	O
antibody	B-protein
,	O
and/or	O
PMA	O
alone	O
.	O

After	O
appropriate	O
stimulation	O
,	O
both	O
NF-AT	B-protein
and	O
AP-1	B-protein
are	O
peculiarly	O
sensitive	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	O
.	O

Our	O
data	O
correlate	O
the	O
activity	O
of	O
NF-AT	B-protein
and	O
AP-1	B-protein
in	O
gel	O
shift	O
assays	O
with	O
the	O
two	O
signals	O
requirements	O
for	O
IL-2	B-DNA
gene	I-DNA
expression	O
.	O

NF-kappa	B-protein
B	I-protein
activity	O
in	O
T	B-cell_type
cells	I-cell_type
stably	O
expressing	O
the	O
Tax	B-protein
protein	I-protein
of	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
.	O

The	O
effect	O
of	O
constitutive	O
Tax	B-protein
expression	O
on	O
the	O
interaction	O
of	O
NF-kappa	B-protein
B	I-protein
with	O
its	O
recognition	B-DNA
sequence	I-DNA
and	O
on	O
NF-kappa	B-protein
B	I-protein
-dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	B-cell_line
lymphoid	I-cell_line
Jurkat	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
19D	B-cell_line
and	O
9J	B-cell_line
)	O
stably	O
transformed	O
with	O
a	O
Tax	B-DNA
expression	I-DNA
vector	I-DNA
.	O

Tax	B-cell_line
expressing	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
contained	O
a	O
constitutive	O
level	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
,	O
detectable	O
by	O
mobility	O
shift	O
assay	O
and	O
uv	O
cross-linking	O
using	O
a	O
palindromic	B-DNA
NF-kappa	I-DNA
B	I-DNA
probe	I-DNA
homologous	O
to	O
the	O
interferon	B-DNA
beta	I-DNA
PRDII	I-DNA
site	I-DNA
.	O

In	O
Jurkat	O
and	O
NC2.10	O
induction	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	B-protein
binding	I-protein
proteins	I-protein
of	O
85	B-protein
,	I-protein
75	I-protein
,	I-protein
and	I-protein
54	I-protein
kDa	I-protein
,	O
whereas	O
in	O
Tax	B-cell_line
expressing	I-cell_line
cells	I-cell_line
the	O
85-kDa	B-protein
protein	I-protein
and	O
a	O
92-kDa	B-protein
DNA	I-protein
binding	I-protein
protein	I-protein
were	O
constitutively	O
induced	O
.	O

Expression	O
of	O
Tax	B-protein
protein	I-protein
in	O
19D	B-cell_line
and	O
9J	B-cell_line
resulted	O
in	O
transcription	O
of	O
the	O
endogenous	B-DNA
NF-kappa	I-DNA
B-dependent	I-DNA
granulocyte-macrophage	I-DNA
colony	I-DNA
stimulating	I-DNA
factor	I-DNA
gene	I-DNA
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF-kappa	B-DNA
B-regulated	I-DNA
promoters	I-DNA
.	O

Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	O
treatment	O
.	O

Tax	B-protein
expression	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
may	O
alter	O
the	O
stoichiometry	O
of	O
NF-kappa	B-protein
B	I-protein
DNA	B-protein
binding	I-protein
proteins	I-protein
and	O
thus	O
change	O
the	O
expression	O
of	O
NF-kappa	B-DNA
B-regulated	I-DNA
promoters	I-DNA
.	O

A	O
nuclear	B-protein
factor	I-protein
NF-GM2	B-protein
that	O
interacts	O
with	O
a	O
regulatory	B-DNA
region	I-DNA
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
essential	O
for	O
its	O
induction	O
in	O
responses	O
to	O
T-cell	O
activation	O
:	O
purification	O
from	O
human	O
T-cell	B-cell_line
leukemia	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
and	O
similarity	O
to	O
NF-kappa	B-protein
B	I-protein
.	O

Activation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
antigen	O
,	O
lectin	B-protein
,	O
or	O
a	O
combination	O
of	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
leads	O
to	O
the	O
induction	O
of	O
genes	O
for	O
a	O
set	O
of	O
lymphokines	B-protein
,	O
including	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
.	O

We	O
demonstrated	O
in	O
earlier	O
studies	O
that	O
the	O
upstream	B-DNA
region	I-DNA
of	O
the	O
mouse	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
at	O
positions	O
between	O
-95	B-DNA
and	I-DNA
-73	I-DNA
is	O
essential	O
for	O
transcriptional	O
activation	O
in	O
response	O
to	O
PMA/A23187	O
.	O

This	O
region	O
contains	O
two	O
DNA-binding	B-DNA
motifs	I-DNA
,	O
GM2	B-DNA
and	O
GC-box	B-DNA
.	O

The	O
GM2	B-DNA
sequence	I-DNA
(	O
GGTAGTTCCC	O
)	O
is	O
recognized	O
by	O
an	O
inducible	B-protein
factor	I-protein
NF-GM2	I-protein
;	O
the	O
other	O
(	O
CCGCCC	O
)	O
by	O
constitutive	B-protein
factors	I-protein
A1	B-protein
,	O
A2	B-protein
,	O
and	O
B	B-protein
.	O

To	O
elucidate	O
the	O
mechanism	O
of	O
GM-CSF	B-protein
gene	O
activation	O
,	O
we	O
have	O
purified	O
the	O
inducible	B-protein
factor	I-protein
NF-GM2	I-protein
from	O
the	O
nuclear	O
extract	O
of	O
stimulated	O
Jurkat	B-cell_line
cells	I-cell_line
on	O
the	O
basis	O
of	O
specific	O
DNA-binding	O
activity	O
.	O

The	O
purified	O
NF-GM2	B-protein
consists	O
of	O
50	O
(	O
p50	B-protein
)	O
and	O
65	O
kDa	O
(	O
p65	B-protein
)	O
polypeptides	O
and	O
has	O
a	O
binding	O
activity	O
specific	O
for	O
both	O
the	O
GM-CSF	B-protein
and	O
immunoglobulin	B-DNA
kappa	I-DNA
(	I-DNA
GGAAAGTCCC	I-DNA
)	I-DNA
enhancers	I-DNA
.	O

Electrophoretically	O
purified	O
p50	B-protein
alone	O
can	O
form	O
a	O
protein-DNA	B-protein
complex	I-protein
,	O
but	O
in	O
the	O
mixture	O
,	O
p50	B-protein
associates	O
preferentially	O
with	O
p65	B-protein
to	O
form	O
the	O
NF-GM2	B-protein
complex	I-protein
.	O

In	O
addition	O
,	O
p65	B-protein
gave	O
per	O
se	O
,	O
with	O
low	O
affinity	O
,	O
a	O
protein-DNA	B-protein
complex	I-protein
that	O
migrated	O
more	O
slowly	O
than	O
native	O
NF-GM2	B-protein
complex	I-protein
.	O

Furthermore	O
,	O
an	O
antiserum	O
against	O
KBF1	B-protein
(	O
identical	O
to	O
50	B-protein
kDa	I-protein
NF-kappa	I-protein
B	I-protein
protein	I-protein
)	O
reacted	O
with	O
the	O
p50	B-protein
of	O
NF-GM2	B-protein
,	O
indicating	O
that	O
the	O
NF-GM2	B-protein
polypeptide	I-protein
can	O
not	O
be	O
immunologically	O
differentiated	O
from	O
the	O
50	B-protein
kDa	I-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
purified	O
NF-GM2	B-protein
activated	O
in	O
vitro	O
transcription	O
from	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
,	O
while	O
it	O
failed	O
to	O
stimulate	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
harboring	O
the	O
GM2	O
sequence	O
.	O

This	O
suggests	O
that	O
the	O
activation	O
mechanism	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
through	O
the	O
GM2/GC-box	B-DNA
sequence	I-DNA
is	O
different	O
from	O
that	O
of	O
genes	O
carrying	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
alone	O
.	O

Characterization	O
of	O
an	O
immediate-early	B-DNA
gene	I-DNA
induced	O
in	O
adherent	B-cell_type
monocytes	I-cell_type
that	O
encodes	O
I	B-protein
kappa	I-protein
B	I-protein
-like	O
activity	O
.	O

We	O
have	O
cloned	O
a	O
group	O
of	O
cDNAs	B-DNA
representing	O
mRNAs	B-RNA
that	O
are	O
rapidly	O
induced	O
following	O
adherence	O
of	O
human	B-cell_type
monocytes	I-cell_type
.	O

One	O
of	O
the	O
induced	O
transcripts	O
(	O
MAD-3	B-RNA
)	O
encodes	O
a	O
protein	O
of	O
317	O
amino	O
acids	O
with	O
one	O
domain	O
containing	O
five	B-protein
tandem	I-protein
repeats	I-protein
of	O
the	O
cdc10/ankyrin	B-protein
motif	I-protein
,	O
which	O
is	O
60	O
%	O
similar	O
(	O
46	O
%	O
identical	O
)	O
to	O
the	O
ankyrin	B-protein
repeat	I-protein
region	I-protein
of	O
the	O
precursor	O
of	O
NF-kappa	B-protein
B/KBF1	I-protein
p50	I-protein
.	O

The	O
C-terminus	B-protein
has	O
a	O
putative	O
protein	B-protein
kinase	I-protein
C	I-protein
phosphorylation	I-protein
site	I-protein
.	O

In	O
vitro	O
translated	O
MAD-3	B-protein
protein	I-protein
was	O
found	O
to	O
specifically	O
inhibit	O
the	O
DNA-binding	O
activity	O
of	O
the	O
p50/p65	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
but	O
not	O
that	O
of	O
the	O
p50/p50	B-protein
KBF1	I-protein
factor	I-protein
or	O
of	O
other	O
DNA-binding	B-protein
proteins	I-protein
.	O

The	O
MAD-3	B-DNA
cDNA	I-DNA
encodes	O
an	O
I	B-protein
kappa	I-protein
B-like	I-protein
protein	I-protein
that	O
is	O
likely	O
to	O
be	O
involved	O
in	O
regulation	O
of	O
transcriptional	O
responses	O
to	O
NF-kappa	B-protein
B	I-protein
,	O
including	O
adhesion-dependent	O
pathways	O
of	O
monocyte	O
activation	O
.	O

Cortivazol	O
mediated	O
induction	O
of	O
glucocorticoid	B-RNA
receptor	I-RNA
messenger	I-RNA
ribonucleic	I-RNA
acid	I-RNA
in	O
wild-type	B-cell_line
and	O
dexamethasone-resistant	B-cell_line
human	I-cell_line
leukemic	I-cell_line
(	I-cell_line
CEM	I-cell_line
)	I-cell_line
cells	I-cell_line
.	O

Cortivazol	O
is	O
a	O
phenylpyrazolo	O
glucocorticoid	O
of	O
high	O
potency	O
and	O
unusual	O
structure	O
.	O

In	O
both	O
wild-type	B-cell_line
and	O
highly	O
dexamethasone	B-cell_line
(	I-cell_line
dex	I-cell_line
)	I-cell_line
-resistant	I-cell_line
clones	I-cell_line
of	O
the	O
human	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
CEM	I-cell_line
,	O
exposure	O
to	O
cortivazol	O
leads	O
to	O
cell	O
death	O
.	O

It	O
has	O
been	O
shown	O
recently	O
that	O
in	O
wild-type	B-cell_line
CEM	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
a	O
dex-resistant	B-cell_line
,	I-cell_line
glucocorticoid	I-cell_line
receptor	I-cell_line
(	I-cell_line
GR	I-cell_line
)	I-cell_line
-defective	I-cell_line
clone	I-cell_line
ICR-27	B-cell_line
TK-3	I-cell_line
,	O
dex	O
induces	O
GR	B-RNA
mRNA	I-RNA
.	O

To	O
test	O
the	O
hypothesis	O
that	O
cortivazol	O
acts	O
in	O
dex-resistant	B-cell_line
cells	I-cell_line
by	O
making	O
use	O
of	O
the	O
residual	O
GR	B-protein
found	O
there	O
,	O
wild-type	O
and	O
dex-resistant	B-cell_line
clones	I-cell_line
were	O
treated	O
with	O
various	O
concentrations	O
of	O
cortivazol	O
and	O
induction	O
of	O
GR	B-RNA
mRNA	I-RNA
was	O
studied	O
.	O

Cortivazol	O
significantly	O
induced	O
GR	B-RNA
mRNA	I-RNA
in	O
the	O
normal	B-cell_line
CEM-C7	I-cell_line
as	O
well	O
as	O
in	O
two	O
classes	O
of	O
dex-resistant	B-cell_line
clones	I-cell_line
,	O
although	O
the	O
dex-resistant	B-cell_line
clones	I-cell_line
needed	O
at	O
least	O
10	O
times	O
more	O
cortivazol	O
than	O
the	O
normal	B-cell_type
cells	I-cell_type
for	O
significant	O
GR	B-RNA
mRNA	I-RNA
induction	O
.	O

Increased	O
levels	O
of	O
GR	B-RNA
mRNA	I-RNA
were	O
noticed	O
as	O
early	O
as	O
3	O
h	O
after	O
treatment	O
.	O

A	O
general	O
correlation	O
between	O
induction	O
of	O
GR	B-RNA
mRNA	I-RNA
and	O
lysis	O
of	O
the	O
normal	O
and	O
dex-resistant	B-cell_line
cells	I-cell_line
was	O
found	O
.	O

Positive	O
induction	O
of	O
GR	B-RNA
mRNA	I-RNA
might	O
be	O
one	O
of	O
the	O
earliest	O
crucial	O
steps	O
in	O
the	O
lysis	O
of	O
normal	B-cell_line
and	I-cell_line
dex-resistant	I-cell_line
CEM	I-cell_line
cells	I-cell_line
,	O
or	O
might	O
serve	O
as	O
a	O
marker	O
for	O
the	O
process	O
.	O

However	O
,	O
the	O
lysis	O
pathway	O
in	O
the	O
dex-resistant	B-cell_line
cells	I-cell_line
is	O
defective	O
in	O
that	O
dex-resistant	B-cell_line
clones	I-cell_line
needed	O
significantly	O
more	O
cortivazol	O
than	O
the	O
normal	B-cell_line
cells	I-cell_line
for	O
lysis	O
of	O
the	O
cells	O
.	O

HIV	B-DNA
enhancer	I-DNA
activity	O
perpetuated	O
by	O
NF-kappa	B-protein
B	I-protein
induction	O
on	O
infection	O
of	O
monocytes	B-cell_type
[	O
see	O
comments	O
]	O

Permissiveness	O
to	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
differs	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
macrophages	B-cell_type
.	O

In	O
T	B-cell_type
cells	I-cell_type
,	O
HIV	O
transcription	O
is	O
poorly	O
detected	O
in	O
vivo	O
.	O

Cloned	O
,	O
normal	O
T	B-cell_type
lymphocytes	I-cell_type
show	O
very	O
little	O
,	O
if	O
any	O
,	O
basal	O
activity	O
of	O
the	O
HIV	B-DNA
enhancer	I-DNA
and	O
low	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
a	O
potent	B-protein
transcriptional	I-protein
activator	I-protein
of	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O

In	O
contrast	O
,	O
fixed	O
tissue	O
macrophages	B-cell_type
express	O
detectable	O
HIV	B-protein
proteins	I-protein
,	O
indicating	O
permanent	O
virus	O
transcription	O
.	O

One	O
explanation	O
for	O
the	O
perpetuation	O
of	O
virus	O
infection	O
in	O
macrophages	B-cell_type
could	O
be	O
sustained	O
nuclear	O
NF-kappa	B-protein
B	I-protein
expression	O
.	O

However	O
,	O
the	O
U937	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
is	O
fully	O
permissive	O
to	O
HIV	O
replication	O
,	O
is	O
known	O
to	O
express	O
only	O
low	O
levels	O
of	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
.	O

We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	B-protein
factor	I-protein
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
permanently	O
increased	O
HIV	B-DNA
enhancer	I-DNA
activity	O
.	O

This	O
phenomenon	O
,	O
which	O
is	O
independent	O
of	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
,	O
is	O
associated	O
with	O
HIV	O
replication	O
,	O
and	O
is	O
thus	O
likely	O
to	O
explain	O
at	O
least	O
in	O
part	O
the	O
perpetuation	O
of	O
HIV	O
infection	O
in	O
monocytes	B-cell_type
.	O

Isolation	O
of	O
a	O
rel-related	B-DNA
human	I-DNA
cDNA	I-DNA
that	O
potentially	O
encodes	O
the	O
65-kD	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1991	O
Oct	O
4	O
;	O
254	O
(	O
5028	O
)	O
:	O
11	O
]	O

A	O
DNA	B-DNA
probe	I-DNA
that	O
spanned	O
a	O
domain	O
conserved	O
among	O
the	O
proto-oncogene	B-DNA
c-rel	I-DNA
,	O
the	O
Drosophila	B-protein
morphogen	I-protein
dorsal	I-protein
,	O
and	O
the	O
p50	B-protein
DNA	I-protein
binding	I-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
was	O
generated	O
from	O
Jurkat	B-DNA
T	I-DNA
cell	I-DNA
complementary	I-DNA
DNA	I-DNA
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
degenerate	O
oligonucleotides	O
.	O

This	O
probe	O
was	O
used	O
to	O
identify	O
a	O
rel-related	B-DNA
complementary	I-DNA
DNA	I-DNA
that	O
hybridized	O
to	O
a	O
2.6-kilobase	B-RNA
messenger	I-RNA
RNA	I-RNA
present	O
in	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	B-DNA
DNA	I-DNA
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	B-protein
kilodaltons	I-protein
(	O
kD	O
)	O
.	O

The	O
translated	O
protein	O
showed	O
weak	O
DNA	O
binding	O
with	O
a	O
specificity	O
for	O
the	O
kappa	O
B	O
binding	O
motif	O
.	O

This	O
protein-DNA	B-protein
complex	I-protein
comigrated	O
with	O
the	O
complex	O
obtained	O
with	O
the	O
purified	B-protein
human	I-protein
p65	I-protein
NF-kappa	I-protein
B	I-protein
subunit	I-protein
and	O
binding	O
was	O
inhibited	O
by	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
and	O
-beta	O
proteins	O
.	O

In	O
addition	O
,	O
the	O
65-kD	B-protein
protein	I-protein
associated	O
with	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
and	O
the	O
kappa	B-DNA
B	I-DNA
probe	I-DNA
to	O
form	O
a	O
complex	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
as	O
the	O
NF-kappa	B-protein
B-DNA	I-protein
complex	I-protein
.	O

Therefore	O
the	O
rel-related	B-protein
65-kD	I-protein
protein	I-protein
may	O
represent	O
the	O
p65	B-protein
subunit	I-protein
of	O
the	O
active	B-protein
NF-kappa	I-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
.	O

The	O
human	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U-937	I-cell_line
as	O
a	O
model	O
for	O
studying	O
alterations	O
in	O
steroid-induced	O
monokine	O
gene	O
expression	O
:	O
marked	O
enhancement	O
of	O
lipopolysaccharide-stimulated	B-RNA
interleukin-1	I-RNA
beta	I-RNA
messenger	I-RNA
RNA	I-RNA
levels	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
.	O

The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
is	O
a	O
potent	O
regulator	O
of	O
human	O
monocyte/macrophage	O
function	O
in	O
vitro	O
.	O

To	O
establish	O
a	O
model	O
for	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
regulation	O
of	O
human	O
monocyte	O
monokine	O
synthesis	O
,	O
three	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
U-937	B-cell_line
,	O
THP-1	B-cell_line
,	O
and	O
HL-60	B-cell_line
)	O
were	O
examined	O
for	O
:	O
1	O
)	O
the	O
presence	O
of	O
functional	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
receptors	O
;	O
2	O
)	O
the	O
accumulation	O
of	O
interleukin-1	B-RNA
beta	I-RNA
(	I-RNA
IL-1	I-RNA
beta	I-RNA
)	I-RNA
mRNA	I-RNA
and	O
IL-1	B-protein
beta	I-protein
protein	I-protein
in	O
response	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
;	O
and	O
3	O
)	O
the	O
regulation	O
of	O
this	O
response	O
by	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O

All	O
three	O
cell	O
lines	O
expressed	O
vitamin	O
D	O
receptor	O
and	O
had	O
increased	O
levels	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
in	O
response	O
to	O
LPS	O
.	O

Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
augmented	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
levels	O
only	O
in	O
U-937	B-cell_line
and	O
HL-60	B-cell_line
cells	O
.	O

From	O
these	O
data	O
,	O
and	O
taking	O
into	O
consideration	O
their	O
state	O
of	O
differentiation	O
and	O
relative	O
ease	O
of	O
culture	O
,	O
U-937	B-cell_line
was	O
chosen	O
over	O
HL-60	B-cell_line
and	O
THP-1	B-cell_line
as	O
the	O
cell	O
line	O
we	O
further	O
characterized	O
.	O

In	O
U-937	B-cell_line
cells	I-cell_line
,	O
optimum	O
time	O
and	O
dose	O
of	O
pretreatment	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
were	O
determined	O
to	O
be	O
12-24	O
h	O
at	O
a	O
receptor	O
saturating	O
concentration	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
nM	O
)	O
.	O

Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
had	O
no	O
effect	O
on	O
the	O
time	O
course	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
appearance	O
in	O
response	O
to	O
LPS	O
.	O

However	O
,	O
exposure	O
of	O
U-937	B-cell_line
cells	I-cell_line
to	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
increased	O
by	O
200	O
%	O
the	O
level	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
detected	O
and	O
decreased	O
by	O
three	O
orders	O
of	O
magnitude	O
the	O
concentration	O
of	O
LPS	O
required	O
to	O
achieve	O
steady	O
state	O
mRNA	O
levels	O
equivalent	O
to	O
those	O
observed	O
in	O
U-937	B-cell_line
cells	I-cell_line
not	O
preincubated	O
with	O
the	O
hormone.2+o	O

Regulation	O
of	O
M-CSF	B-protein
expression	O
by	O
M-CSF	B-protein
:	O
role	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
transcription	B-protein
factor	I-protein
NF	I-protein
kappa	I-protein
B	I-protein
.	O

Macrophage-colony-stimulating	B-protein
factor	I-protein
(	O
M-CSF	B-protein
)	O
,	O
also	O
referred	O
to	O
as	O
CSF-1	B-protein
,	O
regulates	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
and	O
functional	O
activity	O
of	O
monocytes	B-cell_type
by	O
binding	O
to	O
a	O
single	O
class	O
of	O
high-affinity	B-protein
cell	I-protein
surface	I-protein
receptors	I-protein
,	O
known	O
to	O
be	O
the	O
product	O
of	O
the	O
c-fms	B-DNA
protooncogene	I-DNA
.	O

The	O
detection	O
of	O
both	O
M-CSF	O
and	O
c-fms	O
expression	O
by	O
cells	O
of	O
the	O
monocyte	B-cell_type
lineage	I-cell_type
has	O
suggested	O
that	O
M-CSF	B-protein
may	O
act	O
by	O
an	O
autocrine	O
mechanism	O
.	O

Interestingly	O
,	O
it	O
has	O
been	O
shown	O
that	O
M-CSF	B-protein
can	O
induce	O
the	O
expression	O
of	O
its	O
own	O
gene	O
.	O

Although	O
sensitivity	O
to	O
M-CSF	B-protein
can	O
be	O
modulated	O
by	O
regulation	O
of	O
receptor	O
expression	O
and	O
function	O
,	O
M-CSF	B-protein
responsiveness	O
is	O
largely	O
determined	O
at	O
a	O
postreceptor	O
level	O
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	O
pathway	O
of	O
M-CSF	B-protein
signal	O
transduction	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
changes	O
in	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
activity	O
upon	O
exposure	O
of	O
monocytes	B-cell_type
to	O
M-CSF	B-protein
.	O

We	O
show	O
that	O
M-CSF	B-protein
activates	O
and	O
translocates	O
PKC	B-protein
.	O

Inhibition	O
of	O
PKC	B-protein
by	O
the	O
isoquinoline	O
derivative	O
H7	O
abolishes	O
induction	O
of	O
M-CSF	B-protein
by	O
M-CSF	B-protein
.	O

Furthermore	O
,	O
activation	O
of	O
PKC	B-protein
was	O
pertussis-toxin-sensitive	O
and	O
was	O
associated	O
with	O
the	O
detection	O
of	O
an	O
NF	B-protein
kappa	I-protein
B	I-protein
protein	I-protein
in	O
nuclear	O
extracts	O
of	O
M-CSF-induced	B-cell_line
blood	I-cell_line
monocytes	I-cell_line
but	O
not	O
in	O
monocytes	B-cell_type
exposed	O
to	O
medium	O
treatment	O
only	O
.	O

The	O
results	O
suggest	O
that	O
M-CSF	B-protein
induction	O
of	O
M-CSF	B-protein
involves	O
G	B-protein
proteins	I-protein
,	O
PKC	B-protein
and	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

Clone	B-DNA
pAT	I-DNA
133	I-DNA
identifies	O
a	O
gene	O
that	O
encodes	O
another	O
human	O
member	O
of	O
a	O
class	O
of	O
growth	B-DNA
factor-induced	I-DNA
genes	I-DNA
with	O
almost	O
identical	O
zinc-finger	B-protein
domains	I-protein
.	O

We	O
report	O
the	O
structure	O
and	O
regulation	O
of	O
a	O
gene	O
represented	O
by	O
clone	B-DNA
pAT	I-DNA
133	I-DNA
,	O
which	O
is	O
induced	O
upon	O
transition	O
from	O
a	O
resting	O
state	O
(	O
G0	O
)	O
through	O
the	O
early	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
G1	O
)	O
.	O

The	O
pAT	B-DNA
133	I-DNA
gene	I-DNA
is	O
immediately	O
induced	O
,	O
with	O
FOS	B-protein
-like	O
kinetics	O
,	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
in	O
fibroblasts	B-cell_type
.	O

Primary	O
structure	O
analysis	O
showed	O
that	O
the	O
encoded	O
protein	O
contains	O
three	O
tandem	B-protein
zinc-finger	I-protein
sequences	I-protein
of	O
the	O
type	O
Cys2-Xaa12-His2	B-protein
.	O

This	O
zinc-finger	B-protein
region	I-protein
,	O
which	O
is	O
thought	O
to	O
bind	O
DNA	O
in	O
a	O
sequence-specific	O
manner	O
,	O
is	O
similar	O
(	O
greater	O
than	O
80	O
%	O
on	O
the	O
amino	O
acid	O
level	O
)	O
to	O
two	O
previously	O
described	O
transcription	B-protein
factors	I-protein
pAT	B-protein
225/EGR1	I-protein
and	O
pAT	O
591/EGR2	B-protein
.	O

Except	O
for	O
the	O
conserved	O
zinc-finger	B-protein
domains	I-protein
,	O
the	O
amino	B-protein
acid	I-protein
sequences	I-protein
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O

This	O
structural	O
similarity	O
suggests	O
that	O
the	O
pAT	B-DNA
133	I-DNA
gene	I-DNA
encodes	O
a	O
transcription	B-protein
factor	I-protein
with	O
a	O
specific	O
biological	O
function	O
.	O

Comparing	O
the	O
regulation	O
of	O
these	O
related	O
zinc-finger-encoding	B-DNA
genes	I-DNA
showed	O
coordinate	O
induction	O
upon	O
mitogenic	O
stimulation	O
of	O
resting	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
of	O
resting	B-cell_type
fibroblasts	I-cell_type
.	O

However	O
,	O
upon	O
transition	O
from	O
a	O
proliferating	O
(	O
G1	O
)	O
to	O
a	O
resting	O
state	O
of	O
the	O
cell	O
cycle	O
the	O
three	O
genes	O
were	O
differently	O
regulated	O
.	O

In	O
human	B-RNA
histiocytic	I-RNA
U937	I-RNA
cells	I-RNA
mRNA	I-RNA
of	O
clone	O
pAT	O
133	O
was	O
constitutively	O
expressed	O
,	O
whereas	O
mRNA	B-RNA
of	O
pAT	B-protein
225/EGR1	I-protein
was	O
induced	O
upon	O
induction	O
of	O
terminal	O
differentiation	O
.	O

In	O
contrast	O
mRNA	O
representing	O
pAT	O
591/EGR2	B-protein
was	O
not	O
expressed	O
in	O
these	O
cells	O
.	O

This	O
difference	O
in	O
gene	O
regulation	O
suggests	O
distinct	O
biological	O
roles	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
for	O
the	O
respective	O
proteins	O
.	O

v-erbA	B-protein
overexpression	O
is	O
required	O
to	O
extinguish	O
c-erbA	B-protein
function	O
in	O
erythroid	B-cell_type
cell	I-cell_type
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	B-DNA
target	I-DNA
gene	I-DNA
CAII	B-DNA
.	O

The	O
v-erbA	B-protein
oncoprotein	I-protein
represents	O
a	O
retrovirus-transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	B-protein
hormone	I-protein
(	I-protein
T3/T4	I-protein
)	I-protein
receptor	I-protein
c-erbA	B-protein
(	I-protein
type	I-protein
alpha	I-protein
)	I-protein
.	O

It	O
contributes	O
to	O
virus-induced	O
erythroleukemia	O
by	O
efficiently	O
arresting	O
differentiation	O
of	O
red	B-cell_type
cell	I-cell_type
progenitors	I-cell_type
and	O
by	O
suppressing	O
transcription	O
of	O
erythrocyte-specific	B-DNA
genes	I-DNA
.	O

Here	O
,	O
we	O
show	O
that	O
v-erbA	B-protein
and	O
c-erbA	B-protein
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	B-DNA
of	O
the	O
erythrocyte-specific	B-protein
carbonic	I-protein
anhydrase	I-protein
II	I-protein
(	O
CAII	B-DNA
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v-erbA	B-protein
.	O

This	O
erbA-binding	B-DNA
site	I-DNA
confers	O
thyroid	O
hormone	O
responsiveness	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	O
for	O
efficient	O
down-regulation	O
of	O
CAII	B-DNA
transcription	O
by	O
the	O
v-erbA	B-protein
oncoprotein	I-protein
.	O

In	O
stably	B-cell_line
transformed	I-cell_line
erythroblasts	I-cell_line
coexpressing	O
the	O
v-erbA	B-protein
oncoprotein	I-protein
and	O
the	O
c-erbA/T3	B-protein
receptor	I-protein
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c-erbA	B-protein
activity	O
is	O
dominant	O
over	O
v-erbA	B-protein
.	O

T3	O
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v-erbA	B-protein
-mediated	O
differentiation	O
arrest	O
.	O

Likewise	O
,	O
T3	O
activated	O
CAII	B-DNA
transcription	O
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3-responsive	B-DNA
reporter	I-DNA
gene	I-DNA
containing	O
the	O
CAII-specific	B-DNA
erbA-binding	I-DNA
site	I-DNA
.	O

The	O
c-erbA	B-protein
-dependent	O
activation	O
of	O
this	O
CAII	B-DNA
reporter	I-DNA
construct	I-DNA
could	O
only	O
be	O
suppressed	O
by	O
very	O
high	O
amounts	O
of	O
v-erbA	B-protein
.	O

Our	O
results	O
suggest	O
that	O
overexpression	O
of	O
v-erbA	B-protein
is	O
required	O
for	O
its	O
function	O
as	O
an	O
oncoprotein	B-protein
.	O

Anti-CD2	B-protein
receptor	I-protein
antibodies	I-protein
activate	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
CD2	B-protein
T	I-protein
lymphocyte	I-protein
glycoprotein	I-protein
surface	I-protein
molecule	I-protein
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O

Treatment	O
of	O
chronically	B-cell_line
HIV-infected	I-cell_line
PBMC	I-cell_line
with	O
anti-CD2	B-protein
mAb	I-protein
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti-CD2	B-protein
antibodies	I-protein
stimulate	O
viral	O
production	O
.	O

We	O
demonstrate	O
that	O
treatment	O
of	O
transiently	O
transfected	O
T	B-cell_type
lymphocytes	I-cell_type
with	O
anti-CD2	B-protein
antibodies	I-protein
results	O
in	O
activation	O
of	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

Furthermore	O
,	O
CAT	B-protein
assays	O
using	O
mutated	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat-CAT	I-DNA
constructs	I-DNA
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF-kappa	B-DNA
B	I-DNA
enhancer	I-DNA
.	O

These	O
studies	O
suggest	O
that	O
interaction	O
of	O
CD2	B-protein
with	O
its	O
natural	O
ligand	O
,	O
LFA-3	B-protein
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O

Reactive	O
oxygen	O
intermediates	O
as	O
apparently	O
widely	O
used	O
messengers	O
in	O
the	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
and	O
HIV-1	O
.	O

Hydrogen	O
peroxide	O
and	O
oxygen	O
radicals	O
are	O
agents	O
commonly	O
produced	O
during	O
inflammatory	O
processes	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
micromolar	O
concentrations	O
of	O
H2O2	O
can	O
induce	O
the	O
expression	O
and	O
replication	O
of	O
HIV-1	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
effect	O
is	O
mediated	O
by	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factor	I-protein
which	O
is	O
potently	O
and	O
rapidly	O
activated	O
by	O
an	O
H2O2	O
treatment	O
of	O
cells	O
from	O
its	O
inactive	B-protein
cytoplasmic	I-protein
form	I-protein
.	O

N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well	O
characterized	O
antioxidant	O
which	O
counteracts	O
the	O
effects	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
in	O
living	O
cells	O
,	O
prevented	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
H2O2	O
.	O

NAC	O
and	O
other	O
thiol	O
compounds	O
also	O
blocked	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
cycloheximide	O
,	O
double-stranded	B-RNA
RNA	I-RNA
,	O
calcium	O
ionophore	O
,	O
TNF-alpha	B-protein
,	O
active	O
phorbol	O
ester	O
,	O
interleukin-1	B-protein
,	O
lipopolysaccharide	O
and	O
lectin	B-protein
.	O

This	O
suggests	O
that	O
diverse	O
agents	O
thought	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
by	O
distinct	O
intracellular	O
pathways	O
might	O
all	O
act	O
through	O
a	O
common	O
mechanism	O
involving	O
the	O
synthesis	O
of	O
ROI	O
.	O

ROI	O
appear	O
to	O
serve	O
as	O
messengers	O
mediating	O
directly	O
or	O
indirectly	O
the	O
release	O
of	O
the	O
inhibitory	B-protein
subunit	I-protein
I	B-protein
kappa	I-protein
B	I-protein
from	O
NF-kappa	B-protein
B	I-protein
.	O

Inhibition	O
of	O
transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
rel/NF-kappa	B-protein
B	I-protein
family	I-protein
by	O
a	O
transdominant	B-protein
negative	I-protein
mutant	I-protein
.	O

The	O
KBF1	B-protein
factor	I-protein
,	O
which	O
binds	O
to	O
the	O
enhancer	B-DNA
A	I-DNA
located	O
in	O
the	O
promoter	B-DNA
of	O
the	O
mouse	B-DNA
MHC	I-DNA
class	I-DNA
I	I-DNA
gene	I-DNA
H-2Kb	B-DNA
,	O
is	O
indistinguishable	O
from	O
the	O
p50	B-protein
DNA	I-protein
binding	I-protein
subunit	I-protein
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
KBF1/p50	B-protein
factor	I-protein
binds	O
as	O
a	O
homodimer	B-protein
but	O
can	O
also	O
form	O
heterodimers	B-protein
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c-rel	B-DNA
and	I-DNA
v-rel	I-DNA
(	I-DNA
proto	I-DNA
)	I-DNA
oncogenes	I-DNA
.	O

The	O
dimerization	B-protein
domain	I-protein
of	O
KBF1/p50	B-protein
is	O
contained	O
between	B-protein
amino	I-protein
acids	I-protein
201	I-protein
and	I-protein
367	I-protein
.	O

A	O
mutant	O
of	O
KBF1/p50	B-protein
(	O
delta	B-protein
SP	I-protein
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo-	O
or	O
heterodimers	B-protein
,	O
has	O
been	O
constructed	O
.	O

This	O
protein	O
reduces	O
or	O
abolishes	O
in	O
vitro	O
the	O
DNA	O
binding	O
activity	O
of	O
wild-type	B-protein
proteins	I-protein
of	O
the	O
same	O
family	O
(	O
KBF1/p50	B-protein
,	O
c-	B-protein
and	I-protein
v-rel	I-protein
)	O
.	O

This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans-acting	B-protein
dominant	I-protein
negative	I-protein
regulator	I-protein
:	O
the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
which	O
contains	O
two	O
potential	O
NF-kappa	B-protein
B	I-protein
binding	O
sites	O
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co-transfected	O
into	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
the	O
delta	B-protein
SP	I-protein
mutant	O
.	O

Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	B-protein
or	O
IL1-induced	O
activity	O
of	O
the	O
MHC	B-DNA
class	I-DNA
I	I-DNA
H-2Kb	I-DNA
promoter	I-DNA
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	B-cell_line
lines	I-cell_line
.	O

These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel/NF-kappa	B-protein
B	I-protein
family	I-protein
.	O

Tissue-specific	O
expression	O
of	O
the	O
platelet	B-DNA
GPIIb	I-DNA
gene	I-DNA
.	O

One	O
of	O
the	O
major	O
objectives	O
in	O
the	O
study	O
of	O
thrombogenesis	O
is	O
to	O
determine	O
the	O
mechanisms	O
by	O
which	O
a	O
hematopoietic	B-cell_type
progenitor	I-cell_type
is	O
activated	O
and	O
committed	O
to	O
the	O
megakaryocytic	B-cell_type
lineage	I-cell_type
.	O

Recent	O
development	O
of	O
primary	B-cell_line
cultures	I-cell_line
of	O
human	B-cell_line
megakaryocytes	I-cell_line
and	O
the	O
molecular	O
cloning	O
of	O
genes	O
that	O
are	O
specific	O
to	O
this	O
lineage	O
offer	O
the	O
possibility	O
of	O
getting	O
some	O
insights	O
into	O
the	O
genetic	O
mechanisms	O
that	O
control	O
megakaryocytopoiesis	O
.	O

One	O
gene	O
of	O
interest	O
is	O
the	O
glycoprotein	B-DNA
IIb	I-DNA
(	I-DNA
GPIIb	I-DNA
)	I-DNA
gene	I-DNA
;	O
GPIIb	B-DNA
,	O
the	O
alpha	B-protein
subunit	I-protein
of	O
the	O
platelet	B-protein
cytoadhesin	I-protein
GPIIb-IIIa	I-protein
,	O
is	O
produced	O
in	O
megakaryocytes	B-cell_line
at	O
an	O
early	O
stage	O
of	O
the	O
differentiation	O
,	O
whereas	O
the	O
other	O
subunit	O
of	O
this	O
complex	O
,	O
GPIIIa	B-protein
,	O
is	O
expressed	O
in	O
other	O
cells	O
.	O

For	O
these	O
reasons	O
,	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
GPIIb	B-DNA
gene	I-DNA
was	O
used	O
to	O
identify	O
the	O
regions	O
that	O
interact	O
with	O
DNA-binding	B-protein
nuclear	I-protein
factors	I-protein
.	O

A	O
fragment	O
extending	O
from	O
-643	B-DNA
to	I-DNA
+33	I-DNA
is	O
capable	O
of	O
controlling	O
the	O
tissue-specific	O
expression	O
of	O
the	O
CAT	B-DNA
gene	I-DNA
in	O
transfection	O
experiments	O
.	O

Within	O
this	O
region	O
,	O
we	O
have	O
identified	O
several	O
sequences	O
that	O
are	O
implicated	O
in	O
DNA	O
protein	O
interactions	O
as	O
shown	O
in	O
DNAse	B-protein
I	I-protein
footprints	O
and	O
gel	O
mobility	O
shift	O
assays	O
.	O

One	O
region	O
,	O
centered	O
at	O
-54	O
,	O
is	O
similar	O
to	O
a	O
nuclear	B-DNA
factor	I-DNA
E1-binding	I-DNA
site	I-DNA
,	O
and	O
a	O
region	O
located	O
at	O
position	O
-233	O
contains	O
a	O
CCAAT	B-DNA
motif	I-DNA
.	O

Two	O
domains	O
centered	O
at	O
positions	O
-345	O
and	O
-540	O
,	O
respectively	O
,	O
bind	O
proteins	O
that	O
are	O
present	O
in	O
megakaryocytic	B-cell_line
cells	I-cell_line
and	O
nonrelated	B-cell_type
cells	I-cell_type
as	O
well	O
.	O

Finally	O
,	O
two	O
other	O
domains	O
,	O
located	O
at	O
positions	O
-460	O
and	O
-510	O
,	O
interact	O
with	O
proteins	O
that	O
are	O
only	O
present	O
in	O
megakaryocytic	B-cell_line
cells	I-cell_line
.	O

In	O
addition	O
,	O
deletion	O
of	O
the	O
region	O
containing	O
these	O
two	O
domains	O
results	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
promoter	B-DNA
activity	O
.	O

It	O
is	O
very	O
likely	O
that	O
these	O
domains	O
bind	O
megakaryocyte-specific	B-protein
nuclear	I-protein
proteins	I-protein
acting	O
as	O
positive	B-protein
transcription	I-protein
factors	I-protein
.	O

Lymphocyte	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
.	O

Lymphocyte	B-protein
glucocorticoid	I-protein
receptor	I-protein
binding	O
parameters	O
were	O
studied	O
in	O
15	O
severely	O
depressed	O
patients	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
,	O
and	O
in	O
15	O
healthy	O
controls	O
.	O

There	O
was	O
no	O
difference	O
in	O
glucocorticoid	B-protein
receptor	I-protein
number	O
or	O
affinity	O
between	O
depressed	O
patients	O
and	O
recovered	O
or	O
control	O
subjects	O
.	O

Afternoon	O
ACTH	O
and	O
cortisol	O
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
three	O
groups	O
.	O

No	O
relationship	O
could	O
be	O
established	O
between	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
and	O
antidepressant	O
medication	O
.	O

These	O
data	O
support	O
the	O
view	O
of	O
an	O
impaired	O
ligand-induced	O
plasticity	O
of	O
glucocorticoid	B-protein
receptor	I-protein
regulation	O
rather	O
than	O
the	O
hypothesis	O
of	O
decreased	O
glucocorticoid	B-protein
receptor	I-protein
numbers	O
during	O
depression	O
.	O

Every	O
enhancer	O
works	O
with	O
every	O
promoter	B-DNA
for	O
all	O
the	O
combinations	O
tested	O
:	O
could	O
new	O
regulatory	O
pathways	O
evolve	O
by	O
enhancer	O
shuffling	O
?	O

The	O
promoters	B-DNA
and	O
enhancers	B-DNA
of	O
cell	O
type-specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	O
expect	O
that	O
a	O
given	O
enhancer	B-DNA
has	O
evolved	O
to	O
work	O
best	O
with	O
its	O
own	O
promoter	B-DNA
.	O

While	O
this	O
expectation	O
may	O
be	O
realized	O
in	O
some	O
cases	O
,	O
we	O
have	O
not	O
found	O
evidence	O
for	O
it	O
.	O

A	O
total	O
of	O
27	O
combinations	O
of	O
different	O
promoters	B-DNA
and	O
enhancers	B-DNA
were	O
tested	O
by	O
transfection	O
into	O
cultured	B-cell_line
cells	I-cell_line
.	O

We	O
found	O
that	O
the	O
relative	O
efficiency	O
of	O
the	O
enhancers	B-DNA
is	O
approximately	O
the	O
same	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
promoter	B-DNA
used	O
,	O
i.e.	O
,	O
there	O
was	O
no	O
strong	O
preference	O
for	O
any	O
given	O
enhancer/	O
promoter	B-DNA
combination	O
.	O

Notably	O
,	O
we	O
do	O
not	O
see	O
particularly	O
strong	O
transcription	O
when	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
enhancer	I-DNA
(	O
or	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
)	O
is	O
used	O
to	O
activate	O
a	O
kappa	O
gene	O
promoter	B-DNA
.	O

We	O
propose	O
that	O
a	O
generally	O
permissive	O
enhancer/	O
promoter	B-DNA
interaction	O
is	O
of	O
evolutionary	O
benefit	O
for	O
higher	O
eukaryotes	O
:	O
by	O
enhancer	O
shuffling	O
,	O
genes	O
could	O
be	O
easily	O
brought	O
under	O
a	O
new	O
type	O
of	O
inducibility/cell	O
type	O
specificity	O
.	O

Towards	O
a	O
molecular	O
understanding	O
of	O
T-cell	O
differentiation	O
.	O

Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O

Here	O
Hans	O
Clevers	O
and	O
Michael	O
Owen	O
describe	O
how	O
the	O
cloning	O
of	O
the	O
genes	O
that	O
encode	O
T-cell-specific	B-protein
membrane	I-protein
proteins	I-protein
allows	O
the	O
identification	O
of	O
transcription	B-protein
factors	I-protein
that	O
control	O
the	O
expression	O
of	O
these	O
T-cell	B-DNA
genes	I-DNA
.	O

Such	O
transcription	B-protein
factors	I-protein
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
the	O
mature	O
T-cell	O
phenotype	O
by	O
functioning	O
as	O
'master	O
regulators	O
of	O
T-cell	O
differentiation'	O
.	O

A	O
study	O
on	O
the	O
circadian	O
rhythm	O
of	O
glucocorticoid	B-protein
receptor	I-protein
.	O

Circadian	O
rhythm	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
was	O
studied	O
in	O
the	O
rat	B-cell_type
liver	I-cell_type
and	O
human	B-cell_type
peripheral	I-cell_type
leukocytes	I-cell_type
.	O

For	O
rats	O
exposed	O
to	O
a	O
natural	O
environmental	O
photic	O
cycle	O
or	O
a	O
12L	O
:	O
12D	O
artificial	O
light	O
regime	O
,	O
peak	O
values	O
of	O
hepatic	B-protein
GR	I-protein
were	O
detected	O
between	O
23	O
:	O
00	O
and	O
02	O
:	O
00	O
h	O
.	O

Except	O
for	O
a	O
4-hour	O
advancement	O
of	O
the	O
peak	O
,	O
a	O
similar	O
circadian	O
rhythm	O
of	O
hepatic	B-protein
GR	I-protein
was	O
detected	O
in	O
rats	O
reared	O
under	O
a	O
reversed	O
lighting	O
regimen	O
(	O
12D	O
:	O
12L	O
;	O
lights	O
on	O
between	O
18	O
:	O
30	O
and	O
06	O
:	O
30	O
h	O
)	O
.	O

In	O
human	B-cell_type
leukocytes	I-cell_type
,	O
the	O
peak	O
value	O
of	O
GR	B-protein
was	O
found	O
to	O
parallel	O
that	O
of	O
plasma	O
cortisol	O
with	O
high	O
and	O
low	O
values	O
detected	O
at	O
04	O
:	O
00-08	O
:	O
00	O
h	O
and	O
23	O
:	O
00-24	O
:	O
00	O
h	O
,	O
respectively	O
.	O

In	O
patients	O
suffering	O
from	O
Cushing	O
's	O
syndrome	O
,	O
the	O
circadian	O
rhythm	O
of	O
plasma	O
cortisol	O
either	O
disappeared	O
or	O
was	O
inverted	O
while	O
that	O
of	O
GR	B-protein
did	O
not	O
significantly	O
deviate	O
from	O
the	O
normal	O
subjects	O
.	O

For	O
apoplexic	O
patients	O
with	O
lesions	O
localized	O
to	O
the	O
base	O
of	O
the	O
brain	O
as	O
indicated	O
by	O
computerized	O
tomography	O
,	O
the	O
diurnal	O
variation	O
of	O
GR	B-protein
was	O
abolished	O
.	O

Conversely	O
,	O
diurnal	O
rhythmicity	O
persisted	O
in	O
apoplexy	O
patients	O
whose	O
lesions	O
were	O
in	O
the	O
cerebral	O
cortex	O
.	O

Thus	O
,	O
we	O
postulated	O
that	O
the	O
circadian	O
modification	O
of	O
GR	B-protein
was	O
independent	O
of	O
the	O
diurnal	O
fluctuations	O
in	O
plasma	O
cortisol	O
level	O
or	O
the	O
circadian	O
variations	O
in	O
environmental	O
lighting	O
and	O
that	O
the	O
rhythmicity	O
might	O
be	O
regulated	O
by	O
the	O
'circadian	O
pacemaker	O
'	O
located	O
in	O
the	O
human	O
basal	O
brain	O
.	O

These	O
diurnal	O
variations	O
in	O
GR	B-protein
might	O
serve	O
to	O
coordinate	O
the	O
reactivity	O
of	O
the	O
target	B-cell_type
cells	I-cell_type
to	O
cortisol	O
because	O
the	O
diurnal	O
rhythms	O
of	O
a	O
GR	B-protein
-mediated	O
response	O
,	O
the	O
fractional	O
inhibition	O
of	O
chemotactic	O
migration	O
rate	O
of	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
by	O
cortisol	O
,	O
were	O
found	O
to	O
be	O
synchronous	O
with	O
those	O
of	O
GR	B-protein
.	O

Transcription	B-protein
factor	I-protein
requirements	O
for	O
U2	B-RNA
snRNA	I-RNA
-encoding	O
gene	O
activation	O
in	O
B	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

Transcription	O
of	O
a	O
human	O
U2	B-DNA
small	I-DNA
nuclear	I-DNA
RNA	I-DNA
(	I-DNA
snRNA	I-DNA
)	I-DNA
-encoding	I-DNA
gene	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
requires	O
a	O
distal	B-DNA
enhancer	I-DNA
element	I-DNA
,	O
which	O
is	O
composed	O
of	O
one	O
octamer	B-DNA
motif	I-DNA
(	O
Oct	B-DNA
)	O
and	O
three	O
Sp	B-DNA
1-binding	I-DNA
sites	I-DNA
.	O

To	O
study	O
the	O
transcription	B-protein
factor	I-protein
requirement	O
in	O
B-cells	B-cell_type
,	O
different	O
U2	B-DNA
enhancer	I-DNA
constructions	I-DNA
were	O
transfected	O
into	O
the	O
lymphoid	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
BJA-B	B-cell_line
.	O

The	O
results	O
showed	O
that	O
the	O
activation	O
of	O
U2	O
snRNA	O
transcription	O
in	O
B-cells	B-cell_type
also	O
requires	O
an	O
enhancer	O
comprising	O
both	O
the	O
Oct	B-DNA
and	O
at	O
least	O
one	O
Sp	B-DNA
1-binding	I-DNA
site	I-DNA
.	O

Deletion	O
of	O
all	O
the	O
Sp	B-DNA
1-binding	I-DNA
sites	I-DNA
from	O
the	O
enhancer	B-DNA
reduces	O
transcription	O
by	O
80-90	O
%	O
in	O
HeLa	O
,	O
as	O
well	O
as	O
in	O
BJA-B	B-cell_line
cells	I-cell_line
,	O
whereas	O
the	O
removal	O
of	O
the	O
octamer-binding	B-DNA
site	I-DNA
reduces	O
transcription	O
to	O
levels	O
below	O
detection	O
in	O
both	O
cell	O
types	O
.	O

Enhancers	O
containing	O
a	O
single	O
Oct	B-DNA
have	O
,	O
nevertheless	O
,	O
the	O
capacity	O
to	O
partially	O
activate	O
U2	B-RNA
snRNA	I-RNA
transcription	O
in	O
both	O
HeLa	B-cell_line
cells	I-cell_line
,	O
in	O
which	O
only	O
OTF-1	O
is	O
expressed	O
,	O
and	O
in	O
BJA-B	B-cell_line
cells	I-cell_line
in	O
which	O
OTF-2	B-protein
is	O
the	O
predominantly	O
expressed	O
octamer-binding	B-protein
factor	I-protein
.	O

The	O
most	O
likely	O
interpretation	O
of	O
our	O
results	O
is	O
that	O
both	O
the	O
ubiquitous	O
transcription	B-protein
factor	I-protein
,	O
OTF-1	B-protein
,	O
and	O
the	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
OTF-2	B-protein
,	O
can	O
activate	O
U2	B-RNA
snRNA	I-RNA
transcription	O
.	O

The	O
results	O
also	O
revealed	O
a	O
similar	O
functional	O
cooperation	O
between	O
the	O
transcription	O
factors	O
which	O
bind	O
to	O
the	O
Oct	B-DNA
and	O
the	O
adjacent	O
Sp	B-DNA
1-binding	I-DNA
site	I-DNA
in	O
BJA-B	B-cell_line
cells	I-cell_line
,	O
as	O
has	O
been	O
observed	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
since	O
a	O
template	O
which	O
contains	O
a	O
weak	O
binding	O
site	O
for	O
OTFs	B-DNA
expresses	O
wild-type	O
levels	O
of	O
U2	B-RNA
snRNA	I-RNA
in	O
both	O
cell	O
types	O
when	O
the	O
weak	O
octamer-binding	B-DNA
site	I-DNA
is	O
combined	O
with	O
a	O
Sp	B-DNA
1-binding	I-DNA
site	I-DNA
.	O

One	O
base	O
pair	O
change	O
abolishes	O
the	O
T	O
cell-restricted	O
activity	O
of	O
a	O
kB-like	B-DNA
proto-enhancer	I-DNA
element	I-DNA
from	O
the	O
interleukin	B-DNA
2	I-DNA
promoter	I-DNA
.	O

The	O
inducible	O
,	O
T	B-DNA
cell-specific	I-DNA
enhancers	I-DNA
of	O
murine	B-DNA
and	I-DNA
human	I-DNA
Interleukin	I-DNA
2	I-DNA
(	I-DNA
Il-2	I-DNA
)	I-DNA
genes	I-DNA
contain	O
the	O
kB-like	B-DNA
sequence	I-DNA
GGGATTTCACC	O
as	O
an	O
essential	B-DNA
cis-acting	I-DNA
enhancer	I-DNA
motif	I-DNA
.	O

When	O
cloned	O
in	O
multiple	O
copies	O
this	O
so-called	O
TCEd	B-DNA
(	O
distal	B-DNA
T	I-DNA
cell	I-DNA
element	I-DNA
)	O
acts	O
as	O
an	O
inducible	O
proto-enhancer	B-DNA
element	I-DNA
in	O
E14	B-cell_line
T	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

In	O
extracts	O
of	O
induced	O
,	O
Il-2	B-cell_line
secreting	I-cell_line
El4	I-cell_line
cells	I-cell_line
three	O
individual	O
protein	B-protein
factors	I-protein
bind	O
to	O
TCEd	B-DNA
DNA	I-DNA
.	O

The	O
binding	O
of	O
the	O
most	O
prominent	O
factor	O
,	O
named	O
TCF-1	B-protein
(	O
T	B-protein
cell	I-protein
factor	I-protein
1	I-protein
)	O
,	O
is	O
correlated	O
with	O
the	O
proto-enhancer	O
activity	O
of	O
TCEd	O
.	O

TCF-1	B-protein
consists	O
of	O
two	O
polypeptides	O
of	O
about	O
50	O
kD	O
and	O
105	O
kD	O
;	O
the	O
former	O
seems	O
to	O
be	O
related	O
to	O
the	O
50	B-protein
kD	I-protein
polypeptide	I-protein
of	O
NF-kB	B-protein
.	O

Purified	B-protein
NF-kB	I-protein
is	O
also	O
able	O
to	O
bind	O
to	O
the	O
TCEd	B-DNA
,	O
but	O
TCF-1	B-protein
binds	O
stronger	O
than	O
NF-kB	B-protein
to	O
TCEd	B-DNA
DNA	O
.	O

The	O
conversion	O
of	O
the	O
TCEd	B-DNA
to	O
a	O
'perfect	B-DNA
'	I-DNA
NF-kB	I-DNA
binding	I-DNA
site	I-DNA
leads	O
to	O
a	O
tighter	O
binding	O
of	O
NF-kB	B-protein
to	O
TCEd	B-DNA
DNA	I-DNA
and	O
,	O
as	O
a	O
functional	O
consequence	O
,	O
to	O
the	O
activity	O
of	O
the	O
'converted	B-DNA
'	I-DNA
TCEd	I-DNA
motifs	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Thus	O
,	O
the	O
substitution	O
of	O
the	O
underlined	O
A	O
residue	O
to	O
a	O
C	O
within	O
the	O
GGGATTTCACC	B-DNA
motif	I-DNA
abolishes	O
its	O
T	O
cell-restricted	O
activity	O
and	O
leads	O
to	O
its	O
functioning	O
in	O
both	O
El4	B-cell_line
cells	I-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
indicate	O
that	O
lymphocyte-specific	O
factors	O
binding	O
to	O
the	O
TCEd	B-DNA
are	O
involved	O
in	O
the	O
control	O
of	O
T	O
cell	O
specific-transcription	O
of	O
the	O
Il-2	B-DNA
gene	I-DNA
.	O

An	O
erythroid	B-DNA
specific	I-DNA
enhancer	I-DNA
upstream	O
to	O
the	O
gene	O
encoding	O
the	O
cell-type	B-protein
specific	I-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
.	O

The	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
is	O
expressed	O
in	O
a	O
subset	O
of	O
hemopoietic	B-cell_type
cells	I-cell_type
,	O
where	O
it	O
mediates	O
the	O
cell-type	O
specific	O
expression	O
of	O
several	O
genes	O
.	O

We	O
have	O
cloned	O
the	O
mouse	O
and	O
human	O
GATA-1	B-DNA
genes	I-DNA
.	O

A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA-1	B-protein
or	O
to	O
the	O
SV40	O
promoter	O
.	O

The	O
activity	O
of	O
the	O
enhancer	O
is	O
almost	O
completely	O
dependent	O
on	O
the	O
integrity	O
of	O
a	O
dimeric	B-DNA
GATA-1	I-DNA
binding	I-DNA
site	I-DNA
.	O

Demonstration	O
of	O
a	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3-responsive	I-protein
protein	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
:	O
immunologic	O
crossreactivity	O
and	O
inverse	O
regulation	O
with	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
.	O

Using	O
Western	O
blot	O
analysis	O
with	O
a	O
monoclonal	B-protein
antibody	I-protein
recognizing	O
a	O
17-amino	B-protein
acid	I-protein
epitope	I-protein
of	O
the	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
[	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
]	I-protein
receptor	I-protein
,	O
we	O
have	O
detected	O
two	O
crossreacting	B-protein
proteins	I-protein
in	O
activated	B-cell_type
normal	I-cell_type
human	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
smaller	O
of	O
the	O
two	O
proteins	O
(	O
50	B-protein
kDa	I-protein
)	O
was	O
indistinguishable	O
from	O
the	O
classical	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
and	O
,	O
similar	O
to	O
the	O
classical	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
,	O
was	O
upregulated	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

The	O
larger	O
crossreacting	O
protein	O
exhibited	O
an	O
electrophoretic	O
mobility	O
of	O
80	O
kDa	O
,	O
was	O
localized	O
in	O
the	O
cell	O
cytosol	O
,	O
and	O
appeared	O
to	O
be	O
specific	O
for	O
activated	B-cell_type
lymphocytes	I-cell_type
since	O
it	O
was	O
not	O
detected	O
in	O
several	O
other	O
human	B-cell_type
cells	I-cell_type
including	O
monocytes	B-cell_type
.	O

More	O
strikingly	O
,	O
the	O
80-kDa	B-protein
protein	I-protein
was	O
downregulated	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
;	O
this	O
effect	O
was	O
independent	O
of	O
the	O
mode	O
of	O
lymphocyte	O
activation	O
and	O
specific	O
for	O
the	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
metabolite	O
of	O
vitamin	O
D3	O
.	O

However	O
,	O
two	O
potent	O
immunosuppressive	O
agents	O
,	O
glucocorticoids	O
and	O
cyclosporin	O
A	O
,	O
also	O
inhibited	O
the	O
80-kDa	B-protein
protein	I-protein
.	O

Regulation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
effects	O
of	O
glucocorticoid	O
treatment	O
,	O
Cushing	O
's	O
disease	O
and	O
ketoconazole	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
(	O
GcR	B-protein
)	O
were	O
determined	O
by	O
a	O
whole	O
cell	O
assay	O
in	O
human	B-cell_type
mononulear	I-cell_type
leukocytes	I-cell_type
(	O
hMNL	B-cell_type
)	O
from	O
control	O
subjects	O
,	O
patients	O
receiving	O
glucocorticoid	O
therapy	O
for	O
systemic	O
diseases	O
and	O
Cushing	O
's	O
disease	O
patients	O
with	O
or	O
without	O
ketoconazole	O
therapy	O
.	O

Prolonged	O
corticosteroid	O
treatment	O
resulted	O
in	O
down-regulation	O
of	O
GcR	B-protein
,	O
while	O
the	O
mean	O
level	O
of	O
GcR	B-protein
in	O
Cushing	O
's	O
disease	O
was	O
normal	O
.	O

In	O
this	O
group	O
,	O
however	O
,	O
receptor	O
levels	O
and	O
morning	O
plasma	O
cortisol	O
values	O
showed	O
a	O
negative	O
correlation	O
,	O
indicating	O
a	O
subtle	O
down-regulatory	O
effect	O
.	O

Furthermore	O
,	O
GcR	B-protein
were	O
unaltered	O
after	O
these	O
patients	O
received	O
ketoconazole	O
,	O
in	O
spite	O
of	O
a	O
marked	O
reduction	O
in	O
morning	O
plasma	O
cortisol	O
and	O
urinary	O
free	O
cortisol	O
.	O

We	O
also	O
observed	O
that	O
ketoconazole	O
was	O
a	O
weak	O
competitor	O
of	O
GcR	B-protein
in	O
intact	B-cell_type
cells	I-cell_type
,	O
although	O
it	O
significantly	O
inhibited	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosolic	O
preparations	O
from	O
rat	O
tissues	O
.	O

The	O
results	O
suggested	O
that	O
GcR	B-protein
in	O
hMNL	B-cell_type
are	O
down-regulated	O
by	O
synthetic	O
steroids	O
given	O
in	O
vivo	O
,	O
but	O
they	O
showed	O
very	O
mild	O
down-regulation	O
in	O
hypercortisolemic	O
patients	O
suffering	O
from	O
Cushing	O
's	O
disease	O
.	O

Finally	O
,	O
we	O
did	O
not	O
observed	O
either	O
up-regulation	O
or	O
antagonism	O
of	O
GcR	B-protein
by	O
ketoconazole	O
treatment	O
,	O
at	O
the	O
time	O
that	O
cortisol	O
levels	O
of	O
patients	O
with	O
Cushing	O
's	O
disease	O
were	O
reduced	O
.	O

This	O
indicates	O
that	O
the	O
beneficial	O
effects	O
of	O
ketoconazole	O
in	O
Cushing	O
's	O
disease	O
are	O
due	O
to	O
adrenal	O
cortisol	O
suppression	O
and	O
not	O
to	O
interaction	O
with	O
GcR	B-protein
of	O
target	B-cell_type
cells	I-cell_type
,	O
and	O
that	O
the	O
process	O
of	O
GcR	B-protein
regulation	O
in	O
hMNL	B-cell_type
is	O
a	O
complex	O
phenomenon	O
awaiting	O
further	O
elucidation	O
.	O

HTLV-1	B-protein
Tax	I-protein
induces	O
expression	O
of	O
various	O
immediate	B-DNA
early	I-DNA
serum	I-DNA
responsive	I-DNA
genes	I-DNA
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

We	O
showed	O
here	O
by	O
mobility-shift	O
assay	O
that	O
T-cell	B-cell_line
lines	I-cell_line
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP-1	B-protein
activities	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
these	O
cell	O
lines	O
expressed	O
increased	O
levels	O
of	O
mRNAs	B-RNA
encoding	O
the	O
AP-1	B-protein
proteins	I-protein
,	O
c-Fos	B-protein
,	O
Fra-1	B-protein
,	O
c-Jun	B-protein
,	O
JunB	B-protein
,	O
and	O
JunD	B-protein
.	O

Previously	O
,	O
transcription	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	B-protein
transcription	I-protein
factor	I-protein
,	O
Tax1	B-protein
.	O

By	O
using	O
the	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
(	O
JPX-9	B-cell_line
)	O
,	O
in	O
which	O
expression	O
of	O
the	O
Tax1	B-protein
is	O
inducible	O
,	O
we	O
showed	O
that	O
expression	O
of	O
mRNAs	B-RNA
for	O
Fra-1	B-protein
,	O
c-Jun	B-protein
,	O
and	O
JunD	B-protein
was	O
also	O
transactivated	O
by	O
Tax1	B-protein
.	O

Moreover	O
,	O
Tax1	B-protein
activated	O
expression	O
of	O
two	O
other	O
transcription	B-protein
factors	I-protein
having	O
zinc	B-protein
finger	I-protein
motifs	I-protein
,	O
Egr-1	B-protein
and	O
Egr-2	B-protein
,	O
in	O
the	O
same	O
cells	O
.	O

The	O
Tax1-inducible	B-protein
transcription	I-protein
factors	I-protein
identified	O
here	O
are	O
encoded	O
by	O
the	O
members	O
of	O
immediate	B-DNA
early	I-DNA
genes	I-DNA
under	O
the	O
control	O
of	O
growth	O
signals	O
.	O

Thus	O
,	O
Tax1	B-protein
was	O
suggested	O
to	O
replace	O
growth	O
signals	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
this	O
mechanism	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
characteristics	O
in	O
monocytes	B-cell_type
of	O
patients	O
with	O
corticosteroid-resistant	O
bronchial	O
asthma	O
.	O

The	O
mechanism	O
of	O
corticosteroid	O
resistance	O
in	O
bronchial	O
asthma	O
has	O
been	O
studied	O
by	O
determining	O
the	O
rank	O
order	O
of	O
potency	O
for	O
different	O
corticosteroids	O
in	O
inhibiting	O
the	O
generation	O
of	O
a	O
3	O
kD	O
molecule	O
from	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
isolated	O
from	O
corticosteroid-sensitive	O
(	O
CS	O
)	O
and	O
corticosteroid-resistant	O
(	O
CR	O
)	O
asthmatic	O
subjects	O
,	O
which	O
augments	O
leukotriene	O
B4	O
(	O
LTB4	B-protein
)	O
generation	O
by	O
human	B-cell_type
neutrophils	I-cell_type
(	O
PMN	B-cell_type
)	O
stimulated	O
by	O
calcium	O
ionophore	O
.	O

In	O
addition	O
,	O
binding	O
studies	O
with	O
(	O
3H	O
)	O
dexamethasone	O
have	O
been	O
performed	O
to	O
determine	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
receptor	O
numbers	O
(	O
Ro	O
)	O
in	O
the	O
monocytes	B-cell_type
of	O
these	O
two	O
groups	O
of	O
subjects	O
.	O

The	O
concentration	O
of	O
corticosteroid	O
producing	O
50	O
%	O
inhibition	O
(	O
IC50	O
)	O
was	O
600	O
nM	O
,	O
70	O
nM	O
,	O
and	O
0.5	O
nM	O
for	O
hydrocortisone	O
,	O
methylprednisolone	O
,	O
and	O
dexamethasone	O
,	O
respectively	O
,	O
in	O
monocytes	B-cell_type
from	O
CS	O
individuals	O
.	O

There	O
was	O
only	O
weak	O
inhibition	O
of	O
the	O
generation	O
of	O
enhancing	O
activity	O
by	O
the	O
corticosteroids	O
in	O
the	O
CR	O
asthmatic	O
individuals	O
.	O

The	O
dexamethasone	O
Kd	O
was	O
2.45	O
+/-	O
0.58	O
nM	O
(	O
mean	O
+/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CS	O
group	O
and	O
1.6	O
+/-	O
0.35	O
nM	O
(	O
mean	O
+/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
of	O
patients	O
(	O
p	O
=	O
0.14	O
)	O
.	O

The	O
Ro	O
in	O
the	O
CS	O
group	O
was	O
3	O
,	O
605	O
+/-	O
984	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
+/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
and	O
4	O
,	O
757	O
+/-	O
692	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
+/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
(	O
p	O
=	O
0.23	O
)	O
.	O

These	O
findings	O
indicate	O
that	O
corticosteroid	O
resistance	O
in	O
bronchial	O
asthma	O
can	O
not	O
be	O
explained	O
by	O
abnormalities	O
in	O
corticosteroid	O
receptor	O
characteristics	O
.	O

Vitamin	B-protein
D	I-protein
receptor	I-protein
expression	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

Signal	O
requirements	O
and	O
characterization	O
by	O
western	O
blots	O
and	O
DNA	O
sequencing	O
.	O

The	O
signals	O
controlling	O
the	O
expression	O
of	O
the	O
receptor	B-protein
protein	I-protein
for	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	B-cell_type
lymphocytes	I-cell_type
and	O
the	O
relationship	O
of	O
this	O
protein	O
to	O
the	O
classical	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
were	O
examined	O
.	O

Lymphocytes	B-cell_type
activated	O
with	O
the	O
OKT3	B-protein
antibody	I-protein
to	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
expressed	O
fewer	O
binding	O
sites	O
as	O
compared	O
to	O
lymphocytes	B-cell_type
that	O
were	O
activated	O
by	O
the	O
polyclonal	O
activator	O
phytohemagglutinin	B-protein
(	O
PHA	B-protein
)	O
.	O

However	O
,	O
combination	O
of	O
OKT3	B-protein
and	O
phorbol	O
myristate	O
acetate	O
produced	O
a	O
concentration	O
of	O
binding	O
sites	O
similar	O
to	O
the	O
PHA-activated	B-cell_line
cells	I-cell_line
.	O

The	O
receptor	O
from	O
OKT3	B-protein
and	O
OKT3	B-protein
+	O
phorbol	O
myristate	O
acetate	O
-activated	B-cell_type
lymphocytes	I-cell_type
exhibited	O
decreased	O
binding	O
to	O
DNA-cellulose	O
compared	O
to	O
PHA-activated	B-cell_type
lymphocytes	I-cell_type
.	O

In	O
lymphocytes	B-cell_type
activated	O
either	O
by	O
PHA	B-protein
or	O
OKT3	B-protein
(	O
but	O
not	O
in	O
resting	B-cell_type
cells	I-cell_type
)	O
,	O
a	O
50-kDa	B-protein
species	I-protein
cross-reacting	O
with	O
a	O
monoclonal	B-protein
antibody	I-protein
against	O
the	O
intestinal	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
was	O
detected	O
.	O

Finally	O
,	O
RNA	O
from	O
activated	B-cell_type
lymphocytes	I-cell_type
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
using	O
oligonucleotide	O
primers	O
flanking	O
the	O
196	B-DNA
base	I-DNA
pair	I-DNA
long	I-DNA
region	I-DNA
encoding	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
human	B-protein
intestinal	I-protein
receptor	I-protein
.	O

The	O
amplified	O
product	O
showed	O
an	O
identical	B-DNA
nucleotide	I-DNA
sequence	I-DNA
to	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
human	B-protein
intestinal	I-protein
receptor	I-protein
.	O

These	O
findings	O
suggest	O
that	O
expression	O
of	O
the	O
1	B-protein
,	I-protein
25-	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
in	O
lymphocytes	B-cell_type
is	O
triggered	O
by	O
distinct	O
and	O
contingent	O
signals	O
,	O
and	O
that	O
the	O
protein	O
and	O
the	O
mRNA	B-RNA
encoding	O
it	O
are	O
identical	O
to	O
the	O
classical	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
.	O

Comparison	O
of	O
constitutive	O
and	O
inducible	O
transcriptional	O
enhancement	O
mediated	O
by	O
kappa	B-DNA
B-related	I-DNA
sequences	I-DNA
:	O
modulation	O
of	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
by	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
tax	I-DNA
gene	I-DNA
.	O

The	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
(	O
GGGACTTTCC	O
)	O
binds	O
a	O
factor	O
,	O
NF-kappa	B-protein
B	I-protein
,	O
that	O
is	O
constitutively	O
found	O
in	O
its	O
functional	O
,	O
DNA	O
binding	O
form	O
only	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

A	O
factor	O
with	O
apparently	O
indistinguishable	O
sequence	O
specificity	O
can	O
be	O
induced	O
in	O
many	O
other	O
cell	O
types	O
,	O
where	O
it	O
is	O
used	O
to	O
regulate	O
inducible	O
gene	O
expression	O
.	O

For	O
example	O
,	O
kappa	B-DNA
B-related	I-DNA
sequences	I-DNA
have	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
transcription	O
of	O
a	O
few	O
inducible	O
genes	O
,	O
such	O
as	O
the	O
interleukin	B-DNA
2	I-DNA
receptor	I-DNA
alpha-chain	I-DNA
gene	I-DNA
and	O
the	O
beta-interferon	B-DNA
gene	I-DNA
.	O

However	O
,	O
these	O
genes	O
are	O
not	O
constitutively	O
active	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
suggesting	O
that	O
other	O
regulatory	O
mechanisms	O
must	O
play	O
a	O
role	O
in	O
determining	O
the	O
patterns	O
of	O
expression	O
.	O

We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	B-DNA
B-related	I-DNA
sequence	I-DNA
elements	I-DNA
in	O
two	O
different	O
cell	O
types	O
.	O

We	O
show	O
that	O
in	O
S194	B-cell_line
plasma	I-cell_line
cells	I-cell_line
the	O
activity	O
of	O
each	O
element	O
correlates	O
well	O
with	O
the	O
relative	O
affinity	O
of	O
B-cell-derived	B-protein
NF-kappa	I-protein
B	I-protein
for	O
that	O
element	O
.	O

This	O
leads	O
to	O
significantly	O
lower	O
transcription	O
enhancement	O
by	O
sites	O
derived	O
from	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
or	O
T-cell	B-DNA
receptor	I-DNA
genes	I-DNA
in	O
S194	B-cell_line
cells	I-cell_line
.	O

However	O
,	O
in	O
either	O
EL-4	B-cell_line
(	I-cell_line
T	I-cell_line
)	I-cell_line
cells	I-cell_line
or	O
S194	B-cell_line
cells	I-cell_line
,	O
both	O
lower-affinity	O
sites	O
can	O
be	O
significantly	O
induced	O
by	O
the	O
tax	B-protein
gene	I-protein
product	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
,	O
showing	O
that	O
NF-kappa	B-protein
B	I-protein
activity	O
can	O
be	O
modulated	O
even	O
in	O
a	O
B-cell	B-cell_line
line	I-cell_line
that	O
constitutively	O
expresses	O
this	O
factor	O
.	O

Specific	O
depletion	O
of	O
the	O
B-cell	B-cell_line
population	I-cell_line
induced	O
by	O
aberrant	O
expression	O
of	O
human	B-DNA
interferon	I-DNA
regulatory	I-DNA
factor	I-DNA
1	I-DNA
gene	I-DNA
in	O
transgenic	O
mice	O
.	O

Interferons	B-protein
(	O
IFNs	B-protein
)	O
are	O
well	O
known	O
both	O
as	O
antiviral	B-protein
proteins	I-protein
and	O
as	O
potent	O
regulators	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
fact	O
,	O
IFNs	B-protein
inhibit	O
growth	O
of	O
various	O
normal	B-cell_type
and	O
transformed	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

Previously	O
,	O
a	O
nuclear	B-protein
factor	I-protein
,	O
IRF-1	B-protein
(	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
)	O
,	O
which	O
binds	O
to	O
type	B-DNA
I	I-DNA
IFN	I-DNA
and	O
some	O
IFN-inducible	B-DNA
gene	I-DNA
promoters	I-DNA
,	O
was	O
identified	O
and	O
cloned	O
.	O

Since	O
the	O
IRF-1	B-protein
gene	O
is	O
both	O
virus	O
and	O
IFN	B-protein
inducible	O
,	O
an	O
intriguing	O
issue	O
is	O
raised	O
as	O
to	O
whether	O
the	O
IRF-1	B-DNA
gene	I-DNA
is	O
functioning	O
in	O
IFN	B-protein
-mediated	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
transgenic	O
mice	O
carrying	O
the	O
human	B-DNA
IRF-1	I-DNA
gene	I-DNA
linked	O
to	O
the	O
human	B-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
enhancer	I-DNA
.	O

In	O
the	O
transgenic	O
mice	O
,	O
all	O
the	O
lymphoid	O
tissues	O
examined	O
showed	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
(	O
B	B-cell_type
cells	I-cell_type
)	O
.	O

Preparation	O
and	O
analysis	O
of	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
from	O
the	O
chimeric	O
mice	O
indicated	O
that	O
the	O
bone	O
marrow	O
is	O
the	O
effective	O
site	O
for	O
specific	O
depletion	O
of	O
the	O
B-cell	B-cell_type
population	I-cell_type
.	O

In	O
fact	O
,	O
transgenic	B-cell_line
bone	I-cell_line
marrow	I-cell_line
cells	I-cell_line
cocultured	O
with	O
a	O
bone	B-cell_line
marrow-derived	I-cell_line
stromal	I-cell_line
cell	I-cell_line
line	I-cell_line
revealed	O
an	O
altered	O
B-cell	B-cell_type
maturation	O
pattern	O
.	O

Characterization	O
of	O
a	O
cofactor	B-protein
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	B-protein
homeodomain	I-protein
protein	I-protein
.	O

Dimerization	O
among	O
transcription	B-protein
factors	I-protein
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Hepatocyte	B-protein
nuclear	I-protein
factor-1	I-protein
alpha	I-protein
(	O
HNF-1	B-protein
alpha	I-protein
)	O
is	O
a	O
homeodomain-containing	B-protein
protein	I-protein
that	O
functions	O
as	O
a	O
dimer	B-protein
.	O

A	O
dimerization	B-protein
cofactor	I-protein
of	O
HNF-1	B-protein
alpha	I-protein
(	O
DCoH	B-protein
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	O
bind	O
to	O
DNA	O
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF-1	B-protein
alpha	I-protein
dimers	I-protein
.	O

The	O
formation	O
of	O
a	O
stable	O
tetrameric	B-protein
DCoH-HNF-1	I-protein
alpha	I-protein
complex	I-protein
,	O
which	O
required	O
the	O
dimerization	B-protein
domain	I-protein
of	O
HNF-1	B-protein
alpha	I-protein
,	O
did	O
not	O
change	O
the	O
DNA	O
binding	O
characteristics	O
of	O
HNF-1	B-protein
alpha	I-protein
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O

However	O
,	O
DCoH	B-protein
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
.	O

These	O
results	O
indicate	O
that	O
DCoH	B-protein
regulates	O
formation	O
of	O
transcriptionally	O
active	O
tetrameric	B-protein
complexes	I-protein
and	O
may	O
contribute	O
to	O
the	O
developmental	O
specificity	O
of	O
the	O
complex	B-protein
.	O

Glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
.	O

Glucocorticoid	O
pharmacokinetics	O
,	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
,	O
and	O
inhibition	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cell	I-cell_type
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
.	O

A	O
total	O
of	O
37	O
chronic	O
,	O
severe	O
,	O
nonsmoking	O
asthmatic	O
patients	O
with	O
documented	O
reversible	O
airways	O
obstruction	O
were	O
classified	O
as	O
glucocorticoid-sensitive	O
or	O
-resistant	O
on	O
the	O
basis	O
of	O
changes	O
in	O
FEV1	O
,	O
FVC	O
,	O
and	O
peak	O
expiratory	O
flow	O
(	O
PEF	O
)	O
after	O
oral	O
prednisolone	O
.	O

The	O
resistant	O
patients	O
showed	O
no	O
significant	O
improvements	O
in	O
airflow	O
limitation	O
.	O

Phytohemagglutinin	B-protein
(	O
PHA	B-protein
)	O
-induced	O
proliferation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
from	O
the	O
sensitive	O
but	O
not	O
the	O
resistant	O
asthmatic	O
patients	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0.01	O
)	O
inhibited	O
by	O
dexamethasone	O
(	O
10	O
(	O
-7	O
)	O
mol/L	O
)	O
,	O
reflecting	O
a	O
shift	O
of	O
the	O
dose-response	O
curve	O
.	O

When	O
all	O
the	O
asthmatic	O
patients	O
were	O
analyzed	O
together	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
degree	O
of	O
sensitivity	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
dexamethasone	O
and	O
the	O
clinical	O
responsiveness	O
to	O
prednisolone	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

No	O
differences	O
were	O
observed	O
between	O
six	O
of	O
the	O
sensitive	O
and	O
resistant	O
patients	O
in	O
the	O
clearance	O
of	O
plasma	O
prednisolone	O
derived	O
from	O
orally	O
administered	O
prednisone	O
.	O

Peripheral	B-protein
blood	I-protein
mononuclear	I-protein
cell	I-protein
glucocorticoid	I-protein
receptors	I-protein
were	O
also	O
characterized	O
in	O
five	O
sensitive	O
and	O
seven	O
resistant	O
patients	O
.	O

The	O
numbers	O
and	O
binding	O
affinities	O
of	O
these	O
receptors	B-protein
could	O
not	O
account	O
for	O
the	O
observed	O
difference	O
in	O
the	O
susceptibility	O
of	O
these	O
cells	O
to	O
functional	O
inhibition	O
by	O
dexamethasone	O
in	O
vitro	O
.	O

These	O
results	O
suggest	O
that	O
clinical	O
glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
does	O
not	O
reflect	O
abnormal	O
glucocorticoid	O
clearance	O
but	O
may	O
be	O
due	O
at	O
least	O
partly	O
to	O
a	O
relative	O
insensitivity	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
to	O
glucocorticoids	O
.	O

This	O
lack	O
of	O
sensitivity	O
is	O
unexplained	O
but	O
is	O
not	O
attributable	O
to	O
abnormalities	O
of	O
cellular	B-protein
glucocorticoid	I-protein
receptors	I-protein
.	O

Inhibition	O
of	O
phorbol	O
ester-induced	O
monocytic	O
differentiation	O
by	O
dexamethasone	O
is	O
associated	O
with	O
down-regulation	O
of	O
c-fos	B-DNA
and	O
c-jun	B-DNA
(	O
AP-1	B-DNA
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
treatment	O
of	O
human	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
is	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c-jun	B-DNA
and	I-DNA
c-fos	I-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
.	O

The	O
present	O
work	O
demonstrates	O
that	O
the	O
glucocorticoid	O
dexamethasone	O
inhibits	O
TPA-induced	O
increases	O
in	O
c-jun	O
and	O
c-fos	O
mRNA	O
levels	O
in	O
U-937	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

These	O
findings	O
were	O
associated	O
with	O
a	O
block	O
in	O
appearance	O
of	O
the	O
monocytic	B-cell_type
phenotype	I-cell_type
,	O
including	O
inhibition	O
of	O
TPA-induced	O
increases	O
in	O
lamin	B-RNA
A	I-RNA
,	I-RNA
lamin	I-RNA
C	I-RNA
,	I-RNA
and	I-RNA
vimentin	I-RNA
transcripts	I-RNA
.	O

Other	O
studies	O
have	O
demonstrated	O
that	O
TPA-induced	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c-jun	B-DNA
and	O
c-fos	B-DNA
genes	I-DNA
in	O
myeloid	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
are	O
regulated	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O

The	O
finding	O
that	O
dexamethasone	O
has	O
no	O
effect	O
on	O
TPA-induced	O
activation	O
of	O
PKC	B-protein
suggests	O
that	O
this	O
glucocorticoid	O
inhibits	O
signals	O
downstream	O
or	O
parallel	O
to	O
this	O
enzyme	B-protein
.	O

Nuclear	O
run-on	O
assays	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
induction	O
of	O
c-jun	O
and	O
c-fos	O
expression	O
by	O
TPA	O
is	O
regulated	O
by	O
transcriptional	O
mechanisms	O
,	O
(	O
2	O
)	O
TPA-induced	O
expression	O
of	O
c-jun	B-DNA
and	O
c-fos	B-protein
does	O
not	O
require	O
protein	O
synthesis	O
,	O
and	O
(	O
3	O
)	O
TPA-induced	O
expression	O
of	O
both	O
genes	O
is	O
inhibited	O
at	O
the	O
transcriptional	O
level	O
by	O
dexamethasone	O
.	O

To	O
further	O
define	O
the	O
effects	O
of	O
dexamethasone	O
at	O
the	O
molecular	O
level	O
,	O
we	O
prepared	O
a	O
series	O
of	O
deleted	O
c-jun	B-DNA
promoter	I-DNA
fragments	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
.	O

Increases	O
in	O
CAT	B-protein
activity	O
during	O
transient	O
expression	O
of	O
these	O
constructs	O
in	O
TPA-treated	B-cell_line
U-937	I-cell_line
cells	I-cell_line
could	O
be	O
assigned	O
to	O
the	O
region	O
(	O
-97	O
to	O
-20	O
)	O
of	O
the	O
promoter	B-DNA
that	O
contains	O
the	O
AP-1	B-DNA
binding	I-DNA
site	I-DNA
.	O

This	O
induction	O
of	O
CAT	B-protein
activity	O
was	O
sensitive	O
to	O
dexamethasone	O
.	O

These	O
findings	O
suggest	O
that	O
dexamethasone	O
down-regulates	O
TPA-induced	O
transcription	O
of	O
the	O
c-jun	B-DNA
gene	O
during	O
monocytic	O
differentiation	O
by	O
inhibiting	O
activation	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
.	O

Tumor	B-RNA
necrosis	I-RNA
factor-alpha	I-RNA
mRNA	I-RNA
accumulation	O
in	O
human	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Role	O
of	O
transcriptional	O
regulation	O
by	O
DNA	B-DNA
sequence	I-DNA
motifs	I-DNA
and	O
mRNA	O
stabilization	O
.	O

The	O
cytokine	B-protein
TNF	B-protein
mediates	O
many	O
of	O
the	O
pathologic	O
signs	O
of	O
cachexia	O
,	O
inflammation	O
,	O
and	O
sepsis	O
.	O

The	O
current	O
work	O
describes	O
the	O
regulation	O
of	O
TNF	B-protein
in	O
human	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
after	O
PMA	O
stimulation	O
.	O

The	O
cell	B-cell_line
lines	I-cell_line
exhibit	O
a	O
low	O
level	O
of	O
constitutive	O
TNF	B-RNA
mRNA	I-RNA
expression	O
.	O

Within	O
2	O
to	O
4	O
h	O
of	O
PMA	O
exposure	O
,	O
steady	O
state	O
levels	O
of	O
TNF	B-RNA
mRNA	I-RNA
are	O
markedly	O
elevated	O
in	O
all	O
myelomonocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
studied	O
.	O

This	O
rise	O
is	O
due	O
to	O
increased	O
mRNA	O
stability	O
,	O
which	O
increased	O
by	O
almost	O
twofold	O
,	O
and	O
to	O
an	O
overall	O
increase	O
in	O
transcription	O
,	O
which	O
rises	O
by	O
more	O
than	O
sixfold	O
.	O

At	O
the	O
level	O
of	O
the	O
genomic	B-DNA
TNF	I-DNA
gene	I-DNA
,	O
a	O
DNase	B-DNA
I	I-DNA
hypersensitive	I-DNA
site	I-DNA
is	O
detected	O
within	O
the	O
TNF	B-DNA
promoter	I-DNA
between	O
-200	O
to	O
-100	O
bp	O
relative	O
to	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

Although	O
absent	O
in	O
nonexpressing	B-cell_line
erythroleukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
DNase	B-DNA
I	I-DNA
site	I-DNA
is	O
present	O
in	O
uninduced	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
is	O
not	O
changed	O
after	O
PMA	O
induction	O
.	O

The	O
PMA	O
induction	O
of	O
c-fos	B-RNA
mRNA	I-RNA
correlated	O
well	O
with	O
TNF	B-protein
gene	O
induction	O
;	O
expression	O
of	O
genes	O
encoding	O
other	O
proteins	O
in	O
the	O
AP-1	B-protein
complex	I-protein
(	O
junB	B-protein
and	O
junD	B-protein
)	O
were	O
also	O
induced	O
by	O
PMA	O
.	O

The	O
nuclear	O
extracts	O
from	O
resting	O
and	O
induced	B-cell_line
ML-1	I-cell_line
cells	I-cell_line
contain	O
proteins	O
binding	O
specifically	O
to	O
the	O
AP-1	B-DNA
,	I-DNA
AP-2	I-DNA
,	I-DNA
and	I-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
sequence	I-DNA
located	O
within	O
the	O
TNF	B-DNA
promoter	I-DNA
.	O

PMA	O
induction	O
increases	O
the	O
level	O
of	O
a	O
number	O
of	O
specific	B-protein
binding	I-protein
complexes	I-protein
relative	O
to	O
the	O
resting	B-cell_type
cells	I-cell_type
.	O

The	O
regulatory	O
mechanisms	O
of	O
the	O
human	B-DNA
and	I-DNA
murine	I-DNA
TNF	I-DNA
genes	I-DNA
are	O
discussed	O
.	O

Enhancement	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
replication	O
in	O
monocytes	B-cell_type
by	O
1	O
,	O
25-dihydroxycholecalciferol	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
expression	O
and	O
replication	O
are	O
under	O
tight	O
regulatory	O
control	O
.	O

We	O
demonstrate	O
that	O
1	O
,	O
25-dihydroxycholecalciferol	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
enhances	O
the	O
replication	O
of	O
monocyte-	O
and	O
lymphocyte-tropic	O
strains	O
of	O
HIV-1	O
up	O
to	O
10	O
,	O
000-fold	O
in	O
monocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
,	O
and	O
unfractionated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
therefore	O
one	O
of	O
the	O
most	O
potent	O
regulators	O
of	O
HIV-1	O
replication	O
described	O
to	O
date	O
.	O

Precursors	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhance	O
HIV-1	O
replication	O
in	O
proportion	O
to	O
their	O
affinity	O
for	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
intracellular	I-protein
receptor	I-protein
,	O
suggesting	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
influences	O
HIV-1	O
replication	O
by	O
mechanisms	O
involving	O
this	O
receptor	O
.	O

These	O
studies	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
effective	O
therapy	O
of	O
HIV-1	O
infection	O
.	O

Transforming	B-protein
growth	I-protein
factor-beta	I-protein
suppresses	O
human	B-protein
B	I-protein
lymphocyte	I-protein
Ig	I-protein
production	O
by	O
inhibiting	O
synthesis	O
and	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
form	I-RNA
to	O
the	O
secreted	B-RNA
form	I-RNA
of	O
Ig	B-RNA
mRNA	I-RNA
.	O

Transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	O
TGF-beta	B-protein
)	O
inhibits	O
B	B-cell_type
cell	I-cell_type
Ig	B-protein
secretion	O
and	O
reduces	O
B	B-cell_type
cell	I-cell_type
membrane	O
Ig	B-protein
expression	O
.	O

The	O
addition	O
of	O
TGF-beta	B-protein
to	O
human	B-cell_line
B	I-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
stimulated	O
with	O
Staphylococcus	O
aureus	O
Cowan	O
strain	O
I	O
and	O
IL-2	B-protein
completely	O
inhibited	O
B	B-cell_type
cell	I-cell_type
Ig	B-protein
secretion	O
(	O
greater	O
than	O
90	O
%	O
)	O
and	O
decreased	O
B	B-cell_type
cell	I-cell_type
surface	O
IgM	O
,	O
IgD	O
,	O
kappa	O
L	O
chain	O
,	O
and	O
lambda	O
L	O
chain	O
expression	O
.	O

In	O
contrast	O
,	O
TGF-beta	B-protein
had	O
only	O
minimal	O
effects	O
on	O
two	O
other	O
B	B-protein
cell	I-protein
membrane	I-protein
proteins	I-protein
,	O
HLA-DR	B-protein
and	O
CD20	B-protein
.	O

Internal	O
labeling	O
with	O
[	O
35S	O
]	O
methionine	O
and	O
immunoprecipitation	O
with	O
anti-IgM	B-protein
,	O
anti-kappa	B-protein
,	O
and	O
anti-lambda	B-protein
antibodies	I-protein
revealed	O
a	O
striking	O
reduction	O
in	O
kappa	B-protein
L	I-protein
chain	I-protein
in	O
the	O
presence	O
of	O
TGF-beta	B-protein
.	O

A	O
less	O
pronounced	O
reduction	O
in	O
lambda	B-protein
L	I-protein
chain	I-protein
and	O
microH	B-protein
chain	I-protein
was	O
also	O
noted	O
.	O

Northern	O
blot	O
analysis	O
of	O
RNA	O
purified	O
from	O
B	B-cell_type
cells	I-cell_type
treated	O
with	O
TGF-beta	B-protein
for	O
varying	O
time	O
intervals	O
revealed	O
a	O
significant	O
decrease	O
in	O
steady	O
state	O
kappa	O
and	O
lambda	O
L	O
chain	O
mRNA	O
levels	O
.	O

Furthermore	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
forms	I-RNA
of	O
mu	B-RNA
and	O
gamma	B-RNA
to	O
their	O
respective	O
secreted	B-RNA
forms	I-RNA
was	O
noted	O
in	O
the	O
presence	O
of	O
TGF-beta	B-protein
.	O

Nuclear	O
run-on	O
experiments	O
demonstrated	O
decreased	O
transcription	O
of	O
kappa	B-protein
L	I-protein
chain	I-protein
.	O

The	O
effects	O
of	O
TGF-beta	B-protein
on	O
two	O
transcriptional	B-protein
regulatory	I-protein
factors	I-protein
,	O
Oct-2	B-protein
and	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
kappa	I-protein
B	I-protein
,	O
known	O
to	O
be	O
important	O
in	O
Ig	B-protein
gene	O
transcription	O
were	O
examined	O
.	O

Oct-2	B-RNA
mRNA	I-RNA
levels	O
and	O
both	O
Oct-2	B-protein
and	O
NF-kappa	B-protein
B	I-protein
proteins	I-protein
in	O
nuclear	O
extracts	O
were	O
not	O
altered	O
by	O
treatment	O
with	O
TGF-beta	B-protein
.	O

In	O
contrast	O
,	O
levels	O
of	O
the	O
transcriptional	B-protein
factor	I-protein
AP-1	I-protein
,	O
which	O
is	O
not	O
known	O
to	O
be	O
important	O
in	O
B	B-cell_type
cell	I-cell_type
Ig	B-protein
production	O
,	O
were	O
reduced	O
by	O
TGF-beta	B-protein
.	O

These	O
findings	O
demonstrate	O
that	O
TGF-beta	B-protein
decreases	O
B	O
lymphocyte	O
Ig	B-protein
secretion	O
by	O
inhibiting	O
the	O
synthesis	O
of	O
Ig	B-RNA
mRNA	I-RNA
and	O
inhibiting	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
form	I-RNA
to	O
the	O
secreted	B-RNA
forms	I-RNA
of	O
mu	B-RNA
and	I-RNA
gamma	I-RNA
mRNA	I-RNA
.	O

The	O
mechanism	O
by	O
which	O
TGF-beta	B-protein
inhibits	O
Ig	O
chain	O
synthesis	O
is	O
unclear	O
although	O
it	O
does	O
not	O
involve	O
inhibition	O
of	O
the	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
or	O
Oct-2	B-protein
to	O
their	O
respective	O
target	O
sequences	O
.	O

Murine	B-protein
and	I-protein
human	I-protein
T-lymphocyte	I-protein
GATA-3	I-protein
factors	I-protein
mediate	O
transcription	O
through	O
a	O
cis-regulatory	B-DNA
element	I-DNA
within	O
the	O
human	B-DNA
T-cell	I-DNA
receptor	I-DNA
delta	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O

A	O
family	O
of	O
transcriptional	B-protein
activators	I-protein
has	O
recently	O
been	O
identified	O
in	O
chickens	O
;	O
these	O
transcriptional	B-protein
activators	I-protein
recognize	O
a	O
common	O
consensus	B-DNA
motif	I-DNA
(	O
WGATAR	B-DNA
)	O
through	O
a	O
conserved	O
C4	B-protein
zinc	I-protein
finger	I-protein
DNA-binding	I-protein
domain	I-protein
.	O

One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA-3	B-protein
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
T-lymphocyte	B-cell_type
cell	I-cell_type
lineage	I-cell_type
.	O

Analysis	O
of	O
human	B-protein
and	I-protein
murine	I-protein
GATA-3	I-protein
factors	I-protein
shows	O
a	O
striking	O
degree	O
of	O
amino	O
acid	O
sequence	O
identity	O
and	O
similar	O
patterns	O
of	O
tissue	O
specificity	O
of	O
expression	O
in	O
these	O
three	O
organisms	O
.	O

The	O
murine	B-protein
and	I-protein
human	I-protein
factors	I-protein
are	O
abundantly	O
expressed	O
in	O
a	O
variety	O
of	O
human	B-cell_line
and	I-cell_line
murine	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
can	O
activate	O
transcription	O
through	O
a	O
tissue-specific	B-DNA
GATA-binding	I-DNA
site	I-DNA
identified	O
within	O
the	O
human	B-DNA
T-cell	I-DNA
receptor	I-DNA
delta	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O

We	O
infer	O
that	O
the	O
murine	B-protein
and	I-protein
human	I-protein
GATA-3	I-protein
proteins	I-protein
play	O
a	O
central	O
and	O
highly	O
conserved	O
role	O
in	O
vertebrate	O
T-cell-specific	O
transcriptional	O
regulation	O
.	O

Processing	O
of	O
the	O
precursor	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
the	O
HIV-1	B-protein
protease	I-protein
during	O
acute	O
infection	O
.	O

Transcription	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type-1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
genome	I-DNA
is	O
regulated	O
in	O
part	O
by	O
cellular	B-protein
factors	I-protein
and	O
is	O
stimulated	O
by	O
activation	O
of	O
latently	B-cell_type
infected	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

T-cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	O
NF-kappa	B-protein
B	I-protein
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

This	O
factor	O
consists	O
of	O
two	O
DNA-binding	B-protein
subunits	I-protein
of	O
relative	O
molecular	O
mass	O
50	O
,	O
000	O
(	O
50K	O
)	O
associated	O
with	O
two	O
65K	B-protein
subunits	I-protein
.	O

It	O
is	O
located	O
in	O
the	O
nucleus	O
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
is	O
present	O
in	O
other	O
cell	O
types	O
as	O
an	O
inactive	B-protein
cytoplasmic	I-protein
complex	I-protein
.	O

External	O
stimuli	O
,	O
including	O
those	O
that	O
activate	O
T	B-cell_type
cells	I-cell_type
,	O
result	O
in	O
nuclear	O
translocation	O
of	O
active	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
cloning	O
of	O
the	O
complementary	B-DNA
DNA	I-DNA
for	O
the	O
50K	B-protein
subunit	I-protein
helped	O
to	O
identify	O
an	O
exclusively	O
cytoplasmic	B-protein
105K	I-protein
precursor	I-protein
(	O
p105	B-protein
)	O
(	O
V.B.	O
,	O
P.K.	O
and	O
A.I.	O
,	O
manuscript	O
submitted	O
)	O
.	O

The	O
expression	O
of	O
active	O
NF-kappa	B-protein
B	I-protein
might	O
therefore	O
also	O
be	O
regulated	O
by	O
the	O
extent	O
of	O
processing	O
of	O
p105	B-protein
.	O

Because	O
HIV-1	O
requires	O
active	O
NF-kappa	B-protein
B	I-protein
for	O
efficient	O
transcription	O
,	O
we	O
tested	O
the	O
effect	O
of	O
HIV-1	O
infection	O
on	O
the	O
processing	O
of	O
the	O
human	B-protein
105K	I-protein
precursor	I-protein
.	O

We	O
show	O
here	O
that	O
the	O
HIV-1	O
protease	O
can	O
process	O
p105	B-protein
and	O
increases	O
levels	O
of	O
active	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
.	O

1	B-RNA
,	I-RNA
25-Dihydroxyvitamin	I-RNA
D3	I-RNA
receptor	I-RNA
RNA	I-RNA
:	O
expression	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
induces	O
differentiation	O
and	O
inhibits	O
proliferation	O
of	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
from	O
various	O
lines	O
and	O
patients	O
;	O
these	O
effects	O
are	O
probably	O
mediated	O
through	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
.	O

Little	O
is	O
known	O
of	O
expression	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

We	O
examined	O
the	O
expression	O
and	O
modulation	O
of	O
expression	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
in	O
various	O
proliferating	B-cell_type
and	I-cell_type
nonproliferating	I-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
.	O

Constitutive	O
expression	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
was	O
detected	O
in	O
various	O
kinds	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
including	O
macrophages	O
and	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
as	O
well	O
as	O
in	O
cell	O
lines	O
KG-1	B-cell_line
(	O
myeloblasts	B-cell_line
)	O
,	O
HL-60	B-cell_line
(	O
promyelocytes	B-cell_line
)	O
,	O
ML-3	B-cell_line
(	O
myelomonoblasts	B-cell_line
)	O
,	O
U937	B-cell_line
,	O
THP-1	B-cell_line
(	O
monoblasts	B-cell_line
)	O
,	O
K562	B-cell_line
(	O
erythroblasts	B-cell_line
)	O
,	O
and	O
S-LB1	B-cell_line
(	O
HTLV-1-transfected	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
)	O
.	O

Receptor	B-RNA
transcripts	I-RNA
were	O
4.6	O
kilobases	O
(	O
kb	O
)	O
,	O
and	O
no	O
variant	O
sizes	O
were	O
observed	O
.	O

All	O
cell	O
lines	O
examined	O
in	O
this	O
group	O
also	O
expressed	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
.	O

Most	O
B	B-cell_line
lymphocyte	I-cell_line
lines	I-cell_line
expressed	O
negligible	O
levels	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
and	O
protein	O
;	O
however	O
;	O
analysis	O
of	O
a	O
lymphoid/myeloid	B-cell_line
somatic	I-cell_line
hybrid	I-cell_line
suggested	O
that	O
suppression	O
of	O
expression	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
in	O
B	B-cell_type
lymphocytes	I-cell_type
may	O
be	O
a	O
dominant	O
characteristic	O
.	O

HL-60	B-cell_line
cells	I-cell_line
were	O
cultured	O
with	O
10	O
(	O
-7	O
)	O
mol/L	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
for	O
24	O
to	O
72	O
hours	O
,	O
and	O
levels	O
of	O
expression	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
and	O
its	O
RNA	O
were	O
examined	O
.	O

Levels	O
of	O
RNA	O
coding	O
for	O
the	O
receptor	B-protein
were	O
not	O
modulated	O
by	O
exposure	O
to	O
high	O
levels	O
of	O
ligand	O
.	O

Levels	O
of	O
occupied	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
protein	I-protein
increased	O
in	O
these	O
HL-60	B-cell_line
cells	I-cell_line
;	O
but	O
the	O
total	O
number	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
decreased	O
about	O
50	O
%	O
at	O
24	O
hours	O
and	O
returned	O
toward	O
normal	O
at	O
72	O
hours	O
.	O

Steady-state	O
levels	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
were	O
not	O
affected	O
by	O
terminal	O
differentiation	O
of	O
HL-60	B-cell_line
toward	O
either	O
granulocytes	B-cell_type
or	O
macrophages	B-cell_type
.	O

Nondividing	O
macrophages	B-cell_type
from	O
normal	O
individuals	O
also	O
expressed	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
.	O

In	O
contrast	O
,	O
nondividing	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
normal	O
individuals	O
did	O
not	O
express	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
;	O
with	O
stimulation	O
of	O
proliferation	O
of	O
these	O
cells	O
,	O
accumulation	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
increased	O
markedly	O
.	O

Half-life	O
(	O
t1/2	O
)	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
was	O
short	O
(	O
1	O
hour	O
)	O
as	O
determined	O
by	O
measuring	O
decay	O
of	O
the	O
message	O
after	O
addition	O
of	O
actinomycin	O
D	O
.	O

Consistent	O
with	O
this	O
short	O
t1/2	O
,	O
accumulation	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
increased	O
in	O
cells	O
as	O
their	O
protein	O
synthesis	O
was	O
inhibited	O
.	O

Further	O
studies	O
are	O
required	O
to	O
understand	O
the	O
physiologic	O
role	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
and	O
proliferating	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Expression	O
of	O
c-jun	B-DNA
,	I-DNA
jun	I-DNA
B	I-DNA
and	I-DNA
jun	I-DNA
D	I-DNA
proto-oncogenes	I-DNA
in	O
human	B-cell_type
peripheral-blood	I-cell_type
granulocytes	I-cell_type
.	O

We	O
have	O
found	O
that	O
purified	B-cell_type
human	I-cell_type
peripheral-blood	I-cell_type
granulocytes	I-cell_type
express	O
constitutively	O
significant	O
levels	O
of	O
proto-oncogenes	B-DNA
c-jun	B-RNA
,	I-RNA
jun	I-RNA
B	I-RNA
and	I-RNA
jun	I-RNA
D	I-RNA
mRNA	I-RNA
.	O

Upon	O
functional	O
activation	O
of	O
granulocytes	B-cell_type
by	O
4	O
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
the	O
levels	O
of	O
c-jun	B-RNA
,	I-RNA
jun	I-RNA
B	I-RNA
and	I-RNA
jun	I-RNA
D	I-RNA
transcripts	I-RNA
were	O
increased	O
.	O

The	O
three	O
jun	B-DNA
genes	I-DNA
showed	O
a	O
similar	O
time	O
course	O
in	O
their	O
induction	O
by	O
PMA	O
,	O
maximal	O
mRNA	O
levels	O
being	O
reached	O
after	O
60	O
min	O
of	O
induction	O
.	O

These	O
results	O
suggest	O
that	O
expression	O
of	O
c-jun	B-DNA
,	O
jun	B-DNA
B	I-DNA
and	O
jun	B-DNA
D	I-DNA
genes	I-DNA
might	O
be	O
involved	O
in	O
terminal	B-cell_type
granulocyte	I-cell_type
differentiation	O
or	O
in	O
regulating	O
granulocyte	B-cell_type
functionality	O
.	O

The	O
29-kDa	B-protein
proteins	I-protein
phosphorylated	O
in	O
thrombin-activated	B-cell_line
human	I-cell_line
platelets	I-cell_line
are	O
forms	O
of	O
the	O
estrogen	B-protein
receptor-related	I-protein
27-kDa	I-protein
heat	I-protein
shock	I-protein
protein	I-protein
.	O

Thrombin	B-protein
plays	O
a	O
critical	O
role	O
in	O
platelet	O
activation	O
,	O
hemostasis	O
,	O
and	O
thrombosis	O
.	O

Cellular	O
activation	O
by	O
thrombin	O
leads	O
to	O
the	O
phosphorylation	O
of	O
multiple	B-protein
proteins	I-protein
,	O
most	O
of	O
which	O
are	O
unidentified	O
.	O

We	O
have	O
characterized	O
several	O
29-kDa	B-protein
proteins	I-protein
that	O
are	O
rapidly	O
phosphorylated	O
following	O
exposure	O
of	O
intact	B-cell_type
human	I-cell_type
platelets	I-cell_type
to	O
thrombin	B-protein
.	O

A	O
murine	B-protein
monoclonal	I-protein
antibody	I-protein
raised	O
to	O
an	O
unidentified	B-protein
estrogen	I-protein
receptor-related	I-protein
29-kDa	I-protein
protein	I-protein
selectively	O
recognized	O
these	O
proteins	O
as	O
well	O
as	O
a	O
more	O
basic	O
,	O
unphosphorylated	B-protein
27-kDa	I-protein
protein	I-protein
.	O

Cellular	O
activation	O
by	O
thrombin	B-protein
led	O
to	O
a	O
marked	O
shift	O
in	O
the	O
proportion	O
of	O
protein	O
from	O
the	O
27-kDa	B-protein
unphosphorylated	I-protein
form	I-protein
to	O
the	O
29-kDa	B-protein
phosphoprotein	I-protein
species	I-protein
.	O

Using	O
this	O
antibody	O
,	O
we	O
isolated	O
and	O
sequenced	O
a	O
human	O
cDNA	B-DNA
clone	I-DNA
encoding	O
a	O
protein	O
that	O
was	O
identical	O
to	O
the	O
mammalian	B-protein
27-kDa	I-protein
heat	I-protein
shock	I-protein
protein	I-protein
(	O
HSP27	B-protein
)	O
,	O
a	O
protein	O
of	O
uncertain	O
function	O
that	O
is	O
known	O
to	O
be	O
phosphorylated	O
to	O
several	O
forms	O
and	O
to	O
be	O
transcriptionally	O
induced	O
by	O
estrogen	O
.	O

The	O
29-kDa	B-protein
proteins	I-protein
were	O
confirmed	O
to	O
be	O
phosphorylated	O
forms	O
of	O
HSP27	B-protein
by	O
immunoprecipitation	O
studies	O
.	O

Thus	O
,	O
the	O
``	O
estrogen	O
receptor-related	O
protein	O
''	O
is	O
HSP27	B-protein
,	O
and	O
the	O
three	O
major	O
29-kDa	B-protein
proteins	I-protein
phosphorylated	O
in	O
thrombin-activated	B-cell_type
platelets	I-cell_type
are	O
forms	O
of	O
HSP27	B-protein
.	O

These	O
data	O
suggest	O
a	O
role	O
for	O
HSP27	B-protein
in	O
the	O
signal	O
transduction	O
events	O
of	O
platelet	B-cell_type
activation	O
.	O

Isolation	O
of	O
a	O
candidate	O
repressor/activator	O
,	O
NF-E1	B-protein
(	O
YY-1	B-protein
,	O
delta	B-protein
)	O
,	O
that	O
binds	O
to	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
and	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
mu	I-DNA
E1	I-DNA
site	I-DNA
.	O

We	O
have	O
determined	O
that	O
the	O
developmental	O
control	O
of	O
immunoglobulin	B-DNA
kappa	I-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
(	O
kappa	B-DNA
E3	I-DNA
'	I-DNA
)	O
activity	O
is	O
the	O
result	O
of	O
the	O
combined	O
influence	O
of	O
positive-	B-DNA
and	I-DNA
negative-acting	I-DNA
elements	I-DNA
.	O

We	O
show	O
that	O
a	O
central	O
core	O
in	O
the	O
kappa	B-DNA
E3	I-DNA
'	I-DNA
enhancer	I-DNA
is	O
active	O
at	O
the	O
pre-B-cell	O
stage	O
but	O
is	O
repressed	O
by	O
flanking	B-DNA
negative-acting	I-DNA
elements	I-DNA
.	O

The	O
negative-acting	B-DNA
sequences	I-DNA
repress	O
enhancer	O
activity	O
in	O
a	O
position-	O
and	O
orientation-independent	O
manner	O
at	O
the	O
pre-B-cell	O
stage	O
.	O

We	O
have	O
isolated	O
a	O
human	B-DNA
cDNA	I-DNA
clone	I-DNA
encoding	O
a	O
zinc	B-protein
finger	I-protein
protein	I-protein
(	O
NF-E1	B-protein
)	O
that	O
binds	O
to	O
the	O
negative-acting	B-DNA
segment	I-DNA
of	O
the	O
kappa	B-DNA
E3	I-DNA
'	I-DNA
enhancer	I-DNA
.	O

This	O
protein	O
also	O
binds	O
to	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
enhancer	I-DNA
mu	I-DNA
E1	I-DNA
site	I-DNA
.	O

NF-E1	B-protein
is	O
encoded	O
by	O
the	O
same	O
gene	O
as	O
the	O
YY-1	B-protein
protein	I-protein
,	O
which	O
binds	O
to	O
the	O
adeno-associated	B-DNA
virus	I-DNA
P5	I-DNA
promoter	I-DNA
.	O

NF-E1	B-protein
is	O
also	O
the	O
human	B-protein
homologue	I-protein
of	O
the	O
mouse	B-DNA
delta	I-DNA
protein	I-DNA
,	O
which	O
binds	O
to	O
ribosomal	B-DNA
protein	I-DNA
gene	I-DNA
promoters	I-DNA
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
contains	O
features	O
characteristic	O
of	O
transcriptional	B-protein
activators	I-protein
as	O
well	O
as	O
transcriptional	B-protein
repressors	I-protein
.	O

Cotransfection	O
studies	O
with	O
this	O
cDNA	B-DNA
indicate	O
that	O
it	O
can	O
repress	O
basal	B-DNA
promoter	I-DNA
activity	O
.	O

The	O
apparent	O
dual	O
function	O
of	O
this	O
protein	O
is	O
discussed	O
.	O

A	O
human	B-DNA
putative	I-DNA
lymphocyte	I-DNA
G0/G1	I-DNA
switch	I-DNA
gene	I-DNA
containing	O
a	O
CpG-rich	B-DNA
island	I-DNA
encodes	O
a	O
small	B-protein
basic	I-protein
protein	I-protein
with	O
the	O
potential	O
to	O
be	O
phosphorylated	O
.	O

Genes	O
actively	O
involved	O
in	O
the	O
G0/G1	B-DNA
switch	I-DNA
(	O
G0S	B-RNA
genes	I-RNA
)	O
may	O
be	O
differentially	O
expressed	O
during	O
the	O
lectin	B-protein
-induced	O
switch	O
of	O
lymphocytes	B-cell_type
from	O
the	O
G0	O
to	O
the	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

This	O
paper	O
presents	O
studies	O
of	O
G0S2	B-DNA
,	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0S	B-RNA
genes	I-RNA
,	O
for	O
which	O
cDNAs	B-DNA
were	O
cloned	O
and	O
selected	O
on	O
the	O
basis	O
of	O
differential	O
cDNA	O
hybridization	O
.	O

G0S2	B-RNA
mRNA	I-RNA
increases	O
transiently	O
within	O
1-2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	B-protein
or	O
cycloheximide	O
to	O
cultured	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Comparison	O
of	O
a	O
nearly	B-DNA
full-length	I-DNA
cDNA	I-DNA
sequence	I-DNA
with	O
the	O
corresponding	O
genomic	B-DNA
sequence	I-DNA
reveals	O
one	O
small	O
intron	O
and	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
in	O
the	O
second	O
exon	B-DNA
.	O

The	O
derived	O
103-amino-acid	B-protein
basic	I-protein
protein	I-protein
has	O
two	O
potential	O
alpha-helical	B-protein
domains	I-protein
separated	O
by	O
a	O
hydrophobic	B-protein
region	I-protein
with	O
the	O
potential	O
to	O
generate	O
turns	O
and	O
assume	O
a	O
beta-sheet	O
conformation	O
.	O

Consistent	O
with	O
involvement	O
in	O
the	O
G0/G1	B-DNA
switch	I-DNA
,	O
the	O
protein	O
contains	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
casein	B-protein
kinase	I-protein
II	I-protein
.	O

The	O
gene	O
contains	O
a	O
CpG-rich	B-protein
island	I-protein
suggesting	O
expression	O
in	O
the	O
germ	O
line	O
.	O

An	O
upstream	B-DNA
segment	I-DNA
contains	O
tandem	B-DNA
dinucleotide	I-DNA
repeats	I-DNA
(	B-DNA
CT	I-DNA
)	I-DNA
19/	I-DNA
(	I-DNA
CA	I-DNA
)	I-DNA
16	I-DNA
.	O

There	O
is	O
a	O
suitably	O
located	O
TATA	B-DNA
box	I-DNA
,	O
but	O
potential	O
sites	O
for	O
CCAAT-box	B-protein
binding	I-protein
factors	I-protein
are	O
far	O
upstream	O
,	O
embedded	O
in	O
a	O
42-nucleotide	B-DNA
repeat	I-DNA
element	I-DNA
.	O

Potential	O
sites	O
for	O
transcription	B-protein
factors	I-protein
AP1	B-protein
,	O
AP2	B-protein
,	O
and	O
AP3	B-protein
are	O
consistent	O
with	O
rapid	O
transcriptional	O
activation	O
in	O
response	O
to	O
inducing	O
agents	O
.	O

USF-related	B-protein
transcription	I-protein
factor	I-protein
,	O
HIV-TF1	B-protein
,	O
stimulates	O
transcription	O
of	O
human	O
immunodeficiency	O
virus-1	O
.	O

The	O
transcription	B-protein
factor	I-protein
HIV-TF1	B-protein
,	O
which	O
binds	O
to	O
a	O
region	O
about	O
60	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
enhancer	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
,	O
was	O
purified	O
from	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

HIV-TF1	B-protein
had	O
a	O
molecular	O
weight	O
of	O
39	O
,	O
000	O
.	O

Binding	O
of	O
HIV-TF1	B-protein
to	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
activated	O
transcription	O
from	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
vitro	O
.	O

The	O
HIV-TF1-binding	B-DNA
site	I-DNA
in	O
HIV	B-DNA
LTR	I-DNA
was	O
similar	O
to	O
the	O
site	O
recognized	O
by	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
(	O
USF	B-protein
)	O
in	O
the	O
adenovirus	B-DNA
major	I-DNA
late	I-DNA
promoter	I-DNA
.	O

DNA-binding	O
properties	O
of	O
HIV-TF1	B-protein
suggested	O
that	O
HIV-TF1	B-protein
might	O
be	O
identical	O
or	O
related	O
to	O
USF	B-protein
.	O

Interestingly	O
,	O
treatment	O
of	O
purified	O
HIV-TF1	B-protein
by	O
phosphatase	B-protein
greatly	O
reduced	O
its	O
DNA-binding	O
activity	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
HIV-TF1	B-protein
was	O
essential	O
for	O
DNA	O
binding	O
.	O

The	O
disruption	O
of	O
HIV-TF1-binding	B-DNA
site	I-DNA
induced	O
a	O
60	O
%	O
decrease	O
in	O
the	O
level	O
of	O
transcription	O
from	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
vivo	O
.	O

These	O
results	O
suggest	O
that	O
HIV-TF1	B-protein
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
HIV-1	O
.	O

Severe	O
5-fluorouracil	O
toxicity	O
secondary	O
to	O
dihydropyrimidine	B-protein
dehydrogenase	I-protein
deficiency	O
.	O

A	O
potentially	O
more	O
common	O
pharmacogenetic	O
syndrome	O
.	O

This	O
study	O
describes	O
the	O
inheritance	O
of	O
a	O
defect	O
in	O
pyrimidine	O
catabolism	O
and	O
its	O
association	O
with	O
drug-induced	O
toxicity	O
in	O
a	O
patient	O
receiving	O
5-fluorouracil	O
(	O
FUra	O
)	O
as	O
adjuvant	O
chemotherapy	O
for	O
breast	O
carcinoma	O
.	O

The	O
study	O
population	O
included	O
the	O
affected	O
patient	O
(	O
proband	O
)	O
,	O
nine	O
of	O
her	O
blood	O
relatives	O
,	O
and	O
seven	O
healthy	O
volunteers	O
.	O

The	O
activity	O
of	O
dihydropyrimidine	B-protein
dehydrogenase	I-protein
(	O
DPD	B-protein
)	O
,	O
the	O
initial	O
enzyme	B-protein
of	O
pyrimidine	O
(	O
and	O
FUra	O
)	O
catabolism	O
,	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
was	O
measured	O
in	O
each	O
subject	O
by	O
a	O
specific	O
radiometric	O
assay	O
using	O
FUra	O
as	O
the	O
substrate	O
.	O

The	O
proband	O
had	O
no	O
detectable	O
DPD	B-protein
activity	O
.	O

When	O
enzyme	O
levels	O
in	O
the	O
proband	O
and	O
relatives	O
were	O
compared	O
with	O
that	O
in	O
controls	O
,	O
an	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
was	O
demonstrated	O
.	O

This	O
is	O
the	O
third	O
patient	O
with	O
severe	O
FUra	O
toxicity	O
secondary	O
to	O
an	O
alteration	O
in	O
pyrimidine	O
catabolism	O
and	O
the	O
second	O
from	O
our	O
clinic	O
population	O
suggesting	O
that	O
the	O
frequency	O
of	O
this	O
genetic	O
defect	O
may	O
be	O
greater	O
than	O
previously	O
thought	O
.	O

Monitoring	O
DPD	B-protein
activity	O
may	O
be	O
important	O
in	O
the	O
management	O
of	O
patients	O
experiencing	O
severe	O
toxicity	O
secondary	O
to	O
FUra	O
chemotherapy	O
.	O

Transactivation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
promoter	I-DNA
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
strains	O
GS	O
and	O
Z-29	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
identification	O
of	O
transactivating	B-DNA
HHV-6	I-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
gene	I-DNA
fragments	I-DNA
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
activate	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
promoter	I-DNA
and	O
accelerate	O
cytopathic	O
effects	O
in	O
HIV-infected	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

This	O
study	O
examines	O
the	O
regions	O
of	O
the	O
HIV	B-DNA
promoter	I-DNA
required	O
for	O
HHV-6	O
transactivation	O
in	O
a	O
heterogeneous	O
population	O
of	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
with	O
or	O
without	O
antigenic	O
stimulation	O
.	O

Two	O
different	O
strains	O
of	O
HHV-6	O
,	O
GS	O
and	O
Z29	O
,	O
transactivated	O
the	O
HIV	B-DNA
promoter	I-DNA
.	O

The	O
GS	O
strain	O
transactivated	O
the	O
promoter	B-DNA
in	O
both	O
stimulated	O
and	O
resting	O
T	B-cell_type
cells	I-cell_type
,	O
while	O
the	O
Z29	O
strain	O
increased	O
HIV	B-DNA
promoter	I-DNA
activity	O
only	O
in	O
stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Three	O
DNA	O
clones	O
containing	O
HHV-6	B-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
genomic	I-DNA
fragments	I-DNA
transactivated	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
cotransfected	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

A	O
21.4-kb	B-DNA
DNA	I-DNA
clone	I-DNA
,	O
pZVB70	B-DNA
,	O
showed	O
the	O
highest	O
transactivating	O
ability	O
,	O
while	O
two	O
other	O
DNA	B-DNA
fragments	I-DNA
,	O
pZVB10	B-DNA
(	O
6.2	O
kb	O
)	O
and	O
pZVH14	B-DNA
(	O
8.7	O
kb	O
)	O
,	O
showed	O
lower	O
activity	O
.	O

One	O
of	O
these	O
clones	O
,	O
pZVH14	B-DNA
,	O
activated	O
the	O
HIV	B-DNA
promoter	I-DNA
construct	I-DNA
containing	O
a	O
mutation	O
in	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
.	O

However	O
,	O
this	O
mutated	B-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
promoter	I-DNA
was	O
not	O
transactivated	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
or	O
after	O
cotransfection	O
with	O
pZVB70	B-DNA
or	O
pZVB10	B-DNA
.	O

These	O
data	O
indicate	O
that	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
sites	I-DNA
of	O
the	O
HIV	B-DNA
promoter	I-DNA
are	O
essential	O
for	O
its	O
transactivation	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
.	O

By	O
increasing	O
HIV	B-DNA
promoter	I-DNA
activity	O
in	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
HHV-6	O
may	O
consequently	O
increase	O
HIV	O
replication	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
cytopathic	O
effect	O
on	O
coinfected	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Inhibition	O
of	O
HIV-1	O
replication	O
and	O
NF-kappa	B-protein
B	I-protein
activity	O
by	O
cysteine	O
and	O
cysteine	O
derivatives	O
.	O

HIV-1	B-DNA
proviral	I-DNA
DNA	I-DNA
contains	O
two	O
binding	B-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O

HIV-1-infected	O
individuals	O
have	O
,	O
on	O
average	O
,	O
abnormally	O
high	O
levels	O
of	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
and	O
abnormally	O
low	O
plasma	O
cysteine	O
levels	O
.	O

We	O
therefore	O
investigated	O
the	O
effects	O
of	O
cysteine	O
and	O
related	O
thiols	O
on	O
HIV-1	O
replication	O
and	O
NF-kappa	B-protein
B	I-protein
expression	O
.	O

The	O
experiments	O
in	O
this	O
report	O
show	O
that	O
cysteine	O
or	O
N-acetylcysteine	O
(	O
NAC	O
)	O
raise	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
level	O
and	O
inhibit	O
HIV-1	O
replication	O
in	O
persistently	O
infected	O
Molt-4	B-cell_line
and	O
U937	B-cell_line
cells	I-cell_line
.	O

However	O
,	O
inhibition	O
of	O
HIV-1	O
replication	O
appears	O
not	O
to	O
be	O
directly	O
correlated	O
with	O
GSH	O
levels	O
.	O

Cysteine	O
and	O
NAC	O
also	O
inhibit	O
NF-kappa	B-protein
B	I-protein
activity	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chloramphenicol	B-protein
acetyl-transferase	I-protein
(	O
CAT	B-protein
)	O
gene	O
expression	O
under	O
control	O
of	O
NF-kappa	B-protein
B	I-protein
binding	B-DNA
sites	I-DNA
in	O
uninfected	B-cell_type
cells	I-cell_type
.	O

This	O
suggests	O
that	O
the	O
cysteine	O
deficiency	O
in	O
HIV-1-infected	O
individuals	O
may	O
cause	O
an	O
over-expression	O
of	O
NF-kappa	B-DNA
B-dependent	I-DNA
genes	I-DNA
and	O
enhance	O
HIV-1	O
replication	O
.	O

NAC	O
may	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
HIV-1-infected	O
individuals	O
.	O

A	O
thymus-specific	B-protein
member	I-protein
of	O
the	O
HMG	B-protein
protein	I-protein
family	I-protein
regulates	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
C	I-DNA
alpha	I-DNA
enhancer	I-DNA
.	O

The	O
human	B-protein
T	I-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
TCF-1	B-protein
alpha	I-protein
plays	O
a	O
key	O
role	O
in	O
the	O
tissue-specific	O
activation	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
C	O
alpha	O
enhancer	O
and	O
binds	O
to	O
pyrimidine-rich	B-DNA
elements	I-DNA
(	O
5'-PyCTTTG-3	O
'	O
)	O
present	O
in	O
a	O
variety	O
of	O
other	O
T	B-DNA
cell-specific	I-DNA
control	I-DNA
regions	I-DNA
.	O

Using	O
amino	O
acid	O
sequence	O
information	O
derived	O
from	O
the	O
DNA	B-protein
affinity-purified	I-protein
protein	I-protein
,	O
we	O
have	O
now	O
isolated	O
cDNA	B-DNA
clones	I-DNA
encoding	O
TCF-1	B-protein
alpha	I-protein
.	O

The	O
TCF-1	B-DNA
alpha	I-DNA
cDNA	I-DNA
contains	O
a	O
single	O
68-amino-acid	B-protein
domain	I-protein
that	O
is	O
homologous	O
to	O
a	O
region	O
conserved	O
among	O
high-mobility	B-protein
group	I-protein
(	O
HMG	B-protein
)	O
and	O
nonhistone	B-protein
chromosomal	I-protein
proteins	I-protein
.	O

Expression	O
of	O
full-length	B-DNA
and	O
mutant	B-DNA
cDNA	I-DNA
clones	I-DNA
in	O
bacteria	O
reveal	O
that	O
the	O
single	B-protein
HMG	I-protein
motif	I-protein
,	O
which	O
is	O
predicted	O
to	O
contain	O
two	O
extended	O
alpha-helical	B-protein
segments	I-protein
,	O
is	O
sufficient	O
to	O
direct	O
the	O
sequence-specific	O
binding	O
of	O
TCF-1	B-protein
alpha	I-protein
to	O
DNA	O
.	O

Northern	O
blot	O
experiments	O
demonstrate	O
further	O
that	O
TCF-1	B-RNA
alpha	I-RNA
mRNA	I-RNA
is	O
highly	O
tissue	O
specific	O
,	O
found	O
primarily	O
in	O
the	O
thymus	B-cell_line
or	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
immature	B-cell_line
CEM	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
expresses	O
relatively	O
low	O
levels	O
of	O
TCF-1	B-RNA
alpha	I-RNA
mRNA	I-RNA
,	O
which	O
are	O
increased	O
upon	O
activation	O
of	O
these	O
cells	O
by	O
phorbol	O
esters	O
.	O

Interestingly	O
,	O
the	O
cloned	O
TCF-1	B-protein
alpha	I-protein
protein	I-protein
is	O
a	O
potent	O
transcriptional	B-protein
activator	I-protein
of	O
the	O
human	B-DNA
TCR	I-DNA
alpha	I-DNA
enhancer	I-DNA
in	O
nonlymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
whereas	O
the	O
activity	O
of	O
the	O
endogenous	B-protein
protein	I-protein
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
is	O
strongly	O
dependent	O
on	O
an	O
additional	O
T	B-cell_line
cell-specific	I-cell_line
protein	I-cell_line
that	O
interacts	O
with	O
the	O
core	O
enhancer	O
.	O

TCF-1	B-protein
alpha	I-protein
is	O
currently	O
unique	O
among	O
the	O
newly	O
emerging	O
family	O
of	O
DNA-binding	B-protein
regulatory	I-protein
proteins	I-protein
that	O
share	O
the	O
HMG	B-protein
motif	I-protein
in	O
that	O
it	O
is	O
a	O
highly	B-protein
tissue-specific	I-protein
RNA	I-protein
polymerase	I-protein
II	I-protein
transcription	B-protein
factor	I-protein
.	O

A	O
novel	O
HIV-1	O
isolate	O
containing	O
alterations	O
affecting	O
the	O
NF-kappa	B-DNA
B	I-DNA
element	I-DNA
.	O

Three	O
molecular	O
clones	O
of	O
HIV-1	O
,	O
derived	O
from	O
a	O
single	O
isolate	O
(	O
AL1	O
)	O
,	O
exhibited	O
distinct	O
replicative	O
and	O
cytopathic	O
properties	O
during	O
propagation	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
phenotypic	O
differences	O
observed	O
were	O
attributable	O
,	O
in	O
large	O
part	O
,	O
to	O
changes	O
affecting	O
the	O
viral	B-DNA
LTR	I-DNA
.	O

Nucleotide	O
sequence	O
and	O
PCR	O
analyses	O
demonstrated	O
the	O
presence	O
of	O
novel	O
duplications	O
or	O
deletions	O
involving	O
the	O
NF-kappa	B-DNA
B	I-DNA
motif	I-DNA
.	O

These	O
changes	O
in	O
the	O
enhancer	B-DNA
element	I-DNA
were	O
identified	O
in	O
the	O
original	O
AL1	O
virus	O
stock	O
.	O

Subcloning	O
of	O
the	O
variant	B-DNA
NF-kappa	I-DNA
B	I-DNA
segments	I-DNA
into	O
LTR-driven	B-DNA
CAT	I-DNA
expression	I-DNA
vectors	I-DNA
confirmed	O
a	O
correlation	O
between	O
promoter	O
activity	O
and	O
replicative/cytopathic	O
capacity	O
.	O

Multiple	O
Oct2	B-protein
isoforms	I-protein
are	O
generated	O
by	O
alternative	O
splicing	O
.	O

The	O
interaction	O
of	O
the	O
Oct2	B-protein
transcription	I-protein
factor	I-protein
with	O
the	O
cognate	B-DNA
octamer	I-DNA
motif	I-DNA
ATGCAAAT	O
is	O
a	O
critical	O
determinant	O
of	O
the	O
lymphoid-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

Ectopic	O
expression	O
of	O
cloned	B-DNA
Oct2	I-DNA
cDNA	I-DNA
was	O
shown	O
to	O
be	O
sufficient	O
to	O
reconstitute	O
at	O
least	O
some	O
aspects	O
of	O
this	O
regulation	O
in	O
non-lymphoid	B-cell_type
cells	I-cell_type
.	O

We	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
multiple	B-DNA
cDNAs	I-DNA
encoding	O
mouse	B-protein
Oct2	I-protein
from	O
a	O
mature	B-cell_line
B-cell	I-cell_line
line	I-cell_line
and	O
we	O
show	O
that	O
a	O
variety	O
of	O
isoforms	O
of	O
this	O
transcription	B-protein
factor	I-protein
is	O
generated	O
from	O
a	O
single	O
gene	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

All	O
the	O
isoforms	B-protein
retain	O
the	O
previously	O
characterized	O
POU-domain	O
and	O
are	O
therefore	O
able	O
to	O
bind	O
to	O
the	O
octamer	B-DNA
motif	I-DNA
.	O

Different	O
amounts	O
of	O
the	O
various	O
isoforms	B-protein
are	O
present	O
within	O
the	O
same	O
B-cell	B-cell_type
regardless	O
of	O
the	O
developmental	O
stage	O
of	O
B-cell	B-cell_type
differentiation	O
and	O
at	O
least	O
some	O
of	O
the	O
isoforms	B-protein
are	O
conserved	O
between	O
mouse	O
and	O
humans	O
.	O

In	O
cotransfection	O
experiments	O
we	O
show	O
that	O
all	O
the	O
isoforms	B-protein
are	O
able	O
to	O
activate	O
an	O
octamer	B-DNA
containing	O
promoter	B-DNA
element	I-DNA
in	O
fibroblasts	O
revealing	O
an	O
unexpected	O
functional	O
redundancy	O
.	O

Finally	O
,	O
we	O
show	O
that	O
one	O
of	O
the	O
isoforms	B-protein
encodes	O
the	O
previously	O
described	O
lymphoid-specific	B-protein
Oct2B	I-protein
protein	I-protein
which	O
has	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
function	O
of	O
the	O
octamer	B-DNA
motif	I-DNA
in	O
the	O
context	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
enhancer	I-DNA
.	O

[	O
Regulation	O
of	O
intracellular	O
cholesterol	O
synthesis	O
in	O
hypercholesterolemia	O
by	O
glucocorticoids	O
]	O

The	O
rate	O
of	O
endogenous	O
cholesterol	O
synthesis	O
in	O
blood	B-cell_type
lymphocytes	I-cell_type
and	O
skin	B-cell_type
fibroblasts	I-cell_type
from	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
was	O
found	O
to	O
be	O
increased	O
in	O
comparison	O
with	O
healthy	O
donors	O
.	O

The	O
cells	O
of	O
hyperlipidemic	O
patients	O
had	O
lowered	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
concomitantly	O
with	O
a	O
partial	O
loss	O
of	O
their	O
sensitivity	O
to	O
glucocorticoids	O
.	O

In	O
fibroblasts	B-cell_type
from	O
patients	O
with	O
hereditary	O
hypercholesteremia	O
of	O
homozygous	O
type	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
did	O
not	O
exceed	O
10	O
%	O
of	O
their	O
content	O
in	O
normal	B-cell_type
cells	I-cell_type
.	O

The	O
decrease	O
of	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
seems	O
to	O
be	O
a	O
compensatory	O
response	O
of	O
cells	O
culminating	O
in	O
activation	O
of	O
endogenous	O
cholesterol	O
synthesis	O
.	O

Negative	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytes	O
:	O
role	O
of	O
the	O
65-kDa	B-protein
plus	O
50-kDa	B-protein
NF-kappa	I-protein
B	I-protein
dimer	I-protein
.	O

Although	O
monocytic	O
cells	O
can	O
provide	O
a	O
reservoir	O
for	O
viral	O
production	O
in	O
vivo	O
,	O
their	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
transcription	O
can	O
be	O
either	O
latent	O
,	O
restricted	O
,	O
or	O
productive	O
.	O

These	O
differences	O
in	O
gene	O
expression	O
have	O
not	O
been	O
molecularly	O
defined	O
.	O

In	O
THP-1	B-cell_line
cells	I-cell_line
with	O
restricted	O
HIV	O
expression	O
,	O
there	O
is	O
an	O
absence	O
of	O
DNA-protein	B-protein
binding	I-protein
complex	I-protein
formation	O
with	O
the	O
HIV-1	B-DNA
promoter-enhancer	I-DNA
associated	O
with	O
markedly	O
less	O
viral	B-RNA
RNA	I-RNA
production	O
.	O

This	O
absence	O
of	O
binding	O
was	O
localized	O
to	O
the	O
NF-kappa	B-DNA
B	I-DNA
region	I-DNA
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
;	O
the	O
65-kDa	B-protein
plus	I-protein
50-kDa	I-protein
NF-kappa	I-protein
B	I-protein
heterodimer	I-protein
was	O
preferentially	O
lost	O
.	O

Adding	O
purified	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
to	O
nuclear	O
extracts	O
from	O
cells	O
with	O
restricted	O
expression	O
overcomes	O
this	O
lack	O
of	O
binding	O
.	O

In	O
addition	O
,	O
treatment	O
of	O
these	O
nuclear	O
extracts	O
with	O
sodium	O
deoxycholate	O
restored	O
their	O
ability	O
to	O
form	O
the	O
heterodimer	B-protein
,	O
suggesting	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O

Furthermore	O
,	O
treatment	O
of	O
nuclear	O
extracts	O
from	O
these	O
cells	O
that	O
had	O
restricted	O
expression	O
with	O
lipopolysaccharide	O
increased	O
viral	O
production	O
and	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O

Antiserum	O
specific	O
for	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
,	O
but	O
not	O
c-rel-specific	O
antiserum	O
,	O
disrupted	O
heterodimer	B-protein
complex	I-protein
formation	O
.	O

Thus	O
,	O
both	O
NF-kappa	B-protein
B-binding	I-protein
complexes	I-protein
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O

Binding	O
of	O
the	O
65-kDa	B-protein
plus	O
50-kDa	B-protein
heterodimer	I-protein
to	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
can	O
be	O
negatively	O
regulated	O
in	O
monocytes	B-cell_type
,	O
providing	O
one	O
mechanism	O
restricting	O
HIV-1	B-DNA
gene	I-DNA
expression	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
normal	B-cell_type
leukocytes	I-cell_type
:	O
effects	O
of	O
age	O
,	O
gender	O
,	O
season	O
,	O
and	O
plasma	O
cortisol	O
concentrations	O
.	O

We	O
measured	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
(	O
MNL	B-cell_type
)	O
isolated	O
from	O
peripheral	O
blood	O
of	O
145	O
apparently	O
healthy	O
volunteers	O
(	O
86	O
men	O
and	O
59	O
women	O
)	O
.	O

An	O
age-related	O
decrease	O
in	O
the	O
number	O
of	O
GR	B-protein
was	O
suggested	O
between	O
subjects	O
younger	O
than	O
20	O
years	O
and	O
elderly	O
subjects	O
;	O
there	O
was	O
no	O
apparent	O
seasonal	O
variation	O
in	O
GR	B-protein
.	O

Gender	O
difference	O
in	O
the	O
number	O
of	O
GR	B-protein
was	O
not	O
significant	O
,	O
although	O
women	O
showed	O
slightly	O
fewer	O
GR	B-protein
.	O

Eight	O
patients	O
with	O
dermatomyositis/polymyositis	O
were	O
examined	O
to	O
determine	O
whether	O
the	O
number	O
of	O
GR	B-protein
in	O
MNL	B-cell_type
could	O
be	O
down-regulated	O
by	O
their	O
cognate	O
ligands	O
.	O

The	O
number	O
of	O
GR	B-protein
in	O
MNL	B-cell_type
from	O
these	O
patients	O
was	O
significantly	O
decreased	O
one	O
month	O
after	O
the	O
initiation	O
of	O
prednisolone	O
therapy	O
.	O

However	O
,	O
in	O
normal	O
subjects	O
,	O
the	O
GR	B-protein
in	O
MNL	B-cell_type
did	O
not	O
demonstrate	O
circadian	O
variation	O
,	O
in	O
contrast	O
to	O
concentrations	O
of	O
plasma	O
cortisol	O
.	O

Synergism	O
between	O
two	O
distinct	O
elements	O
of	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
during	O
activation	O
by	O
the	O
trans-activator	B-protein
of	O
HTLV-I	O
.	O

We	O
have	O
conducted	O
functional	O
studies	O
of	O
the	O
enhancer	B-DNA
elements	I-DNA
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
using	O
the	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
Jurkat	B-cell_line
and	O
MOLT	B-cell_line
4	I-cell_line
,	O
which	O
are	O
negative	O
for	O
HTLV-I	O
,	O
and	O
MT-2	O
and	O
TL-Mor	O
,	O
which	O
carry	O
the	O
proviral	O
genome	O
of	O
HTLV-I	O
.	O

Two	O
distinct	O
elements	O
have	O
been	O
implicated	O
in	O
function	O
of	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
.	O

One	O
is	O
the	O
21-base-pair	B-DNA
(	I-DNA
bp	I-DNA
)	I-DNA
core	I-DNA
element	I-DNA
that	O
is	O
responsible	O
for	O
trans-activation	O
by	O
the	O
HTLV-I	O
trans-activator	B-protein
p40tax	B-protein
and	O
that	O
has	O
the	O
ability	O
to	O
bind	O
to	O
cyclic-AMP	B-protein
responsive	I-protein
element	I-protein
binding	I-protein
factor	I-protein
(	I-protein
CREB	I-protein
)	I-protein
-like	I-protein
factor	I-protein
(	O
s	O
)	O
.	O

The	O
other	O
is	O
a	O
region	O
interposed	O
between	O
the	O
21-bp	B-DNA
elements	I-DNA
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
a	O
subfragment	O
(	O
C26	O
)	O
in	O
the	O
region	O
between	O
the	O
21-bp	B-DNA
elements	I-DNA
is	O
involved	O
in	O
trans-activation	O
by	O
p40tax	B-protein
,	O
possibly	O
through	O
binding	O
to	O
an	O
NF-kappa	B-protein
B-like	I-protein
nuclear	I-protein
factor	I-protein
or	O
factors	O
.	O

Formation	O
of	O
the	O
protein-DNA	B-protein
complex	I-protein
with	O
the	O
C26	B-protein
subfragment	I-protein
was	O
positively	O
affected	O
by	O
p40tax	B-protein
.	O

The	O
C26	B-DNA
element	I-DNA
conferred	O
partial	O
responsiveness	O
to	O
p40tax	B-protein
when	O
linked	O
to	O
one	O
copy	O
of	O
the	O
21-bp	B-DNA
element	I-DNA
that	O
,	O
by	O
itself	O
,	O
showed	O
little	O
activation	O
in	O
response	O
to	O
p40tax	B-protein
.	O

However	O
,	O
the	O
C26	B-DNA
element	I-DNA
alone	O
,	O
even	O
when	O
repeated	O
,	O
could	O
not	O
be	O
activated	O
by	O
p40tax	B-protein
,	O
unlike	O
other	O
NF-kappa	B-DNA
B-binding	I-DNA
elements	I-DNA
.	O

In	O
contrast	O
,	O
the	O
C26	B-DNA
element	I-DNA
itself	O
was	O
profoundly	O
activated	O
upon	O
stimulation	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
.	O

These	O
findings	O
therefore	O
suggest	O
that	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
contains	O
multiple	B-DNA
functional	I-DNA
elements	I-DNA
,	O
including	O
binding	O
sites	O
for	O
at	O
least	O
CREB-	B-protein
and	I-protein
NF-kappa	I-protein
B-like	I-protein
factors	I-protein
,	O
which	O
synergistically	O
cooperate	O
in	O
activation	O
of	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
in	O
response	O
to	O
p40tax	B-protein
.	O

Our	O
results	O
also	O
demonstrate	O
that	O
TPA-dependent	O
activation	O
of	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
may	O
be	O
mediated	O
through	O
the	O
C26	B-DNA
element	I-DNA
.	O

Human	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
gene	O
regulation	O
in	O
phorbol	O
ester	O
stimulated	B-cell_line
T	I-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
minimal	O
region	O
of	O
the	O
human	B-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
(	I-DNA
TNF-alpha	I-DNA
)	I-DNA
gene	I-DNA
promoter	I-DNA
necessary	O
for	O
its	O
transcriptional	O
induction	O
by	O
phorbol	O
esters	O
(	O
PMA	O
)	O
in	O
human	B-cell_line
T	I-cell_line
and	I-cell_line
B	I-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
lines	I-cell_line
has	O
been	O
localized	O
between	O
-52	B-DNA
and	I-DNA
+89	I-DNA
nucleotides	I-DNA
(	O
nt	O
)	O
relative	O
to	O
the	O
gene	O
's	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
.	O

Comparison	O
of	O
these	O
sequences	O
to	O
those	O
required	O
to	O
mediate	O
virus	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
gene	O
reveal	O
significant	O
differences	O
,	O
and	O
thus	O
,	O
the	O
sequence	O
requirements	O
for	O
PMA	O
induction	O
are	O
distinct	O
from	O
those	O
that	O
mediate	O
induction	O
by	O
virus	O
or	O
LPS	O
.	O

Although	O
three	O
sites	O
in	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
(	O
kappa	O
1	O
,	O
kappa	O
2	O
,	O
and	O
kappa	O
3	O
)	O
specifically	O
bind	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
in	O
lymphoid	O
nuclear	O
extracts	O
,	O
TNF-alpha	B-RNA
mRNA	I-RNA
induction	O
by	O
PMA	O
does	O
not	O
correlate	O
with	O
NF-kappa	B-protein
B	I-protein
binding	O
activities	O
displayed	O
by	O
different	O
T	B-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Moreover	O
,	O
kappa	B-DNA
1-kappa	I-DNA
3	I-DNA
can	O
each	O
be	O
deleted	O
from	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
with	O
little	O
effect	O
on	O
the	O
gene	O
's	O
inducibility	O
by	O
PMA	O
.	O

Therefore	O
,	O
TNF-alpha	B-RNA
mRNA	I-RNA
induction	O
by	O
PMA	O
,	O
like	O
its	O
induction	O
by	O
virus	O
and	O
LPS	O
,	O
is	O
not	O
primarily	O
mediated	O
by	O
NF-kappa	B-protein
B	I-protein
,	O
but	O
rather	O
is	O
mediated	O
through	O
other	O
sequences	O
and	O
protein	B-protein
factors	I-protein
.	O

Surprisingly	O
,	O
multimers	O
of	O
kappa	O
1-kappa	O
3	O
can	O
confer	O
PMA	O
inducibility	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
in	O
a	O
B	B-cell_line
(	I-cell_line
Raji	I-cell_line
)	I-cell_line
,	I-cell_line
but	I-cell_line
not	I-cell_line
a	I-cell_line
T	I-cell_line
(	I-cell_line
HUT78	I-cell_line
)	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

However	O
they	O
are	O
not	O
functional	O
on	O
a	O
truncated	O
TNF-alpha	B-DNA
promoter	I-DNA
,	O
indicating	O
that	O
promoter	O
context	O
and	O
cell	O
type	O
specificity	O
influence	O
the	O
PMA	O
inducible	O
function	O
of	O
these	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
.	O

Differentiation-associated	O
expression	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
BZLF1	I-protein
transactivator	I-protein
protein	I-protein
in	O
oral	O
hairy	O
leukoplakia	O
.	O

The	O
BZLF1	B-protein
protein	I-protein
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
key	O
immediate-early	B-protein
protein	I-protein
which	O
has	O
been	O
shown	O
to	O
disrupt	O
virus	O
latency	O
in	O
EBV-infected	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
generated	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
BZ1	B-protein
,	O
to	O
BZLF1	B-protein
which	O
reacts	O
in	O
immunohistology	O
,	O
immunoblotting	O
,	O
and	O
immunoprecipitation	O
and	O
which	O
recognizes	O
both	O
the	O
active	B-protein
,	I-protein
dimeric	I-protein
form	I-protein
and	O
the	O
inactive	B-protein
,	I-protein
monomeric	I-protein
form	I-protein
of	O
the	O
protein	O
.	O

Biopsies	O
of	O
oral	O
hairy	O
leukoplakia	O
,	O
an	O
AIDS-associated	O
lesion	O
characterized	O
by	O
high-level	O
EBV	O
replication	O
,	O
were	O
examined	O
by	O
immunohistochemistry	O
using	O
the	O
BZ1	B-protein
monoclonal	B-protein
antibody	I-protein
.	O

A	O
differentiation-associated	O
pattern	O
of	O
BZLF1	B-protein
expression	O
was	O
observed	O
,	O
BZ1	B-protein
reacting	O
with	O
nuclei	O
of	O
the	O
upper	O
spinous	O
layer	O
of	O
the	O
lesion	O
.	O

This	O
finding	O
suggests	O
that	O
the	O
BZLF1	B-DNA
promoter	I-DNA
may	O
be	O
regulated	O
by	O
the	O
degree	O
of	O
squamous	O
differentiation	O
.	O

A	O
comparison	O
of	O
in	O
situ	O
hybridization	O
to	O
EBV	B-DNA
DNA	I-DNA
and	O
viral	B-protein
capsid	I-protein
antigen	I-protein
staining	O
with	O
BZ1	B-protein
reactivity	O
suggested	O
that	O
BZLF1	B-protein
expression	O
precedes	O
rampant	O
virus	O
replication	O
.	O

The	O
inability	O
to	O
detect	O
EBV	O
in	O
the	O
lower	O
epithelial	O
layers	O
of	O
oral	O
hairy	O
leukoplakia	O
raises	O
questions	O
concerning	O
the	O
nature	O
of	O
EBV	O
latency	O
and	O
persistence	O
in	O
stratified	O
squamous	O
epithelium	O
.	O

[	O
Changes	O
in	O
levels	O
of	O
leucocytic	B-protein
estrogen	I-protein
receptor	I-protein
in	O
patients	O
with	O
menopausal	O
type	O
II	O
diabetes	O
and	O
its	O
significance	O
]	O

The	O
number	O
of	O
estrogen	B-protein
receptors	I-protein
(	O
ER	B-protein
)	O
in	O
human	B-cell_type
peripheral	I-cell_type
leucocytes	I-cell_type
in	O
12	O
women	O
with	O
menopausal	O
type	O
II	O
diabetes	O
was	O
measured	O
with	O
radio-ligand	O
binding	O
method	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
menopausal	O
women	O
without	O
diabetes	O
and	O
12	O
normal	O
women	O
of	O
childbearing	O
age	O
.	O

It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	B-protein
in	O
the	O
patients	O
was	O
significantly	O
decreased	O
.	O

Our	O
data	O
indicate	O
that	O
decrease	O
of	O
ER	B-protein
level	O
in	O
leukocytes	B-cell_type
may	O
be	O
related	O
to	O
the	O
pathogenesis	O
of	O
type	O
II	O
diabetes	O
in	O
menopausal	O
period	O
.	O

Lymphocyte	O
glucocorticoid	B-protein
receptor	I-protein
number	O
in	O
posttraumatic	O
stress	O
disorder	O
.	O

OBJECTIVE	O
:	O
The	O
authors	O
'	O
objective	O
was	O
to	O
investigate	O
the	O
possibility	O
that	O
glucocorticoid	B-protein
receptor	I-protein
changes	O
may	O
be	O
involved	O
in	O
the	O
dysregulation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
in	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
.	O

METHOD	O
:	O
They	O
measured	O
the	O
number	O
of	O
lymphocyte	B-protein
cytosolic	I-protein
glucocorticoid	I-protein
receptors	I-protein
and	O
plasma	O
cortisol	O
concentrations	O
in	O
15	O
consecutively	O
admitted	O
male	O
combat	O
Vietnam	O
veterans	O
with	O
PTSD	O
and	O
in	O
a	O
normal	O
comparison	O
group	O
of	O
11	O
subjects	O
.	O

RESULTS	O
:	O
Both	O
the	O
patients	O
and	O
the	O
normal	O
comparison	O
subjects	O
showed	O
a	O
morning-to-afternoon	O
decline	O
in	O
glucocorticoid	B-protein
receptor	I-protein
concentrations	O
,	O
paralleling	O
the	O
normal	O
diurnal	O
decline	O
in	O
cortisol	O
levels	O
.	O

The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
was	O
63	O
%	O
greater	O
in	O
the	O
morning	O
and	O
26	O
%	O
greater	O
in	O
the	O
afternoon	O
in	O
the	O
patients	O
with	O
PTSD	O
than	O
in	O
the	O
normal	O
subjects	O
.	O

No	O
group	O
differences	O
in	O
cortisol	O
levels	O
were	O
observed	O
,	O
nor	O
were	O
glucocorticoid	B-protein
receptor	I-protein
number	O
and	O
cortisol	O
levels	O
correlated	O
.	O

The	O
number	O
of	O
morning	B-protein
glucocorticoid	I-protein
receptors	I-protein
was	O
positively	O
correlated	O
with	O
symptoms	O
of	O
PTSD	O
and	O
anxiety	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
provide	O
further	O
evidence	O
for	O
a	O
dysregulation	O
of	O
the	O
HPA	O
axis	O
in	O
PTSD	O
.	O

The	O
finding	O
that	O
patients	O
with	O
PTSD	O
had	O
a	O
substantially	O
greater	O
number	O
of	O
lymphocyte	B-protein
glucocorticoid	I-protein
receptors	I-protein
than	O
normal	O
comparison	O
subjects	O
is	O
consistent	O
with	O
the	O
authors	O
'	O
previous	O
observations	O
of	O
low	O
24-hour	O
urinary	O
cortisol	O
excretion	O
in	O
subjects	O
with	O
PTSD	O
.	O

Furthermore	O
,	O
the	O
receptor	O
changes	O
observed	O
are	O
opposite	O
of	O
those	O
reported	O
in	O
major	O
depressive	O
disorder	O
.	O

The	O
present	O
data	O
,	O
along	O
with	O
other	O
findings	O
of	O
HPA	O
abnormalities	O
in	O
PTSD	O
,	O
support	O
the	O
possibility	O
of	O
a	O
greater	O
negative	O
feedback	O
sensitivity	O
at	O
one	O
or	O
more	O
levels	O
of	O
the	O
HPA	O
axis	O
.	O

Induction	O
of	O
NF-kappa	B-protein
B	I-protein
during	O
monocyte	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
HIV-gene	O
expression	O
.	O

Cells	O
of	O
the	O
monocyte-macrophage	B-cell_type
lineage	I-cell_type
are	O
important	O
targets	O
of	O
HIV	O
infection	O
.	O

We	O
report	O
here	O
that	O
the	O
phenotypic	O
differentiation	O
of	O
monocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
induced	O
by	O
phorbol	O
esters	O
or	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
is	O
associated	O
with	O
expression	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

In	O
parallel	O
with	O
such	O
differentiation	O
,	O
HIV	O
transcription	O
,	O
monitored	O
using	O
an	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
reporter	I-DNA
gene	I-DNA
construct	I-DNA
,	O
is	O
activated	O
in	O
such	O
cells	O
under	O
the	O
influence	O
of	O
enhanced	O
NF-kappa	B-protein
B	I-protein
expression	O
.	O

Also	O
,	O
in	O
a	O
promonocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
chronically	O
infected	O
with	O
HIV	O
,	O
NF-kappa	B-protein
B	I-protein
expression	O
and	O
HIV	O
transcription	O
were	O
enhanced	O
on	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
TNF	B-protein
alpha	I-protein
.	O

Thus	O
,	O
stimulation	O
of	O
monocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
by	O
phorbol	O
esters	O
or	O
TNF	B-protein
alpha	I-protein
induces	O
cell	O
differentiation	O
and	O
activates	O
HIV	O
transcription	O
.	O

Such	O
a	O
process	O
may	O
have	O
fundamental	O
implications	O
in	O
AIDS	O
pathogenesis	O
in	O
vivo	O
and	O
may	O
be	O
important	O
in	O
disease	O
progression	O
induced	O
by	O
opportunistic	O
infections	O
directly	O
or	O
indirectly	O
involving	O
macrophages	B-cell_type
.	O

Demonstration	O
of	O
estrogen	B-protein
and	I-protein
progesterone	I-protein
receptors	I-protein
as	O
well	O
as	O
Ki-67	B-protein
and	I-protein
p-145	I-protein
antigens	I-protein
in	O
single	B-cell_type
tumor	I-cell_type
cells	I-cell_type
from	O
blood	O
and	O
pleural	O
effusions	O
using	O
a	O
slide	O
assay	O
.	O

We	O
describe	O
a	O
slide	O
assay	O
that	O
allows	O
the	O
demonstration	O
of	O
antigens	B-protein
localized	O
in	O
the	O
nucleus	O
from	O
isolated	B-cell_type
white	I-cell_type
blood	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
from	O
single	B-cell_type
tumor	I-cell_type
cells	I-cell_type
derived	O
from	O
malignant	O
effusions	O
.	O

With	O
the	O
antibodies	O
Ki-67	B-protein
and	O
anti-p-145	B-protein
an	O
increased	O
rate	O
of	O
nuclear	O
and	O
nucleolar	O
staining	O
resulted	O
in	O
cells	O
from	O
highly	O
malignant	O
lymphomas	O
.	O

An	O
almost	O
identical	O
reaction	O
was	O
obtained	O
when	O
tumor	B-cell_type
cells	I-cell_type
from	O
malignant	O
effusions	O
were	O
tested	O
.	O

Cells	O
isolated	O
from	O
the	O
blood	O
of	O
patients	O
with	O
leukemic	O
spread	O
of	O
lymphomas	O
of	O
low	O
malignancy	O
yielded	O
a	O
weak	O
staining	O
comparable	O
to	O
that	O
of	O
normal	B-cell_type
mesothelial	I-cell_type
cells	I-cell_type
from	O
non-tumorous	O
cavity	O
fluids	O
.	O

The	O
detection	O
of	O
estrogen	B-protein
and	O
progesterone	B-protein
receptors	I-protein
(	O
ER	B-protein
and	O
PR	B-protein
)	O
localized	O
in	O
the	O
cell	O
nucleus	O
can	O
be	O
achieved	O
by	O
the	O
same	O
assay	O
.	O

The	O
reaction	O
is	O
enhanced	O
by	O
incubation	O
of	O
the	O
tumor	B-cell_type
cells	I-cell_type
for	O
30	O
min	O
at	O
37	O
degrees	O
C	O
prior	O
to	O
fixation	O
.	O

Pleural	O
effusions	O
from	O
20	O
patients	O
with	O
breast	O
cancer	O
were	O
tested	O
.	O

ER	B-protein
was	O
positive	O
in	O
13	O
and	O
PR	B-protein
was	O
positive	O
in	O
12	O
of	O
the	O
20	O
samples	O
.	O

In	O
5	O
cases	O
there	O
was	O
a	O
divergent	O
reaction	O
with	O
ER	B-protein
and	O
PR	B-protein
antibody	O
.	O

The	O
hormone	B-protein
receptors	I-protein
of	O
the	O
primary	O
tumor	O
were	O
known	O
in	O
15	O
(	O
ER	B-protein
)	O
and	O
14	O
(	O
PR	B-protein
)	O
patients	O
,	O
respectively	O
.	O

In	O
each	O
cohort	O
there	O
was	O
only	O
one	O
case	O
with	O
a	O
negative	O
reaction	O
of	O
the	O
primary	O
tumor	O
and	O
a	O
positive	O
reaction	O
with	O
the	O
isolated	O
tumor	B-cell_type
cells	I-cell_type
from	O
the	O
pleural	O
effusions	O
.	O

These	O
results	O
indicate	O
that	O
the	O
demonstration	O
of	O
hormone	B-protein
receptor	I-protein
proteins	I-protein
in	O
cells	O
from	O
malignant	O
effusions	O
is	O
possible	O
and	O
that	O
there	O
is	O
a	O
correlation	O
with	O
the	O
status	O
of	O
the	O
primary	O
site	O
of	O
cancer	O
.	O

Constitutive	O
activation	O
of	O
NF-kB	B-protein
in	O
human	B-cell_type
thymocytes	I-cell_type
.	O

NF-kB	B-protein
is	O
a	O
eukaryotic	B-protein
transcription	I-protein
regulatory	I-protein
factor	I-protein
.	O

In	O
T	B-cell_type
cells	I-cell_type
and	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
NF-kB	B-protein
is	O
bound	O
to	O
a	O
cytoplasmic	B-protein
proteic	I-protein
inhibitor	I-protein
,	O
the	O
IkB	B-protein
.	O

Treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
mitogens	O
(	O
phorbol	O
esters	O
)	O
or	O
cytokines	B-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
induces	O
NF-kB	B-protein
nuclear	O
translocation	O
and	O
the	O
subsequent	O
expression	O
of	O
NF-kB	B-DNA
dependent	I-DNA
T	I-DNA
cell	I-DNA
genes	I-DNA
.	O

Here	O
we	O
examined	O
the	O
activation	O
of	O
NF-kB	B-protein
in	O
human	B-cell_type
T	I-cell_type
cell	I-cell_type
thymic	I-cell_type
progenitors	I-cell_type
.	O

We	O
report	O
differences	O
in	O
(	O
Ca2+	O
)	O
i	O
requirement	O
for	O
NF-kB	B-protein
activation	O
in	O
thymocytes	B-cell_type
as	O
compared	O
to	O
mature	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
our	O
results	O
indicated	O
that	O
thymocytes	B-cell_type
have	O
a	O
constitutively	B-protein
active	I-protein
form	I-protein
of	O
NF-kB	B-protein
,	O
suggesting	O
that	O
they	O
are	O
activated	O
in	O
vivo	O
.	O

TCF-1	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
of	O
the	O
HMG	B-protein
box	I-protein
family	I-protein
,	O
interacts	O
with	O
sequence	B-DNA
motifs	I-DNA
in	O
the	O
TCR	B-DNA
beta	I-DNA
and	I-DNA
TCR	I-DNA
delta	I-DNA
enhancers	I-DNA
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
TCF-1	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
with	O
specificity	O
for	O
the	O
AACAAAG	O
motif	O
in	O
the	O
CD3	O
epsilon	O
enhancer	O
and	O
for	O
the	O
TTCAAAG	B-DNA
motif	I-DNA
in	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
.	O

TCF-1	B-protein
belongs	O
to	O
the	O
family	O
of	O
transcription-regulating	B-protein
proteins	I-protein
which	O
share	O
a	O
region	O
of	O
homology	O
termed	O
the	O
HMG-box	B-protein
.	O

Here	O
,	O
we	O
show	O
by	O
gel	O
retardation	O
analysis	O
that	O
TCF-1	B-protein
specifically	O
recognizes	O
the	O
T	B-DNA
beta	I-DNA
5	I-DNA
element	I-DNA
of	O
the	O
TCR	B-DNA
beta	I-DNA
enhancer	I-DNA
and	O
the	O
T	B-DNA
delta	I-DNA
7	I-DNA
element	I-DNA
of	O
the	O
TCR	B-DNA
delta	I-DNA
enhancer	I-DNA
.	O

Comparison	O
of	O
the	O
sequences	O
of	O
all	O
elements	B-DNA
recognized	O
by	O
TCF-1	B-protein
defines	O
a	O
consensus	B-DNA
motif	I-DNA
A/T	B-DNA
A/T	I-DNA
C	I-DNA
A	I-DNA
A/G	I-DNA
A	I-DNA
G	I-DNA
.	O

These	O
observations	O
imply	O
that	O
TCF-1	B-protein
is	O
involved	O
in	O
the	O
control	O
of	O
several	O
T	B-DNA
cell-specific	I-DNA
genes	I-DNA
and	O
might	O
thus	O
play	O
an	O
important	O
role	O
in	O
the	O
establishment	O
and	O
maintenance	O
of	O
the	O
mature	B-cell_type
T	I-cell_type
cell	I-cell_type
phenotype	I-cell_type
.	O

[	O
Regulatory	O
effect	O
of	O
insulin	B-protein
on	O
glucocorticoid	B-protein
receptor	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
leukocytes	I-cell_type
]	O

The	O
regulatory	O
effect	O
of	O
insulin	B-protein
on	O
the	O
specific	O
binding	O
power	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
of	O
human	B-cell_type
leukocytes	I-cell_type
was	O
assessed	O
by	O
the	O
unoccupied	B-protein
receptor	I-protein
sites	I-protein
capable	O
of	O
combining	O
with	O
[	O
3H	O
]	O
labelled	O
dexamethasone	O
measured	O
at	O
3	O
and	O
24	O
h	O
after	O
incubation	O
with	O
various	O
concentrations	O
of	O
insulin	B-protein
added	O
to	O
the	O
medium	O
.	O

After	O
3	O
h	O
incubation	O
the	O
specific	O
binding	O
power	O
with	O
[	O
3H	O
]	O
Dex	O
was	O
decreased	O
by	O
23.3	O
+/-	O
10.0	O
,	O
32.2	O
+/-	O
13.2	O
and	O
54.3	O
+/-	O
9.2	O
%	O
(	O
P	O
greater	O
than	O
0.05	O
,	O
P	O
greater	O
than	O
0.05	O
and	O
P	O
less	O
than	O
0.01	O
as	O
compared	O
with	O
the	O
control	O
value	O
of	O
100	O
in	O
the	O
absence	O
of	O
insulin	B-protein
)	O
respectively	O
in	O
the	O
presence	O
of	O
20	O
mU/L	O
(	O
physiological	O
testing	O
concentration	O
)	O
,	O
200	O
mU/L	O
(	O
physiological	O
upper	O
limit	O
)	O
and	O
2	O
,	O
000	O
mU/L	O
(	O
pharmacological	O
concentration	O
)	O
insulin	B-protein
in	O
the	O
incubation	O
medium	O
.	O

After	O
24	O
h	O
incubation	O
the	O
decrease	O
of	O
these	O
values	O
increased	O
respectively	O
to	O
43.5	O
+/-	O
19.0	O
,	O
56.1	O
+/-	O
20.7	O
and	O
80.2	O
+/-	O
15.5	O
(	O
P	O
less	O
than	O
0.05	O
,	O
P	O
less	O
than	O
0.01	O
and	O
P	O
less	O
than	O
0.01	O
compared	O
with	O
control	O
)	O
.	O

Thus	O
the	O
inhibitory	O
effect	O
of	O
insulin	B-protein
on	O
the	O
GR	B-protein
binding	O
power	O
is	O
both	O
dose-	O
and	O
time-dependent	O
,	O
which	O
strongly	O
suggests	O
that	O
GR	B-protein
is	O
tonically	O
controlled	O
by	O
insulin	B-protein
concentration	O
change	O
under	O
physiological	O
conditions	O
.	O

The	O
effect	O
of	O
toremifene	O
therapy	O
on	O
serum	B-protein
immunoglobulin	I-protein
levels	O
in	O
breast	O
cancer	O
.	O

Estrogens	O
and	O
anti-estrogens	O
enhance	O
the	O
number	O
of	O
immunoglobulin	B-cell_type
(	I-cell_type
Ig	I-cell_type
)	I-cell_type
-secreting	I-cell_type
cells	I-cell_type
in	O
pokeweed	B-cell_line
mitogen	I-cell_line
(	I-cell_line
PWM	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
.	O

Lymphocytes	B-cell_type
from	O
patients	O
who	O
have	O
received	O
anti-estrogen	O
therapy	O
show	O
similar	O
enhancement	O
of	O
Ig-secreting	B-cell_type
cells	I-cell_type
after	O
PWM	B-protein
stimulation	O
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
anti-estrogen	O
(	O
toremifene	O
)	O
therapy	O
on	O
serum	B-protein
immunoglobulin	I-protein
(	O
IgA	B-protein
,	O
IgM	B-protein
,	O
IgG	B-protein
)	O
levels	O
in	O
breast	O
cancer	O
patients	O
was	O
investigated	O
.	O

Serum	O
Ig	O
levels	O
were	O
followed	O
up	O
to	O
two	O
years	O
after	O
or	O
during	O
the	O
therapy	O
.	O

An	O
unexpected	O
finding	O
was	O
that	O
the	O
Ig	O
levels	O
decreased	O
during	O
the	O
follow-up	O
period	O
.	O

This	O
decrease	O
was	O
seen	O
in	O
patients	O
who	O
responded	O
to	O
the	O
therapy	O
as	O
well	O
as	O
in	O
those	O
who	O
did	O
not	O
.	O

Human	B-protein
erythroid	I-protein
5-aminolevulinate	I-protein
synthase	I-protein
:	O
promoter	B-DNA
analysis	O
and	O
identification	O
of	O
an	O
iron-responsive	B-DNA
element	I-DNA
in	O
the	O
mRNA	B-RNA
.	O

5-Aminolevulinate	B-protein
synthase	I-protein
(	O
ALAS	B-protein
)	O
catalyzes	O
the	O
first	O
step	O
of	O
the	O
heme	B-protein
biosynthetic	O
pathway	O
.	O

cDNA	B-DNA
clones	I-DNA
for	O
the	O
human	B-protein
erythroid	I-protein
ALAS	I-protein
isozyme	I-protein
were	O
isolated	O
from	O
a	O
fetal	O
liver	O
library	O
.	O

It	O
can	O
be	O
deduced	O
that	O
the	O
erythroid	B-protein
ALAS	I-protein
precursor	I-protein
protein	I-protein
has	O
a	O
molecular	O
weight	O
of	O
64.6	O
kd	O
,	O
and	O
is	O
similar	O
in	O
size	O
to	O
the	O
previously	O
isolated	O
human	B-protein
housekeeping	I-protein
ALAS	I-protein
precursor	I-protein
of	O
molecular	O
weight	O
70.6	O
kd	O
.	O

The	O
mature	O
mitochondrial	O
forms	O
of	O
the	O
erythroid	O
and	O
housekeeping	B-protein
ALAS	I-protein
isozymes	I-protein
are	O
predicted	O
to	O
have	O
molecular	O
weights	O
of	O
59.5	O
kd	O
and	O
64.6	O
kd	O
,	O
respectively	O
.	O

The	O
two	O
isozymes	B-protein
show	O
little	O
amino	O
acid	O
identity	O
in	O
their	O
N-terminal	B-protein
signal	I-protein
sequences	I-protein
but	O
have	O
considerable	O
sequence	O
identity	O
in	O
the	O
C-terminal	B-protein
two-thirds	I-protein
of	O
their	O
proteins	O
.	O

An	O
analysis	O
of	O
the	O
immediate	B-DNA
promoter	I-DNA
of	O
the	O
human	B-DNA
erythroid	I-DNA
ALAS	I-DNA
gene	I-DNA
revealed	O
several	O
putative	O
erythroid-specific	B-DNA
cis-acting	I-DNA
elements	I-DNA
including	O
both	O
a	O
GATA-1	B-DNA
and	O
an	O
NF-E2	B-DNA
binding	I-DNA
site	I-DNA
.	O

An	O
iron-responsive	B-RNA
element	I-RNA
(	I-RNA
IRE	I-RNA
)	I-RNA
motif	I-RNA
has	O
been	O
identified	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
human	B-RNA
erythroid	I-RNA
ALAS	I-RNA
mRNA	I-RNA
,	O
but	O
is	O
not	O
present	O
in	O
the	O
housekeeping	B-RNA
ALAS	I-RNA
mRNA	I-RNA
.	O

Gel	O
retardation	O
experiments	O
established	O
that	O
this	O
IRE	B-RNA
motif	I-RNA
formed	O
a	O
protein	B-protein
-	I-protein
RNA	I-protein
complex	I-protein
with	O
cytosolic	O
extracts	O
from	O
human	B-cell_line
K562	I-cell_line
cells	I-cell_line
and	O
this	O
binding	O
was	O
strongly	O
competed	O
with	O
IRE	B-RNA
transcripts	I-RNA
from	O
ferritin	B-RNA
or	I-RNA
transferrin	I-RNA
receptor	I-RNA
mRNAs	I-RNA
.	O

A	O
transcript	O
of	O
the	O
ALAS	B-DNA
IRE	I-DNA
,	O
mutated	O
in	O
the	O
conserved	O
loop	O
of	O
the	O
IRE	B-DNA
,	O
did	O
not	O
readily	O
form	O
this	O
protein	B-protein
-	I-protein
RNA	I-protein
complex	I-protein
.	O

These	O
results	O
suggest	O
that	O
the	O
IRE	B-RNA
motif	I-RNA
in	O
the	O
ALAS	B-RNA
mRNA	I-RNA
is	O
functional	O
and	O
imply	O
that	O
translation	O
of	O
the	O
mRNA	B-RNA
is	O
controlled	O
by	O
cellular	O
iron	O
availability	O
during	O
erythropoiesis	O
.	O

Regulation	O
of	O
jun	O
and	O
fos	O
gene	O
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
by	O
the	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O

The	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
M-CSF	B-protein
)	O
is	O
required	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
mononuclear	B-cell_type
phagocytes	I-cell_type
.	O

However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M-CSF	B-protein
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	B-DNA
and	I-DNA
fos	I-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
.	O

Low	O
levels	O
of	O
c-jun	B-protein
transcripts	I-protein
were	O
detectable	O
in	O
resting	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

Treatment	O
of	O
these	O
cells	O
with	O
10	O
(	O
3	O
)	O
units/ml	O
human	B-protein
recombinant	I-protein
M-CSF	I-protein
was	O
associated	O
with	O
rapid	O
and	O
transient	O
increases	O
in	O
c-jun	B-RNA
mRNA	I-RNA
levels	O
.	O

Nuclear	O
run-on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M-CSF	B-protein
regulates	O
c-jun	B-DNA
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half-life	O
of	O
c-jun	B-RNA
transcripts	I-RNA
.	O

M-CSF	B-protein
treatment	O
was	O
also	O
associated	O
with	O
a	O
rapid	O
induction	O
of	O
the	O
jun-B	B-DNA
gene	I-DNA
,	O
although	O
expression	O
of	O
this	O
gene	O
was	O
prolonged	O
compared	O
to	O
that	O
of	O
c-jun	B-DNA
.	O

We	O
further	O
demonstrate	O
that	O
M-CSF	B-protein
increases	O
c-fos	B-RNA
mRNA	I-RNA
levels	O
in	O
human	B-cell_type
monocytes	I-cell_type
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Maximal	O
induction	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
was	O
followed	O
by	O
that	O
for	O
the	O
fos-B	B-DNA
gene	I-DNA
.	O

Moreover	O
,	O
M-CSF	B-protein
-induced	O
expression	O
of	O
the	O
fos-related	B-DNA
gene	I-DNA
,	O
fra-1	B-DNA
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c-fos	B-DNA
and	O
fos-B	B-DNA
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
M-CSF	B-protein
treatment	O
is	O
associated	O
with	O
differential	O
activation	O
of	O
multiple	O
members	O
of	O
the	O
jun/fos	B-DNA
family	I-DNA
and	O
that	O
expression	O
of	O
these	O
genes	O
could	O
contribute	O
to	O
nuclear	O
signaling	O
mechanisms	O
that	O
regulate	O
a	O
specific	O
program	O
of	O
monocyte	O
differentiation	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
systemic	O
lupus	O
erythematosus	O
.	O

Glucocorticosteroids	O
remain	O
the	O
major	O
treatment	O
modality	O
for	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
but	O
their	O
mechanism	O
of	O
action	O
is	O
unclear	O
.	O

Over	O
the	O
past	O
decade	O
it	O
has	O
become	O
clear	O
that	O
glucocorticosteroid	B-protein
receptors	I-protein
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
glucocorticosteroid	O
action	O
.	O

We	O
studied	O
glucocorticosteroid	B-protein
receptor	I-protein
density	O
and	O
affinity	O
on	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
the	O
glucocorticosteroid	O
binding	O
assay	O
in	O
33	O
patients	O
with	O
SLE	O
who	O
had	O
taken	O
no	O
glucocorticosteroid	O
for	O
the	O
previous	O
6	O
months	O
and	O
in	O
32	O
healthy	O
controls	O
.	O

Patients	O
'	O
disease	O
activity	O
was	O
measured	O
by	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
(	O
SLEDAI	O
)	O
.	O

Glucocorticosteroid	B-protein
receptors	I-protein
on	O
leukocytes	B-cell_type
of	O
patients	O
with	O
SLE	O
were	O
significantly	O
higher	O
than	O
in	O
healthy	O
controls	O
(	O
4419	O
+/-	O
306	O
vs	O
3369	O
+/-	O
196	O
,	O
p	O
less	O
than	O
0.005	O
)	O
.	O

The	O
binding	O
affinity	O
was	O
not	O
different	O
between	O
patients	O
and	O
controls	O
.	O

There	O
was	O
no	O
correlation	O
between	O
glucocorticosteroid	B-protein
receptor	I-protein
number	O
and	O
SLE	O
disease	O
activity	O
.	O

Kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
are	O
constitutively	O
expressed	O
in	O
an	O
IL-2	B-cell_line
autocrine	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
IL-2	B-DNA
and	I-DNA
the	I-DNA
IL-2-R	I-DNA
alpha	I-DNA
genes	I-DNA
are	O
both	O
expressed	O
transiently	O
in	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
after	O
Ag	O
or	O
mitogen	O
activation	O
.	O

In	O
contrast	O
,	O
the	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
IARC	B-cell_line
301	I-cell_line
,	O
expresses	O
these	O
two	O
genes	O
constitutively	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
its	O
growth	O
depends	O
on	O
the	O
autocrine	O
production	O
of	O
this	O
T	B-protein
cell	I-protein
growth	I-protein
factor	I-protein
and	O
high	B-protein
affinity	I-protein
IL-2R	I-protein
.	O

To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusual	O
persistent	O
expression	O
of	O
the	O
IL-2	B-DNA
and	I-DNA
IL-2-R	I-DNA
alpha	I-DNA
genes	I-DNA
in	O
these	O
IARC	B-cell_line
301	I-cell_line
T	B-cell_type
cells	I-cell_type
,	O
we	O
have	O
analyzed	O
the	O
interactions	O
of	O
constitutively	B-protein
expressed	I-protein
nuclear	I-protein
proteins	I-protein
with	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
regions	I-DNA
of	O
the	O
IL-2	B-DNA
and	I-DNA
IL-2-R	I-DNA
alpha	I-DNA
genes	I-DNA
using	O
both	O
DNase	B-protein
I	I-protein
footprinting	O
and	O
gel	O
retardation	O
techniques	O
.	O

We	O
have	O
found	O
that	O
a	O
region	O
in	O
both	O
genes	O
(	O
-276	O
to	O
-250	O
for	O
IL-2-R	B-DNA
alpha	I-DNA
and	O
-203	O
to	O
-183	O
for	O
IL-2	B-DNA
)	O
,	O
which	O
corresponds	O
to	O
a	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
element	I-DNA
,	I-DNA
is	O
specifically	O
protected	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
IARC	B-cell_line
301	I-cell_line
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
both	O
the	O
IL-2	B-DNA
and	I-DNA
IL-2-R	I-DNA
alpha	I-DNA
promoters	I-DNA
are	O
active	O
in	O
transient	O
transfection	O
assays	O
in	O
IARC	B-cell_line
301	I-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
,	O
mutation	O
of	O
the	O
kappa	B-protein
B	I-protein
enhancer	I-protein
results	O
in	O
markedly	O
attenuated	O
activities	O
of	O
both	O
promoters	B-DNA
.	O

Two	O
proteins	O
binding	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
,	O
NF-kappa	B-protein
B	I-protein
and	O
KBF1	B-protein
,	O
are	O
constitutively	O
expressed	O
in	O
IARC	B-cell_line
301	I-cell_line
nuclei	O
and	O
induced	O
by	O
PMA	O
and	O
PHA	B-protein
in	O
Jurkat	B-cell_line
.	O

They	O
bind	O
to	O
the	O
kappa	B-DNA
B	I-DNA
motifs	I-DNA
with	O
different	O
relative	O
affinities	O
that	O
may	O
reflect	O
their	O
different	O
contribution	O
in	O
the	O
expression	O
of	O
various	O
promoters	B-DNA
.	O

HIV1	O
infection	O
of	O
human	B-cell_type
monocytes	I-cell_type
and	O
macrophages	B-cell_type
promotes	O
induction	O
or	O
translocation	O
of	O
NF-KB-related	B-protein
factors	I-protein
.	O

In	O
1991	O
,	O
we	O
demonstrated	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
3	O
different	O
factors	O
(	O
termed	O
B1	B-protein
,	O
B2	B-protein
and	O
B3	B-protein
)	O
with	O
affinity	O
for	O
the	O
KB-enhancer	B-DNA
target	I-DNA
sequence	I-DNA
were	O
specifically	O
detected	O
in	O
nuclear	O
extracts	O
from	O
HIV1-infected	B-cell_type
monocytes	I-cell_type
and	O
macrophages	B-cell_type
.	O

The	O
B2	B-protein
factor	I-protein
was	O
induced	O
in	O
the	O
nuclei	O
of	O
these	O
cells	O
only	O
upon	O
HIV1	O
infection	O
.	O

The	O
B3	B-protein
factor	I-protein
was	O
only	O
slightly	O
evident	O
in	O
nuclei	O
of	O
uninfected	B-cell_type
cells	I-cell_type
but	O
was	O
readily	O
detectable	O
in	O
nuclei	O
of	O
infected	B-cell_type
monocytes	I-cell_type
.	O

Its	O
expression	O
remained	O
very	O
low	O
in	O
nuclei	O
of	O
HIV1-infected	B-cell_type
macrophages	I-cell_type
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
B2	B-protein
factor	I-protein
is	O
expressed	O
in	O
the	O
cytosol	O
of	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
as	O
a	O
DNA-binding	B-protein
protein	I-protein
,	O
indicating	O
that	O
it	O
is	O
not	O
associated	O
with	O
an	O
inhibitor	O
(	O
IKB	O
)	O
.	O

This	O
factor	O
remained	O
clustered	O
in	O
the	O
cytosol	O
and	O
was	O
translocated	O
to	O
the	O
nuclei	O
only	O
after	O
HIV1	O
infection	O
.	O

The	O
B3	B-protein
factor	I-protein
is	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
cells	O
are	O
HIV1-infected	O
.	O

The	O
role	O
of	O
HIV1	O
infection	O
in	O
the	O
expression	O
and	O
the	O
translocation	O
of	O
these	O
factors	O
is	O
discussed	O
.	O

Identification	O
and	O
cloning	O
of	O
TCF-1	B-protein
,	O
a	O
T	B-protein
lymphocyte-specific	I-protein
transcription	I-protein
factor	I-protein
containing	O
a	O
sequence-specific	B-protein
HMG	I-protein
box	I-protein
.	O

CD3	B-protein
-epsilon	O
expression	O
is	O
controlled	O
by	O
a	O
downstream	B-DNA
T	I-DNA
lymphocyte-specific	I-DNA
enhancer	I-DNA
element	I-DNA
.	O

We	O
report	O
the	O
identification	O
of	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
,	O
TCF-1	B-protein
,	O
binding	O
to	O
this	O
element	O
.	O

The	O
multimerized	B-protein
recognition	I-protein
motif	I-protein
of	O
TCF-1	B-protein
constituted	O
a	O
T	O
cell-specific	O
enhancer	O
.	O

Subsequent	O
cloning	O
of	O
TCF-1	B-protein
identified	O
three	O
splice	B-protein
alternatives	I-protein
.	O

TCF-1	B-protein
contained	O
a	O
single	O
DNA-binding	B-protein
HMG	I-protein
box	I-protein
most	O
closely	O
related	O
to	O
similar	O
boxes	O
in	O
the	O
putative	B-DNA
mammalian	I-DNA
sex-determining	I-DNA
gene	I-DNA
SRY	B-DNA
and	O
in	O
the	O
Schizosaccharomyces	B-DNA
pombe	I-DNA
Mc	I-DNA
mating	I-DNA
type	I-DNA
gene	I-DNA
.	O

TCF-1	B-RNA
mRNA	I-RNA
was	O
expressed	O
uniquely	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Upon	O
cotransfection	O
into	O
non-T	B-cell_type
cells	I-cell_type
,	O
TCF-1	B-protein
could	O
transactivate	O
through	O
its	O
cognate	O
motif	O
.	O

These	O
results	O
identify	O
TCF-1	B-protein
as	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
,	O
which	O
might	O
play	O
a	O
role	O
in	O
the	O
establishment	O
of	O
the	O
mature	B-cell_type
T	I-cell_type
cell	I-cell_type
phenotype	I-cell_type
.	O

Identification	O
of	O
transcriptional	B-protein
suppressor	I-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Two	O
different	O
proteins	O
which	O
independently	O
bound	O
to	O
neighboring	O
sequences	O
within	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
(	O
NRE	B-DNA
)	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
were	O
detected	O
in	O
the	O
nuclear	O
extract	O
of	O
a	O
virus-infected	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

One	O
of	O
the	O
factors	O
bound	O
to	O
a	O
novel	B-DNA
dyad	I-DNA
symmetrical	I-DNA
sequence	I-DNA
.	O

This	O
sequence	O
is	O
well	O
conserved	O
in	O
various	O
HIV-1	O
isolates	O
and	O
partial	O
homology	O
was	O
found	O
with	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
human	B-DNA
retinoblastoma	I-DNA
gene	I-DNA
.	O

Similar	O
DNA	O
binding	O
activity	O
was	O
detected	O
in	O
a	O
variety	O
of	O
virus-uninfected	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
by	O
means	O
of	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O

The	O
other	O
factor	O
bound	O
to	O
a	O
putative	B-DNA
AP-1	I-DNA
recognition	I-DNA
sequence	I-DNA
predicted	O
for	O
the	O
HIV-1	O
NRE	B-DNA
.	O

However	O
,	O
this	O
factor	O
did	O
not	O
bind	O
to	O
a	O
typical	O
AP-1	B-DNA
site	I-DNA
.	O

The	O
insertion	O
of	O
multiple	O
copies	O
of	O
the	O
binding	B-DNA
site	I-DNA
for	O
the	O
former	O
or	O
latter	O
factor	O
into	O
a	O
heterologous	B-DNA
promoter	I-DNA
reduced	O
the	O
promoter	O
activity	O
to	O
one-tenth	O
or	O
one-third	O
,	O
respectively	O
.	O

Thus	O
,	O
each	O
factor	O
may	O
function	O
as	O
a	O
novel	B-protein
negative	I-protein
regulator	I-protein
of	O
transcription	O
.	O

Protein	B-protein
kinase	I-protein
C	I-protein
activation	O
and	O
protooncogene	B-DNA
expression	O
in	O
differentiation/retrodifferentiation	O
of	O
human	B-cell_line
U-937	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

Human	B-cell_line
U-937	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
differentiate	O
along	O
the	O
monocytic	B-cell_type
lineage	I-cell_type
following	O
3-day	O
exposures	O
to	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

This	O
induction	O
of	O
differentiation	O
is	O
accompanied	O
by	O
adherence	O
and	O
loss	O
of	O
proliferation	O
,	O
as	O
well	O
as	O
expression/repression	O
of	O
differentiation-associated	B-DNA
genes	I-DNA
.	O

Long	O
term	O
culture	O
of	O
TPA-differentiated	B-cell_type
U-937	I-cell_type
cells	I-cell_type
in	O
the	O
absence	O
of	O
phorbol	O
ester	O
for	O
32-36	O
days	O
resulted	O
in	O
a	O
process	O
of	O
retrodifferentiation	O
.	O

The	O
retrodifferentiated	O
cells	O
detached	O
from	O
the	O
substrate	O
and	O
reinitiated	O
proliferation	O
.	O

Other	O
cellular	O
parameters	O
,	O
such	O
as	O
glycosidase	O
activities	O
,	O
cytokine	B-protein
release	O
,	O
and	O
filament	O
expression	O
,	O
returned	O
to	O
levels	O
similar	O
to	O
that	O
observed	O
in	O
uninduced	B-cell_type
cells	I-cell_type
.	O

Treatment	O
of	O
U-937	B-cell_line
cells	I-cell_line
with	O
TPA	O
resulted	O
in	O
a	O
rapid	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
from	O
the	O
cytosol	O
to	O
cell	O
membrane	O
fractions	O
within	O
2-8	O
min	O
.	O

Increased	O
levels	O
of	O
membrane-associated	O
PKC	B-protein
activity	O
persisted	O
until	O
17-29	O
days	O
.	O

However	O
,	O
longer	O
periods	O
of	O
incubation	O
were	O
associated	O
with	O
a	O
return	O
to	O
the	O
distribution	O
of	O
PKC	B-protein
in	O
control	O
cells	O
.	O

Activation	O
of	O
PKC	B-protein
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
certain	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
,	O
and	O
in	O
the	O
present	O
studies	O
,	O
TPA	O
rapidly	O
induced	O
c-fos	B-DNA
and	O
c-jun	B-DNA
gene	I-DNA
expression	I-DNA
.	O

Levels	O
of	O
c-fos	B-RNA
and	I-RNA
c-jun	I-RNA
transcripts	I-RNA
remained	O
elevated	O
during	O
periods	O
of	O
PKC	B-protein
activation	O
and	O
also	O
returned	O
to	O
levels	O
observed	O
in	O
control	O
cells	O
by	O
30-36	O
days	O
,	O
when	O
the	O
cells	O
entered	O
retrodifferentiation	O
.	O

Staurosporine	O
,	O
a	O
nonspecific	O
inhibitor	O
of	O
PKC	B-protein
,	O
partially	O
blocked	O
TPA-induced	O
adherence	O
and	O
growth	O
inhibition	O
and	O
concomitantly	O
prevented	O
TPA-induced	O
c-fos	O
and	O
c-jun	O
gene	O
expression	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Kappa	B-protein
B-specific	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
are	O
differentially	O
inhibited	O
by	O
enhancer	O
mutations	O
and	O
biological	O
oxidation	O
.	O

Kappa	B-protein
B	I-protein
(	I-protein
kappa	I-protein
B	I-protein
)	I-protein
enhancer	I-protein
binding	I-protein
proteins	I-protein
isolated	O
from	O
the	O
nuclei	O
of	O
activated	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
produce	O
two	O
distinct	O
nucleoprotein	B-protein
complexes	I-protein
when	O
incubated	O
with	O
the	O
kappa	B-DNA
B	I-DNA
element	I-DNA
from	O
the	O
interleukin-2	B-DNA
receptor-alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
.	O

These	O
two	O
DNA-protein	B-protein
complexes	I-protein
are	O
composed	O
of	O
at	O
least	O
four	O
host	O
proteins	O
(	O
p50	B-protein
,	O
p55	B-protein
,	O
p75	B-protein
,	O
p85	B-protein
)	O
,	O
each	O
of	O
which	O
shares	O
structural	O
similarity	O
with	O
the	O
v-rel	B-protein
oncogene	I-protein
product	I-protein
.	O

Nuclear	O
expression	O
of	O
these	O
proteins	O
is	O
induced	O
with	O
distinctly	O
biphasic	O
kinetics	O
following	O
phorbol	O
ester	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
(	O
p55/p75	B-protein
early	I-protein
and	O
p50/p85	B-protein
late	I-protein
)	O
.	O

DNA-protein	O
crosslinking	O
studies	O
have	O
revealed	O
that	O
the	O
more	O
rapidly	O
migrating	O
B2	B-protein
complex	I-protein
contains	O
both	O
p50	B-protein
and	O
p55	B-protein
while	O
the	O
more	O
slowly	O
migrating	O
B1	B-protein
complex	I-protein
is	O
composed	O
of	O
p50	B-protein
,	O
p55	B-protein
,	O
p75	B-protein
,	O
and	O
p85	B-protein
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
wild-type	B-DNA
IL-2R	I-DNA
alpha	I-DNA
kappa	I-DNA
B	I-DNA
enhancer	I-DNA
(	O
GGGGAATCTCCC	O
)	O
has	O
revealed	O
that	O
the	O
binding	O
of	O
p50	O
and	O
p55	B-protein
(	O
B2	B-protein
complex	I-protein
)	O
is	O
particularly	O
sensitive	O
to	O
alteration	O
of	O
the	O
5	B-DNA
'	I-DNA
triplet	I-DNA
of	O
deoxyguanosine	O
residues	O
.	O

In	O
contrast	O
,	O
formation	O
of	O
the	O
B1	B-protein
complex	I-protein
,	O
reflecting	O
the	O
binding	O
of	O
p75	B-protein
and	O
p85	B-protein
,	O
critically	O
depends	O
upon	O
the	O
more	O
3	O
'	O
sequences	O
of	O
this	O
enhancer	B-DNA
element	I-DNA
.	O

DNA	O
binding	O
by	O
all	O
four	O
of	O
these	O
Rel-related	B-protein
factors	I-protein
is	O
blocked	O
by	O
selective	O
chemical	O
modification	O
of	O
lysine	O
and	O
arginine	O
residues	O
,	O
suggesting	O
that	O
both	O
of	O
these	O
basic	O
amino	O
acids	O
are	O
required	O
for	O
binding	O
to	O
the	O
kappa	B-DNA
B	I-DNA
element	I-DNA
.	O

Similarly	O
,	O
covalent	O
modification	O
of	O
free	O
sulfhydryl	O
groups	O
with	O
diamide	O
(	O
reversible	O
)	O
or	O
N-ethylmaleimide	O
(	O
irreversible	O
)	O
results	O
in	O
a	O
complete	O
loss	O
of	O
DNA	O
binding	O
activity	O
.	O

In	O
contrast	O
,	O
mild	O
oxidation	O
with	O
glucose	B-protein
oxidase	I-protein
selectively	O
inhibits	O
p75	B-protein
and	O
p85	B-protein
binding	O
while	O
not	O
blocking	O
p50	B-protein
and	O
p55	B-protein
interactions	O
.	O

These	O
findings	O
suggest	O
that	O
reduced	O
cysteine	O
thiols	O
play	O
an	O
important	O
role	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
this	O
family	O
of	O
Rel-related	B-protein
transcription	I-protein
factors	I-protein
.	O

[	O
Changes	O
in	O
leucocytic	O
estrogen	B-protein
receptor	I-protein
levels	O
in	O
patients	O
with	O
climacteric	O
syndrome	O
and	O
therapeutic	O
effect	O
of	O
liuwei	O
dihuang	O
pills	O
]	O

The	O
numbers	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
human	B-cell_type
peripheral	I-cell_type
leucocytes	I-cell_type
in	O
22	O
women	O
with	O
climacteric	O
syndrome	O
were	O
measured	O
by	O
radioligand	O
method	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
normal	O
child-bearing-age	O
women	O
.	O

It	O
wat	O
found	O
that	O
the	O
contents	O
of	O
leucocytic	B-protein
ER	I-protein
in	O
climacteric	O
syndrome	O
patients	O
were	O
significantly	O
lower	O
than	O
normal	O
child-bearing-age	O
women	O
.	O

The	O
authors	O
used	O
a	O
Chinese	O
prescription	O
--	O
Liuwei	O
Dihuang	O
Pills	O
(	O
LDP	O
)	O
to	O
treat	O
the	O
patients	O
for	O
2	O
months	O
.	O

The	O
numbers	O
of	O
leucocytic	B-protein
ER	I-protein
were	O
significantly	O
increased	O
after	O
treatment	O
.	O

The	O
data	O
indicate	O
that	O
decrease	O
of	O
ER	B-protein
levels	O
in	O
cell	O
may	O
involve	O
in	O
the	O
pathogenesis	O
of	O
climacteric	O
syndrome	O
.	O

LDP	O
not	O
only	O
increases	O
plasma	O
estradiol	O
levels	O
,	O
but	O
also	O
increases	O
the	O
leucocytic	O
ER	B-protein
levels	O
.	O

This	O
may	O
be	O
the	O
basis	O
of	O
the	O
therapeutic	O
effect	O
on	O
the	O
disease	O
.	O

Evaluation	O
of	O
the	O
role	O
of	O
ligand	O
and	O
thermal	O
activation	O
of	O
specific	O
DNA	O
binding	O
by	O
in	B-protein
vitro	I-protein
synthesized	I-protein
human	I-protein
glucocorticoid	I-protein
receptor	I-protein
.	O

We	O
have	O
used	O
a	O
DNA-binding/immunoprecipitation	O
assay	O
to	O
analyze	O
the	O
capacity	O
of	O
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
(	O
hGR	B-protein
)	O
,	O
generated	O
in	O
rabbit	O
reticulocyte	O
lysates	O
,	O
to	O
bind	O
DNA	O
.	O

In	B-protein
vitro	I-protein
translated	I-protein
hGR	I-protein
was	O
indistinguishable	O
from	O
native	B-protein
hGR	I-protein
,	O
as	O
determined	O
by	O
migration	O
on	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gels	O
,	O
sedimentation	O
on	O
sucrose	O
density	O
gradients	O
,	O
and	O
reactivity	O
with	O
antipeptide	B-protein
antibodies	I-protein
generated	O
against	O
hGR	B-protein
.	O

In	O
addition	O
,	O
cell-free	B-protein
synthesized	I-protein
hGR	I-protein
was	O
capable	O
of	O
specific	O
binding	O
to	O
glucocorticoid	B-DNA
response	I-DNA
element	I-DNA
(	I-DNA
GRE	I-DNA
)	I-DNA
-containing	I-DNA
DNA	I-DNA
fragments	I-DNA
.	O

Using	O
this	O
assay	O
system	O
,	O
we	O
have	O
evaluated	O
the	O
contributions	O
of	O
ligand	O
binding	O
and	O
heat	O
activation	O
to	O
DNA	O
binding	O
by	O
these	O
glucocorticoid	B-protein
receptors	I-protein
.	O

In	B-protein
vitro	I-protein
translated	I-protein
hGR	I-protein
was	O
capable	O
of	O
selective	O
DNA	O
binding	O
even	O
in	O
the	O
absence	O
of	O
glucocorticoid	O
.	O

Treatment	O
with	O
dexamethasone	O
or	O
the	O
antiglucocorticoid	O
RU486	O
had	O
no	O
additional	O
effect	O
on	O
the	O
DNA-binding	O
capacity	O
when	O
receptor	O
preparations	O
were	O
maintained	O
at	O
0	O
C	O
(	O
no	O
activation	O
)	O
.	O

In	O
contrast	O
,	O
addition	O
of	O
either	O
ligand	O
or	O
antagonist	O
in	O
combination	O
with	O
a	O
heat	O
activation	O
step	O
promoted	O
DNA	O
binding	O
by	O
approximately	O
3-fold	O
over	O
that	O
of	O
heat-activated	O
unliganded	B-protein
receptors	I-protein
.	O

Agonist	O
(	O
dexamethasone	O
)	O
was	O
slightly	O
more	O
effective	O
in	O
supporting	O
specific	O
DNA	O
binding	O
than	O
antagonist	O
(	O
RU486	O
)	O
.	O

DNA	O
binding	O
by	O
in	B-protein
vitro	I-protein
synthesized	I-protein
GR	I-protein
was	O
blocked	O
by	O
the	O
addition	O
of	O
sodium	O
molybdate	O
to	O
the	O
receptor	O
preparations	O
before	O
steroid	O
addition	O
and	O
thermal	O
activation	O
.	O

Addition	O
of	O
KCl	O
resulted	O
in	O
less	O
DNA	O
binding	O
either	O
due	O
to	O
blockage	O
of	O
DNA-	O
receptor	B-protein
complex	I-protein
formation	O
or	O
disruption	O
of	O
the	O
complexes	O
.	O

The	O
specificity	O
of	O
DNA	O
binding	O
by	O
cell-free	B-protein
synthesized	I-protein
hGR	I-protein
was	O
analyzed	O
further	O
by	O
examining	O
the	O
abilities	O
of	O
various	B-DNA
DNAs	I-DNA
to	O
compete	O
for	O
binding	O
to	O
a	O
naturally	O
occurring	O
GRE	B-DNA
found	O
in	O
the	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus-long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

Oligonucleotides	O
containing	O
the	O
consensus	B-DNA
GRE	I-DNA
were	O
the	O
most	O
efficient	O
competitors	O
,	O
and	O
fragments	O
containing	O
regulatory	B-DNA
sequences	I-DNA
from	O
glucocorticoid-repressible	B-DNA
genes	I-DNA
were	O
somewhat	O
competitive	O
,	O
whereas	O
single	O
stranded	O
oligonucleotides	O
were	O
unable	O
to	O
compete	O
for	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus-long	I-DNA
terminal	I-DNA
repeat	I-DNA
DNA	O
binding	O
,	O
except	O
when	O
competitor	O
was	O
present	O
at	O
extremely	O
high	O
concentrations	O
.	O

Together	O
these	O
studies	O
indicate	O
that	O
hGR	B-protein
synthesized	O
in	O
rabbit	O
reticulocyte	O
lysates	O
displays	O
many	O
of	O
the	O
same	O
properties	O
,	O
including	O
GRE	B-DNA
-specific	O
DNA	O
binding	O
,	O
observed	O
for	O
glucocorticoid	B-protein
receptor	I-protein
present	O
in	O
cytosolic	O
extracts	O
of	O
mammalian	B-cell_type
cells	I-cell_type
and	O
tissues	O
.	O

Similarities	O
between	O
the	O
effects	O
of	O
dexamethasone	O
and	O
RU486	O
suggest	O
that	O
the	O
antiglucocorticoid	O
properties	O
of	O
RU486	O
do	O
not	O
occur	O
at	O
the	O
level	O
of	O
specific	O
DNA	O
binding	O
.	O

Expression	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
on	O
alveolar	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
known	O
to	O
be	O
produced	O
at	O
sites	O
of	O
granulomatous	O
reactions	O
.	O

In	O
order	O
to	O
characterize	O
the	O
cell	O
types	O
that	O
are	O
targets	O
for	O
this	O
immunoregulatory	O
hormone	O
,	O
we	O
have	O
evaluated	O
the	O
expression	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
on	O
peripheral	B-cell_type
blood	I-cell_type
T-lymphocytes	I-cell_type
and	O
those	O
recovered	O
from	O
the	O
lung	O
by	O
bronchoalveolar	O
lavage	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
(	O
tuberculosis	O
and	O
sarcoidosis	O
)	O
and	O
from	O
normal	O
control	O
subjects	O
using	O
combined	O
autoradiographic	O
and	O
immunohistochemical	O
techniques	O
.	O

Lavage	O
T-lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
or	O
with	O
sarcoidosis	O
,	O
but	O
not	O
those	O
from	O
normal	O
control	O
subjects	O
,	O
expressed	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
as	O
demonstrated	O
by	O
binding	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
presence	O
of	O
excess	O
unlabeled	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
not	O
by	O
the	O
presence	O
of	O
unlabeled	O
25	O
(	O
OH	O
)	O
D3	O
(	O
receptor-positive	B-cell_type
lymphocytes	I-cell_type
:	O
sarcoidosis	O
,	O
20	O
+/-	O
12	O
%	O
;	O
tuberculosis	O
,	O
31	O
+/-	O
17	O
%	O
)	O
.	O

In	O
contrast	O
,	O
blood	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
granulomatous	O
diseases	O
did	O
not	O
express	O
detectable	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
.	O

The	O
percentage	O
of	O
lavage	B-cell_type
T-lymphocytes	I-cell_type
expressing	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
was	O
significantly	O
greater	O
for	O
patients	O
with	O
tuberculosis	O
presenting	O
with	O
isolated	O
hilar	O
adenopathy	O
than	O
for	O
patients	O
with	O
pulmonary	O
infiltrates	O
and/or	O
cavities	O
.	O

1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
were	O
expressed	O
to	O
a	O
greater	O
extent	O
on	O
CD8+	B-cell_type
T-lymphocytes	I-cell_type
than	O
on	O
CD4+	B-cell_type
T-lymphocytes	I-cell_type
in	O
sarcoidosis	O
,	O
whereas	O
a	O
greater	O
proportion	O
of	O
CD4+	B-cell_type
than	O
of	O
CD8+	B-cell_type
T-lymphocytes	I-cell_type
from	O
patients	O
with	O
tuberculosis	O
were	O
receptor-positive	O
.	O

These	O
findings	O
support	O
the	O
conclusion	O
that	O
the	O
interaction	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
with	O
its	O
receptor	O
on	O
T-lymphocytes	B-cell_type
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
granulomatous	O
reactions	O
,	O
but	O
because	O
these	O
receptors	O
are	O
expressed	O
on	O
different	O
lymphocyte	B-cell_type
populations	I-cell_type
,	O
the	O
net	O
effect	O
of	O
this	O
potent	O
immunoregulatory	B-protein
molecule	I-protein
is	O
likely	O
different	O
in	O
sarcoidosis	O
and	O
tuberculosis	O
.	O

Role	O
for	O
the	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
in	O
viral	B-DNA
promoter	I-DNA
switching	O
during	O
initial	O
stages	O
of	O
infection	O
.	O

During	O
latent	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
six	B-protein
viral	I-protein
nuclear	I-protein
antigen	I-protein
(	O
EBNAs	B-protein
)	O
are	O
expressed	O
from	O
long	B-RNA
primary	I-RNA
transcripts	I-RNA
by	O
means	O
of	O
alternative	B-RNA
splicing	I-RNA
and	O
alternative	B-RNA
polyadenylylation	I-RNA
sites	I-RNA
.	O

These	O
transcripts	O
initiate	O
from	O
one	O
of	O
two	O
promoters	B-DNA
,	O
Cp	B-DNA
or	O
Wp	O
,	O
that	O
function	O
in	O
a	O
mutually	O
exclusive	O
fashion	O
.	O

Wp	O
is	O
exclusively	O
utilized	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
of	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	B-DNA
usage	O
.	O

These	O
studies	O
have	O
been	O
extended	O
to	O
show	O
that	O
(	O
i	O
)	O
a	O
mutant	O
EBV	O
strain	O
lacking	O
the	O
gene	O
encoding	O
EBNA	B-protein
2	I-protein
fails	O
to	O
switch	O
from	O
Wp	O
to	O
Cp	B-DNA
usage	O
in	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
although	O
the	O
virus	O
contains	O
a	O
functional	O
Cp	B-DNA
;	O
(	O
ii	O
)	O
a	O
region	O
from	O
-429	B-DNA
to	I-DNA
-245	I-DNA
base	I-DNA
pairs	I-DNA
upstream	O
of	O
Cp	B-DNA
is	O
essential	O
for	O
Cp	B-DNA
activity	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
,	O
but	O
only	O
in	O
the	O
context	O
of	O
upstream	B-DNA
and	I-DNA
downstream	I-DNA
sequences	I-DNA
;	O
(	O
iii	O
)	O
this	O
region	O
contains	O
an	O
EBNA	B-DNA
2-dependent	I-DNA
enhancer	I-DNA
;	O
and	O
(	O
iv	O
)	O
DNase	B-protein
I	I-protein
protection	O
employing	O
nuclear	O
extracts	O
from	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
revealed	O
a	O
B-cell-specific	B-DNA
footprint	I-DNA
in	O
the	O
region	O
of	O
the	O
EBNA	B-DNA
2-dependent	I-DNA
enhancer	I-DNA
.	O

These	O
results	O
support	O
a	O
model	O
for	O
viral	B-DNA
promoter	I-DNA
switching	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
in	O
which	O
Wp	O
activity	O
leads	O
to	O
the	O
expression	O
of	O
EBNA	B-protein
2	I-protein
,	O
followed	O
by	O
activation	O
of	O
Cp	B-DNA
through	O
the	O
EBNA	B-DNA
2-dependent	I-DNA
enhancer	I-DNA
.	O

Immune	O
response	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
to	O
HBx-antigen	B-protein
of	O
hepatitis	O
B	O
virus	O
.	O

The	O
hepatitis	B-DNA
B	I-DNA
virus	I-DNA
genome	I-DNA
encodes	O
a	O
transcriptional	B-protein
transactivator	I-protein
protein	I-protein
designated	O
HBxAg	B-protein
.	O

We	O
have	O
investigated	O
whether	O
this	O
antigen	O
is	O
a	O
target	O
structure	O
for	O
human	B-cell_type
T-lymphocytes	I-cell_type
.	O

Using	O
recombinant	B-protein
HBxAg	I-protein
protein	I-protein
,	O
we	O
found	O
HBxAg	B-protein
-specific	O
stimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
in	O
patients	O
with	O
acute	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
6	O
)	O
and	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
17	O
)	O
but	O
not	O
in	O
healthy	O
individuals	O
.	O

With	O
HBxAg	B-protein
-specific	O
synthetic	O
polypeptides	O
,	O
several	O
T-cell	O
epitopes	O
were	O
identified	O
.	O

Most	O
were	O
located	O
in	O
the	O
carboxyterminal	B-protein
half	I-protein
of	O
the	O
HBxAg	B-protein
protein	I-protein
.	O

Five	O
T-cell	B-cell_line
clones	I-cell_line
specific	O
for	O
a	O
T-cell	B-protein
epitope	I-protein
located	O
at	O
the	O
carboxyterminal	B-protein
region	I-protein
of	O
HBxAg	B-protein
were	O
established	O
and	O
found	O
to	O
belong	O
to	O
the	O
CD2/CD4-positive	B-cell_line
,	I-cell_line
CD8-negative	I-cell_line
subtype	I-cell_line
.	O

These	O
data	O
establish	O
for	O
the	O
first	O
time	O
HBxAg	B-protein
as	O
an	O
antigen	O
in	O
the	O
cellular	O
immune	O
response	O
.	O

[	O
Changes	O
in	O
leucocytic	B-protein
estrogen	I-protein
receptor	I-protein
levels	O
in	O
patients	O
with	O
gynecomastia	O
]	O

The	O
number	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
human	B-cell_type
peripheral	I-cell_type
leucocytes	I-cell_type
in	O
13	O
men	O
with	O
gynecomastia	O
were	O
measured	O
by	O
radioligand	O
binding	O
method.	O
The	O
results	O
were	O
compared	O
with	O
those	O
of	O
13	O
sex-and	O
age-matched	O
healthy	O
subjects	O
.	O

It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	B-protein
in	O
leucocytes	B-cell_type
was	O
significantly	O
increased	O
in	O
gynecomastia	O
(	O
Rs	O
of	O
leucocytes	B-cell_type
were	O
1054	O
+/-	O
254	O
sites/cell	O
)	O
.	O

It	O
suggested	O
that	O
increase	O
of	O
ER	O
levels	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
gynecomastia	O
.	O

The	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
independent	I-DNA
cis-acting	I-DNA
sequences	I-DNA
in	O
HIV-1	B-DNA
LTR	I-DNA
responsive	O
to	O
T-cell	O
activation	O
.	O

The	O
rate	O
of	O
transcription	O
initiation	O
directed	O
by	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	O
)	O
of	O
HIV-1	O
increases	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

Here	O
we	O
show	O
that	O
the	O
response	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
may	O
be	O
governed	O
by	O
two	O
independent	O
sequences	O
located	O
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
sequences	O
that	O
bind	O
either	O
NFAT-1	B-protein
or	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

The	O
rate	O
of	O
LTR	B-DNA
-directed	O
gene	O
expression	O
increased	O
in	O
response	O
to	O
treatment	O
with	O
either	O
a	O
phorbol	O
ester	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
if	O
either	O
the	O
NFAT-1	B-protein
or	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
were	O
deleted	O
,	O
but	O
failed	O
to	O
respond	O
to	O
these	O
mitogenic	O
stimuli	O
if	O
both	O
sequences	O
were	O
absent	O
.	O

The	O
HIV-1	O
mutant	O
virus	O
containing	O
both	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
and	I-DNA
NFAT-1	I-DNA
deletion	I-DNA
was	O
able	O
to	O
replicate	O
although	O
at	O
a	O
much	O
decreased	O
growth	O
rate	O
,	O
while	O
the	O
deletion	O
of	O
NFAT-1	B-protein
alone	O
increased	O
the	O
viral	O
growth	O
rate	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Neither	O
deletion	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
nor	O
deletion	O
of	O
NFAT-1	B-protein
decreased	O
activation	O
of	O
viral	O
replication	O
by	O
phorbol	O
ester	O
.	O

cAMP-dependent	O
regulation	O
of	O
proenkephalin	O
by	O
JunD	B-protein
and	O
JunB	B-protein
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP-1	B-protein
proteins	I-protein
.	O

We	O
demonstrate	O
that	O
JunD	B-protein
,	O
a	O
component	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
complex	I-protein
,	O
activates	O
transcription	O
of	O
the	O
human	B-DNA
proenkephalin	I-DNA
gene	I-DNA
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
.	O

Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	B-protein
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP-	B-DNA
,	I-DNA
phorbol	I-DNA
ester-	I-DNA
,	I-DNA
and	I-DNA
Ca	I-DNA
(	I-DNA
2+	I-DNA
)	I-DNA
-inducible	I-DNA
enhancer	I-DNA
,	O
and	O
JunD	B-protein
is	O
shown	O
to	O
bind	O
the	O
enhancer	B-DNA
as	O
a	O
homodimer	B-protein
.	O

Another	O
component	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
complex	I-protein
,	O
JunB	B-protein
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	B-protein
.	O

As	O
a	O
homodimer	O
JunB	B-protein
is	O
unable	O
to	O
bind	O
the	O
enhancer	O
;	O
however	O
in	O
the	O
presence	O
of	O
c-Fos	B-protein
,	O
high-affinity	O
binding	O
is	O
observed	O
.	O

Furthermore	O
,	O
JunD	B-protein
is	O
shown	O
to	O
activate	O
transcription	O
of	O
genes	O
linked	O
to	O
both	O
cAMP	O
and	O
phorbol	O
ester	O
response	O
elements	O
in	O
a	O
protein	B-protein
kinase	I-protein
A	I-protein
-dependent	O
fashion	O
,	O
further	O
blurring	O
the	O
distinction	O
between	O
these	O
response	B-DNA
elements	I-DNA
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP-1-related	B-protein
protein	I-protein
is	O
regulated	O
by	O
the	O
cAMP-dependent	O
second-messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	B-protein
and	O
other	O
AP-1-related	B-protein
proteins	I-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP-dependent	O
intracellular	O
signaling	O
pathways	O
.	O

[	O
Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
deficiency-cold	O
vs	O
deficiency-heat	O
syndromes	O
]	O

Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
were	O
assayed	O
in	O
20	O
patients	O
with	O
deficiency	O
syndromes	O
,	O
10	O
cold	O
in	O
property	O
(	O
deficiency-cold	O
)	O
,	O
the	O
other	O
10	O
hot	O
in	O
property	O
(	O
deficiency-heat	O
)	O
,	O
and	O
also	O
in	O
10	O
healthy	O
individuals	O
as	O
normal	O
control	O
for	O
the	O
purpose	O
of	O
investigating	O
the	O
nature	O
of	O
cold	O
and	O
heat	O
syndromes	O
.	O

As	O
a	O
result	O
,	O
the	O
cases	O
of	O
deficiency-cold	O
syndrome	O
(	O
DCS	O
)	O
had	O
a	O
normal	O
concentration	O
of	O
plasma	O
cortisol	O
but	O
a	O
lowered	O
content	O
of	O
GCR	B-protein
in	O
leukocytes	B-cell_type
when	O
compared	O
with	O
the	O
normal	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
;	O
the	O
cases	O
of	O
deficiency-heat	O
syndrome	O
(	O
DHS	O
)	O
had	O
a	O
higher	O
concentration	O
of	O
plasma	O
cortisol	O
than	O
the	O
normal	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
a	O
slightly	O
higher	O
content	O
of	O
GCR	B-protein
in	O
leukocytes	B-cell_type
.	O

It	O
was	O
concluded	O
that	O
the	O
DCS	O
is	O
characterized	O
by	O
diminished	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
,	O
while	O
the	O
DHS	O
,	O
by	O
augmented	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
.	O

The	O
role	O
of	O
jun	B-DNA
and	I-DNA
fos	I-DNA
gene	I-DNA
family	I-DNA
members	I-DNA
in	O
12-O-tetradecanoylphorbol-13-acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O

Terminal	O
differentiation	O
of	O
the	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
U-937	B-cell_line
and	O
HL-60	B-cell_line
by	O
12-O-tetradecanoylphorbol-13-acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
jun	B-DNA
and	I-DNA
fos	I-DNA
gene	I-DNA
family	I-DNA
members	I-DNA
is	O
induced	O
with	O
variable	O
kinetics	O
during	O
12-O-tetradecanoylphorbol-13-acetate	O
induced	O
differentiation	O
,	O
with	O
c-jun	B-DNA
expression	O
best	O
paralleling	O
differentiation	O
.	O

The	O
generation	O
of	O
AP-1	B-protein
complexes	I-protein
,	O
as	O
measured	O
by	O
DNA	O
binding	O
activity	O
,	O
closely	O
parallels	O
morphological	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP-1	B-DNA
driven	I-DNA
reporter	I-DNA
construct	I-DNA
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	B-DNA
AP-1	I-DNA
regulated	I-DNA
genes	I-DNA
.	O

Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP-1	B-protein
appears	O
.	O

This	O
tight	O
correlation	O
between	O
c-jun	B-DNA
expression	O
,	O
the	O
generation	O
of	O
AP-1	B-protein
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	B-protein
complex	I-protein
during	O
this	O
process	O
.	O

Nuclear	O
association	O
of	O
a	O
T-cell	B-protein
transcription	I-protein
factor	I-protein
blocked	O
by	O
FK-506	O
and	O
cyclosporin	O
A	O
[	O
see	O
comments	O
]	O

Cyclosporin	O
A	O
and	O
FK506	O
inhibit	O
T-	O
and	O
B-cell	O
activation	O
and	O
other	O
processes	O
essential	O
to	O
an	O
effective	O
immune	O
response	O
.	O

In	O
T	B-cell_type
lymphocytes	I-cell_type
these	O
drugs	O
disrupt	O
an	O
unknown	O
step	O
in	O
the	O
transmission	O
of	O
signals	O
from	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
to	O
cytokine	B-DNA
genes	I-DNA
that	O
coordinate	O
the	O
immune	O
response	O
.	O

The	O
putative	B-protein
intracellular	I-protein
receptors	I-protein
for	O
FK506	O
and	O
cyclosporin	O
are	O
cis-trans	O
prolyl	O
isomerases	O
.	O

Binding	O
of	O
the	O
drug	O
inhibits	O
isomerase	B-protein
activity	O
,	O
but	O
studies	O
with	O
other	O
prolyl	O
isomerase	B-protein
inhibitors	O
and	O
analysis	O
of	O
cyclosporin-resistant	B-cell_line
mutants	I-cell_line
in	O
yeast	O
suggest	O
that	O
the	O
effects	O
of	O
the	O
drug	O
result	O
from	O
the	O
formation	O
of	O
an	O
inhibitory	B-protein
complex	I-protein
between	O
the	O
drug	O
and	O
isomerase	B-protein
,	O
and	O
not	O
from	O
inhibition	O
of	O
isomerase	B-protein
activity	O
.	O

A	O
transcription	B-protein
factor	I-protein
,	O
NF-AT	B-protein
,	O
which	O
is	O
essential	O
for	O
early	O
T-cell	O
gene	O
activation	O
,	O
seems	O
to	O
be	O
a	O
specific	O
target	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
action	O
because	O
transcription	O
directed	O
by	O
this	O
protein	O
is	O
blocked	O
in	O
T	B-cell_type
cells	I-cell_type
treated	O
with	O
these	O
drugs	O
,	O
with	O
little	O
or	O
no	O
effect	O
on	O
other	O
transcription	B-protein
factors	I-protein
such	O
as	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O

Here	O
we	O
demonstrate	O
that	O
NF-AT	B-protein
is	O
formed	O
when	O
a	O
signal	O
from	O
the	O
antigen	B-protein
receptor	I-protein
induces	O
a	O
pre-existing	O
cytoplasmic	O
subunit	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
combine	O
with	O
a	O
newly	O
synthesized	O
nuclear	O
subunit	O
of	O
NF-AT	B-protein
.	O

FK506	O
and	O
cyclosporin	O
A	O
block	O
translocation	O
of	O
the	O
cytoplasmic	B-protein
component	I-protein
without	O
affecting	O
synthesis	O
of	O
the	O
nuclear	B-protein
subunit	I-protein
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
in	O
anorexia	O
nervosa	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
was	O
to	O
explore	O
the	O
down-regulation	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
during	O
hypercortisolaemia	O
in	O
anorexia	O
nervosa	O
.	O

DESIGN	O
:	O
Urine	O
and	O
plasma	O
samples	O
were	O
obtained	O
for	O
cortisol	O
determination	O
and	O
blood	B-cell_type
lymphocytes	I-cell_type
were	O
isolated	O
for	O
receptor	O
binding	O
studies	O
.	O

PATIENTS	O
:	O
Sixteen	O
anorexic	O
patients	O
,	O
aged	O
16-27	O
years	O
,	O
with	O
a	O
mean	O
+/-	O
SEM	O
body	O
mass	O
index	O
of	O
14.2	O
+/-	O
2.0	O
(	O
ranging	O
from	O
11.1	O
to	O
17.4	O
)	O
,	O
and	O
15	O
normal	O
women	O
were	O
studied	O
.	O

Six	O
patients	O
were	O
reinvestigated	O
after	O
a	O
significant	O
weight	O
gain	O
.	O

MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
with	O
dexamethasone	O
as	O
ligand	O
on	O
lymphocytes	B-cell_type
.	O

RESULTS	O
:	O
In	O
patients	O
,	O
both	O
total	O
and	O
free	O
plasma	O
cortisol	O
concentrations	O
were	O
higher	O
than	O
in	O
the	O
normal	O
women	O
,	O
as	O
was	O
their	O
urinary	O
free	O
cortisol	O
;	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
per	O
cell	O
(	O
Ro	O
)	O
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
for	O
dexamethasone	O
were	O
,	O
however	O
,	O
not	O
significantly	O
different	O
(	O
Ro	O
:	O
7687	O
+/-	O
1750	O
vs	O
7347	O
+/-	O
1285	O
sites/cell	O
;	O
Kd	O
:	O
7.7	O
+/-	O
2.4	O
vs	O
7.4	O
+/-	O
1.7	O
nM	O
at	O
24	O
degrees	O
C	O
)	O
.	O

After	O
weight	O
gain	O
(	O
14	O
+/-	O
2	O
to	O
16	O
+/-	O
2	O
kg/m2	O
)	O
,	O
receptor	O
numbers	O
were	O
8421	O
+/-	O
2126	O
(	O
pre	O
)	O
and	O
9011	O
+/-	O
500	O
(	O
post	O
)	O
sites/cell	O
,	O
which	O
are	O
not	O
significantly	O
different	O
(	O
P	O
greater	O
than	O
0.2	O
)	O
;	O
the	O
Kd	O
was	O
unchanged	O
(	O
9.3	O
+/-	O
2.6	O
vs	O
9.2	O
+/-	O
2.4	O
nM	O
)	O
.	O

CONCLUSIONS	O
Hypercortisolaemia	O
does	O
not	O
down-regulate	O
the	O
lymphocyte	O
glucocorticoid	B-protein
receptors	I-protein
in	O
anorexia	O
nervosa	O
and	O
a	O
post-receptor	O
defect	O
might	O
be	O
involved	O
in	O
peripheral	O
tissue	O
resistance	O
to	O
the	O
effects	O
of	O
glucocorticoid	O
hormones	O
in	O
undernutrition	O
.	O

Inhibition	O
of	O
protein	B-protein
phosphatases	I-protein
by	O
okadaic	O
acid	O
induces	O
AP1	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

To	O
examine	O
the	O
role	O
of	O
protein	B-protein
phosphatases	I-protein
in	O
T	O
cell	O
activation	O
,	O
Jurkat	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	B-protein
1	I-protein
and	I-protein
2A	I-protein
phosphatases	I-protein
,	O
and	O
nuclear	O
extracts	O
were	O
examined	O
for	O
the	O
presence	O
of	O
AP1	B-protein
as	O
a	O
measure	O
of	O
early	O
T	O
cell	O
activation	O
.	O

Okadaic	O
acid	O
was	O
found	O
to	O
be	O
a	O
potent	O
inducer	O
of	O
AP1	B-protein
.	O

In	O
contrast	O
to	O
phorbol	O
esters	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
induction	O
of	O
AP1	B-protein
by	O
okadaic	O
acid	O
occurs	O
predominantly	O
by	O
transcriptional	O
activation	O
of	O
the	O
jun	B-DNA
and	I-DNA
fos	I-DNA
family	I-DNA
of	O
proto-oncogenes	B-DNA
.	O

Surprisingly	O
,	O
while	O
the	O
addition	O
of	O
phytohemagglutinin	B-protein
further	O
enhanced	O
the	O
induction	O
of	O
AP1	B-protein
,	O
the	O
addition	O
of	O
PMA	O
inhibited	O
it	O
.	O

Okadaic	O
acid	O
treatment	O
was	O
found	O
to	O
dramatically	O
increase	O
mRNA	B-RNA
transcripts	I-RNA
of	O
the	O
jun	B-DNA
family	I-DNA
of	I-DNA
proto-oncogenes	I-DNA
including	O
c-jun	B-DNA
,	O
junD	B-DNA
,	O
and	O
junB	B-DNA
and	O
to	O
a	O
lesser	O
extent	O
the	O
fos	B-DNA
family	I-DNA
including	O
c-fos	B-DNA
and	O
fra-1	B-DNA
.	O

By	O
comparison	O
,	O
PMA	O
is	O
a	O
very	O
inefficient	O
inducer	O
of	O
the	O
jun	B-DNA
gene	I-DNA
family	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Similar	O
to	O
its	O
effect	O
on	O
the	O
induction	O
of	O
AP1	B-protein
by	O
okadaic	O
acid	O
,	O
PMA	O
inhibits	O
the	O
induction	O
of	O
c-jun	B-RNA
mRNA	I-RNA
by	O
okadaic	O
acid	O
.	O

Transfection	O
of	O
c-jun	B-DNA
promoter	I-DNA
constructs	I-DNA
confirmed	O
the	O
marked	O
difference	O
between	O
PMA	O
and	O
okadaic	O
acid	O
in	O
inducing	O
c-jun	B-DNA
transcription	O
.	O

The	O
induction	O
of	O
AP1	B-protein
by	O
okadaic	O
acid	O
suggests	O
that	O
protein	B-protein
phosphatases	I-protein
1	I-protein
and	I-protein
2A	I-protein
(	O
PP1	B-protein
and	O
PP2A	B-protein
)	O
may	O
be	O
involved	O
in	O
T	O
cell	O
activation	O
as	O
important	O
negative	O
regulators	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP1	B-protein
.	O

Cloning	O
of	O
murine	B-protein
TCF-1	I-protein
,	O
a	O
T	O
cell-specific	O
transcription	B-protein
factor	I-protein
interacting	O
with	O
functional	B-DNA
motifs	I-DNA
in	O
the	O
CD3-epsilon	B-DNA
and	I-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
alpha	I-DNA
enhancers	I-DNA
.	O

CD3	B-protein
-epsilon	O
gene	O
expression	O
is	O
confined	O
to	O
the	O
T	B-cell_line
cell	I-cell_line
lineage	I-cell_line
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
a	O
human	B-protein
transcription	I-protein
factor	I-protein
,	O
TCF-1	B-protein
,	O
that	O
binds	O
to	O
a	O
functional	O
element	O
in	O
the	O
T	O
lymphocyte-specific	O
enhancer	O
of	O
CD3-epsilon	O
.	O

In	O
a	O
panel	O
of	O
human	O
cell	O
lines	O
,	O
TCF-1	B-protein
expression	O
was	O
restricted	O
to	O
T	B-cell_type
lineage	I-cell_type
cells	I-cell_type
.	O

TCF-1	B-protein
belonged	O
to	O
a	O
novel	O
family	O
of	O
genes	O
that	O
contain	O
the	O
so-called	O
high	O
mobility	B-DNA
group	I-DNA
1	I-DNA
(	I-DNA
HMG	I-DNA
)	I-DNA
box	I-DNA
.	O

Here	O
we	O
report	O
the	O
cloning	O
of	O
murine	B-protein
TCF-1	I-protein
.	O

Two	O
splice	O
alternatives	O
were	O
identified	O
that	O
were	O
not	O
previously	O
observed	O
in	O
human	B-protein
TCF-1	I-protein
.	O

Murine	B-protein
and	I-protein
human	I-protein
TCF-1	I-protein
displayed	O
a	O
95.5	O
%	O
overall	O
amino	O
acid	O
homology	O
.	O

Recombinant	B-protein
murine	I-protein
and	I-protein
human	I-protein
TCF-1	I-protein
recognized	O
the	O
same	O
sequence	O
motif	O
in	O
the	O
CD3-epsilon	B-DNA
enhancer	I-DNA
as	O
judged	O
by	O
gel	O
retardation	O
and	O
methylation	O
interference	O
assays	O
.	O

With	O
the	O
murine	B-DNA
cDNA	I-DNA
clones	I-DNA
several	O
aspects	O
of	O
TCF-1	B-protein
were	O
analyzed	O
.	O

First	O
,	O
deletion	O
analysis	O
revealed	O
that	O
a	O
region	O
of	O
TCF-1	B-protein
containing	O
the	O
HMG	B-DNA
box	I-DNA
was	O
sufficient	O
for	O
sequence-specific	O
binding	O
.	O

Second	O
,	O
by	O
high	O
stringency	O
Northern	O
blotting	O
and	O
in	O
situ	O
hybridization	O
,	O
TCF-1	B-protein
expression	O
was	O
shown	O
to	O
be	O
confined	O
to	O
the	O
thymus	O
and	O
to	O
the	O
T	O
cell	O
areas	O
of	O
the	O
spleen	O
.	O

Third	O
,	O
TCF-1	B-protein
bound	O
specifically	O
to	O
a	O
functional	O
T	B-DNA
cell-specific	I-DNA
element	I-DNA
in	O
the	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
TCR-alpha	I-DNA
)	I-DNA
enhancer	I-DNA
.	O

The	O
T	O
lineage-specific	O
expression	O
and	O
the	O
affinity	O
for	O
functional	O
motifs	O
in	O
the	O
TCR-alpha	B-DNA
and	I-DNA
CD3-epsilon	I-DNA
enhancers	I-DNA
imply	O
an	O
important	O
role	O
for	O
TCF-1	B-protein
in	O
the	O
establishment	O
of	O
the	O
mature	B-cell_type
T	I-cell_type
cell	I-cell_type
phenotype	I-cell_type
.	O

Cloning	O
of	O
a	O
human	B-DNA
homeobox	I-DNA
gene	I-DNA
that	O
resembles	O
a	O
diverged	B-DNA
Drosophila	I-DNA
homeobox	I-DNA
gene	I-DNA
and	O
is	O
expressed	O
in	O
activated	O
lymphocytes	B-cell_type
.	O

A	O
new	O
homeobox	B-DNA
gene	I-DNA
,	O
HB24	B-DNA
,	O
has	O
been	O
isolated	O
from	O
a	O
human	O
B-lymphocyte	O
cDNA	O
library	O
.	O

Northern	O
blot	O
analysis	O
of	O
polyadenylated	B-RNA
RNA	I-RNA
purified	O
from	O
activated	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
revealed	O
a	O
single	B-RNA
mRNA	I-RNA
transcript	I-RNA
of	O
approximately	O
2.3	O
kb	O
.	O

Two	O
cDNA	B-DNA
clones	I-DNA
were	O
sequenced	O
and	O
provided	O
2	O
,	O
250	O
nucleotides	O
(	O
nt	O
)	O
of	O
DNA	B-DNA
sequence	I-DNA
information	O
.	O

There	O
is	O
a	O
single	O
methionine	B-DNA
codon-initiated	I-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
of	O
1	O
,	O
458	O
nt	O
in	O
frame	O
with	O
a	O
homeobox	B-DNA
and	O
a	O
CAX	B-DNA
repeat	I-DNA
,	O
and	O
the	O
open	B-DNA
reading	I-DNA
frame	I-DNA
is	O
predicted	O
to	O
encode	O
a	O
protein	O
of	O
51	O
,	O
659	O
daltons	O
.	O

When	O
the	O
homeodomain	B-DNA
from	O
HB24	B-DNA
was	O
compared	O
to	O
known	O
mammalian	B-DNA
and	I-DNA
Drosophila	I-DNA
homeodomains	I-DNA
it	O
was	O
found	O
to	O
be	O
only	O
moderately	O
conserved	O
,	O
but	O
when	O
it	O
was	O
compared	O
to	O
a	O
highly	O
diverged	O
Drosophila	B-DNA
homeodomain	I-DNA
,	O
H2.0	O
,	O
it	O
was	O
found	O
to	O
be	O
80	O
%	O
identical	O
.	O

The	O
HB24	B-RNA
mRNA	I-RNA
was	O
absent	O
or	O
present	O
at	O
low	O
levels	O
in	O
normal	O
B	O
and	O
T	B-cell_type
lymphocytes	I-cell_type
;	O
however	O
,	O
with	O
the	O
appropriate	O
activation	O
signal	O
HB24	B-RNA
mRNA	I-RNA
was	O
induced	O
within	O
several	O
hours	O
even	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O

Characterization	O
of	O
HB24	B-DNA
expression	O
in	O
lymphoid	O
and	O
select	O
developing	O
tissues	O
was	O
performed	O
by	O
in	O
situ	O
hybridization	O
.	O

Positive	O
hybridization	O
was	O
found	O
in	O
thymus	O
,	O
tonsil	O
,	O
bone	O
marrow	O
,	O
developing	O
vessels	O
,	O
and	O
in	O
fetal	O
brain	O
.	O

HB24	B-DNA
is	O
likely	O
to	O
have	O
an	O
important	O
role	O
in	O
lymphocytes	B-cell_type
as	O
well	O
as	O
in	O
certain	O
developing	O
tissues	O
.	O

Platelet-activating	B-protein
factor	I-protein
induces	O
phospholipid	O
turnover	O
,	O
calcium	O
flux	O
,	O
arachidonic	O
acid	O
liberation	O
,	O
eicosanoid	O
generation	O
,	O
and	O
oncogene	B-DNA
expression	O
in	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Platelet-activating	B-protein
factor	I-protein
is	O
a	O
potent	O
mediator	O
of	O
the	O
inflammatory	O
response	O
.	O

Studies	O
of	O
the	O
actions	O
of	O
platelet-activating	B-protein
factor	I-protein
have	O
centered	O
mainly	O
around	O
neutrophils	B-cell_type
,	O
monocytes	B-cell_type
,	O
and	O
platelets	B-cell_type
.	O

In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet-activating	B-protein
factor	I-protein
on	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Employing	O
the	O
EBV-transformed	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
SKW6.4	B-cell_line
,	O
we	O
demonstrate	O
that	O
platelet-activating	B-protein
factor	I-protein
significantly	O
alters	O
membrane	O
phospholipid	O
metabolism	O
indicated	O
by	O
the	O
incorporation	O
of	O
32P	O
into	O
phosphatidylcholine	O
,	O
phosphatidylinositol	O
,	O
and	O
phosphatidic	O
acid	O
but	O
not	O
significantly	O
into	O
phosphatidylethanolamine	O
at	O
concentrations	O
ranging	O
from	O
10	O
(	O
-9	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
.	O

The	O
inactive	O
precursor	O
,	O
lyso-platelet-activating	B-protein
factor	I-protein
,	O
at	O
a	O
concentration	O
as	O
high	O
as	O
10	O
(	O
-7	O
)	O
M	O
had	O
no	O
effect	O
on	O
any	O
of	O
the	O
membrane	O
phospholipids	O
.	O

We	O
also	O
show	O
that	O
platelet-activating	B-protein
factor	I-protein
from	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
induced	O
rapid	O
and	O
significant	O
elevation	O
in	O
intracellular	O
calcium	O
levels	O
,	O
whereas	O
lyso-	O
platelet-activating	B-protein
factor	I-protein
was	O
again	O
ineffective	O
.	O

We	O
further	O
demonstrate	O
the	O
impact	O
of	O
platelet-activating	B-protein
factor	I-protein
binding	O
to	O
B	B-cell_type
cells	I-cell_type
by	O
measuring	O
platelet-activating	B-protein
factor	I-protein
induced	O
arachidonic	O
acid	O
release	O
and	O
5-hydroxyeicosatetraenoic	O
acid	O
production	O
.	O

Moreover	O
,	O
platelet-activating	B-protein
factor	I-protein
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	B-DNA
proto-oncogenes	I-DNA
c-fos	B-DNA
and	O
c-jun	B-DNA
.	O

Finally	O
we	O
explored	O
the	O
possible	O
role	O
of	O
5-hydroxyeicosatetraenoic	O
acid	O
as	O
a	O
regulator	O
of	O
arachidonic	O
acid	O
liberation	O
demonstrating	O
that	O
endogenous	O
5-lipoxygenase	B-protein
activity	O
modulates	O
platelet-activating	B-protein
factor	I-protein
induced	O
arachidonic	O
acid	O
release	O
perhaps	O
acting	O
at	O
the	O
level	O
of	O
phospholipase	B-protein
A2	I-protein
.	O

In	O
summary	O
,	O
platelet-activating	B-protein
factor	I-protein
is	O
shown	O
here	O
to	O
have	O
a	O
direct	O
and	O
profound	O
effect	O
on	O
a	O
pure	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
by	O
a	O
novel	O
B-cell-specific	B-DNA
enhancer	I-DNA
element	I-DNA
.	O

A	O
new	O
B-cell-specific	B-DNA
enhancer	I-DNA
element	I-DNA
has	O
been	O
identified	O
3	O
'	O
of	O
E4	B-DNA
and	I-DNA
the	I-DNA
octamerlike	I-DNA
motifs	I-DNA
in	O
the	O
human	B-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O

Tandem	O
copies	O
of	O
this	O
67-bp	B-DNA
MnlI-AluI	I-DNA
fragment	I-DNA
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	I-DNA
driven	O
by	O
the	O
conalbumin	B-DNA
promoter	I-DNA
,	O
stimulated	O
transcription	O
in	O
B	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
or	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Footprinting	O
analysis	O
revealed	O
that	O
the	O
identical	O
sequence	O
CCGAAACTGAAAAGG	O
,	O
designated	O
E6	B-DNA
,	O
was	O
protected	O
by	O
nuclear	O
extracts	O
from	O
B	B-cell_type
cells	I-cell_type
,	O
T	B-cell_type
cells	I-cell_type
,	O
or	O
HeLa	O
cells	O
.	O

Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	B-DNA
E6	I-DNA
motif	I-DNA
detected	O
a	O
B-cell-specific	B-protein
complex	I-protein
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	B-DNA
motif	I-DNA
stimulated	O
transcription	O
in	O
ARH77	B-cell_line
and	O
Raji	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
Jurkat	B-cell_line
or	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
a	O
mutant	B-DNA
E6	I-DNA
motif	I-DNA
lost	O
both	O
in	O
vitro	O
binding	O
activity	O
and	O
in	O
vivo	O
enhancer	O
activity	O
.	O

In	O
striking	O
contrast	O
to	O
the	O
mouse	B-DNA
Ig	I-DNA
heavy-chain	I-DNA
enhancer	I-DNA
,	O
in	O
which	O
the	O
octamer	B-DNA
motif	I-DNA
acts	O
as	O
a	O
B-cell-specific	B-DNA
enhancer	I-DNA
element	I-DNA
,	O
the	O
human	B-DNA
enhancer	I-DNA
contains	O
an	O
octamerlike	B-DNA
sequence	I-DNA
with	O
one	O
base	O
substitution	O
which	O
bound	O
octamer-binding	B-protein
proteins	I-protein
with	O
only	O
very	O
low	O
affinity	O
and	O
showed	O
no	O
enhancer	O
activity	O
of	O
its	O
own	O
.	O

Interestingly	O
,	O
the	O
MnlI-AluI	B-DNA
fragment	I-DNA
could	O
suppress	O
the	O
basal-level	O
activity	O
of	O
the	O
conalbumin	B-DNA
promoter	I-DNA
in	O
both	O
Jurkat	B-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Moreover	O
,	O
simian	O
virus	O
40	O
enhancer	O
activity	O
was	O
blocked	O
by	O
the	O
MnlI-AluI	B-DNA
fragment	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
the	O
novel	O
enhancer	O
element	O
identified	O
in	O
this	O
study	O
is	O
probably	O
a	O
target	O
site	O
for	O
both	O
positive	B-protein
and	I-protein
negative	I-protein
factors	I-protein
.	O

Charybdotoxin-sensitive	O
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
membrane	O
potential	O
changes	O
are	O
not	O
involved	O
in	O
human	O
T	B-cell_type
or	I-cell_type
B	I-cell_type
cell	I-cell_type
activation	O
and	O
proliferation	O
.	O

The	O
involvement	O
of	O
ion	O
channels	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
is	O
supported	O
by	O
many	O
reports	O
of	O
changes	O
in	O
ion	O
fluxes	O
and	O
membrane	O
potential	O
after	O
mitogen	B-protein
binding	O
.	O

Human	B-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
demonstrate	O
an	O
early	O
and	O
transient	O
hyperpolarization	O
after	O
ligand	O
binding	O
.	O

Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	O
,	O
the	O
hyperpolarization	O
is	O
presumably	O
through	O
opening	O
of	O
Ca	O
(	O
2+	O
)	O
-stimulated	O
K+	O
channels	O
.	O

We	O
have	O
used	O
charybdotoxin	O
,	O
a	O
known	O
inhibitor	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-dependent	I-protein
K+	I-protein
channels	I-protein
,	O
to	O
study	O
the	O
role	O
of	O
these	O
channels	O
in	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

We	O
demonstrate	O
that	O
charybdotoxin	O
inhibits	O
the	O
ligand-induced	O
transient	O
membrane	O
hyperpolarization	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
a	O
dose-dependent	O
fashion	O
,	O
without	O
affecting	O
changes	O
in	O
cytosolic	O
Ca2+	O
.	O

However	O
,	O
blockade	O
of	O
the	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-activated	I-protein
K+	I-protein
channel	I-protein
is	O
not	O
associated	O
with	O
changes	O
in	O
cell-cycle	O
gene	O
activation	O
,	O
IL-2	B-protein
production	O
,	O
IL-2R	B-protein
expression	O
or	O
B	O
and	O
T	O
cell	O
mitogenesis	O
.	O

These	O
results	O
imply	O
that	O
membrane	O
potential	O
changes	O
secondary	O
to	O
the	O
ligand-dependent	O
opening	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-activated	I-protein
K+	I-protein
channels	I-protein
are	O
not	O
involved	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocyte	I-cell_type
activation	O
and	O
mitogenesis	O
.	O

Activity	O
of	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
of	O
the	O
interleukin-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
in	O
somatic	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
two	B-protein
nuclear	I-protein
proteins	I-protein
NF-kappa	B-protein
B	I-protein
(	O
consisting	O
of	O
subunits	O
p50	B-protein
an	O
dp65	B-protein
)	O
and	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
(	O
p50	B-protein
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	B-protein
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
IARC	B-cell_line
301.5	I-cell_line
.	O

In	O
order	O
to	O
define	O
the	O
roles	O
of	O
these	O
two	O
factors	B-protein
,	O
which	O
bind	O
to	O
the	O
same	O
kappa	B-DNA
B	I-DNA
enhancers	I-DNA
,	O
in	O
transcription	O
activation	O
we	O
have	O
prepared	O
somatic	O
cell	O
hybrids	O
between	O
IARC	B-cell_line
301.5	I-cell_line
and	O
a	O
murine	B-cell_line
myeloma	I-cell_line
.	O

Most	O
hybrids	O
express	O
both	O
KBF1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
in	O
their	O
nuclei	O
,	O
but	O
one	O
hybrid	O
expresses	O
only	O
KBF1	B-protein
.	O

The	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
of	O
the	O
gene	O
encoding	O
the	O
interleukin-2	B-protein
(	I-protein
IL-2	I-protein
)	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	B-cell_line
expressing	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
.	O

These	O
findings	O
show	O
that	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
is	O
necessary	O
to	O
activate	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
,	O
while	O
KBF1	B-protein
by	O
itself	O
is	O
not	O
sufficient	O
.	O

We	O
propose	O
that	O
KBF1	B-protein
is	O
a	O
competitive	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
discuss	O
how	O
these	O
factors	O
may	O
be	O
involved	O
in	O
the	O
transient	O
expression	O
of	O
IL-2	B-protein
and	O
IL-2	B-protein
alpha	I-protein
genes	O
during	O
the	O
immune	O
response	O
.	O

T-helper-cell	B-protein
determinants	I-protein
in	O
protein	B-protein
antigens	I-protein
are	O
preferentially	O
located	O
in	O
cysteine-rich	B-protein
antigen	I-protein
segments	I-protein
resistant	O
to	O
proteolytic	O
cleavage	O
by	O
cathepsin	B-protein
B	I-protein
,	I-protein
L	I-protein
,	I-protein
and	I-protein
D	I-protein
.	O

We	O
report	O
on	O
a	O
computer	O
algorithm	O
capable	O
of	O
predicting	O
the	O
location	O
of	O
T-helper-cell	B-protein
epitopes	I-protein
in	O
protein	B-protein
antigen	I-protein
(	O
Ag	B-protein
)	O
by	O
analysing	O
the	O
Ag	B-protein
amino	B-protein
acid	I-protein
sequence	I-protein
.	O

The	O
algorithm	O
was	O
constructed	O
with	O
the	O
aim	O
of	O
identifying	O
segments	O
in	O
Ag	B-protein
which	O
are	O
resistant	O
to	O
proteolytic	O
degradation	O
by	O
the	O
enzymes	O
cathepsin	B-protein
B	I-protein
,	I-protein
L	I-protein
,	I-protein
and	I-protein
D	I-protein
.	O

These	O
are	O
prominent	O
enzymes	B-protein
in	O
the	O
endocytic	O
pathway	O
through	O
which	O
soluble	B-protein
protein	I-protein
Ag	I-protein
enter	O
APC	B-protein
,	O
and	O
resistant	B-protein
segments	I-protein
in	O
Ag	B-protein
may	O
,	O
therefore	O
,	O
be	O
expected	O
to	O
contain	O
more	O
T-cell	B-protein
determinants	I-protein
than	O
susceptible	B-protein
segments	I-protein
.	O

From	O
information	O
available	O
in	O
the	O
literature	O
on	O
the	O
substrate	O
specificity	O
of	O
the	O
three	O
enzymes	B-protein
,	O
it	O
is	O
clear	O
that	O
a	O
cysteine	O
is	O
not	O
accepted	O
in	O
any	O
of	O
the	O
S2	B-protein
,	I-protein
S1	I-protein
,	I-protein
S1	I-protein
'	I-protein
,	I-protein
and	I-protein
S2	I-protein
'	I-protein
subsites	I-protein
of	O
cathepsin	B-protein
B	I-protein
and	I-protein
L	I-protein
,	O
and	O
not	O
in	O
the	O
S1	B-protein
and	O
S1	B-protein
'	I-protein
subsites	O
of	O
cathepsin	B-protein
D	I-protein
.	O

Moreover	O
,	O
we	O
have	O
noticed	O
that	O
cysteine-containing	B-protein
T-cell	I-protein
determinants	I-protein
in	O
a	O
number	O
of	O
protein	B-protein
Ag	I-protein
are	O
particularly	O
rich	O
in	O
the	O
amino	O
acids	O
alanine	O
,	O
glycine	O
,	O
lysine	O
,	O
leucine	O
,	O
serine	O
,	O
threonine	O
,	O
and	O
valine	O
.	O

By	O
searching	O
protein	O
Ag	B-protein
for	O
clusters	O
of	O
amino	O
acids	O
containing	O
cysteine	O
and	O
two	O
of	O
the	O
other	O
amino	O
acids	O
we	O
were	O
able	O
to	O
predict	O
17	O
out	O
of	O
23	O
empirically	O
known	O
T-cell	B-protein
determinants	I-protein
in	O
the	O
Ag	B-protein
with	O
a	O
relatively	O
low	O
number	O
of	O
false	O
(	O
positive	O
)	O
predictions	O
.	O

Furthermore	O
,	O
we	O
present	O
a	O
new	O
principle	O
for	O
searching	O
Ag	B-protein
for	O
potential	O
amphipatic	B-protein
alpha-helical	I-protein
protein	I-protein
segments	I-protein
.	O

Such	O
segments	O
accord	O
well	O
with	O
empirically	O
known	O
T-cell	B-protein
determinants	I-protein
and	O
our	O
algorithm	O
produces	O
a	O
lower	O
number	O
of	O
false	O
positive	O
predictions	O
than	O
the	O
principle	O
based	O
on	O
discrete	O
Fourier	O
transformations	O
previously	O
described	O
.	O

Contribution	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-DNA
binding	I-DNA
motifs	I-DNA
to	O
the	O
replicative	O
capacity	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
:	O
distinct	O
patterns	O
of	O
viral	O
growth	O
are	O
determined	O
by	O
T-cell	B-cell_type
types	I-cell_type
.	O

Starting	O
with	O
a	O
replication-incompetent	O
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	O
all	O
the	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
present	O
in	O
the	O
native	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
,	O
proviruses	O
containing	O
reconstructed	B-DNA
LTRs	I-DNA
with	O
individual	O
or	O
combinations	O
of	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
Sp1	I-DNA
elements	I-DNA
were	O
generated	O
and	O
evaluated	O
for	O
their	O
capacity	O
to	O
produce	O
virus	O
progeny	O
following	O
transfection-cocultivation	O
.	O

Virus	O
stocks	O
obtained	O
from	O
these	O
experiments	O
exhibited	O
a	O
continuum	O
of	O
replicative	O
capacities	O
in	O
different	O
human	B-cell_type
T-cell	I-cell_type
types	I-cell_type
depending	O
on	O
which	O
element	B-DNA
(	O
s	O
)	O
was	O
present	O
in	O
the	O
LTR	B-DNA
.	O

For	O
example	O
,	O
in	O
experiments	O
involving	O
proviral	O
clones	O
with	O
LTRs	B-DNA
containing	O
one	O
or	O
two	O
NF-kappa	B-DNA
B	I-DNA
elements	I-DNA
(	O
and	O
no	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
)	O
,	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
=	O
MT4	B-cell_line
greater	O
than	O
H9	B-cell_line
greater	O
than	O
CEM	B-cell_line
greater	O
than	O
Jurkat	B-cell_line
)	O
was	O
observed	O
.	O

Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second-site	B-DNA
LTR	I-DNA
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	B-DNA
box	I-DNA
.	O

These	O
results	O
suggest	O
that	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
LTR	I-DNA
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T-cell	B-cell_type
types	I-cell_type
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	B-protein
factors	I-protein
present	O
.	O

Stimulation	O
of	O
interferon	B-DNA
beta	I-DNA
gene	I-DNA
transcription	O
in	O
vitro	O
by	O
purified	O
NF-kappa	B-protein
B	I-protein
and	O
a	O
novel	O
TH	B-protein
protein	I-protein
.	O

The	O
human	B-DNA
interferon	I-DNA
beta	I-DNA
(	I-DNA
IFN-beta	I-DNA
)	I-DNA
regulatory	I-DNA
element	I-DNA
consists	O
of	O
multiple	O
enhanson	B-DNA
domains	I-DNA
which	O
are	O
targets	O
for	O
transcription	B-protein
factors	I-protein
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	B-DNA
.	O

To	O
further	O
characterize	O
the	O
protein-DNA	O
interactions	O
mediating	O
IFN-beta	B-protein
induction	O
,	O
positive	B-protein
regulatory	I-protein
domain	I-protein
(	I-protein
PRD	I-protein
)	I-protein
II	I-protein
binding	I-protein
proteins	I-protein
were	O
purified	O
from	O
phorbol	O
ester	O
induced	O
Jurkat	B-cell_line
T-cells	I-cell_line
and	O
from	O
IFN	B-cell_line
primed	I-cell_line
,	I-cell_line
cycloheximide/polyinosinic-polycytidylic	I-cell_line
acid	I-cell_line
treated	I-cell_line
HeLa	I-cell_line
S3	I-cell_line
cells	I-cell_line
.	O

From	O
HeLa	B-cell_line
cells	I-cell_line
,	O
two	O
major	O
proteins	O
of	O
52	B-protein
and	I-protein
45	I-protein
kilodaltons	I-protein
(	I-protein
kD	I-protein
)	I-protein
copurified	O
with	O
DNA	O
binding	O
activity	O
,	O
whereas	O
from	O
T-cells	B-cell_type
,	O
four	O
proteins	O
--	O
a	O
major	B-protein
protein	I-protein
of	O
52	B-protein
kD	I-protein
and	O
three	O
minor	B-protein
proteins	I-protein
of	O
82	B-protein
,	O
67	B-protein
,	O
and	O
43-47	B-protein
kD	I-protein
--	O
were	O
purified	O
.	O

Also	O
,	O
an	O
induction	O
specific	B-protein
DNA	I-protein
binding	I-protein
protein	I-protein
was	O
purified	O
from	O
HeLa	B-cell_line
cells	I-cell_line
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	B-DNA
sequence	I-DNA
and	O
the	O
PRDI	B-DNA
domain	I-DNA
.	O

This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF-1/ISGF2	B-protein
.	O

Uninduced	O
or	O
Sendai	O
virus	O
induced	O
HeLa	O
extracts	O
were	O
used	O
to	O
examine	O
transcription	O
in	O
vitro	O
using	O
a	O
series	O
of	O
IFN	B-DNA
beta	I-DNA
promoter	I-DNA
deletions	I-DNA
.	O

Deletions	O
upstream	O
of	O
the	O
PRDII	B-DNA
element	I-DNA
increased	O
transcription	O
in	O
the	O
uninduced	O
extract	O
,	O
indicating	O
predominantly	O
negative	O
regulation	O
of	O
the	O
promoter	B-DNA
.	O

A	O
2-4-fold	O
increase	O
in	O
IFN-beta	B-DNA
promoter	I-DNA
transcription	O
was	O
observed	O
in	O
Sendai	O
virus	O
induced	O
extracts	O
,	O
and	O
deletion	O
of	O
PRDI	B-DNA
and	O
PRDII	B-DNA
elements	I-DNA
decreased	O
this	O
induced	O
level	O
of	O
transcription	O
.	O

When	O
purified	O
PRDII	B-protein
and	I-protein
tetrahexamer	I-protein
binding	I-protein
proteins	I-protein
were	O
added	O
to	O
the	O
induced	O
extract	O
,	O
a	O
4-fold	O
increase	O
in	O
transcription	O
was	O
observed	O
.	O

These	O
experiments	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
modulate	O
IFN-beta	O
transcription	O
in	O
vitro	O
but	O
indicate	O
that	O
additional	O
proteins	O
may	O
be	O
required	O
to	O
fully	O
activate	O
IFN-beta	B-protein
transcription	O
.	O

The	O
rhombotin	B-DNA
family	I-DNA
of	O
cysteine-rich	B-DNA
LIM-domain	I-DNA
oncogenes	I-DNA
:	O
distinct	O
members	O
are	O
involved	O
in	O
T-cell	B-DNA
translocations	I-DNA
to	O
human	B-DNA
chromosomes	I-DNA
11p15	I-DNA
and	I-DNA
11p13	I-DNA
.	O

A	O
chromosomal	O
translocation	O
in	O
a	O
T-cell	O
leukemia	O
involving	O
the	O
short	B-DNA
arm	I-DNA
of	O
human	B-DNA
chromosome	I-DNA
11	I-DNA
at	O
band	B-DNA
11p15	I-DNA
disrupts	O
the	O
rhombotin	B-DNA
gene	I-DNA
.	O

This	O
gene	O
encodes	O
a	O
protein	O
with	O
duplicated	O
cysteine-rich	B-protein
regions	I-protein
called	O
LIM	B-protein
domains	I-protein
,	O
which	O
show	O
homology	O
to	O
zinc-binding	B-protein
proteins	I-protein
and	O
to	O
iron-sulfur	B-protein
centers	I-protein
of	O
ferredoxins	B-protein
.	O

Two	O
homologues	O
of	O
the	O
rhombotin	B-DNA
gene	I-DNA
have	O
now	O
been	O
isolated	O
.	O

One	O
of	O
these	O
,	O
designated	O
Rhom-2	B-DNA
,	O
is	O
located	O
on	O
human	B-DNA
chromosome	I-DNA
11	I-DNA
at	O
band	B-DNA
11p13	I-DNA
,	O
where	O
a	O
cluster	O
of	O
T-cell	B-DNA
leukemia-specific	I-DNA
translocations	I-DNA
occur	O
;	O
all	O
translocation	O
breakpoints	O
at	O
11p13	B-DNA
are	O
upstream	O
of	O
the	O
Rhom-2	B-DNA
gene	I-DNA
.	O

Human	B-DNA
and	I-DNA
mouse	I-DNA
Rhom-2	I-DNA
are	O
highly	O
conserved	O
and	O
,	O
like	O
rhombotin	B-DNA
,	O
encode	O
two	O
tandem	B-DNA
cysteine-rich	I-DNA
LIM	I-DNA
domains	I-DNA
.	O

Rhom-2	B-RNA
mRNA	I-RNA
is	O
expressed	O
in	O
early	O
mouse	O
development	O
in	O
central	O
nervous	O
system	O
,	O
lung	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
spleen	O
but	O
only	O
very	O
low	O
levels	O
occur	O
in	O
thymus	O
.	O

The	O
other	O
gene	O
,	O
designated	O
Rhom-3	B-DNA
,	O
is	O
not	O
on	O
chromosome	O
11	O
but	O
also	O
retains	O
homology	O
to	O
the	O
LIM	B-DNA
domain	I-DNA
of	O
rhombotin	B-DNA
.	O

Since	O
the	O
Rhom-2	B-DNA
gene	I-DNA
is	O
such	O
a	O
common	O
site	O
of	O
chromosomal	O
damage	O
in	O
T-cell	B-cell_type
tumors	I-cell_type
,	O
the	O
consistency	O
of	O
translocations	O
near	O
the	O
rhombotin	B-DNA
gene	I-DNA
was	O
further	O
examined	O
.	O

A	O
second	O
translocation	O
adjacent	O
to	O
rhombotin	B-DNA
was	O
found	O
and	O
at	O
the	O
same	O
position	O
as	O
in	O
the	O
previous	O
example	O
.	O

Therefore	O
,	O
chromosome	B-DNA
bands	I-DNA
11p15	I-DNA
(	O
rhombotin	B-DNA
)	O
and	O
11p13	B-DNA
(	O
Rhom-2	B-DNA
)	O
are	O
consistent	O
sites	O
of	O
chromosome	O
translocation	O
in	O
T-cell	O
leukemia	O
,	O
with	O
the	O
11p15	B-DNA
target	I-DNA
more	O
rarely	O
involved	O
.	O

The	O
results	O
define	O
the	O
rhombotin	B-DNA
gene	O
family	O
as	O
a	O
class	O
of	O
T-cell	B-DNA
oncogenes	I-DNA
with	O
duplicated	O
cysteine-rich	B-DNA
LIM	I-DNA
domains	I-DNA
.	O

NF-kappa	B-protein
B	I-protein
activation	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
in	O
the	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
is	O
independent	O
of	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-regulated	I-protein
kinases	I-protein
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
DNA-binding	B-protein
regulatory	I-protein
factor	I-protein
able	O
to	O
control	O
transcription	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
genes	I-DNA
.	O

In	O
T	B-cell_type
cells	I-cell_type
,	O
NF-kappa	B-protein
B	I-protein
is	O
activated	O
upon	O
cellular	O
treatment	O
by	O
phorbol	O
esters	O
and	O
the	O
cytokine	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
molecular	O
events	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
TNF	B-protein
alpha	I-protein
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
Jurkat	B-cell_line
)	O
and	O
its	O
subclone	O
JCT6	B-cell_line
,	O
which	O
presents	O
a	O
deficiency	O
in	O
the	O
PKA	B-protein
transduction	O
pathway	O
.	O

We	O
found	O
that	O
in	O
both	O
cell	O
lines	O
,	O
both	O
phorbol	O
ester	O
and	O
TNF	B-protein
alpha	I-protein
were	O
able	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
.	O

Phorbol	O
activation	O
was	O
positively	O
modulated	O
by	O
Ca2+	O
influx	O
while	O
TNF	B-protein
alpha	I-protein
activation	O
was	O
not	O
.	O

Furthermore	O
,	O
while	O
PMA	O
activation	O
was	O
inhibited	O
by	O
the	O
PKC	B-protein
inhibitor	O
staurosporin	O
,	O
the	O
TNF	B-protein
alpha	I-protein
effect	O
was	O
unchanged	O
.	O

TNF	B-protein
alpha	I-protein
did	O
not	O
activate	O
cAMP	O
production	O
and	O
its	O
signal	O
was	O
not	O
modulated	O
by	O
cAMP	O
activators	O
.	O

Moreover	O
,	O
cAMP	O
activators	O
did	O
not	O
activate	O
NF-kappa	B-protein
B	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Thus	O
,	O
TNF	B-protein
alpha	I-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
found	O
to	O
be	O
mediated	O
by	O
none	O
of	O
the	O
major	O
signal-mediating	B-protein
kinases	I-protein
such	O
as	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
or	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-regulated	I-protein
kinases	I-protein
.	O

Furthermore	O
,	O
we	O
found	O
that	O
cytoplasmic	O
acidification	O
facilitated	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
both	O
TNF	B-protein
alpha	I-protein
and	O
PKC	B-protein
,	O
by	O
a	O
mechanism	O
that	O
increases	O
NF-kappa	B-protein
B	I-protein
/I	B-protein
kappa	I-protein
B	I-protein
dissociation	O
without	O
affecting	O
the	O
NF-kappa	B-protein
B	I-protein
translocation	O
step	O
.	O

The	O
functional	O
domains	O
of	O
the	O
murine	B-DNA
Thy-1	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

The	O
Thy-1	B-DNA
gene	I-DNA
promoter	I-DNA
resembles	O
a	O
``	B-DNA
housekeeping	I-DNA
''	I-DNA
promoter	I-DNA
in	O
that	O
it	O
is	O
located	O
within	O
a	O
methylation-free	B-DNA
island	I-DNA
,	O
lacks	O
a	O
canonical	B-DNA
TATA	I-DNA
box	I-DNA
,	O
and	O
displays	O
heterogeneity	O
in	O
the	O
5'-end	B-RNA
termini	I-RNA
of	O
the	O
mRNA	B-RNA
.	O

Using	O
transgenic	O
mice	O
,	O
we	O
show	O
that	O
this	O
promoter	B-DNA
does	O
not	O
confer	O
any	O
tissue	O
specificity	O
and	O
is	O
active	O
only	O
in	O
a	O
position-dependent	O
manner	O
.	O

It	O
can	O
only	O
be	O
activated	O
in	O
a	O
tissue-specific	O
manner	O
by	O
elements	O
that	O
lie	O
downstream	O
of	O
the	O
initiation	B-DNA
site	I-DNA
.	O

We	O
have	O
analyzed	O
the	O
functional	O
domains	O
of	O
the	O
minimal	B-DNA
Thy-1	I-DNA
promoter	I-DNA
and	O
show	O
that	O
the	O
dominant	B-DNA
promoter	I-DNA
elements	I-DNA
consist	O
of	O
multiple	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
Sp1	B-protein
,	O
an	O
inverted	O
CCAAT	B-DNA
box	I-DNA
,	O
and	O
sequences	O
proximal	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O

DNase	O
I	O
and	O
gel	O
mobility	O
shift	O
assays	O
show	O
the	O
binding	O
of	O
a	O
number	O
of	O
nuclear	B-protein
factors	I-protein
to	O
these	O
elements	B-DNA
,	O
including	O
Sp1	B-protein
and	O
CP1	B-protein
.	O

Our	O
results	O
show	O
that	O
the	O
structure	O
of	O
this	O
promoter	B-DNA
only	O
permits	O
productive	O
interactions	O
of	O
the	O
two	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
CP1	B-protein
with	O
the	O
basal	O
transcription	O
machinery	O
in	O
the	O
presence	O
of	O
enhancer	B-DNA
sequences	I-DNA
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
activates	O
proenkephalin	O
transcription	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Upon	O
activation	O
,	O
T	B-cell_type
lymphocytes	I-cell_type
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	B-RNA
mRNA	I-RNA
in	O
the	O
cells	O
.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O

The	O
proenkephalin	O
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	B-DNA
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O

Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
induces	O
an	O
NF-kappa	B-protein
B	I-protein
-like	O
binding	O
activity	O
to	O
the	O
B2	B-DNA
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	B-DNA
promoter	I-DNA
.	O

Mutations	O
at	O
the	O
B2	B-DNA
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

The	O
purified	O
homodimer	B-protein
(	O
two	O
p50s	B-protein
)	O
of	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
binds	O
the	O
B2	B-DNA
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	B-protein
(	O
two	O
p65s	B-protein
plus	O
two	O
p50s	B-protein
)	O
form	O
of	O
the	O
factor	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
T-cell-specific	O
activation	O
of	O
the	O
proenkephalin	B-DNA
promoter	I-DNA
is	O
mediated	O
by	O
NF-kappa	B-protein
B	I-protein
.	O

However	O
,	O
as	O
NF-kappa	B-protein
B	I-protein
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	B-DNA
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T-cell-specific	B-protein
factor	I-protein
which	O
synergizes	O
with	O
NF-kappa	B-protein
B	I-protein
should	O
be	O
considered	O
.	O

Induction	O
of	O
NF-KB	B-protein
during	O
monocyte	B-cell_type
differentiation	O
by	O
HIV	O
type	O
1	O
infection	O
.	O

The	O
production	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
progeny	O
was	O
followed	O
in	O
the	O
U937	B-cell_line
promonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
after	O
stimulation	O
either	O
with	O
retinoic	O
acid	O
or	O
PMA	O
,	O
and	O
in	O
purified	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	I-cell_type
macrophages	I-cell_type
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Southwestern	O
blotting	O
experiments	O
were	O
used	O
to	O
detect	O
the	O
binding	O
of	O
cellular	B-protein
transactivation	I-protein
factor	I-protein
NF-KB	B-protein
to	O
the	O
double	B-DNA
repeat-KB	I-DNA
enhancer	I-DNA
sequence	I-DNA
located	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O

PMA	O
treatment	O
,	O
and	O
not	O
retinoic	O
acid	O
treatment	O
of	O
the	O
U937	B-cell_line
cells	I-cell_line
acts	O
in	O
inducing	O
NF-KB	B-protein
expression	O
in	O
the	O
nuclei	O
.	O

In	O
nuclear	O
extracts	O
from	O
monocytes	B-cell_type
or	O
macrophages	B-cell_type
,	O
induction	O
of	O
NF-KB	B-protein
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV-1	O
.	O

When	O
U937	B-cell_line
cells	I-cell_line
were	O
infected	O
with	O
HIV-1	O
,	O
no	O
induction	O
of	O
NF-KB	B-protein
factor	I-protein
was	O
detected	O
,	O
whereas	O
high	O
level	O
of	O
progeny	O
virions	O
was	O
produced	O
,	O
suggesting	O
that	O
this	O
factor	O
was	O
not	O
required	O
for	O
viral	O
replication	O
.	O

These	O
results	O
indicate	O
that	O
in	O
monocytic	B-cell_line
cell	I-cell_line
lineage	I-cell_line
,	O
HIV-1	O
could	O
mimic	O
some	O
differentiation/activation	O
stimuli	O
allowing	O
nuclear	O
NF-KB	B-protein
expression	O
.	O

Disruption	O
of	O
the	O
human	B-DNA
SCL	I-DNA
locus	I-DNA
by	O
``	O
illegitimate	O
''	O
V-	O
(	O
D	O
)	O
-J	O
recombinase	O
activity	O
.	O

A	O
fusion	B-DNA
complementary	I-DNA
DNA	I-DNA
in	O
the	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
HSB-2	I-cell_line
elucidates	O
a	O
provocative	O
mechanism	O
for	O
the	O
disruption	O
of	O
the	O
putative	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
SCL	B-protein
.	O

The	O
fusion	B-DNA
cDNA	I-DNA
results	O
from	O
an	O
interstitial	O
deletion	O
between	O
a	O
previously	O
unknown	B-DNA
locus	I-DNA
,	O
SIL	B-DNA
(	O
SCL	B-DNA
interrupting	I-DNA
locus	I-DNA
)	O
,	O
and	O
the	O
5	B-DNA
'	I-DNA
untranslated	I-DNA
region	I-DNA
of	O
SCL	B-protein
.	O

Similar	O
to	O
1	O
;	O
14	O
translocations	O
,	O
this	O
deletion	O
disrupts	O
the	O
SCL	B-DNA
5	I-DNA
'	I-DNA
regulatory	I-DNA
region	I-DNA
.	O

This	O
event	O
is	O
probably	O
mediated	O
by	O
V-	O
(	O
D	O
)	O
-J	O
recombinase	O
activity	O
,	O
although	O
neither	O
locus	O
is	O
an	O
immunoglobulin	B-protein
or	O
a	O
T	B-protein
cell	I-protein
receptor	I-protein
.	O

Two	O
other	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
CEM	B-cell_line
and	O
RPMI	B-cell_line
8402	I-cell_line
,	O
have	O
essentially	O
identical	O
deletions	O
.	O

Thus	O
,	O
in	O
lymphocytes	B-cell_type
,	O
growth-affecting	B-DNA
genes	I-DNA
other	O
than	O
immune	B-protein
receptors	I-protein
risk	O
rearrangements	O
.	O

Thyroid	B-protein
hormone	I-protein
receptors	I-protein
form	O
distinct	O
nuclear	B-protein
protein-dependent	I-protein
and	I-protein
independent	I-protein
complexes	I-protein
with	O
a	O
thyroid	B-DNA
hormone	I-DNA
response	I-DNA
element	I-DNA
.	O

We	O
have	O
examined	O
the	O
binding	O
of	O
nuclear	B-protein
proteins	I-protein
and	O
recombinant	B-protein
thyroid	I-protein
hormone	I-protein
receptors	I-protein
(	O
TRs	B-protein
)	O
to	O
the	O
palindromic	B-DNA
thyroid	I-DNA
hormone	I-DNA
responsive	I-DNA
element	I-DNA
AGGTCATGACCT	O
(	O
TREp	B-DNA
)	O
using	O
a	O
gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Four	O
specific	O
protein-DNA	B-protein
complexes	I-protein
were	O
detected	O
after	O
incubation	O
of	O
nuclear	O
extracts	O
(	O
NE	O
)	O
from	O
T3-responsive	B-cell_line
pituitary	I-cell_line
(	I-cell_line
GH3	I-cell_line
)	I-cell_line
cells	I-cell_line
with	O
a	O
TREp-containing	B-DNA
DNA	I-DNA
fragment	I-DNA
.	O

This	O
was	O
compared	O
with	O
the	O
TREp	B-DNA
binding	O
of	O
reticulocyte	B-protein
lysate-synthesized	I-protein
TRs	I-protein
.	O

TR	B-protein
alpha	I-protein
1	I-protein
and	O
TR	B-protein
beta	I-protein
2	I-protein
each	O
formed	O
a	O
single	O
major	O
TR	B-protein
:	I-protein
TREp	I-protein
complex	I-protein
which	O
comigrated	O
with	O
the	O
least	O
retarded	O
complex	O
formed	O
by	O
GH3	O
NE	O
,	O
while	O
TR	B-protein
beta	I-protein
1	I-protein
formed	O
multiple	O
complexes	O
suggesting	O
that	O
it	O
can	O
bind	O
to	O
TREp	B-DNA
as	O
an	O
oligomer	B-protein
.	O

Interestingly	O
,	O
coincubation	O
of	O
35S-TR	B-protein
alpha	I-protein
1	I-protein
,	O
GH3	O
NE	O
,	O
and	O
unlabeled	O
TREp	B-DNA
resulted	O
in	O
not	O
only	O
the	O
35S-TR	B-protein
:	I-protein
TREp	I-protein
complex	I-protein
,	O
but	O
in	O
two	O
additional	O
more	O
greatly	O
retarded	O
complexes	O
containing	O
35S-TR	B-protein
alpha	I-protein
1	I-protein
and	O
comigrating	O
with	O
those	O
formed	O
by	O
GH3	O
extract	O
alone	O
.	O

Incubation	O
of	O
each	O
of	O
the	O
TRs	B-protein
with	O
NE	O
from	O
COS-7	B-cell_line
cells	I-cell_line
,	O
which	O
do	O
not	O
possess	O
sufficient	O
endogenous	O
TRs	B-protein
to	O
mediate	O
T3-responses	O
,	O
resulted	O
in	O
formation	O
of	O
a	O
new	O
,	O
more	O
greatly	B-protein
shifted	I-protein
complex	I-protein
.	O

A	O
similar	O
,	O
heat	O
labile	O
activity	O
which	O
altered	O
mobility	O
of	O
the	O
TR	B-protein
:	I-protein
TRE	I-protein
complex	I-protein
was	O
also	O
present	O
in	O
NE	O
from	O
T3-unresponsive	B-cell_line
JEG-3	I-cell_line
cells	I-cell_line
.	O

At	O
high	O
concentration	O
of	O
NE	O
,	O
all	O
of	O
the	O
TR	B-protein
bound	O
to	O
TREp	B-DNA
was	O
more	O
greatly	O
retarded	O
than	O
in	O
the	O
absence	O
of	O
NE	O
.	O

Truncation	O
of	O
TR	B-protein
alpha	I-protein
1	I-protein
at	O
amino	B-protein
acid	I-protein
210	I-protein
prevented	O
additional	O
complex	O
formation	O
in	O
the	O
presence	O
of	O
NE	O
without	O
affecting	O
DNA	O
binding	O
,	O
suggesting	O
that	O
the	O
carboxyl-terminus	B-protein
of	O
the	O
TRs	B-protein
is	O
essential	O
for	O
interaction	O
with	O
nuclear	B-protein
proteins	I-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Cell-specific	O
differences	O
in	O
activation	O
of	O
NF-kappa	B-DNA
B	I-DNA
regulatory	I-DNA
elements	I-DNA
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
and	I-DNA
beta	I-DNA
interferon	I-DNA
promoters	I-DNA
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
.	O

Three	O
aspects	O
of	O
the	O
involvement	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
pathogenesis	O
were	O
examined	O
.	O

Tumor	B-RNA
necrosis	I-RNA
factor	I-RNA
alpha	I-RNA
(	I-RNA
TNF-alpha	I-RNA
)	I-RNA
mRNA	I-RNA
production	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
in	O
monocytic	B-cell_line
U937	I-cell_line
cells	I-cell_line
and	O
in	O
a	O
chronically	B-cell_line
HIV	I-cell_line
infected	I-cell_line
U937	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
U9-IIIB	B-cell_line
)	O
.	O

TNF-alpha	B-RNA
RNA	I-RNA
was	O
undetectable	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
whereas	O
a	O
low	O
constitutive	O
level	O
was	O
detected	O
in	O
U9-IIIB	B-cell_line
cells	I-cell_line
.	O

Paramyxovirus	O
infection	O
induced	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
steady-state	O
level	O
of	O
TNF-alpha	B-RNA
RNA	I-RNA
in	O
U9-IIIB	B-cell_line
cells	I-cell_line
compared	O
with	O
U937	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
HIV-infected	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
produced	O
higher	O
levels	O
of	O
TNF-alpha	B-protein
than	O
did	O
normal	O
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O

The	O
effects	O
of	O
TNF-alpha	B-protein
on	O
gene	O
expression	O
were	O
examined	O
by	O
transient	O
expression	O
assays	O
using	O
reporter	B-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
plasmids	I-DNA
linked	O
to	O
regulatory	B-DNA
elements	I-DNA
from	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
and	O
the	O
beta	B-DNA
interferon	I-DNA
promoter	I-DNA
.	O

In	O
U937	B-cell_line
and	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
the	O
inducibility	O
of	O
the	O
different	O
hybrid	B-DNA
promoters	I-DNA
by	O
TNF-alpha	B-protein
or	O
phorbol	O
ester	O
varied	O
in	O
a	O
cell	O
type-	O
and	O
promoter	O
context-specific	O
manner	O
;	O
the	O
levels	O
of	O
gene	O
activity	O
of	O
NF-kappa	B-DNA
B-containing	I-DNA
plasmids	I-DNA
correlated	O
directly	O
with	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
.	O

Although	O
the	O
intact	O
beta	B-DNA
interferon	I-DNA
promoter	I-DNA
was	O
only	O
weakly	O
stimulated	O
by	O
phorbol	O
ester	O
or	O
TNF-alpha	B-protein
,	O
multimers	O
of	O
the	O
PRDII	B-DNA
NF-kappa	I-DNA
B-binding	I-DNA
domain	I-DNA
were	O
inducible	O
by	O
both	O
agents	O
.	O

TNF-alpha	B-protein
was	O
able	O
to	O
increase	O
expression	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
TNF-alpha	B-protein
did	O
not	O
induce	O
the	O
HIV	B-DNA
LTR	I-DNA
above	O
a	O
constitutive	O
level	O
of	O
activity	O
.	O

This	O
level	O
of	O
NF-kappa	B-protein
B	I-protein
-independent	O
activity	O
appears	O
to	O
be	O
sufficient	O
for	O
virus	O
multiplication	O
,	O
since	O
TNF-alpha	B-protein
treatment	O
had	O
no	O
effect	O
on	O
the	O
kinetics	O
of	O
de	O
novo	O
HIV	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
viral	B-RNA
RNA	I-RNA
production	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

However	O
,	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
TNF-alpha	B-protein
dramatically	O
enhanced	O
the	O
spread	O
of	O
HIV-1	O
through	O
the	O
cell	O
population	O
and	O
increased	O
viral	B-RNA
RNA	I-RNA
synthesis	O
,	O
indicating	O
that	O
in	O
T	B-cell_type
cells	I-cell_type
HIV-1	O
multiplication	O
was	O
stimulated	O
by	O
TNF-alpha	B-protein
treatment	O
.	O

Functional	O
analysis	O
of	O
cis-linked	B-DNA
regulatory	I-DNA
sequences	I-DNA
in	O
the	O
HLA	B-DNA
DRA	I-DNA
promoter	I-DNA
by	O
transcription	O
in	O
vitro	O
.	O

Two	O
consensus	O
sequences	O
,	O
called	O
X	B-DNA
and	I-DNA
Y	I-DNA
boxes	I-DNA
,	O
capable	O
of	O
binding	O
nuclear	B-protein
proteins	I-protein
and	O
regulating	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
have	O
been	O
defined	O
within	O
the	O
immediate	O
upstream	O
region	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
promoters	I-DNA
.	O

Unlike	O
other	O
class	B-DNA
II	I-DNA
promoters	I-DNA
,	O
the	O
HLA-DR	B-DNA
alpha	I-DNA
(	I-DNA
DRA	I-DNA
)	I-DNA
promoter	I-DNA
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
``	B-DNA
octamer	I-DNA
''	I-DNA
motif	I-DNA
of	O
immunoglobulin	B-DNA
variable	I-DNA
region	I-DNA
promoters	I-DNA
that	O
is	O
responsible	O
for	O
B	O
cell-specific	O
transcription	O
.	O

This	O
``	O
octamer	B-DNA
``	O
in	O
the	O
context	O
of	O
DRA	B-protein
appears	O
capable	O
of	O
binding	O
both	O
the	O
ubiquitous	B-protein
(	O
OTF-1	B-protein
)	O
and	O
lymphoid-specific	B-protein
(	I-protein
OTF-2	I-protein
)	I-protein
``	I-protein
octamer	I-protein
''	I-protein
binding	I-protein
proteins	I-protein
,	O
but	O
at	O
least	O
one	O
other	O
distinct	O
``	B-protein
octamer	I-protein
''	I-protein
complex	I-protein
was	O
found	O
.	O

In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis-acting	B-DNA
elements	I-DNA
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	B-DNA
promoter	I-DNA
construct	I-DNA
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	B-cell_type
cells	I-cell_type
than	O
in	O
extracts	O
from	O
class	B-cell_line
II-negative	I-cell_line
HeLa	I-cell_line
cells	I-cell_line
.	O

5	O
'	O
deletion	O
constructs	O
which	O
lacked	O
the	O
Y	B-DNA
box	I-DNA
,	O
but	O
retained	O
the	O
``	B-DNA
octamer	I-DNA
''	I-DNA
motif	I-DNA
and	O
TATA	B-DNA
box	I-DNA
were	O
completely	O
inactive	O
,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	B-DNA
box	I-DNA
reduced	O
transcription	O
by	O
95	O
%	O
.	O

Using	O
supercoiled	O
,	O
but	O
not	O
linear	O
templates	O
,	O
we	O
observed	O
differences	O
in	O
transcription	O
efficiencies	O
from	O
templates	O
lacking	O
or	O
disrupting	O
the	O
X	B-DNA
consensus	I-DNA
element	I-DNA
that	O
reflect	O
effects	O
of	O
random	O
replacement	O
of	O
X	B-DNA
box	I-DNA
sequences	I-DNA
in	O
transient	O
expression	O
assays	O
.	O

Demonstration	O
of	O
the	O
complete	O
dependence	O
on	O
the	O
Y	B-DNA
box	I-DNA
in	O
this	O
system	O
suggests	O
that	O
,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	B-DNA
promoter	I-DNA
,	O
the	O
DRA	B-DNA
``	I-DNA
octamer	I-DNA
''	I-DNA
does	O
not	O
utilize	O
OTF-2	B-protein
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	B-DNA
promoters	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
.	O

Lipopolysaccharide	O
is	O
a	O
potent	O
monocyte/macrophage-specific	O
stimulator	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
potently	O
stimulates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1-long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
HIV-1-LTR	I-DNA
)	I-DNA
CAT	I-DNA
constructs	I-DNA
transfected	O
into	O
monocyte/macrophage-like	B-cell_line
cell	I-cell_line
lines	I-cell_line
but	O
not	O
a	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

This	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
induction	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
LPS	O
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF-kappa	B-protein
B	I-protein
in	O
U937	B-cell_line
and	O
THP-1	B-cell_line
cells	I-cell_line
.	O

LPS	O
is	O
also	O
shown	O
to	O
dramatically	O
increase	O
HIV-1	O
production	O
from	O
a	O
chronically	B-cell_line
infected	I-cell_line
monocyte/macrophage-like	I-cell_line
cloned	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
U1	B-cell_line
,	O
which	O
produces	O
very	O
low	O
levels	O
of	O
HIV-1	O
at	O
baseline	O
.	O

The	O
stimulation	O
of	O
viral	O
production	O
from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
before	O
treatment	O
with	O
LPS	O
.	O

This	O
stimulation	O
of	O
HIV-1	O
production	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
level	O
of	O
HIV-1	B-RNA
RNA	I-RNA
and	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

LPS	O
is	O
not	O
able	O
to	O
induce	O
HIV-1	O
production	O
in	O
a	O
cloned	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
effect	O
of	O
LPS	O
on	O
HIV-1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV-1	O
infection	O
.	O

Steroid	O
dose	O
sparing	O
:	O
pharmacodynamic	O
responses	O
to	O
single	O
versus	O
divided	O
doses	O
of	O
methylprednisolone	O
in	O
man	O
.	O

Inhibitory	O
drug	O
interactions	O
affecting	O
the	O
metabolism	O
of	O
methylprednisolone	O
(	O
MP	O
)	O
may	O
produce	O
either	O
steroid	O
sparing	O
or	O
adverse	O
effects	O
partly	O
by	O
increasing	O
the	O
exposure	O
time	O
to	O
the	O
steroid	O
.	O

This	O
phenomenon	O
can	O
be	O
mimicked	O
by	O
administering	O
MP	O
in	O
divided	O
doses	O
.	O

Two	O
types	O
of	O
responses	O
were	O
compared	O
after	O
a	O
single	O
MP	O
dose	O
(	O
40	O
mg	O
bolus	O
)	O
and	O
a	O
divided	O
regimen	O
(	O
20	O
mg	O
bolus	O
and	O
a	O
5	O
mg	O
bolus	O
8	O
hours	O
later	O
)	O
in	O
six	O
healthy	O
male	O
volunteers	O
.	O

The	O
suppression	O
of	O
basophils	B-cell_type
measured	O
as	O
whole	O
blood	O
histamine	O
and	O
plasma	O
cortisol	O
concentrations	O
was	O
assessed	O
during	O
32	O
hours	O
.	O

The	O
37.5	O
%	O
reduction	O
in	O
dose	O
produced	O
a	O
23	O
%	O
overall	O
decreased	O
blood	O
histamine	O
response	O
.	O

A	O
pharmacodynamic	O
model	O
for	O
basophil	O
cell	O
distribution	O
to	O
and	O
from	O
an	O
extravascular	O
compartment	O
describes	O
the	O
effects	O
of	O
MP	O
after	O
both	O
regimens	O
.	O

A	O
slower	O
initial	O
decline	O
in	O
blood	O
histamine	O
after	O
the	O
divided	O
regimen	O
may	O
be	O
related	O
to	O
incomplete	O
suppression	O
of	O
basophil	B-cell_type
cell	I-cell_type
return	O
to	O
blood	O
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
of	O
about	O
5	O
ng/ml	O
were	O
similar	O
for	O
both	O
regimens	O
.	O

The	O
decline	O
and	O
return	O
of	O
cortisol	O
concentrations	O
were	O
similar	O
between	O
MP	O
treatments	O
with	O
suppression	O
continuing	O
for	O
24	O
hours	O
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
values	O
for	O
adrenal	O
suppression	O
were	O
about	O
1	O
ng/ml	O
.	O

Pharmacodynamic	O
modeling	O
is	O
useful	O
in	O
quantitating	O
corticosteroid	O
responses	O
and	O
generally	O
predicted	O
the	O
``	O
dose-sparing	O
''	O
effects	O
that	O
were	O
achieved	O
by	O
prolonging	O
MP	O
plasma	O
concentrations	O
.	O

This	O
study	O
supports	O
previous	O
clinical	O
observations	O
that	O
patients	O
may	O
require	O
morning	O
through	O
evening	O
exposure	O
to	O
MP	O
to	O
optimize	O
efficacy	O
while	O
adrenal	O
suppression	O
is	O
being	O
minimized	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D2	O
production	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
alveolar	B-cell_type
macrophages	I-cell_type
recovered	O
by	O
lavage	O
from	O
normocalcemic	O
patients	O
with	O
tuberculosis	O
.	O

To	O
compare	O
extra-renal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
in	O
different	O
types	O
of	O
granulomatous	O
disease	O
,	O
and	O
to	O
identify	O
the	O
cell	O
types	O
responsible	O
,	O
we	O
have	O
evaluated	O
the	O
conversion	O
of	O
25	O
(	O
OH	O
)	O
D3	O
in	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
by	O
uncultured	B-cell_type
cells	I-cell_type
recovered	O
by	O
bronchoalveolar	O
lavage	O
and	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
normocalcemic	O
patients	O
with	O
sarcoidosis	O
and	O
tuberculosis	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
produced	O
both	O
by	O
lavage	B-cell_type
cells	I-cell_type
(	O
12/12	O
tuberculosis	O
patients	O
,	O
2/6	O
sarcoidosis	O
patients	O
)	O
and	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
3/5	O
tuberculosis	O
patients	O
,	O
0/3	O
sarcoidosis	O
patients	O
)	O
from	O
patients	O
but	O
not	O
controls	O
,	O
but	O
significantly	O
greater	O
amounts	O
were	O
produced	O
by	O
lavage	O
cells	O
from	O
tuberculosis	O
patients	O
than	O
those	O
of	O
sarcoidosis	O
patients	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
by	O
lavage	B-cell_type
cells	I-cell_type
from	O
tuberculosis	O
patients	O
correlated	O
with	O
the	O
number	O
of	O
CD8+	O
T	B-cell_type
lymphocytes	I-cell_type
present	O
but	O
not	O
other	O
cell	O
types	O
.	O

T	B-cell_type
lymphocytes	I-cell_type
appeared	O
to	O
be	O
an	O
important	O
source	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
,	O
since	O
purified	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
all	O
patients	O
with	O
tuberculosis	O
produced	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
by	O
these	O
cells	O
correlated	O
closely	O
with	O
that	O
produced	O
by	O
unseparated	O
lavage	B-cell_type
cells	I-cell_type
.	O

Because	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
improve	O
the	O
capacity	O
of	O
macrophages	B-cell_type
to	O
kill	O
mycobacteria	O
,	O
our	O
results	O
support	O
the	O
conclusion	O
that	O
macrophage-lymphocyte	O
interactions	O
,	O
mediated	O
at	O
least	O
in	O
part	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
may	O
be	O
an	O
important	O
component	O
of	O
a	O
successful	O
antituberculous	O
immune	O
response	O
.	O

Megakaryocytic	B-cell_line
and	I-cell_line
erythrocytic	I-cell_line
lineages	I-cell_line
share	O
specific	O
transcription	B-protein
factors	I-protein
.	O

Erythroid-specific	B-DNA
genes	I-DNA
contain	O
binding	O
sites	O
for	O
NF-E1	B-protein
(	O
also	O
called	O
GF-1	B-protein
and	O
Eryf-1	B-protein
;	O
refs	O
1-3	O
respectively	O
)	O
,	O
the	O
principal	O
DNA-binding	B-protein
protein	I-protein
of	O
the	O
erythrocytic	B-cell_type
lineage	I-cell_type
.	O

NF-E1	B-protein
expression	O
seems	O
to	O
be	O
restricted	O
to	O
the	O
erythrocytic	B-cell_type
lineage	I-cell_type
.	O

A	O
closely	O
related	O
(	O
if	O
not	O
identical	O
)	O
protein	O
is	O
found	O
in	O
both	O
a	O
human	B-cell_line
megakaryocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
purified	B-cell_line
human	I-cell_line
megakaryocytes	I-cell_line
;	O
it	O
binds	O
to	O
promoter	B-DNA
regions	I-DNA
of	O
two	O
megakaryocytic-specific	B-DNA
genes	I-DNA
.	O

The	O
binding	O
sites	O
and	O
partial	O
proteolysis	O
profile	O
of	O
this	O
protein	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
erythroid	B-protein
protein	I-protein
;	O
also	O
,	O
NF-E1	B-RNA
messenger	I-RNA
RNA	I-RNA
is	O
the	O
same	O
size	O
in	O
both	O
the	O
megakaryocytic	B-cell_line
and	I-cell_line
erythroid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Furthermore	O
,	O
point	O
mutations	O
that	O
abolish	O
binding	O
of	O
NF-E1	B-protein
result	O
in	O
a	O
70	O
%	O
decrease	O
in	O
the	O
transcriptional	O
activity	O
of	O
a	O
megakaryocytic-specific	B-DNA
promoter	I-DNA
.	O

We	O
also	O
find	O
that	O
NF-E2	B-protein
,	O
another	O
trans-acting	B-protein
factor	I-protein
of	O
the	O
erythrocytic	B-cell_type
lineage	I-cell_type
,	O
is	O
present	O
in	O
megakaryocytes	B-cell_line
.	O

Transcriptional	O
effects	O
in	O
both	O
lineages	O
might	O
then	O
be	O
mediated	O
in	O
part	O
by	O
the	O
same	O
specific	O
trans-acting	B-protein
factors	I-protein
.	O

Our	O
data	O
strengthen	O
the	O
idea	O
of	O
a	O
close	O
association	O
between	O
the	O
erythrocytic	B-cell_line
and	I-cell_line
the	I-cell_line
megakaryocytic	I-cell_line
lineages	I-cell_line
and	O
could	O
also	O
explain	O
the	O
expression	O
of	O
markers	O
specific	O
to	O
the	O
erythrocytic	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
in	O
most	O
erythroblastic	B-cell_line
and	I-cell_line
megakaryoblastic	I-cell_line
permanent	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Transcriptional	O
down-regulation	O
of	O
c-myc	B-DNA
expression	O
by	O
protein	O
synthesis-dependent	O
and	O
-independent	O
pathways	O
in	O
a	O
human	B-cell_line
T	I-cell_line
lymphoblastic	I-cell_line
tumor	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

We	O
show	O
that	O
in	O
the	O
human	B-cell_line
T	I-cell_line
lymphoblastic	I-cell_line
tumor	I-cell_line
cell	I-cell_line
line	I-cell_line
Molt4	B-RNA
c-myc	I-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
is	O
down-regulated	O
after	O
exposure	O
to	O
dimethyl	O
sulfoxide	O
,	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
or	O
to	O
the	O
calcium	O
ionophore	O
A23187	O
,	O
which	O
raises	O
the	O
intracellular	O
calcium	O
concentration	O
.	O

A	O
block	O
to	O
RNA	O
elongation	O
is	O
largely	O
responsible	O
for	O
decreased	O
c-myc	B-DNA
transcription	O
.	O

Although	O
negative	O
regulation	O
by	O
dimethyl	O
sulfoxide	O
takes	O
place	O
even	O
when	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	O
,	O
the	O
phorbol	O
myristate	O
acetate	O
effect	O
is	O
blocked	O
to	O
some	O
extent	O
only	O
by	O
cycloheximide	O
.	O

The	O
calcium	O
ionophore-induced	O
c-myc	B-DNA
suppression	O
,	O
however	O
,	O
strictly	O
requires	O
de	O
novo	O
protein	O
synthesis	O
.	O

Therefore	O
,	O
two	O
different	O
negative	O
regulatory	O
pathways	O
are	O
involved	O
in	O
c-myc	B-DNA
regulation	O
:	O
one	O
which	O
is	O
independent	O
and	O
one	O
which	O
depends	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

The	O
latter	O
one	O
appears	O
to	O
be	O
mediated	O
by	O
a	O
rapidly	O
calcium-dependent	B-protein
induced	I-protein
gene	I-protein
product	I-protein
.	O

Oestrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
analysis	O
in	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
:	O
correlation	O
of	O
biochemical	O
and	O
immunocytochemical	O
methods	O
.	O

Oestrogen	B-protein
receptors	I-protein
(	O
ER	B-protein
)	O
are	O
present	O
in	O
neoplastic	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
and	O
have	O
been	O
considered	O
a	O
physiological	O
marker	O
of	O
growth	O
rate	O
or	O
differentiation	O
.	O

Tamoxifen	O
,	O
an	O
oestrogen	O
antagonist	O
,	O
has	O
been	O
given	O
in	O
some	O
patients	O
with	O
CLL	O
and	O
Hodgkin	O
's	O
disease	O
,	O
with	O
dramatic	O
response	O
in	O
single	O
cases	O
.	O

Until	O
now	O
,	O
ER	B-protein
status	O
has	O
been	O
assessed	O
using	O
a	O
steroid	O
binding	O
assay	O
(	O
SBA	O
)	O
which	O
has	O
many	O
inherent	O
problems	O
.	O

Recently	O
,	O
the	O
development	O
of	O
monoclonal	O
antibodies	O
directed	O
against	O
ER	B-protein
has	O
been	O
applied	O
to	O
the	O
study	O
of	O
breast	O
carcinomas	O
and	O
results	O
obtained	O
show	O
good	O
correlation	O
with	O
the	O
quantitative	O
SBA	O
.	O

We	O
studied	O
49	O
cases	O
of	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
using	O
immunostaining	O
of	O
cytospin	O
preparations	O
.	O

In	O
30	O
of	O
these	O
cases	O
ER	B-protein
enzyme	O
immunoassay	O
(	O
ER	B-protein
-EIA	O
)	O
was	O
also	O
performed	O
.	O

Cultured	B-cell_line
MCF-7	I-cell_line
cells	I-cell_line
,	O
derived	O
from	O
a	O
pleural	O
effusion	O
of	O
a	O
breast	O
cancer	O
patient	O
,	O
known	O
to	O
contain	O
high	O
levels	O
of	O
ER	B-protein
were	O
used	O
as	O
a	O
positive	O
control	O
(	O
40-48	O
%	O
ER	B-cell_type
positive	I-cell_type
cells	I-cell_type
by	O
immunocytochemistry	O
;	O
200	O
fmol/mg	O
protein	O
by	O
EIA	O
)	O
.	O

All	O
of	O
the	O
CLL	O
cases	O
except	O
two	O
(	O
96	O
%	O
)	O
were	O
negative	O
for	O
ER	B-protein
(	O
less	O
than	O
1	O
%	O
staining	O
;	O
less	O
than	O
4	O
fmol/mg	O
protein	O
)	O
.	O

The	O
two	O
positive	O
cases	O
expressed	O
granular	O
ER	B-protein
staining	O
over	O
the	O
nucleus	O
(	O
9.2	O
and	O
12.1	O
%	O
positive	O
cells	O
)	O
and	O
were	O
positive	O
by	O
EIA	O
and	O
SBA	O
.	O

It	O
is	O
concluded	O
that	O
(	O
i	O
)	O
patients	O
with	O
CLL	O
rarely	O
express	O
ER	B-protein
and	O
(	O
ii	O
)	O
immunocytochemical	O
staining	O
of	O
cytospin	O
preparations	O
is	O
a	O
valid	O
technique	O
for	O
the	O
measurement	O
of	O
ER	B-protein
.	O

It	O
is	O
of	O
interest	O
that	O
one	O
of	O
the	O
positive	O
cases	O
was	O
diagnosed	O
as	O
CLL	O
with	O
Richter	O
's	O
transformation	O
confirming	O
earlier	O
findings	O
.	O

Type-II	B-protein
estrogen	I-protein
binding	I-protein
sites	I-protein
in	O
a	O
lymphoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
growth-inhibitory	O
effect	O
of	O
estrogen	O
,	O
anti-estrogen	O
and	O
bioflavonoids	O
.	O

Type-II	B-protein
estrogen-binding	I-protein
sites	I-protein
(	O
type-II	B-protein
EBS	I-protein
)	O
have	O
been	O
demonstrated	O
in	O
the	O
human	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
IM-9	B-cell_line
using	O
a	O
whole-cell	O
assay	O
with	O
(	O
6	O
,	O
7-3H	O
)	O
estradiol	O
(	O
3H-E2	O
)	O
as	O
tracer	O
.	O

Competition	O
analysis	O
showed	O
that	O
the	O
anti-estrogen	O
tamoxifen	O
and	O
the	O
flavonoids	O
quercetin	O
and	O
rutin	O
competed	O
for	O
(	O
3H	O
)	O
-E2	O
binding	O
to	O
type-II	B-protein
EBS	I-protein
.	O

Growth	O
experiments	O
demonstrated	O
that	O
diethylstilbestrol	O
(	O
DES	O
)	O
tamoxifen	O
(	O
TAM	O
)	O
,	O
quercetin	O
and	O
rutin	O
exerted	O
a	O
reversible	O
dose-dependent	O
inhibition	O
of	O
cell	O
proliferation	O
in	O
the	O
range	O
of	O
concentrations	O
between	O
10	O
nM	O
and	O
10	O
microM	O
.	O

The	O
relative	O
binding	O
affinity	O
of	O
quercetin	O
,	O
rutin	O
,	O
DES	O
and	O
TAM	O
for	O
type-II	B-protein
EBS	I-protein
correlated	O
well	O
with	O
their	O
potency	O
as	O
cell	O
growth	O
inhibitors	O
.	O

Moreover	O
,	O
hesperidin	O
,	O
a	O
flavonoid	O
which	O
does	O
not	O
bind	O
to	O
type-II	B-protein
EBS	I-protein
,	O
was	O
ineffective	O
in	O
inhibiting	O
cell	O
growth	O
.	O

Cell-cycle	O
analysis	O
showed	O
that	O
the	O
growth-inhibitory	O
effect	O
of	O
DES	O
,	O
TAM	O
or	O
quercetin	O
was	O
due	O
to	O
a	O
blocking	O
effect	O
in	O
the	O
G0-G1	O
phases	O
.	O

Our	O
results	O
suggest	O
that	O
high	O
estrogen	O
and	O
anti-estrogen	O
concentrations	O
and	O
flavonoids	O
may	O
regulate	O
IM-9	B-cell_line
cell	O
growth	O
through	O
a	O
common	O
mechanism	O
involving	O
a	O
binding	O
interaction	O
with	O
type-II	B-protein
EBS	I-protein
.	O

[	O
Glucocorticoid	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
patients	O
with	O
bronchial	O
asthma	O
]	O

Quantitation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
and	O
the	O
study	O
of	O
their	O
affinity	O
for	O
glucocorticosteroids	O
(	O
GCS	O
)	O
were	O
made	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
bronchial	O
asthma	O
(	O
BA	O
)	O
patients	O
in	O
consideration	O
of	O
GCR	B-protein
treatment	O
and	O
serum	O
levels	O
of	O
endogenous	O
cortisol	O
.	O

It	O
is	O
stated	O
that	O
GCR	B-protein
of	O
healthy	O
controls	O
and	O
GCS-untreated	O
patients	O
outnumbered	O
those	O
of	O
cortisol-dependent	O
BA	O
patients	O
on	O
hormone	O
therapy	O
.	O

Following	O
discontinuation	O
of	O
glucocorticoid	O
drugs	O
GCR	B-protein
count	O
in	O
cortisol-dependent	O
BA	O
tends	O
to	O
rise	O
.	O

Endogenous	O
cortisol	O
has	O
no	O
effect	O
on	O
GCR	B-protein
level	O
estimated	O
by	O
3H-triamcinolone	O
acetonide	O
.	O

Two	O
glucocorticoid	B-protein
binding	I-protein
sites	I-protein
on	O
the	O
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
.	O

Glucocorticoids	O
are	O
known	O
to	O
have	O
a	O
lytic	O
effect	O
in	O
leukemic	B-cell_type
cells	I-cell_type
via	O
interactions	O
with	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
.	O

Cortisol	O
and	O
various	O
synthetic	O
glucocorticoids	O
bind	O
to	O
the	O
GR	B-protein
with	O
one-site	O
kinetics	O
.	O

Cortivazol	O
(	O
CVZ	O
)	O
is	O
a	O
unique	O
,	O
high	O
potency	O
synthetic	O
glucocorticoid	O
,	O
which	O
has	O
a	O
phenylpyrazol	O
fused	O
to	O
the	O
A-ring	O
of	O
the	O
steroid	O
nucleus	O
and	O
displays	O
binding	O
consistent	O
with	O
two	O
or	O
more	O
sites	O
in	O
the	O
cytosol	O
from	O
CEM	B-cell_line
C7	I-cell_line
cells	I-cell_line
(	O
a	O
human	B-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
T-cell	I-cell_line
line	I-cell_line
)	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
lower	O
affinity	O
class	O
of	O
sites	O
are	O
similar	O
in	O
affinity	O
and	O
site	O
molarity	O
to	O
those	O
recognized	O
by	O
dexamethasone	O
.	O

The	O
higher	O
affinity	O
sites	O
bind	O
CVZ	O
with	O
20-	O
to	O
50-fold	O
greater	O
affinity	O
,	O
consistent	O
with	O
CVZ	O
's	O
enhanced	O
biological	O
effects	O
.	O

In	O
mutant	O
leukemic	B-cell_type
cells	I-cell_type
resistant	O
to	O
the	O
lytic	O
effects	O
of	O
dexamethasone	O
,	O
CVZ	O
both	O
lyses	O
the	O
cells	O
and	O
recognizes	O
a	O
single	O
class	O
of	O
sites	O
similar	O
to	O
the	O
high	O
affinity	O
site	O
in	O
CEM	B-cell_line
C7	I-cell_line
cells	I-cell_line
.	O

We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	B-protein
affinity	I-protein
CVZ	I-protein
binding	I-protein
site	I-protein
.	O

We	O
now	O
show	O
that	O
:	O
1	O
)	O
CVZ	O
has	O
more	O
than	O
one	O
binding	O
site	O
in	O
a	O
second	O
,	O
independent	O
,	O
B-cell	B-cell_line
line	I-cell_line
,	O
IM-9	B-cell_line
;	O
2	O
)	O
the	O
antiglucocorticoid	O
RU	O
38486	O
is	O
able	O
to	O
block	O
both	O
CVZ	O
's	O
higher	O
and	O
lower	O
affinity	O
sites	O
;	O
3	O
)	O
all	O
of	O
CVZ	B-protein
's	I-protein
binding	I-protein
sites	I-protein
are	O
on	O
a	O
protein	O
immunologically	O
indistinguishable	O
from	O
the	O
human	O
GR	B-protein
;	O
and	O
4	O
)	O
freshly	O
isolated	O
clones	O
of	O
CVZ-resistant	O
cells	O
have	O
lost	O
all	O
binding	O
sites	O
for	O
CVZ	O
.	O

These	O
data	O
indicate	O
that	O
CVZ	O
is	O
recognizing	O
two	O
glucocorticoid	B-protein
binding	I-protein
sites	I-protein
on	O
the	O
human	O
GR	B-protein
or	O
a	O
protein	O
very	O
similar	O
to	O
it	O
.	O

Retroviral	O
mediated	O
transfer	O
and	O
expression	O
of	O
exogenous	B-DNA
genes	I-DNA
in	O
primary	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
:	O
assaying	O
for	O
a	O
viral	O
transactivator	B-protein
activity	O
in	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
use	O
of	O
recombinant	O
retroviruses	O
to	O
characterize	O
the	O
activity	O
of	O
an	O
exogenous	B-DNA
promoter	I-DNA
in	O
primary	O
cells	O
obtained	O
from	O
patients	O
with	O
lymphoproliferative	O
disorders	O
.	O

The	O
infection	O
of	O
a	O
variety	O
of	O
cultured	O
and	O
primary	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
with	O
a	O
recombinant	O
retrovirus	O
containing	O
a	O
histone	B-DNA
promoter-driven	I-DNA
beta-galactosidase	I-DNA
gene	I-DNA
is	O
shown	O
to	O
result	O
in	O
the	O
expression	O
of	O
beta-galactosidase	B-protein
in	O
50	O
%	O
to	O
100	O
%	O
of	O
the	O
cells	O
.	O

A	O
similar	O
infection	O
with	O
a	O
recombinant	O
retrovirus	O
containing	O
the	O
beta-galactosidase	B-DNA
gene	I-DNA
with	O
an	O
adenovirus	B-DNA
E2	I-DNA
promoter	I-DNA
,	O
results	O
in	O
beta-galactosidase	B-protein
activity	O
in	O
a	O
limited	O
number	O
of	O
cultured	B-cell_line
and	O
primary	B-cell_type
cells	I-cell_type
.	O

Since	O
the	O
adenovirus	B-DNA
E2	I-DNA
promoter	I-DNA
has	O
been	O
well	O
characterized	O
and	O
is	O
known	O
to	O
be	O
regulated	O
by	O
transactivators	B-protein
encoded	O
by	O
many	O
viruses	O
,	O
the	O
activity	O
of	O
this	O
promoter	O
in	O
specific	O
cell	O
types	O
is	O
discussed	O
in	O
reference	O
to	O
both	O
the	O
biology	O
of	O
the	O
cell	O
and	O
the	O
possible	O
presence	O
of	O
as	O
yet	O
undetected	O
viral	B-protein
gene	I-protein
products	I-protein
.	O

[	O
The	O
effect	O
of	O
24	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
dioxyvit	O
)	O
on	O
Ca	O
metabolism	O
and	O
immune	O
status	O
during	O
chronic	O
kidney	O
failure	O
]	O

Active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
24R	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
dioxyvit	O
)	O
was	O
used	O
at	O
a	O
daily	O
dose	O
of	O
100	O
micrograms	O
in	O
treatment	O
of	O
children	O
affected	O
with	O
tubulointerstitial	O
disease	O
of	O
kidney	O
and	O
with	O
chronic	O
glomerulonephritis	O
under	O
conditions	O
of	O
kidney	O
insufficiency	O
.	O

The	O
drug	O
exhibited	O
distinct	O
normalizing	O
effect	O
on	O
patterns	O
of	O
calcium	O
metabolism	O
:	O
increase	O
of	O
total	O
and	O
ionized	O
Ca2+	O
and	O
of	O
25-OHD	O
,	O
decrease	O
in	O
concentration	O
of	O
parath	O
hormone	O
and	O
osteocalcine	O
in	O
blood	O
serum	O
as	O
well	O
as	O
on	O
immunological	O
parameters	O
:	O
restoration	O
of	O
decreased	O
content	O
of	O
T-	B-cell_type
and	I-cell_type
0-lymphocytes	I-cell_type
.	O

Concentration	O
of	O
receptors	O
of	O
hormonal	O
form	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
found	O
to	O
be	O
minimal	O
in	O
lymphocytes	B-cell_type
under	O
conditions	O
of	O
chronic	O
kidney	O
insufficiency	O
,	O
while	O
their	O
expression	O
,	O
after	O
the	O
dioxyvit	O
action	O
,	O
was	O
detected	O
only	O
in	O
patients	O
with	O
glomerulonephritis	O
.	O

Specific	O
calcitropic	O
effect	O
of	O
dioxyvit	O
with	O
simultaneous	O
correction	O
of	O
vitamin	O
D	O
deficiency	O
were	O
apparently	O
responsible	O
for	O
high	O
efficacy	O
of	O
the	O
drug	O
in	O
treatment	O
of	O
calcium	O
metabolism	O
and	O
immunity	O
impairments	O
in	O
children	O
with	O
renal	O
deteriorations	O
at	O
the	O
step	O
of	O
chronic	O
kidney	O
insufficiency	O
.	O

[	O
The	O
role	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
HLA	B-protein
antigens	I-protein
in	O
the	O
pathogenesis	O
of	O
Cushing	O
's	O
syndrome	O
]	O

Lymphocytic	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
were	O
evaluated	O
in	O
114	O
patients	O
suffering	O
from	O
Icenko-Cushing	O
's	O
syndrome	O
.	O

Incidence	O
of	O
HLA	B-protein
antigens	I-protein
was	O
determined	O
in	O
94	O
of	O
them	O
.	O

A	O
significant	O
rise	O
of	O
A10	B-protein
and	O
B27	B-protein
antigen	I-protein
incidence	O
compared	O
to	O
that	O
in	O
normal	O
subjects	O
allows	O
these	O
antigens	O
to	O
be	O
considered	O
genetic	O
markers	O
of	O
Icenko-Cushing	O
's	O
syndrome	O
.	O

The	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
the	O
patients	O
are	O
lower	O
than	O
in	O
normal	O
subjects	O
both	O
in	O
the	O
active	O
stage	O
of	O
the	O
disease	O
and	O
following	O
bilateral	O
total	O
adrenalectomy	O
.	O

The	O
patients	O
carrying	O
B27	B-protein
antigen	I-protein
had	O
lymphocytic	O
receptor	O
concentrations	O
under	O
the	O
levels	O
of	O
such	O
in	O
patients	O
free	O
of	O
the	O
antigen	O
carriage	O
.	O

Antigen	B-protein
B27	I-protein
seems	O
to	O
be	O
a	O
cause	O
of	O
lower	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
blood	B-cell_type
lymphocytes	I-cell_type
.	O

Effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
on	O
the	O
human	B-cell_line
chronic	I-cell_line
myelogenous	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
RWLeu-4	B-cell_line
.	O

The	O
effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
on	O
proliferation	O
,	O
differentiation	O
,	O
and	O
macromolecular	O
synthesis	O
in	O
the	O
new	O
Philadelphia	B-cell_line
chromosome-positive	I-cell_line
chronic	I-cell_line
myelogenous	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
RWLeu-4	B-cell_line
,	O
were	O
investigated	O
.	O

Binding	O
of	O
[	O
3H	O
]	O
VD3	O
was	O
saturable	O
,	O
with	O
approximately	O
2000-3000	O
sites/cell	O
,	O
and	O
half-maximal	O
binding	O
occurring	O
at	O
0.21-0.33	O
nM	O
.	O

Treatment	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
with	O
VD3	O
induced	O
24R-hydroxylase	B-protein
activity	O
,	O
a	O
marker	O
of	O
vitamin	O
D3	O
responsiveness	O
in	O
many	O
tissues	O
.	O

Exposure	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
to	O
VD3	O
also	O
inhibited	O
proliferation	O
and	O
DNA	O
synthesis	O
with	O
a	O
50	O
%	O
effective	O
dose	O
of	O
3.5-10	O
nM	O
within	O
72	O
h	O
;	O
in	O
addition	O
,	O
protein	O
and	O
RNA	O
synthesis	O
were	O
inhibited	O
by	O
VD3	O
treatment	O
.	O

Exposure	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
to	O
5	O
nM	O
VD3	O
for	O
72	O
h	O
caused	O
50	O
%	O
of	O
the	O
cells	O
to	O
differentiate	O
into	O
macrophage/monocyte	B-cell_type
type	I-cell_type
cells	I-cell_type
as	O
judged	O
by	O
nitroblue	O
tetrazolium	O
staining	O
and	O
adherence	O
to	O
plastic	O
.	O

Progressive	O
expression	O
of	O
cell	B-protein
surface	I-protein
maturation-specific	I-protein
antigens	I-protein
of	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
was	O
induced	O
by	O
treatment	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
with	O
VD3	O
for	O
24	O
to	O
72	O
h	O
at	O
doses	O
that	O
inhibited	O
cellular	O
proliferation	O
.	O

c-myc	B-RNA
RNA	I-RNA
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
RWLeu-4	B-cell_line
cells	I-cell_line
,	O
increased	O
after	O
0.5	O
h	O
of	O
treatment	O
with	O
50	O
nM	O
VD3	O
and	O
then	O
rapidly	O
decreased	O
to	O
barely	O
detectable	O
levels	O
after	O
4	O
h	O
of	O
treatment	O
.	O

Finally	O
,	O
the	O
in	O
vitro	O
tyrosine	O
kinase	O
activity	O
associated	O
with	O
the	O
p210bcr-abl	B-protein
oncogene	I-protein
product	I-protein
was	O
decreased	O
approximately	O
50	O
%	O
by	O
VD3	O
treatment	O
.	O

Because	O
of	O
the	O
presence	O
of	O
a	O
functional	O
receptor-effector	O
system	O
for	O
VD3	O
and	O
multiple	O
biological	O
responses	O
to	O
the	O
hormone	O
,	O
these	O
cells	O
provide	O
a	O
unique	O
model	O
system	O
with	O
which	O
to	O
probe	O
the	O
specific	O
effects	O
of	O
VD3	O
on	O
cell	O
growth	O
and	O
differentiation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

A	O
new	O
member	O
of	O
the	O
leucine	B-protein
zipper	I-protein
class	I-protein
of	O
proteins	O
that	O
binds	O
to	O
the	O
HLA	B-DNA
DR	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Several	O
mutants	O
derived	O
from	O
transformed	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
are	O
defective	O
in	O
expressing	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O

The	O
failure	O
to	O
express	O
a	O
class	B-DNA
II	I-DNA
gene	I-DNA
in	O
at	O
least	O
one	O
such	O
mutant	B-cell_line
line	I-cell_line
has	O
been	O
mapped	O
to	O
the	O
MHC	B-DNA
class	I-DNA
II	I-DNA
X	I-DNA
box	I-DNA
,	O
a	O
conserved	B-DNA
transcriptional	I-DNA
element	I-DNA
in	O
the	O
promoter	B-DNA
region	I-DNA
.	O

A	O
complementary	B-DNA
DNA	I-DNA
encoding	O
a	O
DNA-binding	B-protein
protein	I-protein
(	O
human	B-protein
X	I-protein
box	I-protein
binding	I-protein
protein	I-protein
,	O
hXBP-1	B-protein
)	O
whose	O
target	O
is	O
the	O
human	B-DNA
DR	I-DNA
alpha	I-DNA
X	I-DNA
box	I-DNA
and	O
the	O
3	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
has	O
now	O
been	O
cloned	O
.	O

This	O
complementary	B-DNA
DNA	I-DNA
encoded	O
a	O
protein	O
with	O
structural	O
similarities	O
to	O
the	O
c-jun	B-protein
proto-oncogene	I-protein
product	I-protein
,	O
and	O
its	O
target	O
sequence	O
was	O
closely	O
related	O
to	O
the	O
palindromic	B-DNA
target	I-DNA
sequence	I-DNA
of	O
c-jun	B-DNA
.	O

Mutation	O
of	O
the	O
hXBP-1	B-DNA
DNA	I-DNA
target	I-DNA
sequence	I-DNA
decreased	O
DR	B-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
in	O
vivo	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
hXBP-1	B-protein
protein	I-protein
acts	O
as	O
a	O
transcription	B-protein
factor	I-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

Pseudohypoaldosteronism	O
in	O
eight	O
families	O
:	O
different	O
forms	O
of	O
inheritance	O
are	O
evidence	O
for	O
various	O
genetic	O
defects	O
.	O

Pseudohypoaldosteronism	O
is	O
a	O
rare	O
hereditary	O
disorder	O
presenting	O
in	O
early	O
infancy	O
with	O
renal	O
salt	O
loss	O
leading	O
to	O
hyponatremia	O
and	O
hyperkalemia	O
despite	O
high	O
levels	O
of	O
plasma	O
aldosterone	O
.	O

The	O
patients	O
are	O
insensitive	O
to	O
mineralocorticoids	O
;	O
however	O
,	O
sodium	O
supplementation	O
is	O
able	O
to	O
correct	O
electrolyte	O
abnormalities	O
.	O

Absent	O
or	O
greatly	O
diminished	O
type	O
I	B-protein
aldosterone	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leucocytes	I-cell_type
have	O
been	O
recently	O
demonstrated	O
and	O
explain	O
the	O
lack	O
of	O
response	O
to	O
mineralocorticoids	O
.	O

We	O
have	O
studied	O
the	O
mode	O
of	O
inheritance	O
in	O
eight	O
families	O
with	O
a	O
total	O
of	O
nine	O
patients	O
.	O

There	O
was	O
evidence	O
for	O
an	O
autosomal	O
recessive	O
form	O
of	O
inheritance	O
in	O
four	O
families	O
,	O
while	O
the	O
other	O
four	O
families	O
appeared	O
to	O
have	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
.	O

In	O
three	O
families	O
the	O
autosomal	O
recessive	O
form	O
was	O
characterized	O
by	O
normal	B-protein
receptor	I-protein
as	O
well	O
as	O
hormone	O
data	O
in	O
both	O
parents	O
,	O
while	O
in	O
one	O
family	O
receptor	O
levels	O
in	O
both	O
parents	O
were	O
greatly	O
reduced	O
,	O
but	O
hormone	O
levels	O
were	O
normal	O
.	O

In	O
the	O
four	O
families	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
there	O
was	O
always	O
one	O
parent	O
with	O
reduced	O
receptor	O
binding	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leucocytes	I-cell_type
and	O
elevated	O
serum	O
hormone	O
levels	O
.	O

These	O
parents	O
were	O
entirely	O
asymptomatic	O
.	O

In	O
an	O
extended	O
family	O
we	O
were	O
able	O
to	O
study	O
an	O
aunt	O
and	O
her	O
newborn	O
daughter	O
,	O
who	O
were	O
both	O
also	O
biochemically	O
affected	O
but	O
clinically	O
asymptomatic	O
.	O

It	O
,	O
therefore	O
,	O
appears	O
that	O
this	O
dual	O
pattern	O
of	O
genetic	O
transmission	O
may	O
indicate	O
differing	O
genetic	O
defects	O
which	O
cause	O
the	O
same	O
clinical	O
picture	O
of	O
pseudohypoaldosteronism	O
.	O

Perceived	O
social	O
support	O
and	O
tumor	O
estrogen/progesterone	B-protein
receptor	I-protein
status	O
as	O
predictors	O
of	O
natural	B-cell_type
killer	I-cell_type
cell	I-cell_type
activity	O
in	O
breast	O
cancer	O
patients	O
.	O

This	O
report	O
is	O
concerned	O
with	O
the	O
prediction	O
of	O
natural	O
killer	B-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
in	O
61	O
Stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
,	O
between	O
the	O
ages	O
of	O
25	O
and	O
70	O
,	O
who	O
were	O
accrued	O
to	O
this	O
project	O
.	O

All	O
baseline	O
interview	O
and	O
testing	O
data	O
were	O
obtained	O
either	O
just	O
before	O
patients	O
were	O
discharged	O
from	O
the	O
hospital	O
,	O
or	O
at	O
their	O
first	O
outpatient	O
visit	O
,	O
within	O
two	O
weeks	O
of	O
discharge	O
.	O

A	O
major	O
interest	O
of	O
this	O
project	O
is	O
the	O
predictive	O
value	O
of	O
perceived	O
social	O
support	O
,	O
as	O
a	O
potential	O
``	O
stress	O
''	O
buffer	O
,	O
related	O
to	O
NK	O
activity	O
.	O

In	O
the	O
main	O
model	O
reported	O
here	O
,	O
we	O
found	O
that	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
could	O
be	O
explained	O
by	O
five	O
variables	O
.	O

Higher	O
NK	O
activity	O
could	O
be	O
predicted	O
by	O
the	O
perception	O
of	O
high	O
quality	O
emotional	O
support	O
from	O
a	O
spouse	O
or	O
intimate	O
other	O
,	O
perceived	O
social	O
support	O
from	O
the	O
patient	O
's	O
physician	O
,	O
estrogen	B-protein
receptor	I-protein
-negative	O
tumor	O
status	O
,	O
having	O
an	O
excisional	O
biopsy	O
as	O
surgical	O
treatment	O
,	O
and	O
actively	O
seeking	O
social	O
support	O
as	O
a	O
major	O
coping	O
strategy	O
(	O
R2	O
=	O
0.33	O
,	O
F	O
(	O
5	O
,	O
55	O
)	O
=	O
5.5	O
,	O
p	O
less	O
than	O
0.0004	O
)	O
.	O

Findings	O
are	O
discussed	O
in	O
terms	O
of	O
host	O
interaction	O
with	O
tumor	O
endocrine	O
status	O
,	O
and	O
the	O
role	O
that	O
social	O
support	O
might	O
play	O
in	O
modulating	O
such	O
activity	O
.	O

[	O
Estrogen	B-protein
receptor	I-protein
content	O
of	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
]	O

ER	O
content	O
in	O
lymphocytes	B-cell_type
of	O
peripheral	O
blood	O
from	O
27	O
SLE	O
patients	O
and	O
20	O
healthy	O
controls	O
were	O
determined	O
by	O
dextran-coated	O
charcoal	O
assay	O
.	O

ER	B-protein
content	O
in	O
lymphocytes	B-cell_type
of	O
each	O
sample	O
was	O
expressed	O
by	O
both	O
fmol/mg	O
of	O
lymphocyte	B-protein
cytosolic	I-protein
protein	I-protein
and	O
fmol/micrograms	O
of	O
lymphocyte	B-DNA
DNA	I-DNA
.	O

The	O
results	O
showed	O
that	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
ER	B-protein
content	O
of	O
lymphocytes	B-cell_type
from	O
the	O
controls	O
and	O
that	O
from	O
patients	O
with	O
SLE	O
.	O

But	O
the	O
logarithmic	O
mean	O
of	O
ER	B-protein
content	O
in	O
lymphocytes	B-cell_type
,	O
expressed	O
by	O
fmol/mg	O
of	O
cytosolic	B-protein
protein	I-protein
,	O
in	O
14	O
patients	O
with	O
active	O
SLE	O
(	O
0.9356	O
+/-	O
0.31	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
13	O
patients	O
with	O
inactive	O
SLE	O
(	O
0.2979	O
+/-	O
0.23	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
0.6204	O
+/-	O
0.52	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O

The	O
normal	O
upper	O
limit	O
of	O
ER	B-protein
content	O
in	O
lymphocytes	B-cell_type
,	O
expressed	O
by	O
fmol/micrograms	O
of	O
DNA	O
,	O
was	O
0.136	O
.	O

The	O
elevated	O
rate	O
of	O
ER	B-protein
content	O
in	O
lymphocytes	B-cell_type
in	O
14	O
active	O
SLE	O
(	O
92.9	O
%	O
)	O
was	O
also	O
higher	O
than	O
that	O
in	O
quieiescent	O
patients	O
(	O
23.1	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
10	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O

Moreover	O
,	O
the	O
elevated	O
level	O
of	O
ER	B-protein
content	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
positive	O
antidsDNA	B-protein
antibody	I-protein
and	O
hypocomplementemia	O
.	O

An	O
in	O
vitro	O
globin	B-DNA
gene	I-DNA
switching	O
model	O
based	O
on	O
differentiated	B-cell_type
embryonic	I-cell_type
stem	I-cell_type
cells	I-cell_type
.	O

We	O
used	O
mouse	B-cell_type
embryonic	I-cell_type
stem	I-cell_type
(	I-cell_type
ES	I-cell_type
)	I-cell_type
cells	I-cell_type
to	O
study	O
globin	B-DNA
gene	I-DNA
expression	O
and	O
switching	O
in	O
vitro	O
.	O

We	O
show	O
that	O
ES-derived	B-cell_type
embryoid	I-cell_type
bodies	I-cell_type
express	O
the	O
full	O
complement	O
of	O
mouse	B-DNA
embryonic	I-DNA
globin	I-DNA
genes	I-DNA
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O
on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal/adult	B-DNA
genes	I-DNA
.	O

In	O
addition	O
,	O
the	O
erythroid-specific	B-protein
transcription	I-protein
factor	I-protein
NF-E1	B-protein
was	O
shown	O
to	O
be	O
expressed	O
coordinately	O
with	O
that	O
of	O
globin	B-protein
in	O
embryoid	B-cell_type
bodies	I-cell_type
.	O

We	O
conclude	O
from	O
these	O
experiments	O
that	O
the	O
ES	O
cell	O
system	O
provides	O
a	O
good	O
model	O
to	O
study	O
hematopoietic	O
development	O
.	O

When	O
the	O
human	B-DNA
epsilon-	I-DNA
or	I-DNA
beta-globin	I-DNA
genes	I-DNA
driven	O
by	O
the	O
dominant	B-DNA
control	I-DNA
region	I-DNA
(	O
DCR	B-DNA
)	O
are	O
introduced	O
into	O
this	O
system	O
,	O
the	O
human	B-DNA
epsilon-globin	I-DNA
gene	I-DNA
,	O
in	O
contrast	O
to	O
the	O
beta-globin	B-DNA
gene	I-DNA
,	O
is	O
not	O
deregulated	O
by	O
the	O
presence	O
of	O
the	O
DCR	B-DNA
and	O
is	O
expressed	O
strictly	O
as	O
an	O
embryonic	B-DNA
gene	I-DNA
.	O

We	O
conclude	O
from	O
this	O
that	O
the	O
epsilon-globin	B-DNA
gene	I-DNA
is	O
not	O
regulated	O
by	O
competition	O
with	O
other	O
genes	O
in	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	I-DNA
.	O

Cloning	O
of	O
a	O
mitogen-inducible	B-DNA
gene	I-DNA
encoding	O
a	O
kappa	B-protein
B	I-protein
DNA-binding	I-protein
protein	I-protein
with	O
homology	O
to	O
the	O
rel	B-DNA
oncogene	I-DNA
and	O
to	O
cell-cycle	B-DNA
motifs	I-DNA
.	O

We	O
have	O
cloned	O
and	O
characterized	O
a	O
mitogen-inducible	B-DNA
gene	I-DNA
isolated	O
from	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
that	O
predicts	O
a	O
protein	O
of	O
968	B-protein
amino	I-protein
acids	I-protein
.	O

The	O
amino-terminal	B-protein
domain	I-protein
has	O
regions	O
homologous	O
to	O
the	O
oncogene	B-DNA
rel	I-DNA
and	O
to	O
the	O
developmentally	O
important	O
gene	O
dorsal	B-DNA
of	O
Drosophila	O
.	O

The	O
carboxy-terminal	B-protein
domain	I-protein
contains	O
repeat	O
structures	O
found	O
in	O
a	O
variety	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cell-cycle	O
control	O
of	O
yeast	O
and	O
in	O
tissue	O
differentiation	O
in	O
Drosophila	O
and	O
Ceanorhabditis	O
elegans	O
,	O
as	O
well	O
as	O
in	O
the	O
putative	B-DNA
human	I-DNA
oncogene	I-DNA
bcl-3	I-DNA
and	O
in	O
the	O
ankyrin	B-protein
protein	I-protein
.	O

A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA-binding	B-protein
protein	I-protein
which	O
interacts	O
specifically	O
with	O
the	O
kappa	B-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
found	O
in	O
many	O
inducible	B-DNA
genes	I-DNA
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O

This	O
gene	O
is	O
yet	O
another	O
in	O
a	O
growing	O
list	O
of	O
important	O
regulatory	O
molecules	O
whose	O
expression	O
is	O
transcriptionally	O
induced	O
upon	O
cellular	O
activation	O
.	O

Extrarenal	O
receptor-effector-mechanisms	O
for	O
aldosterone	O
:	O
the	O
sequence	O
of	O
effects	O
on	O
the	O
cellular	O
electrolyte	O
transport	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
and	O
their	O
implications	O
for	O
disorders	O
of	O
the	O
water	O
and	O
electrolyte	O
balances	O
.	O

High	O
affinity	O
aldosterone	O
binding	O
sites	O
have	O
not	O
only	O
been	O
described	O
in	O
the	O
classic	O
target	O
tissues	O
such	O
as	O
the	O
renal	O
tubules	O
,	O
but	O
also	O
in	O
non-classic	O
target	O
tissues	O
such	O
as	O
the	O
hippocampus	O
,	O
mammary	O
gland	O
,	O
endothelial	B-cell_type
cells	I-cell_type
and	O
,	O
recently	O
,	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O

An	O
in	O
vitro	O
effect	O
of	O
aldosterone	O
on	O
intracellular	O
sodium	O
,	O
potassium	O
and	O
calcium	O
concentrations	O
and	O
cell	O
volume	O
was	O
shown	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O

In	O
the	O
absence	O
of	O
aldosterone	O
,	O
the	O
intracellular	O
Na+	O
,	O
K+	O
and	O
Ca2+	O
concentrations	O
and	O
the	O
cell	O
volume	O
decreased	O
significantly	O
,	O
but	O
remained	O
constant	O
when	O
aldosterone	O
(	O
1.4	O
nmol/l	O
)	O
was	O
added	O
to	O
the	O
incubation	O
medium	O
.	O

These	O
effects	O
of	O
aldosterone	O
were	O
blocked	O
by	O
the	O
aldosterone	O
antagonist	O
canrenone	O
(	O
140	O
nmol/l	O
)	O
.	O

The	O
sodium/proton	B-protein
exchanger	I-protein
of	O
the	O
cell	O
membrane	O
could	O
be	O
identified	O
as	O
the	O
primary	O
target	O
of	O
the	O
aldosterone	O
action	O
,	O
possibly	O
non-genomically	O
mediated	O
through	O
membrane	B-protein
receptors	I-protein
.	O

The	O
clinical	O
significance	O
of	O
this	O
model	O
was	O
underlined	O
by	O
the	O
demonstration	O
of	O
absent	O
or	O
a	O
decreased	O
number	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
and	O
the	O
lack	O
of	O
electrolyte	O
response	O
to	O
aldosterone	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
patients	O
with	O
pseudohypoaldosteronism	O
and	O
aldosteronism	O
.	O

Additionally	O
,	O
an	O
abnormal	O
effector	O
mechanism	O
could	O
be	O
demonstrated	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
from	O
essential	O
hypertensives	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
significance	O
of	O
extrarenal	B-protein
,	I-protein
nonepithelial	I-protein
mineralocorticoid	I-protein
receptors	I-protein
and	O
the	O
related	O
effector	O
mechanism	O
in	O
different	O
disorders	O
of	O
the	O
water	O
and	O
electrolyte	O
balance	O
in	O
man	O
.	O

Immunohistochemical	O
study	O
of	O
steroid	O
hormones	O
and	O
an	O
estrogen	O
binding	O
assay	O
in	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	I-cell_type
.	O

Immunohistochemically	O
,	O
the	O
immunoreaction	O
against	O
5	O
steroid	O
hormone	O
anti-sera	O
(	O
estradiol	O
,	O
estriol	O
,	O
cortisol	O
,	O
progesterone	O
and	O
testosterone	O
)	O
was	O
examined	O
in	O
39	O
cases	O
with	O
the	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	I-cell_type
(	O
fibrosarcoma	O
:	O
8	O
,	O
malignant	O
fibrous	O
histiocytoma	O
:	O
6	O
,	O
rhabdomyosarcoma	O
:	O
10	O
,	O
leiomyosarcoma	O
:	O
10	O
,	O
liposarcoma	O
:	O
5	O
)	O
.	O

Seventeen	O
cases	O
revealed	O
distinct	O
immunostaining	O
against	O
at	O
least	O
1	O
of	O
the	O
5	O
steroid	O
hormones	O
.	O

Immunostained	B-cell_type
tumor	I-cell_type
cells	I-cell_type
were	O
more	O
frequently	O
distributed	O
in	O
the	O
area	O
where	O
tumor	O
cell	O
infiltration	O
was	O
more	O
invasive	O
.	O

The	O
majority	O
of	O
the	O
positive	O
cases	O
occurred	O
in	O
female	O
cases	O
.	O

Furthermore	O
,	O
the	O
existence	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
estrogen	O
binding	O
activity	O
)	O
was	O
examined	O
histochemically	O
in	O
39	O
cases	O
and	O
it	O
was	O
detected	O
in	O
8	O
.	O

We	O
concluded	O
that	O
steroid	O
hormones	O
might	O
be	O
closely	O
related	O
to	O
tumor	O
cell	O
infiltration	O
of	O
some	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	I-cell_type
.	O

Involvement	O
of	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinases	I-protein
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
interleukin-1	B-protein
.	O

Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinases	I-protein
in	O
interleukin-1	B-cell_line
(	I-cell_line
IL-1	I-cell_line
)	I-cell_line
-responsive	I-cell_line
cells	I-cell_line
blocked	O
IL-1-induced	B-DNA
gene	I-DNA
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	B-DNA
immunoglobulin	I-DNA
enhancer	I-DNA
or	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

This	O
inhibitor	O
did	O
not	O
affect	O
protein	B-protein
kinase	I-protein
C	I-protein
-mediated	O
gene	O
transcription	O
,	O
suggesting	O
that	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinases	I-protein
are	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
IL-1	B-protein
in	O
a	O
number	O
of	O
responsive	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

The	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
ORI1yt	I-DNA
enhancer	I-DNA
is	O
not	O
B-cell	O
specific	O
and	O
does	O
not	O
respond	O
synergistically	O
to	O
the	O
EBV	B-protein
transcription	I-protein
factors	I-protein
R	I-protein
and	I-protein
Z	I-protein
.	O

The	O
Epstein-Barr	B-DNA
virus	I-DNA
DR	I-DNA
promoter	I-DNA
is	O
located	O
upstream	O
of	O
the	O
PstI	B-DNA
repeats	I-DNA
,	O
and	O
in	O
addition	O
to	O
the	O
TATA	B-DNA
box	I-DNA
,	O
it	O
contains	O
an	O
upstream	B-DNA
region	I-DNA
(	O
positions	O
-69	O
to	O
-220	O
)	O
responsive	O
to	O
EB1	B-protein
(	I-protein
Z	I-protein
)	I-protein
(	O
the	O
BZLF1-encoded	B-protein
transcription	I-protein
factor	I-protein
)	O
and	O
an	O
enhancer	B-DNA
with	O
two	O
functionally	O
distinct	O
domains	O
,	O
A	O
and	O
B	B-DNA
.	O

Domain	B-DNA
B	I-DNA
has	O
been	O
described	O
as	O
a	O
B-cell-specific	B-DNA
EB1-responsive	I-DNA
element	I-DNA
(	O
P.M.Lieberman	O
,	O
J.M.Hardwick	O
,	O
and	O
S.D.Hayward	O
,	O
J.Virol.63	O
:	O
3040-3050	O
,	O
1989	O
)	O
activated	O
synergistically	O
by	O
EB1	B-protein
and	O
R	B-protein
,	O
an	O
EBV	B-protein
early	I-protein
product	I-protein
encoded	O
by	O
the	O
open	B-DNA
reading	I-DNA
frame	I-DNA
BRLF1	I-DNA
(	O
M.A.	O
Cox	O
,	O
J.Leahy	O
,	O
and	O
J.M.Hardwick	O
,	O
J.Virol.64	O
:	O
313-321	O
,	O
1990	O
)	O
.	O

We	O
show	O
here	O
that	O
domain	B-DNA
B	I-DNA
is	O
an	O
R-responsive	B-DNA
element	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
and	O
is	O
therefore	O
not	O
an	O
EB1-responsive	B-DNA
B-cell-specific	I-DNA
element	I-DNA
.	O

However	O
,	O
there	O
is	O
an	O
EB1-binding	B-DNA
site	I-DNA
(	O
ZRE-B	B-DNA
)	O
located	O
within	O
the	O
R-responsive	B-DNA
enhancer	I-DNA
region	I-DNA
.	O

ZRE-B	B-DNA
can	O
be	O
deleted	O
without	O
affecting	O
the	O
R-dependent	O
enhancer	O
activity	O
.	O

Moreover	O
,	O
there	O
is	O
no	O
cooperation	O
or	O
synergy	O
between	O
R	B-protein
and	O
EB1	B-protein
when	O
activating	O
the	O
B	B-DNA
domain	I-DNA
(	O
ZRE-B	B-DNA
plus	O
the	O
R-responsive	B-DNA
element	I-DNA
)	O
positioned	O
as	O
an	O
enhancer	B-DNA
.	O

ZRE-B	B-DNA
is	O
therefore	O
not	O
part	O
of	O
the	O
R-	B-DNA
inducible	I-DNA
enhancer	I-DNA
.	O

We	O
have	O
tested	O
several	O
subregions	O
of	O
the	O
DR	B-DNA
enhancer	I-DNA
B	B-DNA
domain	I-DNA
,	O
either	O
alone	O
or	O
in	O
combination	O
,	O
for	O
their	O
capacity	O
to	O
transmit	O
the	O
R-activating	O
signal	O
to	O
the	O
rabbit	B-DNA
beta-globin	I-DNA
promoter	I-DNA
.	O

We	O
found	O
that	O
the	O
R-responsive	B-DNA
element	I-DNA
is	O
composed	O
of	O
four	O
protoenhancers	B-DNA
that	O
span	O
the	O
whole	O
B	B-DNA
domain	I-DNA
.	O

These	O
protoenhancers	B-DNA
alone	O
are	O
weakly	O
or	O
not	O
responsive	O
to	O
R	B-protein
.	O

One	O
of	O
the	O
protoenhancers	B-DNA
contains	O
the	O
overlapping	B-DNA
palindromes	I-DNA
5'-TTGTCCcgtGGACAAaTGTCC-3'	O
.	O

However	O
,	O
one	O
palindrome	B-DNA
,	O
either	O
alone	O
or	O
duplicated	O
,	O
or	O
the	O
overlapping	B-DNA
palindromes	I-DNA
did	O
not	O
respond	O
to	O
R	O
.	O

Nuclear	O
3	B-protein
,	I-protein
5	I-protein
,	I-protein
3'-triiodothyronine	I-protein
receptors	I-protein
(	O
T3R	B-protein
)	O
of	O
circulating	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
in	O
hyper-	O
and	O
hypothyroidism	O
and	O
nonthyroidal	O
diseases	O
.	O

The	O
clinical	O
implications	O
of	O
nuclear	O
T3R	B-protein
alterations	O
of	O
circulating	B-cell_type
lymphocytes	I-cell_type
in	O
hyperthyroidism	O
,	O
hypothyroidism	O
and	O
nonthyroidal	O
diseases	O
were	O
investigated	O
.	O

Nuclear	O
T3R	B-protein
in	O
lymphocytes	B-cell_type
was	O
determined	O
by	O
radio-ligand	O
binding	O
analysis	O
.	O

The	O
results	O
showed	O
that	O
in	O
hyper-	O
and	O
hypothyroid	O
patients	O
the	O
nuclear	O
affinity	O
(	O
Ka	O
)	O
for	O
T3	O
was	O
similar	O
to	O
that	O
of	O
normal	O
subjects	O
.	O

In	O
hyperthyroidism	O
nuclear	O
T3	O
maximal	O
binding	O
capacity	O
(	O
MBC	O
)	O
was	O
unaltered	O
,	O
whereas	O
in	O
hypothyroidism	O
the	O
MBC	O
was	O
significantly	O
increased	O
.	O

In	O
the	O
patients	O
with	O
diabetes	O
mellitus	O
,	O
chronic	O
renal	O
failure	O
and	O
hepatic	O
cirrhosis	O
,	O
the	O
nuclear	B-protein
T3R	I-protein
MBC	O
of	O
lymphocytes	B-cell_type
was	O
about	O
1.5-1.6	O
times	O
of	O
the	O
normal	O
controls	O
.	O

It	O
was	O
concluded	O
that	O
there	O
existed	O
hormonal	O
regulation	O
of	O
nuclear	B-protein
T3R	I-protein
,	O
and	O
up-regulation	O
was	O
seen	O
in	O
hypothyroidism	O
and	O
low	O
T3	O
syndrome	O
.	O

Lymphocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
vitamin	O
D-dependent	O
rickets	O
type	O
II	O
show	O
functional	O
defects	O
in	O
the	O
1	B-protein
alpha	I-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
receptor	I-protein
.	O

Lymphocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
established	O
from	O
five	O
patients	O
with	O
vitamin	O
D-dependent	O
rickets	O
,	O
type	O
II	O
(	O
VDDR-II	O
)	O
.	O

These	O
lines	O
were	O
established	O
by	O
infection	O
with	O
human	O
T-lymphotrophic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
.	O

Binding	O
of	O
[	O
3H	O
]	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
its	O
receptor	O
in	O
these	O
cell	O
lines	O
was	O
compared	O
to	O
binding	O
studies	O
using	O
a	O
T-lymphocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
S-LB1	B-cell_line
)	O
from	O
a	O
normal	O
individual	O
.	O

The	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
of	O
S-LB1	B-cell_line
was	O
comparable	O
to	O
the	O
well-characterized	O
chick	B-protein
intestinal	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
in	O
terms	O
of	O
its	O
ligand	O
binding	O
affinity	O
and	O
capacity	O
,	O
its	O
mobility	O
on	O
5-20	O
%	O
sucrose	O
gradients	O
,	O
and	O
its	O
adsorption	O
to	O
and	O
elution	O
properties	O
from	O
DNA-cellulose	O
.	O

Three	O
cell	B-cell_line
lines	I-cell_line
established	O
from	O
patients	O
with	O
VDDR-II	O
(	O
Rh-	O
VDR	B-protein
,	O
Sh-	O
VDR	B-protein
,	O
and	O
Ab-	O
VDR	B-protein
)	O
showed	O
no	O
specific	O
binding	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
a	O
receptor	B-protein
and	O
treatment	O
of	O
the	O
cultured	B-cell_line
cells	I-cell_line
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
did	O
not	O
stimulate	O
production	O
of	O
24	O
,	O
25-dihydroxy-vitamin	O
D3	O
(	O
24	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
,	O
a	O
response	O
which	O
is	O
diagnostic	O
of	O
the	O
presence	O
of	O
a	O
functional	B-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
.	O

In	O
a	O
fourth	O
cell	B-cell_line
line	I-cell_line
,	O
A1-VDR	B-cell_line
,	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
had	O
a	O
low	O
binding	O
capacity	O
and	O
25	B-protein
(	I-protein
OH	I-protein
)	I-protein
D3-24-hydroxylase	I-protein
activity	O
was	O
not	O
detectable	O
.	O

Induction	O
of	O
24	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
synthesis	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
observed	O
in	O
the	O
fifth	O
cell	B-cell_line
line	I-cell_line
,	O
designated	O
Ro-VDR	B-cell_line
,	O
although	O
the	O
sensitivity	O
to	O
hormone	O
treatment	O
was	O
lower	O
than	O
in	O
the	O
control	B-cell_line
cell	I-cell_line
line	I-cell_line
from	O
a	O
normal	O
donor	O
.	O

The	O
capacity	O
of	O
the	O
receptor	B-protein
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
low	O
in	O
Ro-VDR	B-cell_line
.	O

In	O
all	O
cell	B-cell_line
lines	I-cell_line
where	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
binding	O
to	O
a	O
receptor	B-protein
was	O
detectable	O
,	O
the	O
receptor	B-protein
had	O
the	O
typical	O
sedimentation	O
coefficient	O
of	O
3.7	O
S	O
on	O
sucrose	O
density	O
gradient	O
analysis	O
.	O

Binding	O
and	O
elution	O
properties	O
to	O
DNA-cellulose	O
,	O
however	O
,	O
differed	O
from	O
normal	O
in	O
both	O
Ro-VDR	B-cell_line
and	O
A1-VDR	B-cell_line
cells	I-cell_line
where	O
elution	O
from	O
DNA-cellulose	O
occurred	O
at	O
a	O
lower	O
salt	O
concentration	O
than	O
is	O
typical	O
of	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
.	O

While	O
Ro-VDR	B-cell_line
cells	I-cell_line
showed	O
typical	O
nuclear	O
localization	O
of	O
the	O
unoccupied	B-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
,	O
neither	O
the	O
unoccupied	O
nor	O
the	O
occupied	O
receptor	B-protein
from	O
A1-VDR	B-cell_line
cells	I-cell_line
was	O
completely	O
localized	O
in	O
the	O
nucleus	O
.	O

In	O
a	O
series	O
of	O
functional	O
studies	O
we	O
found	O
that	O
modulation	O
of	O
the	O
level	O
of	O
the	O
mRNAs	B-RNA
coding	O
for	O
both	O
the	O
c-myc	B-DNA
oncogene	I-DNA
and	O
the	O
growth	O
factor	O
known	O
as	O
granulocyte-monocyte	O
colony	O
stimulating	O
activity	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
correlated	O
with	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
status	O
of	O
these	O
cells	O
.	O

Use	O
of	O
these	O
cell	B-cell_line
lines	I-cell_line
will	O
facilitate	O
further	O
study	O
of	O
the	O
molecular	O
defect	O
(	O
s	O
)	O
in	O
the	O
receptor	B-protein
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
vitamin	O
D-dependent	O
rickets	O
type	O
II	O
and	O
will	O
allow	O
a	O
correlation	O
with	O
impairment	O
of	O
cellular	O
functions	O
.	O

Transcriptional	O
and	O
post-transcriptional	O
regulation	O
of	O
c-jun	B-DNA
expression	O
during	O
monocytic	O
differentiation	O
of	O
human	B-cell_line
myeloid	I-cell_line
leukemic	I-cell_line
cells	I-cell_line
.	O

AP-1	B-protein
,	O
the	O
polypeptide	O
product	O
of	O
c-jun	B-DNA
,	O
recognizes	O
and	O
binds	O
to	O
specific	O
DNA	O
sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	B-DNA
responsive	O
to	O
certain	O
growth	O
factors	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c-jun	B-DNA
gene	O
expression	O
in	O
HL-60	B-cell_line
cells	I-cell_line
during	O
monocytic	O
differentiation	O
.	O

Low	O
levels	O
of	O
c-jun	B-RNA
transcripts	I-RNA
were	O
detectable	O
in	O
untreated	B-cell_line
HL-60	I-cell_line
leukemic	I-cell_line
cells	I-cell_line
,	O
increased	O
significantly	O
by	O
6	O
h	O
,	O
and	O
reached	O
near	O
maximal	O
levels	O
by	O
24	O
h	O
of	O
exposure	O
to	O
32	O
nM	O
TPA	O
.	O

Similar	O
kinetics	O
of	O
c-jun	B-DNA
induction	O
by	O
TPA	O
were	O
observed	O
in	O
human	B-cell_line
U-937	I-cell_line
and	O
THP-1	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	O
1	O
(	O
10	O
nM	O
)	O
,	O
another	O
activator	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

Furthermore	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
0.5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL-60	O
monocytic	O
differentiation	O
,	O
increased	O
c-jun	B-DNA
expression	O
.	O

TPA	O
treatment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
in	O
the	O
presence	O
of	O
cycloheximide	O
was	O
associated	O
with	O
superinduction	O
of	O
c-jun	B-DNA
transcripts	O
.	O

Run-on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c-jun	B-DNA
gene	O
transcription	O
in	O
untreated	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
,	O
and	O
that	O
exposure	O
to	O
TPA	O
increases	O
this	O
rate	O
3.3-fold	O
.	O

Treatment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
with	O
both	O
TPA	O
and	O
cycloheximide	O
had	O
no	O
effect	O
on	O
the	O
rates	O
of	O
c-jun	B-DNA
transcription	O
.	O

The	O
half-life	O
of	O
c-jun	B-RNA
RNA	I-RNA
as	O
determined	O
by	O
treating	O
HL-60	B-cell_line
cells	I-cell_line
with	O
TPA	O
and	O
actinomycin	O
D	O
was	O
30	O
min	O
.	O

In	O
contrast	O
,	O
the	O
half-life	O
of	O
c-jun	B-RNA
RNA	I-RNA
in	O
TPA-treated	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
exposed	O
to	O
cycloheximide	O
and	O
actinomycin	O
D	O
was	O
greater	O
than	O
2	O
h	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
increase	O
in	O
c-jun	B-RNA
RNA	I-RNA
observed	O
during	O
TPA-induced	O
monocytic	O
differentiation	O
is	O
mediated	O
by	O
both	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
.	O

[	O
Hormonal	O
interactions	O
and	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
the	O
nephrotic	O
syndrome	O
]	O

As	O
many	O
as	O
27	O
children	O
aged	O
6	O
to	O
15	O
years	O
with	O
morphologically	O
verified	O
nephropathies	O
were	O
examined	O
.	O

Four	O
variants	O
of	O
changes	O
in	O
the	O
thyroid	O
status	O
,	O
characteristic	O
of	O
children	O
with	O
different	O
variants	O
of	O
nephrotic	O
syndrome	O
were	O
distinguished	O
:	O
1	O
)	O
biochemical	O
signs	O
of	O
primary	O
hypothyroidism	O
,	O
2	O
)	O
biochemical	O
signs	O
of	O
secondary	O
hypothyroidism	O
,	O
3	O
)	O
low	O
content	O
of	O
T3	O
,	O
4	O
)	O
dysfunction	O
of	O
the	O
hypophyseal	O
and	O
thyroid	O
system	O
.	O

It	O
is	O
shown	O
that	O
the	O
low	O
level	O
of	O
steroid	B-protein
receptors	I-protein
,	O
thyroid	O
hormones	O
that	O
the	O
low	O
level	O
of	O
steroid	B-protein
receptors	I-protein
,	O
thyroid	O
hormones	O
(	O
T3	O
and	O
T4	O
)	O
and	O
cortisol	O
is	O
typical	O
of	O
children	O
with	O
the	O
signs	O
of	O
renal	O
dysplasia	O
.	O

It	O
is	O
assumed	O
that	O
superaddition	O
under	O
such	O
conditions	O
of	O
immune	O
glomerulopathy	O
(	O
glomerulonephritis	O
and	O
nephrotic	O
syndrome	O
)	O
gives	O
rise	O
to	O
the	O
resistance	O
to	O
the	O
treatment	O
with	O
glucocorticoids	O
.	O

Lymphoid	O
specific	O
gene	O
expression	O
of	O
the	O
adenovirus	B-DNA
early	I-DNA
region	I-DNA
3	I-DNA
promoter	I-DNA
is	O
mediated	O
by	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
motifs	I-DNA
.	O

A	O
primary	O
site	O
of	O
infection	O
by	O
human	O
adenoviruses	O
is	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
analysis	O
of	O
the	O
viral	B-DNA
control	I-DNA
elements	I-DNA
and	O
the	O
cellular	B-protein
factors	I-protein
that	O
regulate	O
adenoviral	O
gene	O
expression	O
in	O
lymphocytes	B-cell_type
has	O
not	O
been	O
reported	O
.	O

The	O
adenovirus	B-protein
early	I-protein
region	I-protein
3	I-protein
(	I-protein
ES	I-protein
)	I-protein
gene	I-protein
products	I-protein
are	O
involved	O
in	O
the	O
maintenance	O
of	O
viral	O
persistence	O
by	O
complexing	O
with	O
the	O
class	B-protein
I	I-protein
MHC	I-protein
antigens	I-protein
,	O
thus	O
preventing	O
their	O
cell	O
surface	O
expression	O
with	O
a	O
resultant	O
decrease	O
in	O
host	O
immunologic	O
destruction	O
.	O

To	O
determine	O
whether	O
different	O
cellular	B-protein
factors	I-protein
were	O
involved	O
in	O
E3	O
regulation	O
in	O
lymphocytes	B-cell_type
as	O
compared	O
with	O
HeLa	B-cell_line
cells	I-cell_line
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	B-DNA
promoter	I-DNA
in	O
both	O
cell	O
types	O
were	O
performed	O
.	O

These	O
studies	O
detected	O
two	O
novel	B-DNA
domains	I-DNA
referred	O
to	O
as	O
L1	B-DNA
and	O
L2	B-DNA
with	O
a	O
variety	O
of	O
lymphoid	O
but	O
not	O
HeLa	O
extracts	O
.	O

Each	O
of	O
these	O
domains	O
possessed	O
strong	O
homology	O
to	O
motifs	O
previously	O
found	O
to	O
bind	O
the	O
cellular	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O

Transfections	O
of	O
E3	B-DNA
constructs	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	I-DNA
revealed	O
that	O
mutagenesis	O
of	O
the	O
distal	B-DNA
NF-kappa	I-DNA
B	I-DNA
motif	I-DNA
(	O
L2	B-DNA
)	O
had	O
minimal	O
effects	O
on	O
promoter	O
expression	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
but	O
resulted	O
in	O
dramatic	O
decreases	O
in	O
expression	O
by	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
mutagenesis	O
of	O
proximal	B-DNA
NF-kappa	I-DNA
B	I-DNA
motif	I-DNA
(	O
L1	B-DNA
)	O
had	O
minimal	O
effects	O
on	O
gene	O
expression	O
in	O
both	O
HeLa	B-cell_line
cells	I-cell_line
and	O
lymphoid	B-cell_type
cells	I-cell_type
but	O
resulted	O
in	O
a	O
small	O
,	O
but	O
reproducible	O
,	O
increase	O
in	O
gene	O
expression	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
when	O
coupled	O
to	O
the	O
L2	B-DNA
mutation	O
.	O

Reversing	O
the	O
position	O
and	O
subsequent	O
mutagenesis	O
of	O
the	O
L1	B-DNA
and	O
L2	B-DNA
domains	I-DNA
indicated	O
that	O
the	O
primary	B-DNA
sequence	I-DNA
of	O
these	O
motifs	O
rather	O
than	O
their	O
position	O
in	O
the	O
E3	B-DNA
promoter	I-DNA
was	O
critical	O
for	O
regulating	O
gene	O
expression	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Characterization	O
of	O
defensin	B-protein
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	B-DNA
virulence	I-DNA
regulon	I-DNA
of	O
Salmonella	O
typhimurium	O
.	O

The	O
defensin	B-protein
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP/phoQ	B-DNA
two-component	I-DNA
virulence	I-DNA
regulon	I-DNA
were	O
tested	O
by	O
using	O
purified	B-protein
defensins	I-protein
NP-1	B-protein
and	O
NP-2	B-protein
.	O

Strains	O
with	O
mutations	O
in	O
either	O
gene	O
of	O
the	O
regulatory	B-DNA
pair	I-DNA
(	O
phoP	B-DNA
[	O
transcriptional	B-DNA
activator	I-DNA
]	O
or	O
phoQ	B-DNA
[	O
membrane	B-protein
sensor	I-protein
kinase	I-protein
]	O
)	O
had	O
increased	O
sensitivities	O
to	O
defensin	B-protein
.	O

The	O
predicted	O
periplasmic	B-protein
domain	I-protein
of	O
the	O
PhoQ	B-protein
protein	I-protein
contained	O
a	O
markedly	O
anionic	O
domain	O
that	O
could	O
interact	O
with	O
cationic	B-protein
proteins	I-protein
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	B-protein
.	O

Because	O
insertion	O
mutations	O
in	O
phoP	B-DNA
are	O
polar	O
on	O
phoQ	B-DNA
,	O
we	O
constructed	O
strains	O
that	O
expressed	O
the	O
PhoQ	B-protein
protein	I-protein
in	O
the	O
absence	O
of	O
PhoP	B-protein
to	O
test	O
whether	O
resistance	O
to	O
defensin	O
requires	O
only	O
the	O
phoQ	B-protein
gene	I-protein
product	I-protein
.	O

We	O
found	O
that	O
resistance	O
to	O
defensin	O
requires	O
the	O
function	O
of	O
both	O
components	O
of	O
this	O
regulatory	O
system	O
,	O
because	O
strains	O
expressing	O
PhoQ	B-protein
without	O
PhoP	B-protein
were	O
still	O
markedly	O
sensitive	O
to	O
defensins	B-protein
.	O

This	O
implied	O
that	O
a	O
pag	B-protein
(	I-protein
phoP-activated	I-protein
gene	I-protein
)	I-protein
product	I-protein
is	O
responsible	O
for	O
defensin	B-protein
resistance	O
.	O

We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	B-protein
NP-1	B-protein
,	O
NP-5	B-protein
,	O
and	O
HNP-1	B-protein
to	O
activate	O
pag	B-DNA
expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	O
effect	O
.	O

Defensin	O
resistance	O
is	O
not	O
the	O
only	O
virulence	O
characteristic	O
controlled	O
by	O
the	O
PhoP-PhoQ	B-protein
regulon	I-protein
because	O
mutations	O
in	O
pagC	B-DNA
,	O
as	O
well	O
as	O
ones	O
in	O
the	O
phoP	B-DNA
locus	I-DNA
that	O
resulted	O
in	O
constitutive	O
pag	B-DNA
activation	O
(	O
phenotype	O
PhoPc	B-protein
)	O
,	O
had	O
no	O
effect	O
on	O
defensin	B-protein
resistance	O
,	O
even	O
though	O
they	O
rendered	O
the	O
organism	O
avirulent	O
and	O
deficient	O
in	O
survival	O
within	O
macrophages	B-cell_type
.	O

The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	B-DNA
-phoQ	B-DNA
two-component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	B-protein
proteins	I-protein
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S.	O
typhimurium	O
survival	O
within	O
macrophages	B-cell_type
.	O

Stimulation	O
of	O
a	O
human	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
with	O
anti-CD3	B-protein
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
induces	O
NF-kappa	B-protein
B	I-protein
translocation	O
but	O
not	O
human	O
immunodeficiency	O
virus	O
1	O
enhancer-dependent	O
transcription	O
.	O

The	O
expression	O
of	O
transiently	O
transfected	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
or	O
its	O
enhancer	B-DNA
sequence	I-DNA
and	O
the	O
translocation	O
of	O
the	O
HIV	B-protein
enhancer-binding	I-protein
protein	I-protein
NF-kappa	B-protein
B	I-protein
were	O
analyzed	O
in	O
two	O
human	O
T-cell	B-cell_line
clones	I-cell_line
stimulated	O
through	O
their	O
T-cell	B-protein
receptor	I-protein
complex	I-protein
or	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

We	O
found	O
a	O
dissociation	O
of	O
NF-kappa	B-protein
B	I-protein
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	B-DNA
LTR	I-DNA
or	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O

Interleukin	B-protein
2	I-protein
induced	O
proliferation	O
but	O
not	O
NF-kappa	B-protein
B	I-protein
translocation	O
or	O
LTR	B-DNA
transactivation	O
.	O

Phorbol	O
ester	O
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	B-DNA
LTR	I-DNA
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
antibody	O
to	O
CD3	B-protein
did	O
not	O
.	O

The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF-kappa	B-protein
B	I-protein
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band-shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O

Our	O
finding	O
that	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
antibody	B-protein
to	I-protein
CD3	I-protein
is	O
not	O
sufficient	O
to	O
induce	O
HIV	B-DNA
enhancer	I-DNA
-dependent	O
transcription	O
in	O
cloned	B-cell_line
T	I-cell_line
cells	I-cell_line
contrasts	O
with	O
results	O
obtained	O
in	O
most	O
lymphoblastoid	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
indicates	O
that	O
normal	O
T	B-cell_type
lymphocytes	I-cell_type
differ	O
from	O
tumoral	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
terms	O
of	O
requirements	O
for	O
HIV	B-DNA
LTR	I-DNA
activation	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T-cell	O
activation	O
,	O
in	O
addition	O
to	O
NF-kappa	B-protein
B	I-protein
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
with	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O

Decreased	O
concentration	O
of	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
patients	O
with	O
X-linked	O
hypophosphatemic	O
rickets	O
:	O
effect	O
of	O
phosphate	O
supplementation	O
.	O

Abnormal	O
renal	O
tubular	O
phosphate	O
transport	O
is	O
considered	O
to	O
be	O
the	O
primary	O
defect	O
in	O
X-linked	O
hypophosphatemic	O
rickets	O
(	O
XLH	O
)	O
.	O

However	O
,	O
the	O
resistance	O
to	O
vitamin	O
D	O
treatment	O
in	O
XLH	O
can	O
not	O
be	O
explained	O
by	O
hypophosphatemia	O
alone	O
.	O

Since	O
most	O
of	O
the	O
actions	O
of	O
vitamin	O
D	O
are	O
mediated	O
by	O
its	O
receptors	O
(	O
VDR	B-protein
)	O
,	O
abnormalities	O
of	O
VDR	B-protein
have	O
been	O
postulated	O
in	O
XLH	O
.	O

In	O
order	O
to	O
investigate	O
this	O
possibility	O
,	O
we	O
measured	O
the	O
concentration	O
of	O
VDR	B-protein
in	O
PHA-activated	B-cell_line
peripheral	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
from	O
10	O
XLH	O
patients	O
.	O

Patients	O
without	O
phosphate	O
supplementation	O
showed	O
significantly	O
lower	O
concentration	O
(	O
21.7	O
+/-	O
5.1	O
fmol/mg	O
protein	O
,	O
mean	O
+/-	O
SEM	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
60.7	O
+/-	O
4.0	O
)	O
.	O

On	O
the	O
contrary	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
phosphate-supplemented	O
patients	O
(	O
58.3	O
+/-	O
2.7	O
)	O
and	O
controls	O
.	O

There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
VDR	B-protein
concentration	O
and	O
serum	O
phosphate	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

In	O
two	O
patients	O
,	O
VDR	B-protein
was	O
increased	O
after	O
daily	O
phosphate	O
supplementation	O
was	O
started	O
.	O

These	O
results	O
indicate	O
that	O
a	O
decreased	O
concentration	O
of	O
VDR	B-protein
secondary	O
to	O
persistent	O
hypophosphatemia	O
is	O
one	O
of	O
the	O
causes	O
of	O
vitamin	O
D	O
resistance	O
in	O
XLH	O
.	O

Two	O
distinct	O
forms	O
of	O
active	B-protein
transcription	I-protein
factor	I-protein
CREB	I-protein
(	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
.	O

Mammalian	B-cell_type
cells	I-cell_type
express	O
two	O
distinct	O
forms	O
of	O
transcription	B-protein
factor	I-protein
CREB	I-protein
(	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
that	O
are	O
apparently	O
the	O
products	O
of	O
alternative	O
splicing	O
of	O
the	O
CREB	B-RNA
gene	I-RNA
transcript	I-RNA
.	O

The	O
two	O
proteins	O
differ	O
by	O
a	O
14-amino	B-protein
acid	I-protein
serine-rich	I-protein
insertion	I-protein
present	O
in	O
one	O
of	O
the	O
CREB	B-protein
isoforms	I-protein
.	O

We	O
show	O
that	O
both	O
CREB	B-protein
isoforms	I-protein
are	O
expressed	O
in	O
many	B-cell_type
cell	I-cell_type
types	I-cell_type
and	O
mammalian	O
species	O
.	O

Both	O
encode	O
proteins	O
that	O
bind	O
specifically	O
to	O
a	O
cAMP	B-DNA
response	I-DNA
element	I-DNA
in	I-DNA
vitro	I-DNA
.	O

As	O
expected	O
for	O
proteins	O
of	O
this	O
class	O
,	O
the	O
CREB	B-protein
proteins	I-protein
bind	O
DNA	O
as	O
dimers	O
.	O

Both	O
proteins	O
impart	O
cAMP-regulated	O
transcriptional	O
activity	O
to	O
a	O
heterologous	B-DNA
DNA-binding	I-DNA
domain	I-DNA
,	O
showing	O
that	O
cAMP	O
directly	O
modulates	O
the	O
transcriptional	O
stimulatory	O
activity	O
of	O
CREB	B-protein
.	O

The	O
presence	O
of	O
multiple	O
CREB	B-protein
isoforms	I-protein
with	O
identical	O
DNA-binding	O
specificities	O
but	O
differences	O
in	O
the	O
presumed	O
regulatory	B-protein
domain	I-protein
raises	O
the	O
possibility	O
that	O
CREB	B-protein
proteins	I-protein
may	O
be	O
able	O
to	O
integrate	O
distinct	O
regulatory	O
signals	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Human	O
immunodeficiency	O
virus	O
vpr	O
product	O
is	O
a	O
virion-associated	B-protein
regulatory	I-protein
protein	I-protein
.	O

The	O
vpr	B-protein
product	I-protein
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
acts	O
in	O
trans	O
to	O
accelerate	O
virus	O
replication	O
and	O
cytopathic	O
effect	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	O
viral	O
particle	O
contains	O
multiple	O
copies	O
of	O
the	O
vpr	B-protein
protein	I-protein
.	O

The	O
vpr	B-protein
product	I-protein
is	O
the	O
first	O
regulatory	O
protein	O
of	O
HIV-1	O
to	O
be	O
found	O
in	O
the	O
virus	O
particle	O
.	O

This	O
observation	O
raises	O
the	O
possibility	O
that	O
vpr	B-DNA
acts	O
to	O
facilitate	O
the	O
early	O
steps	O
of	O
infection	O
before	O
de	O
novo	O
viral	O
protein	O
synthesis	O
occurs	O
.	O

A	O
novel	O
B-cell	B-protein
lineage-specific	I-protein
transcription	I-protein
factor	I-protein
present	O
at	O
early	O
but	O
not	O
late	O
stages	O
of	O
differentiation	O
.	O

A	O
novel	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
BSAP	B-protein
,	O
was	O
identified	O
as	O
a	O
mammalian	B-protein
homolog	I-protein
of	O
the	O
sea	B-protein
urchin	I-protein
protein	I-protein
TSAP	B-protein
,	O
which	O
interacts	O
with	O
the	O
promoters	B-DNA
of	O
four	O
tissue-specific	B-DNA
late	I-DNA
histone	I-DNA
H2A-2	I-DNA
and	I-DNA
H2B-2	I-DNA
genes	I-DNA
.	O

As	O
shown	O
by	O
mobility-shift	O
,	O
methylation	O
interference	O
,	O
and	O
mutational	O
analyses	O
,	O
the	O
mammalian	B-protein
protein	I-protein
BSAP	B-protein
recognizes	O
all	O
four	O
sea	B-DNA
urchin	I-DNA
binding	I-DNA
sites	I-DNA
in	O
a	O
manner	O
indistinguishable	O
from	O
TSAP	B-protein
;	O
however	O
,	O
the	O
two	O
proteins	O
differ	O
in	O
molecular	O
weight	O
.	O

BSAP	B-protein
is	O
exclusively	O
restricted	O
to	O
the	O
B-cell	O
lineage	O
of	O
lymphoid	O
differentiation	O
.	O

Its	O
expression	O
appears	O
to	O
be	O
activated	O
during	O
pro-B-cell	O
development	O
,	O
is	O
abundant	O
at	O
the	O
pre-B-	O
and	O
mature	O
B-cell	O
stages	O
,	O
but	O
is	O
absent	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
plasma	I-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
BSAP	B-protein
is	O
clearly	O
a	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
as	O
a	O
wild-type	B-DNA
but	O
not	O
a	O
mutant	B-DNA
TSAP-binding	I-DNA
site	I-DNA
of	O
the	O
sea	O
urchin	O
functions	O
only	O
in	O
transfected	B-cell_line
B	I-cell_line
cells	I-cell_line
as	O
an	O
upstream	B-DNA
promoter	I-DNA
element	I-DNA
.	O

Competition	O
experiments	O
did	O
not	O
reveal	O
any	O
high-affinity	B-DNA
binding	I-DNA
site	I-DNA
for	O
BSAP	B-protein
in	O
known	O
regulatory	B-DNA
regions	I-DNA
of	O
immunoglobulin	B-DNA
and	I-DNA
class	I-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
genes	I-DNA
,	O
suggesting	O
that	O
BSAP	B-protein
is	O
a	O
regulator	O
of	O
a	O
different	O
set	O
of	O
B-lymphoid-specific	B-DNA
genes	I-DNA
.	O

Octamer	B-protein
transcription	I-protein
factors	I-protein
and	O
the	O
cell	B-DNA
type-specificity	I-DNA
of	I-DNA
immunoglobulin	I-DNA
gene	I-DNA
expression	O
.	O

Antibodies	B-protein
are	O
produced	O
exclusively	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
expression	O
of	O
the	O
antibody-encoding	B-DNA
genes	I-DNA
,	O
the	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
genes	I-DNA
,	O
is	O
also	O
restricted	O
to	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
octamer	B-DNA
sequence	I-DNA
ATGCAAAT	O
is	O
present	O
in	O
the	O
promoter	B-DNA
and	O
the	O
enhancer	B-DNA
of	O
Ig	B-DNA
genes	I-DNA
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
its	O
tissue-specific	O
expression	O
.	O

This	O
sequence	B-DNA
motif	I-DNA
is	O
a	O
binding	O
site	O
for	O
nuclear	B-protein
proteins	I-protein
,	O
the	O
so-called	O
octamer	B-protein
transcription	I-protein
factors	I-protein
(	O
Oct	B-protein
or	O
OTF	B-protein
factors	I-protein
)	O
.	O

The	O
Oct-1	B-protein
protein	I-protein
is	O
present	O
in	O
all	O
cell	O
types	O
analyzed	O
so	O
far	O
,	O
whereas	O
Oct-2A	B-protein
and	O
Oct-2B	B-protein
are	O
found	O
mainly	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

All	O
three	O
proteins	O
show	O
the	O
same	O
sequence	O
specificity	O
and	O
binding	O
affinity	O
.	O

It	O
appears	O
that	O
the	O
B	O
cell-specific	O
expression	O
of	O
Ig	B-DNA
genes	I-DNA
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	O
type-specific	B-protein
Oct	I-protein
factors	I-protein
,	O
and	O
that	O
there	O
are	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct-1	B-protein
and	O
Oct-2	B-protein
factors	I-protein
.	O

Recently	O
,	O
a	O
number	O
of	O
other	O
octamer	B-protein
factor	I-protein
variants	I-protein
were	O
identified	O
.	O

Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	B-RNA
transcript	I-RNA
of	O
one	O
Oct	O
factor	O
gene	O
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O
tuning	O
of	O
gene	O
expression	O
.	O

A	O
factor	O
known	O
to	O
bind	O
to	O
endogenous	B-DNA
Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
only	O
in	O
lymphocytes	B-cell_type
is	O
a	O
ubiquitously	B-protein
active	I-protein
transcription	I-protein
factor	I-protein
.	O

The	O
transcriptional	B-DNA
enhancer	I-DNA
located	O
in	O
the	O
first	O
intron	O
of	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
constant	I-DNA
region	I-DNA
is	O
a	O
major	O
determinant	O
of	O
B-cell-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

Like	O
other	O
enhancers	B-DNA
,	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
contains	O
several	O
short	O
sequence	B-DNA
motifs	I-DNA
that	O
bind	O
specific	B-protein
transcription	I-protein
factors	I-protein
.	O

Each	O
binding	B-DNA
site	I-DNA
contributes	O
to	O
the	O
overall	O
activity	O
of	O
the	O
enhancer	B-DNA
,	O
however	O
no	O
single	O
element	O
seems	O
absolutely	O
required	O
for	O
activity	O
.	O

For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
components	I-DNA
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O
sequence	B-DNA
elements	I-DNA
.	O

We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	B-DNA
enhancer	I-DNA
motif	I-DNA
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
.	O

It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	B-cell_type
cells	I-cell_type
and	O
non-B	B-cell_type
cells	I-cell_type
,	O
where	O
it	O
can	O
mediate	O
transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

However	O
,	O
despite	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
a	O
transfected	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
the	O
factor	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B-DNA
Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
in	O
non-lymphoid	B-cell_type
cells	I-cell_type
:	O
In	O
previous	O
experiments	O
by	O
others	O
,	O
the	O
characteristic	O
in	O
vivo	O
footprint	O
of	O
this	O
factor	O
,	O
designated	O
NF-muE3	B-protein
,	O
was	O
detected	O
in	O
B	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
non-B	B-cell_type
cells	I-cell_type
.	O

From	O
this	O
and	O
other	O
findings	O
the	O
picture	O
emerges	O
that	O
there	O
are	O
at	O
least	O
three	O
categories	O
of	O
factors	O
which	O
mediate	O
cell-type-specific	O
transcription	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
:	O
(	O
a	O
)	O
cell-specific	B-protein
factors	I-protein
such	O
as	O
Oct-2A	B-protein
and	O
Oct-2B	B-protein
that	O
are	O
not	O
expressed	O
in	O
most	O
other	O
cell	O
types	O
:	O
(	O
b	O
)	O
ubiquitous	B-protein
factors	I-protein
such	O
as	O
NF-kappa	B-protein
B	I-protein
that	O
are	O
constitutively	O
active	O
in	O
B	B-cell_type
cells	I-cell_type
but	O
are	O
sequestered	O
in	O
an	O
inactive	O
form	O
in	O
other	O
cells	O
;	O
(	O
c	O
)	O
ubiquitously	B-protein
active	I-protein
factors	I-protein
,	O
exemplified	O
by	O
the	O
one	O
binding	O
to	O
the	O
E3	B-DNA
sequence	I-DNA
motif	I-DNA
.	O

This	O
factor	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B-DNA
Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
in	O
non-B	B-cell_type
cells	I-cell_type
,	O
perhaps	O
due	O
to	O
a	O
non-permissive	O
chromatin	B-DNA
structure	O
of	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
locus	I-DNA
.	O

[	O
Endocrine	O
status	O
changes	O
in	O
children	O
with	O
bronchial	O
asthma	O
]	O

A	O
study	O
was	O
made	O
of	O
adrenocortical	O
function	O
by	O
measuring	O
blood	O
plasma	O
cortisol	O
concentration	O
and	O
amount	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
as	O
well	O
as	O
thyroid	O
function	O
by	O
measuring	O
blood	O
plasma	O
triidothyronine	O
and	O
thyroxine	O
concentration	O
in	O
58	O
bronchial	O
asthma	O
children	O
aged	O
1	O
to	O
14	O
years	O
.	O

The	O
authors	O
revealed	O
alterations	O
in	O
the	O
functional	O
activity	O
of	O
the	O
indicated	O
endocrine	O
glands	O
depending	O
on	O
the	O
intensity	O
of	O
bronchial	O
patency	O
disorders	O
and	O
the	O
nature	O
of	O
the	O
therapeutic	O
measures	O
carried	O
out	O
.	O

TAR	B-DNA
independent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
phorbol	O
ester	O
stimulated	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Multiple	B-DNA
regulatory	I-DNA
elements	I-DNA
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
HIV	B-DNA
LTR	I-DNA
)	O
are	O
required	O
for	O
activation	O
of	O
HIV	O
gene	O
expression	O
.	O

Previous	O
transfection	O
studies	O
of	O
HIV	B-DNA
LTR	I-DNA
constructs	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	I-DNA
indicated	O
that	O
multiple	O
regulatory	B-DNA
regions	I-DNA
including	O
the	O
enhancer	B-DNA
,	O
SP1	B-DNA
,	O
TATA	B-DNA
and	O
TAR	B-DNA
regions	I-DNA
were	O
important	O
for	O
HIV	O
gene	O
expression	O
.	O

To	O
characterize	O
these	O
regulatory	B-DNA
elements	I-DNA
further	O
,	O
mutations	O
in	O
these	O
regions	O
were	O
inserted	O
into	O
both	O
the	O
5	O
'	O
and	O
3	O
'	O
HIV	B-DNA
LTRs	I-DNA
and	O
infectious	O
proviral	O
constructs	O
were	O
assembled	O
.	O

These	O
constructs	O
were	O
transfected	O
into	O
either	O
HeLa	B-cell_line
cells	I-cell_line
,	O
Jurkat	B-cell_line
cells	I-cell_line
or	O
U937	B-cell_line
cells	I-cell_line
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
phorbol	O
esters	O
which	O
have	O
previously	O
been	O
demonstrated	O
to	O
activate	O
HIV	O
gene	O
expression	O
.	O

Viral	O
gene	O
expression	O
was	O
assayed	O
by	O
the	O
level	O
of	O
p24	B-protein
gag	I-protein
protein	I-protein
released	O
from	O
cultures	O
transfected	O
with	O
the	O
proviral	O
constructs	O
.	O

Results	O
in	O
all	O
cell	O
lines	O
indicated	O
that	O
mutations	O
of	O
the	O
SP1	B-DNA
,	O
TATA	B-DNA
and	O
the	O
TAR	O
loop	O
and	O
stem	O
secondary	O
structure	O
resulted	O
in	O
marked	O
decreases	O
in	O
gene	O
expression	O
while	O
mutations	O
of	O
the	O
enhancer	B-DNA
motif	I-DNA
or	O
TAR	B-DNA
primary	I-DNA
sequence	I-DNA
resulted	O
in	O
only	O
slight	O
decreases	O
.	O

However	O
,	O
viruses	O
containing	O
mutations	O
in	O
either	O
the	O
TAR	B-DNA
loop	I-DNA
sequences	I-DNA
or	O
stem	O
secondary	O
structure	O
which	O
were	O
very	O
defective	O
for	O
gene	O
expression	O
in	O
untreated	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
gave	O
nearly	O
wild-type	O
levels	O
of	O
gene	O
expression	O
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
HeLa	I-cell_line
or	O
U937	B-cell_line
cells	I-cell_line
.	O

High	O
level	O
gene	O
expression	O
of	O
these	O
TAR	B-DNA
mutant	I-DNA
constructs	I-DNA
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
was	O
eliminated	O
by	O
second	O
site	O
mutations	O
in	O
the	O
enhancer	B-DNA
region	I-DNA
or	O
by	O
disruption	O
of	O
the	O
tat	B-DNA
gene	I-DNA
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
case	O
of	O
hypersensitivity	O
to	O
thyroid	O
hormones	O
with	O
normally	O
functioning	O
thyroid	O
gland	O
and	O
increased	O
nuclear	O
triiodothyronine	B-protein
receptors	I-protein
.	O

A	O
52-year-old	O
male	O
presented	O
himself	O
with	O
tachycardia	O
crises	O
which	O
appeared	O
first	O
during	O
childhood	O
,	O
increased	O
in	O
frequency	O
without	O
goiter	O
or	O
exophthalmos	O
.	O

Cardiac	O
and	O
adrenergic	O
diseases	O
were	O
excluded	O
.	O

The	O
thyroid	O
function	O
was	O
normal	O
regarding	O
T4	O
,	O
free	O
T4	O
and	O
T3	O
,	O
TBG	O
,	O
radioiodine	O
uptake	O
,	O
TSH	O
and	O
T3	O
suppressibility	O
;	O
however	O
the	O
TSH	O
response	O
to	O
TRH	O
was	O
decreased	O
.	O

The	O
lymphocyte	B-protein
nuclear	I-protein
T3	I-protein
receptor	I-protein
was	O
found	O
with	O
an	O
affinity	O
close	O
to	O
that	O
of	O
normal	O
volunteers	O
(	O
Ka	O
:	O
1.42	O
x	O
10	O
(	O
10	O
)	O
M-1	O
vs	O
1.95	O
+/-	O
0.35	O
x	O
10	O
(	O
10	O
)	O
M-1	O
)	O
and	O
a	O
binding	O
capacity	O
markedly	O
increased	O
(	O
9.9	O
vs	O
3.7	O
+/-	O
0.4	O
fmol	O
T3/100	O
micrograms	O
DNA	O
)	O
.	O

Pindolol	O
was	O
inefficient	O
on	O
the	O
dysrhythmia	O
which	O
disappeared	O
with	O
carbimazole	O
and	O
relapsed	O
after	O
withdrawal	O
of	O
the	O
antithyroid	O
drug	O
.	O

Under	O
carbimazole	O
,	O
the	O
plasma	O
T4	O
markedly	O
decreased	O
(	O
27.7	O
+/-	O
3.6	O
nmol/l	O
)	O
but	O
the	O
patient	O
remained	O
euthyroid	O
.	O

The	O
clinical	O
course	O
and	O
the	O
laboratory	O
data	O
suggest	O
that	O
the	O
tachycardia	O
crises	O
are	O
the	O
consequence	O
of	O
a	O
hypersensitivity	O
of	O
the	O
heart	O
to	O
thyroid	O
hormones	O
,	O
associated	O
with	O
an	O
increased	O
number	O
of	O
T3	B-protein
nuclear	I-protein
receptor	I-protein
sites	O
in	O
lymphocytes	B-cell_type
.	O

Induction	O
of	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
by	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

A	O
group	O
of	O
coordinately	O
induced	O
protooncogenes	B-DNA
,	O
cytoskeletal	B-DNA
,	I-DNA
and	I-DNA
extracellular	I-DNA
matrix	I-DNA
genes	I-DNA
have	O
been	O
termed	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
,	O
and	O
their	O
induction	O
has	O
been	O
associated	O
with	O
growth	B-protein
factor	I-protein
-stimulated	O
cell	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
induction	O
of	O
these	O
genes	O
by	O
macrophage-CSF	B-protein
(	O
M-CSF	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
that	O
do	O
not	O
proliferate	O
in	O
response	O
to	O
M-CSF	B-protein
but	O
require	O
the	O
factor	O
for	O
optimal	O
cell	O
differentiation	O
.	O

Normal	O
human	B-cell_type
monocytes	I-cell_type
were	O
isolated	O
,	O
carefully	O
washed	O
,	O
and	O
incubated	O
for	O
36	O
to	O
48	O
h	O
in	O
fetal	O
bovine	O
serum-containing	O
medium	O
.	O

At	O
the	O
end	O
of	O
this	O
incubation	O
the	O
resting	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
M-CSF	B-protein
,	O
and	O
RNA	O
was	O
isolated	O
for	O
analysis	O
by	O
Northern	O
blotting	O
.	O

RNA	O
from	O
control	O
resting	B-cell_type
cells	I-cell_type
contained	O
low	O
to	O
undetectable	O
levels	O
of	O
c-jun	B-RNA
,	O
fibronectin	B-RNA
receptor	I-RNA
,	O
and	O
actin	B-RNA
mRNA	I-RNA
.	O

Within	O
15	O
to	O
30	O
min	O
of	O
addition	O
of	O
M-CSF	B-protein
,	O
however	O
,	O
there	O
was	O
a	O
dramatic	O
coordinate	O
induction	O
of	O
these	O
genes	O
.	O

The	O
c-jun	B-DNA
gene	I-DNA
expression	O
was	O
very	O
transient	O
and	O
was	O
not	O
detectable	O
by	O
60	O
min	O
after	O
M-CSF	B-protein
addition	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
actin	B-RNA
and	I-RNA
fibronectin	I-RNA
receptor	I-RNA
mRNA	I-RNA
was	O
more	O
sustained	O
,	O
and	O
the	O
expression	O
of	O
these	O
genes	O
remained	O
elevated	O
at	O
24	O
to	O
48	O
h	O
after	O
M-CSF	B-protein
addition	O
.	O

We	O
also	O
observed	O
the	O
induction	O
of	O
the	O
myelomonocytic	B-DNA
specific	I-DNA
tyrosine	I-DNA
kinase	I-DNA
hck	I-DNA
gene	I-DNA
simultaneously	O
with	O
the	O
other	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
.	O

The	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
did	O
not	O
block	O
the	O
induction	O
of	O
any	O
of	O
these	O
genes	O
,	O
and	O
in	O
fact	O
,	O
super-induced	O
the	O
expression	O
of	O
c-jun	B-DNA
and	O
hck	B-DNA
.	O

Nuclear	O
run	O
on	O
transcription	O
of	O
the	O
c-jun	B-DNA
,	O
hck	B-DNA
,	O
and	O
actin	B-DNA
genes	I-DNA
.	O

Therefore	O
,	O
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
M-CSF	B-protein
induces	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
without	O
inducing	O
cell	O
proliferation	O
.	O

These	O
genes	O
may	O
then	O
play	O
a	O
role	O
in	O
altering	O
the	O
physiologic	O
status	O
of	O
the	O
cells	O
in	O
response	O
to	O
CSF	B-protein
.	O

Inducible	O
nuclear	B-protein
factor	I-protein
binding	O
to	O
the	O
kappa	B-DNA
B	I-DNA
elements	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
enhancer	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal-dependent	O
manner	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
expression	O
of	O
a	O
distinct	O
set	O
of	O
lymphokine	B-DNA
genes	I-DNA
which	O
are	O
induced	O
upon	O
T-cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin-2	B-protein
.	O

In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	B-protein
factors	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

Here	O
we	O
report	O
that	O
the	O
formation	O
of	O
two	O
distinct	O
mitogen-inducible	B-protein
DNA-binding	I-protein
complexes	I-protein
,	O
the	O
kappa	B-protein
B	I-protein
complex	I-protein
within	O
the	O
HIV	B-DNA
enhancer	I-DNA
and	O
the	O
NFAT-1	B-protein
complex	I-protein
within	O
the	O
interleukin-2	B-DNA
enhancer	I-DNA
,	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
CsA	O
.	O

The	O
kappa	O
B-binding	O
activity	O
with	O
the	O
HIV	B-DNA
enhancer	I-DNA
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	B-protein
phytohemagglutinin	B-protein
whereas	O
phorbol	O
myristate	O
acetate-mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O

This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	B-protein
B	I-protein
complexes	I-protein
can	O
be	O
activated	O
via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	O
.	O

Purification	O
of	O
TCF-1	B-protein
alpha	I-protein
,	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
activates	O
the	O
T-cell	B-DNA
receptor	I-DNA
C	I-DNA
alpha	I-DNA
gene	I-DNA
enhancer	I-DNA
in	O
a	O
context-dependent	O
manner	O
.	O

The	O
differentiation	O
of	O
T	B-cell_type
cells	I-cell_type
into	O
functionally	O
diverse	O
subpopulations	O
is	O
controlled	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
and	O
silencing	O
;	O
however	O
,	O
little	O
is	O
known	O
in	O
detail	O
about	O
the	O
proteins	O
that	O
influence	O
this	O
developmental	O
process	O
.	O

We	O
have	O
purified	O
a	O
new	O
T-cell-specific	B-protein
factor	I-protein
,	O
TCF-1	B-protein
alpha	I-protein
,	O
that	O
is	O
implicated	O
in	O
the	O
activation	O
of	O
genes	O
encoding	O
a	O
major	O
component	O
of	O
the	O
human	B-protein
T-cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
.	O

TCF-1	B-protein
alpha	I-protein
,	O
originally	O
identified	O
and	O
purified	O
through	O
its	O
binding	O
sites	O
on	O
the	O
HIV-1	B-DNA
promoter	I-DNA
,	O
was	O
found	O
to	O
bind	O
to	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
and	O
to	O
promoters	B-DNA
for	O
several	O
genes	B-DNA
expressed	O
at	O
significantly	O
earlier	O
stages	O
of	O
T-cell	O
development	O
than	O
the	O
TCR	B-DNA
alpha	I-DNA
gene	I-DNA
(	O
e.g.	O
,	O
p56lck	B-DNA
and	O
CD3	B-DNA
delta	I-DNA
)	O
.	O

Sequences	O
related	O
to	O
the	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
motif	I-DNA
(	O
5'-GGCACCCTTTGA-3	O
'	O
)	O
are	O
also	O
found	O
in	O
the	O
human	B-DNA
TCR	I-DNA
delta	I-DNA
(	O
and	O
possibly	O
TCR	B-DNA
beta	I-DNA
)	O
enhancers	B-DNA
.	O

Southwestern	O
and	O
gel	O
renaturation	O
experiments	O
with	O
the	O
use	O
of	O
purified	O
protein	O
fractions	O
revealed	O
that	O
TCF-1	B-protein
alpha	I-protein
activity	O
is	O
derived	O
from	O
a	O
family	O
of	O
57-	B-protein
to	I-protein
53-kD	I-protein
proteins	I-protein
that	O
are	O
abundantly	O
expressed	O
in	O
mature	B-cell_line
and	I-cell_line
immature	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
(	O
Jurkat	B-cell_line
,	O
CCRF-CEM	B-cell_line
)	O
and	O
not	O
in	O
mature	B-cell_line
B	I-cell_line
cells	I-cell_line
(	O
JY	B-cell_line
,	O
Namalwa	B-cell_line
)	O
or	O
nonlymphoid	B-cell_line
(	I-cell_line
HeLa	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

A	O
small	O
95-bp	O
fragment	O
of	O
the	O
TCR	B-DNA
alpha	I-DNA
control	I-DNA
region	I-DNA
that	O
contains	O
the	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
site	I-DNA
juxtaposed	O
between	O
a	O
cAMP-response	B-DNA
element	I-DNA
(	O
the	O
CRE	B-DNA
or	O
T	B-DNA
alpha	I-DNA
1	I-DNA
motif	I-DNA
)	O
and	O
the	O
binding	B-DNA
site	I-DNA
for	O
a	O
distinct	O
lymphoid-specific	B-protein
protein	I-protein
(	O
TCF-2	B-protein
alpha	I-protein
)	O
behaved	O
as	O
a	O
potent	O
T-cell-specific	B-DNA
enhancer	I-DNA
in	O
vivo	O
.	O

Tandem	O
copies	O
of	O
this	O
enhancer	O
functioned	O
synergistically	O
in	O
mature	B-cell_line
(	I-cell_line
Jurkat	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
as	O
well	O
as	O
resting	O
and	O
activated	O
immature	B-cell_line
(	I-cell_line
CCRF-CEM	I-cell_line
)	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

Mutation	O
of	O
the	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
site	I-DNA
diminished	O
enhancer	O
activity	O
and	O
disrupted	O
the	O
synergism	O
observed	O
in	O
vivo	O
between	O
tandem	B-DNA
enhancer	I-DNA
repeats	I-DNA
.	O

The	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
site	I-DNA
was	O
also	O
required	O
for	O
TCR	B-protein
alpha	O
enhancer	O
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	B-cell_line
but	O
not	O
HeLa	B-cell_line
cells	I-cell_line
,	O
confirming	O
that	O
TCF-1	B-protein
alpha	I-protein
is	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
.	O

Curiously	O
,	O
the	O
TCF-1	B-protein
alpha	I-protein
binding	O
element	O
was	O
inactive	O
in	O
vivo	O
when	O
removed	O
from	O
its	O
neighboring	O
elements	O
on	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
and	O
positioned	O
in	O
one	O
or	O
more	O
copies	O
upstream	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

Thus	O
,	O
the	O
transcriptional	O
activity	O
of	O
TCF-1	B-protein
alpha	I-protein
appears	O
to	O
depend	O
on	O
the	O
TCF-2	B-protein
alpha	I-protein
and	O
T	B-protein
alpha	I-protein
1	I-protein
(	O
CREB	B-protein
)	O
transcription	B-protein
factors	I-protein
and	O
the	O
context	O
of	O
its	O
binding	O
site	O
within	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
.	O

Tandem	B-DNA
AP-1-binding	I-DNA
sites	I-DNA
within	O
the	O
human	B-DNA
beta-globin	I-DNA
dominant	I-DNA
control	I-DNA
region	I-DNA
function	O
as	O
an	O
inducible	B-DNA
enhancer	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

A	O
powerful	O
enhancer	O
has	O
been	O
mapped	O
to	O
an	O
18-bp	B-DNA
DNA	I-DNA
segment	I-DNA
located	O
11	O
kb	O
5	O
'	O
to	O
the	O
human	B-DNA
epsilon-globin	I-DNA
gene	I-DNA
within	O
the	O
dominant	B-DNA
control	I-DNA
or	O
locus-activating	B-DNA
region	I-DNA
.	O

This	O
enhancer	B-DNA
is	O
inducible	O
in	O
K562	B-cell_line
human	I-cell_line
erythroleukemia	I-cell_line
cells	I-cell_line
,	O
increasing	O
linked	O
gamma-globin	B-DNA
promoter	I-DNA
/luciferase	B-protein
gene	O
expression	O
to	O
170-fold	O
over	O
an	O
enhancerless	B-DNA
construct	I-DNA
.	O

The	O
enhancer	B-DNA
consists	O
of	O
tandem	B-DNA
AP-1-binding	I-DNA
sites	I-DNA
,	O
phased	O
10	O
bp	O
apart	O
,	O
which	O
are	O
both	O
required	O
for	O
full	O
activity	O
.	O

DNA-protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	B-protein
molecular	I-protein
weight	I-protein
complex	I-protein
on	O
the	O
enhancer	B-DNA
.	O

The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O
both	O
AP-1	B-DNA
sites	I-DNA
and	O
correlates	O
with	O
maximal	O
enhancer	B-DNA
activity	O
.	O

Induction	O
of	O
the	O
enhancer	B-DNA
may	O
have	O
a	O
role	O
in	O
the	O
increase	O
in	O
globin	B-DNA
gene	I-DNA
transcription	O
that	O
characterizes	O
erythroid	O
maturation	O
.	O

Enhancer	O
activity	O
appears	O
to	O
be	O
mediated	O
by	O
the	O
binding	O
of	O
a	O
complex	O
of	O
proteins	O
from	O
the	O
jun	B-DNA
and	I-DNA
fos	I-DNA
families	I-DNA
to	O
tandem	B-DNA
AP-1	I-DNA
consensus	I-DNA
sequences	I-DNA
.	O

Identification	O
of	O
a	O
novel	B-protein
factor	I-protein
that	O
interacts	O
with	O
an	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	I-DNA
and	O
stimulates	O
transcription	O
in	O
conjunction	O
with	O
the	O
lymphoid	B-protein
cell-specific	I-protein
factor	I-protein
OTF2	B-protein
.	O

The	O
tissue-specific	O
expression	O
of	O
the	O
MOPC	B-DNA
141	I-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
gene	I-DNA
was	O
studied	O
by	O
using	O
in	O
vitro	O
transcription	O
.	O

B-cell-specific	O
transcription	O
of	O
this	O
gene	O
was	O
dependent	O
on	O
the	O
octamer	B-DNA
element	I-DNA
5'-ATGCAAAG-3	O
'	O
,	O
located	O
in	O
the	O
upstream	B-DNA
region	I-DNA
of	O
this	O
promoter	B-DNA
and	O
in	O
the	O
promoters	B-DNA
of	O
all	O
other	O
immunoglobulin	B-DNA
heavy-	I-DNA
and	I-DNA
light-chain	I-DNA
genes	I-DNA
.	O

The	O
interaction	O
of	O
purified	O
octamer	B-protein
transcription	I-protein
factors	I-protein
1	O
and	O
2	O
(	O
OTF1	B-protein
and	O
OTF2	B-protein
)	O
with	O
the	O
MOPC	B-DNA
141	I-DNA
promoter	I-DNA
was	O
studied	O
by	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNase	B-protein
I	I-protein
footprinting	O
.	O

Purified	O
OTF1	B-protein
from	O
HeLa	B-cell_line
cells	I-cell_line
and	O
OTF1	B-protein
and	O
OTF2	B-protein
from	O
B	B-cell_type
cells	I-cell_type
bound	O
to	O
identical	O
sequences	O
within	O
the	O
heavy-chain	B-DNA
promoter	I-DNA
.	O

The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	B-DNA
element	I-DNA
5'-CTCAGGA-3	O
'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	B-protein
factors	I-protein
involves	O
cooperation	O
between	O
octamer	B-DNA
and	I-DNA
heptamer	I-DNA
sites	I-DNA
in	O
this	O
promoter	B-DNA
.	O

In	O
addition	O
to	O
these	O
elements	O
,	O
we	O
identified	O
a	O
second	O
regulatory	B-DNA
element	I-DNA
,	O
the	O
N	B-DNA
element	I-DNA
with	O
the	O
sequence	O
5'-GGAACCTCCCCC-3'	O
.	O

The	O
N	B-DNA
element	I-DNA
could	O
independently	O
mediate	O
low	O
levels	O
of	O
transcription	O
in	O
both	O
B-cell	O
and	O
HeLa-cell	O
extracts	O
,	O
and	O
,	O
in	O
conjunction	O
with	O
the	O
octamer	B-DNA
element	I-DNA
,	O
it	O
can	O
promote	O
high	O
levels	O
of	O
transcription	O
in	O
B-cell	O
extracts	O
.	O

The	O
N	B-DNA
element	I-DNA
bound	O
a	O
transcription	B-protein
factor	I-protein
,	O
NTF	B-protein
,	O
that	O
is	O
ubiquitous	O
in	O
cell-type	O
distribution	O
,	O
and	O
NTF	B-protein
was	O
distinct	O
from	O
any	O
of	O
the	O
previously	B-protein
described	I-protein
proteins	I-protein
that	O
bind	O
to	O
similar	O
sequences	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
propose	O
that	O
NTF	B-protein
and	O
OTF2	B-protein
interactions	O
(	O
both	O
with	O
their	O
cognate	B-DNA
DNA	I-DNA
elements	I-DNA
and	O
possibly	O
at	O
the	O
protein-protein	O
level	O
)	O
may	O
be	O
critical	O
to	O
B-cell-specific	O
expression	O
and	O
that	O
these	O
interactions	O
provide	O
additional	O
pathways	O
for	O
regulating	O
gene	O
expression	O
.	O

NF-kappa	B-protein
B	I-protein
as	O
inducible	O
transcriptional	B-protein
activator	I-protein
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
.	O

The	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
induced	O
upon	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
phytohemagglutinin	B-protein
and	O
active	O
phorbolester	O
and	O
upon	O
expression	O
of	O
tax1	B-protein
,	O
a	O
transactivating	B-protein
protein	I-protein
of	O
the	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
.	O

The	O
same	O
agents	O
induce	O
transcription	O
from	O
the	O
interleukin-2	B-DNA
receptor	I-DNA
alpha-chain	I-DNA
and	I-DNA
interleukin-2	I-DNA
genes	I-DNA
,	O
depending	O
on	O
promoter	B-DNA
elements	I-DNA
that	O
bind	O
the	O
inducible	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
(	O
or	O
an	O
NF-kappa	B-protein
B-like	I-protein
factor	I-protein
)	O
.	O

We	O
therefore	O
tested	O
the	O
possibility	O
that	O
the	O
GM-CSF	B-DNA
gene	I-DNA
is	O
also	O
regulated	O
by	O
a	O
cognate	O
motif	O
for	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
.	O

A	O
recent	O
functional	O
analysis	O
by	O
Miyatake	O
et	O
al.	O
(	O
S.	O
Miyatake	O
,	O
M.	O
Seiki	O
,	O
M.	O
Yoshida	O
,	O
and	O
K.	O
Arai	O
,	O
Mol.	O
Cell.	O
Biol.	O
8	O
:	O
5581-5587	O
,	O
1988	O
)	O
described	O
a	O
short	B-DNA
promoter	I-DNA
region	I-DNA
in	O
the	O
GM-CSF	B-DNA
gene	I-DNA
that	O
conferred	O
strong	O
inducibility	O
by	O
T-cell-activating	O
signals	O
and	O
tax1	B-protein
,	O
but	O
no	O
NF-kappa	B-DNA
B-binding	I-DNA
motifs	I-DNA
were	O
identified	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
showed	O
binding	O
of	O
purified	O
human	B-protein
NF-kappa	I-protein
B	I-protein
and	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
activated	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
to	O
an	O
oligonucleotide	O
comprising	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
element	I-DNA
responsible	O
for	O
mediating	O
responsiveness	O
to	O
T-cell-activating	O
signals	O
and	O
tax1	B-protein
.	O

As	O
shown	O
by	O
a	O
methylation	O
interference	O
analysis	O
and	O
oligonucleotide	O
competition	O
experiments	O
,	O
purified	O
NF-kappa	B-protein
B	I-protein
binds	O
at	O
positions	B-DNA
-82	I-DNA
to	I-DNA
-91	I-DNA
(	O
GGGAACTACC	O
)	O
of	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
sequence	O
with	O
an	O
affinity	O
similar	O
to	O
that	O
with	O
which	O
it	O
binds	O
to	O
the	O
biologically	B-DNA
functional	I-DNA
kappa	I-DNA
B	I-DNA
motif	I-DNA
in	O
the	O
beta	B-DNA
interferon	I-DNA
promoter	I-DNA
(	O
GGGAAATTCC	O
)	O
.	O

Two	O
kappa	B-DNA
B-like	I-DNA
motifs	I-DNA
at	O
positions	B-DNA
-98	I-DNA
to	I-DNA
-108	I-DNA
of	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
were	O
also	O
recognized	O
but	O
with	O
much	O
lower	O
affinities	O
.	O

Our	O
data	O
provide	O
strong	O
evidence	O
that	O
the	O
expression	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
following	O
T-cell	O
activation	O
is	O
controlled	O
by	O
binding	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
to	O
a	O
high-affinity	B-DNA
binding	I-DNA
site	I-DNA
in	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O

Effects	O
of	O
mitogenic	O
agents	O
upon	O
glucocorticoid	O
action	O
in	O
human	B-cell_type
tonsillar	I-cell_type
T-lymphocytes	I-cell_type
.	O

The	O
treatment	O
of	O
human	B-cell_type
tonsillar	I-cell_type
T-lymphocytes	I-cell_type
with	O
4-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
resulted	O
in	O
about	O
two	O
fold	O
increase	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
number	O
,	O
without	O
any	O
significant	O
change	O
in	O
the	O
receptor	O
affinity	O
.	O

This	O
increase	O
disappeared	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O

Alone	O
,	O
PMA	O
and	O
calcium	O
ionophore	O
A23187	O
did	O
not	O
affect	O
,	O
but	O
together	O
stimulated	O
,	O
like	O
phytohaemagglutinin	B-protein
(	O
PHA	B-protein
)	O
,	O
leucine	O
and	O
,	O
in	O
particular	O
,	O
thymidine	O
incorporation	O
.	O

PMA	O
enhanced	O
slightly	O
the	O
stimulatory	O
effect	O
of	O
PHA	B-protein
.	O

Alone	O
,	O
these	O
agents	O
failed	O
to	O
alter	O
the	O
suppressive	O
effect	O
of	O
dexamethasone	O
on	O
thymidine	O
and	O
leucine	O
incorporation	O
;	O
however	O
,	O
PMA-A23187	O
and	O
PMA	O
-PHA	B-protein
combinations	O
appeared	O
to	O
antagonize	O
the	O
suppression	O
by	O
dexamethasone	O
.	O

To	O
be	O
or	O
not	O
to	O
be	O
a	O
responder	O
in	O
T-cell	O
responses	O
:	O
ubiquitous	O
oligopeptides	O
in	O
all	O
proteins	O
.	O

Amino	O
acid	O
sequences	O
of	O
all	O
proteins	O
are	O
essays	O
written	O
in	O
the	O
same	O
language	O
.	O

Accordingly	O
,	O
the	O
same	O
set	O
of	O
words	O
and	O
phrases	O
(	O
oligopeptides	O
)	O
appear	O
in	O
totally	O
unrelated	O
proteins	O
.	O

The	O
reason	O
that	O
only	O
certain	O
individuals	O
of	O
particular	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
haplotypes	I-protein
can	O
mount	O
T-cell	O
responses	O
against	O
a	O
given	O
antigen	O
of	O
pathogens	O
is	O
found	O
in	O
the	O
fact	O
that	O
T-cell	B-protein
receptors	I-protein
are	O
designed	O
to	O
recognize	O
18-20	O
residue-long	O
peptide	O
fragments	O
sandwiched	O
between	O
two	O
alpha-helices	B-protein
of	O
class	B-protein
I	I-protein
or	O
class	O
II	O
MHC	O
molecules	O
.	O

At	O
this	O
range	O
of	O
peptide	O
lengths	O
,	O
most	O
would	O
appear	O
as	O
self	O
,	O
while	O
nonselfness	O
of	O
the	O
remainders	O
are	O
destined	O
to	O
be	O
quite	O
ambiguous	O
,	O
hence	O
creating	O
responders	O
and	O
nonresponders	O
.	O

Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	B-protein
and	O
either	O
FK506	O
or	O
rapamycin	O
.	O

Proliferation	O
and	O
immunologic	O
function	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	B-protein
receptor	I-protein
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	O
by	O
its	O
structural	O
analog	O
,	O
rapamycin	O
.	O

On	O
the	O
other	O
hand	O
,	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
-induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	O
but	O
not	O
by	O
FK506	O
.	O

Remarkably	O
,	O
these	O
two	O
drugs	O
inhibit	O
each	O
other	O
's	O
actions	O
,	O
raising	O
the	O
possibility	O
that	O
both	O
act	O
by	O
means	O
of	O
a	O
common	O
immunophilin	B-protein
(	O
immunosuppressant	B-protein
binding	I-protein
protein	I-protein
)	O
.	O

We	O
find	O
that	O
the	O
dissociation	O
constant	O
of	O
rapamycin	O
to	O
the	O
FK506	B-protein
binding	I-protein
protein	I-protein
FKBP	B-protein
(	O
Kd	O
=	O
0.2	O
nM	O
)	O
is	O
close	O
to	O
the	O
dissociation	O
constant	O
of	O
FK506	O
to	O
FKBP	B-protein
(	O
Kd	O
=	O
0.4	O
nM	O
)	O
and	O
to	O
their	O
effective	O
biologic	O
inhibitory	O
concentrations	O
.	O

However	O
,	O
an	O
excess	O
of	O
rapamycin	O
is	O
needed	O
to	O
revert	O
FK506-mediated	O
inhibition	O
of	O
IL-2	B-protein
production	O
,	O
apoptosis	O
,	O
and	O
transcriptional	O
activation	O
of	O
NF-AT	B-protein
,	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
necessary	O
for	O
IL-2	B-DNA
gene	I-DNA
activation	O
.	O

Similarly	O
,	O
an	O
excess	O
of	O
FK506	O
is	O
needed	O
to	O
revert	O
rapamycin-mediated	O
inhibition	O
of	O
IL-2	B-protein
-induced	O
proliferation	O
.	O

The	O
drug	O
concentrations	O
required	O
for	O
antagonism	O
may	O
be	O
explained	O
by	O
the	O
relative	O
affinity	O
of	O
the	O
drugs	O
to	O
,	O
and	O
by	O
the	O
abundance	O
of	O
,	O
the	O
immunophilin	B-protein
FKBP	B-protein
.	O

FKBP	B-protein
has	O
been	O
shown	O
to	O
catalyze	O
the	O
interconversion	O
of	O
the	O
cis-	O
and	O
trans-rotamers	O
of	O
the	O
peptidyl-prolyl	B-protein
amide	I-protein
bond	I-protein
of	O
peptide	O
substrates	O
;	O
here	O
we	O
show	O
that	O
rapamycin	O
,	O
like	O
FK506	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rotamase	O
activity	O
of	O
FKBP	B-protein
(	O
Ki	O
=	O
0.2	O
nM	O
)	O
.	O

Neither	O
FKBP	B-protein
binding	O
nor	O
inhibition	O
of	O
rotamase	O
activity	O
of	O
FKBP	B-protein
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
biologic	O
actions	O
of	O
these	O
drugs	O
.	O

Rather	O
,	O
these	O
findings	O
suggest	O
that	O
immunophilin	B-protein
bound	O
to	O
FK506	O
interferes	O
with	O
antigen	B-protein
receptor	I-protein
-induced	O
signals	O
,	O
while	O
rapamycin	O
bound	O
to	O
the	O
immunophilin	B-protein
interferes	O
with	O
IL-2	B-protein
-induced	O
signals	O
.	O

Adherence-dependent	O
increase	O
in	O
human	B-RNA
monocyte	I-RNA
PDGF	I-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
is	O
associated	O
with	O
increases	O
in	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
and	I-RNA
EGR2	I-RNA
mRNA	I-RNA
.	O

Adherence	O
is	O
an	O
important	O
initial	O
step	O
in	O
the	O
transition	O
of	O
a	O
circulating	B-cell_type
monocyte	I-cell_type
to	O
a	O
tissue	B-cell_type
macrophage	I-cell_type
.	O

This	O
differentiation	O
is	O
accompanied	O
by	O
an	O
augmented	O
capacity	O
to	O
generate	O
growth	B-protein
factors	I-protein
.	O

We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	O
in	O
cells	O
with	O
increased	O
mRNA	B-RNA
encoding	O
profibrotic	O
growth	B-protein
factors	I-protein
such	O
as	O
platelet-derived	B-protein
growth	I-protein
factor	I-protein
B	I-protein
subunit	I-protein
(	O
PDGF	B-protein
[	I-protein
B	I-protein
]	I-protein
)	O
and	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	O
TGF-beta	B-protein
)	O
.	O

After	O
in	O
vitro	O
adherence	O
,	O
human	O
monocytes	O
had	O
a	O
biphasic	O
increase	O
in	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d	O
.	O

No	O
increase	O
in	O
TGF-beta	B-RNA
mRNA	I-RNA
was	O
observed	O
.	O

The	O
6-h	O
increase	O
in	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
was	O
adherence	O
dependent	O
,	O
and	O
in	O
addition	O
,	O
was	O
abrogated	O
when	O
the	O
cytoskeletal	O
integrity	O
was	O
compromised	O
by	O
cytochalasin	O
D	O
.	O

The	O
6-h	O
increase	O
in	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
was	O
unaltered	O
by	O
adherence	O
in	O
the	O
presence	O
of	O
the	O
monocyte	O
stimulus	O
lipopolysaccharide	O
.	O

Adherence	O
to	O
either	O
fibronectin	O
or	O
collagen-coated	O
plastic	O
had	O
little	O
consistent	O
effect	O
on	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
accumulation	O
.	O

The	O
increased	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
observed	O
in	O
adherent	B-cell_type
monocytes	I-cell_type
was	O
accompanied	O
by	O
increases	O
in	O
mRNAs	B-RNA
of	O
the	O
early	B-DNA
growth	I-DNA
response	I-DNA
genes	I-DNA
c-fos	B-DNA
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c-jun	O
,	O
and	O
EGR2	O
(	O
maximal	O
at	O
6-24	O
h	O
)	O
.	O

The	O
increase	O
in	O
c-jun	O
and	O
EGR2	O
,	O
but	O
not	O
c-fos	B-DNA
,	O
mRNA	O
was	O
also	O
abrogated	O
by	O
cytochalasin	O
D	O
.	O

These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
EGR2	I-RNA
,	I-RNA
and	I-RNA
PDGF	I-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
.	O

In	O
addition	O
,	O
the	O
increases	O
in	O
c-jun	B-DNA
,	O
EGR2	B-DNA
,	O
and	O
PDGF	B-protein
(	I-protein
B	I-protein
)	I-protein
may	O
depend	O
on	O
cytoskeletal	O
rearrangement	O
.	O

Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O

Single	O
cell	O
assay	O
of	O
a	O
transcription	B-protein
factor	I-protein
reveals	O
a	O
threshold	O
in	O
transcription	O
activated	O
by	O
signals	O
emanating	O
from	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
.	O

Stimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
through	O
their	O
antigen	B-protein
receptor	I-protein
leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	B-protein
factors	I-protein
,	O
including	O
NF-AT	B-protein
and	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
are	O
involved	O
in	O
regulating	O
genes	O
required	O
for	O
immunologic	O
activation	O
.	O

To	O
investigate	O
the	O
activity	O
of	O
a	O
single	O
transcription	B-protein
factor	I-protein
in	O
individual	B-cell_type
viable	I-cell_type
cells	I-cell_type
,	O
we	O
have	O
applied	O
an	O
assay	O
that	O
uses	O
the	O
fluorescence-activated	O
cell	O
sorter	O
to	O
quantitate	O
beta-galactosidase	B-protein
(	O
beta-gal	B-protein
)	O
.	O

We	O
have	O
analyzed	O
the	O
distribution	O
of	O
NF-AT	B-protein
transcriptional	O
activity	O
among	O
T	B-cell_type
cells	I-cell_type
undergoing	O
activation	O
by	O
using	O
a	O
construct	O
in	O
which	O
three	O
tandem	O
copies	O
of	O
the	O
NF-AT-binding	B-DNA
site	I-DNA
directs	O
transcription	O
of	O
the	O
lacZ	B-DNA
gene	I-DNA
.	O

Unexpectedly	O
,	O
stimulation	O
of	O
cloned	B-cell_line
stably	I-cell_line
transfected	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta-gal	O
expression	O
in	O
which	O
some	O
cells	O
express	O
no	O
beta-gal	B-protein
and	O
others	O
express	O
high	O
levels	O
.	O

This	O
expression	O
pattern	O
can	O
not	O
be	O
accounted	O
for	O
by	O
cell-cycle	O
position	O
or	O
heritable	O
variation	O
.	O

Further	O
results	O
,	O
in	O
which	O
beta-gal	B-protein
activity	O
is	O
correlated	O
with	O
NF-AT	B-protein
-binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF-AT	B-protein
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O

This	O
threshold	O
likely	O
reflects	O
the	O
NF-AT	B-protein
concentration-dependent	O
assembly	O
of	O
transcription	B-protein
complexes	I-protein
at	O
the	O
promoter	B-DNA
.	O

Similar	O
constructs	O
controlled	O
by	O
NF-kappa	B-protein
B	I-protein
or	O
the	O
entire	O
interleukin-2	B-DNA
enhancer	I-DNA
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	B-protein
factors	I-protein
may	O
be	O
a	O
common	O
property	O
of	O
inducible	B-DNA
genes	I-DNA
.	O

The	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
BMRF1	I-DNA
promoter	I-DNA
for	O
early	B-protein
antigen	I-protein
(	O
EA-D	B-protein
)	O
is	O
regulated	O
by	O
the	O
EBV	B-protein
transactivators	I-protein
,	O
BRLF1	B-protein
and	O
BZLF1	B-protein
,	O
in	O
a	O
cell-specific	O
manner	O
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
early	I-protein
antigen	I-protein
diffuse	I-protein
component	I-protein
(	O
EA-D	B-protein
)	O
is	O
essential	O
for	O
Epstein-Barr	O
virus	B-DNA
DNA	I-DNA
polymerase	O
activity	O
,	O
and	O
its	O
activity	O
is	O
suppressed	O
during	O
latent	O
infection	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
the	O
promoter	B-DNA
(	O
BMRF1	B-DNA
)	O
for	O
this	O
early	O
gene	O
by	O
studying	O
its	O
responsiveness	O
in	O
vitro	O
to	O
two	O
immediate-early	B-protein
viral	I-protein
transactivators	I-protein
,	O
BZLF1	B-protein
(	O
Z	B-protein
)	O
and	O
BRLF1	B-protein
(	O
R	B-protein
)	O
,	O
focusing	O
on	O
the	O
differences	O
in	O
response	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
.	O

In	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
Z	B-protein
or	O
R	B-protein
alone	O
produced	O
only	O
small	O
increases	O
in	O
EA-D	B-DNA
promoter	I-DNA
activity	O
,	O
whereas	O
both	O
transactivators	B-protein
together	O
produced	O
a	O
large	O
stimulatory	O
effect	O
.	O

In	O
epithelial	B-cell_type
cells	I-cell_type
,	O
the	O
Z	B-protein
transactivator	I-protein
alone	O
produced	O
maximal	O
stimulation	O
of	O
the	O
EA-D	B-DNA
promoter	I-DNA
;	O
the	O
effect	O
of	O
R	B-protein
and	O
Z	B-protein
together	O
was	O
no	O
greater	O
than	O
that	O
of	O
Z	B-protein
alone	O
.	O

Deletional	O
analysis	O
and	O
site-directed	O
mutagenesis	O
of	O
the	O
EA-D	B-DNA
promoter	I-DNA
demonstrated	O
that	O
in	O
epithelial	B-cell_type
cells	I-cell_type
the	O
potential	O
AP-1	B-DNA
binding	I-DNA
site	I-DNA
plays	O
an	O
essential	O
role	O
in	O
Z	B-protein
responsiveness	O
,	O
although	O
sequences	O
further	O
upstream	O
are	O
also	O
important	O
.	O

In	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
only	O
the	O
upstream	B-DNA
sequences	I-DNA
are	O
required	O
for	O
transactivation	O
by	O
the	O
Z/R	B-protein
combination	O
,	O
and	O
the	O
AP-1	B-protein
site	I-protein
is	O
dispensable	O
.	O

These	O
data	O
suggest	O
that	O
EA-D	B-DNA
(	I-DNA
BMRF1	I-DNA
)	I-DNA
promoter	I-DNA
regulation	O
by	O
Z	B-protein
and	O
R	B-protein
is	O
cell	O
type	O
specific	O
and	O
appears	O
to	O
involve	O
different	O
mechanisms	O
in	O
each	O
cell	O
type	O
.	O

Complementary	B-DNA
DNA	I-DNA
encoding	O
the	O
human	B-protein
T-cell	I-protein
FK506-binding	I-protein
protein	I-protein
,	O
a	O
peptidylprolyl	B-protein
cis-trans	I-protein
isomerase	I-protein
distinct	O
from	O
cyclophilin	B-protein
.	O

The	O
recently	O
discovered	O
macrolide	O
FK506	O
has	O
been	O
demonstrated	O
to	O
have	O
potent	O
immunosuppressive	O
activity	O
at	O
concentrations	O
100-fold	O
lower	O
than	O
cyclosporin	O
A	O
,	O
a	O
cyclic	O
undecapeptide	O
that	O
is	O
used	O
to	O
prevent	O
rejection	O
after	O
transplantation	O
of	O
bone	O
marrow	O
and	O
organs	O
,	O
such	O
as	O
kidney	O
,	O
heart	O
,	O
and	O
liver	O
.	O

After	O
the	O
recent	O
discovery	O
that	O
the	O
cyclosporin	B-protein
A-binding	I-protein
protein	I-protein
cyclophilin	B-protein
is	O
identical	O
to	O
peptidylprolyl	B-protein
cis-trans	I-protein
isomerase	I-protein
,	O
a	O
cellular	B-protein
binding	I-protein
protein	I-protein
for	O
FK506	O
was	O
found	O
to	O
be	O
distinct	O
from	O
cyclophilin	B-protein
but	O
to	O
have	O
the	O
same	O
enzymatic	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
a	O
cDNA	B-DNA
coding	O
for	O
FK506-binding	O
protein	O
(	O
FKBP	B-protein
)	O
from	O
human	O
peripheral	O
blood	O
T	B-cell_type
cells	I-cell_type
by	O
using	O
mixed	O
20-mer	O
oligonucleotide	O
probes	O
synthesized	O
on	O
the	O
basis	O
of	O
the	O
sequence	O
,	O
Glu-Asp-Gly-Lys-Lys-Phe-Asp	O
,	O
reported	O
for	O
bovine	B-protein
FKBP	I-protein
.	O

The	O
DNA	O
isolated	O
contained	O
an	O
open	O
reading	O
frame	O
encoding	O
108	O
amino	O
acid	O
residues	O
.	O

The	O
first	O
40	O
residues	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
were	O
identical	O
to	O
those	O
of	O
the	O
reported	O
amino-terminal	O
sequence	O
of	O
bovine	O
FKBP	B-protein
,	O
indicating	O
that	O
the	O
DNA	O
sequence	O
isolated	O
represents	O
the	O
gene	O
coding	O
for	O
FKBP	B-protein
.	O

Computer-assisted	O
analysis	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
indicates	O
that	O
FKBP	B-protein
exhibits	O
no	O
internal	O
homology	O
and	O
does	O
not	O
have	O
significant	O
sequence	O
similarity	O
to	O
any	O
other	O
amino	O
acid	O
sequences	O
of	O
known	O
proteins	O
,	O
including	O
cyclophilin	B-protein
.	O

This	O
result	O
suggests	O
that	O
two	O
catalytically	O
similar	O
proteins	O
,	O
cyclophilin	B-protein
and	O
FKBP	B-protein
,	O
evolved	O
independently	O
.	O

In	O
Northern	O
blot	O
analysis	O
,	O
mRNA	B-RNA
species	I-RNA
of	O
approximately	O
1.8	O
kilobases	O
that	O
hybridized	O
with	O
human	B-DNA
FKBP	I-DNA
cDNA	I-DNA
were	O
detected	O
in	O
poly	B-RNA
(	I-RNA
A	I-RNA
)	I-RNA
+	I-RNA
RNAs	I-RNA
from	O
brain	O
,	O
lung	O
,	O
liver	O
,	O
and	O
placental	B-cell_type
cells	I-cell_type
and	O
leukocytes	B-cell_type
.	O

Induction	O
of	O
Jurkat	B-cell_line
leukemic	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
did	O
not	O
affect	O
the	O
level	O
of	O
FKBP	B-RNA
mRNA	I-RNA
.	O

Southern	O
blot	O
analysis	O
of	O
human	B-DNA
genomic	I-DNA
DNA	I-DNA
digested	O
with	O
different	O
restriction	B-protein
enzymes	I-protein
suggests	O
the	O
existence	O
of	O
only	O
a	O
few	O
copies	O
of	O
the	O
DNA	O
sequence	O
encoding	O
FKBP	B-protein
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
result	O
that	O
as	O
many	O
as	O
20	O
copies	O
of	O
the	O
cyclophilin	B-DNA
gene	I-DNA
and	O
possible	O
pseudogenes	O
may	O
be	O
present	O
in	O
the	O
mammalian	B-DNA
genome	I-DNA
.	O

Involvement	O
of	O
a	O
second	O
lymphoid-specific	B-DNA
enhancer	I-DNA
element	I-DNA
in	O
the	O
regulation	O
of	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
gene	I-DNA
expression	O
.	O

To	O
determine	O
whether	O
enhancer	B-DNA
elements	I-DNA
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	B-DNA
(	I-DNA
OCTA	I-DNA
)	I-DNA
-nucleotide	I-DNA
motif	I-DNA
are	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
gene	I-DNA
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	B-DNA
site	I-DNA
for	O
a	O
putative	B-protein
additional	I-protein
lymphoid-specific	I-protein
transcription	I-protein
factor	I-protein
,	O
designated	O
NF-microB	B-protein
,	O
in	O
the	O
murine	B-DNA
IgH	I-DNA
enhancer	I-DNA
.	O

We	O
demonstrate	O
that	O
the	O
NF-microB-binding	B-DNA
site	I-DNA
plays	O
a	O
critical	O
role	O
in	O
the	O
IgH	B-DNA
enhancer	I-DNA
,	O
because	O
mutation	O
of	O
the	O
microB	O
DNA	O
motif	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
IgH	B-DNA
enhancer	I-DNA
in	O
cells	O
of	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
but	O
not	O
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
.	O

This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	B-DNA
site	I-DNA
.	O

Moreover	O
,	O
combined	O
mutation	O
of	O
both	O
microB	B-DNA
and	O
OCTA	B-DNA
sites	I-DNA
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

Interestingly	O
,	O
alteration	O
of	O
either	O
the	O
microB	B-DNA
or	O
E3	B-DNA
site	I-DNA
in	O
a	O
70-base-pair	B-DNA
fragment	I-DNA
of	O
the	O
IgH	B-DNA
enhancer	I-DNA
that	O
lacks	O
the	O
binding	O
site	O
for	O
OCTA	O
abolished	O
enhancer	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
completely	O
.	O

Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O
microB	B-DNA
motif	I-DNA
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O

DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid-specific	B-protein
protein	I-protein
binds	O
to	O
the	O
microB	B-DNA
DNA	I-DNA
motif	I-DNA
.	O

Our	O
results	O
suggest	O
that	O
the	O
microB	B-DNA
element	I-DNA
is	O
a	O
new	O
crucial	O
element	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
IgH	O
gene	O
but	O
that	O
interaction	O
with	O
another	O
enhancer	B-DNA
element	I-DNA
is	O
essential	O
for	O
its	O
activity	O
.	O

Stimulation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
gene	O
expression	O
by	O
the	O
cytomegalovirus	O
and	O
HIV-2	B-DNA
transactivator	I-DNA
gene	I-DNA
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
often	O
causes	O
latent	O
infection	O
.	O

Transactivation	O
by	O
some	O
DNA	O
viruses	O
has	O
been	O
implicated	O
in	O
inducing	O
HIV-1	O
replication	O
and	O
pathogenesis	O
.	O

The	O
transactivator	B-DNA
(	I-DNA
IE-2	I-DNA
)	I-DNA
gene	I-DNA
of	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
enhance	O
HIV-2	O
as	O
well	O
as	O
HIV-1	O
gene	O
expression	O
in	O
vitro	O
.	O

This	O
inducer	O
can	O
act	O
in	O
concert	O
with	O
the	O
HIV-2	B-DNA
tat	I-DNA
gene	I-DNA
and	O
T-cell	O
activation	O
in	O
enhancing	O
gene	O
expression	O
in	O
human	B-cell_type
CD4+	I-cell_type
lymphocytes	I-cell_type
.	O

While	O
the	O
HIV-2	O
and	O
HIV-1	B-DNA
tat	I-DNA
genes	I-DNA
and	O
T-cell	B-protein
activators	I-protein
apparently	O
employ	O
independent	O
modes	O
of	O
action	O
,	O
the	O
CMV	B-DNA
transactivator	I-DNA
in	O
combination	O
with	O
the	O
HIV-2	B-DNA
tat	I-DNA
or	O
T-cell	B-protein
activators	I-protein
may	O
employ	O
a	O
gene	O
activation	O
pathway	O
with	O
some	O
common	O
and	O
some	O
distinct	O
components	O
.	O

Both	O
HIV-2	O
and	O
CMV	B-DNA
transactivators	I-DNA
enhance	O
HIV-2	O
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O
as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	B-DNA
transactivator	I-DNA
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O

A	O
significant	O
proportion	O
of	O
transcripts	B-RNA
appear	O
to	O
terminate	O
prematurely	O
in	O
the	O
absence	O
of	O
transactivators	B-protein
.	O

Deletion	O
mutation	O
analysis	O
of	O
the	O
HIV-2	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
suggests	O
that	O
the	O
element	O
that	O
responds	O
to	O
CMV	O
transactivation	O
in	O
human	B-cell_type
CD4+	I-cell_type
lymphocytes	I-cell_type
is	O
either	O
a	O
diffuse	O
one	O
or	O
located	O
downstream	O
of	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
element	I-DNA
.	O

Quantitative	O
immunohistochemical	O
analysis	O
of	O
mononuclear	B-cell_type
infiltrates	I-cell_type
in	O
breast	O
carcinomas	O
--	O
correlation	O
with	O
tumour	O
differentiation	O
.	O

Inflammatory	B-cell_type
infiltrates	I-cell_type
were	O
analysed	O
in	O
tissue	O
sections	O
of	O
76	O
breast	O
carcinomas	O
by	O
counting	O
the	O
percentage	O
of	O
macrophages	B-cell_type
,	O
IgA+	B-cell_type
and	I-cell_type
IgG+	I-cell_type
plasma	I-cell_type
cells	I-cell_type
,	O
T	B-cell_type
cells	I-cell_type
with	O
their	O
subpopulations	O
,	O
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
,	O
and	O
by	O
measuring	O
postcapillary	O
venules	O
(	O
PCVs	O
,	O
found	O
in	O
12	O
cases	O
)	O
within	O
the	O
infiltrates	O
.	O

These	O
parameters	O
were	O
correlated	O
with	O
nuclear	O
grade	O
and	O
biochemically	O
determined	O
hormone	O
receptor	O
status	O
,	O
known	O
markers	O
of	O
tumour	O
differentiation	O
.	O

A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
extent	O
of	O
inflammation	O
and	O
nuclear	O
grade	O
(	O
P	O
less	O
than	O
0.0001	O
)	O
,	O
and	O
an	O
inverse	O
correlation	O
between	O
inflammation	O
and	O
oestrogen	B-protein
receptor	I-protein
(	O
OR	B-protein
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O
as	O
well	O
as	O
inflammation	O
and	O
progesterone	B-protein
receptor	I-protein
(	O
PR	B-protein
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
percentage	O
of	O
the	O
OKT8+	B-cell_line
suppressor/cytotoxic	I-cell_line
T	I-cell_line
cells	I-cell_line
increased	O
when	O
the	O
inflammation	O
expanded	O
from	O
scanty	O
to	O
moderate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

The	O
diameter	O
of	O
the	O
PCVs	O
also	O
increased	O
with	O
increasing	O
inflammatory	O
infiltrate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

In	O
addition	O
,	O
a	O
direct	O
correlation	O
exists	O
between	O
the	O
diameter	O
of	O
the	O
PCVs	O
and	O
both	O
the	O
percentage	O
of	O
the	O
OKT8+	B-cell_line
T	I-cell_line
cells	I-cell_line
(	O
P	O
less	O
than	O
0.04	O
)	O
and	O
the	O
Leu-7+	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
(	O
P	O
less	O
than	O
0.03	O
)	O
.	O

Reactivity	O
of	O
lymphocytes	B-cell_line
to	O
a	O
progesterone	B-protein
receptor-specific	I-protein
monoclonal	I-protein
antibody	I-protein
.	O

In	O
this	O
study	O
we	O
present	O
evidence	O
for	O
reactivity	O
of	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
,	O
but	O
not	O
nonpregnancy	B-cell_type
lymphocytes	I-cell_type
,	O
with	O
the	O
progesterone	B-protein
receptor-specific	I-protein
monoclonal	I-protein
antibody	I-protein
mPRI	B-protein
.	O

Using	O
an	O
avidin	B-protein
-biotin	B-protein
peroxidase	I-protein
detection	O
system	O
,	O
we	O
found	O
a	O
nuclear	O
staining	O
in	O
14.6	O
+/-	O
3.7	O
%	O
(	O
mean	O
+/-	O
SEM	O
,	O
N	O
=	O
27	O
)	O
of	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
,	O
while	O
only	O
0.47	O
+/-	O
0.33	O
%	O
(	O
mean	O
+/-	O
SEM	O
,	O
N	O
=	O
15	O
)	O
of	O
nonpregnancy	B-cell_type
lymphocytes	I-cell_type
reacted	O
with	O
the	O
antibody	O
.	O

To	O
characterize	O
the	O
receptor-bearing	O
subset	O
,	O
CD8+	B-cell_line
and	I-cell_line
CD4+	I-cell_line
cells	I-cell_line
were	O
depleted	O
by	O
complement-dependent	O
lysis	O
.	O

Depletion	O
of	O
CD8+	B-cell_line
cells	I-cell_line
was	O
accompanied	O
by	O
62	O
+/-	O
18	O
%	O
loss	O
of	O
progesterone	B-cell_line
receptor-bearing	I-cell_line
cells	I-cell_line
,	O
while	O
depletion	O
of	O
CD4+	B-cell_line
cells	I-cell_line
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
positively	O
staining	O
lymphocytes	B-cell_line
.	O

In	O
nonpregnancy	B-cell_line
lymphocytes	I-cell_line
a	O
3-day	O
PHA	B-protein
treatment	O
,	O
as	O
well	O
as	O
allogeneic	O
stimulation	O
,	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
receptor-containing	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
suggest	O
that	O
pregnancy	O
,	O
but	O
not	O
nonpregnancy	O
,	O
lymphocytes	B-cell_line
contain	O
progesterone	B-protein
binding	I-protein
structures	I-protein
,	O
and	O
that	O
these	O
are	O
inducible	O
by	O
mitogenic	O
or	O
alloantigenic	O
stimuli	O
.	O

Activation	O
of	O
human	B-cell_line
CD4	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

Interaction	O
of	O
fibronectin	B-protein
with	O
VLA-5	B-protein
receptor	I-protein
on	O
CD4	B-cell_line
cells	I-cell_line
induces	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
.	O

Fibronectin	B-protein
synergized	O
with	O
anti-CD3	B-protein
antibody	I-protein
to	O
promote	O
CD4	B-protein
cell	O
proliferation	O
in	O
a	O
serum-free	O
culture	O
system	O
whereas	O
no	O
proliferation	O
was	O
observed	O
when	O
CD4	B-cell_line
cells	I-cell_line
were	O
cultured	O
with	O
anti-CD3	B-protein
alone	O
or	O
fibronectin	B-protein
alone	O
.	O

In	O
addition	O
,	O
anti-CD29	B-protein
(	O
integrin	B-protein
beta	I-protein
1	I-protein
)	O
as	O
well	O
as	O
anti-VLA-5	B-protein
(	O
human	B-protein
fibronectin	I-protein
receptor	I-protein
)	O
antibodies	O
blocked	O
this	O
CD4	B-cell_line
cell	I-cell_line
activation	O
in	O
this	O
system	O
.	O

Although	O
anti-CD3	B-protein
alone	O
or	O
fibronectin	B-protein
alone	O
can	O
not	O
induce	O
IL-2	B-protein
message	O
by	O
CD4	B-cell_line
cells	I-cell_line
,	O
the	O
combination	O
of	O
anti-CD3	B-protein
plus	O
fibronectin	B-protein
induced	O
IL-2	B-protein
message	O
by	O
CD4	B-cell_line
cells	I-cell_line
.	O

In	O
an	O
analysis	O
of	O
the	O
molecular	O
mechanism	O
by	O
which	O
IL-2	B-protein
message	O
was	O
generated	O
,	O
we	O
showed	O
that	O
a	O
fibronectin	B-protein
-VLA-5	O
fibronectin	B-protein
receptor	I-protein
interaction	O
may	O
contribute	O
an	O
independent	O
signal	O
distinct	O
from	O
the	O
CD3	B-protein
pathway	O
of	O
activation	O
by	O
the	O
induction	O
of	O
an	O
AP-1	B-protein
transcriptional	I-protein
factor	I-protein
.	O

Thus	O
the	O
VLA-5	B-protein
fibronectin	I-protein
receptor	I-protein
on	O
CD4	B-cell_line
cells	I-cell_line
can	O
play	O
a	O
complementary	O
role	O
in	O
CD3	B-protein
-	O
TCR	B-protein
-mediated	O
signal	O
transduction	O
through	O
its	O
interaction	O
with	O
fibronectin	B-protein
.	O

Glucocorticoid	B-protein
receptors	I-protein
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
Alzheimer	O
's	O
disease	O
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
disturbances	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
system	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

In	O
an	O
exploration	O
of	O
the	O
potential	O
role	O
of	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
in	O
AD	O
,	O
GR	O
density	O
and	O
affinity	O
were	O
assessed	O
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
of	O
12	O
AD	O
patients	O
and	O
12	O
healthy	O
controls	O
.	O

GR	O
binding	O
characteristics	O
did	O
not	O
differ	O
between	O
patients	O
and	O
controls	O
or	O
between	O
patients	O
subdivided	O
according	O
to	O
diagnosis	O
or	O
associated	O
clinical	O
features	O
.	O

These	O
data	O
suggest	O
that	O
the	O
abnormalities	O
of	O
the	O
HPA	O
system	O
in	O
AD	O
are	O
not	O
related	O
to	O
a	O
GR	B-protein
deficiency	O
.	O

Oncogene	O
amplification	O
correlates	O
with	O
dense	O
lymphocyte	O
infiltration	O
in	O
human	O
breast	O
cancers	O
:	O
a	O
role	O
for	O
hematopoietic	B-protein
growth	I-protein
factor	I-protein
release	O
by	O
tumor	B-cell_type
cells	I-cell_type
?	O

One	O
hundred	O
six	O
primary	O
breast	O
cancer	O
samples	O
were	O
analysed	O
for	O
c-erbB2	O
,	O
int-2	O
,	O
and	O
c-myc	O
gene	O
amplification	O
.	O

Surgically	O
confirmed	O
nodal	O
involvement	O
was	O
observed	O
in	O
42	O
%	O
.	O

Level	O
of	O
gene	O
amplification	O
was	O
studied	O
by	O
Southern	O
and/or	O
slot	O
blot	O
techniques	O
.	O

Amplified	O
c-erbB2	B-DNA
gene	I-DNA
sequences	I-DNA
were	O
present	O
in	O
21.5	O
%	O
of	O
all	O
samples	O
.	O

Int-2	B-DNA
was	O
amplified	O
in	O
13.1	O
%	O
and	O
c-myc	B-DNA
was	O
amplified	O
in	O
10.3	O
%	O
.	O

In	O
a	O
non-parametric	O
test	O
(	O
Kruskal-Wallis	O
)	O
a	O
strong	O
negative	O
association	O
was	O
found	O
between	O
high	O
levels	O
of	O
c-erbB2	B-DNA
amplification	O
and	O
absence	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
(	O
P	O
=	O
.0009	O
)	O
or	O
progesterone	B-protein
receptor	I-protein
(	O
PR	B-protein
)	O
(	O
P	O
=	O
.011	O
)	O
expression	O
.	O

No	O
correlations	O
were	O
found	O
between	O
all	O
or	O
high	O
levels	O
of	O
amplification	O
of	O
each	O
oncogene	O
separately	O
or	O
combined	O
with	O
T	O
,	O
N	O
,	O
grade	O
,	O
multifocality	O
of	O
tumor	O
,	O
or	O
associated	O
carcinoma	O
in	O
situ	O
.	O

There	O
was	O
a	O
trend	O
approaching	O
statistical	O
significance	O
for	O
patients	O
with	O
c-erbB2	B-DNA
amplifications	O
to	O
have	O
positive	O
lymph	O
nodes	O
at	O
surgery	O
(	O
P	O
=	O
0.09	O
)	O
.	O

A	O
somewhat	O
surprising	O
finding	O
however	O
was	O
a	O
very	O
strong	O
association	O
between	O
oncogene	B-DNA
amplification	O
and	O
dense	O
lymphocyte	O
infiltration	O
of	O
the	O
tumor	O
(	O
P	O
=	O
.05	O
)	O
.	O
This	O
correlation	O
is	O
even	O
stronger	O
when	O
only	O
high	O
levels	O
of	O
amplification	O
are	O
considered	O
,	O
either	O
for	O
each	O
oncogene	O
separately	O
(	O
P	O
=	O
.0048	O
)	O
or	O
in	O
combination	O
(	O
P	O
=	O
.0007	O
)	O
.	O

We	O
propose	O
that	O
malignant	O
cell	O
cytokine	B-protein
production	O
may	O
help	O
explain	O
this	O
observation	O
.	O

Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	O
cells	O
constitutively	O
expressing	O
the	O
HTLV-I	B-protein
Tax	I-protein
protein	I-protein
.	O

Transient	O
short-term	O
expression	O
of	O
the	O
Tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type-I	O
(	O
HTLV-I	O
)	O
leads	O
to	O
activation	O
of	O
the	O
pleiotropic	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O

Consistent	O
with	O
findings	O
obtained	O
with	O
transient	O
expression	O
assays	O
,	O
we	O
observed	O
marked	O
accumulation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	O
the	O
nucleus	O
of	O
Namalwa	B-cell_line
B	I-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
which	O
constitutively	O
express	O
Tax	B-protein
.	O

In	O
contrast	O
,	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
not	O
detected	O
in	O
the	O
nucleus	O
following	O
long-term	O
expression	O
of	O
Tax	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

The	O
ability	O
of	O
both	O
mitogens	O
and	O
cytokines	B-protein
to	O
activate	O
NF-kappa	B-protein
B	I-protein
was	O
also	O
blocked	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
constitutively	O
expressing	O
Tax	B-protein
.	O

However	O
,	O
the	O
activation	O
of	O
other	O
mitogen-inducible	B-protein
transcription	I-protein
factors	I-protein
,	O
such	O
as	O
Fos	B-protein
and	O
Jun	B-protein
,	O
was	O
unaffected	O
.	O

Thus	O
,	O
depending	O
on	O
the	O
cellular	O
environment	O
,	O
the	O
short-	O
and	O
long-term	O
effects	O
of	O
Tax	B-protein
expression	O
can	O
be	O
quite	O
different	O
.	O

Consequently	O
,	O
one	O
function	O
of	O
Tax	B-protein
in	O
cells	O
infected	O
with	O
HTLV-I	O
might	O
involve	O
cell-type-specific	O
suppression	O
,	O
as	O
opposed	O
to	O
activation	O
,	O
of	O
distinct	O
signal	O
pathways	O
.	O

The	O
cells	O
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O
selective	O
regulation	O
of	O
gene	O
expression	O
.	O

Interferon-gamma	B-protein
and	O
the	O
sexual	O
dimorphism	O
of	O
autoimmunity	O
.	O

The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
has	O
remained	O
an	O
enigma	O
for	O
many	O
years	O
.	O

In	O
the	O
examination	O
of	O
the	O
induction	O
of	O
autoimmunity	O
in	O
transgenic	O
mice	O
,	O
evidence	O
has	O
been	O
obtained	O
further	O
implicating	O
the	O
lymphokine	B-protein
interferon-gamma	B-protein
in	O
the	O
etiology	O
of	O
autoimmunity	O
.	O

Sex	O
steroid	O
regulation	O
of	O
the	O
production	O
of	O
this	O
molecule	O
,	O
as	O
well	O
as	O
other	O
cytokines	B-protein
,	O
may	O
help	O
explain	O
the	O
gender-specific	O
differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O

Cloning	O
of	O
a	O
transcriptionally	B-protein
active	I-protein
human	I-protein
TATA	I-protein
binding	I-protein
factor	I-protein
.	O

Transcription	B-protein
factor	I-protein
IID	I-protein
(	O
TFIID	B-protein
)	O
binds	O
to	O
the	O
TATA	B-DNA
box	I-DNA
promoter	I-DNA
element	I-DNA
and	O
regulates	O
the	O
expression	O
of	O
most	O
eukaryotic	B-DNA
genes	I-DNA
transcribed	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
.	O

Complementary	B-DNA
DNA	I-DNA
(	O
cDNA	B-DNA
)	O
encoding	O
a	O
human	B-protein
TFIID	I-protein
protein	I-protein
has	O
been	O
cloned	O
.	O

The	O
human	B-protein
TFIID	I-protein
polypeptide	I-protein
has	O
339	O
amino	O
acids	O
and	O
a	O
molecular	O
size	O
of	O
37	O
,	O
745	O
daltons	O
.	O

The	O
carboxyl-terminal	B-protein
181	I-protein
amino	I-protein
acids	I-protein
of	O
the	O
human	B-protein
TFIID	I-protein
protein	I-protein
shares	O
80	O
%	O
identity	O
with	O
the	O
TFIID	B-protein
protein	O
from	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
amino	B-protein
terminus	I-protein
contains	O
an	O
unusual	O
repeat	O
of	O
38	O
consecutive	O
glutamine	O
residues	O
and	O
an	O
X-Thr-Pro	B-protein
repeat	I-protein
.	O

Expression	O
of	O
DNA	O
in	O
reticulocyte	O
lysates	O
or	O
in	O
Escherichia	O
coli	O
yielded	O
a	O
protein	O
that	O
was	O
competent	O
for	O
both	O
DNA	O
binding	O
and	O
transcription	O
activation	O
.	O

A	O
novel	O
T-cell	B-protein
trans-activator	I-protein
that	O
recognizes	O
a	O
phorbol	B-DNA
ester-inducible	I-DNA
element	I-DNA
of	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
.	O

The	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
recognized	O
by	O
several	O
cell-type-specific	B-protein
and	I-protein
ubiquitous	I-protein
transcriptional	I-protein
regulators	I-protein
that	O
integrate	O
information	O
transmitted	O
by	O
various	O
signaling	O
systems	O
leading	O
to	O
IL-2	B-protein
production	O
and	O
T-cell	B-cell_type
activation	O
.	O

Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein-DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	B-protein
T-cell-specific	I-protein
transcriptional	I-protein
activator	I-protein
TCF-1	B-protein
(	O
for	O
T-Cell	B-protein
Factor-1	I-protein
)	O
,	O
which	O
recognizes	O
a	O
T-cell-specific	B-DNA
response	I-DNA
element	I-DNA
(	O
TCE	B-DNA
)	O
located	O
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

Although	O
the	O
TCE	B-DNA
is	O
similar	O
in	O
sequence	O
to	O
a	O
consensus	B-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
,	O
several	O
criteria	O
indicate	O
that	O
TCF-1	B-protein
is	O
distinct	O
from	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

However	O
,	O
like	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
TCF-1	B-protein
activity	O
is	O
induced	O
by	O
phorbol	O
esters	O
and	O
other	O
T-cell	O
activators	O
.	O

Risk	O
factors	O
for	O
breast	O
recurrence	O
in	O
premenopausal	O
and	O
postmenopausal	O
patients	O
with	O
ductal	O
cancers	O
treated	O
by	O
conservation	O
therapy	O
.	O

Risk	O
factors	O
for	O
local	O
failure	O
were	O
evaluated	O
for	O
496	O
clinical	O
Stage	O
I-II	O
patients	O
with	O
infiltrating	O
ductal	O
carcinomas	O
(	O
median	O
follow-up	O
,	O
71	O
months	O
)	O
treated	O
by	O
conservative	O
surgery	O
and	O
radiotherapy	O
.	O

Monofactorial	O
analysis	O
identified	O
the	O
following	O
factors	O
to	O
be	O
correlated	O
with	O
increased	O
risk	O
:	O
moderate/marked	O
mononuclear	O
cell	O
reaction	O
(	O
MCR	O
)	O
,	O
high	O
histologic	O
grade	O
(	O
G	O
)	O
,	O
extensive	O
intraductal	O
component	O
(	O
EIC	O
)	O
,	O
tumor	O
necrosis	O
,	O
macroscopic	O
multiplicity	O
,	O
estrogen	B-protein
receptor	I-protein
negativity	O
,	O
anatomic	O
tumor	O
size	O
,	O
age	O
younger	O
than	O
40	O
years	O
,	O
and	O
vascular	O
invasion	O
.	O

Only	O
MCR	O
,	O
G	O
,	O
and	O
EIC	O
proved	O
significant	O
in	O
Cox	O
multivariate	O
analysis	O
.	O

These	O
risk	O
factors	O
were	O
highly	O
age	O
dependent	O
,	O
with	O
EIC	O
markedly	O
more	O
prevalent	O
in	O
women	O
younger	O
than	O
50	O
,	O
MCR	O
and	O
G	O
in	O
women	O
younger	O
than	O
40	O
.	O

Separate	O
Cox	O
analysis	O
for	O
premenopausal	O
patients	O
showed	O
that	O
MCR/EIC	O
determined	O
risk	O
independent	O
of	O
resection	O
margins	O
:	O
tumors	O
with	O
MCR	O
had	O
a	O
28	O
%	O
,	O
and	O
with	O
EIC	O
a	O
22	O
%	O
probability	O
of	O
recurring	O
locally	O
by	O
5	O
years	O
.	O

Premenopausal	O
patients	O
with	O
neither	O
risk	O
factor	O
had	O
a	O
very	O
low	O
failure	O
rate	O
(	O
2.6	O
%	O
at	O
5	O
years	O
)	O
,	O
regardless	O
of	O
age	O
.	O

For	O
postmenopausal	O
patients	O
risk	O
of	O
breast	O
recurrence	O
was	O
determined	O
both	O
by	O
adequacy	O
of	O
resection	O
margins	O
and	O
grade	O
,	O
with	O
a	O
high	O
local	O
failure	O
rate	O
for	O
patients	O
having	O
G3	O
tumors	O
with	O
positive	O
or	O
indeterminate	O
margins	O
(	O
31	O
%	O
at	O
5	O
years	O
)	O
.	O

The	O
authors	O
conclude	O
that	O
the	O
microscopic	O
examination	O
is	O
the	O
only	O
useful	O
tool	O
for	O
assessing	O
the	O
risk	O
of	O
local	O
failure	O
,	O
which	O
is	O
quite	O
low	O
for	O
the	O
majority	O
of	O
patients	O
treated	O
with	O
breast	O
conservation	O
.	O

High-risk	O
patients	O
can	O
be	O
recognized	O
morphologically	O
.	O

The	O
age	O
dependence	O
of	O
morphologic	O
risk	O
factors	O
appears	O
to	O
explain	O
the	O
high	O
local	O
failure	O
rate	O
seen	O
in	O
patients	O
younger	O
than	O
40	O
.	O

Tax	B-protein
-independent	O
binding	O
of	O
multiple	O
cellular	B-protein
factors	I-protein
to	O
Tax-response	B-DNA
element	I-DNA
DNA	I-DNA
of	O
HTLV-I	O
.	O

The	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
promoter	I-DNA
contains	O
three	O
copies	O
of	O
imperfect	O
repeats	O
of	O
a	O
21-base	O
pair	O
sequence	O
designated	O
here	O
as	O
TRE	B-DNA
(	O
Tax-response	B-DNA
element	I-DNA
)	O
that	O
is	O
responsive	O
to	O
the	O
virally	B-protein
encoded	I-protein
transactivator	I-protein
protein	I-protein
Tax	B-protein
.	O

We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	B-protein
proteins	I-protein
from	O
C81-66-45	O
cells	O
,	O
an	O
HTLV-I	B-cell_line
immortalized	I-cell_line
Tax-expressing	I-cell_line
human	I-cell_line
T-lymphocyte	I-cell_line
line	I-cell_line
(	O
Salahuddin	O
et	O
al.	O
,	O
1983	O
)	O
,	O
that	O
interact	O
with	O
the	O
TRE-DNA	B-DNA
,	O
none	O
of	O
which	O
are	O
identical	O
with	O
the	O
Tax-protein	B-protein
.	O

The	O
proteins	O
identified	O
have	O
molecular	O
weights	O
of	O
about	O
32	O
,	O
36	O
to	O
42	O
,	O
50	O
and	O
110	O
kD	O
.	O

Four	O
different	O
methods	O
were	O
used	O
to	O
identify	O
the	O
proteins	O
.	O

First	O
,	O
from	O
different	O
cell	O
lines	O
three	O
or	O
all	O
four	O
of	O
the	O
nuclear	B-protein
proteins	I-protein
were	O
specifically	O
cross-linked	O
by	O
UV	O
irradiation	O
to	O
the	O
radioactively	O
labeled	O
TRE-DNA	B-DNA
fragment	I-DNA
.	O

Second	O
,	O
TRE-DNA	B-protein
binding	I-protein
proteins	I-protein
sedimented	O
through	O
a	O
glycerol	O
density	O
gradient	O
at	O
rates	O
corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD	O
.	O

Third	O
,	O
only	O
the	O
50	B-protein
kD	I-protein
protein	I-protein
was	O
retained	O
on	O
a	O
biotinylated	O
DNA-streptavidin	O
matrix	O
when	O
the	O
DNA	O
fragment	O
contained	O
the	O
TRE-DNA	B-DNA
.	O

Fourth	O
,	O
extensive	O
purification	O
by	O
several	O
cycles	O
of	O
TRE	B-DNA
-DNA	O
affinity	O
chromatography	O
resulted	O
in	O
the	O
32	B-protein
,	I-protein
36	I-protein
to	I-protein
42	I-protein
and	I-protein
110	I-protein
kD	I-protein
proteins	I-protein
and	O
to	O
less	O
extent	O
the	O
50	B-protein
kD	I-protein
factor	I-protein
.	O

Two	O
abundant	O
proteins	O
of	O
75	O
and	O
80	O
kD	O
were	O
competed	O
out	O
by	O
poly	O
[	O
d	O
(	O
I-C	O
)	O
]	O
in	O
all	O
reactions	O
.	O

The	O
cAMP-response	B-DNA
element	I-DNA
CRE	B-DNA
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	B-DNA
base-pair	I-DNA
sequence	I-DNA
,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein-	O
TRE	B-DNA
-DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
's	O
destroys	O
this	O
complex	O
.	O

This	O
result	O
suggests	O
that	O
the	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
,	O
CREB	B-protein
,	O
is	O
involved	O
in	O
the	O
protein-TRE-DNA	B-protein
complex	I-protein
and	O
in	O
mediating	O
the	O
Tax	B-protein
response	O
.	O

Two	O
distinct	O
transcription	B-protein
factors	I-protein
that	O
bind	O
the	O
immunoglobulin	B-DNA
enhancer	I-DNA
microE5/kappa	B-DNA
2	I-DNA
motif	I-DNA
.	O

Activity	O
of	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
and	I-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
gene	I-DNA
enhancers	I-DNA
depends	O
on	O
a	O
complex	O
interplay	O
of	O
ubiquitous	B-protein
and	I-protein
developmentally	I-protein
regulated	I-protein
proteins	I-protein
.	O

Two	O
complementary	B-DNA
DNAs	I-DNA
were	O
isolated	O
that	O
encode	O
proteins	O
,	O
denoted	O
ITF-1	B-protein
and	O
ITF-2	B-protein
,	O
that	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
bind	O
the	O
microE5/kappa	B-DNA
2	I-DNA
motif	I-DNA
found	O
in	O
both	O
heavy	B-DNA
and	I-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
enhancers	I-DNA
.	O

The	O
complementary	B-DNA
DNAs	I-DNA
are	O
the	O
products	O
of	O
distinct	O
genes	O
,	O
yet	O
both	O
ITF-1	B-protein
and	O
ITF-2	B-protein
are	O
structurally	O
and	O
functionally	O
similar	O
.	O

The	O
two	O
proteins	O
interact	O
with	O
one	O
another	O
through	O
their	O
putative	O
helix-loop-helix	B-protein
motifs	I-protein
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O

Elevated	O
glucocorticoid	B-protein
receptor	I-protein
concentrations	O
before	O
and	O
after	O
glucocorticoid	O
therapy	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
patients	O
with	O
atopic	O
dermatitis	O
.	O

The	O
number	O
and	O
affinity	O
of	O
glucocorticoid	O
binding	O
sites	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
patients	O
with	O
atopic	O
dermatitis	O
(	O
AD	O
)	O
and	O
healthy	O
controls	O
were	O
determined	O
under	O
baseline	O
conditions	O
and	O
after	O
a	O
defined	O
oral	O
glucocorticoid	O
treatment	O
.	O

Patients	O
with	O
AD	O
(	O
n	O
=	O
15	O
)	O
exhibited	O
significantly	O
more	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
per	O
cell	O
than	O
the	O
control	O
group	O
(	O
n	O
=	O
22	O
)	O
,	O
while	O
the	O
GR	B-protein
affinity	O
did	O
not	O
differ	O
.	O

Methylprednisolone	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
GR	B-protein
sites	O
per	O
cell	O
in	O
the	O
steroid-treated	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
contrast	O
to	O
the	O
patients	O
.	O

The	O
dissociation	O
constant	O
was	O
not	O
affected	O
by	O
methylprednisolone	O
treatment	O
in	O
either	O
group	O
.	O

In	O
view	O
of	O
the	O
therapeutic	O
efficiency	O
of	O
glucocorticoids	O
in	O
AD	O
and	O
findings	O
of	O
abnormal	O
cAMP	O
and	O
cAMP-phosphodiesterase	O
activity	O
,	O
the	O
elevated	O
GR	B-protein
concentrations	O
in	O
AD	O
lend	O
support	O
to	O
the	O
hypothesis	O
of	O
a	O
compensatory	O
GR	B-protein
upregulation	O
due	O
to	O
an	O
insufficient	O
action	O
of	O
endogenous	O
cortisol	O
or	O
to	O
altered	O
cAMP-induced	O
GR	B-protein
expression	O
.	O

The	O
actions	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
suggest	O
a	O
novel	O
step	O
in	O
the	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Cyclosporin	O
A	O
and	O
FK506	O
are	O
immunosuppressive	O
compounds	O
that	O
have	O
similar	O
inhibitory	O
effects	O
on	O
the	O
expression	O
of	O
several	O
lymphokines	B-protein
produced	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Despite	O
their	O
similar	O
effects	O
the	O
drugs	O
bind	O
to	O
two	O
different	O
cytosolic	B-protein
protein	I-protein
,	O
cyclophilin	B-protein
and	O
FKBP	B-protein
respectively	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
they	O
have	O
different	O
modes	O
of	O
action	O
.	O

Using	O
constructs	O
in	O
which	O
mRNA	B-RNA
production	O
controlled	O
by	O
a	O
specific	O
transcription	B-protein
factor	I-protein
could	O
be	O
readily	O
measured	O
we	O
found	O
that	O
both	O
cyclosporin	O
A	O
and	O
FK506	O
completely	O
inhibited	O
transcription	O
activated	O
by	O
NF-AT	B-protein
,	O
NFIL2	B-protein
A	I-protein
,	O
NFIL2	B-protein
B	I-protein
and	O
partially	O
inhibited	O
transcription	O
activated	O
by	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

Cyclosporin	O
A	O
and	O
FK506	O
inhibited	O
only	O
transcriptional	O
activation	O
that	O
was	O
dependent	O
on	O
Ca2+	O
mobilization	O
.	O

However	O
,	O
cyclosporin	O
A	O
and	O
FK506	O
did	O
not	O
inhibit	O
Ca2+	O
mobilization	O
dependent	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
indicating	O
that	O
only	O
a	O
subset	O
of	O
signalling	O
pathways	O
regulated	O
by	O
Ca2+	O
is	O
sensitive	O
to	O
these	O
drugs	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
qualitative	O
differences	O
between	O
the	O
effect	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
on	O
six	O
different	O
transcription	B-protein
factors	I-protein
which	O
suggests	O
that	O
these	O
drugs	O
may	O
interfere	O
with	O
the	O
activity	O
of	O
a	O
novel	O
Ca2+	O
dependent	O
step	O
that	O
regulates	O
several	O
transcription	B-protein
factors	I-protein
.	O

The	O
internal	O
methionine	O
codons	O
of	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
II	I-DNA
rex	I-DNA
gene	I-DNA
are	O
not	O
required	O
for	O
p24rex	B-protein
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
types	O
I	O
(	O
HTLV-I	O
)	O
and	O
II	O
(	O
HTLV-II	O
)	O
have	O
two	O
nonstructural	B-DNA
trans-acting	I-DNA
regulatory	I-DNA
genes	I-DNA
,	O
tax	B-DNA
and	O
rex	B-DNA
,	O
located	O
in	O
the	O
3	B-DNA
'	I-DNA
region	I-DNA
of	O
the	O
viral	B-DNA
genome	I-DNA
.	O

The	O
tax	B-protein
gene	I-protein
product	I-protein
(	O
HTLV-I	B-protein
p40tax	I-protein
and	O
HTLV-II	B-protein
p37tax	I-protein
)	O
is	O
the	O
transcriptional	O
activator	O
of	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

The	O
rex	B-DNA
gene	I-DNA
encodes	O
two	O
protein	O
products	O
,	O
p27rex/p21rex	B-protein
and	O
p26rex/p24rex	B-protein
in	O
HTLV-I	O
and	O
HTLV-II	O
,	O
respectively	O
.	O

Rex	B-protein
acts	O
posttranscriptionally	O
to	O
facilitate	O
accumulation	O
of	O
full-length	O
gag/pol	B-protein
and	O
singly	O
spliced	O
env	B-RNA
mRNA	I-RNA
in	O
the	O
cytoplasm	O
of	O
HTLV-infected	B-cell_type
cells	I-cell_type
.	O

Previous	O
studies	O
showed	O
that	O
the	O
first	O
ATG	O
of	O
the	O
rex	B-DNA
gene	I-DNA
is	O
critical	O
for	O
Rex	B-protein
production	O
and	O
function	O
.	O

The	O
importance	O
of	O
the	O
internal	O
ATGs	O
to	O
Rex	B-protein
function	O
is	O
not	O
known	O
.	O

However	O
,	O
in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV-I	O
rex	B-DNA
gene	I-DNA
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	B-protein
,	O
and	O
by	O
analogy	O
HTLV-II	O
p24rex	B-protein
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	O
AUG	O
of	O
the	O
tax/rex	B-RNA
mRNA	I-RNA
.	O

By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV-II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	B-DNA
gene	I-DNA
on	O
Rex	B-protein
protein	O
production	O
and	O
function	O
.	O

Our	O
results	O
indicate	O
that	O
p24rex	B-protein
of	O
HTLV-II	O
is	O
not	O
initiated	O
at	O
an	O
internal	O
AUG	O
and	O
that	O
the	O
internal	O
methionine	O
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	B-DNA
gene	I-DNA
and	O
,	O
ultimately	O
,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O

Astrocytes	B-cell_type
and	O
glioblastoma	B-cell_type
cells	I-cell_type
express	O
novel	O
octamer-DNA	B-protein
binding	I-protein
proteins	I-protein
distinct	O
from	O
the	O
ubiquitous	B-protein
Oct-1	I-protein
and	I-protein
B	I-protein
cell	I-protein
type	I-protein
Oct-2	I-protein
proteins	I-protein
.	O

The	O
'octamer	B-DNA
'	I-DNA
sequence	I-DNA
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
in	O
B-lymphocytes	B-cell_type
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	B-DNA
genes	I-DNA
in	O
all	O
cell	O
types	O
.	O

In	O
lymphocytes	B-cell_type
,	O
the	O
octamer-binding	B-protein
protein	I-protein
Oct-2A	B-protein
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
B-cell	B-DNA
specific	I-DNA
gene	I-DNA
expression	O
,	O
while	O
the	O
ubiquitous	O
protein	O
Oct-1	O
seems	O
to	O
control	O
general	O
octamer	B-DNA
site	I-DNA
-dependent	O
transcription	O
.	O

Various	O
other	O
genes	O
,	O
for	O
example	O
interleukin-1	B-DNA
and	I-DNA
MHC	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
,	O
contain	O
an	O
octamer	B-DNA
sequence	I-DNA
in	O
the	O
promoter	B-DNA
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

This	O
prompted	O
us	O
to	O
analyze	O
the	O
octamer-binding	B-protein
proteins	I-protein
in	O
the	O
latter	O
cells	O
.	O

Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
at	O
least	O
six	O
novel	O
octamer	B-protein
binding	I-protein
proteins	I-protein
were	O
detected	O
in	O
nuclear	O
extracts	O
of	O
cultured	B-cell_type
mouse	I-cell_type
astrocytes	I-cell_type
.	O

These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	B-cell_line
glioblastoma	I-cell_line
and	I-cell_line
neuroblastoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
nervous	B-protein
system-derived	I-protein
(	I-protein
N-Oct	I-protein
)	I-protein
proteins	I-protein
bound	O
to	O
the	O
octamer	B-DNA
DNA	I-DNA
sequence	I-DNA
in	O
a	O
manner	O
which	O
is	O
indistinguishable	O
from	O
the	O
Oct-1	B-protein
and	O
Oct-2A	B-protein
proteins	I-protein
.	O

The	O
relationship	O
of	O
the	O
N-Oct	B-protein
proteins	I-protein
to	O
Oct-1	B-protein
and	O
Oct-2A	B-protein
was	O
analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	O
Oct-1	B-protein
and	O
Oct-2A	B-protein
proteins	O
.	O

On	O
the	O
basis	O
of	O
these	O
assays	O
,	O
all	O
N-Oct-factors	B-protein
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
ubiquitous	B-protein
Oct-1	I-protein
and	O
the	O
lymphoid-specific	B-protein
Oct-2A	I-protein
proteins	O
.	O

In	O
melanoma	B-cell_type
cells	I-cell_type
that	O
contain	O
the	O
N-Oct-3	B-protein
factor	I-protein
,	O
a	O
transfected	O
lymphocyte-specific	O
promoter	O
was	O
neither	O
activated	O
nor	O
was	O
it	O
repressed	O
upon	O
contransfection	O
with	O
an	O
Oct-2A	B-DNA
expression	I-DNA
vector	I-DNA
.	O

We	O
therefore	O
speculate	O
that	O
N-Oct-3	B-protein
and	O
other	O
N-Oct	B-protein
factors	I-protein
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
.	O

Detection	O
in	O
non-erythroid	B-cell_type
cells	I-cell_type
of	O
a	O
factor	O
with	O
the	O
binding	O
characteristics	O
of	O
the	O
erythroid	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
EF1	B-protein
.	O

The	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
erythroid	B-protein
factor-1	I-protein
(	O
EF1	B-protein
)	O
plays	O
a	O
critical	O
role	O
in	O
the	O
transcription	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
.	O

Here	O
we	O
report	O
the	O
presence	O
of	O
a	O
factor	O
with	O
the	O
mobility	O
and	O
sequence-specific	O
DNA-binding	O
characteristics	O
of	O
EF1	B-protein
at	O
low	O
abundance	O
in	O
a	O
wide	O
variety	O
of	O
non-erythroid	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
EF1	B-protein
-like	O
activity	O
in	O
non-erythroid	B-cell_type
cells	I-cell_type
and	O
indicates	O
that	O
this	O
factor	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	B-DNA
expressed	O
in	O
such	O
cells	O
.	O

Protein	O
kinase	O
inhibitor	O
H-7	O
blocks	O
accumulation	O
of	O
unspliced	B-RNA
mRNA	I-RNA
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
.	O

Rex	B-protein
,	O
the	O
post-transcriptional	B-protein
regulator	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
,	O
is	O
known	O
to	O
induce	O
accumulation	O
of	O
the	O
unspliced	B-RNA
viral	I-RNA
gag-pol	I-RNA
mRNA	I-RNA
.	O

Rex	B-protein
is	O
a	O
phosphoprotein	B-protein
found	O
in	O
the	O
cell	O
nucleolus	O
,	O
whose	O
function	O
may	O
be	O
regulated	O
by	O
its	O
localization	O
and	O
phosphorylation	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
phosphorylation	O
on	O
Rex	B-protein
function	O
by	O
using	O
a	O
protein	O
kinase	O
inhibitor	O
,	O
H-7	O
[	O
1-	O
(	O
5-isoquinolinyl-sulfonyl	O
)	O
-2-methylpiperazine	O
]	O
.	O

Treatment	O
of	O
an	O
HTLV-I	B-cell_line
infected	I-cell_line
human	I-cell_line
T-cell	I-cell_line
line	I-cell_line
with	O
H-7	O
blocked	O
specifically	O
accumulation	O
of	O
the	O
unspliced	B-RNA
gag-pol	I-RNA
mRNA	I-RNA
,	O
resulting	O
in	O
the	O
decreased	O
Gag	B-protein
protein	I-protein
synthesis	O
that	O
corresponds	O
with	O
the	O
decreased	O
in	O
vivo	O
phosphorylation	O
of	O
Rex	B-protein
.	O

In	O
contrast	O
,	O
other	O
viral	O
and	O
cellular	O
products	O
have	O
not	O
been	O
influenced	O
by	O
the	O
level	O
of	O
H-7	O
used	O
.	O

Therefore	O
,	O
the	O
phosphorylation	O
of	O
Rex	B-protein
is	O
required	O
for	O
the	O
viral	O
RNA	O
partition	O
of	O
HTLV-I	O
.	O

Increased	O
glucocorticoid	O
responsiveness	O
of	O
CD4+	B-cell_line
T-cell	I-cell_line
clonal	I-cell_line
lines	I-cell_line
grown	O
in	O
serum-free	O
media	O
.	O

CEM-C7	B-cell_line
,	O
a	O
human	B-cell_line
leukemic	I-cell_line
CD4+	I-cell_line
T-lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
three	O
of	O
its	O
subclones	O
,	O
CEM-4R4	B-cell_line
,	O
CEM-3R43	B-cell_line
,	O
and	O
ICR-27	B-cell_line
,	O
previously	O
cultured	O
in	O
a	O
medium	O
supplemented	O
with	O
5	O
to	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
have	O
been	O
adapted	O
to	O
serum-free	O
media	O
.	O

The	O
best	O
medium	O
of	O
those	O
tested	O
was	O
RPMI	O
1640	O
supplemented	O
with	O
5	O
micrograms/ml	O
each	O
transferrin	B-protein
and	O
insulin	B-protein
+	O
5	O
ng/ml	O
sodium	O
selenite	O
+/-	O
0.1	O
%	O
bovine	B-protein
serum	I-protein
albumin	I-protein
.	O

While	O
growing	O
either	O
with	O
or	O
without	O
albumin	O
,	O
the	O
several	O
clonal	B-cell_line
lines	I-cell_line
of	O
CEM	B-cell_line
cells	O
displayed	O
growth	O
similar	O
to	O
serum-supplemented	O
cultures	O
.	O

Cell	O
proliferation	O
of	O
CEM-C7	B-cell_line
cells	O
cultured	O
in	O
both	O
serum-free	O
media	O
has	O
been	O
sustained	O
for	O
3	O
mo	O
.	O

with	O
culture	O
doubling	O
times	O
of	O
about	O
25	O
h	O
for	O
both	O
serum-supplemented	B-cell_line
and	I-cell_line
serum-free	I-cell_line
cultures	I-cell_line
(	O
viability	O
greater	O
than	O
or	O
equal	O
to	O
90	O
%	O
)	O
.	O

Cell	O
morphology	O
remained	O
essentially	O
the	O
same	O
in	O
serum-free	O
or	O
serum	O
containing	O
media	O
.	O

The	O
expression	O
of	O
CD4	B-protein
,	O
a	O
marker	O
for	O
T-derived	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
was	O
not	O
significantly	O
different	O
in	O
serum-free	O
medium	O
.	O

When	O
grown	O
in	O
serum-free	O
medium	O
,	O
CEM-C7	B-cell_line
cells	O
exhibited	O
increased	O
steroid	O
responsiveness	O
as	O
evidenced	O
by	O
increased	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
sites	O
,	O
increased	O
induction	O
of	O
glutamine	B-protein
synthetase	I-protein
,	O
and	O
cell	O
lysis	O
at	O
lower	O
concentrations	O
of	O
steroid	O
.	O

Receptor	O
mutant	O
subclones	O
of	O
CEM-C7	B-cell_line
,	O
which	O
are	O
proven	O
to	O
be	O
completely	O
unresponsive	O
to	O
micromolar	O
concentrations	O
of	O
dexamethasone	O
when	O
grown	O
in	O
serum-supplemented	O
medium	O
,	O
become	O
partially	O
sensitive	O
to	O
the	O
hormone	O
after	O
growth	O
in	O
defined	O
medium	O
.	O

The	O
increased	O
sensitivity	O
of	O
CEM-C7	B-cell_line
cells	I-cell_line
and	O
its	O
subclones	O
to	O
dexamethasone	O
in	O
serum-free	O
medium	O
returned	O
to	O
previous	O
levels	O
when	O
these	O
cells	O
were	O
recultured	O
in	O
serum-containing	O
medium	O
.	O

Our	O
results	O
suggest	O
that	O
substances	O
in	O
serum	O
influence	O
steroid	O
effects	O
on	O
these	O
cells	O
and	O
that	O
the	O
molecular	O
details	O
of	O
glucocorticoid	O
hormone	O
action	O
may	O
be	O
pursued	O
more	O
precisely	O
in	O
a	O
clearly	O
defined	O
culture	O
medium	O
.	O

[	O
Glucocorticoid	B-protein
receptors	I-protein
on	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	I-cell_type
:	O
changes	O
in	O
patients	O
with	O
yang-deficiency	O
]	O

It	O
was	O
found	O
that	O
,	O
in	O
former	O
works	O
,	O
the	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
on	O
peripheral	B-cell_type
mixed	I-cell_type
leucocytes	I-cell_type
in	O
patients	O
with	O
Yang-deficiency	O
were	O
decreased	O
.	O

In	O
this	O
work	O
,	O
the	O
mixed	B-cell_type
leucocytes	I-cell_type
were	O
further	O
separated	O
into	O
mononuclear	B-cell_type
(	I-cell_type
MNL	I-cell_type
)	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
(	I-cell_type
PML	I-cell_type
)	I-cell_type
leucocytes	I-cell_type
,	O
and	O
GCR	B-protein
were	O
determined	O
in	O
each	O
part	O
of	O
leucocytes	B-cell_type
.	O

GCR	B-protein
on	O
MNL	B-cell_type
and	O
PML	B-cell_type
in	O
6	O
Yang	O
deficient	O
patients	O
were	O
3473	O
+/-	O
413	O
and	O
4433	O
+/-	O
651	O
sites/cell	O
respectively	O
,	O
statistically	O
significant	O
from	O
the	O
normal	O
control	O
group	O
(	O
4462	O
+/-	O
962	O
and	O
5622	O
+/-	O
782	O
sites/cell	O
respectively	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

GCR	B-protein
on	O
MNL	B-cell_type
,	O
PML	B-cell_type
and	O
mixed	B-cell_type
leucocytes	I-cell_type
in	O
5	O
patients	O
were	O
determined	O
simultaneously	O
,	O
and	O
all	O
lowered	O
from	O
the	O
control	O
group	O
.	O

The	O
results	O
were	O
3369	O
+/-	O
370	O
,	O
4986	O
+/-	O
419	O
and	O
4524	O
+/-	O
852	O
sites/cell	O
respectively	O
,	O
with	O
the	O
lowest	O
GCR	B-protein
on	O
MNL	B-cell_type
and	O
highest	O
on	O
PML	B-cell_type
.	O

The	O
ubiquitous	B-protein
octamer-binding	I-protein
protein	I-protein
(	O
s	O
)	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

All	O
immunoglobulin	B-DNA
genes	I-DNA
contain	O
a	O
conserved	O
octanucleotide	B-DNA
promoter	I-DNA
element	I-DNA
,	O
ATGCAAAT	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B-cell-specific	O
transcription	O
.	O

Proteins	O
that	O
bind	O
this	O
octamer	O
have	O
been	O
purified	O
,	O
and	O
cDNAs	B-DNA
encoding	O
octamer-binding	B-protein
proteins	I-protein
have	O
been	O
cloned	O
.	O

Some	O
of	O
these	O
proteins	O
(	O
referred	O
to	O
as	O
OTF-2	B-protein
)	O
are	O
lymphoid	O
specific	O
,	O
whereas	O
at	O
least	O
one	O
other	O
,	O
and	O
possibly	O
more	O
(	O
referred	O
to	O
as	O
OTF-1	B-protein
)	O
,	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O
types	O
.	O

The	O
exact	O
role	O
of	O
these	O
different	O
proteins	O
in	O
directing	O
the	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
is	O
unclear	O
.	O

We	O
have	O
identified	O
two	O
human	B-cell_line
pre-B-cell	I-cell_line
lines	I-cell_line
that	O
contain	O
extremely	O
low	O
levels	O
of	O
OTF-2	B-protein
yet	O
still	O
express	O
high	O
levels	O
of	O
steady-state	B-RNA
immunoglobulin	I-RNA
heavy-chain	I-RNA
mRNA	I-RNA
in	O
vivo	O
and	O
efficiently	O
transcribe	O
an	O
immunoglobulin	B-DNA
gene	I-DNA
in	O
vitro	O
.	O

Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF-1	B-protein
made	O
from	O
one	O
of	O
these	O
pre-B	B-cell_line
cells	I-cell_line
or	O
from	O
HeLa	B-cell_line
cells	I-cell_line
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O
immunoglobulin	B-DNA
gene	I-DNA
.	O

Furthermore	O
,	O
OFT-1	O
appeared	O
to	O
have	O
approximately	O
the	O
same	O
transactivation	O
ability	O
as	O
OTF-2	B-protein
when	O
normalized	O
for	O
binding	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
OTF-1	B-protein
,	O
without	O
OTF-2	B-protein
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
and	O
that	O
OTF-2	B-protein
alone	O
is	O
not	O
responsible	O
for	O
the	O
B-cell-specific	O
regulation	O
of	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
.	O

Effects	O
of	O
aldosterone	O
on	O
intralymphocytic	O
sodium	O
and	O
potassium	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O

In	O
vitro	O
binding	O
of	O
aldosterone	O
to	O
mineralocorticoid	B-protein
receptors	I-protein
on	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
HML	B-cell_type
)	O
and	O
its	O
effects	O
on	O
the	O
intracellular	O
sodium	O
and	O
potassium	O
concentrations	O
of	O
HML	B-cell_type
have	O
already	O
been	O
described	O
.	O

In	O
the	O
present	O
paper	O
this	O
easily	O
accessible	O
human	O
cell	O
model	O
was	O
investigated	O
in	O
13	O
patients	O
with	O
essential	O
hypertension	O
.	O

In	O
only	O
four	O
patients	O
sodium	O
in	O
HML	B-cell_type
without	O
incubation	O
was	O
elevated	O
compared	O
with	O
the	O
range	O
for	O
normal	O
persons	O
.	O

A	O
decrease	O
of	O
intracellular	O
sodium	O
or	O
potassium	O
occurred	O
during	O
incubation	O
without	O
aldosterone	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

The	O
addition	O
of	O
1.4	O
nM	O
aldosterone	O
did	O
not	O
prevent	O
this	O
loss	O
of	O
electrolytes	O
as	O
observed	O
in	O
normal	O
persons	O
.	O

Plasma	B-protein
renin	I-protein
activity	O
and	O
aldosterone	O
were	O
not	O
correlated	O
with	O
the	O
electrolyte	O
response	O
and	O
were	O
within	O
the	O
normal	O
limits	O
.	O

The	O
number	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
/cell	O
were	O
within	O
or	O
close	O
to	O
the	O
normal	O
range	O
(	O
n	O
=	O
9	O
)	O
.	O

The	O
independence	O
of	O
intracellular	O
electrolytes	O
from	O
aldosterone	O
despite	O
a	O
normal	O
number	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
may	O
reflect	O
an	O
impairment	O
of	O
the	O
mineralocorticoid	O
effector	O
mechanism	O
in	O
the	O
HML	B-cell_type
of	O
patients	O
with	O
essential	O
hypertension	O
.	O

[	O
Differential	O
diagnostic	O
value	O
of	O
receptors	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
determination	O
in	O
lymphocytes	B-cell_type
of	O
children	O
with	O
rickets	O
and	O
rickets-like	O
diseases	O
]	O

The	O
authors	O
provide	O
the	O
results	O
of	O
studying	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
in	O
lymphocytes	B-cell_type
of	O
children	O
with	O
rickets	O
and	O
rickets-like	O
diseases	O
.	O

It	O
is	O
proposed	O
that	O
the	O
character	O
of	O
their	O
expression	O
under	O
the	O
influence	O
of	O
vitamin	O
D	O
may	O
be	O
used	O
with	O
differential	O
diagnostic	O
purposes	O
in	O
view	O
.	O

Regulation	O
of	O
gene	O
expression	O
with	O
double-stranded	O
phosphorothioate	O
oligonucleotides	O
.	O

Alteration	O
of	O
gene	O
transcription	O
by	O
inhibition	O
of	O
specific	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
is	O
necessary	O
for	O
determining	O
how	O
these	O
factors	O
participate	O
in	O
cellular	O
differentiation	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods	O
,	O
each	O
with	O
specific	O
limitations	O
.	O

Inhibition	O
of	O
sequence-specific	B-protein
DNA-binding	I-protein
proteins	I-protein
was	O
achieved	O
with	O
double-stranded	O
(	O
ds	O
)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	B-DNA
or	I-DNA
kappa	I-DNA
B	I-DNA
consensus	I-DNA
sequences	I-DNA
.	O

The	O
phosphorothioate	O
oligonucleotides	O
specifically	O
bound	O
either	O
octamer	B-protein
transcription	I-protein
factor	I-protein
or	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O

The	O
modified	O
oligonucleotides	O
accumulated	O
in	O
cells	O
more	O
effectively	O
than	O
standard	O
ds	O
oligonucleotides	O
and	O
modulated	O
gene	O
expression	O
in	O
a	O
specific	O
manner	O
.	O

Octamer-dependent	O
activation	O
of	O
a	O
reporter	B-DNA
plasmid	I-DNA
or	O
NF-kappa	B-protein
B	I-protein
-dependent	O
activation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
enhancer	I-DNA
was	O
inhibited	O
when	O
the	O
appropriate	O
phosphorothioate	O
oligonucleotide	O
was	O
added	O
to	O
a	O
transiently	B-cell_line
transfected	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	B-DNA
consensus	I-DNA
to	O
Jurkat	B-cell_line
T	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
inhibited	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
secretion	O
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	B-DNA
octamer	I-DNA
site	I-DNA
in	O
the	O
IL-2	B-DNA
enhancer	I-DNA
.	O

The	O
ds	O
phosphorothioate	O
oligonucleotides	O
probably	O
compete	O
for	O
binding	O
of	O
specific	O
transcription	O
factors	O
and	O
may	O
provide	O
anti-viral	O
,	O
immunosuppressive	O
,	O
or	O
other	O
therapeutic	O
effects	O
.	O

[	O
Effect	O
of	O
the	O
regimen	O
of	O
kidney-tonifying	O
and	O
qi-invigorating	O
on	O
aging	O
changes	O
of	O
glucocorticoid	B-protein
receptor	I-protein
]	O

The	O
plasma	O
cortisol	O
concentration	O
and	O
the	O
sites	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GCR	B-protein
)	O
in	O
the	O
peripheral	B-cell_type
lymphocytes	I-cell_type
were	O
measured	O
in	O
32	O
healthy	O
aged	O
persons	O
and	O
13	O
young	O
adults	O
.	O

In	O
animal	O
experiment	O
,	O
GCR	B-protein
of	O
spleen	B-cell_type
lymphocytic	I-cell_type
cell	I-cell_type
was	O
also	O
measured	O
in	O
18	O
aged	O
rats	O
and	O
9	O
young	O
rats	O
.	O

The	O
results	O
showed	O
that	O
GCR	B-protein
was	O
significantly	O
lower	O
in	O
the	O
aged	O
persons	O
or	O
rats	O
than	O
that	O
in	O
the	O
young	O
while	O
the	O
plasma	O
cortisol	O
level	O
did	O
n't	O
change	O
with	O
aging	O
.	O

So	O
we	O
think	O
that	O
GCR	B-protein
is	O
more	O
sensitive	O
than	O
the	O
plasma	O
cortisol	O
level	O
to	O
reflect	O
the	O
aging	O
change	O
of	O
the	O
adrenal	O
cortex	O
function	O
.	O

After	O
the	O
treatment	O
with	O
the	O
regimen	O
of	O
Kidney-tonifying	O
and	O
Qi-invigorating	O
,	O
the	O
GCR	B-protein
of	O
the	O
aged	O
persons	O
and	O
rats	O
was	O
enhanced	O
,	O
and	O
in	O
this	O
way	O
,	O
the	O
function	O
of	O
the	O
aged	O
adrenal	O
cortex	O
was	O
improved	O
.	O

Interferon	O
affects	O
nuclear	B-protein
proteins	I-protein
in	O
cells	O
of	O
clinically	O
sensitive	O
chronic	O
myelogenous	O
leukemia	O
patients	O
.	O

Cytoplasmic	O
protein	O
extracts	O
from	O
chronic	B-cell_type
myelogenous	I-cell_type
leukemia	I-cell_type
(	I-cell_type
CML	I-cell_type
)	I-cell_type
cells	I-cell_type
contained	O
an	O
activity	O
that	O
altered	O
the	O
electrophoretic	O
mobility	O
of	O
complexes	O
formed	O
between	O
nuclear	B-protein
proteins	I-protein
and	O
the	O
transcriptional	O
enhancers	O
of	O
interferon	O
(	O
IFN	O
)	O
-inducible	O
genes	O
.	O

Exposure	O
of	O
CML	B-cell_type
cells	I-cell_type
to	O
IFN-alpha	B-protein
diminished	O
the	O
effect	O
of	O
the	O
CML	B-protein
cytoplasmic	I-protein
proteins	I-protein
on	O
these	O
nuclear	B-protein
protein-DNA	I-protein
complexes	I-protein
.	O

The	O
presence	O
of	O
clinical	O
responsiveness	O
to	O
IFN-alpha	B-protein
correlated	O
with	O
the	O
sensitivity	O
to	O
the	O
IFN	B-protein
-induced	O
change	O
in	O
the	O
electrophoretic	O
mobility	O
of	O
nuclear	B-protein
protein-DNA	I-protein
complexes	I-protein
.	O

These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
IFN-alpha	B-protein
in	O
CML	O
may	O
be	O
linked	O
to	O
a	O
pathway	O
that	O
can	O
result	O
in	O
posttranslational	O
modification	O
of	O
nuclear	B-protein
proteins	I-protein
.	O

Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
transactivates	O
latent	B-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
.	O

Several	O
lines	O
of	O
evidence	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA-2	B-protein
)	O
or	O
leader	B-protein
protein	I-protein
(	O
EBNA-LP	B-protein
)	O
affects	O
expression	O
of	O
the	O
EBV	B-protein
latent	I-protein
infection	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
.	O

We	O
now	O
demonstrate	O
the	O
following	O
.	O

(	O
i	O
)	O
Acute	O
transfection	O
and	O
expression	O
of	O
EBNA-2	B-protein
under	O
control	O
of	O
simian	B-DNA
virus	I-DNA
40	I-DNA
or	I-DNA
Moloney	I-DNA
murine	I-DNA
leukemia	I-DNA
virus	I-DNA
promoters	I-DNA
resulted	O
in	O
increased	O
LMP1	B-protein
expression	O
in	O
P3HR-1-infected	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
and	O
the	O
P3HR-1	B-cell_line
or	O
Daudi	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

(	O
ii	O
)	O
Transfection	O
and	O
expression	O
of	O
EBNA-LP	B-protein
alone	O
had	O
no	O
effect	O
on	O
LMP1	B-protein
expression	O
and	O
did	O
not	O
act	O
synergistically	O
with	O
EBNA-2	B-protein
to	O
affect	O
LMP1	B-protein
expression	O
.	O

(	O
iii	O
)	O
LMP1	B-protein
expression	O
in	O
Daudi	B-cell_line
and	O
P3HR-1-infected	B-cell_line
cells	I-cell_line
was	O
controlled	O
at	O
the	O
mRNA	B-RNA
level	O
,	O
and	O
EBNA-2	B-protein
expression	O
in	O
Daudi	B-cell_line
cells	I-cell_line
increased	O
LMP1	B-RNA
mRNA	I-RNA
.	O

(	O
iv	O
)	O
No	O
other	O
EBV	B-DNA
genes	I-DNA
were	O
required	O
for	O
EBNA-2	B-protein
transactivation	O
of	O
LMP1	B-protein
since	O
cotransfection	O
of	O
recombinant	B-DNA
EBNA-2	I-DNA
expression	I-DNA
vectors	I-DNA
and	O
genomic	O
LMP1	B-DNA
DNA	I-DNA
fragments	I-DNA
enhanced	O
LMP1	B-protein
expression	O
in	O
the	O
EBV-negative	B-cell_line
B-lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
BJAB	B-cell_line
,	O
Louckes	B-cell_line
,	O
and	O
BL30	B-cell_line
.	O

(	O
v	O
)	O
An	O
EBNA-2-responsive	B-DNA
element	I-DNA
was	O
found	O
within	O
the	O
-512	B-DNA
to	I-DNA
+40	I-DNA
LMP1	I-DNA
DNA	I-DNA
since	O
this	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
was	O
transactivated	O
by	O
cotransfection	O
with	O
an	O
EBNA-2	B-DNA
expression	I-DNA
vector	I-DNA
.	O

(	O
vi	O
)	O
The	O
EBV	O
type	O
2	O
EBNA-2	B-protein
transactivated	O
LMP1	B-protein
as	O
well	O
as	O
the	O
EBV	B-protein
type	I-protein
1	I-protein
EBNA-2	I-protein
.	O

(	O
vii	O
)	O
Two	O
deletions	O
within	O
the	O
EBNA-2	B-protein
gene	O
which	O
rendered	O
EBV	O
transformation	O
incompetent	O
did	O
not	O
transactivate	O
LMP1	B-protein
,	O
whereas	O
a	O
transformation-competent	B-DNA
EBNA-2	I-DNA
deletion	I-DNA
mutant	I-DNA
did	O
transactivate	O
LMP1	B-protein
.	O

LMP1	B-protein
is	O
a	O
potent	O
effector	O
of	O
B-lymphocyte	O
activation	O
and	O
can	O
act	O
synergistically	O
with	O
EBNA-2	B-protein
to	O
induce	O
cellular	O
CD23	O
gene	O
expression	O
.	O

Thus	O
,	O
EBNA-2	B-protein
transactivation	O
of	O
LMP1	B-protein
amplifies	O
the	O
biological	O
impact	O
of	O
EBNA-2	B-protein
and	O
underscores	O
its	O
central	O
role	O
in	O
EBV-induced	O
growth	O
transformation	O
.	O

The	O
expression	O
of	O
c-fos	B-DNA
,	O
c-jun	B-DNA
,	O
and	O
c-myc	B-DNA
genes	I-DNA
is	O
regulated	O
by	O
heat	O
shock	O
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

The	O
effect	O
of	O
heat	O
shock	O
on	O
the	O
expression	O
of	O
the	O
nuclear	B-DNA
protooncogenes	I-DNA
c-fos	B-DNA
,	O
c-jun	B-DNA
,	O
and	O
c-myc	B-DNA
was	O
studied	O
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

Heat	O
shock	O
caused	O
an	O
increase	O
in	O
c-fos	O
and	O
c-jun	O
mRNA	O
levels	O
and	O
a	O
decrease	O
in	O
c-myc	B-RNA
mRNA	I-RNA
levels	O
in	O
pre-B	B-cell_line
(	I-cell_line
Hyon	I-cell_line
)	I-cell_line
and	I-cell_line
T	I-cell_line
(	I-cell_line
DND-41	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
well	O
as	O
in	O
freshly	O
isolated	O
normal	O
human	O
thymocytes	O
.	O

The	O
changes	O
in	O
the	O
mRNA	O
levels	O
of	O
these	O
protooncogenes	B-DNA
in	O
Hyon	B-cell_line
cells	I-cell_line
were	O
most	O
pronounced	O
at	O
42	O
and	O
43	O
degrees	O
C	O
;	O
kinetic	O
analysis	O
demonstrated	O
that	O
the	O
changes	O
could	O
be	O
detected	O
within	O
30	O
min	O
of	O
heat	O
shock	O
.	O

Altered	O
transcription	O
of	O
c-fos	B-DNA
and	O
c-myc	B-DNA
genes	I-DNA
was	O
the	O
primary	O
effect	O
of	O
heat	O
shock	O
.	O

Secondarily	O
,	O
heat	O
shock	O
of	O
Hyon	B-cell_line
cells	I-cell_line
stabilized	O
the	O
c-myc	B-RNA
mRNA	I-RNA
level	O
by	O
increasing	O
its	O
half-life	O
from	O
24	O
to	O
45	O
min	O
.	O

The	O
overall	O
effect	O
of	O
heat	O
shock	O
on	O
c-myc	B-RNA
mRNA	I-RNA
level	O
,	O
however	O
,	O
was	O
a	O
marked	O
inhibition	O
of	O
its	O
transcription	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcription	O
of	O
nuclear	B-DNA
protooncogenes	I-DNA
is	O
regulated	O
by	O
heat	O
shock	O
indicating	O
a	O
role	O
for	O
nuclear	B-DNA
protooncogenes	I-DNA
in	O
the	O
stress	O
response	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

Mapping	O
of	O
B-cell	B-protein
epitopes	I-protein
of	O
the	O
human	B-protein
hepatitis	I-protein
B	I-protein
virus	I-protein
X	I-protein
protein	I-protein
.	O

The	O
immune	O
response	O
to	O
the	O
X	B-protein
protein	I-protein
of	O
human	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
was	O
studied	O
by	O
epitope	O
mapping	O
by	O
using	O
a	O
set	O
of	O
MS2-HBx	B-protein
fusion	I-protein
proteins	I-protein
and	O
synthetic	O
peptides	O
.	O

Antibodies	O
in	O
sera	O
of	O
patients	O
with	O
acute	O
and	O
chronic	O
HBV	O
infection	O
showed	O
a	O
multispecific	O
immune	O
response	O
.	O

Each	O
serum	O
contained	O
antibodies	B-protein
to	O
a	O
different	O
set	O
of	O
epitopes	B-protein
,	O
which	O
taken	O
together	O
cover	O
most	O
of	O
the	O
HBx	B-protein
sequence	I-protein
.	O

Some	O
of	O
the	O
epitopes	O
were	O
detectable	O
only	O
by	O
immunoblotting	O
with	O
fusion	B-protein
proteins	I-protein
;	O
others	O
were	O
detectable	O
only	O
by	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
synthetic	O
peptides	O
.	O

The	O
carboxy-terminal	B-protein
half	I-protein
of	O
the	O
HBx	B-protein
protein	I-protein
was	O
preferentially	O
recognized	O
by	O
antibodies	B-protein
from	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
contained	O
a	O
short	O
immunodominant	B-protein
antigenic	I-protein
region	I-protein
with	O
at	O
least	O
two	O
major	O
nonoverlapping	B-protein
epitopes	I-protein
.	O

Anti-	O
HBx	B-protein
antibody	O
titers	O
as	O
revealed	O
by	O
peptide	O
ELISAs	O
were	O
highest	O
and	O
most	O
frequent	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
usually	O
low	O
in	O
acutely	O
infected	O
patients	O
and	O
asymptomatic	O
carriers	O
.	O

The	O
data	O
demonstrate	O
a	O
remarkable	O
qualitative	O
and	O
quantitative	O
heterogeneity	O
of	O
the	O
humoral	O
HBx	B-protein
immune	O
response	O
which	O
can	O
be	O
monitored	O
by	O
HBx	B-protein
-specific	O
peptide	O
ELISAs	O
.	O

Such	O
tests	O
may	O
become	O
useful	O
diagnostic	O
tools	O
.	O

[	O
The	O
inhibitory	O
effect	O
of	O
hydrocortisone	O
on	O
the	O
chemotactic	O
migration	O
of	O
human	B-cell_type
leukocytes	I-cell_type
]	O

Random	O
migration	O
(	O
RM	O
)	O
and	O
chemotactic	O
migration	O
(	O
ChtM	O
)	O
of	O
human	B-cell_type
leukocytes	I-cell_type
to	O
yeast	O
activated	O
serum	O
were	O
studied	O
with	O
the	O
modified	O
Boyden	O
chamber	O
method	O
.	O

Both	O
RM	O
and	O
ChtM	O
showed	O
circadian	O
rhythm	O
.	O

Leukocytes	B-cell_type
migrated	O
most	O
rapidly	O
at	O
night	O
.	O

The	O
difference	O
between	O
the	O
peak	O
(	O
0	O
:	O
00	O
)	O
and	O
trough	O
values	O
(	O
8	O
:	O
00	O
)	O
of	O
RM	O
and	O
ChtM	O
was	O
significant	O
statistically	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

ChtM	O
was	O
inhibited	O
by	O
hydrocortisone	O
(	O
F	O
)	O
of	O
physiological	O
concentration	O
(	O
10	O
(	O
-9	O
)	O
-10	O
(	O
-7	O
)	O
mol/L	O
)	O
which	O
was	O
dose-dependent	O
and	O
completely	O
antagonized	O
by	O
the	O
competitive	O
antagonist	O
,	O
RU38486	O
.	O

The	O
inhibitory	O
effect	O
was	O
much	O
more	O
evident	O
with	O
higher	O
dose	O
(	O
more	O
than	O
10	O
(	O
-5	O
)	O
mol/L	O
)	O
and	O
it	O
was	O
also	O
reversed	O
by	O
RU38486	O
,	O
but	O
only	O
partially	O
.	O

It	O
is	O
suggested	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
may	O
be	O
a	O
physiological	O
regulator	O
of	O
the	O
activity	O
of	O
leukocytes	B-cell_type
and	O
its	O
inhibitory	O
action	O
on	O
ChtM	O
may	O
be	O
involved	O
in	O
antiinflammatory	O
mechanisms	O
of	O
GC	O
of	O
pharmacological	O
doses	O
.	O

The	O
action	O
of	O
physiological	O
and	O
pharmacological	O
concentration	O
of	O
GC	O
may	O
be	O
mediated	O
by	O
low	B-protein
affinity	I-protein
specific	I-protein
binding	I-protein
sites	I-protein
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O

Heterogeneity	O
of	O
antigen	B-protein
molecules	I-protein
recognized	O
by	O
anti-tax1	B-protein
monoclonal	I-protein
antibody	I-protein
Lt-4	B-protein
in	O
cell	O
lines	O
bearing	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
related	O
retroviruses	O
.	O

Using	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
Lt-4	B-protein
,	O
directed	O
against	O
human	B-protein
T	I-protein
cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
(	I-protein
HTLV-I	I-protein
)	I-protein
trans-activator	I-protein
(	I-protein
tax1	I-protein
)	I-protein
antigen	I-protein
,	O
we	O
examined	O
the	O
expression	O
of	O
tax1	B-protein
and	O
related	O
antigens	B-protein
in	O
a	O
variety	O
of	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
bearing	O
HTLV-I	O
and	O
related	O
retroviruses	O
,	O
simian	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
STLV-I	O
)	O
and	O
HTLV-II	O
,	O
by	O
immunofluorescence	O
and	O
immunoblot	O
assays	O
.	O

Lt-4	B-protein
reacted	O
with	O
all	O
HTLV-I-bearing	B-cell_line
cell	I-cell_line
lines	I-cell_line
tested	O
and	O
five	O
out	O
of	O
eight	O
simian	B-cell_line
cell	I-cell_line
lines	I-cell_line
bearing	O
STLV-I	O
,	O
but	O
not	O
with	O
an	O
HTLV-II-bearing	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Lt-4	B-protein
detected	O
40	O
kd	O
tax1	B-protein
antigen	I-protein
molecules	I-protein
in	O
most	O
HTLV-I-bearing	B-cell_line
cell	I-cell_line
lines	I-cell_line
except	O
one	O
cell	O
line	O
that	O
expressed	O
39	B-protein
kd	I-protein
tax1	I-protein
antigen	I-protein
.	O

In	O
the	O
STLV-I-bearing	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
tax1-related	B-protein
antigen	I-protein
molecules	I-protein
detected	O
by	O
Lt-4	B-protein
were	O
heterogeneous	O
,	O
having	O
molecular	O
weights	O
in	O
the	O
range	O
of	O
36-41	O
kd	O
.	O

Characterization	O
of	O
the	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
enhancer-binding	I-protein
proteins	I-protein
from	O
the	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
Jurkat	B-cell_line
.	O

The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	B-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

Among	O
the	O
protein-binding	O
regions	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
is	O
the	O
transcription-enhancer	B-DNA
region	I-DNA
.	O

We	O
show	O
that	O
at	O
least	O
one	O
inducible	B-protein
,	O
C1	B-protein
,	O
and	O
one	O
constitutive	B-protein
,	I-protein
C2	I-protein
,	I-protein
protein	I-protein
can	O
bind	O
to	O
the	O
HIV	B-DNA
enhancer	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion-exchange	O
chromatography	O
.	O

Bivalent	O
cations	O
such	O
as	O
Mg2+	O
and	O
Zn2+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV-enhancer	B-DNA
domain	I-DNA
.	O

Both	O
C1	B-protein
and	O
C2	B-protein
proteins	I-protein
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2-receptor	B-DNA
alpha-subunit	I-DNA
enhancer	I-DNA
.	O

The	O
inducible	B-protein
C1	I-protein
protein	I-protein
was	O
partially	O
purified	O
by	O
three	O
chromatographic	O
steps	O
and	O
characterized	O
by	O
u.v.	O
cross-linking	O
as	O
a	O
47	B-protein
kDa	I-protein
protein	I-protein
.	O

Differences	O
in	O
transcriptional	B-DNA
enhancers	I-DNA
of	O
HIV-1	O
and	O
HIV-2	O
.	O

Response	O
to	O
T	B-cell_type
cell	I-cell_type
activation	O
signals	O
.	O

T	B-cell_type
cell	I-cell_type
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O
one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O

In	O
HIV-1	O
,	O
the	O
sequences	O
that	O
respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
and	O
comprise	O
the	O
transcriptional	B-DNA
enhancer	I-DNA
,	O
which	O
contains	O
two	O
conserved	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
.	O

The	O
corresponding	O
region	O
in	O
the	O
second	O
AIDS	O
retrovirus	O
,	O
HIV-2	O
,	O
contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
.	O

We	O
demonstrate	O
that	O
the	O
HIV-1	B-DNA
LTR	I-DNA
responds	O
better	O
than	O
the	O
HIV-2	B-DNA
LTR	I-DNA
to	O
T	O
cell	O
activation	O
signals	O
.	O

These	O
qualitative	O
differences	O
in	O
the	O
response	O
to	O
T	B-cell_type
cell	I-cell_type
activation	O
are	O
reproduced	O
not	O
only	O
when	O
HIV-1	B-DNA
or	I-DNA
HIV-2	I-DNA
enhancers	I-DNA
are	O
placed	O
upstream	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
but	O
also	O
when	O
these	O
enhancers	B-DNA
are	O
switched	O
between	O
their	O
respective	O
LTR	B-DNA
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
NF	B-protein
kappa	I-protein
B	I-protein
binds	O
to	O
both	O
conserved	O
sites	O
in	O
the	O
HIV-1	B-DNA
transcriptional	I-DNA
enhancer	I-DNA
and	O
only	O
to	O
the	O
single	O
conserved	O
site	O
in	O
the	O
HIV-2	B-DNA
transcriptional	I-DNA
enhancer	I-DNA
.	O

Instead	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
the	O
activator	B-protein
protein	I-protein
3	I-protein
binds	O
to	O
the	O
divergent	O
site	O
in	O
HIV-2	O
.	O

In	O
conclusion	O
,	O
HIV-1	O
and	O
HIV-2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals	O
,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV-2	O
than	O
with	O
HIV-1	O
infection	O
.	O

NF-X2	B-protein
that	O
binds	O
to	O
the	O
DRA	B-DNA
X2-box	I-DNA
is	O
activator	B-protein
protein	I-protein
1	I-protein
.	O

Expression	O
cloning	O
of	O
c-Jun	B-protein
.	O

Human	B-protein
class	I-protein
II	I-protein
MHC	I-protein
Ag	I-protein
are	O
a	O
family	O
of	O
cell	B-protein
surface	I-protein
glycoproteins	I-protein
.	O

Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
thymic	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN-gamma	B-protein
.	O

Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue-specific	O
expression	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
.	O

In	O
the	O
DRA	B-DNA
promoter	I-DNA
,	O
one	O
of	O
these	O
cis-acting	B-DNA
regulatory	I-DNA
motifs	I-DNA
is	O
the	O
X2-box	B-DNA
to	O
which	O
nuclear	B-protein
factor	I-protein
X2	I-protein
(	O
NF-X2	B-protein
)	O
binds	O
.	O

Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full-length	B-DNA
cDNA	I-DNA
clone	I-DNA
encoding	O
NF-X2	B-protein
.	O

This	O
cDNA	B-DNA
clone	I-DNA
was	O
isolated	O
by	O
expression	O
cDNA	B-DNA
cloning	O
,	O
and	O
encodes	O
the	O
human	B-protein
c-Jun	I-protein
protein	I-protein
,	O
which	O
together	O
with	O
c-Fos	B-protein
forms	O
the	O
heterodimeric	B-protein
activator	I-protein
protein-1	I-protein
transcription	I-protein
complex	I-protein
.	O

Whereas	O
c-Fos/c-Jun	B-protein
heterodimers	I-protein
do	O
not	O
exist	O
in	O
B	B-cell_line
cells	I-cell_line
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2-box	B-DNA
in	O
class	B-cell_line
II	I-cell_line
nonexpressing	I-cell_line
cells	I-cell_line
.	O

Thus	O
,	O
c-Fos/c-Jun	B-protein
heterodimers	I-protein
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	B-DNA
gene	I-DNA
expression	O
.	O

Synthesis	O
of	O
4	O
,	O
19-disubstituted	O
derivatives	O
of	O
DOC	O
.	O

Radioreceptor	O
assay	O
of	O
some	O
corticosteroid	O
derivatives	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O

Several	O
new	O
4	O
,	O
19-substituted	O
steroids	O
and	O
previously	O
synthesized	O
corticosteroids	O
were	O
assayed	O
for	O
affinity	O
to	O
type	B-protein
1	I-protein
receptors	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O

11	O
beta	O
,	O
19-epoxy-4	O
,	O
21-dihydroxypregn-4-ene-3	O
,	O
20-dione	O
(	O
2	O
)	O
was	O
hydrogenated	O
with	O
Pd-C	O
to	O
yield	O
a	O
mixture	O
of	O
all	O
four	O
dihydro	O
derivatives	O
5	O
,	O
accompanied	O
by	O
4	O
,	O
21-diacetoxy-11	O
beta	O
,	O
19-epoxy-3-hydroxypregnan-20-one	O
(	O
6	O
)	O
and	O
21-acetoxy-11	O
beta	O
,	O
19-epoxy-4-hydroxypregnane-3	O
,	O
20-dione	O
(	O
7	O
)	O
.	O

With	O
hot	O
acetic	O
+	O
p-toluenesulfonic	O
acid	O
5	O
underwent	O
rearrangement	O
to	O
21-acetoxy-11	O
beta	O
,	O
19-epoxypregn-5-ene-4	O
,	O
20-dione	O
(	O
8	O
)	O
Pd-C	O
hydrogenation	O
of	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregna-2	O
,	O
9	O
(	O
11	O
)	O
-diene-4	O
,	O
20-dione	O
(	O
10	O
)	O
gave	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregn-5-ene-4	O
,	O
20-dione	O
(	O
11	O
)	O
and	O
the	O
9	O
,	O
11-dihydro	O
derivative	O
of	O
the	O
latter	O
.	O

Treatment	O
of	O
10	O
with	O
warm	O
HCl	O
furnished	O
19-chloro-4	O
,	O
21-dihydroxypregna-4	O
,	O
9	O
(	O
11	O
)	O
-diene-3	O
,	O
20-dione	O
(	O
13	O
)	O
.	O

Pd-C	O
hydrogenation	O
of	O
its	O
diacetate	O
14	O
afforded	O
the	O
4	O
,	O
5-dihydro	O
derivative	O
18	O
,	O
19-chloro-21-acetoxypregn-9	O
(	O
11	O
)	O
-en-20-one	O
(	O
15	O
)	O
,	O
its	O
4-acetoxy	O
derivative	O
16	O
and	O
the	O
3	O
,	O
4-diacetoxy	O
derivative	O
17	O
.	O

When	O
tested	O
in	O
a	O
radioreceptor	O
assay	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
the	O
synthesized	O
compounds	O
showed	O
only	O
low	O
relative	O
binding	O
affinities	O
(	O
RBA	O
)	O
to	O
type	B-protein
1	I-protein
receptor	I-protein
,	O
the	O
highest	O
being	O
0.72	O
%	O
for	O
13	O
(	O
aldosterone	O
=	O
100	O
%	O
)	O
.	O

For	O
comparison	O
,	O
other	O
RBA	O
in	O
this	O
system	O
were	O
:	O
19-noraldosterone	O
,	O
20	O
%	O
;	O
18-deoxyaldosterone	O
,	O
5.8	O
%	O
;	O
18-deoxy-19-noraldosterone	O
,	O
4.7	O
%	O
;	O
18	O
,	O
21-anhydroaldosterone	O
,	O
0.37	O
%	O
;	O
17-isoaldosterone	O
,	O
7.6	O
%	O
and	O
apoaldosterone	O
,	O
4.3	O
%	O

Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT-1	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	B-protein
factor	I-protein
.	O

Nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
(	O
NFAT-1	B-protein
)	O
is	O
a	O
transcription	B-protein
factor	I-protein
which	O
is	O
considered	O
to	O
be	O
an	O
important	O
regulator	O
in	O
early	O
T-cell	O
activation	O
.	O

We	O
have	O
developed	O
a	O
system	O
to	O
monitor	O
the	O
transcriptional	O
activity	O
of	O
NFAT-1	B-protein
at	O
the	O
single	O
cell	O
level	O
in	O
whole	O
animals	O
.	O

The	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
an	O
oligomerized	O
NFAT-1	B-protein
binding	O
motif	O
that	O
directs	O
transcription	B-protein
of	I-protein
SV40	I-protein
T-antigen	I-protein
in	O
transgenic	O
mice	O
.	O

This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	O
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O

NFAT-1	B-protein
activity	O
had	O
previously	O
been	O
thought	O
to	O
be	O
confined	O
to	O
activated	B-cell_type
T-lymphocytes	I-cell_type
upon	O
release	O
of	O
intracellular	B-cell_type
calcium	I-cell_type
.	O

By	O
targeting	O
NFAT-1	B-protein
-dependent	O
gene	O
expression	O
in	O
transgenic	O
mice	O
we	O
discovered	O
new	O
sites	O
of	O
NFAT-1	B-protein
activity	O
.	O

Besides	O
in	O
T-lymphocytes	B-cell_type
NFAT-1	B-protein
activity	O
could	O
also	O
be	O
induced	O
in	O
T-lymphocyte-depleted	B-cell_type
spleen	I-cell_type
cells	I-cell_type
and	O
purified	B-cell_type
B-lymphocytes	I-cell_type
and	O
requires	O
agents	O
that	O
both	O
release	O
intracellular	O
calcium	O
and	O
activate	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

A	O
difference	O
in	O
the	O
time	O
course	O
of	O
appearance	O
of	O
NFAT-1	B-protein
activity	O
between	O
T-lymphocytes	B-cell_type
and	O
non-T-lymphocytes	B-cell_type
was	O
revealed	O
.	O

Constitutive	O
expression	O
was	O
observed	O
in	O
a	O
small	O
population	O
of	O
cells	O
in	O
the	O
dermis	O
and	O
some	O
mice	O
have	O
developed	O
skin	O
lesions	O
.	O

Interestingly	O
,	O
the	O
tissue	O
pattern	O
of	O
expression	O
of	O
the	O
NFAT-1	B-protein
activity	O
resembles	O
the	O
expression	O
pattern	O
described	O
for	O
HIV-LTR/tat	O
transgenic	O
mice	O
(	O
Vogel	O
,	O
J.	O
,	O
Hinrichs	O
,	O
S.	O
H.	O
,	O
Reynolds	O
,	O
R.	O
K.	O
,	O
Luciw	O
,	O
P.	O
A.	O
,	O
and	O
Jay	O
,	O
G.	O
(	O
1988	O
)	O
Nature	O
335	O
,	O
606-611	O
)	O
.	O

This	O
similarity	O
in	O
expression	O
and	O
the	O
fact	O
that	O
NFAT-1	B-protein
has	O
been	O
shown	O
to	O
bind	O
functional	B-DNA
sequences	I-DNA
in	O
HIV-LTR	B-DNA
suggest	O
a	O
role	O
for	O
NFAT-1	B-protein
in	O
dermal	O
activation	O
of	O
the	O
HIV-LTR	B-DNA
.	O

A	O
novel	O
T-cell	B-protein
protein	I-protein
which	O
recognizes	O
a	O
palindromic	B-DNA
sequence	I-DNA
in	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

Two	O
major	B-DNA
protein-binding	I-DNA
sites	I-DNA
within	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
have	O
been	O
identified	O
.	O

One	O
(	O
site	B-DNA
B	I-DNA
)	O
contained	O
a	O
palindromic	B-DNA
sequence	I-DNA
with	O
homology	O
to	O
steroid/thyroid	B-DNA
hormone	I-DNA
response	I-DNA
elements	I-DNA
but	O
was	O
distinct	O
from	O
previously	O
described	O
binding	O
sites	O
of	O
this	O
class	O
.	O

A	O
novel	O
T-cell	B-protein
protein	I-protein
recognized	O
the	O
palindromic	B-DNA
sequence	I-DNA
within	O
site	B-DNA
B	I-DNA
and	O
also	O
bound	O
estrogen-	B-DNA
or	I-DNA
thyroid	I-DNA
hormone-response	I-DNA
elements	I-DNA
with	O
lower	O
affinity	O
.	O

A	O
7-base-pair	O
mutation	O
in	O
the	O
site	B-DNA
B	I-DNA
palindrome	I-DNA
,	O
which	O
destroyed	O
protein	O
binding	O
,	O
resulted	O
in	O
increased	O
expression	O
from	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Progesterone	O
suppression	O
of	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
is	O
not	O
mediated	O
by	O
glucocorticoid	O
effect	O
.	O

This	O
study	O
investigated	O
whether	O
the	O
suppressive	O
effect	O
of	O
progesterone	O
on	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
is	O
mediated	O
by	O
specific	O
progesterone	B-protein
receptors	I-protein
.	O

The	O
effects	O
of	O
a	O
competitive	O
progesterone	O
antagonist	O
(	O
RU486	O
)	O
and	O
a	O
specific	O
glucocorticoid	B-protein
receptor	I-protein
blocker	O
(	O
RU43044	O
)	O
were	O
tested	O
on	O
the	O
release	O
of	O
a	O
blocking	B-protein
factor	I-protein
by	O
progesterone-treated	B-cell_line
pregnancy	I-cell_line
lymphocytes	I-cell_line
.	O

RU	O
486	O
tested	O
at	O
an	O
equal	O
concentration	O
as	O
progesterone	O
significantly	O
inhibited	O
the	O
production	O
of	O
the	O
blocking	B-protein
factor	I-protein
,	O
while	O
RU	O
43044	O
was	O
without	O
effect	O
.	O

These	O
data	O
suggest	O
that	O
in	O
pregnancy	O
,	O
lymphocyte	O
progesterone	O
acts	O
on	O
specific	O
progesterone	B-protein
receptors	I-protein
and	O
glucocorticoid	B-protein
binding	I-protein
sites	I-protein
are	O
not	O
involved	O
.	O

The	O
56-59-kilodalton	B-protein
protein	I-protein
identified	O
in	O
untransformed	B-protein
steroid	I-protein
receptor	I-protein
complexes	I-protein
is	O
a	O
unique	B-protein
protein	I-protein
that	O
exists	O
in	O
cytosol	O
in	O
a	O
complex	O
with	O
both	O
the	O
70-	B-protein
and	I-protein
90-kilodalton	I-protein
heat	I-protein
shock	I-protein
proteins	I-protein
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
9S	B-protein
,	O
untransformed	B-protein
progestin	I-protein
,	I-protein
estrogen	I-protein
,	I-protein
androgen	I-protein
,	I-protein
and	I-protein
glucocorticoid	I-protein
receptor	I-protein
complexes	I-protein
in	O
rabbit	O
uterine	O
and	O
liver	O
cytosols	O
contain	O
a	O
59-kDa	B-protein
protein	I-protein
[	O
Tai	O
,	O
P.K.	O
,	O
Maeda	O
,	O
Y.	O
,	O
Nakao	O
,	O
K.	O
,	O
Wakim	O
,	O
N.G.	O
,	O
Duhring	O
,	O
J.L.	O
,	O
&	O
Faber	O
,	O
L.E.	O
(	O
1986	O
)	O
Biochemistry	O
25	O
,	O
5269-5275	O
]	O
.	O

In	O
this	O
work	O
we	O
show	O
that	O
the	O
monoclonal	B-protein
antibody	I-protein
KN	I-protein
382/EC1	I-protein
raised	O
against	O
the	O
rabbit	B-protein
59-kDa	I-protein
protein	I-protein
reacts	O
with	O
9S	B-protein
,	O
untransformed	B-protein
glucocorticoid	I-protein
receptor	I-protein
complexes	I-protein
in	O
cytosol	O
prepared	O
from	O
human	B-cell_line
IM-9	I-cell_line
lymphocytes	I-cell_line
but	O
not	O
with	O
4S	B-protein
salt-transformed	I-protein
receptors	I-protein
.	O

The	O
human	O
protein	O
recognized	O
by	O
the	O
EC1	B-protein
antibody	I-protein
is	O
a	O
56-kDa	B-protein
protein	I-protein
(	O
p56	B-protein
)	O
of	O
moderate	O
abundance	O
located	O
predominantly	O
in	O
the	O
cytoplasm	O
by	O
indirect	O
immunofluorescence	O
.	O

There	O
are	O
at	O
least	O
six	O
isomorphs	B-protein
of	O
p56	B-protein
by	O
two-dimensional	O
gel	O
analysis	O
.	O

N-Terminal	O
sequencing	O
(	O
20	O
amino	O
acids	O
)	O
shows	O
that	O
p56	B-protein
is	O
a	O
unique	B-protein
human	I-protein
protein	I-protein
.	O

When	O
p56	B-protein
is	O
immunoadsorbed	O
from	O
IM-9	B-cell_line
cell	I-cell_line
cytosol	O
,	O
both	O
the	O
70-	B-protein
and	I-protein
90-kDa	I-protein
heat	I-protein
shock	I-protein
proteins	I-protein
are	O
coadsorbed	O
in	O
an	O
immune-specific	O
manner	O
.	O

Neither	O
heat	B-protein
shock	I-protein
protein	I-protein
reacts	O
directly	O
with	O
the	O
EC1	B-protein
antibody	I-protein
.	O

We	O
conclude	O
that	O
p56	B-protein
exists	O
in	O
cytosol	O
in	O
a	O
higher	O
order	O
complex	O
containing	O
hsp70	B-protein
and	O
hsp90	B-protein
,	O
both	O
of	O
which	O
in	O
turn	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
untransformed	B-protein
steroid	I-protein
receptors	I-protein
.	O

Sequence-specific	O
DNA	O
binding	O
of	O
the	O
proto-oncoprotein	B-protein
ets-1	B-protein
defines	O
a	O
transcriptional	B-DNA
activator	I-DNA
sequence	I-DNA
within	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
.	O

The	O
ets	B-DNA
proto-oncogene	I-DNA
family	I-DNA
is	O
a	O
group	O
of	O
sequence-related	B-DNA
genes	I-DNA
whose	O
normal	O
cellular	O
function	O
is	O
unknown	O
.	O

In	O
a	O
study	O
of	O
cellular	B-protein
proteins	I-protein
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
murine	O
retroviruses	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
we	O
have	O
discovered	O
that	O
a	O
member	O
of	O
the	O
ets	B-DNA
gene	I-DNA
family	I-DNA
encodes	O
a	O
sequence-specific	B-protein
DNA-binding	I-protein
protein	I-protein
.	O

A	O
mouse	B-DNA
ets-1	I-DNA
cDNA	I-DNA
clone	I-DNA
was	O
obtained	O
by	O
screening	O
a	O
mouse	O
thymus	O
cDNA	O
expression	O
library	O
with	O
a	O
double-stranded	B-DNA
oligonucleotide	I-DNA
probe	I-DNA
representing	O
20	O
bp	O
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
(	O
MSV	O
)	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

The	O
cDNA	B-DNA
sequence	I-DNA
has	O
an	O
813-bp	B-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
(	O
ORF	B-DNA
)	O
whose	O
predicted	O
amino	O
acid	O
sequence	O
is	O
97.6	O
%	O
identical	O
to	O
the	O
272	B-protein
carboxy-terminal	I-protein
amino	I-protein
acids	I-protein
of	O
the	O
human	B-protein
ets-1	I-protein
protein	I-protein
.	O

The	O
ORF	B-DNA
was	O
expressed	O
in	O
bacteria	O
,	O
and	O
the	O
30-kD	B-protein
protein	I-protein
product	I-protein
was	O
shown	O
to	O
bind	O
DNA	O
in	O
a	O
sequence-specific	O
manner	O
by	O
mobility-shift	O
assays	O
,	O
Southwestern	O
blot	O
analysis	O
,	O
and	O
methylation	O
interference	O
.	O

A	O
mutant	B-DNA
LTR	I-DNA
containing	O
four	O
base	O
pair	O
substitutions	O
in	O
the	O
ets-1	B-DNA
binding	I-DNA
site	I-DNA
was	O
constructed	O
and	O
was	O
shown	O
to	O
have	O
reduced	O
binding	O
in	O
vitro	O
.	O

Transcriptional	O
efficiency	O
of	O
the	O
MSV	B-DNA
LTR	I-DNA
promoter	I-DNA
containing	O
this	O
disrupted	O
ets-1	B-DNA
binding	I-DNA
site	I-DNA
was	O
compared	O
to	O
the	O
activity	O
of	O
a	O
wild-type	B-DNA
promoter	I-DNA
in	O
mouse	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
culture	O
,	O
and	O
15-	O
to	O
20-fold	O
reduction	O
in	O
expression	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
was	O
observed	O
.	O

We	O
propose	O
that	O
ets-1	B-protein
functions	O
as	O
a	O
transcriptional	O
activator	O
of	O
mammalian	O
type-C	O
retroviruses	O
and	O
speculate	O
that	O
ets-related	B-DNA
genes	I-DNA
constitute	O
a	O
new	O
group	O
of	O
eukaryotic	B-protein
DNA-binding	I-protein
proteins	I-protein
.	O

Type	B-protein
II	I-protein
estrogen	I-protein
binding	I-protein
sites	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
variations	O
during	O
the	O
menstrual	O
cycle	O
.	O

We	O
have	O
previously	O
reported	O
that	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
contain	O
type	O
II	B-protein
estrogen	I-protein
binding	I-protein
sites	I-protein
(	O
type	B-protein
II	I-protein
EBS	I-protein
)	O
.	O

In	O
this	O
study	O
,	O
the	O
fluctuations	O
of	O
type	B-protein
II	I-protein
EBS	I-protein
during	O
the	O
menstrual	O
cycle	O
were	O
analyzed	O
in	O
6	O
normally	O
menstruating	O
women	O
.	O

Approximately	O
3	O
times	O
higher	O
levels	O
of	O
type	B-protein
II	I-protein
EBS	I-protein
were	O
found	O
in	O
the	O
periovulatory	O
period	O
with	O
respect	O
to	O
both	O
follicular	O
and	O
luteal	O
phases	O
.	O

In	O
postmenopausal	O
women	O
the	O
mean	O
type	B-protein
II	I-protein
EBS	I-protein
levels	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
follicular	O
phase	O
of	O
the	O
cycle	O
.	O

However	O
,	O
in	O
3	O
postmenopausal	O
patients	O
a	O
short	O
course	O
of	O
estrogen	O
or	O
tamoxifen	O
resulted	O
in	O
a	O
marked	O
increase	O
of	O
type	B-protein
II	I-protein
EBS	I-protein
levels	O
.	O

Tamoxifen	O
was	O
also	O
found	O
to	O
compete	O
with	O
17	O
beta-estradiol	O
for	O
type	B-protein
II	I-protein
EBS	I-protein
in	O
PBMC	B-cell_type
,	O
although	O
to	O
a	O
lesser	O
extent	O
than	O
diethylstilbestrol	O
.	O

Mononuclear	B-cell_type
leukocyte	I-cell_type
glucocorticoid	B-protein
receptor	I-protein
binding	O
characteristics	O
and	O
down-regulation	O
in	O
major	O
depression	O
.	O

Some	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
have	O
elevated	O
plasma	O
cortisol	O
concentrations	O
and	O
show	O
failure	O
to	O
suppress	O
cortisol	O
secretion	O
upon	O
administration	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
yet	O
they	O
do	O
not	O
have	O
Cushingoid	O
features	O
.	O

To	O
study	O
whether	O
this	O
represents	O
glucocorticoid	O
(	O
GC	O
)	O
resistance	O
,	O
[	O
3H	O
]	O
-DEX-binding	O
assays	O
were	O
used	O
to	O
measure	O
,	O
in	O
vitro	O
,	O
the	O
GC	B-protein
receptor	I-protein
affinity	O
(	O
1/Kd	O
)	O
and	O
number	O
(	O
Bmax	O
)	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
of	O
11	O
MDD	O
patients	O
and	O
15	O
control	O
subjects	O
.	O

No	O
receptor	O
abnormalities	O
were	O
detected	O
in	O
the	O
MDD	O
group	O
;	O
thus	O
any	O
cellular	O
defect	O
leading	O
to	O
a	O
lack	O
of	O
responsiveness	O
to	O
GC	O
in	O
the	O
MDD	O
patients	O
,	O
if	O
present	O
,	O
probably	O
lies	O
beyond	O
the	O
initial	O
receptor	O
binding	O
.	O

DEX	O
(	O
1.0	O
mg	O
orally	O
)	O
was	O
administered	O
to	O
study	O
in	O
vivo	B-protein
GC	I-protein
receptor	I-protein
down-regulation	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
fewer	O
depressed	O
subjects	O
down-regulated	O
Bmax	O
after	O
DEX	O
.	O

By	O
paired	O
t-test	O
,	O
Bmax	O
decreased	O
significantly	O
in	O
the	O
control	O
group	O
but	O
not	O
in	O
the	O
depressed	O
group	O
.	O

Receptor	O
number	O
on	O
the	O
control	O
day	O
did	O
not	O
correlate	O
significantly	O
with	O
the	O
degree	O
of	O
receptor	O
down-regulation	O
,	O
severity	O
of	O
depression	O
or	O
cortisol	O
concentrations	O
across	O
all	O
the	O
subjects	O
.	O

These	O
results	O
do	O
not	O
lend	O
support	O
to	O
previous	O
reports	O
suggesting	O
that	O
GC	O
resistance	O
in	O
MDD	O
results	O
from	O
a	O
GC	O
receptor-binding	O
abnormality	O
,	O
and	O
they	O
emphasize	O
the	O
importance	O
of	O
considering	O
receptor	O
studies	O
in	O
the	O
context	O
of	O
GC-mediated	O
cell	O
processes	O
in	O
order	O
to	O
identify	O
the	O
exact	O
cellular	O
defect	O
(	O
s	O
)	O
leading	O
to	O
GC	O
resistance	O
.	O

Ras-related	B-protein
GTP-binding	I-protein
proteins	I-protein
and	O
leukocyte	B-cell_type
signal	O
transduction	O
.	O

Many	O
aspects	O
of	O
leukocyte	B-cell_type
function	O
are	O
regulated	O
by	O
both	O
heterotrimeric	B-protein
and	O
Ras-related	B-protein
GTP-binding	I-protein
proteins	I-protein
,	O
but	O
there	O
is	O
little	O
definite	O
information	O
about	O
their	O
roles	O
in	O
the	O
specialized	O
processes	O
utilized	O
by	O
leukocytes	B-cell_type
for	O
cell	O
killing	O
.	O

Recent	O
progress	O
in	O
understanding	O
the	O
regulation	O
of	O
the	O
phagocyte	B-protein
NADPH	I-protein
oxidase	I-protein
by	O
the	O
Rac	B-protein
GTP-binding	I-protein
proteins	I-protein
provides	O
a	O
basis	O
for	O
defining	O
the	O
operational	O
characteristics	O
of	O
one	O
such	O
phagocyte	O
system	O
.	O

It	O
is	O
clear	O
from	O
various	O
studies	O
that	O
the	O
activity	O
of	O
the	O
NADPH	B-protein
oxidase	I-protein
can	O
be	O
modulated	O
through	O
the	O
regulation	O
of	O
the	O
GTP-GDP	O
state	O
of	O
Rac	B-protein
.	O

Proteins	O
exist	O
in	O
leukocytes	B-cell_type
able	O
to	O
modify	O
GTP-binding	B-protein
protein	I-protein
function	O
in	O
this	O
manner	O
,	O
and	O
their	O
activity	O
may	O
be	O
regulated	O
by	O
signals	O
generated	O
on	O
phagocyte	O
stimulation	O
.	O

Proteins	O
of	O
the	O
Ras	B-protein
superfamily	I-protein
are	O
likely	O
to	O
be	O
involved	O
in	O
a	O
variety	O
of	O
normal	O
phagocyte	O
functions	O
through	O
their	O
ability	O
to	O
modulate	O
the	O
assembly	O
of	O
actin	B-protein
filaments	I-protein
,	O
direct	O
vesicle	O
trafficking	O
and	O
fusion	O
,	O
and	O
so	O
forth	O
.	O

BSAP	B-protein
:	O
a	O
key	O
regulator	O
of	O
B-cell	B-cell_type
development	O
and	O
differentiation	O
.	O

B-cell-specific	B-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
Pax-gene	B-DNA
family	I-DNA
of	O
transcription	B-protein
factors	I-protein
;	O
in	O
the	O
lymphoid	O
system	O
,	O
BSAP	B-protein
is	O
produced	O
only	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Here	O
,	O
Markus	O
Neurath	O
,	O
Eckhard	O
Stuber	O
and	O
Warren	O
Strober	O
describe	O
the	O
molecular	O
structure	O
of	O
BSAP	B-protein
and	O
focus	O
on	O
the	O
ability	O
of	O
this	O
protein	O
to	O
regulate	O
the	O
expression	O
of	O
B-cell-specific	B-DNA
genes	I-DNA
.	O

They	O
propose	O
that	O
BSAP	B-protein
is	O
a	O
key	B-protein
protein	I-protein
of	O
B	B-cell_type
cells	I-cell_type
and	O
that	O
it	O
not	O
only	O
influence	O
B-cell	O
development	O
but	O
also	O
influences	O
the	O
balance	O
between	O
B-cell	O
proliferation	O
and	O
immunoglobulin	B-protein
secretion	O
at	O
later	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

Down-regulation	O
of	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
levels	O
in	O
activated	O
human	O
lymphocytes	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jan	O
9	O
;	O
93	O
(	O
1	O
)	O
:	O
524	O
]	O

The	O
effect	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2	O
)	O
D3	O
]	O
,	O
a	O
steroid	O
hormone	O
with	O
immunomodulating	O
properties	O
,	O
on	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
proteins	O
was	O
examined	O
in	O
in	B-cell_line
vitro	I-cell_line
activated	I-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	I-cell_line
by	O
Western	O
blot	O
analysis	O
.	O

Over	O
a	O
72-hr	O
period	O
of	O
activation	O
,	O
the	O
expression	O
of	O
the	O
50-kDa	B-protein
NF-kappa	I-protein
B	I-protein
,	O
p50	B-protein
,	O
and	O
its	O
precursor	O
,	O
p105	B-protein
,	O
was	O
increased	O
progressively	O
.	O

When	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
the	O
levels	O
of	O
the	O
mature	O
protein	O
as	O
well	O
as	O
its	O
precursor	O
were	O
decreased	O
.	O

The	O
effect	O
of	O
the	O
hormone	O
on	O
the	O
levels	O
of	O
p50	B-protein
was	O
demonstrable	O
in	O
the	O
cytosolic	O
and	O
nuclear	O
compartments	O
;	O
it	O
required	O
between	O
4	O
and	O
8	O
hr	O
and	O
was	O
specific	O
,	O
as	O
25-hydroxyvitamin	O
D3	O
and	O
24	O
,	O
25-dihydroxyvitamin	O
D3	O
were	O
ineffective	O
.	O

Besides	O
p50	B-protein
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
levels	O
of	O
another	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
,	O
namely	O
c-rel	B-protein
.	O

In	O
addition	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
abundance	O
of	O
a	O
specific	B-protein
DNA-protein	I-protein
complex	I-protein
formed	O
upon	O
incubation	O
of	O
nuclear	O
extracts	O
from	O
activated	O
lymphocytes	O
with	O
a	O
labeled	O
NF-kappa	B-protein
B	I-protein
DNA	I-protein
binding	I-protein
motif	I-protein
.	O

Further	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
inhibited	O
the	O
transcriptional	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
transiently	O
transfected	O
with	O
a	O
construct	B-DNA
containing	O
four	O
tandem	B-DNA
repeats	I-DNA
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sequence	I-DNA
of	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
gene	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

These	O
observations	O
demonstrate	O
directly	O
that	O
there	O
is	O
de	O
novo	O
synthesis	O
of	O
NF-kappa	B-protein
B	I-protein
during	O
human	O
lymphocyte	O
activation	O
and	O
suggest	O
that	O
this	O
process	O
is	O
hormonally	O
regulated	O
.	O

The	O
myeloid	B-DNA
zinc	I-DNA
finger	I-DNA
gene	I-DNA
,	O
MZF-1	B-DNA
,	O
regulates	O
the	O
CD34	B-DNA
promoter	I-DNA
in	O
vitro	O
.	O

MZF-1	B-DNA
is	O
a	O
C2H2	B-DNA
zinc	I-DNA
finger	I-DNA
gene	I-DNA
encoding	O
a	O
putative	B-protein
transcriptional	I-protein
regulator	I-protein
of	O
myeloid	O
differentiation	O
.	O

The	O
MZF-1	B-DNA
protein	O
contains	O
13	O
C2H2	B-protein
zinc	I-protein
fingers	I-protein
arranged	O
in	O
bipartite	O
DNA	B-protein
binding	I-protein
domains	I-protein
containing	O
zinc	B-protein
fingers	I-protein
through	O
4	O
and	O
,	O
in	O
the	O
carboxy-terminus	B-protein
,	O
5	O
through	O
13	O
.	O

We	O
previously	O
identified	O
the	O
DNA	B-DNA
consensus	I-DNA
binding	I-DNA
site	I-DNA
recognized	O
by	O
the	O
two	O
DNA	B-protein
binding	I-protein
domains	I-protein
.	O

To	O
assess	O
the	O
transcription	O
regulatory	O
function	O
of	O
MZF-1	B-DNA
,	O
the	O
full-length	O
MZF-1	B-DNA
coding	O
region	O
was	O
fused	O
to	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
yeast	B-protein
transactivator	I-protein
GAL4	I-protein
.	O

The	O
expression	O
vector	O
was	O
cotransfected	O
with	O
the	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
regulated	O
by	O
the	O
thymidine	B-DNA
kinase	I-DNA
promoter	I-DNA
containing	O
GAL4	B-DNA
DNA	I-DNA
binding	I-DNA
sites	I-DNA
into	O
NIH	B-cell_line
3T3	I-cell_line
,	O
293	B-cell_line
,	O
K562	B-cell_line
,	O
and	O
Jurkat	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

MZF-1	B-DNA
represses	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
expression	O
via	O
GAL4	B-protein
binding	O
sites	O
in	O
the	O
nonhematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
NIH	B-cell_line
3T3	I-cell_line
and	O
293	B-cell_line
.	O

In	O
contrast	O
,	O
MZF-1	B-DNA
activates	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
expression	O
in	O
the	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
K562	B-cell_line
and	O
Jurkat	B-cell_line
.	O

The	O
MZF-1	B-DNA
binding	I-DNA
sites	I-DNA
are	O
present	O
in	O
the	O
promoters	B-DNA
of	O
several	O
genes	B-DNA
expressed	O
during	O
myeloid	O
differentiation	O
,	O
including	O
the	O
CD34	B-DNA
promoter	I-DNA
.	O

MZF-1	B-DNA
transcriptional	O
regulation	O
of	O
this	O
physiologically	B-DNA
relevant	I-DNA
promoter	I-DNA
was	O
assessed	O
in	O
both	O
hematopoietic	B-cell_line
and	O
nonhematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Recombinant	B-protein
MZF-1	I-protein
protein	I-protein
specifically	O
binds	O
to	O
the	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
CD34	B-DNA
promoter	I-DNA
in	O
mobility	O
shift	O
assays	O
.	O

MZF-1	B-DNA
expression	O
vectors	O
were	O
cotransfected	O
with	O
the	O
luciferase	B-DNA
reporter	I-DNA
plasmids	I-DNA
regulated	O
by	O
the	O
CD34	B-DNA
promoter	I-DNA
into	O
both	O
nonhematopoietic	B-cell_line
and	I-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

As	O
with	O
the	O
heterologous	O
DNA	B-protein
binding	I-protein
domain	I-protein
,	O
MZF-1	B-DNA
represses	O
reporter	B-DNA
gene	I-DNA
expression	O
in	O
nonhematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
activates	O
expression	O
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Activation	O
of	O
CD34	B-protein
expression	O
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
is	O
dependent	O
on	O
the	O
presence	O
of	O
intact	O
MZF-1	B-DNA
binding	I-DNA
sites	I-DNA
.	O

The	O
cell	O
type-specific	O
regulation	O
of	O
the	O
CD34	B-DNA
promoter	I-DNA
by	O
MZF-1	B-DNA
suggests	O
the	O
presence	O
of	O
tissue-specific	O
regulators/adapters	O
or	O
differential	O
MZF-1	B-DNA
modifications	O
that	O
determine	O
MZF-1	B-DNA
transcriptional	O
regulatory	O
function	O
.	O

The	O
murine	O
BCL6	B-DNA
gene	I-DNA
is	O
induced	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
as	O
an	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
.	O

The	O
chromosomal	O
translocation	O
involving	O
3q27	B-DNA
is	O
often	O
detected	O
in	O
human	B-cell_type
B-cell	I-cell_type
lymphomas	I-cell_type
,	O
especially	O
diffuse	O
lymphomas	O
with	O
a	O
large-cell	O
component	O
.	O

The	O
BCL6	B-DNA
gene	I-DNA
has	O
been	O
isolated	O
from	O
the	O
chromosomal	O
breakpoint	O
in	O
these	O
lymphomas	O
.	O

Here	O
we	O
cloned	O
the	O
murine	B-DNA
BCL6	I-DNA
(	I-DNA
mBCL6	I-DNA
)	I-DNA
cDNA	I-DNA
from	O
the	O
muscle	B-DNA
cDNA	I-DNA
library	I-DNA
using	O
the	O
human	B-DNA
BCL6	I-DNA
(	I-DNA
hBCL6	I-DNA
)	I-DNA
cDNA	I-DNA
as	O
a	O
probe	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
was	O
95	O
%	O
identical	O
to	O
that	O
of	O
hBCL6	B-protein
.	O

It	O
contains	O
six	O
repeats	O
of	O
the	O
Kruppel-like	B-protein
zinc-finger	I-protein
motif	I-protein
that	O
are	O
completely	O
identical	O
to	O
those	O
of	O
hBCL6	B-protein
,	O
indicating	O
that	O
the	O
BCL6	B-DNA
gene	I-DNA
is	O
well	O
conserved	O
between	O
humans	O
and	O
mice	O
.	O

Expression	O
of	O
the	O
mBCL6	B-DNA
gene	I-DNA
was	O
ubiquitously	O
detected	O
in	O
adult	O
mouse	O
tissues	O
including	O
lymphatic	O
organs	O
.	O

Furthermore	O
,	O
it	O
was	O
induced	O
in	O
lymphocytes	B-cell_type
activated	O
with	O
phorbol	O
ester	O
and	O
Ca2+	O
ionophore	O
within	O
30	O
min	O
after	O
stimulation	O
.	O

This	O
induction	O
was	O
not	O
inhibited	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
.	O

These	O
results	O
suggest	O
that	O
BCL6	B-protein
plays	O
a	O
role	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
as	O
an	O
immediate	O
early	O
gene	O
.	O

The	O
role	O
of	O
BSAP	B-protein
(	O
Pax-5	B-protein
)	O
in	O
B-cell	O
development	O
.	O

The	O
hierarchy	O
of	O
transcriptional	O
control	O
in	O
B-cell	O
development	O
has	O
recently	O
been	O
analyzed	O
by	O
targeted	O
gene	O
inactivation	O
in	O
the	O
mouse	O
.	O

In	O
this	O
manner	O
,	O
the	O
paired	B-DNA
box	I-DNA
containing	I-DNA
gene	I-DNA
Pax-5	B-DNA
,	O
encoding	O
the	O
B	B-protein
cell	I-protein
specific	I-protein
transcription	I-protein
factor	I-protein
BSAP	B-protein
,	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
early	O
B	O
lymphopoiesis	O
.	O

Other	O
experimental	O
strategies	O
have	O
implicated	O
BSAP	B-protein
in	O
the	O
control	O
of	O
cell	O
proliferation	O
,	O
isotype	O
switching	O
and	O
transcription	O
of	O
the	O
immunoglobulin	B-protein
heavy-chain	I-protein
gene	O
at	O
late	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

The	O
DNA-binding	O
properties	O
of	O
two	B-protein
heat	I-protein
shock	I-protein
factors	I-protein
,	O
HSF1	B-protein
and	O
HSF3	B-protein
,	O
are	O
induced	O
in	O
the	O
avian	B-cell_line
erythroblast	I-cell_line
cell	I-cell_line
line	I-cell_line
HD6	B-cell_line
.	O

Avian	O
cells	O
express	O
three	O
heat	B-DNA
shock	I-DNA
transcription	I-DNA
factor	I-DNA
(	I-DNA
HSF	I-DNA
)	I-DNA
genes	I-DNA
corresponding	O
to	O
a	O
novel	B-protein
factor	I-protein
,	O
HSF3	B-protein
,	O
and	O
homologs	O
of	O
mouse	O
and	O
human	O
HSF1	B-protein
and	O
HSF2	B-protein
.	O

Analysis	O
of	O
the	O
biochemical	O
and	O
cell	O
biological	O
properties	O
of	O
these	O
HSFs	B-protein
reveals	O
that	O
HSF3	B-protein
has	O
properties	O
in	O
common	O
with	O
both	O
HSF1	B-protein
and	O
HSF2	B-protein
and	O
yet	O
has	O
features	O
which	O
are	O
distinct	O
from	O
both	O
.	O

HSF3	B-protein
is	O
constitutively	O
expressed	O
in	O
the	O
erythroblast	B-cell_line
cell	I-cell_line
line	I-cell_line
HD6	I-cell_line
,	O
the	O
lymphoblast	B-cell_line
cell	I-cell_line
line	I-cell_line
MSB	I-cell_line
,	O
and	O
embryo	B-cell_line
fibroblasts	I-cell_line
,	O
and	O
yet	O
its	O
DNA-binding	O
activity	O
is	O
induced	O
only	O
upon	O
exposure	O
of	O
HD6	O
cells	O
to	O
heat	O
shock	O
.	O

Acquisition	O
of	O
HSF3	B-protein
DNA-binding	O
activity	O
in	O
HD6	B-cell_line
cells	I-cell_line
is	O
accompanied	O
by	O
oligomerization	O
from	O
a	O
non-DNA-binding	B-protein
dimer	I-protein
to	O
a	O
DNA-binding	B-protein
trimer	I-protein
,	O
whereas	O
the	O
effect	O
of	O
heat	O
shock	O
on	O
HSF1	B-protein
is	O
oligomerization	O
of	O
an	O
inert	B-protein
monomer	I-protein
to	O
a	O
DNA-binding	B-protein
trimer	I-protein
.	O

Induction	O
of	O
HSF3	B-protein
DNA-binding	O
activity	O
is	O
delayed	O
compared	O
with	O
that	O
of	O
HSF1	B-protein
.	O

As	O
occurs	O
for	O
HSF1	B-protein
,	O
heat	O
shock	O
leads	O
to	O
the	O
translocation	O
of	O
HSF3	B-protein
to	O
the	O
nucleus	O
.	O

HSF	O
exhibits	O
the	O
properties	O
of	O
a	O
transcriptional	B-protein
activator	I-protein
,	O
as	O
judged	O
from	O
the	O
stimulatory	O
activity	O
of	O
transiently	B-protein
overexpressed	I-protein
HSF3	I-protein
measured	O
by	O
using	O
a	O
heat	B-DNA
shock	I-DNA
element-containing	I-DNA
reporter	I-DNA
construct	I-DNA
and	O
as	O
independently	O
assayed	O
by	O
the	O
activity	O
of	O
a	O
chimeric	B-protein
GAL4-HSF3	I-protein
protein	I-protein
on	O
a	O
GAL4	B-DNA
reporter	I-DNA
construct	I-DNA
.	O

These	O
results	O
reveal	O
that	O
HSF3	B-protein
is	O
negatively	O
regulated	O
in	O
avian	B-cell_type
cells	I-cell_type
and	O
acquires	O
DNA-binding	O
activity	O
in	O
certain	O
cells	O
upon	O
heat	O
shock	O
.	O

Direct	O
demonstration	O
of	O
NFATp	B-protein
dephosphorylation	O
and	O
nuclear	O
localization	O
in	O
activated	B-cell_line
HT-2	I-cell_line
cells	I-cell_line
using	O
a	O
specific	O
NFATp	B-protein
polyclonal	I-protein
antibody	I-protein
.	O

Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	B-protein
genes	I-protein
,	O
and	O
NFAT	B-protein
DNA	O
binding	O
activity	O
is	O
stimulated	O
following	O
T	O
cell	O
activation	O
.	O

Several	O
lines	O
of	O
evidence	O
have	O
suggested	O
that	O
NFAT	B-protein
is	O
a	O
substrate	O
for	O
calcineurin	B-protein
,	O
a	O
serine/threonine	B-protein
phosphatase	I-protein
.	O

Using	O
a	O
polyclonal	O
antibody	O
to	O
murine	B-protein
NFATp	I-protein
,	O
Western	O
blot	O
analysis	O
of	O
various	O
mouse	O
tissues	O
demonstrated	O
that	O
the	O
110-130-kDa	O
NFATp	B-protein
protein	I-protein
was	O
highly	O
expressed	O
in	O
thymus	O
and	O
spleen	O
.	O

Treatment	O
of	O
immunoprecipitated	O
NFATp	B-protein
from	O
untreated	O
HT-2	B-cell_line
cells	I-cell_line
with	O
calcineurin	B-protein
resulted	O
in	O
the	O
dephosphorylation	O
of	O
NFATp	B-protein
,	O
demonstrating	O
that	O
NFATp	B-protein
is	O
an	O
in	O
vitro	O
substrate	O
for	O
calcineurin	B-protein
.	O

NFATp	B-protein
immunoprecipitated	O
from	O
32P-labeled	B-cell_line
HT-2	I-cell_line
cells	I-cell_line
migrated	O
as	O
an	O
approximately	O
120-kDa	O
protein	O
that	O
was	O
localized	O
to	O
the	O
cytosol	O
of	O
the	O
cells	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
ionomycin	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	B-protein
and	O
a	O
loss	O
of	O
32P	O
,	O
consistent	O
with	O
NFATp	B-protein
dephosphorylation	O
.	O

The	O
dephosphorylation	O
of	O
NFATp	B-protein
was	O
accompanied	O
by	O
localization	O
of	O
the	O
protein	O
to	O
the	O
nuclear	O
fraction	O
.	O

Both	O
of	O
these	O
events	O
were	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
FK506	O
,	O
a	O
calcineurin	B-protein
inhibitor	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
NFATp	B-protein
is	O
a	O
calcineurin	B-protein
substrate	O
in	O
cells	O
.	O

Activation	O
and	O
expression	O
of	O
the	O
nuclear	B-protein
factors	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
in	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
:	O
regulation	O
upon	O
CD16	B-protein
ligand	O
binding	O
.	O

The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	B-protein
synthesis	O
in	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
have	O
not	O
been	O
elucidated	O
.	O

We	O
report	O
here	O
that	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
NFATp	B-protein
)	O
,	O
a	O
cyclosporin	B-protein
A	I-protein
(	I-protein
CsA	I-protein
)	I-protein
-sensitive	I-protein
factor	I-protein
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	B-protein
,	O
mediates	O
CD16	B-protein
-induced	O
activation	O
of	O
cytokine	B-protein
genes	I-protein
in	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
.	O

CD16	B-protein
(	O
Fc	B-protein
gamma	I-protein
RIIIA	I-protein
)	O
-induced	O
expression	O
of	O
cytokine	B-RNA
mRNA	I-RNA
in	O
NK	B-cell_type
cells	I-cell_type
occurs	O
via	O
a	O
CsA-sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
mechanism	O
.	O

Stimulation	O
of	O
NK	B-cell_type
cells	I-cell_type
with	O
CD16	B-protein
ligands	O
induces	O
NFAT	B-protein
-like	O
DNA	O
binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells	O
,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

This	O
occurs	O
with	O
fast	O
kinetics	O
after	O
stimulation	O
,	O
via	O
a	O
CsA-sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
mechanism	O
that	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
.	O

NK	B-protein
cell	I-protein
NFAT	I-protein
is	O
present	O
in	O
the	O
cytosol	O
of	O
nonstimulated	B-cell_type
cells	I-cell_type
,	O
migrates	O
to	O
the	O
nucleus	O
upon	O
stimulation	O
,	O
and	O
can	O
associate	O
with	O
AP-1	B-protein
.	O

Two	O
distinct	O
molecules	O
,	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
have	O
been	O
reported	O
to	O
mediate	O
NFAT	B-protein
activity	O
.	O

The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp-	B-protein
and	I-protein
NFATc-	I-protein
specific	I-protein
antibodies	I-protein
indicate	O
that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	B-protein
ligand	O
binding	O
involves	O
primarily	O
,	O
if	O
not	O
exclusively	O
,	O
NFATp	B-protein
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O
mobility	O
(	O
approximately	O
120	O
kD	O
)	O
as	O
that	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

NK	B-cell_type
cells	I-cell_type
do	O
not	O
express	O
NFATc	B-protein
constitutively	O
,	O
but	O
NFATc	B-RNA
mRNA	I-RNA
accumulation	O
is	O
induced	O
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O

However	O
,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	B-protein
recognizing	O
the	O
T	B-protein
cell	I-protein
NFATc	I-protein
revealed	O
no	O
detectable	O
NFATc	B-protein
protein	O
in	O
nuclear	O
and	O
cytoplasmic	O
extracts	O
from	O
CD16-	O
or	O
phorbol	B-cell_line
ester-stimulated	I-cell_line
cells	I-cell_line
at	O
any	O
time	O
tested	O
,	O
up	O
to	O
4	O
h	O
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
both	O
CsA-sensitive	B-protein
transcription	I-protein
factors	I-protein
,	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
are	O
expressed	O
in	O
human	O
NK	B-cell_type
cells	I-cell_type
,	O
and	O
that	O
their	O
activation	O
and/or	O
expression	O
can	O
be	O
regulated	O
in	O
primary	O
cells	O
by	O
a	O
single	O
stimulus	O
,	O
that	O
,	O
in	O
the	O
case	O
of	O
CD16	O
in	O
NK	B-cell_type
cells	I-cell_type
,	O
results	O
in	O
early	O
activation	O
of	O
NFATp	B-protein
and	O
subsequently	O
induced	O
expression	O
of	O
NFATc	B-RNA
mRNA	I-RNA
.	O

Interleukin	O
2	O
signaling	O
involves	O
the	O
phosphorylation	O
of	O
Stat	B-protein
proteins	I-protein
.	O

One	O
of	O
the	O
most	O
important	O
cytokines	B-protein
involved	O
in	O
immune	O
response	O
regulation	O
is	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
proliferation	O
and	O
function	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL-2	B-protein
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood	O
.	O

While	O
the	O
binding	O
of	O
IL-2	B-protein
to	O
its	O
receptor	O
was	O
recently	O
shown	O
to	O
lead	O
to	O
the	O
activation	O
of	O
two	O
kinases	B-protein
,	O
Jak-1	B-protein
and	O
Jak-3	B-protein
,	O
subsequent	O
steps	O
in	O
the	O
signaling	O
pathway	O
to	O
the	O
nucleus	O
that	O
lead	O
to	O
the	O
activation	O
of	O
specific	O
genes	O
had	O
not	O
been	O
characterized	O
.	O

Since	O
many	O
cytokines	B-protein
that	O
activate	O
Jak	B-protein
kinases	I-protein
also	O
lead	O
to	O
the	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
Stat	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
the	O
ability	O
of	O
IL-2	B-protein
to	O
trigger	O
Stat	O
phosphorylation	O
was	O
examined	O
.	O

Exposure	O
of	O
activated	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
or	O
of	O
a	O
natural	B-cell_line
killer	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
NKL	B-cell_line
)	O
to	O
IL-2	B-protein
leads	O
to	O
the	O
phosphorylation	O
of	O
Stat1	B-protein
alpha	I-protein
,	O
Stat1	O
beta	O
,	O
and	O
Stat3	B-protein
,	O
as	O
well	O
as	O
of	O
two	O
Stat-related	B-protein
proteins	I-protein
,	O
p94	B-protein
and	O
p95	B-protein
.	O

p94	B-protein
and	O
p95	B-protein
share	O
homology	O
with	O
Stat1	B-protein
at	O
the	O
phosphorylation	B-protein
site	I-protein
and	O
in	O
the	O
Src	B-protein
homology	I-protein
2	I-protein
(	I-protein
SH2	I-protein
)	I-protein
domain	I-protein
,	O
but	O
otherwise	O
are	O
immunologically	O
distinct	O
from	O
Stat1	B-protein
.	O

These	O
Stat	B-protein
proteins	I-protein
were	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
to	O
bind	O
to	O
a	O
specific	B-DNA
DNA	I-DNA
sequence	I-DNA
.	O

These	O
findings	O
suggest	O
a	O
mechanism	O
by	O
which	O
IL-2	B-protein
binding	O
to	O
its	O
receptor	O
may	O
activate	O
specific	B-DNA
genes	I-DNA
involved	O
in	O
immune	O
cell	O
function	O
.	O

Expression	O
of	O
c-fos	B-DNA
correlates	O
with	O
IFN-alpha	B-protein
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O

This	O
study	O
evaluates	O
(	O
i	O
)	O
constitutive	O
levels	O
of	O
oncogene	B-DNA
and	O
p53	B-RNA
transcripts	I-RNA
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(	O
ii	O
)	O
their	O
modulations	O
subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN-alpha	B-protein
2c	I-protein
.	O

Peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
pbmc	B-cell_type
)	O
and	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
of	O
26	O
patients	O
were	O
examined	O
for	O
c-fos	O
,	O
c-myc	O
,	O
p53	O
and	O
the	O
hybrid	O
bcr/abl	O
mRNA	O
levels	O
.	O

Results	O
indicated	O
that	O
(	O
i	O
)	O
constitutive	O
c-fos	B-RNA
transcript	I-RNA
levels	O
are	O
significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN-alpha	B-protein
therapy	O
(	O
p	O
<	O
0.01	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	B-cell_type
(	O
r	O
=	O
0.6895	O
,	O
p	O
<	O
0.01	O
)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	B-cell_type
cells	I-cell_type
(	O
r	O
=	O
-0.568	O
,	O
p	O
<	O
0.01	O
)	O
contained	O
in	O
the	O
pbmc	B-cell_type
preparations	O
tested	O
,	O
(	O
ii	O
)	O
constitutive	B-RNA
mRNA	I-RNA
levels	O
of	O
the	O
hybrid	B-DNA
bcr/abl	I-DNA
,	O
c-myc	B-DNA
and	O
p53	B-DNA
are	O
positively	O
correlated	O
with	O
each	O
other	O
,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters	O
,	O
and	O
(	O
iii	O
)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN-alpha	B-protein
is	O
accompanied	O
by	O
upregulation	O
of	O
c-fos	B-DNA
and	O
downregulation	O
of	O
c-myc	B-RNA
mRNA	I-RNA
levels	O
in	O
responder	O
patients	O
.	O

Menopause	O
is	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
blood	O
monocyte	O
number	O
and	O
a	O
relative	O
decrease	O
in	O
the	O
expression	O
of	O
estrogen	B-protein
receptors	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
.	O

PROBLEM	O
:	O
The	O
clinical	O
significance	O
of	O
the	O
differential	O
expression	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
was	O
evaluated	O
.	O

METHOD	O
:	O
Two	O
color	O
flow	O
cytometry	O
analysis	O
was	O
used	O
on	O
peripheral	O
blood	O
samples	O
of	O
young	O
and	O
postmenopausal	O
females	O
and	O
postmenopausal	O
females	O
treated	O
with	O
estrogen	O
replacement	O
therapy	O
.	O

In	O
addition	O
,	O
the	O
monocyte	O
and	O
lymphocyte	O
counts	O
and	O
the	O
blood	O
estrogen	O
levels	O
of	O
each	O
patient	O
were	O
determine	O
.	O

RESULTS	O
:	O
During	O
menopause	O
there	O
is	O
a	O
significant	O
decrease	O
in	O
the	O
percentage	O
of	O
ER	B-cell_type
positive	I-cell_type
monocytes	I-cell_type
,	O
and	O
an	O
increase	O
in	O
blood	B-cell_type
monocyte	I-cell_type
number	O
,	O
which	O
declines	O
following	O
estrogen	O
replacement	O
therapy	O
to	O
values	O
of	O
the	O
young	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
estrogen	O
modulates	O
the	O
monocyte	B-cell_type
numbers	O
and	O
its	O
effects	O
may	O
be	O
mediated	O
through	O
the	O
ER	B-protein
in	O
the	O
monocytes	B-cell_type
.	O

Staphylococcal	B-protein
enterotoxins	I-protein
modulate	O
interleukin	B-protein
2	I-protein
receptor	I-protein
expression	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
protein-tyrosine	I-protein
kinase	I-protein
3	I-protein
(	O
Jak3	B-protein
)	O
and	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
Stat	B-protein
proteins	I-protein
)	O
.	O

Staphylococcal	B-protein
enterotoxins	I-protein
(	O
SE	B-protein
)	O
stimulate	O
T	B-cell_type
cells	I-cell_type
expressing	O
the	O
appropriate	O
variable	B-protein
region	I-protein
beta	I-protein
chain	I-protein
of	I-protein
(	I-protein
V	I-protein
beta	I-protein
)	I-protein
T-cell	I-protein
receptors	I-protein
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
diseases	O
.	O

Depending	O
on	O
costimulatory	O
signals	O
,	O
SE	B-protein
induce	O
either	O
proliferation	O
or	O
anergy	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
SE	B-protein
can	O
induce	O
an	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
nonresponsive	O
state	O
and	O
apoptosis	O
.	O

Here	O
,	O
we	O
show	O
that	O
SE	B-protein
induce	O
dynamic	O
changes	O
in	O
the	O
expression	O
of	O
and	O
signal	O
transduction	O
through	O
the	O
IL-2	B-protein
receptor	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
beta	I-protein
and	I-protein
gamma	I-protein
chains	I-protein
(	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
)	O
in	O
human	B-cell_line
antigen-specific	I-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

Thus	O
,	O
after	O
4	O
hr	O
of	O
exposure	O
to	O
SEA	B-protein
and	O
SEB	B-protein
,	O
the	O
expression	O
of	O
IL-2R	B-protein
beta	I-protein
was	O
down-regulated	O
,	O
IL-2R	B-protein
gamma	I-protein
was	O
slightly	O
up-regulated	O
,	O
while	O
IL-2R	B-protein
alpha	I-protein
remained	O
largely	O
unaffected	O
.	O

The	O
changes	O
in	O
the	O
composition	O
of	O
IL-2Rs	B-protein
were	O
accompanied	O
by	O
inhibition	O
of	O
IL-2	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
protein-tyrosine	I-protein
kinase	I-protein
3	I-protein
(	O
Jak3	B-protein
)	O
and	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
called	O
Stat3	B-protein
and	O
Stat5	B-protein
.	O

In	O
parallel	O
experiments	O
,	O
IL-2	B-protein
-driven	O
proliferation	O
was	O
inhibited	O
significantly	O
.	O

After	O
16	O
hr	O
of	O
exposure	O
to	O
SE	B-protein
,	O
the	O
expression	O
of	O
IL-2R	B-protein
beta	I-protein
remained	O
low	O
,	O
while	O
that	O
of	O
IL2R	B-protein
alpha	I-protein
and	O
IL2R	B-protein
gamma	I-protein
was	O
further	O
up-regulated	O
,	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-protein
and	O
Stat	B-protein
proteins	I-protein
was	O
partly	O
normalized	O
.	O

Yet	O
,	O
IL-2	B-protein
-driven	O
proliferation	O
remained	O
profoundly	O
inhibited	O
,	O
suggesting	O
that	O
signaling	O
events	O
other	O
than	O
Jak3	B-protein
/Stat	B-protein
activation	O
had	O
also	O
been	O
changed	O
following	O
SE	B-protein
stimulation	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
SE	B-protein
can	O
modulate	O
IL-2R	B-protein
expression	O
and	O
signal	O
transduction	O
involving	O
the	O
Jak/Stat	B-protein
pathway	O
in	O
CD4+	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

Constitutive	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
enhanced	O
granulopoiesis	O
,	O
and	O
neonatal	O
lethality	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-deficient	O
mice	O
.	O

Transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
NF-kappa	B-protein
B	I-protein
family	I-protein
are	O
controlled	O
by	O
inhibitory	B-protein
I	I-protein
kappa	I-protein
B	I-protein
proteins	I-protein
,	O
mainly	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
.	O

Apparently	O
normal	O
at	O
birth	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-/-	O
mice	O
exhibit	O
severe	O
runting	O
,	O
skin	O
defects	O
,	O
and	O
extensive	O
granulopoiesis	O
postnatally	O
,	O
typically	O
dying	O
by	O
8	O
days	O
.	O

Hematopoietic	O
tissues	O
from	O
these	O
mice	O
display	O
elevated	O
levels	O
of	O
both	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
and	O
mRNAs	B-RNA
of	O
some	O
,	O
but	O
not	O
all	O
,	O
genes	O
thought	O
to	O
be	O
regulated	O
by	O
NF-kappa	B-protein
B	I-protein
.	O

NF-kappa	B-protein
B	I-protein
elevation	O
results	O
in	O
these	O
phenotypic	O
abnormalities	O
because	O
mice	O
lacking	O
both	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
show	O
a	O
dramatically	O
delayed	O
onset	O
of	O
abnormalities	O
.	O

In	O
contrast	O
to	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
I	B-cell_line
kappa	I-cell_line
B	I-cell_line
alpha-/-	I-cell_line
embryonic	I-cell_line
fibroblasts	I-cell_line
show	O
minimal	O
constitutive	B-protein
NF-kappa	I-protein
B	I-protein
,	O
as	O
well	O
as	O
normal	O
signal-dependent	O
NF-kappa	B-protein
B	I-protein
activation	O
that	O
is	O
concomitant	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
degradation	O
.	O

Our	O
results	O
indicate	O
that	O
I	O
kappa	O
b	O
beta	O
,	O
but	O
not	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
is	O
required	O
for	O
the	O
signal-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
fibroblasts	B-cell_type
.	O

However	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
required	O
for	O
the	O
postinduction	O
repression	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
fibroblasts	B-cell_type
.	O

These	O
results	O
define	O
distinct	O
roles	O
for	O
the	O
two	O
forms	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
and	O
demonstrate	O
the	O
necessity	O
for	O
stringent	O
control	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Interleukin-7	B-protein
can	O
induce	O
the	O
activation	O
of	O
Jak	B-protein
1	I-protein
,	O
Jak	B-protein
3	I-protein
and	O
STAT	B-protein
5	I-protein
proteins	I-protein
in	O
murine	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
activation	O
of	O
Janus	B-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
(	O
Jak	B-protein
)	O
and	O
STAT	B-protein
(	I-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	I-protein
proteins	I-protein
has	O
recently	O
been	O
linked	O
to	O
the	O
signal	O
transduction	O
mechanism	O
of	O
several	O
cytokines	B-protein
.	O

IL-7	B-protein
was	O
observed	O
to	O
induce	O
a	O
rapid	O
and	O
dose-dependent	O
tyrosine	O
phosphorylation	O
of	O
Jak	B-protein
1	I-protein
and	O
Jak	B-protein
3	I-protein
and	O
concomitantly	O
,	O
the	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
multiple	O
STAT	B-protein
proteins	I-protein
.	O

The	O
STAT	B-protein
proteins	I-protein
utilized	O
by	O
IL-7	B-protein
were	O
identical	O
to	O
those	O
induced	O
by	O
IL-2	B-protein
and	O
could	O
be	O
identified	O
as	O
various	O
STAT	B-protein
5	I-protein
isoforms	I-protein
.	O

Moreover	O
,	O
the	O
induction	O
of	O
both	O
Jak	B-protein
1	I-protein
and	I-protein
3	I-protein
,	O
and	O
STAT	B-protein
5	I-protein
activity	O
strongly	O
correlated	O
with	O
the	O
growth-promoting	O
effects	O
of	O
IL-7	B-protein
,	O
suggesting	O
that	O
this	O
signal	O
transduction	O
mechanism	O
may	O
play	O
a	O
key	O
role	O
in	O
IL-7	B-protein
-induced	O
proliferation	O
.	O

Cytokine	B-protein
-modulating	O
activity	O
of	O
tepoxalin	O
,	O
a	O
new	O
potential	O
antirheumatic	O
.	O

Tepoxalin	O
is	O
a	O
new	O
dual	O
cyclooxygenase/5-lipoxygenase	O
anti-inflammatory	O
compound	O
currently	O
under	O
clinical	O
investigation	O
.	O

It	O
has	O
been	O
shown	O
to	O
possess	O
anti-inflammatory	O
activity	O
in	O
a	O
variety	O
of	O
animal	O
models	O
and	O
more	O
recently	O
to	O
inhibit	O
IL-2	B-protein
induced	O
signal	O
transduction	O
.	O

The	O
current	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
cytokine	B-protein
modulating	O
activity	O
of	O
tepoxalin	O
and	O
the	O
role	O
of	O
iron	O
in	O
these	O
effects	O
.	O

In	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
stimulated	O
with	O
OKT3/PMA	O
,	O
tepoxalin	O
inhibited	O
lymphocyte	B-cell_type
proliferation	O
with	O
an	O
IC50	O
of	O
6	O
microM	O
.	O

Additionally	O
,	O
it	O
inhibited	O
the	O
production	O
of	O
LTB4	B-protein
(	O
IC50	O
=	O
0.5	O
microM	O
)	O
and	O
the	O
cytokines	B-protein
IL-2	B-protein
,	O
IL-6	B-protein
and	O
TNF	B-protein
alpha	I-protein
(	O
IC50	O
=	O
10-12	O
microM	O
)	O
.	O

Cytotoxicity	O
was	O
not	O
demonstrated	O
at	O
these	O
concentrations	O
.	O

Add-back	O
experiments	O
with	O
either	O
cytokines	B-protein
(	O
IL-2	B-protein
or	O
IL-6	B-protein
)	O
,	O
LTB4	B-protein
or	O
conditioned	O
media	O
failed	O
to	O
restore	O
the	O
proliferative	O
response	O
in	O
the	O
presence	O
of	O
tepoxalin	O
.	O

However	O
,	O
the	O
concurrent	O
addition	O
of	O
iron	O
(	O
in	O
the	O
form	O
of	O
ferrous	O
or	O
ferric	O
chloride	O
and	O
other	O
iron	O
salts	O
)	O
reversed	O
the	O
inhibition	O
of	O
proliferation	O
caused	O
by	O
tepoxalin	O
.	O

Tepoxalin	O
also	O
inhibits	O
the	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
which	O
acts	O
on	O
several	O
cytokine	B-DNA
genes	I-DNA
.	O

Tepoxalin	O
's	O
effect	O
on	O
NF	B-protein
kappa	I-protein
B	I-protein
is	O
also	O
reversed	O
by	O
the	O
addition	O
of	O
iron	O
salts	O
.	O

These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
tepoxalin	O
to	O
inhibit	O
proliferation	O
in	O
PBMC	B-cell_type
may	O
be	O
at	O
least	O
in	O
part	O
due	O
to	O
its	O
ability	O
to	O
reduce	O
the	O
amount	O
of	O
available	O
iron	O
resulting	O
in	O
decreased	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
and	O
subsequent	O
inhibition	O
of	O
cytokine	B-protein
production	O
.	O

N-	B-protein
and	I-protein
C-terminal	I-protein
sequences	I-protein
control	O
degradation	O
of	O
MAD3/I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
in	O
response	O
to	O
inducers	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O

The	O
proteolytic	O
degradation	O
of	O
the	O
inhibitory	B-protein
protein	I-protein
MAD3/I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
in	O
response	O
to	O
extracellular	O
stimulation	O
is	O
a	O
prerequisite	O
step	O
in	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O

Analysis	O
of	O
the	O
expression	O
of	O
human	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	I-protein
in	O
stable	O
transfectants	O
of	O
mouse	B-cell_line
70Z/3	I-cell_line
cells	I-cell_line
shows	O
that	O
,	O
as	O
for	O
the	O
endogenous	O
murine	O
protein	O
,	O
exogenous	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
degraded	O
in	O
response	O
to	O
inducers	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
,	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
lipopolysaccharide	O
.	O

In	O
addition	O
,	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
proteasome	B-protein
inhibitor	O
N-Ac-Leu-Leu-norleucinal	O
inhibits	O
this	O
ligand-induced	O
degradation	O
and	O
,	O
in	O
agreement	O
with	O
previous	O
studies	O
,	O
stabilizes	O
a	O
hyperphosphorylated	O
form	O
of	O
the	O
human	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	I-protein
.	O

By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	O
protein	O
in	O
this	O
cell	B-cell_line
line	I-cell_line
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand-induced	O
phosphorylation	O
and	O
the	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Our	O
results	O
show	O
that	O
deletion	O
of	O
the	O
C	B-protein
terminus	I-protein
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
molecule	O
up	O
to	O
amino	B-protein
acid	I-protein
279	I-protein
abolishes	O
constitutive	O
but	O
not	O
ligand-inducible	O
phosphorylation	O
and	O
inhibits	O
ligand-inducible	O
degradation	O
.	O

Further	O
analysis	O
reveals	O
that	O
the	O
inducible	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
maps	O
to	O
two	O
serines	O
in	O
the	O
N	B-protein
terminus	I-protein
of	O
the	O
protein	O
(	O
residues	O
32	O
and	O
36	O
)	O
and	O
that	O
the	O
mutation	O
of	O
either	O
residue	O
is	O
sufficient	O
to	O
abolish	O
ligand-induced	O
degradation	O
,	O
whereas	O
both	O
residues	O
must	O
be	O
mutated	O
to	O
abolish	O
inducible	O
phosphorylation	O
of	O
the	O
protein	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Microtubules	B-protein
mediate	O
cellular	O
25-hydroxyvitamin	O
D3	O
trafficking	O
and	O
the	O
genomic	O
response	O
to	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	B-cell_type
monocytes	I-cell_type
.	O

The	O
genomic	O
actions	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
are	O
mediated	O
by	O
the	O
intracellular	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O

Although	O
immunocytochemistry	O
has	O
shown	O
that	O
disruption	O
of	O
microtubular	O
assembly	O
prevents	O
nuclear	O
access	O
of	O
the	O
sterol-VDR	B-protein
complex	I-protein
,	O
the	O
role	O
of	O
microtubules	B-protein
in	O
the	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
has	O
not	O
been	O
studied	O
in	O
viable	B-cell_type
cells	I-cell_type
.	O

Our	O
studies	O
examined	O
this	O
interaction	O
in	O
normal	O
human	B-cell_type
monocytes	I-cell_type
.	O

Monocytes	O
convert	O
25	O
(	O
OH	O
)	O
D3	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
to	O
24-hydroxylated	O
metabolites	O
more	O
polar	O
than	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Microtubule	O
disruption	O
totally	O
abolished	O
the	O
ability	O
of	O
exogenous	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
suppress	O
its	O
own	O
synthesis	O
and	O
to	O
induce	O
24-hydroxylase	B-RNA
mRNA	I-RNA
and	O
activity	O
,	O
without	O
affecting	O
either	O
total	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
uptake	O
or	O
maximal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-VDR	B-protein
binding	O
.	O

Thus	O
,	O
intact	O
microtubules	B-protein
are	O
essential	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-dependent	O
modulation	O
of	O
gene	O
transcription	O
.	O

Interestingly	O
,	O
microtubule	B-protein
disruption	O
also	O
decreased	O
monocyte	B-cell_type
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
,	O
not	O
by	O
decreasing	O
the	O
Vmax	O
of	O
monocyte	B-protein
mitochondrial	I-protein
1	I-protein
alpha-hydroxylase	I-protein
but	O
through	O
an	O
increase	O
in	O
the	O
Km	O
for	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
examined	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
.	O

Microtubule	O
disruption	O
did	O
not	O
affect	O
total	O
cellular	O
25	O
(	O
OH	O
)	O
D3	O
uptake	O
but	O
reduced	O
its	O
intracellular	O
trafficking	O
to	O
the	O
mitochondria	O
.	O

Thus	O
,	O
microtubules	B-protein
participate	O
in	O
intracellular	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
,	O
and	O
their	O
integrity	O
determines	O
normal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
.	O

Relationship	O
between	O
Rap1	B-protein
protein	I-protein
phosphorylation	O
and	O
regulation	O
of	O
Ca2+	O
transport	O
in	O
platelets	B-cell_type
:	O
a	O
new	O
approach	O
.	O

Although	O
the	O
interrelationship	O
between	O
the	O
two	O
messengers	O
Ca2+	O
and	O
cyclic	O
AMP	O
in	O
platelet	O
function	O
is	O
well	O
documented	O
,	O
its	O
mechanism	O
of	O
action	O
still	O
remains	O
to	O
be	O
established	O
.	O

We	O
investigated	O
here	O
the	O
question	O
of	O
the	O
regulation	O
of	O
platelet	B-protein
Ca	I-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPases	I-protein
by	O
cyclic	O
AMP	O
through	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B-protein
protein	I-protein
using	O
a	O
pathological	O
model	O
.	O

We	O
first	O
found	O
experimental	O
conditions	O
where	O
Ca	O
(	O
2+	O
)	O
-transport	O
by	O
platelet	O
membrane	O
vesicles	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B-protein
protein	I-protein
.	O

Then	O
,	O
we	O
studied	O
platelets	B-cell_type
of	O
patients	O
with	O
congestive	O
heart	O
failure	O
for	O
their	O
expression	O
of	O
the	O
potential	O
97	B-protein
kDa	I-protein
Ca	I-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPase	I-protein
target	I-protein
of	O
regulation	O
through	O
the	O
Rap1	B-protein
protein	I-protein
as	O
well	O
as	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B-protein
protein	I-protein
using	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
the	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinase	I-protein
(	O
C.	B-protein
Sub	I-protein
.	I-protein
)	O
.	O

In	O
the	O
first	O
patients	O
studied	O
,	O
we	O
found	O
no	O
significant	O
modification	O
in	O
the	O
expression	O
of	O
the	O
97	B-protein
kDa	I-protein
Ca	I-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPase	I-protein
by	O
Western	O
blotting	O
using	O
the	O
PL/IM	B-protein
430	I-protein
monoclonal	I-protein
antibody	I-protein
which	O
specifically	O
recognized	O
this	O
isoform	O
.	O

In	O
contrast	O
,	O
the	O
Rap1	B-protein
protein	I-protein
was	O
differentially	O
phosphorylated	O
when	O
using	O
15	O
micrograms/ml	O
of	O
the	O
C.	B-protein
Sub	I-protein
.	I-protein

These	O
results	O
allowed	O
us	O
to	O
use	O
these	O
pathological	O
platelets	B-cell_type
to	O
study	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
Rap1	B-protein
protein	I-protein
and	O
the	O
regulation	O
of	O
Ca2+	O
transport	O
by	O
selecting	O
a	O
patient	O
with	O
severe	O
heart	O
failure	O
.	O

We	O
could	O
show	O
a	O
decrease	O
in	O
the	O
expression	O
as	O
well	O
as	O
in	O
the	O
phosphorylation	O
of	O
Rap1	B-protein
protein	I-protein
and	O
demonstrate	O
a	O
lower	O
effect	O
of	O
C.	B-protein
Sub	I-protein
.	I-protein
on	O
Ca2+	O
transport	O
.	O

Finally	O
,	O
by	O
studying	O
a	O
further	O
series	O
of	O
patients	O
,	O
we	O
could	O
confirm	O
that	O
the	O
decrease	O
in	O
Rap1	B-protein
protein	I-protein
expression	O
in	O
heart	O
failure	O
,	O
whatever	O
its	O
extent	O
,	O
was	O
variable	O
,	O
and	O
could	O
strictly	O
correlate	O
the	O
expression	O
of	O
Rap1	B-protein
protein	I-protein
with	O
the	O
stimulatory	O
effect	O
of	O
C.	B-protein
Sub	I-protein
.	I-protein
on	O
Ca2+	O
transport	O
.	O

Besides	O
the	O
evidence	O
for	O
regulation	O
of	O
the	O
expression	O
of	O
the	O
Rap1	B-protein
protein	I-protein
in	O
platelets	B-cell_type
from	O
patients	O
with	O
heart	O
failure	O
,	O
these	O
findings	O
constitute	O
a	O
new	O
approach	O
in	O
favour	O
of	O
the	O
regulation	O
of	O
platelet	O
Ca2+	O
transport	O
through	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B-protein
protein	I-protein
.	O

An	O
IRF-1	B-protein
-dependent	O
pathway	O
of	O
DNA	O
damage-induced	O
apoptosis	O
in	O
mitogen-activated	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

Lymphocytes	B-cell_line
are	O
particularly	O
susceptible	O
to	O
DNA	O
damage-induced	O
apoptosis	O
,	O
a	O
response	O
which	O
may	O
serve	O
as	O
a	O
form	O
of	O
'altruistic	O
suicide	O
'	O
to	O
counter	O
their	O
intrinsic	O
high	O
potential	O
for	O
mutation	O
and	O
clonal	O
expansion	O
.	O

The	O
tumour	B-protein
suppressor	I-protein
p53	I-protein
has	O
been	O
shown	O
to	O
regulate	O
this	O
type	O
of	O
apoptosis	O
in	O
thymocytes	B-cell_type
,	O
but	O
an	O
as	O
yet	O
unknown	O
,	O
p53	B-protein
-independent	O
pathway	O
(	O
s	O
)	O
appears	O
to	O
mediate	O
the	O
same	O
event	O
in	O
mitogen-activated	B-cell_line
mature	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

Here	O
we	O
show	O
DNA	O
damage-induced	O
apoptosis	O
in	O
these	O
T	B-cell_type
lymphocytes	I-cell_type
is	O
dependent	O
on	O
the	O
antioncogenic	B-protein
transcription	I-protein
factor	I-protein
interferon	I-protein
regulatory	I-protein
factor	I-protein
(	B-protein
IRF	I-protein
)	I-protein
-1	I-protein
.	O

Thus	O
two	O
different	O
anti-onco-genic	B-protein
transcription	I-protein
factors	I-protein
,	O
p53	B-protein
and	O
IRF-1	B-protein
,	O
are	O
required	O
for	O
distinct	O
apoptotic	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
also	O
show	O
that	O
mitogen	O
induction	O
of	O
the	O
interleukin-1	B-DNA
beta	I-DNA
converting	I-DNA
enzyme	I-DNA
(	I-DNA
ICE	I-DNA
)	I-DNA
gene	I-DNA
,	O
a	O
mammalian	B-protein
homologue	I-protein
of	O
the	O
Caenorhabditis	B-DNA
elegans	I-DNA
cell	I-DNA
death	I-DNA
gene	I-DNA
ced-3	B-DNA
,	O
is	O
IRF-1	B-protein
-dependent	O
.	O

Ectopic	O
overexpression	O
of	O
IRF-1	B-protein
results	O
in	O
the	O
activation	O
of	O
the	O
endogenous	B-DNA
gene	I-DNA
for	O
ICE	B-protein
and	O
enhances	O
the	O
sensitivity	O
of	O
cells	O
to	O
radiation-induced	O
apoptosis	O
.	O

Circadian	O
rhythm	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
leukocytes	I-cell_type
and	O
their	O
reactivity	O
to	O
glucocorticoids	O
.	O

1	O
)	O
There	O
exists	O
a	O
CR	O
of	O
GR	B-protein
in	O
human	B-cell_type
leukocytes	I-cell_type
,	O
PMN	B-cell_type
,	O
and	O
monocytes	B-cell_type
with	O
the	O
peak	O
values	O
from	O
0400	O
to	O
0800	O
hr	O
and	O
the	O
trough	O
values	O
between	O
2300	O
and	O
0000	O
hr	O
.	O

The	O
difference	O
between	O
them	O
was	O
significant	O
statistically	O
.	O

2	O
)	O
The	O
FI	O
of	O
the	O
chemotactic	O
migration	O
rate	O
of	O
PMN	B-cell_type
by	O
cortisol	O
also	O
showed	O
diurnal	O
changes	O
which	O
were	O
synchronous	O
with	O
that	O
of	O
GR	B-protein
.	O

This	O
indicates	O
that	O
the	O
CR	O
of	O
GR	B-protein
may	O
be	O
of	O
functional	O
significance	O
.	O

3	O
)	O
In	O
Cushing	O
's	O
syndrome	O
,	O
the	O
CR	O
of	O
GR	B-protein
was	O
normal	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
CR	O
of	O
plasma	O
cortisol	O
was	O
disturbed	O
.	O

This	O
indicates	O
the	O
independency	O
of	O
the	O
CR	O
of	O
GR	B-protein
from	O
that	O
of	O
cortisol	O
.	O

4	O
)	O
In	O
apoplexy	O
caused	O
by	O
brain	O
ischemia	O
,	O
the	O
CR	O
of	O
GR	B-protein
was	O
abolished	O
in	O
patients	O
with	O
basal	O
lesions	O
but	O
preserved	O
when	O
the	O
lesions	O
were	O
located	O
in	O
the	O
cerebral	O
cortex	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
main	O
``	O
circadian	O
pacemaker	O
''	O
of	O
GR	B-protein
is	O
located	O
in	O
the	O
basal	O
brain	O
,	O
most	O
probably	O
in	O
the	O
suprachiasmatic	O
nuclei	O
as	O
has	O
been	O
suggested	O
for	O
rodents	O
.	O

B-lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
multiple	O
sclerosis	O
patients	O
and	O
a	O
healthy	O
control	O
producing	O
a	O
putative	O
new	O
human	O
retrovirus	O
and	O
Epstein-Barr	O
virus	O
.	O

On	O
several	O
occasions	O
we	O
have	O
observed	O
retrovirus-like	O
particles	O
(	O
RVLPs	O
)	O
by	O
transmission	O
electron	O
microscopy	O
(	O
EM	O
)	O
of	O
cultured	B-cell_line
T	I-cell_line
cells	I-cell_line
from	O
a	O
patient	O
with	O
MS	O
.	O

Later	O
we	O
established	O
spontaneously	O
formed	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
LCLs	B-cell_line
)	O
from	O
a	O
patient	O
with	O
an	O
MS-like	O
disease	O
and	O
from	O
another	O
patient	O
with	O
MS	O
who	O
had	O
a	O
reactivated	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
.	O

Both	O
LCLs	B-cell_line
were	O
found	O
by	O
EM	O
to	O
produce	O
RVLP	O
and	O
EBV	O
particles	O
.	O

Reverse	O
transcriptase	O
(	O
RT	O
)	O
assays	O
were	O
positive	O
in	O
purified	O
viral	O
material	O
from	O
both	O
LCLs	B-cell_line
.	O

To	O
substantiate	O
these	O
findings	O
we	O
initiated	O
an	O
intensified	O
culturing	O
procedure	O
and	O
were	O
able	O
to	O
establish	O
LCLs	B-cell_line
from	O
5	O
out	O
of	O
21	O
consecutive	O
MS	O
patients	O
and	O
1	O
out	O
of	O
13	O
consecutive	O
healthy	O
controls	O
.	O

All	O
LCLs	B-cell_line
were	O
found	O
to	O
produce	O
both	O
RVLP	O
and	O
EBV	O
particles	O
by	O
EM	O
.	O

Whether	O
the	O
putative	O
new	O
retrovirus	O
(	O
es	O
)	O
and	O
EBV	O
have	O
any	O
causal	O
relationship	O
to	O
MS	O
is	O
still	O
not	O
known	O
,	O
but	O
the	O
findings	O
support	O
this	O
possibility	O
.	O

Identification	O
of	O
an	O
ionomycin/cyclosporin	B-DNA
A-responsive	I-DNA
element	I-DNA
within	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
gamma	I-DNA
enhancer	I-DNA
.	O

Activation	O
through	O
the	O
Ca2+/	O
calcineurin	B-protein
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	B-DNA
genes	I-DNA
.	O

The	O
conserved	B-DNA
cis-acting	I-DNA
sequence	I-DNA
,	O
GGAAAA	O
,	O
and	O
transcription	B-protein
factors	I-protein
binding	O
to	O
this	O
sequence	O
are	O
involved	O
in	O
the	O
response	O
to	O
increased	O
intracellular	O
Ca2+	O
concentrations	O
.	O

Here	O
we	O
report	O
the	O
identification	O
and	O
importance	O
of	O
the	O
same	O
sequence	O
in	O
a	O
non-cytokine	B-DNA
gene	I-DNA
,	O
the	O
human	B-DNA
T	I-DNA
cell	I-DNA
receptor	I-DNA
gamma	I-DNA
(	I-DNA
TCRG	I-DNA
)	I-DNA
enhancer	I-DNA
.	O

Results	O
from	O
site-directed	O
mutations	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O
that	O
this	O
sequence	O
mediates	O
the	O
ionomycin-induced	O
activation	O
of	O
the	O
TCRG	B-DNA
enhancer	I-DNA
.	O

Our	O
studies	O
provide	O
an	O
explanation	O
for	O
a	O
previous	O
observation	O
that	O
TCRG	B-RNA
mRNA	I-RNA
levels	O
,	O
but	O
not	O
mRNA	O
levels	O
for	O
T	B-protein
cell	I-protein
receptor	I-protein
alpha	I-protein
and	I-protein
-beta	I-protein
,	O
are	O
increased	O
by	O
ionomycin	O
treatment	O
.	O

Coexpression	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
and	O
Sp1	B-protein
transcription	B-protein
factors	I-protein
in	O
human	O
immunodeficiency	O
virus	O
1-induced	O
,	O
dendritic	O
cell-T-cell	O
syncytia	O
.	O

Productive	O
infection	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
typically	O
requires	O
that	O
the	O
T	B-cell_type
cells	I-cell_type
be	O
stimulated	O
with	O
antigens	O
or	O
mitogens	O
.	O

This	O
requirement	O
has	O
been	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
,	O
which	O
synergizes	O
with	O
the	O
constitutive	B-protein
transcription	I-protein
factor	I-protein
Sp1	B-protein
to	O
drive	O
the	O
HIV-1	B-DNA
promoter	I-DNA
.	O

Recently	O
,	O
we	O
have	O
found	O
that	O
vigorous	O
replication	O
of	O
HIV-1	O
takes	O
place	O
in	O
nonactivated	O
memory	B-cell_type
T	I-cell_type
cells	I-cell_type
after	O
syncytium	O
formation	O
with	O
dendritic	B-cell_type
cells	I-cell_type
(	O
DCs	B-cell_type
)	O
.	O

These	O
syncytia	O
lack	O
activated	B-cell_type
cells	I-cell_type
as	O
determined	O
by	O
an	O
absence	O
of	O
staining	O
for	O
Ki-67	O
cell	O
cycle	O
antigen	O
.	O

The	O
expression	O
and	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-protein
were	O
,	O
therefore	O
,	O
analyzed	O
in	O
isolated	O
T	B-cell_type
cells	I-cell_type
and	O
DCs	B-cell_type
from	O
humans	O
and	O
mice	O
.	O

We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O

T	B-cell_type
cells	I-cell_type
lack	O
active	O
NF-kappa	B-protein
B	I-protein
but	O
express	O
Sp1	B-protein
as	O
expected	O
.	O

DCs	B-cell_type
express	O
high	O
levels	O
of	O
all	O
known	O
NF-kappa	B-protein
B	I-protein
and	O
Rel	B-protein
proteins	I-protein
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
.	O

However	O
,	O
DCs	B-cell_type
lack	O
Sp1	B-protein
,	O
which	O
may	O
explain	O
the	O
failure	O
of	O
HIV-1	O
to	O
replicate	O
in	O
purified	O
DCs	B-cell_type
.	O

Coexpression	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-protein
occurs	O
in	O
the	O
heterologous	B-cell_type
DC-T-cell	I-cell_type
syncytia	I-cell_type
that	O
are	O
induced	O
by	O
HIV-1	O
.	O

Therefore	O
,	O
HIV-1-induced	O
cell	O
fusion	O
brings	O
together	O
factors	O
that	O
upregulate	O
virus	O
transcription	O
.	O

Since	O
DCs	B-cell_type
and	O
memory	O
T	B-cell_type
cells	I-cell_type
frequently	O
traffic	O
together	O
in	O
situ	O
,	O
these	O
unusual	O
heterologous	B-cell_type
syncytia	I-cell_type
could	O
develop	O
in	O
infected	O
individuals	O
and	O
lead	O
to	O
chronic	O
HIV-1	O
replication	O
without	O
ostensible	O
immune	O
stimulation	O
.	O

Cupric	O
ion	O
blocks	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
through	O
inhibiting	O
the	O
signal-induced	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

A	O
transcription	B-protein
factor	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	B-DNA
genes	I-DNA
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	B-protein
protein	I-protein
I	I-protein
kappa	I-protein
B	I-protein
.	O

Various	O
extracellular	O
signals	O
induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
to	O
release	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

Cu2+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
induced	O
by	O
TNF-alpha	B-protein
,	O
TPA	O
,	O
or	O
H2O2	O
.	O

Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF-alpha	B-protein
in	O
the	O
presence	O
of	O
Cu2+	O
resulted	O
in	O
the	O
release	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
from	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
indicating	O
that	O
Cu2+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	B-protein
kappa	I-protein
B-I	I-protein
kappa	I-protein
B	I-protein
complex	I-protein
.	O

Neither	O
phosphorylation	O
nor	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
was	O
observed	O
upon	O
TNF-alpha	B-protein
stimulation	O
in	O
the	O
presence	O
of	O
Cu2+	O
.	O

These	O
results	O
indicate	O
that	O
Cu2+	O
inhibits	O
the	O
release	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Cloning	O
a	O
cDNA	B-DNA
from	O
human	O
NK/T	B-cell_type
cells	I-cell_type
which	O
codes	O
for	O
a	O
protein	O
with	O
high	O
proline	O
content	O
.	O

A	O
cDNA	B-DNA
clone	I-DNA
,	O
B4-2	B-DNA
,	O
was	O
isolated	O
from	O
a	O
natural	B-DNA
killer	I-DNA
(	I-DNA
NK	I-DNA
)	I-DNA
minus	I-DNA
T	I-DNA
cell	I-DNA
subtractive	I-DNA
library	I-DNA
.	O

The	O
B4-2	B-DNA
clone	O
coded	O
for	O
an	O
mRNA	B-RNA
of	O
2061	O
bp	O
in	O
length	O
.	O

It	O
encodes	O
a	O
deduced	O
327	B-protein
aa	I-protein
protein	I-protein
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
35.2	O
kDa	O
.	O

Searching	O
of	O
B4-2	B-DNA
DNA	I-DNA
and	O
protein	O
sequences	O
against	O
various	O
databases	O
revealed	O
no	O
high	O
homology	O
to	O
other	O
sequences	O
.	O

However	O
,	O
B4-2	B-DNA
has	O
an	O
unusually	O
high	O
proline	O
content	O
(	O
13	O
%	O
)	O
,	O
contains	O
a	O
putative	O
nuclear	B-protein
targeting	I-protein
sequence	I-protein
,	O
and	O
has	O
several	O
SPXX	B-protein
motifs	I-protein
which	O
are	O
frequently	O
found	O
in	O
gene	B-protein
regulatory	I-protein
proteins	I-protein
.	O

One	O
of	O
the	O
stretches	O
of	O
prolines	O
in	O
B4-2	B-DNA
closely	O
resembles	O
the	O
ligand	O
for	O
proteins	O
with	O
SH3	B-protein
domains	I-protein
.	O

Northern	O
hybridization	O
data	O
showed	O
that	O
B4-2	B-DNA
is	O
not	O
a	O
lymphoid	B-DNA
specific	I-DNA
gene	I-DNA
and	O
is	O
expressed	O
in	O
a	O
hepatoma	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
also	O
weakly	O
transcribed	O
or	O
absent	O
in	O
a	O
variety	O
of	O
other	O
cells	O
.	O

A	O
polyclonal	O
antiserum	O
raised	O
against	O
recombinant	B-protein
B4-2	I-protein
recognizes	O
a	O
32-34	B-protein
kDa	I-protein
protein	I-protein
in	O
lymphocytes	B-cell_type
.	O

Activation	O
of	O
JAK3	B-protein
,	O
but	O
not	O
JAK1	B-protein
,	O
is	O
critical	O
for	O
IL-2	B-protein
-induced	O
proliferation	O
and	O
STAT5	B-protein
recruitment	O
by	O
a	O
COOH-terminal	B-protein
region	I-protein
of	O
the	O
IL-2	B-protein
receptor	I-protein
beta-chain	I-protein
.	O

A	O
number	O
of	O
cytokines	B-protein
and	O
growth	B-protein
factors	I-protein
use	O
the	O
JAK	B-protein
-STAT	B-protein
pathway	O
to	O
signal	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
.	O

While	O
homodimerizing	B-protein
cytokine	I-protein
receptors	I-protein
may	O
transmit	O
signal	O
via	O
a	O
single	O
form	O
of	O
JAK	B-protein
(	O
i.e	O
.	O
growth	B-protein
hormone	I-protein
receptors	I-protein
)	O
,	O
several	O
multicomponent	B-protein
cytokine	I-protein
receptors	I-protein
have	O
been	O
shown	O
to	O
require	O
simultaneous	O
activation	O
of	O
pairs	O
of	O
different	O
JAK	B-protein
kinases	I-protein
(	O
i.e	O
.	O
interferon	B-protein
receptors	I-protein
)	O
.	O

Recent	O
evidence	O
for	O
a	O
preferential	O
coupling	O
of	O
JAK3	B-protein
to	O
interleukin-2	B-protein
receptor-gamma	I-protein
(	O
IL-2R	B-protein
gamma	I-protein
)	O
and	O
JAK1	B-protein
to	O
IL-2R	B-protein
beta	I-protein
supports	O
the	O
concept	O
of	O
heterotrans-activation	O
of	O
JAK1	B-protein
and	O
JAK3	B-protein
caused	O
by	O
IL-2	B-protein
-induced	O
heterodimerization	O
of	O
their	O
receptor	O
partners	O
.	O

The	O
present	O
study	O
verified	O
the	O
ability	O
of	O
IL-2	B-protein
to	O
cause	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
JAK1	B-protein
and	O
JAK3	B-protein
,	O
but	O
demonstrated	O
that	O
IL-2	B-protein
stimulated	O
JAK3	B-protein
to	O
a	O
significantly	O
larger	O
extent	O
than	O
JAK1	B-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
the	O
YT	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

This	O
conclusion	O
was	O
based	O
upon	O
several	O
independent	O
criteria	O
,	O
including	O
more	O
vigorous	O
tyrosine	O
phosphorylation	O
of	O
JAK3	B-protein
,	O
more	O
marked	O
enzymatic	O
activation	O
of	O
JAK3	B-protein
as	O
well	O
as	O
higher	O
abundance	O
of	O
JAK3	B-protein
in	O
activated	O
IL-2	B-protein
receptor	I-protein
complexes	I-protein
.	O

Furthermore	O
,	O
when	O
human	B-protein
IL-2R	I-protein
beta	I-protein
was	O
stably	O
expressed	O
in	O
murine	B-cell_line
BA/F3	I-cell_line
cells	I-cell_line
,	O
robust	O
IL-2	B-protein
-induced	O
proliferation	O
and	O
JAK3	B-protein
activation	O
occurred	O
without	O
detectable	O
involvement	O
of	O
either	O
JAK1	B-protein
,	O
JAK2	B-protein
or	O
TYK2	B-protein
.	O

We	O
therefore	O
propose	O
that	O
IL-2	B-protein
receptor	I-protein
signal	O
transduction	O
does	O
not	O
depend	O
on	O
equimolar	O
heterodimerization	O
of	O
JAK1	B-protein
and	O
JAK3	B-protein
following	O
IL-2	B-protein
-induced	O
heterodimerization	O
of	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
.	O

Nonetheless	O
,	O
a	O
membrane-proximal	B-protein
region	I-protein
of	O
human	O
IL-2R	B-protein
beta	I-protein
(	O
Asn240-Leu335	B-protein
)	O
was	O
critical	O
for	O
JAK3	B-protein
activation	O
,	O
and	O
the	O
amount	O
of	O
JAK3	B-protein
present	O
in	O
activated	O
IL-2	B-protein
receptor	I-protein
complexes	I-protein
increased	O
with	O
time	O
,	O
suggesting	O
that	O
stabilization	O
of	O
JAK3	B-protein
binding	O
to	O
the	O
receptor	B-protein
complex	I-protein
relies	O
on	O
both	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
.	O

Moreover	O
,	O
STAT5	B-protein
was	O
found	O
to	O
be	O
the	O
predominant	O
STAT	B-protein
transcription	I-protein
factor	I-protein
used	O
by	O
IL-2	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
specifically	O
required	O
a	O
COOH-terminal	B-protein
region	I-protein
of	O
IL-2R	B-protein
beta	I-protein
(	O
Ser386-Val525	B-protein
)	O
,	O
while	O
STAT5	B-protein
recruitment	O
was	O
not	O
correlated	O
to	O
activation	O
of	O
IL-2R	B-protein
gamma	I-protein
or	O
JAK3	B-protein
.	O

Up-regulation	O
of	O
high-affinity	O
dehydroepiandrosterone	O
binding	O
activity	O
by	O
dehydroepiandrosterone	O
in	O
activated	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Although	O
evidence	O
indicates	O
that	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
exerts	O
direct	O
physiological	O
effects	O
,	O
its	O
mechanism	O
of	O
action	O
remains	O
unknown	O
.	O

DHEA	O
binding	O
sites	O
were	O
examined	O
using	O
a	O
whole-cell	O
binding	O
assay	O
in	O
a	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PEER	B-cell_line
,	O
revealing	O
that	O
a	O
single	O
class	O
of	O
high-affinity	O
binding	O
sites	O
for	O
DHEA	O
(	O
dissociation	O
constant	O
=	O
7.4	O
+/-	O
0.53	O
nmol/L	O
,	O
mean	O
+/-	O
SE	O
,	O
n	O
=	O
4	O
)	O
was	O
greatly	O
increased	O
when	O
treated	O
with	O
DHEA	O
,	O
phorbol-12-myristate-13-acetate	O
,	O
and	O
the	O
Ca2+	O
ionophore	O
A23187	O
.	O

Bound	O
[	O
3H	O
]	O
DHEA	O
was	O
displaced	O
sensitively	O
by	O
DHEA	O
and	O
secondarily	O
by	O
dihydrotestosterone	O
,	O
but	O
not	O
effectively	O
by	O
other	O
steroids	O
,	O
including	O
DHEA	O
sulfate	O
.	O

These	O
results	O
not	O
only	O
indicate	O
the	O
existence	O
of	O
a	O
DHEA	B-protein
receptor	I-protein
,	O
but	O
also	O
suggest	O
that	O
T	B-cell_type
cells	I-cell_type
become	O
susceptible	O
to	O
regulation	O
by	O
DHEA	O
during	O
the	O
process	O
of	O
signal-induced	O
activation	O
.	O

Ubiquitin-mediated	O
processing	O
of	O
NF-kappa	B-protein
B	I-protein
transcriptional	B-protein
activator	I-protein
precursor	I-protein
p105	B-protein
.	O

Reconstitution	O
of	O
a	O
cell-free	O
system	O
and	O
identification	O
of	O
the	O
ubiquitin-carrier	B-protein
protein	I-protein
,	O
E2	B-protein
,	O
and	O
a	O
novel	O
ubiquitin-protein	B-protein
ligase	I-protein
,	O
E3	B-protein
,	O
involved	O
in	O
conjugation	O
.	O

In	O
most	O
cases	O
,	O
the	O
transcriptional	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
is	O
a	O
heterodimer	B-protein
consisting	O
of	O
two	O
subunits	O
,	O
p50	B-protein
and	O
p65	B-protein
,	O
which	O
are	O
encoded	O
by	O
two	O
distinct	O
genes	O
of	O
the	O
Rel	B-DNA
family	I-DNA
.	O

p50	B-protein
is	O
translated	O
as	O
a	O
precursor	O
of	O
105	B-protein
kDa	I-protein
.	O

The	O
C-terminal	B-protein
domain	I-protein
of	O
the	O
precursor	O
is	O
rapidly	O
degraded	O
,	O
forming	O
the	O
mature	B-protein
p50	I-protein
subunit	I-protein
consisted	O
of	O
the	O
N-terminal	B-protein
region	I-protein
of	O
the	O
molecule	O
.	O

The	O
mechanism	O
of	O
generation	O
of	O
p50	B-protein
is	O
not	O
known	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin	B-protein
-proteasome	B-protein
system	O
is	O
involved	O
in	O
the	O
process	O
;	O
however	O
,	O
the	O
specific	O
enzymes	B-protein
involved	O
and	O
the	O
mechanism	O
of	O
limited	O
proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared	O
,	O
have	O
been	O
obscure	O
.	O

Palombella	O
and	O
colleagues	O
(	O
Palombella	O
,	O
V.J.	O
,	O
Rando	O
,	O
O.J.	O
,	O
Goldberg	O
,	O
A.L.	O
,	O
and	O
Maniatis	O
,	O
T.	O
(	O
1994	O
)	O
Cell	O
78	O
,	O
773-785	O
)	O
have	O
shown	O
that	O
ubiquitin	B-protein
is	O
required	O
for	O
the	O
processing	O
in	O
a	O
cell-free	O
system	O
of	O
a	O
truncated	O
,	O
artificially	O
constructed	O
,	O
60-kDa	B-protein
precursor	I-protein
.	O

They	O
have	O
also	O
shown	O
that	O
proteasome	B-protein
inhibitors	O
block	O
the	O
processing	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
reconstitution	O
of	O
a	O
cell-free	O
processing	O
system	O
and	O
demonstrate	O
directly	O
that	O
:	O
(	O
a	O
)	O
the	O
ubiquitin	B-protein
-proteasome	B-protein
system	O
is	O
involved	O
in	O
processing	O
of	O
the	O
intact	O
p105	B-protein
precursor	O
,	O
(	O
b	O
)	O
conjugation	O
of	O
ubiquitin	B-protein
to	O
the	O
precursor	O
is	O
an	O
essential	O
intermediate	O
step	O
in	O
the	O
processing	O
,	O
(	O
c	O
)	O
the	O
recently	O
discovered	O
novel	O
species	O
of	O
the	O
ubiquitin-carrier	B-protein
protein	I-protein
,	O
E2-F1	B-protein
,	O
that	O
is	O
involved	O
in	O
the	O
conjugation	O
and	O
degradation	O
of	O
p53	B-protein
,	O
is	O
also	O
required	O
for	O
the	O
limited	O
processing	O
of	O
the	O
p105	B-protein
precursor	I-protein
,	O
and	O
(	O
d	O
)	O
a	O
novel	O
,	O
approximately	O
320-kDa	B-protein
species	I-protein
of	O
ubiquitin-protein	B-protein
ligase	I-protein
,	O
is	O
involved	O
in	O
the	O
process	O
.	O

This	O
novel	O
enzyme	O
is	O
distinct	O
from	O
E6-AP	B-protein
,	O
the	O
p53-conjugating	B-protein
ligase	I-protein
,	O
and	O
from	O
E3	B-protein
alpha	I-protein
,	O
the	O
``	B-protein
N-end	I-protein
rule	I-protein
''	I-protein
ligase	I-protein
.	O

Flutamide	O
in	O
the	O
treatment	O
of	O
hirsutism	O
:	O
long-term	O
clinical	O
effects	O
,	O
endocrine	O
changes	O
,	O
and	O
androgen	B-protein
receptor	I-protein
behavior	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
long-term	O
effects	O
of	O
treatment	O
with	O
low	O
doses	O
of	O
flutamide	O
on	O
clinical	O
and	O
hormonal	O
parameters	O
,	O
as	O
well	O
as	O
on	O
the	O
androgen	B-protein
receptor	I-protein
status	O
,	O
in	O
hirsute	O
women	O
.	O

DESIGN	O
:	O
Eighteen	O
hirsute	O
patients	O
with	O
regular	O
menses	O
were	O
studied	O
basally	O
and	O
during	O
treatment	O
with	O
125	O
mg	O
flutamide	O
,	O
three	O
times	O
per	O
day	O
for	O
12	O
months	O
.	O

Barrier	O
or	O
intrauterine	O
contraception	O
was	O
used	O
during	O
the	O
study	O
in	O
sexually	O
active	O
women	O
.	O

Safety	O
parameters	O
were	O
assessed	O
throughout	O
the	O
study	O
.	O

Hirsutism	O
,	O
graded	O
by	O
the	O
modified	O
Ferriman-Gallwey	O
score	O
,	O
and	O
hormonal	O
parameters	O
were	O
evaluated	O
basally	O
and	O
at	O
4-month	O
intervals	O
during	O
treatment	O
.	O

Gonadotropin-releasing	O
hormone	O
and	O
ACTH	O
stimulation	O
tests	O
were	O
performed	O
before	O
and	O
after	O
3	O
to	O
4	O
months	O
of	O
therapy	O
.	O

In	O
addition	O
,	O
the	O
concentration	O
of	O
androgen	B-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
was	O
measured	O
,	O
in	O
both	O
the	O
follicular	O
and	O
luteal	O
phases	O
of	O
the	O
menstrual	O
cycle	O
,	O
basally	O
and	O
after	O
4	O
months	O
of	O
flutamide	O
treatment	O
.	O

RESULTS	O
:	O
Flutamide	O
was	O
well	O
tolerated	O
in	O
all	O
women	O
,	O
with	O
the	O
noticeable	O
exception	O
of	O
one	O
patient	O
who	O
presented	O
increased	O
serum	B-protein
transaminase	I-protein
after	O
8	O
months	O
of	O
therapy	O
.	O

Hirsutism	O
markedly	O
improved	O
in	O
all	O
women	O
during	O
the	O
treatment	O
(	O
Ferriman-Gallwey	O
score	O
after	O
1	O
year	O
:	O
4.1	O
+/-	O
0.5	O
versus	O
14.1	O
+/-	O
0.9	O
)	O
.	O

A	O
reduction	O
of	O
serum	O
androgens	O
was	O
found	O
,	O
whereas	O
no	O
change	O
was	O
observed	O
in	O
either	O
basal	O
or	O
GnRH-stimulated	O
gonadotropins	O
or	O
in	O
the	O
cortisol	O
and	O
17	O
alpha-hydroxyprogesterone	O
response	O
to	O
ACTH	O
.	O

Cycles	O
remained	O
ovulatory	O
.	O

Before	O
treatment	O
,	O
the	O
number	O
of	O
androgen	B-protein
receptors	I-protein
was	O
higher	O
in	O
the	O
luteal	O
than	O
in	O
the	O
follicular	O
phase	O
.	O

This	O
rhythmic	O
differentiation	O
disappeared	O
after	O
the	O
patients	O
had	O
been	O
given	O
the	O
antiandrogen	O
drug	O
.	O

CONCLUSIONS	O
:	O
Flutamide	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
but	O
requires	O
constant	O
surveillance	O
of	O
liver	O
function	O
.	O

Androgen	O
receptor	O
blockade	O
might	O
be	O
potentiated	O
by	O
a	O
reduction	O
of	O
serum	O
androgens	O
.	O

Flutamide	O
affects	O
androgen	B-protein
receptor	I-protein
behavior	O
during	O
the	O
menstrual	O
cycle	O
.	O

The	O
meaning	O
of	O
this	O
finding	O
remains	O
to	O
be	O
elucidated	O
.	O

Constitutive	O
expression	O
of	O
HIV-1	B-protein
tat	I-protein
protein	I-protein
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
using	O
a	O
BK	O
virus	O
vector	O
.	O

The	O
production	O
and	O
characterization	O
of	O
Jurkat	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
constitutively	O
express	O
functional	O
human	B-protein
immune	I-protein
deficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
tat	I-protein
protein	I-protein
,	O
using	O
a	O
BK	O
virus	O
plasmid	O
expression	O
vector	O
and	O
HIV-1	B-DNA
tat	I-DNA
cDNA	I-DNA
,	O
is	O
described	O
.	O

An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat-tat	B-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
compared	O
with	O
control	B-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
observed	O
.	O

A	O
PEBP2	B-protein
alpha/AML-1-related	I-protein
factor	I-protein
increases	O
osteocalcin	B-DNA
promoter	I-DNA
activity	O
through	O
its	O
binding	O
to	O
an	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
element	I-DNA
.	O

To	O
identify	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
elements	I-DNA
and	O
trans-acting	B-protein
factors	I-protein
,	O
we	O
initiated	O
an	O
analysis	O
of	O
the	O
promoter	B-DNA
of	O
a	O
mouse	B-DNA
osteocalcin	I-DNA
gene	I-DNA
,	O
an	O
osteoblast-specific	B-DNA
gene	I-DNA
.	O

In	O
this	O
promoter	O
,	O
we	O
identified	O
two	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
elements	I-DNA
(	O
Ducy	O
,	O
P.and	O
Karsenty	O
,	O
G.	O
(	O
1995	O
)	O
Mol.Cell.Biol.15	O
,	O
1858-1869	O
)	O
.	O

The	O
sequence	O
of	O
one	O
of	O
these	O
elements	B-DNA
,	O
OSE2	O
,	O
is	O
identical	O
to	O
the	O
DNA-binding	B-DNA
site	I-DNA
of	O
the	O
PEBP2	B-protein
alpha/AML-1	I-protein
transcription	I-protein
factors	I-protein
,	O
the	O
mammalian	B-protein
homologues	I-protein
of	O
the	O
Drosophila	B-protein
Runt	I-protein
protein	I-protein
.	O

Here	O
we	O
show	O
,	O
using	O
nuclear	O
extracts	O
,	O
recombinant	B-protein
protein	I-protein
,	O
and	O
a	O
specific	O
antiserum	O
against	O
AML-1	B-protein
proteins	I-protein
in	O
DNA-binding	O
assays	O
,	O
that	O
one	O
member	O
of	O
this	O
family	O
,	O
AML-1B	B-protein
,	O
binds	O
specifically	O
to	O
OSE2	O
and	O
is	O
immunologically	O
related	O
to	O
OSF2	B-protein
,	O
the	O
factor	O
present	O
in	O
osteoblast	O
nuclear	O
extracts	O
that	O
binds	O
to	O
OSE2	O
.	O

By	O
DNA	O
cotransfection	O
experiments	O
,	O
we	O
also	O
demonstrate	O
that	O
AML-1B	B-protein
can	O
increase	O
the	O
activity	O
of	O
a	O
short	O
osteocalcin	B-DNA
promoter	I-DNA
through	O
its	O
binding	O
to	O
OSE2	O
.	O

Lastly	O
,	O
the	O
different	O
mobilities	O
of	O
osteoblast	B-protein
nuclear	I-protein
extract-DNA	I-protein
complexes	I-protein
compared	O
with	O
T-cell	B-protein
nuclear	I-protein
extract-DNA	I-protein
complexes	I-protein
,	O
along	O
with	O
the	O
inability	O
of	O
OSF2	B-protein
to	O
be	O
upregulated	O
by	O
retinoic	O
acid	O
,	O
unlike	O
the	O
other	O
PEBP2	B-protein
alpha	I-protein
factors	I-protein
,	O
suggest	O
that	O
OSF2	B-protein
is	O
a	O
new	O
member	O
of	O
this	O
family	O
of	O
transcription	B-protein
factors	I-protein
.	O

Thus	O
,	O
this	O
study	O
demonstrates	O
that	O
AML-1B	B-protein
can	O
increase	O
gene	O
expression	O
of	O
an	O
osteoblast-specific	B-DNA
gene	I-DNA
through	O
its	O
binding	O
to	O
an	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
element	I-DNA
and	O
presents	O
evidence	O
that	O
OSF2	B-protein
is	O
a	O
member	O
of	O
the	O
PEBP2	B-protein
alpha/AML-1	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Initiation	B-protein
binding	I-protein
repressor	I-protein
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
of	O
the	O
histone	B-DNA
h5	I-DNA
gene	I-DNA
,	O
is	O
a	O
glycosylated	B-protein
member	I-protein
of	O
a	O
family	O
of	O
cell	B-protein
growth	I-protein
regulators	I-protein
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O

Initiation	B-protein
binding	I-protein
repressor	I-protein
[	O
corrected	O
]	O
(	O
IBR	B-protein
)	O
is	O
a	O
chicken	B-protein
erythrocyte	I-protein
factor	I-protein
(	O
apparent	O
molecular	O
mass	O
,	O
70	O
to	O
73	O
kDa	O
)	O
that	O
binds	O
to	O
the	O
sequences	O
spanning	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
of	O
the	O
histone	B-DNA
h5	I-DNA
gene	I-DNA
,	O
repressing	O
its	O
transcription	O
.	O

A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	B-cell_type
erythroid	I-cell_type
precursors	I-cell_type
,	O
do	O
not	O
have	O
IBR	B-protein
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	B-protein
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	O
the	O
same	O
IBR	B-protein
sites	O
.	O

We	O
have	O
cloned	O
the	O
IBR	B-DNA
cDNA	I-DNA
and	O
studied	O
the	O
relationship	O
of	O
IBR	B-protein
and	O
IBF	B-protein
.	O

IBR	B-protein
is	O
a	O
503-amino-acid-long	B-protein
acidic	I-protein
protein	I-protein
which	O
is	O
99.0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	B-protein
NRF-1/alpha-Pal	I-protein
factor	I-protein
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	B-protein
factors	I-protein
P3A2	B-protein
and	O
erected	B-protein
wing	I-protein
gene	I-protein
product	I-protein
(	O
EWG	B-protein
)	O
.	O

We	O
present	O
evidence	O
that	O
IBR	B-protein
and	O
IBF	B-protein
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O

We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR/F	B-protein
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	B-protein
and	O
that	O
the	O
dimer	B-protein
is	O
the	O
relevant	B-protein
DNA-binding	I-protein
species	I-protein
.	O

The	O
evolutionarily	O
conserved	O
N-terminal	B-protein
half	I-protein
of	O
IBR/F	B-protein
harbors	O
the	O
DNA-binding/dimerization	B-protein
domain	I-protein
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	B-protein
kinase	I-protein
II	I-protein
sites	I-protein
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	B-protein
nuclear	I-protein
localization	I-protein
signal	I-protein
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O

Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	B-protein
RCGCRYGCGY	I-protein
consensus	I-protein
constitutes	O
high-affinity	O
IBR/F	B-DNA
binding	I-DNA
sites	I-DNA
and	O
that	O
the	O
direct-repeat	B-DNA
palindrome	I-DNA
TGCGCATGCGCA	O
is	O
the	O
optimal	B-DNA
site	I-DNA
.	O

A	O
survey	O
of	O
genes	B-DNA
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	B-protein
primarily	O
revealed	O
genes	B-DNA
involved	O
in	O
growth-related	O
metabolism	O
.	O

Triggering	O
of	O
the	O
human	O
interleukin-6	O
gene	O
by	O
interferon-gamma	O
and	O
tumor	O
necrosis	O
factor-alpha	O
in	O
monocytic	O
cells	O
involves	O
cooperation	O
between	O
interferon	B-protein
regulatory	I-protein
factor-1	I-protein
,	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
Sp1	B-protein
transcription	B-protein
factors	I-protein
.	O

We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
synergistic	O
induction	O
by	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
/	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
of	O
human	B-DNA
interleukin-6	I-DNA
(	I-DNA
IL-6	I-DNA
)	I-DNA
gene	I-DNA
in	O
THP-1	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
,	O
and	O
compared	O
it	O
with	O
the	O
basis	O
of	O
this	O
induction	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Functional	O
studies	O
with	O
IL-6	B-DNA
promoter	I-DNA
demonstrated	O
that	O
three	O
regions	O
are	O
the	O
targets	O
of	O
the	O
IFN-gamma	B-protein
and/or	O
TNF-alpha	B-protein
action	O
,	O
whereas	O
only	O
one	O
of	O
these	O
regions	O
seemed	O
to	O
be	O
implicated	O
in	O
LPS	O
activation	O
.	O

The	O
three	O
regions	O
concerned	O
are	O
:	O
1	O
)	O
a	O
region	O
between	O
-73	O
and	O
-36	O
,	O
which	O
is	O
the	O
minimal	B-DNA
element	I-DNA
inducible	O
by	O
LPS	O
or	O
TNF-alpha	B-protein
;	O
2	O
)	O
an	O
element	O
located	O
between	O
-181	O
and	O
-73	O
,	O
which	O
appeared	O
to	O
regulate	O
the	O
response	O
to	O
IFN-gamma	B-protein
and	O
TNF-alpha	B-protein
negatively	O
;	O
and	O
3	O
)	O
a	O
distal	B-DNA
element	I-DNA
upstream	I-DNA
of	O
-224	O
,	O
which	O
was	O
inducible	O
by	O
IFN-gamma	B-protein
alone	O
.	O

LPS	O
signaling	O
was	O
found	O
to	O
involve	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
by	O
the	O
p50/p65	B-protein
heterodimers	I-protein
.	O

Synergistic	O
induction	O
of	O
the	O
IL-6	B-DNA
gene	I-DNA
by	O
IFN-gamma	B-protein
and	O
TNF-alpha	B-protein
,	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
involved	O
cooperation	O
between	O
the	O
IRF-1	B-protein
and	O
NF	B-protein
kappa	I-protein
B	I-protein
p65	I-protein
homodimers	I-protein
with	O
concomitant	O
removal	O
of	O
the	O
negative	O
effect	O
of	O
the	O
retinoblastoma	B-DNA
control	I-DNA
element	I-DNA
present	O
in	O
the	O
IL-6	B-DNA
promoter	I-DNA
.	O

This	O
removal	O
occurred	O
by	O
activation	O
of	O
the	O
constitutive	B-protein
Sp1	I-protein
factor	I-protein
,	O
whose	O
increased	O
binding	O
activity	O
and	O
phosphorylation	O
were	O
mediated	O
by	O
IFN-gamma	B-protein
.	O

Mutation	O
of	O
Jak3	B-protein
in	O
a	O
patient	O
with	O
SCID	O
:	O
essential	O
role	O
of	O
Jak3	B-protein
in	O
lymphoid	O
development	O
.	O

Males	O
with	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
have	O
defects	O
in	O
the	O
common	O
cytokine	B-DNA
receptor	I-DNA
gamma	I-DNA
chain	I-DNA
(	I-DNA
gamma	I-DNA
c	I-DNA
)	I-DNA
gene	I-DNA
that	O
encodes	O
a	O
shared	O
,	O
essential	O
component	O
of	O
the	O
receptors	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
,	O
IL-4	B-protein
,	O
IL-7	B-protein
,	O
IL-9	B-protein
,	O
and	O
IL-15	B-protein
.	O

The	O
Janus	B-protein
family	I-protein
tyrosine	I-protein
kinase	I-protein
Jak3	B-protein
is	O
the	O
only	O
signaling	O
molecule	O
known	O
to	O
be	O
associated	O
with	O
gamma	B-protein
c	I-protein
,	O
so	O
it	O
was	O
hypothesized	O
that	O
defects	O
in	O
Jak3	B-protein
might	O
cause	O
an	O
XSCID-like	O
phenotype	O
.	O

A	O
girl	O
with	O
immunological	O
features	O
indistinguishable	O
from	O
those	O
of	O
XSCID	O
was	O
therefore	O
selected	O
for	O
analysis	O
.	O

An	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
-transformed	I-cell_line
cell	I-cell_line
line	I-cell_line
derived	O
from	O
her	O
lymphocytes	B-cell_type
had	O
normal	O
gamma	B-protein
c	I-protein
expression	O
but	O
lacked	O
Jak3	B-protein
protein	I-protein
and	O
had	O
greatly	O
diminished	O
Jak3	B-RNA
messenger	I-RNA
RNA	I-RNA
.	O

Sequencing	O
revealed	O
a	O
different	O
mutation	O
on	O
each	O
allele	O
:	O
a	O
single	O
nucleotide	O
insertion	O
resulting	O
in	O
a	O
frame	O
shift	O
and	O
premature	O
termination	O
in	O
the	O
Jak3	B-protein
JH4	I-protein
domain	I-protein
and	O
a	O
nonsense	O
mutation	O
in	O
the	O
Jak3	B-protein
JH2	O
domain	O
.	O

The	O
lack	O
of	O
Jak3	B-protein
expression	O
correlated	O
with	O
impaired	O
B	O
cell	O
signaling	O
,	O
as	O
demonstrated	O
by	O
the	O
inability	O
of	O
IL-4	B-protein
to	O
activate	O
Stat6	B-protein
in	O
the	O
EBV-transformed	B-cell_line
cell	I-cell_line
line	I-cell_line
from	O
the	O
patient.	O
These	O
observations	O
indicate	O
that	O
the	O
functions	O
of	O
gamma	B-protein
c	I-protein
are	O
dependent	O
on	O
Jak3	B-protein
and	O
that	O
Jak3	B-protein
is	O
essential	O
for	O
lymphoid	O
development	O
and	O
signaling	O
.	O

Constitutive	O
overexpression	O
of	O
the	O
L-selectin	B-DNA
gene	I-DNA
in	O
fresh	O
leukemic	B-cell_type
cells	I-cell_type
of	O
adult	O
T-cell	O
leukemia	O
that	O
can	O
be	O
transactivated	O
by	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
.	O

L-selectin	B-protein
is	O
an	O
adhesion	O
molecule	O
of	O
the	O
selectin	O
family	O
that	O
mediates	O
the	O
initial	O
step	O
of	O
leukocyte	O
adhesion	O
to	O
vascular	O
endothelium	O
.	O

Upon	O
cellular	O
activation	O
,	O
expression	O
of	O
the	O
L-selectin	B-DNA
gene	I-DNA
is	O
downregulated	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O

To	O
understand	O
the	O
mechanism	O
of	O
leukemic	B-cell_type
cell	I-cell_type
infiltration	O
into	O
organs	O
,	O
we	O
studied	O
the	O
expression	O
and	O
regulation	O
of	O
L-selectin	B-RNA
mRNA	I-RNA
in	O
fresh	O
leukemic	B-cell_type
cells	I-cell_type
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
patients	O
and	O
investigated	O
the	O
response	O
of	O
the	O
L-selectin	B-DNA
promoter	I-DNA
to	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
Tax	I-protein
,	O
which	O
is	O
a	O
viral	B-protein
transcriptional	I-protein
transactivator	I-protein
.	O

Flow	O
cytometry	O
showed	O
that	O
L-selectin	B-protein
was	O
expressed	O
on	O
fresh	O
ATL	B-cell_line
cells	I-cell_line
along	O
with	O
other	O
activation	B-protein
antigens	I-protein
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
ATL	B-cell_line
cells	I-cell_line
overexpressed	O
that	O
L-selectin	B-RNA
mRNA	I-RNA
and	O
that	O
the	O
level	O
was	O
aberrantly	O
upregulated	O
after	O
PMA	O
stimulation	O
.	O

Studies	O
using	O
in	O
situ	O
hybridization	O
showed	O
expression	O
of	O
the	O
L-selectin	B-RNA
mRNA	I-RNA
in	O
the	O
infiltrating	O
leukemic	B-cell_type
cells	I-cell_type
in	O
the	O
liver	O
of	O
two	O
ATL	O
patients	O
.	O

Intravenous	O
injection	O
of	O
a	O
rat	B-cell_line
T-cell	I-cell_line
line	I-cell_line
that	O
overexpresses	O
L-selectin	B-protein
showed	O
increased	O
organ	O
infiltration	O
.	O

The	O
induction	O
of	O
Tax	B-protein
expression	O
in	O
JPX9	B-cell_line
cells	I-cell_line
resulted	O
in	O
about	O
a	O
twofold	O
increase	O
in	O
the	O
mRNA	B-RNA
expression	O
levels	O
compared	O
with	O
the	O
basal	O
level	O
.	O

Chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
assay	O
after	O
transient	O
cotransfection	O
showed	O
about	O
a	O
fivefold	O
transactivation	O
of	O
the	O
L-selectin	B-DNA
promoter	I-DNA
by	O
Tax	B-protein
.	O

The	O
serum	O
level	O
of	O
the	O
shed	O
form	O
of	O
L-selectin	B-protein
was	O
significantly	O
increased	O
in	O
ATL	O
patients	O
(	O
mean	O
+/-	O
SD	O
,	O
4	O
,	O
215.4	O
+/-	O
4	O
,	O
111	O
ng/mL	O
)	O
compared	O
with	O
those	O
of	O
asymptomatic	O
carriers	O
and	O
healthy	O
blood	O
donors	O
(	O
mean	O
+/-	O
SD	O
,	O
1	O
,	O
148.0	O
+/-	O
269.0	O
ng/mL	O
and	O
991.9	O
+/-	O
224	O
ng/mL	O
,	O
respectively	O
)	O
.	O

These	O
results	O
indicated	O
that	O
ATL	B-cell_line
cells	I-cell_line
constitutively	O
overexpress	O
the	O
L-selectin	B-DNA
gene	I-DNA
that	O
can	O
be	O
transactivated	O
by	O
HTLV-1	O
Tax	B-protein
.	O

The	O
overexpression	O
of	O
L-selectin	B-protein
,	O
as	O
well	O
as	O
of	O
inflammatory	B-protein
cytokines	I-protein
,	O
by	O
ATL	B-cell_line
cells	I-cell_line
may	O
provide	O
a	O
basis	O
for	O
ATL	B-cell_line
cells	I-cell_line
to	O
attach	O
the	O
vascular	O
endothelium	O
,	O
leading	O
to	O
transmigration	O
and	O
organ	O
infitration	O
.	O

Human	O
herpesvirus	O
6	O
variant	O
A	O
,	O
but	O
not	O
variant	O
B	O
,	O
infects	O
EBV-positive	B-cell_line
B	I-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
activating	O
the	O
latent	B-DNA
EBV	I-DNA
genome	I-DNA
through	O
a	O
BZLF-1	B-protein
-dependent	O
mechanism	O
.	O

Human	O
herpesvirus	O
6	O
,	O
a	O
predominantly	O
T	O
lymphotropic	O
virus	O
,	O
has	O
been	O
recently	O
shown	O
to	O
infect	O
some	O
EBV-positive	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
to	O
induce	O
in	O
them	O
the	O
activation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
.	O

Here	O
we	O
have	O
confirmed	O
and	O
extended	O
such	O
observations	O
,	O
showing	O
that	O
(	O
1	O
)	O
this	O
phenomenon	O
is	O
restricted	O
to	O
the	O
variant	O
A	O
of	O
HHV-6	O
:	O
in	O
fact	O
two	O
isolates	O
belonging	O
to	O
the	O
HHV-6	O
variant	O
B	O
(	O
BA92	O
and	O
Z29	O
)	O
were	O
neither	O
able	O
to	O
infect	O
any	O
B	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
independently	O
of	O
the	O
EBV	O
status	O
,	O
nor	O
to	O
induce	O
the	O
EBV	O
genome	O
expression	O
.	O

The	O
only	O
exception	O
is	O
represented	O
by	O
the	O
P3HR1	B-cell_line
cells	I-cell_line
,	O
in	O
which	O
,	O
however	O
,	O
the	O
infection	O
by	O
the	O
variant	O
B	O
does	O
not	O
determine	O
induction	O
of	O
EBV	B-protein
antigens	I-protein
;	O
(	O
2	O
)	O
the	O
presence	O
of	O
the	O
EBV	B-DNA
genome	I-DNA
contributes	O
to	O
the	O
susceptibility	O
of	O
the	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
HHV-6	O
infection	O
,	O
increasing	O
the	O
binding	O
sites	O
and	O
the	O
percentage	O
of	O
infectable	B-cell_type
cells	I-cell_type
,	O
as	O
detected	O
by	O
immunoelectron	O
microscopy	O
;	O
and	O
(	O
3	O
)	O
HHV-6	B-cell_line
infected	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
transfected	O
with	O
plasmids	B-DNA
bearing	O
the	O
promoter	B-DNA
regions	I-DNA
of	O
the	O
EBV	O
early	O
genes	O
BZLF1	O
and	O
BMRF1	B-DNA
,	O
show	O
a	O
strong	O
transactivation	O
of	O
these	O
promoters	B-DNA
.	O

Evidence	O
for	O
normal	O
vitamin	B-RNA
D	I-RNA
receptor	I-RNA
messenger	I-RNA
ribonucleic	I-RNA
acid	I-RNA
and	O
genotype	O
in	O
absorptive	O
hypercalciuria	O
.	O

Absorptive	O
hypercalciuria	O
(	O
a	O
stone-forming	O
condition	O
)	O
is	O
characterized	O
by	O
gut	O
hyperabsorption	O
of	O
calcium	O
,	O
hypercalciuria	O
,	O
and	O
reduced	O
bone	O
density	O
.	O

Inasmuch	O
as	O
these	O
features	O
implicate	O
enhanced	O
calcitriol	O
action	O
in	O
gut	O
and	O
bone	O
,	O
we	O
analyzed	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
(	I-DNA
VDR	I-DNA
)	I-DNA
gene	I-DNA
to	O
ascertain	O
whether	O
an	O
abnormality	O
of	O
this	O
gene	O
marks	O
patients	O
with	O
intestinal	O
hyperabsorption	O
of	O
calcium	O
.	O

We	O
have	O
compared	O
the	O
frequency	O
of	O
a	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
(	O
Bsm	O
I	O
)	O
associated	O
with	O
different	O
alleles	O
of	O
the	O
VDR	B-DNA
gene	I-DNA
in	O
a	O
group	O
of	O
33	O
well	O
characterized	O
absorptive	O
hypercalciuric	O
patients	O
and	O
a	O
group	O
of	O
36	O
normal	O
race-	O
and	O
age-matched	O
control	O
subjects	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
distribution	O
of	O
the	O
VDR	B-protein
alleles	O
in	O
the	O
patient	O
population	O
when	O
compared	O
with	O
the	O
normal	O
population	O
.	O

The	O
coding	O
region	O
of	O
VDR	B-RNA
messenger	I-RNA
RNA	I-RNA
was	O
also	O
normal	O
,	O
as	O
determined	O
by	O
both	O
DNA	B-DNA
sequence	I-DNA
analysis	O
and	O
chemical	O
mismatch	O
cleavage	O
analysis	O
of	O
copy	O
DNA	O
from	O
11	O
index	O
absorptive	O
hypercalciuric	O
patients	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
the	O
enhanced	O
intestinal	O
calcium	O
absorption	O
invariably	O
seen	O
in	O
absorptive	O
hypercalciuria	O
and	O
attendant	O
symptoms	O
of	O
this	O
disorder	O
are	O
not	O
attributable	O
to	O
mutations	O
of	O
the	O
VDR	B-protein
and	O
are	O
not	O
linked	O
to	O
a	O
common	O
VDR	B-DNA
genotype	I-DNA
.	O

Transcriptional	O
regulation	O
of	O
the	O
gene	O
encoding	O
the	O
human	B-protein
C-type	I-protein
lectin	I-protein
leukocyte	I-protein
receptor	I-protein
AIM/CD69	B-protein
and	O
functional	O
characterization	O
of	O
its	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha-responsive	I-DNA
elements	I-DNA
.	O

The	O
human	B-protein
activation	I-protein
antigen	I-protein
CD69	B-protein
is	O
a	O
member	O
of	O
the	O
C-type	B-protein
animal	I-protein
lectin	I-protein
superfamily	I-protein
that	O
functions	O
as	O
a	O
signal-transmitting	B-protein
receptor	I-protein
.	O

Although	O
the	O
expression	O
of	O
CD69	B-protein
can	O
be	O
induced	O
in	O
vitro	O
on	O
cells	O
of	O
most	O
hematopoietic	O
lineages	O
with	O
a	O
wide	O
variety	O
of	O
stimuli	O
,	O
in	O
vivo	O
it	O
is	O
mainly	O
expressed	O
by	O
T-lymphocytes	B-cell_type
located	O
in	O
the	O
inflammatory	O
infiltrates	O
of	O
several	O
human	O
diseases	O
.	O

To	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
CD69	B-protein
by	O
leukocytes	B-cell_type
,	O
we	O
isolated	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
CD69	B-protein
gene	O
and	O
carried	O
out	O
its	O
functional	O
characterization	O
.	O

Sequence	O
analysis	O
of	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
CD69	B-DNA
gene	I-DNA
revealed	O
the	O
presence	O
of	O
a	O
potential	O
TATA	B-DNA
element	I-DNA
30	B-DNA
base	I-DNA
pairs	I-DNA
upstream	I-DNA
of	O
the	O
major	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
and	O
several	O
putative	O
binding	O
sequences	O
for	O
inducible	O
transcription	B-protein
factors	I-protein
(	O
NF-kappa	B-protein
B	I-protein
,	O
Egr-1	B-protein
,	O
AP-1	B-protein
)	O
,	O
which	O
might	O
mediate	O
the	O
inducible	O
expression	O
of	O
this	O
gene	O
.	O

Transient	O
expression	O
of	O
CD69	B-DNA
promoter-based	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
indicated	O
that	O
the	O
proximal	B-DNA
promoter	I-DNA
region	I-DNA
spanning	O
positions	O
-78	O
to	O
+16	O
contained	O
the	O
cis-acting	B-DNA
sequences	I-DNA
necessary	O
for	O
basal	O
and	O
phorbol	O
12-myristate	O
13-acetate-inducible	O
transcription	O
of	O
the	O
CD69	B-DNA
gene	I-DNA
.	O

Removal	O
of	O
the	O
upstream	O
sequences	O
located	O
between	O
positions	O
-78	O
and	O
-38	O
resulted	O
in	O
decreased	O
promoter	O
strength	O
and	O
abolished	O
the	O
response	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

We	O
also	O
found	O
that	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
is	O
capable	O
of	O
inducing	O
the	O
surface	O
expression	O
of	O
the	O
CD69	B-protein
molecule	O
as	O
well	O
as	O
the	O
promoter	O
activity	O
of	O
fusion	O
plasmids	O
that	O
contain	O
5'-flanking	O
sequences	O
of	O
the	O
CD69	B-protein
gene	O
,	O
suggesting	O
that	O
this	O
cytokine	O
may	O
regulate	O
in	O
vivo	O
the	O
expression	O
of	O
CD69	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Characterization	O
of	O
5	B-DNA
'	I-DNA
end	I-DNA
of	I-DNA
human	I-DNA
thromboxane	I-DNA
receptor	I-DNA
gene	I-DNA
.	O

Organizational	O
analysis	O
and	O
mapping	O
of	O
protein	B-DNA
kinase	I-DNA
C	I-DNA
--	I-DNA
responsive	I-DNA
elements	I-DNA
regulating	O
expression	O
in	O
platelets	B-cell_type
.	O

Platelet	B-protein
thromboxane	I-protein
receptors	I-protein
are	O
acutely	O
and	O
reversibly	O
upregulated	O
after	O
acute	O
myocardial	O
infarction	O
.	O

To	O
determine	O
if	O
platelet	O
thromboxane	B-protein
receptors	I-protein
are	O
under	O
transcriptional	O
control	O
,	O
we	O
isolated	O
and	O
characterized	O
human	B-DNA
genomic	I-DNA
DNA	I-DNA
clones	I-DNA
containing	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
.	O

The	O
exon-intron	B-DNA
structure	I-DNA
of	O
the	O
5	B-DNA
'	I-DNA
portion	I-DNA
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
was	O
determined	O
initially	O
by	O
comparing	O
the	O
nucleotide	B-DNA
sequence	I-DNA
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
genomic	I-DNA
clone	I-DNA
with	O
that	O
of	O
a	O
novel	B-DNA
human	I-DNA
uterine	I-DNA
thromboxane	I-DNA
receptor	I-DNA
cDNA	I-DNA
that	O
extended	O
the	O
mRNA	B-RNA
141	B-DNA
bp	I-DNA
further	I-DNA
upstream	I-DNA
than	O
the	O
previously	B-DNA
identified	I-DNA
human	I-DNA
placental	I-DNA
cDNA	I-DNA
.	O

A	O
major	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
was	O
located	O
in	O
three	O
human	O
tissues	O
approximately	O
560	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
translation	B-DNA
initiation	I-DNA
codon	I-DNA
and	O
380	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
any	O
previously	O
identified	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

The	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
has	O
neither	O
a	O
TATA	B-DNA
nor	O
a	O
CAAT	B-DNA
consensus	I-DNA
site	I-DNA
.	O

Promoter	O
function	O
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
promoter/chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
chimera	I-DNA
plasmids	I-DNA
into	O
platelet-like	O
K562	B-cell_line
cells	I-cell_line
.	O

Thromboxane	O
receptor	B-DNA
promoter	I-DNA
activity	O
,	O
as	O
assessed	O
by	O
CAT	B-protein
expression	O
,	O
was	O
relatively	O
weak	O
but	O
was	O
significantly	O
enhanced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

Functional	O
analysis	O
of	O
5	B-DNA
'	I-DNA
deletion	I-DNA
constructs	I-DNA
in	O
transfected	O
K562	B-cell_line
cells	I-cell_line
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester-responsive	O
motifs	O
in	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
promoter	O
to	O
a	O
cluster	O
of	O
activator	B-DNA
protein-2	I-DNA
(	I-DNA
AP-2	I-DNA
)	I-DNA
binding	I-DNA
consensus	I-DNA
sites	I-DNA
located	O
approximately	O
1.8	O
kb	O
5	O
'	O
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
and	O
demonstrate	O
that	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
expression	O
can	O
be	O
regulated	O
by	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
via	O
induction	O
of	O
an	O
AP-2-like	B-protein
nuclear	I-protein
factor	I-protein
binding	O
to	O
upstream	B-DNA
promoter	I-DNA
elements	I-DNA
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
the	O
mechanism	O
for	O
previously	O
described	O
upregulation	O
of	O
platelet	B-protein
thromboxane	I-protein
receptors	I-protein
after	O
acute	O
myocardial	O
infarction	O
is	O
increased	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
transcription	O
in	O
platelet-progenitor	B-cell_type
cells	I-cell_type
.	O

Estrogen	B-protein
receptor	I-protein
concentration	O
and	O
social	O
factors	O
as	O
predictors	O
of	O
natural	O
killer	O
cell	O
activity	O
in	O
early-stage	O
breast	O
cancer	O
patients	O
.	O

Confirmation	O
of	O
a	O
model	O
.	O

Previous	O
work	O
of	O
ours	O
has	O
demonstrated	O
that	O
a	O
significant	O
amount	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
activity	O
variance	O
after	O
surgery	O
in	O
stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
both	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
status	O
of	O
the	O
tumor	O
and	O
by	O
social	O
factors	O
,	O
namely	O
,	O
perceived	O
social	O
support	O
and	O
seeking	O
social	O
support	O
as	O
a	O
general	O
coping	O
strategy	O
.	O

As	O
considerable	O
evidence	O
has	O
accumulated	O
that	O
social	O
support	O
in	O
both	O
animal	O
and	O
human	O
populations	O
may	O
have	O
survival	O
value	O
,	O
we	O
sought	O
to	O
test	O
the	O
reliability	O
of	O
this	O
regression	O
model	O
,	O
using	O
coping	O
and	O
perceived	O
support	O
factor	O
values	O
obtained	O
at	O
3	O
months	O
after	O
surgery	O
to	O
account	O
for	O
concurrent	O
follow-up	O
NK	O
activity	O
in	O
this	O
serially	O
assessed	O
group	O
of	O
patients	O
.	O

It	O
was	O
found	O
that	O
the	O
most	O
significant	O
variable	O
predicting	O
NK	O
activity	O
at	O
follow-up	O
was	O
tumor	O
ER	B-protein
concentration	O
,	O
with	O
higher	O
NK	O
activity	O
associated	O
with	O
ER	B-protein
-status	O
.	O

In	O
addition	O
,	O
seeking	O
social	O
support	O
as	O
a	O
coping	O
strategy	O
,	O
as	O
well	O
as	O
the	O
perceived	O
quality	O
of	O
support	O
,	O
also	O
entered	O
the	O
model	O
to	O
account	O
for	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
(	O
multivariate	O
F	O
=	O
5.25	O
,	O
p	O
less	O
than	O
0.001	O
)	O
.	O

If	O
,	O
as	O
the	O
literature	O
suggests	O
,	O
NK	O
activity	O
is	O
relevant	O
to	O
breast	O
cancer	O
control	O
,	O
and	O
since	O
ER	B-protein
-tumors	O
have	O
a	O
worse	O
prognosis	O
,	O
we	O
suggest	O
here	O
that	O
perhaps	O
such	O
tumors	O
are	O
resistant	O
to	O
control	O
by	O
NK	B-cell_type
cells	I-cell_type
because	O
they	O
lack	O
the	O
ability	O
to	O
attract	O
an	O
accumulation	O
of	O
effector	B-cell_type
cells	I-cell_type
to	O
the	O
tumor	O
site	O
,	O
or	O
because	O
blocking	O
factors	O
at	O
the	O
site	O
of	O
the	O
tumor	O
prevent	O
local	O
tumor	O
control	O
at	O
the	O
site	O
of	O
action	O
.	O

The	O
finding	O
related	O
to	O
social	O
support	O
also	O
replicates	O
results	O
from	O
an	O
independent	O
sample	O
of	O
breast	O
cancer	O
patients	O
.	O

This	O
finding	O
,	O
taken	O
together	O
with	O
other	O
evidence	O
that	O
this	O
social	O
variable	O
is	O
associated	O
with	O
longer	O
survival	O
in	O
breast	O
cancer	O
populations	O
,	O
underscores	O
the	O
potential	O
importance	O
of	O
this	O
social	O
support	O
variable	O
.	O

Our	O
findings	O
also	O
suggest	O
one	O
possible	O
immunological	O
variable	O
involved	O
,	O
with	O
potential	O
clinical	O
significance	O
,	O
for	O
this	O
patient	O
population	O
.	O

Solution	O
structure	O
of	O
the	O
sequence-specific	B-DNA
HMG	I-DNA
box	I-DNA
of	O
the	O
lymphocyte	B-protein
transcriptional	I-protein
activator	I-protein
Sox-4	B-protein
.	O

Two	O
groups	O
of	O
HMG	B-protein
box	I-protein
proteins	I-protein
are	O
distinguished	O
.	O

Proteins	O
in	O
the	O
first	O
group	O
contain	O
multiple	O
HMG	B-protein
boxes	I-protein
,	O
are	O
non-sequence-specific	O
,	O
and	O
recognize	O
structural	O
features	O
as	O
found	O
in	O
cruciform	B-DNA
DNA	I-DNA
and	O
cross-over	B-DNA
DNA	I-DNA
.	O

The	O
abundant	O
chromosomal	B-protein
protein	I-protein
HMG-1	B-protein
belongs	O
to	O
this	O
subgroup	O
.	O

Proteins	O
in	O
the	O
second	O
group	O
carry	O
a	O
single	B-protein
HMG	I-protein
box	I-protein
with	O
affinity	O
for	O
the	O
minor	O
groove	O
of	O
the	O
heptamer	B-DNA
motif	I-DNA
AACAAAG	O
or	O
variations	O
thereof	O
.	O

A	O
solution	O
structure	O
for	O
the	O
non-sequence-specific	O
C-terminal	B-protein
HMG	I-protein
box	I-protein
of	O
HMG-1	B-protein
has	O
recently	O
been	O
proposed	O
.	O

Now	O
,	O
we	O
report	O
the	O
solution	O
structure	O
of	O
the	O
sequence-specific	B-protein
HMG-box	I-protein
of	O
the	O
SRY-related	B-protein
protein	I-protein
Sox-4	B-protein
.	O

NMR	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
three	O
alpha-helices	B-protein
(	O
Val10-Gln22	B-protein
,	O
Glu30-Leu41	B-protein
and	O
Phe50-Tyr65	B-protein
)	O
connected	O
by	O
loop	B-protein
regions	I-protein
(	O
Ser23-Ala49	B-protein
and	O
Leu42-Pro49	B-protein
)	O
.	O

Helices	B-protein
I	I-protein
and	I-protein
II	I-protein
are	O
positioned	O
in	O
an	O
antiparallel	B-protein
mode	I-protein
and	O
form	O
one	O
arm	O
of	O
the	O
HMG	B-protein
box	I-protein
.	O

Helix	B-protein
III	I-protein
is	O
less	O
rigid	O
,	O
makes	O
an	O
average	O
angle	O
of	O
about	O
90	O
degrees	O
with	O
helices	B-protein
I	I-protein
and	I-protein
II	I-protein
,	O
and	O
constitutes	O
the	O
other	O
arm	O
of	O
the	O
molecule	O
.	O

As	O
in	O
HMG1B	B-protein
,	O
the	O
overall	O
structure	O
of	O
the	O
Sox-4	B-protein
HMG	B-protein
box	I-protein
is	O
L-shaped	O
and	O
is	O
maintained	O
by	O
a	O
cluster	O
of	O
conserved	O
,	O
mainly	O
aromatic	O
residues	O
.	O

Nuclear	B-protein
factor-IL6	I-protein
activates	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Positive	B-DNA
regulatory	I-DNA
element	I-DNA
I	I-DNA
(	O
PRE-I	B-DNA
)	O
is	O
a	O
strong	O
enhancer	B-DNA
element	I-DNA
essential	O
for	O
expression	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
gene	I-DNA
.	O

To	O
identify	O
transcription	B-protein
factors	I-protein
binding	O
to	O
PRE-I	B-DNA
,	O
we	O
screened	O
a	O
cDNA	B-DNA
expression	I-DNA
library	I-DNA
from	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
isolated	O
a	O
cDNA	B-DNA
encoding	O
nuclear	B-protein
factor	I-protein
(	B-protein
NF	I-protein
)	I-protein
-IL6	I-protein
(	O
also	O
known	O
as	O
C/EBP	B-protein
beta	I-protein
)	O
.	O

NF-IL6	B-RNA
mRNA	I-RNA
was	O
found	O
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
and	O
in	O
the	O
mouse	B-cell_line
Th2	I-cell_line
clone	I-cell_line
D10	B-cell_line
,	O
but	O
not	O
in	O
Th1	B-cell_line
clone	I-cell_line
29	I-cell_line
.	O

rNF-IL6	B-protein
expressed	O
in	O
bacteria	O
was	O
shown	O
to	O
specifically	O
bind	O
to	O
PRE-I	B-DNA
.	O

PRE-I	B-DNA
forms	O
multiple	B-protein
DNA-protein	I-protein
complexes	I-protein
with	O
nuclear	O
extracts	O
from	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Some	O
of	O
these	O
complexes	O
were	O
demonstrated	O
to	O
contain	O
NF-IL6	B-protein
by	O
using	O
anti-C/EBP	B-protein
beta	I-protein
Abs	I-protein
.	O

Overexpression	O
of	O
NF-IL6	B-protein
enhanced	O
expression	O
of	O
the	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
reporter	I-DNA
gene	I-DNA
linked	O
to	O
the	O
PRE-I-thymidine	B-protein
kinase	I-protein
or	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
more	O
than	O
10-fold	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Promoter	O
deletion	O
studies	O
revealed	O
two	O
additional	O
NF-IL6	B-DNA
binding	I-DNA
sites	I-DNA
located	O
at	O
positions	O
-44	O
to	O
-36	O
(	O
C/EBP	B-protein
proximal	I-protein
)	O
and	O
-87	O
to	O
-79	O
(	O
C/EBP	B-protein
medial	I-protein
)	O
,	O
respectively	O
.	O

Our	O
results	O
demonstrate	O
that	O
NF-IL6	B-protein
is	O
involved	O
in	O
transcriptional	O
activation	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Identification	O
of	O
an	O
I	B-protein
kappa	I-protein
B	I-protein
alpha-associated	I-protein
protein	I-protein
kinase	I-protein
in	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
determination	O
of	O
its	O
phosphorylation	B-protein
sites	I-protein
on	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
stored	O
in	O
the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
.	O

Stimulation	O
of	O
cells	O
leads	O
to	O
a	O
rapid	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
which	O
is	O
presumed	O
to	O
be	O
important	O
for	O
the	O
subsequent	O
degradation	O
.	O

We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-dependent	O
cell-free	O
activation	O
system	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
association	O
with	O
the	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
kinase	B-protein
in	O
cell	O
extracts	O
from	O
the	O
LPS-stimulated	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
,	O
that	O
specifically	O
binds	O
and	O
phosphorylates	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

LPS	O
stimulation	O
transiently	O
enhanced	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-bound	B-protein
kinase	I-protein
activity	O
in	O
THP-1	B-cell_line
cells	I-cell_line
.	O

Mutational	O
analyses	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O
phosphorylation	B-protein
sites	I-protein
by	O
the	O
bound	O
kinase	B-protein
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C-terminal	B-protein
acidic	I-protein
domain	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Moreover	O
,	O
we	O
show	O
that	O
the	O
peptide	O
,	O
corresponding	O
to	O
the	O
C-terminal	B-protein
acidic	I-protein
domain	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
blocked	O
the	O
LPS-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
as	O
well	O
as	O
inducible	O
phosphorylation	O
of	O
endogenous	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
in	O
a	O
cell-free	O
system	O
using	O
THP-1	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
suggested	O
that	O
the	O
bound	B-protein
kinase	I-protein
is	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
LPS	O
by	O
inducing	O
the	O
phosphorylation	O
of	O
the	O
C-terminal	B-protein
region	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
subsequent	O
dissociation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
.	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
complex	I-protein
.	O

Bik	B-protein
,	O
a	O
novel	O
death-inducing	B-protein
protein	I-protein
shares	O
a	O
distinct	O
sequence	O
motif	O
with	O
Bcl-2	B-protein
family	I-protein
proteins	I-protein
and	O
interacts	O
with	O
viral	O
and	O
cellular	B-protein
survival-promoting	I-protein
proteins	I-protein
.	O

The	O
survival-promoting	O
activity	O
of	O
the	O
Bcl-2	B-protein
family	I-protein
of	O
proteins	O
appears	O
to	O
be	O
modulated	O
by	O
interactions	O
between	O
various	O
cellular	B-protein
proteins	I-protein
.	O

We	O
have	O
identified	O
a	O
novel	O
cellular	B-protein
protein	I-protein
,	O
Bik	B-protein
,	O
that	O
interacts	O
with	O
the	O
cellular	B-protein
survival-promoting	I-protein
proteins	I-protein
,	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
,	O
as	O
well	O
as	O
the	O
viral	B-protein
survival-promoting	I-protein
proteins	I-protein
,	O
Epstein	B-protein
Barr	I-protein
virus-BHRF1	I-protein
and	O
adenovirus	B-protein
E1B-19	I-protein
kDa	I-protein
.	O

In	O
transient	O
transfection	O
assays	O
,	O
Bik	B-protein
promotes	O
cell	O
death	O
in	O
a	O
manner	O
similar	O
to	O
the	O
death-promoting	B-protein
members	I-protein
of	O
the	O
Bcl-2	B-protein
family	I-protein
,	O
Bax	B-protein
and	O
Bak	B-protein
.	O

This	O
death-promoting	O
activity	O
of	O
Bik	B-protein
can	O
be	O
suppressed	O
by	O
coexpression	O
of	O
Bcl-2	B-protein
,	O
Bcl-XL	B-protein
,	O
EBV-BHRF1	B-protein
and	O
E1B-19	B-protein
kDa	I-protein
proteins	O
suggesting	O
that	O
Bik	B-protein
may	O
be	O
a	O
common	O
target	O
for	O
both	O
cellular	B-protein
and	I-protein
viral	I-protein
anti-apoptotic	I-protein
proteins	I-protein
.	O

While	O
Bik	B-protein
does	O
not	O
show	O
overt	O
homology	O
to	O
the	O
BH1	B-protein
and	O
BH2	B-protein
conserved	O
domains	O
characteristic	O
of	O
the	O
Bcl-2	B-protein
family	I-protein
,	O
it	O
does	O
share	O
a	O
9	O
amino	B-protein
acid	I-protein
domain	I-protein
(	O
BH3	B-protein
)	O
with	O
Bax	B-protein
and	O
Bak	B-protein
which	O
may	O
be	O
a	O
critical	O
determinant	O
for	O
the	O
death-promoting	O
activity	O
of	O
these	O
proteins	O
.	O

The	O
human	B-DNA
TCF-1	I-DNA
gene	I-DNA
encodes	O
a	O
nuclear	B-protein
DNA-binding	I-protein
protein	I-protein
uniquely	O
expressed	O
in	O
normal	B-cell_line
and	I-cell_line
neoplastic	I-cell_line
T-lineage	I-cell_line
lymphocytes	I-cell_line
.	O

The	O
TCF-1	B-DNA
gene	I-DNA
encodes	O
a	O
putative	B-protein
transcription	I-protein
factor	I-protein
with	O
affinity	O
for	O
a	O
sequence	O
motif	O
occurring	O
in	O
a	O
number	O
of	O
T-cell	B-DNA
enhancers	I-DNA
.	O

TCF-1	B-RNA
mRNA	I-RNA
was	O
originally	O
found	O
to	O
be	O
expressed	O
in	O
a	O
T	O
cell-specific	O
fashion	O
within	O
a	O
set	O
of	O
human	B-cell_line
and	I-cell_line
mouse	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
contrast	O
,	O
expression	O
reportedly	O
occurs	O
in	O
multiple	O
nonlymphoid	O
tissues	O
during	O
murine	O
embryogenesis	O
.	O

We	O
have	O
now	O
raised	O
a	O
monoclonal	B-protein
antibody	I-protein
to	O
document	O
expression	O
and	O
biochemistry	O
of	O
the	O
human	B-protein
TCF-1	I-protein
protein	I-protein
.	O

As	O
expected	O
,	O
the	O
TCF-1	B-protein
protein	I-protein
was	O
detectable	O
only	O
in	O
cell	B-cell_line
lines	I-cell_line
of	I-cell_line
T	I-cell_line
lineage	I-cell_line
.	O

Its	O
expression	O
was	O
always	O
restricted	O
to	O
the	O
nucleus	O
.	O

Immunohistochemistry	O
on	O
a	O
panel	O
of	O
human	O
tissues	O
revealed	O
that	O
the	O
TCF-1	B-protein
protein	I-protein
was	O
found	O
exclusively	O
in	O
thymocytes	O
and	O
in	O
CD3+	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
peripheral	O
lymphoid	O
tissues	O
.	O

Western	O
blotting	O
yielded	O
a	O
set	O
of	O
bands	O
ranging	O
from	O
25	O
kD	O
to	O
55	O
kD	O
,	O
resulting	O
from	O
extensive	O
alternative	O
splicing	O
.	O

The	O
TCF-1	B-protein
protein	O
was	O
detectable	O
in	O
all	O
samples	O
of	O
a	O
set	O
of	O
22	O
T-cell	B-cell_type
malignancies	I-cell_type
of	O
various	O
stages	O
of	O
maturation	O
,	O
but	O
was	O
absent	O
from	O
a	O
large	O
number	O
of	O
other	O
hematologic	B-cell_type
neoplasms	I-cell_type
.	O

These	O
observations	O
imply	O
a	O
T	O
cell-specific	O
function	O
for	O
TCF-1	B-protein
,	O
a	O
notion	O
corroborated	O
by	O
recent	O
observations	O
on	O
Tcf-1	O
knock-out	O
mice	O
.	O

In	O
addition	O
,	O
these	O
results	O
indicate	O
that	O
nuclear	O
TCF-1	B-protein
expression	O
can	O
serve	O
as	O
a	O
pan-T-lineage	O
marker	O
in	O
the	O
diagnosis	O
of	O
lymphoid	O
malignancies	O
.	O

Cross-linking	O
of	O
Fc	B-protein
gamma	I-protein
receptors	I-protein
activates	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
-driven	O
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Elevation	O
of	O
the	O
levels	O
of	O
circulating	B-protein
immune	I-protein
complexes	I-protein
frequently	O
accompanies	O
HIV-1	O
infection	O
and	O
is	O
a	O
prognostic	O
indicator	O
of	O
clinical	O
progression	O
from	O
asymptomatic	O
infection	O
to	O
AIDS	O
.	O

Here	O
we	O
report	O
that	O
cross-linking	O
of	O
Fc	B-protein
gamma	I-protein
RI	I-protein
or	O
Fc	B-protein
gamma	I-protein
RII	I-protein
by	O
adherent	B-protein
human	I-protein
IgG	I-protein
or	O
by	O
specific	O
anti-Fc	B-protein
gamma	I-protein
R	I-protein
mAb	I-protein
activates	O
HIV-1	O
gene	O
expression	O
in	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
BF24	B-cell_line
and	O
increased	O
HIV	B-RNA
RNA	I-RNA
expression	O
in	O
monocytes	B-cell_type
from	O
HIV	O
infected	O
patients	O
as	O
assayed	O
by	O
reverse	O
transcription-PCR	O
.	O

In	O
THP-1	B-cell_line
cells	I-cell_line
,	O
Fc	B-protein
gamma	I-protein
R	I-protein
cross-linking	O
induced	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
regulatory	B-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
HIV-1	O
and	O
to	O
activate	O
HIV-1	O
transcription	O
.	O
Anti-TNF-alpha	B-protein
antibody	I-protein
but	O
not	O
anti-IL-1	B-protein
beta	I-protein
antibody	I-protein
strongly	O
inhibited	O
both	O
the	O
induction	O
of	O
HIV-1-	O
LTR	B-DNA
-driven	O
transcription	O
and	O
the	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
Fc	B-protein
gamma	I-protein
R	I-protein
cross-linking	O
.	O

These	O
results	O
indicate	O
that	O
Fc	B-protein
gamma	I-protein
R	I-protein
can	O
mediate	O
a	O
TNF-alpha	B-protein
-dependent	O
induction	O
of	O
HIV-1	B-DNA
gene	I-DNA
transcription	O
and	O
suggest	O
that	O
immune	B-protein
complexes	I-protein
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
HIV-1	O
infection	O
by	O
augmenting	O
viral	O
replication	O
in	O
monocytes	B-cell_type
.	O

Signalling	O
via	O
CD28	B-protein
of	O
human	B-cell_line
naive	I-cell_line
neonatal	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

Accessory	O
molecules	O
play	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
the	O
T	O
cell	O
response	O
to	O
antigenic	O
challenge	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
CD28	B-protein
in	O
modulating	O
the	O
'naive	O
'	O
neonatal	O
T	O
cell	O
response	O
to	O
anti-CD2	B-protein
-mediated	O
activation	O
.	O

To	O
compare	O
the	O
role	O
of	O
CD28	B-protein
,	O
neonatal	B-cell_type
and	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
a	O
pair	O
of	O
mitogenic	B-protein
anti-CD2	I-protein
antibodies	I-protein
in	O
the	O
presence	O
or	O
absence	O
of	O
anti-CD28	B-protein
MoAb	I-protein
.	O

With	O
anti-CD2	B-protein
alone	O
,	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
proliferated	O
slightly	O
but	O
produced	O
no	O
detectable	O
IL-2	B-protein
,	O
whereas	O
adult	O
T	B-cell_type
cells	I-cell_type
proliferated	O
vigorously	O
,	O
with	O
significant	O
IL-2	B-protein
production	O
.	O

Costimulation	O
with	O
anti-CD28	B-protein
MoAb	I-protein
greatly	O
enhanced	O
the	O
proliferative	O
response	O
of	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
levels	O
equivalent	O
to	O
those	O
of	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whereas	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
showed	O
only	O
slight	O
increases	O
.	O

Although	O
IL-2	B-protein
secretion	O
was	O
increased	O
in	O
the	O
presence	O
of	O
anti-CD28	B-protein
MoAb	I-protein
,	O
neonatal	B-cell_type
T	I-cell_type
cell	I-cell_type
IL-2	B-protein
production	O
remained	O
lower	O
than	O
in	O
adults	O
.	O

In	O
contrast	O
,	O
enhancement	O
of	O
IL-2	B-RNA
mRNA	I-RNA
expression	O
in	O
neonates	O
was	O
similar	O
to	O
adult	O
levels	O
.	O

Anti-	O
CD28	B-protein
MoAb	I-protein
costimulation	O
increased	O
NF	B-protein
kappa	I-protein
B	I-protein
levels	O
in	O
neonates	O
,	O
albeit	O
to	O
levels	O
lower	O
than	O
that	O
of	O
adults	O
.	O

The	O
cellular	O
mechanism	O
governing	O
the	O
diminished	O
proliferative	O
response	O
of	O
neonatal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
to	O
anti-CD2	B-protein
may	O
therefore	O
be	O
due	O
to	O
decreased	O
NF	B-protein
kappa	I-protein
B	I-protein
induction	O
,	O
reduced	O
IL-2	B-RNA
mRNA	I-RNA
expression	O
and	O
deficient	O
IL-2	B-protein
production	O
.	O

Although	O
anti-CD28	B-protein
MoAb	I-protein
costimulation	O
enhances	O
all	O
of	O
the	O
above	O
signals	O
,	O
NF	O
kappa	O
B	O
and	O
IL-2	O
levels	O
remain	O
lower	O
than	O
in	O
adults	O
,	O
suggesting	O
the	O
need	O
for	O
further	O
activation	O
requirements	O
in	O
the	O
neonate	O
.	O

TCL1	O
oncogene	O
activation	O
in	O
preleukemic	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
a	O
case	O
of	O
ataxia-telangiectasia	O
.	O

The	O
TCL1	B-DNA
oncogene	I-DNA
on	O
human	B-DNA
chromosome	I-DNA
14q32.1	B-DNA
is	O
involved	O
in	O
chromosome	O
translocations	O
[	O
t	B-DNA
(	I-DNA
14	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q11	I-DNA
;	I-DNA
q32.1	I-DNA
)	I-DNA
and	O
t	B-DNA
(	I-DNA
7	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q35	I-DNA
;	I-DNA
q32.1	I-DNA
)	I-DNA
]	O
and	O
inversions	O
[	O
inv14	B-DNA
(	I-DNA
q11	I-DNA
;	I-DNA
q32.1	I-DNA
)	I-DNA
]	O
with	O
TCR	B-DNA
alpha/beta	I-DNA
loci	I-DNA
in	O
T-cell	O
leukemias	O
,	O
such	O
as	O
T-prolymphocytic	O
(	O
T-PLL	O
)	O
.	O

It	O
is	O
also	O
involved	O
in	O
T-	O
acute	O
and-	O
chronic	O
leukemias	O
arising	O
in	O
cases	O
of	O
ataxia-telangiectasia	O
(	O
AT	O
)	O
,	O
an	O
immunodeficiency	O
syndrome	O
.	O

Similar	O
chromosomal	O
rearrangements	O
occur	O
also	O
in	O
the	O
clonally	O
expanded	O
T	B-cell_type
cells	I-cell_type
in	O
AT	O
patients	O
before	O
the	O
appearance	O
of	O
the	O
overt	O
leukemia	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
of	O
TCL1	B-RNA
mRNA	I-RNA
and	O
protein	B-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBLs	B-cell_type
)	O
from	O
four	O
AT	O
cases	O
and	O
from	O
healthy	O
controls	O
.	O

We	O
found	O
that	O
the	O
TCL1	B-DNA
gene	I-DNA
was	O
overexpressed	O
in	O
the	O
PBLs	B-cell_type
of	O
an	O
AT	O
patient	O
with	O
a	O
large	B-cell_line
clonal	I-cell_line
T-cell	I-cell_line
population	I-cell_line
exhibiting	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
but	O
not	O
in	O
the	O
lymphocytes	B-cell_type
of	O
the	O
other	O
cases	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	B-DNA
genomic	I-DNA
locus	I-DNA
to	O
lymphocyte	O
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T-cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
lies	O
within	O
the	O
TCL1	B-DNA
locus	I-DNA
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	B-DNA
part	I-DNA
of	O
chromosome	B-DNA
14	I-DNA
.	O

These	O
data	O
indicate	O
that	O
TCL1	B-DNA
is	O
activated	O
in	O
preleukemic	B-cell_line
clonal	I-cell_line
cells	I-cell_line
as	O
a	O
consequence	O
of	O
chromosome	O
translocation	O
involving	O
sequences	O
from	O
the	O
TCR	B-DNA
locus	I-DNA
at	O
14q11	B-DNA
.	O

Deregulation	O
of	O
TCL1	B-DNA
is	O
the	O
first	O
event	O
in	O
the	O
initiation	O
of	O
malignancy	O
in	O
these	O
types	O
of	O
leukemias	O
and	O
represents	O
a	O
potential	O
tool	O
for	O
clinical	O
evaluation	O
.	O

C/EBP	B-protein
proteins	I-protein
activate	O
transcription	O
from	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
macrophages/	O
monocytes	B-cell_type
.	O

Three	O
binding	O
sites	O
for	O
C/EBP	B-protein
proteins	I-protein
are	O
found	O
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
(	O
V.M.	O
Tesmer	O
,	O
A.Rajadhyaksha	O
,	O
J.Babin	O
,	O
and	O
M.Bina	O
,	O
Proc.Natl.Acad.Sci.	O
USA	O
90	O
:	O
7298-7302	O
,	O
1993	O
)	O
.	O

We	O
have	O
determined	O
the	O
functional	O
role	O
of	O
C/EBP	B-protein
proteins	I-protein
and	O
C/EBP	B-DNA
sites	I-DNA
in	O
regulating	O
transcription	O
from	O
the	O
HIV-	B-DNA
1	I-DNA
LTR	I-DNA
in	O
monocytes/macrophages	B-cell_type
.	O

Inhibition	O
of	O
endogenous	B-protein
C/EBP	I-protein
proteins	I-protein
,	O
using	O
either	O
an	O
excess	O
of	O
C/EBP	B-DNA
binding	I-DNA
sites	I-DNA
or	O
a	O
trans-	B-DNA
dominant	I-DNA
negative	I-DNA
inhibitor	I-DNA
,	O
demonstrated	O
that	O
C/EBP	B-protein
proteins	I-protein
are	O
required	O
for	O
basal	O
and	O
activated	O
levels	O
of	O
HIV-1	B-DNA
LTR	I-DNA
transcription	O
in	O
the	O
promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O

Northern	O
(	O
RNA	O
)	O
blots	O
and	O
binding	O
assays	O
showed	O
that	O
NF-IL6	B-protein
is	O
the	O
only	O
known	O
C/EBP	B-protein
family	I-protein
member	I-protein
which	O
is	O
increased	O
when	O
U937	B-cell_line
cells	I-cell_line
are	O
activated	O
.	O

Mutational	O
analyses	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
showed	O
that	O
one	O
C/EBP	B-DNA
site	I-DNA
is	O
required	O
for	O
normal	O
LTR	B-DNA
transcription	O
both	O
before	O
and	O
after	O
cellular	O
activation	O
and	O
that	O
the	O
two	O
3	O
'	O
C/EBP	B-DNA
sites	I-DNA
are	O
functionally	O
equivalent	O
.	O

However	O
,	O
transcription	O
from	O
crippled	B-DNA
HIV-1	I-DNA
LTRs	I-DNA
lacking	O
C/EBP	B-DNA
sites	I-DNA
can	O
still	O
be	O
induced	O
following	O
activation	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O

Several	O
models	O
are	O
suggested	O
for	O
how	O
elevated	O
NF-IL6	B-protein
may	O
participate	O
in	O
an	O
autostimulatory	O
loop	O
involving	O
HIV	O
infection	O
,	O
macrophage	O
activation	O
,	O
cytokine	B-protein
expression	O
,	O
and	O
HIV	O
replication	O
.	O

Human	O
immunodeficiency	O
virus	O
type-2	O
gene	O
expression	O
:	O
two	O
enhancers	B-DNA
and	O
their	O
activation	O
by	O
T-cell	B-cell_type
activators	O
.	O

The	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
may	O
include	O
a	O
spectrum	O
of	O
retroviruses	O
with	O
varying	O
potential	O
to	O
infect	O
their	O
host	O
,	O
undergo	O
long	O
periods	O
of	O
latent	O
infection	O
,	O
and	O
induce	O
pathology	O
.	O

Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	B-DNA
elements	I-DNA
in	O
their	O
long	B-DNA
terminal	I-DNA
repeats	I-DNA
(	O
LTRs	B-DNA
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	B-DNA
elements	I-DNA
in	O
the	O
HIV-2	B-DNA
LTR	I-DNA
.	O

The	O
HIV-2	B-DNA
LTR	I-DNA
was	O
found	O
to	O
contain	O
two	O
enhancers	B-DNA
.	O

One	O
of	O
these	O
enhancers	B-DNA
is	O
,	O
in	O
part	O
,	O
identical	O
to	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
.	O

This	O
enhancer	B-DNA
in	O
HIV-1	O
is	O
the	O
T-cell	B-DNA
activation	I-DNA
response	I-DNA
element	I-DNA
;	O
in	O
HIV-2	O
,	O
however	O
,	O
it	O
is	O
the	O
second	B-DNA
enhancer	I-DNA
that	O
is	O
mainly	O
responsible	O
for	O
activation	O
in	O
response	O
to	O
T-cell	O
activators	O
.	O

The	O
second	O
enhancer	B-DNA
interacts	O
with	O
two	O
nuclear	B-protein
binding	I-protein
proteins	I-protein
(	O
85	O
kD	O
and	O
27	O
kD	O
mobility	O
)	O
that	O
appear	O
to	O
be	O
required	O
for	O
optimal	O
enhancer	O
function	O
and	O
activation	O
.	O

Observations	O
such	O
as	O
these	O
encourage	O
the	O
speculation	O
that	O
there	O
may	O
be	O
subtle	O
differences	O
in	O
the	O
regulation	O
of	O
HIV-1	O
and	O
HIV-2	O
expression	O
that	O
may	O
be	O
relevant	O
to	O
the	O
possible	O
longer	O
latency	O
and	O
reduced	O
pathogenicity	O
of	O
HIV-2	O
.	O

NF-M	B-protein
(	O
chicken	B-protein
C/EBP	I-protein
beta	I-protein
)	O
induces	O
eosinophilic	O
differentiation	O
and	O
apoptosis	O
in	O
a	O
hematopoietic	B-cell_line
progenitor	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

CAAT/enhancer	B-protein
binding	I-protein
proteins	I-protein
(	O
C/EBPs	B-protein
)	O
are	O
transcriptional	O
activators	O
implicated	O
in	O
the	O
differentiation	O
processes	O
of	O
various	O
cell	O
lineages	O
.	O

We	O
have	O
shown	O
earlier	O
that	O
NF-M	B-protein
,	O
the	O
chicken	B-protein
homolog	I-protein
of	O
C/EBP	B-protein
beta	I-protein
,	O
is	O
specifically	O
expressed	O
in	O
myelomonocytic	B-cell_type
and	I-cell_type
eosinophilic	I-cell_type
cells	I-cell_type
of	O
the	O
hematopoietic	O
system	O
.	O

To	O
investigate	O
the	O
role	O
of	O
NF-M	B-protein
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lineage	I-cell_line
commitment	O
,	O
we	O
constructed	O
a	O
conditional	O
form	O
of	O
the	O
protein	O
by	O
fusing	O
it	O
to	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
human	B-protein
estrogen	I-protein
receptor	I-protein
.	O

This	O
construct	O
was	O
stably	O
expressed	O
in	O
a	O
multipotent	B-cell_line
progenitor	I-cell_line
cell	I-cell_line
line	I-cell_line
transformed	O
by	O
the	O
Myb-Ets	B-protein
oncoprotein	I-protein
.	O

We	O
report	O
here	O
that	O
both	O
NF-M-dependent	B-DNA
promoter	I-DNA
constructs	I-DNA
and	O
resident	O
genes	O
could	O
be	O
activated	O
by	O
addition	O
of	O
beta-estradiol	O
to	O
the	O
NF-M-estrogen	B-cell_line
receptor	I-cell_line
expressing	I-cell_line
progenitors	I-cell_line
.	O

At	O
the	O
same	O
time	O
,	O
we	O
observed	O
a	O
down-regulation	O
of	O
progenitor-specific	B-protein
surface	I-protein
markers	I-protein
and	O
the	O
up-regulation	O
of	O
differentiation	B-protein
markers	I-protein
restricted	O
to	O
the	O
eosinophil	B-cell_type
and	O
myeloid	B-cell_type
lineages	I-cell_type
.	O

In	O
addition	O
to	O
the	O
onset	O
of	O
differentiation	O
,	O
cell	O
death	O
was	O
induced	O
with	O
typical	O
apoptotic	O
features	O
.	O

Our	O
results	O
suggest	O
that	O
NF-M	B-protein
plays	O
an	O
important	O
role	O
in	O
commitment	O
along	O
the	O
eosinophil	B-cell_type
lineage	I-cell_type
and	O
in	O
the	O
induction	O
of	O
apoptosis	O
.	O

Prolactin	B-protein
and	O
interleukin-2	B-protein
receptors	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
signal	O
through	O
a	O
MGF-STAT5-like	B-protein
transcription	I-protein
factor	I-protein
.	O

The	O
cell	O
surface	O
receptors	O
for	O
PRL	B-protein
and	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
are	O
structurally	O
distinct	O
,	O
but	O
share	O
regulatory	O
tasks	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

They	O
can	O
stimulate	O
proliferation	O
and	O
activate	O
transcription	O
of	O
over-lapping	O
sets	O
of	O
genes	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

PRL	B-protein
and	O
IL-2	B-protein
receptor	O
activation	O
are	O
both	O
linked	O
to	O
the	O
Jak/Stat	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	O
pathway	O
.	O

We	O
investigated	O
the	O
ability	O
of	O
PRL	B-protein
and	O
IL-2	B-protein
to	O
activate	O
Stat	B-protein
proteins	I-protein
in	O
different	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
DNA	O
binding	O
specificities	O
,	O
the	O
reactivities	O
toward	O
Stat-specific	O
antisera	O
,	O
and	O
the	O
mol	O
wt	O
of	O
IL-2	B-protein
-and	O
PRL-induced	B-protein
DNA-binding	I-protein
proteins	I-protein
in	O
Nb2	B-cell_line
and	I-cell_line
C196	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
investigated	O
.	O

A	O
comparison	O
with	O
the	O
Stat	B-protein
proteins	I-protein
induced	O
by	O
interferon-gamma	B-protein
,	O
PRL	B-protein
,	O
and	O
IL-6	B-protein
in	O
T47D	B-cell_line
mammary	I-cell_line
tumor	I-cell_line
cells	I-cell_line
was	O
made	O
.	O

We	O
found	O
that	O
these	O
parameters	O
were	O
indistinguishable	O
for	O
one	O
of	O
the	O
PRL-	B-protein
and	I-protein
IL-2-induced	I-protein
factors	I-protein
.	O

A	O
transcription	O
factor	O
closely	O
related	O
to	O
mammary	B-protein
gland	I-protein
factor-Stat5	I-protein
is	O
rapidly	O
activated	O
upon	O
interaction	O
of	O
IL-2	B-protein
and	O
PRL	B-protein
with	O
their	O
respective	O
receptors	O
.	O

Activation	O
of	O
a	O
second	O
protein	O
related	O
to	O
Stat1	B-protein
was	O
also	O
observed	O
.	O

Our	O
results	O
emphasize	O
the	O
role	O
of	O
PRL	B-protein
as	O
a	O
regulator	O
of	O
the	O
immune	O
response	O
and	O
indicate	O
that	O
the	O
Stat	B-protein
factors	I-protein
mammary	B-protein
gland	I-protein
factor-Stat5	I-protein
and	O
Stat1	B-protein
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
T	O
cell	O
development	O
.	O

ETS1	B-protein
transactivates	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Activation	O
of	O
T	B-cell_type
helper	I-cell_type
cells	I-cell_type
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	B-protein
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
one	O
such	O
cytokine	B-protein
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis-acting	B-DNA
elements	I-DNA
with	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
AP-1	B-protein
and	O
ETS-like	B-DNA
motifs	I-DNA
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O

A	O
number	O
of	O
the	O
ETS	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
are	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
including	O
ETS1	B-protein
and	O
ELF1	B-protein
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	B-DNA
)	O
,	O
located	O
within	O
the	O
CLE0	B-DNA
element	I-DNA
,	O
-47	B-DNA
to	I-DNA
-40	I-DNA
upstream	I-DNA
of	O
the	O
GM-CSF	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
.	O

Exogenous	O
ETS1	B-protein
,	O
but	O
not	O
ELF1	B-protein
,	O
can	O
transactivate	O
GM-CSF	B-protein
,	O
through	O
the	O
GM5	B-DNA
site	O
,	O
in	O
a	O
PMA/ionomycin	O
dependent	O
manner	O
.	O

Other	O
unidentified	O
ETS-like	B-protein
factors	I-protein
present	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
are	O
also	O
capable	O
of	O
binding	O
GM5	B-DNA
.	O

Mutation	O
of	O
the	O
core	O
ETS	B-DNA
binding	I-DNA
site	I-DNA
from	O
-GGAA-	B-DNA
to	I-DNA
-GGAT-	I-DNA
prevents	O
the	O
binding	O
of	O
ETS-like	B-protein
factors	I-protein
with	O
the	O
exception	O
of	O
ETS1	B-protein
.	O

The	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	B-protein
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA/ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	B-protein
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
ETS1	B-protein
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM-CSF	B-protein
production	O
associated	O
with	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O

Quantitation	O
of	O
beta	B-RNA
1	I-RNA
triiodothyronine	I-RNA
receptor	I-RNA
mRNA	I-RNA
in	O
human	O
tissues	O
by	O
competitive	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O

Thyroid	O
hormones	O
act	O
by	O
binding	O
to	O
nuclear	B-protein
receptor	I-protein
proteins	I-protein
,	O
the	O
thyroid	B-protein
hormone	I-protein
receptors	I-protein
(	I-protein
TR	I-protein
)	I-protein
alpha	I-protein
and	I-protein
beta	I-protein
.	O

Data	O
from	O
cell	O
culture	O
and	O
animal	O
studies	O
indicate	O
that	O
TR	B-protein
expression	O
may	O
be	O
regulated	O
to	O
modulate	O
target	O
organ	O
responsiveness	O
to	O
thyroid	O
hormone	O
.	O

To	O
investigate	O
whether	O
such	O
adaptive	O
changes	O
in	O
TR	B-protein
expression	O
occur	O
in	O
humans	O
,	O
we	O
determined	O
the	O
mRNA	O
levels	O
of	O
the	O
hTR	B-protein
beta	I-protein
1	I-protein
in	O
various	O
thyroid	O
states	O
.	O

Patients	O
with	O
overt	O
hypo	O
-or	O
hyperthyroidism	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
determined	O
by	O
quantitative	O
competitive	O
reverse	O
transcription	O
PCR	O
.	O

For	O
comparison	O
,	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
were	O
determined	O
in	O
lymphocytes	B-cell_type
and	O
normal	O
thyroid	O
tissue	O
of	O
euthyroid	O
patients	O
.	O

Human	B-RNA
TR	I-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
in	O
lymphocytes	B-cell_type
were	O
1.8	O
+/-	O
0.4	O
,	O
1.9	O
+/-	O
0.5	O
,	O
1.1	O
+/-	O
0.4	O
10	O
(	O
-18	O
)	O
mol/microgram	O
RNA	O
in	O
hypo-	O
,	O
eu	O
-and	O
hyperthyroid	O
patients	O
,	O
respectively	O
,	O
corresponding	O
to	O
an	O
estimated	O
0.5	O
-2	O
molecules	O
per	O
cell	O
.	O

Although	O
the	O
mean	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
were	O
40	O
%	O
lower	O
in	O
hyperthyroid	O
than	O
in	O
euthyroid	O
subjects	O
,	O
this	O
difference	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

Similar	O
levels	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
were	O
detected	O
in	O
thyroid	O
gland	O
from	O
euthyroid	O
patients	O
.	O

In	O
summary	O
,	O
we	O
developed	O
an	O
assay	O
for	O
the	O
quantitative	O
determination	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
in	O
small	O
human	O
tissue	O
samples	O
,	O
containing	O
as	O
little	O
as	O
50	O
ng	O
of	O
total	O
RNA	O
.	O

Absolute	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
are	O
very	O
low	O
with	O
an	O
estimated	O
one	O
molecule	O
of	O
mRNA	B-RNA
being	O
present	O
in	O
a	O
mononuclear	B-cell_type
blood	I-cell_type
cell	I-cell_type
or	O
thyrocyte	B-cell_type
.	O

No	O
up-regulation	O
of	O
hTR	B-protein
beta	I-protein
1	I-protein
was	O
seen	O
in	O
hypothyroid	O
relative	O
to	O
euthyroid	O
patients	O
.	O

However	O
,	O
there	O
is	O
a	O
non-significant	O
trend	O
towards	O
a	O
down-regulation	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
in	O
hyperthyroid	O
patients	O
.	O

Multiple	O
proteins	O
interact	O
with	O
the	O
nuclear	B-DNA
inhibitory	I-DNA
protein	I-DNA
repressor	I-DNA
element	I-DNA
in	O
the	O
human	B-DNA
interleukin-3	I-DNA
promoter	I-DNA
.	O

T	O
cell	O
expression	O
of	O
interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
is	O
directed	O
by	O
positive	B-DNA
and	I-DNA
negative	I-DNA
cis-acting	I-DNA
DNA	I-DNA
elements	I-DNA
clustered	O
within	O
300	O
base	O
pairs	O
of	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
.	O

A	O
strong	O
repressor	B-protein
element	I-protein
,	O
termed	O
nuclear	B-protein
inhibitory	I-protein
protein	I-protein
(	O
NIP	B-protein
)	O
,	O
was	O
previously	O
mapped	O
to	O
a	O
segment	O
of	O
the	O
IL-3	B-DNA
promoter	I-DNA
between	O
nucleotides	B-DNA
-271	I-DNA
and	I-DNA
-250	I-DNA
.	O

Functional	O
characterization	O
of	O
this	O
element	O
demonstrates	O
that	O
it	O
can	O
mediate	O
repression	O
when	O
linked	O
in	O
cis	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

DNA	O
binding	O
experiments	O
were	O
carried	O
out	O
to	O
characterize	O
the	O
repressor	O
activity	O
.	O

Using	O
varying	O
conditions	O
,	O
three	O
distinct	O
complexes	O
were	O
shown	O
to	O
interact	O
specifically	O
with	O
the	O
NIP	B-DNA
region	I-DNA
,	O
although	O
only	O
one	O
correlates	O
with	O
repressor	O
activity	O
.	O

Complex	B-protein
1	I-protein
results	O
from	O
binding	O
of	O
a	O
ubiquitous	O
polypeptide	O
that	O
recognizes	O
the	O
3	B-DNA
'	I-DNA
portion	I-DNA
of	O
this	O
sequence	O
and	O
is	O
not	O
required	O
for	O
repression	O
.	O

Complex	B-protein
2	I-protein
corresponds	O
to	O
binding	O
of	O
transcription	B-protein
factor	I-protein
(	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
)	O
to	O
an	O
E-box	B-DNA
motif	I-DNA
in	O
the	O
5	B-DNA
'	I-DNA
portion	I-DNA
of	O
the	O
NIP	B-DNA
region	I-DNA
.	O

DNA	O
binding	O
specificity	O
of	O
complex	O
3	O
overlaps	O
with	O
that	O
of	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
but	O
is	O
clearly	O
distinct	O
.	O

To	O
determine	O
which	O
of	O
the	O
latter	O
two	O
complexes	O
represents	O
NIP	B-protein
activity	O
,	O
we	O
incorporated	O
small	O
alterations	O
into	O
the	O
NIP	B-DNA
site	I-DNA
of	O
an	O
IL-3	B-DNA
promoter-linked	I-DNA
reporter	I-DNA
construct	I-DNA
and	O
examined	O
their	O
effects	O
on	O
NIP	B-protein
-mediated	O
repression	O
.	O

Functional	O
specificity	O
for	O
repression	O
matches	O
the	O
DNA	O
binding	O
specificity	O
of	O
complex	B-protein
3	I-protein
;	O
both	O
repressor	O
activity	O
and	O
complex	B-protein
3	I-protein
binding	O
require	O
the	O
consensus	B-DNA
sequence	I-DNA
CTCACNTNC	O
.	O

The	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
is	O
downregulated	O
in	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

PU.1	B-protein
is	O
a	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
belonging	O
to	O
the	O
Ets-family	B-protein
.	O

It	O
is	O
identical	O
to	O
the	O
Spi-1	B-DNA
oncogene	I-DNA
,	O
which	O
is	O
implicated	O
in	O
spleen	O
focus-forming	O
virus-induced	O
murine	O
erythroleukemias	O
.	O

PU.1	B-protein
seems	O
to	O
be	O
required	O
for	O
early	O
development	O
of	O
multiple	B-cell_type
hematopoietic	I-cell_type
lineages	I-cell_type
,	O
but	O
its	O
expression	O
in	O
mature	B-cell_type
cells	I-cell_type
is	O
preferentially	O
observed	O
in	O
cells	O
of	O
the	O
B-cell-and	B-cell_type
monocyte/macrophage-differentiation	I-cell_type
lineage	I-cell_type
.	O

It	O
binds	O
the	O
so-called	O
Pu	B-DNA
box	I-DNA
,	O
an	O
important	O
tissue-specific	B-DNA
regulatory	I-DNA
DNA	I-DNA
element	I-DNA
present	O
in	O
a	O
number	O
of	O
genes	O
expressed	O
in	O
these	O
cell	B-cell_type
lineages	I-cell_type
.	O

We	O
have	O
analyzed	O
the	O
expression	O
and	O
activity	O
of	O
PU.1	B-protein
during	O
human	O
B-cell	O
development	O
using	O
a	O
panel	O
of	O
B-cell	B-cell_line
lines	I-cell_line
representing	O
different	O
stages	O
of	O
maturation	O
,	O
from	O
early	B-cell_line
precursors	I-cell_line
to	O
differentiated	B-cell_line
plasma	I-cell_line
cells	I-cell_line
.	O

PU.1	B-RNA
mRNA	I-RNA
expression	O
and	O
PU.1	B-protein
DNA	O
binding	O
activity	O
,	O
as	O
measured	O
by	O
Northern	O
blot	O
analysis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
were	O
evident	O
in	O
cell	B-cell_line
lines	I-cell_line
representing	O
pro-B	B-cell_line
,	I-cell_line
pre-B	I-cell_line
,	I-cell_line
and	I-cell_line
mature	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

We	O
could	O
also	O
show	O
Pu	B-DNA
box	I-DNA
-dependent	O
transactivation	O
of	O
a	O
reporter	O
gene	O
in	O
transient	O
transfections	O
in	O
these	O
cell	B-cell_line
lines	I-cell_line
.	O

In	O
contrast	O
,	O
in	O
a	O
number	O
of	O
multiple	B-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
representing	O
differentiated	B-cell_type
,	I-cell_type
plasma	I-cell_type
cell-like	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
PU.1	B-protein
DNA	O
binding	O
activity	O
,	O
mRNA	O
expression	O
,	O
and	O
Pu	B-DNA
box	I-DNA
-dependent	O
transactivation	O
were	O
absent	O
or	O
detectable	O
at	O
a	O
very	O
low	O
level	O
.	O

In	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
which	O
exemplify	O
an	O
intermediate	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
a	O
reduced	O
expression	O
and	O
activity	O
were	O
observed	O
.	O

The	O
findings	O
in	O
the	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
represent	O
the	O
first	O
examples	O
of	O
B	B-cell_type
cells	I-cell_type
with	O
downregulated	O
PU.1	B-protein
expression	O
and	O
apparently	O
contradict	O
observations	O
in	O
the	O
murine	O
system	O
in	O
which	O
PU.1	B-protein
is	O
expressed	O
and	O
active	O
in	O
plasmacytoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

At	O
present	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	O
of	O
PU.1	B-protein
expression	O
and	O
activity	O
in	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
represents	O
a	O
malignancy-associated	O
defect	O
in	O
these	O
cells	O
or	O
exemplifies	O
a	O
normal	O
developmental	O
regulation	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Regulation	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
E-selectin	B-protein
expression	O
in	O
endothelial	B-cell_type
cells	I-cell_type
by	O
cyclosporin	O
A	O
and	O
the	O
T-cell	B-protein
transcription	I-protein
factor	I-protein
NFAT	B-protein
.	O

Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
was	O
originally	O
described	O
as	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
athat	O
supported	O
the	O
activation	O
of	O
cytokine	B-protein
gene	O
expression	O
and	O
mediated	O
the	O
immunoregulatory	B-protein
effects	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

As	O
we	O
observed	O
that	O
activated	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
also	O
expressed	O
NFAT	B-protein
,	O
we	O
tested	O
the	O
antiinflammatory	O
properties	O
of	O
CsA	O
in	O
endothelial	B-cell_type
cells	I-cell_type
.	O

Significantly	O
,	O
CsA	O
completely	O
suppressed	O
the	O
induction	O
of	O
NFAT	B-protein
in	O
endothelial	B-cell_type
cells	I-cell_type
and	O
inhibited	O
the	O
activity	O
of	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
regulatory	I-DNA
elements	I-DNA
that	O
use	O
NFAT	B-protein
by	O
60	O
%	O
.	O

CsA	O
similarly	O
mediated	O
a	O
reduction	O
of	O
up	O
to	O
65	O
%	O
in	O
GM-CSF	B-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
in	O
activated	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

CsA	O
also	O
suppressed	O
E-selectin	B-protein
,	O
but	O
not	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
expression	O
in	O
endothelial	O
cells	O
,	O
even	O
though	O
the	O
E-selectin	B-DNA
promoter	I-DNA
is	O
activated	O
by	O
NF-kappa	B-protein
B	I-protein
rather	O
than	O
NFAT	B-protein
.	O

Hence	O
,	O
induction	O
of	O
cell	O
surface	O
expression	O
of	O
this	O
leukocyte	B-protein
adhesion	I-protein
molecule	I-protein
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
was	O
reduced	O
by	O
40	O
%	O
in	O
the	O
presence	O
of	O
CsA	O
,	O
and	O
this	O
was	O
reflected	O
by	O
a	O
29	O
%	O
decrease	O
in	O
neutrophil	B-cell_type
adhesion	O
.	O

The	O
effects	O
of	O
CsA	O
on	O
endothelial	B-cell_type
cells	I-cell_type
were	O
also	O
detected	O
at	O
the	O
chromatin	B-DNA
structure	O
level	O
,	O
as	O
DNasel	B-DNA
hypersensitive	I-DNA
sites	I-DNA
within	O
both	O
the	O
GM-CSF	B-protein
enhancer	O
and	O
the	O
E-selectin	B-DNA
promoter	I-DNA
were	O
suppressed	O
by	O
CsA	O
.	O

This	O
represents	O
the	O
first	O
report	O
of	O
NFAT	B-protein
in	O
endothelial	B-cell_type
cells	I-cell_type
and	O
suggests	O
mechanisms	O
by	O
which	O
CsA	O
could	O
function	O
as	O
an	O
antiinflammatory	O
agent	O
.	O

Costimulation	O
requirement	O
for	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
transcription	O
factor	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
requires	O
T-cell	B-cell_type
costimulation	O
delivered	O
by	O
the	O
TCR	B-protein
and	O
the	O
auxiliary	B-protein
receptor	I-protein
CD28	I-protein
.	O

Several	O
transcription	B-protein
factors	I-protein
participate	O
in	O
IL-2	B-protein
promoter	O
activation	O
,	O
among	O
which	O
are	O
AP-1-like	B-protein
factors	I-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O

Protein	O
phosphorylation	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors	O
:	O
(	O
1	O
)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP-1	B-protein
protein	I-protein
c-Jun	B-protein
;	O
and	O
(	O
2	O
)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	B-protein
inhibitor	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
from	O
NF-kappa	B-protein
B	I-protein
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O

We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T-cell	O
costimulation	O
.	O

Furthermore	O
,	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
the	O
kinetics	O
of	O
the	O
two	O
phosphorylation	O
events	O
are	O
essentially	O
similar	O
.	O

According	O
to	O
our	O
results	O
,	O
however	O
,	O
the	O
kinases	O
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O
entities	O
.	O

Whereas	O
TPCK	B-protein
inhibits	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
and	O
,	O
consequently	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	B-protein
,	O
the	O
MAP	B-protein
kinase-related	I-protein
kinase	I-protein
that	O
phosphorylates	O
the	O
transactivation	B-protein
domain	I-protein
of	O
c-Jun	B-protein
.	O

We	O
,	O
therefore	O
,	O
propose	O
the	O
activation	O
scheme	O
presented	O
in	O
FIGURE	O
3	O
for	O
T-cell	O
costimulation	O
.	O

Costimulation	O
results	O
in	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
that	O
leads	O
to	O
the	O
simultaneous	O
induction	O
of	O
the	O
two	O
transcription	B-protein
factors	I-protein
,	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O

Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	B-protein
and	O
CD28	B-protein
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	B-protein
kappa	I-protein
B	I-protein
phosphorylation	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
on	O
the	O
one	O
hand	O
,	O
and	O
JNK	B-protein
activation	O
and	O
c-Jun	B-protein
phosphorylation	O
on	O
the	O
other	O
.	O

We	O
are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP-1	B-protein
/	O
NF-kappa	B-protein
B	I-protein
pathway	O
.	O

Regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
cytokine	O
gene	O
expression	O
in	O
myeloid	B-cell_type
cells	I-cell_type
by	O
NF-kappa	B-protein
B/Rel	I-protein
transcription	B-protein
factors	I-protein
.	O

CD4+	B-cell_line
macrophages	I-cell_line
in	O
tissues	O
such	O
as	O
lung	O
,	O
skin	O
,	O
and	O
lymph	O
nodes	O
,	O
promyelocytic	B-cell_type
cells	I-cell_type
in	O
bone	O
marrow	O
,	O
and	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
serve	O
as	O
important	O
targets	O
and	O
reservoirs	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O

HIV-1-infected	O
myeloid	B-cell_type
cells	I-cell_type
are	O
often	O
diminished	O
in	O
their	O
ability	O
to	O
participate	O
in	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
intracellular	O
killing	O
.	O

HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	I-cell_type
can	O
lead	O
to	O
the	O
expression	O
of	O
surface	B-protein
receptors	I-protein
associated	O
with	O
cellular	O
activation	O
and/or	O
differentiation	O
that	O
increase	O
the	O
responsiveness	O
of	O
these	O
cells	O
to	O
cytokines	B-protein
secreted	O
by	O
neighboring	O
cells	O
as	O
well	O
as	O
to	O
bacteria	O
or	O
other	O
pathogens	O
.	O

Enhancement	O
of	O
HIV-1	O
replication	O
is	O
related	O
in	O
part	O
to	O
increased	O
DNA-binding	O
activity	O
of	O
cellular	B-protein
transcription	I-protein
factors	I-protein
such	O
as	O
NF-kappa	B-protein
B	I-protein
.	O

NF-kappa	B-protein
B	I-protein
binds	O
to	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
region	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
and	O
contributes	O
to	O
the	O
inducibility	O
of	O
HIV-1	O
gene	O
expression	O
in	O
response	O
to	O
multiple	O
activating	O
agents	O
.	O

Phosphorylation	O
and	O
degradation	O
of	O
the	O
cytoplasmic	B-protein
inhibitor	I-protein
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
are	O
crucial	O
regulatory	O
events	O
in	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
.	O

Both	O
N-	O
and	O
C-terminal	O
residues	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
are	O
required	O
for	O
inducer-mediated	O
degradation	O
.	O

Chronic	O
HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	I-cell_type
leads	O
to	O
constitutive	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
and	O
provides	O
an	O
intranuclear	O
environment	O
capable	O
of	O
perpetuating	O
HIV-1	O
replication	O
.	O

Increased	O
intracellular	O
stores	O
of	O
latent	B-protein
NF-kappa	I-protein
B	I-protein
may	O
also	O
result	O
in	O
rapid	O
inducibility	O
of	O
NF-kappa	B-protein
B	I-protein
-dependent	O
cytokine	B-protein
gene	O
expression	O
.	O

In	O
response	O
to	O
secondary	O
pathogenic	O
infections	O
or	O
antigenic	O
challenge	O
,	O
cytokine	B-protein
gene	O
expression	O
is	O
rapidly	O
induced	O
,	O
enhanced	O
,	O
and	O
sustained	O
over	O
prolonged	O
periods	O
in	O
HIV-1-infected	B-cell_line
myeloid	I-cell_line
cells	I-cell_line
compared	O
with	O
uninfected	B-cell_type
cells	I-cell_type
.	O

Elevated	O
levels	O
of	O
several	O
inflammatory	B-protein
cytokines	I-protein
have	O
been	O
detected	O
in	O
the	O
sera	O
of	O
HIV-1-infected	O
individuals	O
.	O

Secretion	O
of	O
myeloid	B-protein
cell-derived	I-protein
cytokines	I-protein
may	O
both	O
increase	O
virus	O
production	O
and	O
contribute	O
to	O
AIDS-associated	O
disorders	O
.	O

Steroid	O
mediated	O
lysis	O
of	O
lymphoblasts	B-cell_type
requires	O
the	O
DNA	O
binding	O
region	O
of	O
the	O
steroid	O
hormone	O
receptor	O
.	O

Glucocorticoids	O
kill	O
certain	O
types	O
of	O
lymphoblasts	B-cell_type
,	O
but	O
the	O
mechanisms	O
are	O
unknown	O
.	O

It	O
is	O
clear	O
that	O
sufficient	O
numbers	O
of	O
functional	O
glucocorticoid	B-protein
receptors	I-protein
are	O
required	O
to	O
mediate	O
lysis	O
,	O
but	O
whether	O
they	O
do	O
so	O
through	O
the	O
classical	O
model	O
of	O
steroid	O
hormone	O
activation	O
and	O
modulation	O
of	O
gene	O
expression	O
has	O
not	O
been	O
established	O
.	O

In	O
this	O
report	O
we	O
have	O
asked	O
which	O
region	O
(	O
s	O
)	O
of	O
the	O
steroid	B-protein
receptor	I-protein
are	O
important	O
for	O
mediating	O
lysis	O
in	O
leukemic	B-cell_type
T	I-cell_type
lymphoblasts	I-cell_type
.	O

CEM-ICR	B-cell_line
27	I-cell_line
leukemic	I-cell_line
lymphoblasts	I-cell_line
,	O
a	O
clone	O
of	O
CEM	B-cell_line
cells	I-cell_line
which	O
lack	O
functional	O
glucocorticoid	B-protein
receptors	I-protein
and	O
therefore	O
are	O
neither	O
lysed	O
by	O
dexamethasone	O
nor	O
capable	O
of	O
showing	O
glutamine	B-protein
synthetase	I-protein
induction	O
,	O
were	O
provided	O
with	O
steroid	B-protein
receptors	I-protein
by	O
DNA	O
transfections	O
of	O
various	O
receptor	O
gene	O
constructs	O
.	O

We	O
measured	O
steroid	O
mediated	O
lysis	O
,	O
receptor	O
number	O
and	O
induction	O
of	O
glutamine	B-protein
synthetase	I-protein
in	O
the	O
transfected	B-cell_line
cells	I-cell_line
.	O

Our	O
results	O
provide	O
evidence	O
that	O
the	O
lysis	O
mechanism	O
in	O
the	O
ICR27	B-cell_line
lymphoblasts	I-cell_line
is	O
restored	O
when	O
functional	O
receptor	O
number	O
is	O
restored	O
.	O

The	O
DNA	B-protein
binding	I-protein
region	I-protein
specifying	O
high	O
affinity	O
for	O
GRE	B-DNA
sites	I-DNA
is	O
required	O
.	O

Lysis	O
is	O
mediated	O
by	O
any	O
steroid	O
that	O
allows	O
for	O
activation	O
of	O
the	O
receptor	O
containing	O
such	O
a	O
region	O
.	O

Our	O
data	O
support	O
the	O
view	O
that	O
steroid-mediated	O
cell	O
death	O
occurs	O
by	O
a	O
process	O
requiring	O
direct	O
interaction	O
of	O
steroid-receptor	B-protein
complexes	I-protein
with	O
the	O
genome	O
.	O

Functional	O
characterization	O
of	O
the	O
murine	B-protein
homolog	I-protein
of	O
the	O
B	B-protein
cell-specific	I-protein
coactivator	I-protein
BOB.1/OBF.1	B-protein
.	O

B	O
cell-specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	B-DNA
motif	I-DNA
requires	O
the	O
Oct1	B-protein
or	O
Oct2	B-protein
protein	I-protein
and	O
additional	O
B	B-protein
cell-restricted	I-protein
cofactors	I-protein
.	O

One	O
such	O
cofactor	B-protein
,	O
BOB.1/OBF.1	B-protein
,	O
was	O
recently	O
isolated	O
from	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
describe	O
the	O
isolation	O
and	O
detailed	O
characterization	O
of	O
the	O
murine	B-protein
homolog	I-protein
.	O

Full-length	O
cDNAs	B-DNA
and	O
genomic	B-DNA
clones	I-DNA
were	O
isolated	O
,	O
and	O
the	O
gene	O
structure	O
was	O
determined.	O
Comparison	O
of	O
the	O
deduced	O
amino	O
acids	O
shows	O
88	O
%	O
sequence	O
identity	O
between	O
mouse	B-protein
and	I-protein
human	I-protein
BOB.1/OBF.1	I-protein
.	O

The	O
NH2-terminal	B-protein
126	I-protein
amino	I-protein
acids	I-protein
of	O
BOB.1/OBF.1	B-protein
are	O
both	O
essential	O
and	O
sufficient	O
for	O
interaction	O
with	O
the	O
POU	B-protein
domains	I-protein
of	O
either	O
Oct1	B-protein
or	O
Oct2	B-protein
.	O

This	O
protein-protein	O
interaction	O
does	O
not	O
require	O
the	O
simultaneous	O
binding	O
of	O
Oct	B-protein
proteins	I-protein
to	O
DNA	O
,	O
and	O
high	O
resolution	O
footprinting	O
of	O
the	O
Oct	B-DNA
-DNA	O
interaction	O
reveals	O
that	O
binding	O
of	O
BOB.1/OBF.1	B-protein
to	O
Oct1	B-protein
or	O
Oct2	B-protein
does	O
not	O
alter	O
the	O
interaction	O
with	O
DNA	O
.	O

BOB.1/OBF.1	B-protein
can	O
efficiently	O
activate	O
octamer-dependent	O
promoters	O
in	O
fibroblasts	B-cell_type
;	O
however	O
,	O
it	O
fails	O
to	O
stimulate	O
octamer-dependent	B-DNA
enhancer	I-DNA
activity	O
.	O

Fusion	O
of	O
subdomains	O
of	O
BOB.1/OBF.1	B-protein
with	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
reveals	O
that	O
both	O
NH2-	B-protein
and	I-protein
COOH-terminal	I-protein
domains	I-protein
of	O
BOB.1/OBF.1	B-protein
contribute	O
to	O
full	O
transactivation	O
function	O
,	O
the	O
COOH-terminal	B-protein
domain	I-protein
is	O
more	O
efficient	O
in	O
this	O
transactivation	O
assay	O
.	O

Consistent	O
with	O
the	O
failure	O
of	O
full-length	B-protein
BOB.1/OBF.1	I-protein
to	O
stimulate	O
octamer-dependent	B-DNA
enhancer	I-DNA
elements	I-DNA
in	O
non	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
the	O
GAL4	B-protein
fusions	I-protein
likewise	O
only	O
stimulate	O
from	O
a	O
promoter-proximal	O
position	O
.	O

Anti-immunoglobulin	B-protein
M	I-protein
activates	O
nuclear	B-protein
calcium/calmodulin-dependent	I-protein
protein	I-protein
kinase	I-protein
II	I-protein
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
and	O
others	O
have	O
previously	O
shown	O
that	O
the	O
nuclear	B-protein
protein	I-protein
,	O
Ets-1	B-protein
,	O
is	O
phosphorylated	O
in	O
a	O
calcium-dependent	O
manner	O
after	O
ligation	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
M	O
on	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

As	O
this	O
phosphorylation	O
was	O
independent	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
activity	O
,	O
we	O
tested	O
whether	O
a	O
calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
(	O
CaM	B-protein
kinase	I-protein
)	O
might	O
phosphorylate	O
the	O
Ets-1	B-protein
protein	I-protein
after	O
elevation	O
of	O
intracellular	O
free	O
calcium	O
concentrations	O
.	O

The	O
dephosphorylated	O
form	O
of	O
Ets-1	B-protein
has	O
been	O
shown	O
to	O
bind	O
to	O
chromatin	O
,	O
suggesting	O
that	O
the	O
operative	B-protein
kinase	I-protein
should	O
be	O
detectable	O
in	O
the	O
nucleus	O
.	O

We	O
prepared	O
nuclear	O
extracts	O
from	O
two	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
levels	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
the	O
Ets-1	B-protein
protein	O
.	O

Activity	O
of	O
the	O
CaM	B-protein
kinases	I-protein
was	O
determined	O
using	O
a	O
synthetic	O
peptide	O
substrate	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
inhibitor	O
specific	O
for	O
the	O
CaM	B-protein
kinase	I-protein
family	I-protein
,	O
KN-62	O
.	O

Stimulation	O
of	O
cells	O
with	O
anti-IgM	B-protein
led	O
to	O
increased	O
activity	O
of	O
a	O
nuclear	B-protein
kinase	I-protein
that	O
could	O
phosphorylate	O
the	O
peptide	O
,	O
and	O
this	O
activity	O
was	O
reduced	O
by	O
10	O
microM	O
KN-62	O
.	O

Kinase	O
activity	O
was	O
reduced	O
in	O
lysates	O
preadsorbed	O
using	O
an	O
antibody	B-protein
specific	O
for	O
CaM	B-protein
kinase	I-protein
II	I-protein
.	O

Two-dimensional	O
phosphopeptide	O
maps	O
of	O
the	O
Ets-1	B-protein
protein	O
from	O
cells	O
incubated	O
with	O
ionomycin	O
or	O
anti-IgM	B-protein
contained	O
two	O
unique	O
phosphopeptides	O
that	O
were	O
absent	O
in	O
untreated	O
cells	O
.	O

Incubation	O
of	O
isolated	B-protein
Ets-1	I-protein
protein	I-protein
with	O
purified	O
CaM	B-protein
kinase	I-protein
II	I-protein
produced	O
phosphorylation	O
of	O
peptides	O
that	O
migrated	O
identically	O
to	O
those	O
found	O
in	O
cells	O
incubated	O
with	O
either	O
anti-IgM	B-protein
or	O
ionomycin	O
.	O

These	O
data	O
suggest	O
a	O
model	O
of	O
signal	O
transduction	O
by	O
the	O
antigen	B-protein
receptor	I-protein
on	O
B	B-cell_type
lymphocytes	I-cell_type
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
can	O
rapidly	O
activate	O
nuclear	B-protein
CaM	I-protein
kinase	I-protein
II	I-protein
,	O
potentially	O
resulting	O
in	O
phosphorylation	O
and	O
regulation	O
of	O
DNA-binding	B-protein
proteins	I-protein
.	O

Transcriptional	O
activation	O
and	O
repression	O
,	O
two	O
properties	O
of	O
the	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct-2a	B-protein
.	O

The	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct-2a	B-protein
contains	O
two	O
transcriptional	B-protein
activation	I-protein
domains	I-protein
which	O
are	O
located	O
within	O
the	O
N-terminal	B-protein
and	O
C-terminal	B-protein
regions	I-protein
.	O

To	O
study	O
their	O
differential	O
activation	O
properties	O
,	O
we	O
linked	O
the	O
isolated	O
effector	B-protein
domains	I-protein
to	O
the	O
GAL4	B-protein
DNA-binding	I-protein
domain	I-protein
.	O

We	O
have	O
shown	O
that	O
both	O
activating	O
regions	O
of	O
Oct-2a	B-protein
,	O
isolated	O
from	O
their	O
natural	O
context	O
,	O
can	O
activate	O
transcription	O
as	O
promoter	B-protein
factors	I-protein
.	O

In	O
contrast	O
to	O
the	O
C-terminus	B-protein
,	O
activation	O
by	O
the	O
N-terminal	B-protein
domain	I-protein
is	O
dependent	O
on	O
a	O
yet	O
unidentified	O
factor	O
(	O
s	O
)	O
binding	O
to	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
enhancer	I-DNA
.	O

The	O
results	O
obtained	O
by	O
duplication	O
of	O
activation	B-protein
domains	I-protein
or	O
their	O
mixed	O
combination	O
suggest	O
that	O
the	O
domains	O
are	O
functionally	O
independent	O
.	O

However	O
,	O
activation	O
from	O
a	O
remote	O
position	O
could	O
only	O
be	O
achieved	O
with	O
the	O
C-terminus	B-protein
of	O
Oct-2a	B-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

In	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
higher	O
activation	O
levels	O
were	O
observed	O
,	O
suggesting	O
that	O
distinct	O
B-cell-specific	B-protein
cofactors	I-protein
in	O
concert	O
with	O
the	O
effector	B-protein
domains	I-protein
of	O
Oct-2a	B-protein
might	O
be	O
involved	O
in	O
mediating	O
transcription	O
from	O
proximal	O
and	O
remote	O
positions	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
repression	O
domain	O
at	O
the	O
N-terminus	O
of	O
Oct-2a	B-protein
.	O

When	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcriptional	O
stimulation	O
was	O
inhibited	O
efficiently	O
.	O

These	O
results	O
underscore	O
the	O
modular	O
structure	O
of	O
Oct-2a	B-protein
with	O
separable	O
domains	O
for	O
activation	O
and	O
repression	O
and	O
suggest	O
that	O
Oct-2a	B-protein
might	O
have	O
complex	O
regulatory	O
functions	O
in	O
vivo	O
.	O

Nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
by	O
macrophages	B-cell_type
and	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
requires	O
the	O
presence	O
of	O
the	O
bacterial	O
flagellum	O
.	O

Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described	O
,	O
the	O
bacterial	O
ligands	O
required	O
are	O
poorly	O
understood	O
.	O

To	O
identify	O
the	O
requisite	O
bacterial	O
ligands	O
,	O
studies	O
with	O
isogenic	O
mutants	O
of	O
P.	O
aeruginosa	O
PAK	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
the	O
RpoN	B-protein
sigma	I-protein
factor	I-protein
were	O
undertaken	O
.	O

The	O
RpoN	O
mutant	O
,	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
nonpilus	B-protein
adhesins	I-protein
,	O
bound	O
poorly	O
and	O
was	O
resistant	O
to	O
ingestion	O
by	O
both	O
macrophages	B-cell_type
and	O
neutrophils	B-cell_type
.	O

Pili	O
were	O
not	O
absolutely	O
required	O
for	O
binding	O
or	O
phagocytosis	O
of	O
P.	O
aeruginosa	O
.	O

The	O
presence	O
of	O
a	O
flagellum	O
was	O
not	O
required	O
for	O
binding	O
of	O
P.	O
aeruginosa	O
to	O
macrophages	B-cell_type
but	O
was	O
critical	O
for	O
the	O
subsequent	O
internalization	O
of	O
the	O
bacterium	O
,	O
suggesting	O
that	O
this	O
factor	O
or	O
a	O
surface	O
ligand	O
associated	O
with	O
its	O
assembly	O
was	O
responsible	O
for	O
stimulation	O
of	O
nonopsonic	O
phagocytosis	O
.	O

Identification	O
of	O
essential	O
GATA	B-DNA
and	O
Ets	B-DNA
binding	I-DNA
motifs	I-DNA
within	O
the	O
promoter	O
of	O
the	O
platelet	B-DNA
glycoprotein	I-DNA
Ib	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

Platelet	B-protein
glycoprotein	I-protein
(	O
GP	B-protein
)	O
Ib-IX-V	B-protein
is	O
a	O
multisubunit	B-protein
adhesion	I-protein
receptor	I-protein
that	O
supports	O
platelet	O
attachment	O
to	O
thrombogenic	O
surfaces	O
at	O
sites	O
of	O
vascular	O
injury	O
.	O

The	O
congenital	O
absence	O
of	O
the	O
receptor	O
results	O
in	O
a	O
bleeding	O
disorder	O
associated	O
with	O
``	B-cell_type
giant	I-cell_type
''	I-cell_type
platelets	I-cell_type
,	O
a	O
condition	O
linking	O
the	O
expression	O
of	O
the	O
complex	O
to	O
platelet	O
morphogenesis	O
.	O

To	O
understand	O
better	O
the	O
expression	O
of	O
the	O
GP	B-protein
Ib-IX-V	I-protein
complex	I-protein
,	O
studies	O
were	O
undertaken	O
to	O
define	O
the	O
essential	O
genetic	B-DNA
elements	I-DNA
supporting	O
the	O
expression	O
of	O
the	O
alpha-subunit	B-protein
of	O
the	O
complex	O
(	O
GP	B-protein
Ib	I-protein
alpha	I-protein
)	O
.	O

GP	B-DNA
Ib	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
was	O
evaluated	O
by	O
transfection	O
of	O
human	B-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
with	O
reporter	O
plasmids	O
coding	O
for	O
the	O
enzyme	B-protein
,	O
luciferase	B-protein
.	O

Studies	O
were	O
initiated	O
with	O
a	O
fragment	O
extending	O
2	O
,	O
738	O
nucleotides	O
5	O
'	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
and	O
lead	O
to	O
the	O
identification	O
of	O
253	O
nucleotides	O
retaining	O
full	O
promoter	O
activity	O
in	O
human	B-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
.	O

In	O
cells	O
of	O
nonhematopoietic	B-cell_type
lineage	I-cell_type
,	O
human	B-cell_type
endothelial	I-cell_type
and	O
HeLa	B-cell_type
cells	I-cell_type
,	O
the	O
GP	B-DNA
Ib	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
was	O
no	O
greater	O
than	O
background	O
levels	O
obtained	O
with	O
promoterless	B-DNA
constructs	I-DNA
.	O

Gel	O
shift	O
assays	O
and	O
site-directed	O
mutagenesis	O
studies	O
defined	O
essential	O
GATA	B-DNA
and	O
Ets	B-DNA
binding	I-DNA
motifs	I-DNA
93	B-DNA
and	I-DNA
150	I-DNA
nucleotides	I-DNA
upstream	I-DNA
of	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
,	O
a	O
finding	O
which	O
further	O
substantiates	O
these	O
elements	O
as	O
important	O
determinants	O
of	O
megakaryocytic	O
gene	O
expression	O
.	O

The	O
results	O
define	O
essential	O
cis-acting	B-DNA
elements	I-DNA
responsible	O
for	O
the	O
expression	O
of	O
GP	B-protein
Ib	I-protein
alpha	I-protein
and	O
provide	O
insights	O
into	O
molecular	O
events	O
coinciding	O
with	O
the	O
release	O
of	O
normal	B-cell_type
platelets	I-cell_type
into	O
the	O
bloodstream	O
.	O

CD30	B-protein
ligation	O
induces	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
in	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

CD30	B-protein
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor/nerve	I-protein
growth	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
following	O
incubation	O
of	O
L540	B-cell_line
cells	I-cell_line
(	O
Hodgkin	B-cell_line
's	I-cell_line
disease-derived	I-cell_line
,	I-cell_line
T	I-cell_line
cell-like	I-cell_line
,	I-cell_line
CD30+	I-cell_line
cells	I-cell_line
)	O
with	O
the	O
agonistic	B-protein
anti-CD30	I-protein
monoclonal	I-protein
antibodies	I-protein
(	O
mAb	B-protein
)	O
M44	B-protein
and	O
M67	B-protein
,	O
two	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
DNA	O
binding	O
activities	O
were	O
induced	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
retardation	O
assays	O
.	O

The	O
effect	O
of	O
the	O
mAb	B-protein
towards	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
rapid	O
,	O
as	O
it	O
occurred	O
within	O
20	O
min	O
,	O
and	O
was	O
sustained	O
for	O
up	O
to	O
6	O
h	O
.	O

By	O
comparison	O
,	O
an	O
isotype-matched	B-protein
antibody	I-protein
had	O
no	O
effect	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Moreover	O
,	O
in	O
human	B-cell_line
T	I-cell_line
helper	I-cell_line
(	I-cell_line
Th	I-cell_line
)	I-cell_line
clones	I-cell_line
functionally	O
characterized	O
as	O
being	O
of	O
the	O
type	O
0	O
,	O
type	O
1	O
and	O
type	O
2	O
(	O
28	O
%	O
,	O
<	O
1	O
%	O
und	O
93	O
%	O
CD30+	O
,	O
respectively	O
)	O
,	O
the	O
extent	O
of	O
CD30	B-protein
-mediated	O
NF-kappa	B-protein
B	I-protein
activation	O
correlated	O
with	O
the	O
proportion	O
of	O
CD30+	B-cell_line
cells	I-cell_line
.	O

In	O
all	O
cell	O
lines	O
investigated	O
,	O
the	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
induced	O
following	O
CD30	B-protein
engagement	O
were	O
shown	O
to	O
contain	O
p50	B-protein
NF-kappa	I-protein
B1	I-protein
,	O
p65	B-protein
RelA	I-protein
,	O
and	O
possibly	O
other	O
transcription	B-protein
factors	I-protein
.	O

Collectively	O
,	O
our	O
results	O
demonstrate	O
that	O
nuclear	O
translocation	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
rank	O
among	O
the	O
short-term	O
cellular	O
responses	O
elicited	O
following	O
CD30	B-protein
ligation	O
.	O

Pathogenesis	O
of	O
atherosclerosis	O
.	O

The	O
earliest	O
lesion	O
in	O
the	O
development	O
of	O
an	O
atherosclerotic	O
plaque	O
is	O
the	O
fatty	O
streak	O
.	O

This	O
chronic	O
inflammatory	O
reaction	O
results	O
from	O
a	O
sequence	O
of	O
events	O
that	O
begins	O
with	O
the	O
trapping	O
of	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
in	O
the	O
subendothelial	O
space	O
of	O
the	O
artery	O
wall	O
.	O

The	O
trapped	O
LDL	O
is	O
seeded	O
with	O
oxidative	O
species	O
released	O
by	O
the	O
overlying	O
endothelium	O
,	O
and	O
lipid	O
oxidation	O
is	O
initiated	O
within	O
the	O
LDL	O
particle.	O
Some	O
of	O
the	O
lipids	O
that	O
result	O
lead	O
to	O
the	O
activation	O
of	O
NFkB-like	B-protein
transcription	I-protein
factors	I-protein
that	O
cause	O
the	O
expression	O
of	O
genes	O
whose	O
protein	B-protein
products	I-protein
mediate	O
monocyte	O
binding	O
,	O
monocyte	B-cell_type
chemotaxis	O
into	O
the	O
subendothelial	O
space	O
,	O
and	O
conversion	O
into	O
macrophages	B-cell_type
.	O

At	O
least	O
1	O
major	B-DNA
gene	I-DNA
modulates	O
the	O
oxidation	O
of	O
LDL	O
lipids	O
and/or	O
the	O
biologic	O
response	O
to	O
these	O
lipids	O
.	O

The	O
inverse	O
relation	O
between	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
and	O
atherosclerotic	O
events	O
may	O
in	O
part	O
be	O
due	O
to	O
enzymes	B-protein
associated	O
with	O
HDL	O
that	O
destroy	O
the	O
biologically	O
active	O
lipids	O
generated	O
in	O
LDL	O
.	O

Estrogen	B-protein
and	O
progesterone	B-protein
receptors	I-protein
in	O
vernal	O
keratoconjunctivitis	O
.	O

PURPOSE	O
:	O
Sex-related	O
influences	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
vernal	O
keratoconjunctivitis	O
(	O
VKC	O
)	O
,	O
an	O
allergic	O
eosinophilic	O
disease	O
.	O

METHODS	O
:	O
The	O
authors	O
evaluated	O
tarsal	O
and	O
bulbar	O
conjunctival	O
biopsies	O
from	O
seven	O
patients	O
with	O
severe	O
and	O
symptomatic	O
VKC	O
for	O
the	O
presence	O
of	O
estrogen	B-protein
and	O
progesterone	B-protein
receptors	I-protein
by	O
using	O
monoclonal	B-protein
antibodies	I-protein
with	O
a	O
peroxidase-antiperoxidase	O
technique	O
.	O

RESULTS	O
:	O
Both	O
the	O
epithelium	O
and	O
subepithelium	O
of	O
the	O
tarsal	O
and	O
bulbar	O
conjunctiva	O
of	O
patients	O
with	O
VKC	O
,	O
but	O
not	O
those	O
of	O
four	O
nonatopic	O
control	O
subjects	O
,	O
showed	O
intense	O
positive	O
staining	O
for	O
estrogen	O
and	O
progesterone	B-protein
receptors	I-protein
.	O

Immunofluorescence	O
colocalization	O
of	O
both	O
estrogen	B-protein
and	O
progesterone	B-protein
receptors	I-protein
with	O
eosinophil	B-protein
cationic	I-protein
protein	I-protein
showed	O
that	O
approximately	O
70	O
%	O
of	O
positive	B-cell_type
cells	I-cell_type
were	O
eosinophils	B-cell_type
.	O

CONCLUSIONS	O
:	O
Sexual	O
hormones	O
,	O
through	O
their	O
receptors	B-protein
,	O
may	O
influence	O
the	O
activity	O
of	O
eosinophils	B-cell_type
in	O
patients	O
with	O
VKC	O
.	O

CIITA	B-protein
activates	O
the	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
mouse	O
T	O
cells	O
.	O

It	O
has	O
long	O
been	O
a	O
puzzle	O
that	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	I-protein
are	O
expressed	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
after	O
activation	O
but	O
not	O
in	O
mouse	B-cell_type
T	I-cell_type
cells	I-cell_type
;	O
this	O
expression	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
cell	O
mediated	O
immune	O
response	O
.	O

Recently	O
the	O
MHC	B-protein
class	I-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	B-protein
regulatory	I-protein
factor	I-protein
for	O
both	O
the	O
constitutive	O
and	O
IFN	O
inducible	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O

Here	O
we	O
show	O
that	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
expressing	O
MHC	O
class	O
II	O
have	O
CIITA	B-protein
transcripts	O
while	O
MHC	O
class	O
II-negative	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
mouse	B-cell_type
T	I-cell_type
cells	I-cell_type
do	O
not	O
.	O

The	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
mouse	B-cell_type
T	I-cell_type
cells	I-cell_type
can	O
be	O
reconstituted	O
upon	O
transfection	O
with	O
the	O
human	B-DNA
CIITA	I-DNA
cDNA	I-DNA
.	O

These	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
CIITA	B-protein
explains	O
the	O
expression	O
or	O
lack	O
of	O
expression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
in	O
human	B-cell_type
and	O
mouse	B-cell_type
T	I-cell_type
cells	I-cell_type
respectively	O
.	O

Anti-Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
autoantibodies	I-protein
are	O
associated	O
with	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
beta	I-DNA
genes	I-DNA
in	O
systemic	O
lupus	O
erythematosus	O
patients	O
.	O

Several	O
of	O
the	O
heterogeneous	O
clinical	O
manifestations	O
of	O
systemic	O
lupus	O
erythematosus	O
have	O
been	O
associated	O
with	O
specific	O
autoantibodies	B-protein
.	O

Associations	O
between	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
and	O
autoantibodies	B-protein
to	O
the	O
ribonucleoproteins	B-protein
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
and	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
have	O
been	O
reported	O
in	O
these	O
patients	O
.	O

Because	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
present	O
antigen	O
to	O
T	B-protein
cell	I-protein
receptors	I-protein
(	O
TCRs	B-protein
)	O
,	O
we	O
have	O
searched	O
for	O
a	O
TCR	B-DNA
gene	I-DNA
associated	O
with	O
the	O
production	O
of	O
anti-Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
antibodies	I-protein
.	O

A	O
pair	O
of	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphisms	I-DNA
(	O
RFLPs	B-DNA
)	O
,	O
one	O
of	O
which	O
hybridizes	O
to	O
the	O
TCR	B-DNA
constant	I-DNA
region	I-DNA
C	I-DNA
beta	I-DNA
1	I-DNA
and	O
the	O
other	O
to	O
the	O
C	B-DNA
beta	I-DNA
2	I-DNA
gene	I-DNA
,	O
has	O
been	O
identified	O
,	O
suggesting	O
these	O
may	O
be	O
genotypic	O
markers	O
for	O
an	O
extended	O
region	O
of	O
the	O
TCR	B-DNA
beta	I-DNA
locus	I-DNA
.	O

This	O
RFLP	B-DNA
pair	I-DNA
occurs	O
in	O
76	O
%	O
of	O
patients	O
with	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
precipitins	O
,	O
84	O
%	O
of	O
anti-	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
-positive	O
patients	O
lacking	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
precipitins	B-protein
,	O
but	O
only	O
41	O
%	O
of	O
the	O
patients	O
lacking	O
both	O
precipitins	B-protein
(	O
P	O
=	O
0.0004	O
)	O
.	O

This	O
disproportionate	O
occurrence	O
in	O
a	O
subset	O
of	O
lupus	O
patients	O
indicates	O
that	O
these	O
RFLPs	B-DNA
are	O
not	O
disease	O
susceptibility	O
markers	O
,	O
but	O
rather	O
are	O
important	O
markers	O
for	O
TCR	B-DNA
genes	I-DNA
whose	O
products	O
are	O
involved	O
in	O
the	O
production	O
of	O
anti-Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
antibodies	I-protein
.	O

The	O
majority	O
of	O
patients	O
who	O
have	O
these	O
RFLPs	B-DNA
and	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
previously	O
associated	O
with	O
the	O
anti-	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
response	O
make	O
this	O
antibody	O
,	O
suggesting	O
that	O
interactions	O
between	O
products	O
of	O
these	O
loci	B-DNA
occur	I-DNA
in	O
response	O
to	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
.	O

Inhibition	O
of	O
NF-AT	B-protein
-dependent	O
transcription	O
by	O
NF-kappa	B-protein
B	I-protein
:	O
implications	O
for	O
differential	O
gene	O
expression	O
in	O
T	B-cell_type
helper	I-cell_type
cell	I-cell_type
subsets	I-cell_type
.	O

Activation	O
of	O
individual	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
results	O
in	O
differential	O
lymphokine	B-protein
expression	O
:	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
is	O
preferentially	O
produced	O
by	O
T	B-cell_line
helper	I-cell_line
type	I-cell_line
1	I-cell_line
(	I-cell_line
TH1	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
which	O
are	O
involved	O
in	O
cell-mediated	O
immune	O
responses	O
,	O
whereas	O
IL-4	B-protein
is	O
synthesized	O
by	O
TH2	B-cell_line
cells	I-cell_line
,	O
which	O
are	O
essential	O
for	O
humoral	O
immunity	O
.	O

The	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-dependent	I-protein
factor	I-protein
NF-ATp	B-protein
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
transcription	O
of	O
both	O
these	O
lymphokine	B-DNA
genes	I-DNA
.	O

However	O
,	O
while	O
IL2	B-protein
expression	O
requires	O
the	O
contribution	O
of	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
-dependent	O
signals	O
,	O
we	O
report	O
that	O
activation	O
of	O
human	B-protein
IL4	I-protein
transcription	O
through	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathway	O
is	O
diminished	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
stimulation	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

This	O
phenomenon	O
is	O
due	O
to	O
mutually	O
exclusive	O
binding	O
of	O
NF-ATp	B-protein
and	O
NF-kappa	B-protein
B	I-protein
to	O
the	O
P	B-DNA
sequence	I-DNA
,	O
an	O
element	O
located	O
69	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
IL4	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
.	O

Human	B-DNA
IL4	I-DNA
promoter	I-DNA
-mediated	O
transcription	O
is	O
downregulated	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
stimulated	O
with	O
the	O
NF-kappa	B-protein
B-activating	I-protein
cytokine	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
suppressed	O
in	O
RelA-overexpressing	B-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
,	O
protein	B-protein
kinase	I-protein
C	I-protein
stimulation	O
or	O
RelA	B-protein
overexpression	O
does	O
not	O
affect	O
the	O
activity	O
of	O
a	O
human	B-DNA
IL4	I-DNA
promoter	I-DNA
containing	O
a	O
mouse	B-DNA
P	I-DNA
sequence	I-DNA
,	O
which	O
is	O
a	O
higher-affinity	B-DNA
site	I-DNA
for	O
NF-ATp	B-protein
and	O
a	O
lower-affinity	B-DNA
site	I-DNA
for	O
RelA	B-protein
.	O

Thus	O
,	O
competition	O
between	O
two	O
general	O
transcriptional	B-protein
activators	I-protein
,	O
RelA	B-protein
and	O
NF-ATp	B-protein
,	O
mediates	O
the	O
inhibitory	O
effect	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
stimulation	O
on	O
IL4	B-protein
expression	O
and	O
may	O
contribute	O
to	O
differential	O
gene	O
expression	O
in	O
TH	B-cell_line
cells	I-cell_line
.	O

Regulation	O
of	O
the	O
balance	O
of	O
cytokine	B-protein
production	O
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	B-protein
)	O
transcription	O
factor	O
activity	O
by	O
cytokines	B-protein
and	O
inflammatory	O
synovial	O
fluids	O
.	O

The	O
balance	O
between	O
type	O
1	O
and	O
2	O
T	O
helper	O
cell	O
cytokine	O
production	O
plays	O
an	O
important	O
role	O
in	O
several	O
animal	O
models	O
of	O
autoimmunity	O
,	O
and	O
skewed	O
patterns	O
of	O
cytokine	B-protein
expression	O
have	O
been	O
described	O
in	O
human	O
inflammatory	O
diseases	O
.	O

Many	O
cytokines	B-protein
activate	O
signal	B-protein
transducer	I-protein
and	I-protein
activation	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
,	O
which	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
inflammatory	O
effector	O
genes	O
.	O

We	O
used	O
mononuclear	B-cell_line
cell	I-cell_line
priming	I-cell_line
cultures	I-cell_line
and	O
inflammatory	B-cell_type
synovial	I-cell_type
fluids	I-cell_type
(	O
SFs	B-cell_type
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	B-protein
production	O
and	O
STAT	B-protein
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O

Exposure	O
to	O
SFs	B-cell_type
during	O
priming	O
resulted	O
in	O
an	O
81	O
%	O
inhibition	O
of	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
,	O
but	O
not	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
4	I-protein
,	O
production	O
by	O
effector	B-cell_type
cells	I-cell_type
generated	O
in	O
priming	O
cultures	O
.	O

SF	O
suppression	O
was	O
mediated	O
by	O
IL-4	B-protein
and	O
IL-10	B-protein
and	O
inhibition	O
of	O
IL-12	B-protein
expression	O
,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL-12	O
.	O

SFs	B-cell_type
blocked	O
the	O
sustained	O
activity	O
of	O
transcription	B-protein
factor	I-protein
Stat1	I-protein
,	O
but	O
not	O
Stat3	B-protein
,	O
during	O
the	O
priming	O
period	O
,	O
and	O
Stat1	B-protein
activity	O
was	O
differentially	O
regulated	O
by	O
cytokines	B-protein
in	O
parallel	O
with	O
their	O
positive	O
or	O
negative	O
regulation	O
of	O
IFN-gamma	B-protein
production	O
.	O

Active	O
Stat3	B-protein
,	O
but	O
not	O
Stat1	B-protein
,	O
was	O
detected	O
in	O
cells	O
from	O
inflamed	O
joints	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
altered	O
balance	O
of	O
Stat1	O
and	O
Stat3	O
transcriptional	O
activity	O
in	O
the	O
regulation	O
of	O
T	B-cell_type
cell	I-cell_type
differentiation	O
and	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
synovitis	O
.	O

Triggering	O
of	O
complement	B-protein
receptors	I-protein
CR1	B-protein
(	O
CD35	B-protein
)	O
and	O
CR3	B-protein
(	O
CD11b/CD18	B-protein
)	O
induces	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
(	O
p50/p65	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Monocyte/macrophages	B-cell_type
may	O
harbor	O
HIV	O
in	O
a	O
nonproductive	O
fashion	O
for	O
prolonged	O
periods	O
of	O
time	O
.	O

Viral	O
gene	O
expression	O
may	O
be	O
reactivated	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
LPS	O
or	O
cytokines	B-protein
such	O
as	O
TNF-alpha	B-protein
in	O
vitro	O
.	O

The	O
effect	O
of	O
LPS	O
and	O
TNF-alpha	B-protein
is	O
mediated	O
by	O
their	O
ability	O
to	O
induce	O
nuclear	O
translocation	O
of	O
the	O
DNA-binding	B-protein
heterodimer	I-protein
NF-kappa	B-protein
B	I-protein
(	O
p50/p65	B-protein
)	O
,	O
which	O
binds	O
to	O
a	O
specific	O
sequence	O
in	O
the	O
HIV-long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O

The	O
present	O
study	O
demonstrates	O
that	O
triggering	O
of	O
complement	B-protein
receptors	I-protein
CR1	B-protein
(	O
CD35	B-protein
)	O
and	O
CR3	B-protein
(	O
CD11b/CD18	B-protein
)	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O

Monocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
normal	O
peripheral	O
blood	O
monocytes	O
were	O
infected	O
with	O
HIV-1	O
in	O
vitro	O
and	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
F	B-protein
(	I-protein
ab	I-protein
'	I-protein
)	I-protein
2	I-protein
fragments	I-protein
of	O
monoclonal	B-protein
anti-CR1	I-protein
or	O
anti-CR3	B-protein
Abs	I-protein
or	O
with	O
C3	B-protein
fragments	I-protein
.	O

Stimulation	O
of	O
CR1	B-protein
or	O
CR3	B-protein
induces	O
a	O
two-	O
to	O
fourfold	O
increase	O
in	O
the	O
amount	O
of	O
cell-associated	O
and	O
released	O
p24	B-protein
Ag	I-protein
in	O
cell	B-cell_line
cultures	I-cell_line
that	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
control	B-cell_line
cultures	I-cell_line
triggered	O
with	O
LPS	O
.	O

We	O
further	O
observed	O
that	O
stimulation	O
of	O
CR1	B-protein
or	O
CR3	B-protein
induces	O
the	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
p50/p65	B-protein
in	O
infected	B-cell_type
cells	I-cell_type
.	O

Translocation	O
of	O
NF-kappa	B-protein
B	I-protein
p50/p65	B-protein
was	O
also	O
observed	O
following	O
stimulation	O
of	O
CR1	B-protein
or	O
CR3	B-protein
of	O
uninfected	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
from	O
HIV-seronegative	O
donors	O
.	O

The	O
amount	O
of	O
protein	O
translocated	O
was	O
similar	O
to	O
that	O
observed	O
when	O
cells	O
were	O
stimulated	O
with	O
rhTNF-alpha	B-protein
.	O

TNF-alpha	B-protein
did	O
not	O
mediate	O
the	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
p50/p65	B-protein
induced	O
by	O
triggering	O
of	O
complement	B-protein
receptors	I-protein
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
HIV	O
gene	O
expression	O
may	O
be	O
activated	O
in	O
infected	B-cell_type
monocytes	I-cell_type
through	O
interaction	O
of	O
the	O
cells	O
with	O
complement-opsonized	B-protein
particles	I-protein
and	O
that	O
enhanced	O
viral	O
replication	O
is	O
associated	O
with	O
C3	B-protein
receptor	I-protein
-mediated	O
nuclear	O
translocation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
.	O

Attenuation	O
of	O
gamma	B-protein
interferon	I-protein
-induced	O
tyrosine	O
phosphorylation	O
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
infected	O
with	O
Leishmania	O
donovani	O
:	O
selective	O
inhibition	O
of	O
signaling	O
through	O
Janus	B-protein
kinases	I-protein
and	O
Stat1	B-protein
.	O

The	O
induction	O
of	O
gene	O
transcription	O
in	O
response	O
to	O
gamma	B-protein
interferon	I-protein
is	O
impaired	O
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
infected	O
with	O
Leishmania	O
donovani	O
,	O
and	O
the	O
mechanisms	O
involved	O
are	O
not	O
fully	O
understood	O
.	O

The	O
changes	O
in	O
gene	O
expression	O
brought	O
about	O
by	O
gamma	B-protein
interferon	I-protein
are	O
thought	O
to	O
involve	O
transient	O
increases	O
in	O
the	O
activities	O
of	O
cellular	B-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
,	O
including	O
the	O
Janus	B-protein
kinases	I-protein
Jak1	B-protein
and	O
Jak2	B-protein
,	O
leading	O
to	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B-protein
factor	I-protein
Stat1	I-protein
.	O

To	O
investigate	O
the	O
mechanisms	O
accounting	O
for	O
the	O
impaired	O
responses	O
to	O
gamma	B-protein
interferon	I-protein
,	O
a	O
model	O
system	O
for	O
examining	O
overall	O
changes	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
activation	O
of	O
Jak1	B-protein
and	O
Jak2	B-protein
and	O
phosphorylation	O
of	O
Stat1	B-protein
was	O
developed	O
in	O
phorbol	B-cell_line
12-myristate	I-cell_line
13-acetate-differentiated	I-cell_line
U-937	I-cell_line
cells	I-cell_line
.	O

Analysis	O
of	O
whole-cell	O
lysates	O
by	O
antiphosphotyrosine	O
immunoblotting	O
showed	O
that	O
incubation	O
with	O
gamma	B-protein
interferon	I-protein
brought	O
about	O
specific	O
increases	O
in	O
phosphotyrosine	O
labeling	O
of	O
several	O
proteins	O
.	O

Increased	O
labeling	O
of	O
these	O
proteins	O
occurred	O
to	O
similar	O
extents	O
in	O
control	B-cell_type
cells	I-cell_type
and	O
in	O
cells	O
that	O
had	O
been	O
infected	O
with	O
L.	O
donovani	O
for	O
16	O
h	O
.	O

Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1	B-protein
were	O
immunoprecipitated	O
from	O
control	O
and	O
interferon-treated	B-cell_line
cells	I-cell_line
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
these	O
proteins	O
,	O
detected	O
by	O
antiphosphotyrosine	O
immunoblotting	O
was	O
used	O
to	O
measured	O
their	O
activation	O
.	O

Tyrosine	O
phosphorylation	O
of	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1	B-protein
increased	O
markedly	O
,	O
in	O
a	O
dose-dependent	O
manner	O
,	O
in	O
U-937	B-cell_line
cells	I-cell_line
incubated	O
with	O
gamma	B-protein
interferon	I-protein
.	O

In	O
contrast	O
,	O
in	O
cells	O
infected	O
with	O
L.	O
donovani	O
,	O
tyrosine	O
phosphorylation	O
of	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1	B-protein
was	O
markedly	O
impaired	O
.	O

This	O
effect	O
was	O
dependent	O
upon	O
the	O
duration	O
of	O
exposure	O
to	O
L.	O
donovani	O
and	O
was	O
maximal	O
and	O
complete	O
at	O
16	O
h	O
.	O

Results	O
similar	O
to	O
those	O
observed	O
with	O
U-937	B-cell_line
cells	I-cell_line
were	O
also	O
obtained	O
with	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

These	O
findings	O
indicate	O
that	O
infection	O
of	O
human	B-cell_type
mononuclear	I-cell_type
phagocytes	I-cell_type
with	O
L.	O
donovani	O
leads	O
to	O
impaired	O
gamma	B-protein
interferon	I-protein
-mediated	O
tyrosine	O
phosphorylation	O
and	O
selective	O
effects	O
on	O
the	O
Jak-	O
Stat1	B-protein
pathway	O
.	O

Unresponsiveness	O
to	O
gamma	B-protein
interferon	I-protein
for	O
activation	O
of	O
this	O
pathway	O
may	O
explain	O
impaired	O
transcriptional	O
responses	O
in	O
leishmania-infected	B-cell_type
cells	I-cell_type
.	O

Mutually	O
exclusive	O
interaction	O
of	O
a	O
novel	O
matrix	B-protein
attachment	I-protein
region	I-protein
binding	I-protein
protein	I-protein
and	O
the	O
NF-muNR	B-protein
enhancer	I-protein
repressor	I-protein
.	O

Implications	O
for	O
regulation	O
of	O
immunoglobulin	B-protein
heavy	I-protein
chain	I-protein
expression	O
.	O

The	O
immunoglobulin	B-protein
heavy	I-protein
chain	I-protein
(	O
IgH	B-protein
)	O
intronic	O
enhancer	O
stimulates	O
transcription	O
from	O
functional	O
promoters	O
in	O
B	O
lymphocytes	O
but	O
not	O
other	O
cell	O
types	O
.	O

The	O
observation	O
that	O
binding	O
sites	O
for	O
the	O
nuclear	B-protein
factor-mu	I-protein
negative	I-protein
regulator	I-protein
(	I-protein
NF-muNR	I-protein
)	I-protein
enhancer	I-protein
repressor	I-protein
overlap	I-protein
nuclear	I-protein
matrix	I-protein
attachment	I-protein
regions	I-protein
(	O
MARs	B-protein
)	O
in	O
this	O
enhancer	B-DNA
has	O
lead	O
to	O
the	O
hypothesis	O
that	O
the	O
cell	O
type	O
specificity	O
of	O
the	O
enhancer	B-DNA
might	O
be	O
controlled	O
by	O
regulating	O
nuclear	O
matrix	O
attachment	O
(	O
Scheuermann	O
,	O
R.	O
H.	O
,	O
and	O
Chen	O
,	O
U.	O
(	O
1989	O
)	O
Genes	O
&	O
Dev.	O
3	O
,	O
1255-1266	O
)	O
.	O

To	O
understand	O
the	O
role	O
of	O
MARs	B-protein
in	O
IgH	B-DNA
enhancer	I-DNA
regulation	O
,	O
we	O
have	O
identified	O
a	O
novel	O
MAR-binding	B-protein
protein	I-protein
,	O
MAR-BP1	B-protein
,	O
from	O
soluble	O
nuclear	O
matrix	O
preparations	O
based	O
on	O
its	O
ability	O
to	O
bind	O
to	O
the	O
MARs	B-protein
associated	O
with	O
the	O
IgH	B-DNA
enhancer	I-DNA
.	O

Purified	O
MAR-BP1	B-protein
migrates	O
as	O
a	O
33-kDa	B-protein
protein	I-protein
,	O
and	O
it	O
can	O
be	O
found	O
in	O
nuclear	O
matrix	O
preparations	O
from	O
a	O
number	O
of	O
different	O
types	O
of	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Although	O
specific	O
binding	O
sites	O
have	O
been	O
difficult	O
to	O
localize	O
by	O
chemical	O
or	O
enzymatic	O
footprinting	O
procedures	O
,	O
NF-muNR	B-protein
binding	O
sites	O
are	O
critical	O
for	O
efficient	O
MAR-BP1	B-protein
binding	O
.	O

Indeed	O
,	O
binding	O
of	O
the	O
IgH	B-DNA
enhancer	I-DNA
to	O
either	O
intact	O
nuclear	O
matrix	O
preparations	O
or	O
to	O
MAR-BP1	B-protein
is	O
mutually	O
exclusive	O
to	O
NF-muNR	B-protein
binding	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
model	O
for	O
cell-type	O
specific	O
regulation	O
in	O
which	O
binding	O
of	O
the	O
NF-muNR	B-protein
repressor	I-protein
to	O
the	O
IgH	B-DNA
enhancer	I-DNA
prevents	O
nuclear	O
matrix	O
attachment	O
in	O
inappropriate	O
cells	O
by	O
interfering	O
with	O
MAR-BP1	B-protein
/enhancer	B-DNA
interaction	O
.	O

PU.1	B-protein
(	O
Spi-1	B-protein
)	O
and	O
C/EBP	B-protein
alpha	I-protein
regulate	O
expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

Growth	B-protein
factor	I-protein
receptors	I-protein
play	O
an	O
important	O
role	O
in	O
hematopoiesis	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
mechanisms	O
directing	O
the	O
expression	O
of	O
these	O
key	O
regulators	O
of	O
hematopoiesis	O
,	O
we	O
initiated	O
a	O
study	O
investigating	O
the	O
transcription	B-protein
factors	I-protein
activating	O
the	O
expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
GM-CSF	I-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
directs	O
reporter	B-DNA
gene	I-DNA
activity	O
in	O
a	O
tissue-specific	O
fashion	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
,	O
which	O
correlates	O
with	O
its	O
expression	O
pattern	O
as	O
analyzed	O
by	O
reverse	O
transcription	O
PCR	O
.	O

The	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
contains	O
an	O
important	O
functional	O
site	O
between	O
positions	O
-53	O
and	O
-41	O
as	O
identified	O
by	O
deletion	O
analysis	O
of	O
reporter	B-DNA
constructs	I-DNA
.	O

We	O
show	O
that	O
the	O
myeloid	O
and	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
binds	O
specifically	O
to	O
this	O
site	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
a	O
CCAAT	B-DNA
site	I-DNA
located	O
upstream	O
of	O
the	O
PU.1	B-DNA
site	I-DNA
between	O
positions	O
-70	O
and	O
-54	O
is	O
involved	O
in	O
positive-negative	O
regulation	O
of	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
.	O

C/EBP	B-protein
alpha	I-protein
is	O
the	O
major	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	O
C/EBP	B-protein
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O

Point	O
mutations	O
of	O
either	O
the	O
PU.1	B-DNA
site	I-DNA
or	O
the	O
C/EBP	B-DNA
site	I-DNA
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
only	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
in	O
myeloid	O
and	O
B	O
cell	O
extracts	O
,	O
PU.1	B-protein
forms	O
a	O
novel	O
,	O
specific	O
,	O
more	O
slowly	O
migrating	O
complex	O
(	O
PU-SF	B-protein
)	O
when	O
binding	O
the	O
GM-CSF	B-protein
receptor	I-protein
alpha	I-protein
promoter	O
PU.1	B-DNA
site	I-DNA
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
specific	O
interaction	O
with	O
PU.1	B-protein
on	O
a	O
myeloid	B-DNA
PU.1	I-DNA
binding	I-DNA
site	I-DNA
.	O

The	O
novel	O
complex	O
is	O
distinct	O
from	O
that	O
described	O
previously	O
as	O
binding	O
to	O
B	B-DNA
cell	I-DNA
enhancer	I-DNA
sites	I-DNA
and	O
can	O
be	O
formed	O
by	O
addition	O
of	O
PU.1	B-protein
to	O
extracts	O
from	O
certain	O
nonmyeloid	B-cell_type
cell	I-cell_type
types	I-cell_type
which	O
do	O
not	O
express	O
PU.1	B-protein
,	O
including	O
T	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
from	O
erythroid	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
PU-SF	B-protein
complex	I-protein
binds	O
to	O
PU.1	B-protein
sites	O
found	O
on	O
a	O
number	O
of	O
myeloid	B-DNA
promoters	I-DNA
,	O
and	O
its	O
formation	O
requires	O
an	O
intact	O
PU.1	B-DNA
site	I-DNA
adjacent	O
to	O
a	O
single-stranded	O
region	O
.	O

Expression	O
of	O
PU.1	B-protein
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
can	O
activate	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Deletion	O
of	O
the	O
amino-terminal	B-protein
region	I-protein
of	O
PU.1	B-protein
results	O
in	O
a	O
failure	O
to	O
form	O
the	O
PU-SF	B-protein
complex	O
and	O
in	O
a	O
concomitant	O
loss	O
of	O
transactivation	O
,	O
suggesting	O
that	O
formation	O
of	O
the	O
PU-SF	B-protein
complex	I-protein
is	O
of	O
functional	O
importance	O
for	O
the	O
activity	O
of	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
C/EBP	B-protein
alpha	I-protein
can	O
also	O
active	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

HMG-I	B-protein
binds	O
to	O
GATA	B-DNA
motifs	I-DNA
:	O
implications	O
for	O
an	O
HPFH	O
syndrome	O
.	O

We	O
have	O
examined	O
binding	O
of	O
the	O
nuclear	B-protein
protein	I-protein
HMG-I	B-protein
to	O
the	O
human	B-DNA
gamma-globin	I-DNA
promoter	I-DNA
.	O

We	O
find	O
that	O
HMG-I	B-protein
binds	O
preferentially	O
to	O
the	O
more	O
3	O
'	O
of	O
a	O
pair	O
of	O
GATA	B-DNA
motifs	I-DNA
in	O
the	O
gamma-globin	B-DNA
promoter	I-DNA
;	O
this	O
paired	O
motif	O
is	O
bound	O
by	O
the	O
erythroid	B-protein
factor	I-protein
GATA-1	I-protein
.	O

A	O
naturally	O
occurring	O
mutation	O
(	O
-175	O
T-C	O
)	O
in	O
the	O
area	O
bound	O
by	O
HMG-I	B-protein
results	O
in	O
overexpression	O
of	O
gamma-globin	B-protein
in	O
adult	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	I-cell_type
(	O
HPFH	B-cell_type
)	O
and	O
up-regulation	O
of	O
the	O
gamma-globin	B-DNA
promoter	I-DNA
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG-I	B-protein
does	O
not	O
bind	O
to	O
this	O
mutant	B-DNA
sequence	I-DNA
.	O

A	O
survey	O
of	O
GATA	B-DNA
motifs	I-DNA
from	O
other	O
globin	B-DNA
cis-elements	I-DNA
demonstrates	O
HMG-I	B-protein
binding	O
to	O
most	O
of	O
them	O
.	O

These	O
findings	O
implicate	O
HMG-I	B-protein
in	O
the	O
HPFH	B-cell_type
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	B-protein
complexes	I-protein
that	O
regulate	O
globin	O
gene	O
expression	O
.	O

Constitutive	O
activation	O
of	O
different	O
Jak	B-protein
tyrosine	I-protein
kinases	I-protein
in	O
human	B-protein
T	I-protein
cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
tax	I-protein
protein	I-protein
or	O
virus-transformed	B-cell_line
cells	I-cell_line
.	O

HTLV-1	O
infection	O
causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O

The	O
viral	B-protein
encoded	I-protein
protein	I-protein
tax	B-protein
,	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
oncogenesis	O
.	O

Our	O
previous	O
data	O
obtained	O
from	O
a	O
tax	B-protein
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	B-protein
transforms	O
mouse	B-cell_type
fibroblasts	I-cell_type
but	O
not	O
thymocytes	B-cell_type
,	O
despite	O
comparable	O
levels	O
of	O
tax	B-protein
expression	O
in	O
both	O
tissues	O
.	O

Constitutive	O
tyrosine	O
phosphorylation	O
of	O
a	O
130-kD	B-protein
protein	I-protein
(	O
s	O
)	O
was	O
observed	O
in	O
the	O
tax	B-protein
transformed	B-cell_line
fibroblast	I-cell_line
B	I-cell_line
line	I-cell_line
and	O
in	O
HTLV-1	B-cell_line
transformed	I-cell_line
human	I-cell_line
lymphoid	I-cell_line
lines	I-cell_line
,	O
but	O
not	O
in	O
thymocytes	B-cell_type
from	O
Thy-tax	O
transgenic	O
mice	O
.	O

Phosphotyrosine	O
immunoprecipitation	O
followed	O
by	O
Western	O
blot	O
analysis	O
with	O
a	O
set	O
of	O
Jak	B-protein
kinase	I-protein
specific	I-protein
antibodies	I-protein
,	O
identified	O
p130	O
as	O
Jak2	B-protein
in	O
the	O
tax	B-protein
transformed	O
mouse	B-cell_line
fibroblastic	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
Jak3	B-protein
in	O
HTLV-1	B-cell_line
transformed	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Phosphorylation	O
of	O
Jak2	B-protein
in	O
tax	B-cell_line
transformed	I-cell_line
cells	I-cell_line
resulted	O
from	O
high	O
expression	O
of	O
IL-6	O
.	O

Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O
in	O
Balb/c3T3	B-cell_line
cells	I-cell_line
using	O
a	O
supernatant	O
from	O
the	O
B	B-cell_line
line	I-cell_line
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O

Both	O
phosphorylation	O
and	O
proliferation	O
were	O
inhibited	O
by	O
IL-6	B-protein
neutralizing	I-protein
antibodies	I-protein
.	O

Constitutive	O
phosphorylation	O
of	O
Jak	B-protein
kinases	I-protein
may	O
facilitate	O
tumor	O
growth	O
in	O
both	O
HTLV-1	B-cell_type
infected	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
the	O
transgenic	O
mouse	O
model	O
.	O

Regulation	O
of	O
c-jun	B-RNA
mRNA	I-RNA
expression	O
by	O
hydroxyurea	O
in	O
human	B-cell_line
K562	I-cell_line
cells	I-cell_line
during	O
erythroid	O
differentiation	O
[	O
published	O
erratum	O
appears	O
in	O
Biochim	O
Biophys	O
Acta	O
1995	O
Dec	O
27	O
;	O
1264	O
(	O
3	O
)	O
:	O
409	O
]	O

Hydroxyurea	O
(	O
HU	O
)	O
is	O
an	O
antitumor	O
agent	O
which	O
also	O
induces	O
hemoglobinization	O
during	O
erythroid	O
differentiation	O
.	O

In	O
addition	O
,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	B-protein
hemoglobin	I-protein
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O

To	O
further	O
understand	O
its	O
mechanism	O
of	O
action	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
HU	O
on	O
regulation	O
of	O
c-jun	B-DNA
expression	O
prior	O
to	O
the	O
onset	O
of	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
.	O

HU	O
induced	O
a	O
dose-dependent	O
stimulation	O
of	O
c-jun	B-DNA
synthesis	O
.	O

The	O
levels	O
of	O
c-jun	B-RNA
mRNA	I-RNA
was	O
elevated	O
4	O
to	O
7.5-fold	O
by	O
HU	O
within	O
2	O
h	O
.	O

This	O
was	O
followed	O
by	O
a	O
gradual	O
decline	O
to	O
the	O
basal	O
level	O
by	O
24	O
h	O
.	O

Both	O
nuclear	O
run-on	O
and	O
actinomycin	O
D	O
pulse	O
experiments	O
strongly	O
indicate	O
that	O
HU	O
regulates	O
c-jun	B-RNA
mRNA	I-RNA
expression	O
by	O
increasing	O
the	O
rate	O
of	O
synthesis	O
as	O
well	O
as	O
stabilizing	O
the	O
c-jun	B-RNA
mRNA	I-RNA
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
jun	B-protein
protein	I-protein
was	O
elevated	O
by	O
2	O
to	O
5-fold	O
within	O
4	O
h	O
in	O
HU	B-cell_line
treated	I-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
concentrations	O
of	O
HU	O
below	O
250	O
microM	O
slightly	O
increased	O
the	O
5X	O
AP-1	B-protein
/CAT	B-protein
activity	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
HU	O
induces	O
both	O
transcriptional	O
and	O
post-transcription	O
regulation	O
of	O
c-jun	B-DNA
during	O
erythroid	O
differentiation	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	O
proliferation	O
in	O
man	O
:	O
relationship	O
to	O
glucocorticoid	B-protein
receptors	I-protein
.	O

Interrelations	O
between	O
the	O
hypothalamic-pituitary-adrenal	O
system	O
(	O
HPA	O
)	O
and	O
the	O
immune	O
system	O
represent	O
a	O
well-documented	O
biological	O
phenomenon	O
.	O

While	O
in	O
vitro	O
administration	O
of	O
glucocorticoids	O
may	O
inhibit	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
-	O
and	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-induced	O
T-cell	O
proliferation	O
,	O
pokeweed	B-protein
mitogen	I-protein
(	O
PWM	B-protein
)	O
-driven	O
B-cell	O
mitogenesis	O
is	O
relatively	O
resistant	O
to	O
glucocorticoids	O
.	O

To	O
further	O
explore	O
the	O
link	O
between	O
the	O
HPA	O
and	O
the	O
immune	O
system	O
in	O
relation	O
to	O
glucocorticoid	B-protein
receptor	I-protein
function	O
,	O
dose-response	O
curves	O
were	O
obtained	O
for	O
Con	O
A	O
-and	O
PHA	B-protein
-induced	O
T-cell	O
mitogenesis	O
,	O
PWM	B-protein
-generated	O
B-cell	O
mitogenesis	O
and	O
spontaneous	O
lymphocyte	O
proliferation	O
in	O
13	O
healthy	O
controls	O
.	O

Glucocorticoid	O
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
PWM	B-protein
-induced	O
B-cell	O
mitogenesis	O
and	O
a	O
more	O
pronounced	O
effect	O
of	O
DEX	O
administered	O
in	O
vitro	O
on	O
spontaneous	O
lymphocyte	O
proliferation	O
after	O
MET	O
treatment	O
when	O
compared	O
with	O
the	O
DEX	O
plus	O
MET	O
pretreated	O
condition	O
in	O
vivo	O
.	O

These	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
spontaneous	O
lymphocyte	O
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
is	O
related	O
to	O
glucocorticoid	B-protein
receptor	I-protein
function	O
.	O

The	O
decrease	O
in	O
PWM	B-protein
-generated	O
B-cell	O
proliferation	O
following	O
cortisol	O
depletion	O
by	O
MET	O
may	O
be	O
seen	O
in	O
connection	O
with	O
impaired	O
glucocorticoid-mediated	O
induction	O
of	O
interleukin-1	B-protein
receptor	I-protein
synthesis	O
.	O

Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O

Application	O
of	O
a	O
``	O
formamide	O
free	O
''	O
and	O
thus	O
``	O
material	O
preserving	O
''	O
in	O
situ	O
hybridization	O
technique	O
using	O
the	O
cDNA	B-DNA
of	O
the	O
myf3	B-DNA
gene	I-DNA
revealed	O
the	O
following	O
results	O
:	O
Human	B-cell_type
rhabdomyosarcoma	I-cell_type
cells	I-cell_type
,	O
characterized	O
by	O
a	O
high	O
expression	O
of	O
myf3	B-DNA
show	O
intensive	O
hybridization	O
signals	O
in	O
their	O
interphase	O
.	O

RNase	B-protein
treatment	O
prior	O
to	O
hybridization	O
considerably	O
reduces	O
the	O
size	O
of	O
this	O
signals	O
.	O

In	O
comparison	O
,	O
isolated	O
nuclei	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
in	O
which	O
no	O
need	O
for	O
the	O
expression	O
of	O
this	O
gene	O
exists	O
,	O
show	O
barely	O
hybridization	O
signals	O
.	O

Correspondingly	O
,	O
RNase	B-protein
treatment	O
had	O
no	O
effect	O
on	O
hybridization	O
pattern	O
at	O
all	O
.	O

In	O
conclusion	O
an	O
increased	O
transcription	O
efficiency	O
of	O
a	O
cell	O
type	O
specific	O
gene	O
is	O
accompanied	O
by	O
a	O
higher	O
hybridization	O
accessibility	O
in	O
the	O
corresponding	O
cell	O
nuclei	O
.	O

Oncogenicity	O
of	O
human	B-cell_line
papillomavirus-	I-cell_line
or	I-cell_line
adenovirus-transformed	I-cell_line
cells	I-cell_line
correlates	O
with	O
resistance	O
to	O
lysis	O
by	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

The	O
reasons	O
for	O
the	O
dissimilar	O
oncogenicities	O
of	O
human	O
adenoviruses	O
and	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
in	O
humans	O
are	O
unknown	O
but	O
may	O
relate	O
to	O
differences	O
in	O
the	O
capacities	O
of	O
the	O
E1A	B-protein
and	O
E7	B-protein
proteins	I-protein
to	O
target	B-cell_type
cells	I-cell_type
for	O
rejection	O
by	O
the	O
host	B-cell_type
natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
response	O
.	O

As	O
one	O
test	O
of	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
E1A	B-protein
-and	O
E7	B-protein
-expressing	O
human	B-cell_line
fibroblastic	I-cell_line
or	I-cell_line
keratinocyte-derived	I-cell_line
human	I-cell_line
cells	I-cell_line
to	O
be	O
selectively	O
killed	O
by	O
either	O
unstimulated	B-cell_type
or	O
interferon	B-cell_line
(	I-cell_line
IFN	I-cell_line
)	I-cell_line
-activated	I-cell_line
NK	I-cell_line
cells	I-cell_line
.	O

Cells	O
expressing	O
the	O
E1A	B-protein
oncoprotein	I-protein
were	O
selectively	O
killed	O
by	O
unstimulated	B-cell_line
NK	I-cell_line
cells	I-cell_line
,	O
while	O
the	O
same	O
parental	B-cell_type
cells	I-cell_type
but	O
expressing	O
the	O
HPV	O
type	O
16	O
(	O
HPV-16	O
)	O
or	O
HPV-18	O
E7	B-protein
oncoprotein	I-protein
were	O
resistant	O
to	O
NK	O
cell	O
lysis	O
.	O

The	O
ability	O
of	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	I-cell_line
to	O
selectively	O
kill	O
virally	O
transformed	O
cells	O
depends	O
on	O
IFN	B-protein
's	O
ability	O
to	O
induce	O
resistance	O
to	O
NK	O
cell	O
lysis	O
in	O
normal	O
(	O
i.e.	O
,	O
non-viral	B-cell_line
oncogene-expressing	I-cell_line
)	O
but	O
not	O
virally	B-cell_line
transformed	I-cell_line
cells	I-cell_line
.	O

E1A	B-protein
blocked	O
IFN	B-protein
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
resulting	O
in	O
the	O
selective	O
lysis	O
of	O
adenovirus-transformed	B-cell_line
cells	I-cell_line
by	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	I-cell_line
.	O

The	O
extent	O
of	O
IFN	B-protein
-induced	O
NK	O
cell	O
killing	O
of	O
E1A-expressing	B-cell_line
cells	I-cell_line
was	O
proportional	O
to	O
the	O
level	O
of	O
E1A	B-protein
expression	O
and	O
correlated	O
with	O
the	O
ability	O
of	O
E1A	B-protein
to	O
block	O
IFN	B-protein
-stimulated	O
gene	O
expression	O
in	O
target	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
E7	B-protein
blocked	O
neither	O
IFN	B-protein
-stimulated	O
gene	O
expression	O
nor	O
IFN	B-protein
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
thereby	O
precluding	O
the	O
selective	O
lysis	O
of	O
HPV-transformed	B-cell_line
cells	I-cell_line
by	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	I-cell_line
.	O

In	O
conclusion	O
,	O
E1A	B-protein
expression	O
marks	O
cells	O
for	O
destruction	O
by	O
the	O
host	O
NK	B-cell_type
cell	I-cell_type
response	O
,	O
whereas	O
the	O
E7	B-protein
oncoprotein	I-protein
lacks	O
this	O
activity	O
.	O

Regulation	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
by	O
PKC-	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal	O
transduction	O
pathways	O
.	O

The	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-dependent	I-protein
phosphatase	I-protein
calcineurin	B-protein
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O
,	O
synergizes	O
with	O
PKC	B-protein
-induced	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
two	O
pathways	O
lead	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

While	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
,	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
calcineurin	B-protein
is	O
also	O
sufficient	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
.	O

Having	O
previously	O
shown	O
that	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
PKC-dependent	O
pathways	O
synergize	O
by	O
accelerating	O
the	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
.	O

While	O
PKC	B-protein
-dependent	O
pathways	O
sequentially	O
result	O
in	O
the	O
phosphorylation	O
and	O
in	O
an	O
incomplete	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
co-activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
accelerates	O
the	O
rate	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
and	O
results	O
in	O
its	O
complete	O
degradation	O
.	O

Activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
alone	O
do	O
not	O
result	O
in	O
the	O
phosphorylation	O
and/or	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
or	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

Treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
the	O
selective	O
PKC	B-protein
inhibitor	O
GF109203X	O
abrogates	O
the	O
PMA-induced	O
IkB	B-protein
alpha	I-protein
phosphorylation/degradation	O
irrespective	O
of	O
activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O
but	O
not	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
induced	O
by	O
TNF-alpha	B-protein
,	O
a	O
PKC	B-protein
-independent	O
stimulus	O
.	O

Contrary	O
to	O
the	O
interaction	O
with	O
PKC	B-protein
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
synergize	O
with	O
TNF-alpha	B-protein
not	O
at	O
the	O
level	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	O
.	O

These	O
results	O
indicate	O
that	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	B-protein
calcineurin	B-protein
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	O
with	O
PKC	B-protein
-dependent	O
and	O
-independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
and	O
degradation	O
.	O

Vitamin	O
E	O
therapy	O
of	O
acute	O
CCl4-induced	O
hepatic	O
injury	O
in	O
mice	O
is	O
associated	O
with	O
inhibition	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
binding	O
.	O

Oxidative	O
stress	O
,	O
with	O
reactive	O
oxygen	O
intermediate	O
formation	O
,	O
may	O
represent	O
a	O
common	O
mechanism	O
by	O
which	O
liver	O
injury	O
is	O
induced	O
by	O
diverse	O
etiologies	O
.	O

Oxidative	O
stress	O
enhances	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activity	O
,	O
and	O
NF-kappa	B-protein
B	I-protein
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	B-protein
cytokines	I-protein
.	O

Acute	O
hepatic	O
injury	O
caused	O
by	O
reactive	O
oxygen	O
intermediate	O
production	O
was	O
induced	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
CCl4	O
in	O
mice	O
.	O

This	O
injury	O
was	O
significantly	O
inhibited	O
by	O
intravenous	O
pretreatment	O
of	O
the	O
mice	O
with	O
a	O
water-soluble	O
emulsion	O
of	O
alpha-tocopherol	O
.	O

Alpha-tocopherol	O
treatment	O
of	O
the	O
mice	O
given	O
the	O
CCl4	O
also	O
reduced	O
the	O
NF-kappa	B-protein
B	I-protein
binding	O
to	O
levels	O
approaching	O
those	O
found	O
in	O
normal	O
mice	O
.	O

In	O
vitro	O
treatment	O
of	O
a	O
monocyte/macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	O
and	O
an	O
increase	O
in	O
tumor	B-RNA
necrosis	I-RNA
factor-alpha	I-RNA
(	I-RNA
TNF-alpha	I-RNA
)	I-RNA
messenger	I-RNA
RNA	I-RNA
levels	O
.	O

Liver	O
specimens	O
taken	O
from	O
patients	O
with	O
acute	O
fulminant	O
hepatitis	O
had	O
markedly	O
increased	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
comparison	O
with	O
the	O
binding	O
of	O
normal	O
livers	O
.	O

These	O
data	O
demonstrate	O
that	O
abolishing	O
acute	O
hepatic	O
injury	O
with	O
alpha-tocopherol	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
also	O
eliminated	O
increased	O
NF-kappa	B-protein
B	I-protein
binding	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
enhanced	O
NF-kappa	B-protein
B	I-protein
expression	O
caused	O
by	O
free	O
radical	O
production/oxidative	O
stress	O
may	O
modulate	O
liver	O
injury	O
,	O
perhaps	O
through	O
an	O
effect	O
on	O
cytotoxic	B-protein
cytokine	I-protein
synthesis	O
.	O

Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
through	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
synthesis	O
[	O
see	O
comments	O
]	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
anti-inflammatory	O
and	O
immunosuppressive	O
agents	O
.	O

They	O
inhibit	O
synthesis	O
of	O
almost	O
all	O
known	O
cytokines	B-protein
and	O
of	O
several	O
cell	B-protein
surface	I-protein
molecules	I-protein
required	O
for	O
immune	O
function	O
,	O
but	O
the	O
mechanism	O
underlying	O
this	O
activity	O
has	O
been	O
unclear.	O
Here	O
it	O
is	O
shown	O
that	O
glucocorticoids	O
are	O
potent	O
inhibitors	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
in	O
mice	O
and	O
cultured	B-cell_line
cells	I-cell_line
.	O

This	O
inhibition	O
is	O
mediated	O
by	O
induction	O
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
inhibitory	O
protein	O
,	O
which	O
traps	O
activated	O
NF-kappa	B-protein
B	I-protein
in	O
inactive	B-protein
cytoplasmic	I-protein
complexes	I-protein
.	O

Because	O
NF-kappa	B-protein
B	I-protein
activates	O
many	O
immunoregulatory	B-DNA
genes	I-DNA
in	O
response	O
to	O
pro-inflammatory	O
stimuli	O
,	O
the	O
inhibition	O
of	O
its	O
activity	O
can	O
be	O
a	O
major	O
component	O
of	O
the	O
anti-inflammatory	O
activity	O
of	O
glucocorticoids	O
.	O

Transcriptional	O
repression	O
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp/AP-1	B-protein
complex	I-protein
formation	O
by	O
a	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
.	O

T-lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
and	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
gamma	O
interferon	O
,	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
mRNA	O
levels	O
.	O

We	O
report	O
here	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL-2	B-protein
expression	O
by	O
the	O
vitamin	B-protein
D3	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O

We	O
therefore	O
examined	O
vitamin	O
D3-mediated	O
repression	O
of	O
activated	O
IL-2	B-protein
expression	O
by	O
cotransfecting	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
IL-2	B-DNA
promoter/reporter	I-DNA
constructs	I-DNA
and	O
a	O
VDR	B-DNA
overexpression	I-DNA
vector	I-DNA
and	O
by	O
DNA	O
binding	O
.	O

We	O
delineated	O
an	O
element	O
conferring	O
both	O
DNA	O
binding	O
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40-bp	B-DNA
region	I-DNA
encompassing	O
an	O
important	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
,	O
NF-AT-1	B-DNA
,	O
which	O
is	O
bound	O
by	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
NFATp	B-protein
,	O
as	O
well	O
as	O
by	O
AP-1	B-protein
.	O

VDR	B-protein
DNA-binding	I-protein
mutants	I-protein
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	O
in	O
vivo	O
;	O
the	O
VDR	B-protein
DNA-binding	I-protein
domain	I-protein
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	O
IL-2	B-protein
expression	O
.	O

These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	B-protein
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL-2	B-protein
repression	O
.	O

By	O
combining	O
partially	B-protein
purified	I-protein
proteins	I-protein
in	O
vitro	O
,	O
we	O
observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp/AP-1-DNA	B-protein
complex	I-protein
upon	O
inclusion	O
of	O
VDR	B-protein
or	O
VDR-retinoid	B-protein
X	I-protein
receptor	I-protein
.	O

Order	O
of	O
addition	O
and	O
off-rate	O
experiments	O
indicate	O
that	O
the	O
VDR-retinoid	B-protein
X	I-protein
receptor	I-protein
heterodimer	I-protein
blocks	O
NFATp/AP-1	B-protein
complex	I-protein
formation	O
and	O
then	O
stably	O
associates	O
with	O
the	O
NF-AT-1	B-DNA
element	I-DNA
.	O

This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	B-protein
activators	I-protein
of	O
the	O
IL-2	B-DNA
gene	I-DNA
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O

Tissue-specific	O
regulation	O
of	O
the	O
rabbit	B-DNA
15-lipoxygenase	I-DNA
gene	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
by	O
a	O
transcriptional	B-DNA
silencer	I-DNA
.	O

The	O
15-lipoxygenase	B-DNA
(	I-DNA
lox	I-DNA
)	I-DNA
gene	I-DNA
is	O
expressed	O
in	O
a	O
tissue-specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	B-cell_type
cells	I-cell_type
but	O
also	O
in	O
airway	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
and	O
eosinophils	B-cell_type
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
of	O
the	O
15-lox	B-DNA
gene	I-DNA
contains	O
sequences	O
which	O
down-regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non-erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
but	O
not	O
in	O
two	O
erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	B-DNA
'silencer	I-DNA
'	I-DNA
since	O
it	O
functions	O
in	O
both	O
orientations	O
.	O

The	O
main	O
activity	O
of	O
the	O
silencer	B-DNA
has	O
been	O
mapped	O
to	O
the	O
first	O
900	O
bp	O
of	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
,	O
which	O
contains	O
nine	O
binding	O
sites	O
for	O
a	O
nuclear	B-protein
factor	I-protein
present	O
in	O
non-	O
erythroid	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	B-DNA
sites	I-DNA
confer	O
tissue-specific	O
down-regulation	O
when	O
attached	O
to	O
a	O
minimal	B-DNA
lox	I-DNA
promoter	I-DNA
fragment	I-DNA
.	O

The	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	B-DNA
sites	I-DNA
for	O
the	O
GATA	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Phosphorylation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NFATp	B-protein
inhibits	O
its	O
DNA	O
binding	O
activity	O
in	O
cyclosporin	B-cell_line
A-treated	I-cell_line
human	I-cell_line
B	I-cell_line
and	O
T	B-cell_type
cells	I-cell_type
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
exerts	O
its	O
immunosuppressive	O
effect	O
by	O
inhibiting	O
the	O
activity	O
of	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	B-cell_type
cells	I-cell_type
(	O
NFAT	B-protein
)	O
,	O
thus	O
preventing	O
transcriptional	O
induction	O
of	O
several	O
cytokine	O
genes	O
.	O

This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	O
calcineurin	B-protein
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	B-protein
component	O
to	O
the	O
nucleus	O
.	O

Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	B-cell_line
B	I-cell_line
and	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	B-protein
that	O
is	O
inhibited	O
in	O
DNA-binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
.	O

Immunoblot	O
analyses	O
and	O
metabolic	O
labeling	O
with	O
[	O
32P	O
]	O
orthophosphate	O
show	O
that	O
CsA	O
alters	O
NFATp	B-protein
migration	O
on	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
by	O
increasing	O
its	O
phosphorylation	O
level	O
without	O
affecting	O
subcellular	O
distribution	O
.	O

Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	B-protein
or	O
alkaline	B-protein
phosphatase	I-protein
restores	O
NFATp	B-protein
DNA	O
binding	O
activity	O
and	O
its	O
ability	O
to	O
reconstitute	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
proteins	O
.	O

These	O
data	O
point	O
to	O
a	O
new	O
mechanism	O
for	O
CsA-sensitive	O
regulation	O
of	O
NFATp	B-protein
in	O
which	O
dephosphorylation	O
is	O
critical	O
for	O
DNA	O
binding	O
.	O

Transcription	B-protein
factors	I-protein
as	O
targets	O
for	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O
activation	O
.	O

In	O
the	O
current	O
study	O
,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

Treatment	O
of	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
with	O
cysteamine	O
in	O
vitro	O
was	O
found	O
to	O
inhibit	O
proliferation	O
in	O
a	O
dose-dependent	O
manner	O
,	O
with	O
essentially	O
complete	O
inhibition	O
occurring	O
at	O
a	O
dose	O
of	O
400	O
microM	O
.	O

This	O
inhibitory	O
effect	O
was	O
limited	O
to	O
the	O
first	O
2	O
h	O
after	O
mitogenic	O
activation	O
,	O
localizing	O
the	O
time-frame	O
of	O
action	O
of	O
cysteamine	O
to	O
within	O
the	O
commitment	O
period	O
.	O

It	O
therefore	O
was	O
of	O
interest	O
to	O
establish	O
which	O
,	O
if	O
any	O
,	O
commitment	O
events	O
were	O
affected	O
by	O
oxidative	O
signalling	O
during	O
cell	O
cycle	O
entry	O
.	O

Taking	O
the	O
IL-2	B-DNA
gene	I-DNA
as	O
a	O
candidate	O
,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	O
treatment	O
on	O
early	B-DNA
gene	I-DNA
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
NF-AT	B-protein
and	O
Oct1	B-protein
,	O
whose	O
functions	O
are	O
required	O
for	O
expression	O
of	O
the	O
IL-2	B-protein
mRNA	O
.	O

Cysteamine	O
treatment	O
inhibited	O
both	O
expression	O
of	O
the	O
IL-2	B-RNA
mRNA	I-RNA
and	O
secretion	O
of	O
IL-2	B-protein
into	O
the	O
culture	O
medium	O
.	O

The	O
inhibitory	O
effect	O
of	O
cysteamine	O
may	O
be	O
mediated	O
at	O
least	O
in	O
part	O
by	O
an	O
effect	O
on	O
transcription	B-protein
factor	I-protein
function	O
,	O
as	O
the	O
DNA	O
binding	O
activities	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
extracted	O
from	O
mitogen-stimulated	B-cell_type
cells	I-cell_type
were	O
significantly	O
inhibited	O
by	O
cysteamine	O
treatment	O
.	O

Interestingly	O
,	O
Oct1	O
and	O
NF-AT	O
DNA	O
binding	O
activity	O
were	O
not	O
affected	O
by	O
cysteamine	O
treatment	O
,	O
suggesting	O
that	O
oxidative	O
signalling	O
processes	O
operate	O
in	O
a	O
selective	O
manner	O
.	O

The	O
identification	O
of	O
regulatory	B-protein
proteins	I-protein
,	O
such	O
as	O
transcription	B-protein
factors	I-protein
,	O
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
provides	O
further	O
evidence	O
to	O
implicate	O
oxidative	O
signalling	O
as	O
being	O
intimately	O
involved	O
in	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Sex	O
and	O
age	O
distribution	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
normal	O
human	O
subjects	O
.	O

Specific	O
receptors	O
for	O
1	O
,	O
25	O
Dihydroxyvitamin	O
D3	O
have	O
been	O
described	O
in	O
human	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

We	O
have	O
tried	O
to	O
find	O
out	O
whether	O
these	O
receptors	O
could	O
show	O
any	O
difference	O
in	O
sex	O
or	O
age	O
distribution	O
.	O

Twenty	O
two	O
healthy	O
men	O
aged	O
21-66	O
yr	O
(	O
mean	O
+/-	O
SD	O
41.0	O
+/-	O
13.6	O
)	O
and	O
nineteen	O
healthy	O
women	O
aged	O
22-60	O
yr	O
(	O
38.9	O
+/-	O
13.9	O
)	O
have	O
been	O
studied	O
.	O

The	O
mean	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
both	O
sexes	O
(	O
1.35	O
+/-	O
0.70	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
males	O
,	O
1.13	O
+/-	O
0.66	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
females	O
)	O
,	O
but	O
the	O
concentration	O
of	O
binding	O
sites	O
(	O
Nmax	O
)	O
was	O
significantly	O
lower	O
in	O
females	O
(	O
2.32	O
+/-	O
0.92	O
fmol/10	O
(	O
7	O
)	O
PBMC	B-cell_type
vs	O
4.43	O
+/-	O
1.38	O
fmol/10	O
(	O
7	O
)	O
PBMC	B-cell_type
in	O
males	O
;	O
p	O
=	O
0.0001	O
)	O
.	O

Neither	O
Kd	O
nor	O
Nmax	O
were	O
significantly	O
correlated	O
with	O
age	O
.	O

No	O
difference	O
was	O
found	O
between	O
pre	O
and	O
postmenopausal	O
women	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
elucidate	O
if	O
this	O
sex	O
difference	O
in	O
PBMC	B-protein
receptors	I-protein
for	O
1.25	O
Dihydroxyvitamin	O
D3	O
is	O
of	O
any	O
pathophysiological	O
relevance	O
.	O

Expression	O
of	O
Id2	O
and	O
Id3	O
mRNA	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

Helix-loop-helix	B-protein
(	I-protein
HLH	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
are	O
involved	O
in	O
cellular	O
growth	O
and	O
differentiation	O
.	O

The	O
Id	B-protein
(	O
inhibitor	O
of	O
DNA	O
binding	O
and	O
differentiation	O
)	O
HLH	B-protein
proteins	I-protein
,	O
in	O
a	O
dominantly	O
negative	O
fashion	O
,	O
regulate	O
transcriptional	O
activities	O
of	O
basic	B-protein
HLH	I-protein
proteins	I-protein
.	O

We	O
examined	O
by	O
northern	O
hybridization	O
the	O
expression	O
of	O
Id2	B-RNA
and	I-RNA
Id3	I-RNA
mRNA	I-RNA
in	O
human	B-cell_line
leukemia/lymphoma	I-cell_line
lines	I-cell_line
and	O
patient	O
samples	O
,	O
as	O
well	O
as	O
resting	O
and	O
activated	B-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	I-cell_line
from	O
peripheral	O
blood	O
(	O
PBL	B-cell_type
)	O
.	O

The	O
Id2	B-RNA
mRNA	I-RNA
was	O
abundantly	O
expressed	O
in	O
5/12	B-cell_line
T-cell	I-cell_line
and	O
3/4	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
and	O
Id3	B-RNA
mRNA	I-RNA
was	O
detected	O
in	O
4/12	B-cell_line
T-cell	I-cell_line
and	O
3/4	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
.	O

Interestingly	O
,	O
Id2	B-RNA
,	O
but	O
not	O
Id3	B-RNA
,	O
mRNA	O
was	O
strongly	O
expressed	O
in	O
4/5	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
infected	O
with	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
(	O
ATL-1k	B-cell_line
,	O
MT-2	B-cell_line
,	O
S-LB1	B-cell_line
)	O
and	O
type	O
II	O
(	O
Mo	B-cell_line
)	O
.	O

Another	O
unexpected	O
finding	O
was	O
that	O
T-cell	O
leukemias	O
and	O
T-cell	B-cell_line
lines	I-cell_line
often	O
expressed	O
either	O
Id2	B-RNA
or	O
Id3	B-RNA
mRNA	I-RNA
.	O

In	O
addition	O
,	O
resting	B-cell_type
PBL	I-cell_type
constitutively	O
expressed	O
prominent	O
levels	O
of	O
Id2	B-RNA
mRNA	I-RNA
,	O
but	O
not	O
Id3	B-RNA
mRNA	I-RNA
.	O

Upon	O
PHA	B-protein
-stimulation	O
,	O
Id2	B-protein
expression	O
decreased	O
and	O
Id3	B-protein
levels	O
increased	O
with	O
biphasic	O
kinetics	O
.	O

Taken	O
together	O
,	O
our	O
studies	O
revealed	O
three	O
unexpected	O
findings	O
which	O
require	O
further	O
analysis	O
:	O
(	O
1	O
)	O
expression	O
of	O
Id2	B-RNA
mRNA	I-RNA
is	O
often	O
associated	O
with	O
lymphocytic	O
transformation	O
by	O
HTLV-I	O
or	O
-II	O
;	O
(	O
2	O
)	O
T-cells	O
usually	O
express	O
either	O
Id2	B-protein
or	O
Id3	B-RNA
mRNA	I-RNA
,	O
but	O
B-cells	O
often	O
express	O
both	O
simultaneously	O
;	O
(	O
3	O
)	O
non-dividing	O
,	O
normal	O
PBL	B-cell_type
express	O
high	O
levels	O
of	O
Id2	B-protein
and	O
no	O
Id3	B-RNA
mRNA	I-RNA
;	O
and	O
with	O
the	O
onset	O
of	O
cellular	O
proliferation	O
,	O
levels	O
of	O
Id2	B-RNA
mRNA	I-RNA
decrease	O
while	O
levels	O
of	O
Id3	B-RNA
mRNA	I-RNA
increase	O
,	O
suggesting	O
that	O
regulation	O
of	O
expression	O
of	O
these	O
closely	O
related	O
genes	B-DNA
is	O
disparate	O
.	O

Salicylates	O
inhibit	O
lipopolysaccharide-induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Binding	O
of	O
plasma	B-protein
Factor	I-protein
VII/VIIa	I-protein
to	O
the	O
tissue	B-protein
factor	I-protein
(	I-protein
TF	I-protein
)	I-protein
receptor	I-protein
initiates	O
the	O
coagulation	B-protein
protease	I-protein
cascades	O
.	O

TF	O
expression	O
by	O
circulating	B-cell_type
monocytes	I-cell_type
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	B-DNA
TF	I-DNA
gene	I-DNA
in	O
monocytic	B-cell_type
cells	I-cell_type
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
in	O
the	O
TF	B-DNA
promoter	I-DNA
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti-inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
activity	O
and	O
TF	B-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
at	O
clinically	O
relevant	O
doses	O
.	O

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS-induced	O
proteolytic	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B-DNA
gene	I-DNA
.	O

These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-DNA
gene	I-DNA
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
preventing	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O

Activation	O
of	O
the	O
signal	O
transducer	O
and	O
transcription	O
(	O
STAT	B-protein
)	O
signaling	O
pathway	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

Critical	O
role	O
for	O
IL-6	B-protein
.	O

The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	O
Ags	B-protein
with	O
TCR	B-protein
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O

The	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	I-protein
in	O
a	O
primary	O
TCR	B-protein
-mediated	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
have	O
been	O
explored	O
.	O

In	O
purified	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
nuclear	B-protein
STAT	I-protein
proteins	I-protein
were	O
activated	O
approximately	O
3	O
h	O
after	O
activation	O
by	O
cross-linked	O
anti-CD3	B-protein
Abs	I-protein
.	O

These	O
STAT	B-protein
proteins	I-protein
were	O
detected	O
by	O
using	O
the	O
IFN-gamma-activated	B-DNA
sequence	I-DNA
(	O
GAS	B-DNA
)	O
and	O
related	O
oligonucleotides	O
as	O
probes	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
anti-STAT	B-protein
Abs	I-protein
indicated	O
that	O
they	O
contained	O
STAT-3	B-protein
and	O
additional	O
proteins	O
crossreactive	O
with	O
the	O
STAT	B-protein
family	I-protein
.	O

The	O
induction	O
of	O
STAT	B-protein
activity	O
was	O
inhibited	O
completely	O
by	O
pretreatment	O
with	O
either	O
cycloheximide	O
or	O
cyclosporin	O
A	O
,	O
thus	O
indicating	O
that	O
the	O
induction	O
was	O
due	O
to	O
a	O
secondary	B-protein
factor	I-protein
produced	O
by	O
the	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

As	O
neutralizing	B-protein
anti-IL-6	I-protein
Abs	I-protein
effectively	O
down-regulated	O
the	O
early	O
induction	O
of	O
STAT	B-protein
proteins	I-protein
and	O
as	O
exogenously	O
added	O
IL-6	B-protein
rapidly	O
activated	O
DNA	O
binding	O
similar	O
to	O
TCR	B-protein
-mediated	O
bindings	O
,	O
it	O
can	O
be	O
concluded	O
that	O
IL-6	B-protein
is	O
the	O
factor	O
responsible	O
for	O
the	O
activation	O
of	O
STAT	B-protein
proteins	I-protein
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

The	O
normal	O
cell	O
cycle	O
activation	O
program	O
is	O
exploited	O
during	O
the	O
infection	O
of	O
quiescent	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
by	O
Epstein-Barr	O
virus	O
.	O

B	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non-proliferative	O
state	O
.	O

Antigen	O
recognition	O
stimulates	O
limited	O
proliferation	O
,	O
whereas	O
infection	O
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
continual	O
proliferation	O
and	O
the	O
outgrowth	O
of	O
immortal	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Because	O
it	O
is	O
not	O
clear	O
at	O
which	O
point	O
in	O
cell	O
cycle	O
the	O
peripheral	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
are	O
arrested	O
,	O
we	O
characterized	O
the	O
expression	O
of	O
several	O
cell	B-DNA
cycle-associated	I-DNA
genes	I-DNA
in	O
quiescent	B-cell_type
and	I-cell_type
stimulated	I-cell_type
cells	I-cell_type
.	O

We	O
show	O
that	O
the	O
expression	O
of	O
four	O
cell	B-DNA
genes	I-DNA
,	O
cdc-2	B-DNA
,	O
cyclin	B-DNA
E	I-DNA
,	O
CD23	B-DNA
,	O
and	O
cyclin	B-DNA
D2	I-DNA
,	O
are	O
up-regulated	O
approximately	O
100-fold	O
as	O
a	O
result	O
of	O
EBV-mediated	O
immortalization	O
.	O

Because	O
these	O
genes	O
play	O
a	O
positive	O
role	O
in	O
cell	O
proliferation	O
,	O
we	O
suggest	O
that	O
this	O
regulatory	O
switch	O
contributes	O
to	O
controlling	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O

Transient	O
stimulation	O
of	O
quiescent	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
with	O
either	O
a	O
cocktail	O
of	O
anti-CD40	B-protein
,	O
anti-IgM	B-protein
,	O
and	O
IL4	B-protein
,	O
or	O
EBV	O
results	O
in	O
the	O
rapid	O
expression	O
of	O
the	O
same	O
four	O
genes	O
,	O
suggesting	O
that	O
,	O
after	O
infection	O
,	O
EBV	O
exploits	O
the	O
normal	O
program	O
of	O
B-lymphocyte	B-cell_type
cell	O
cycle	O
activation	O
.	O

Expression	O
of	O
the	O
chemokine	B-protein
receptor	I-protein
BLR2/EBI1	B-protein
is	O
specifically	O
transactivated	O
by	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
.	O

In	O
our	O
attempt	O
to	O
identify	O
chemokine	B-protein
receptors	I-protein
that	O
are	O
related	O
to	O
Burkitt	B-protein
's	I-protein
lymphoma	I-protein
receptor	I-protein
1	I-protein
(	O
BLR1	B-protein
)	O
and	O
are	O
expressed	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
we	O
used	O
RT-PCR	O
resulting	O
in	O
the	O
isolation	O
of	O
a	O
cDNA	O
encoding	O
a	O
seven	B-protein
transmembrane	I-protein
receptor	I-protein
termed	O
BLR2	B-protein
.	O

The	O
protein	O
shows	O
significant	O
sequence	O
similarities	O
to	O
the	O
family	O
of	O
G-protein	B-protein
coupled	I-protein
chemokine	I-protein
receptors	I-protein
and	O
turned	O
out	O
to	O
be	O
identical	O
to	O
the	O
recently	O
described	O
receptor	B-protein
EBI1	I-protein
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
BLR2	B-RNA
mRNA	I-RNA
could	O
be	O
highly	O
stimulated	O
in	O
mitogen-	B-cell_line
and	I-cell_line
anti-CD3-treated	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
.	O

BLR2-specific	B-RNA
mRNA	I-RNA
could	O
be	O
detected	O
in	O
all	O
Epstein-Barr	B-cell_line
virus	I-cell_line
positive	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
show	O
that	O
transcription	O
of	O
the	O
BLR2	B-DNA
gene	I-DNA
could	O
be	O
specifically	O
induced	O
in	O
Epstein-Barr	B-cell_line
virus	I-cell_line
negative	I-cell_line
BL	I-cell_line
41	I-cell_line
cells	I-cell_line
via	O
estrogen-mediated	O
activation	O
of	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
,	O
a	O
key	O
regulator	O
of	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	I-DNA
in	O
immortalized	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Our	O
data	O
suggest	O
an	O
involvement	O
of	O
BLR2	B-protein
in	O
the	O
regulation	O
of	O
migration	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
and	O
in	O
viral	O
pathogenesis	O
.	O

A	O
central	O
role	O
for	O
a	O
single	B-DNA
c-Myb	I-DNA
binding	I-DNA
site	I-DNA
in	O
a	O
thymic	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
.	O

Locus	B-DNA
control	I-DNA
regions	I-DNA
(	O
LCRs	B-DNA
)	O
are	O
powerful	O
assemblies	O
of	O
cis	B-DNA
elements	I-DNA
that	O
organize	O
the	O
actions	O
of	O
cell-type-specific	B-protein
trans-acting	I-protein
factors	I-protein
.	O

A	O
2.3-kb	B-protein
LCR	I-protein
in	O
the	O
human	B-DNA
adenosine	I-DNA
deaminase	I-DNA
(	I-DNA
ADA	I-DNA
)	I-DNA
gene	I-DNA
first	I-DNA
intron	I-DNA
,	O
which	O
controls	O
expression	O
in	O
thymocytes	B-cell_type
,	O
is	O
composed	O
of	O
a	O
200-bp	B-DNA
enhancer	I-DNA
domain	I-DNA
and	O
extended	O
flanking	O
sequences	O
that	O
facilitate	O
activation	O
from	O
within	O
chromatin	B-DNA
.	O

Prior	O
analyses	O
have	O
demonstrated	O
that	O
the	O
enhancer	B-DNA
contains	O
a	O
28-bp	B-DNA
core	I-DNA
region	I-DNA
and	O
local	O
adjacent	O
augmentative	O
cis	B-DNA
elements	I-DNA
.	O

We	O
now	O
show	O
that	O
the	O
core	O
contains	O
a	O
single	O
critical	O
c-Myb	B-DNA
binding	I-DNA
site	I-DNA
.	O

In	O
both	O
transiently	B-cell_line
cotransfected	I-cell_line
human	I-cell_line
cells	I-cell_line
and	O
stable	O
chromatin-integrated	B-cell_line
yeast	I-cell_line
cells	I-cell_line
,	O
c-Myb	B-protein
strongly	O
transactivated	B-DNA
reporter	I-DNA
constructs	I-DNA
that	O
contained	O
polymerized	B-DNA
core	I-DNA
sequences	I-DNA
.	O

c-Myb	B-protein
protein	I-protein
was	O
strongly	O
evident	O
in	O
T	B-cell_type
lymphoblasts	I-cell_type
in	O
which	O
the	O
enhancer	B-DNA
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O

Fetal	O
murine	O
thymus	O
exhibited	O
a	O
striking	O
concordance	O
of	O
endogenous	O
c-myb	B-DNA
expression	O
with	O
that	O
of	O
mouse	B-DNA
ADA	I-DNA
and	O
human	B-DNA
ADA	I-DNA
LCR	I-DNA
-directed	O
transgene	O
expression	O
.	O

Point	O
mutation	O
of	O
the	O
c-Myb	B-DNA
site	I-DNA
within	O
the	O
intact	O
2.3-kb	B-protein
LCR	I-protein
severely	O
attenuated	O
enhancer	O
activity	O
in	O
transfections	O
and	O
LCR	B-DNA
activity	O
in	O
transgenic	B-cell_line
thymocytes	I-cell_line
.	O

Within	O
the	O
context	O
of	O
a	O
complex	B-DNA
enhancer	I-DNA
and	O
LCR	B-DNA
,	O
c-Myb	B-protein
can	O
act	O
as	O
an	O
organizer	O
of	O
thymocyte-specific	B-DNA
gene	I-DNA
expression	O
via	O
a	O
single	O
binding	O
site	O
.	O

A	O
regulatory	B-DNA
element	I-DNA
in	O
the	O
human	B-DNA
interleukin	I-DNA
2	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
a	O
binding	B-DNA
site	I-DNA
for	O
the	O
zinc	B-protein
finger	I-protein
proteins	I-protein
Sp1	B-protein
and	O
EGR-1	B-protein
.	O

Activation	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
transcription	B-protein
factors	I-protein
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
stimulated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Here	O
we	O
describe	O
a	O
novel	O
regulatory	B-DNA
element	I-DNA
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cell	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
domain	I-DNA
.	O

This	O
region	O
(	O
termed	O
the	O
zinc	B-DNA
finger	I-DNA
protein	I-DNA
binding	I-DNA
region	I-DNA
(	O
ZIP	B-DNA
)	O
)	O
serves	O
as	O
binding	O
site	O
for	O
two	O
differently	O
regulated	O
zinc	B-protein
finger	I-protein
proteins	I-protein
:	O
the	O
constitutively	B-protein
expressed	I-protein
transcription	I-protein
factor	I-protein
Sp1	B-protein
and	O
the	O
inducible	B-protein
early	I-protein
growth	I-protein
response	I-protein
protein	I-protein
EGR-1	B-protein
.	O

In	O
unstimulated	B-cell_type
cells	I-cell_type
which	O
do	O
not	O
secrete	O
IL-2	B-protein
,	O
only	O
Sp1	B-protein
binds	O
to	O
this	O
region	O
,	O
while	O
in	O
stimulated	B-cell_line
IL-2	I-cell_line
secreting	I-cell_line
cells	I-cell_line
the	O
inducible	B-protein
EGR-1	I-protein
protein	I-protein
recognizes	O
this	O
element	O
.	O

In	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
the	O
ZIP	B-DNA
site	I-DNA
serves	O
as	O
an	O
activator	O
for	O
IL-2	B-protein
gene	O
expression	O
,	O
and	O
a	O
combination	O
of	O
ZIP	B-DNA
and	O
NFAT	B-DNA
binding	I-DNA
sites	I-DNA
is	O
required	O
for	O
maximal	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
the	O
ZIP	B-DNA
site	I-DNA
for	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O

Activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
by	O
the	O
LEF-1	B-protein
HMG	I-protein
protein	I-protein
on	O
nucleosome-assembled	B-DNA
DNA	I-DNA
in	O
vitro	O
.	O

Lymphoid	B-protein
enhancer-binding	I-protein
factor	I-protein
1	I-protein
(	O
LEF-1	B-protein
)	O
is	O
a	O
regulatory	B-protein
high	I-protein
mobility	I-protein
group	I-protein
(	I-protein
HMG	I-protein
)	I-protein
protein	I-protein
that	O
activates	O
the	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
TCR	I-DNA
alpha	I-DNA
)	I-DNA
enhancer	I-DNA
in	O
a	O
context-restricted	O
manner	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
paper	O
we	O
demonstrate	O
that	O
the	O
distal	O
region	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus-1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
enhancer	I-DNA
,	O
which	O
contains	O
DNA-binding	B-DNA
sites	I-DNA
for	O
LEF-1	B-protein
and	O
Ets-1	O
,	O
also	O
provides	O
a	O
functional	O
context	O
for	O
activation	O
by	O
LEF-1	B-protein
.	O

First	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
LEF-1-binding	B-DNA
site	I-DNA
inhibit	O
the	O
activity	O
of	O
multimerized	B-DNA
copies	I-DNA
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
and	O
that	O
LEF-1/GAL4	B-protein
can	O
activate	O
a	O
GAL4-substituted	B-DNA
HIV-1	I-DNA
enhancer	I-DNA
80-	O
to	O
100-fold	O
in	O
vivo	O
.	O

Second	O
,	O
recombinant	B-protein
LEF-1	I-protein
is	O
shown	O
to	O
activate	O
HIV-1	O
transcription	O
on	O
chromatin-assembled	B-DNA
DNA	I-DNA
in	O
vitro	O
.	O

By	O
using	O
a	O
nucleosome	B-protein
-assembly	O
system	O
derived	O
from	O
Drosophila	O
embryos	O
,	O
we	O
find	O
that	O
the	O
packaging	O
of	O
DNA	O
into	O
chromatin	B-DNA
in	O
vitro	O
strongly	O
represses	O
HIV-1	O
transcription	O
and	O
that	O
repression	O
can	O
be	O
counteracted	O
efficiently	O
by	O
preincubation	O
of	O
the	O
DNA	O
with	O
LEF-1	B-protein
(	O
or	O
LEF-1	B-protein
and	O
Ets-1	B-protein
)	O
supplemented	O
with	O
fractions	O
containing	O
the	O
promoter-binding	B-protein
protein	I-protein
,	O
Sp1	B-protein
.	O

Addition	O
of	O
TFE-3	B-protein
,	O
which	O
binds	O
to	O
an	O
E-box	B-DNA
motif	I-DNA
upstream	O
of	O
the	O
LEF-1	B-DNA
and	I-DNA
Ets-1	I-DNA
sites	I-DNA
,	O
further	O
augments	O
transcription	O
in	O
this	O
system	O
.	O

Individually	O
or	O
collectively	O
,	O
none	O
of	O
the	O
three	O
enhancer-binding	B-protein
proteins	I-protein
(	O
LEF-1	B-protein
,	O
Ets-1	B-protein
,	O
and	O
TFE-3	B-protein
)	O
could	O
activate	O
transcription	O
in	O
the	O
absence	O
of	O
Sp1	B-protein
.	O

A	O
truncation	B-protein
mutant	I-protein
of	O
LEF-1	B-protein
(	O
HMG-88	B-protein
)	O
,	O
which	O
contains	O
the	O
HMG	B-protein
box	I-protein
but	O
lacks	O
the	O
trans-activation	B-protein
domain	I-protein
,	O
did	O
not	O
activate	O
transcription	O
from	O
nucleosomal	B-DNA
DNA	I-DNA
,	O
indicating	O
that	O
bending	O
of	O
DNA	O
by	O
the	O
HMG	B-protein
domain	I-protein
is	O
not	O
sufficient	O
to	O
activate	O
transcription	O
in	O
vitro	O
.	O

We	O
conclude	O
that	O
transcription	O
activation	O
by	O
LEF-1	B-protein
in	O
vitro	O
is	O
a	O
chromatin	B-DNA
-dependent	O
process	O
that	O
requires	O
a	O
functional	O
trans-activation	B-protein
domain	I-protein
in	O
addition	O
to	O
the	O
HMG	B-protein
domain	I-protein
.	O

HIV-1	B-protein
envelope	I-protein
glycoproteins	I-protein
induce	O
activation	O
of	O
activated	O
protein-1	B-protein
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Dec	O
1	O
;	O
270	O
(	O
48	O
)	O
:	O
29038	O
]	O

Activation	O
of	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
a	O
primary	O
requirement	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
entry	O
,	O
efficient	O
HIV	O
replication	O
,	O
and	O
progression	O
to	O
AIDS	O
,	O
Utilizing	O
CD4	B-cell_line
positive	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
,	O
we	O
have	O
demonstrated	O
that	O
native	B-protein
envelope	I-protein
glycoproteins	I-protein
of	O
HIV	O
,	O
gp	B-protein
160	I-protein
,	O
can	O
induce	O
activation	O
of	O
transcription	B-protein
factor	I-protein
,	I-protein
activated	I-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	B-protein
are	O
mediated	O
through	O
the	O
CD4	B-protein
molecule	I-protein
,	O
since	O
treatment	O
of	O
gp160	B-protein
with	O
soluble	O
CD4-IgG	B-protein
abrogates	O
its	O
activity	O
,	O
and	O
CD4	B-cell_line
negative	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
fail	O
to	O
be	O
stimulated	O
with	O
gp160	B-protein
.	O

Immunoprecipitation	O
of	O
the	O
gp	B-protein
160	I-protein
-induced	O
nuclear	O
extracts	O
with	O
polyclonal	B-protein
antibodies	I-protein
to	O
Fos	B-protein
and	O
Jun	B-protein
proteins	I-protein
indicates	O
that	O
AP-1	B-protein
complex	I-protein
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O

The	O
gp160-induced	B-protein
AP-1	I-protein
complex	I-protein
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
and	O
is	O
protein	O
synthesis-independent	O
.	O

This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O
channel	O
blocker	O
or	O
cyclosporine	O
A	O
.	O

This	O
gp160	B-protein
treatment	O
adversely	O
affects	O
the	O
functional	O
capabilities	O
of	O
T	B-cell_type
cells	I-cell_type
:	O
pre-treatment	O
of	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
gp160	B-protein
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
inhibited	O
anti-CD3	B-protein
-induced	O
interleukin-2	B-protein
secretion	O
.	O

Effects	O
similar	O
to	O
gp160	B-protein
were	O
seen	O
with	O
anti-CD4	B-protein
mAb	I-protein
.	O

The	O
aberrant	O
activation	O
of	O
AP-1	B-protein
by	O
gp160	B-protein
in	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
could	O
result	O
in	O
up-regulation	O
of	O
cytokines	B-protein
containing	O
AP-1	B-DNA
sites	I-DNA
,	O
e.g	O
.	O
interleukin-3	B-protein
and	O
granulocyte	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
,	O
and	O
concurrently	O
lead	O
to	O
T	B-cell_type
cell	I-cell_type
unresponsiveness	O
by	O
inhibiting	O
interleukin-2	B-protein
secretion	O
.	O